CSA295113

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
INVENTARIO

3

87

Industria y Comercio
SUPERINTENDENCIA
PROPIEDAD INDUSTRIAL

Organizacion y Digitalizacion CSA Ltda

Delegatura de Propiedad Industrial
División de Nuevas Creaciones

SOLICITUD DE PCT

PATENTE DE INVENCION
PCT ENTRADA EN FASE NACIONAL

21. EXPEDIENTE No. 09111589

54. TITULO: INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1

52. CLASIFICACION INTERNACIONAL: C07D 209/34, A61P 35/00, A61K 31/404

71. SOLICITANTES: ABBOTT LABORATORIES

DOMICILIO: 100 Abbott Park Road, Abbott Park, Illinois 60064, ESTADOS UNIDOS DE AMERICA

74. APODERADO: Dra. MARGARITA CASTELLANOS A.

22. BOGOTA, D.C., 8 OCT. 2009

1/2

16-11-2009

Industria y Comercio
SUPERINTENDENCIA

PETITORIO

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
No. 09-111589- -00000-0000
Fecha: 2009-10-08 14:40:14 Dep. 2020 NUECREACIONI
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 597

FORMULARIO UNICO DE SOLICITUD DE PATENTES
PCT
ENTRADA EN FASE NACIONAL

SOLICITUD DE:

(1)

[X] Patente de Invención. [ ] Patente de Modelo de Utilidad.

[X] Capítulo I [ ] Capítulo II

(2) SOLICITANTE (71)	Nombre: **ABBOTT LABORATORIES** Dirección: **100 Abbott Park Road Abbott Park, Illinois 60064 ESTADOS UNIDOS DE AMERICA** Domicilio: **Abbott Park, Illinois - ESTADOS UNIDOS DE AMERICA** Lugar de Constitución: **ESTADOS UNIDOS DE AMERICA** Teléfono: Fax: E-mail:	**IDENTIFICACIÓN** C.C. [ ] NIT [ ] C.E. [ ] Otro [ ] Cual Número
(3) REPRESENTANTE O APODERADO	Nombre: **MARGARITA CASTELLANOS A.** Dirección: **CALLE 94A No. 7A-09** Teléfono: **7560770** Fax: **7550158** E-mail: info@castellanosyco.com	**IDENTIFICACIÓN** C.C. [X] NIT [ ] C.E. [ ] Otro [ ] Cual Número **39'779.654** TPA **70.819**
(4) INVENTOR (ES) (72)	**VER ANEXO No. 1**	

(5) **PCT (86)**

Solicitud Internacional No. **PCT/US2008/060472** Fecha **16/04/2008**

Publicación Internacional No. **WO 2008/131000 A3** Fecha **30/10/2008**

(6) **Título (54)** **INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1**

(7) **Clasificación Internacional (51)** **C07D 209/34, A61P 35/00, A61K 31/404**

(8) **Prioridad** SI [X] NO [ ]

(33) País de Origen	(32) Fecha	(31) Número de Solicitud
US	16/04/2007	60/912,038
US	13/07/2007	60/949,650


(9) **Comprobantes de pago Nos.** **09-75,531** **Fecha** **Octubre 7 de 2009**

Instrucciones para el diligenciamiento del presente formulario, ver reverso de esta página.

(10) Anexos

- [X] Comprobante de pago de la tasa de presentación de la solicitud.
- [X] Documento que acredita la existencia y representación legal cuando el solicitante sea persona jurídica.
- [X] Poderes, si fuere el caso, junto con la sustitución del mismo a mi favor
- [ ] Documento de cesión del inventor al solicitante o a su causante.
- [ ] Declaraciones.
- [X] Copia de la solicitud internacional (Resumen, descripción, reivindicaciones, dibujos).
- [X] Traducción de la solicitud internacional al castellano (Resumen, descripción, reivindicaciones, dibujos).
- [ ] Copia del examen preliminar internacional efectuado por la Autoridad Internacional de Examen Preliminar (IPEA).
- [ ] Traducción del examen preliminar internacional efectuado por la IPEA.
- [ ] De ser el caso, copia del contrato de acceso.
- [ ] De ser el caso, documento que acredite la licencia o autorización de uso de conocimientos tradicionales de las comunidades indígenas.
- [ ] De ser el caso, certificado de depósito del material biológico.
- [X] Arte final 12x12
- [ ] De ser el caso, información sobre otras solicitudes de patente o títulos obtenidos en el extranjero por el mismo titular o su causante, relacionadas parcial o totalmente con la invención de esta solicitud.
- [ ] De ser el caso, modificaciones efectuadas a la solicitud internacional.
- [X] Otros: **Tarjeta Propietario, Extracto para la publicación y PCT/IB/306**

(11) FIGURA CARACTERISTICA:



(I)

(12) Solicito la concesión de la patente,

NOMBRE: **MARGARITA CASTELLANOS ABONDANO**

FIRMA:

C.C. No. 39'779.654 Usaquén - TPA 70.819 C.S.J.

-8 OCT. 2009

Instrucciones para el diligenciamiento del presente formulario, ver reverso de esta página. - MCA/gcb - P1827

CASTELLANOS & CO LTDA
ABOGADOS
Calle 94 A No. 7 A-09
Bogotá, D.C. – COLOMBIA

ANEXO # 1
INVENTORES

1. **STEVEN ELMORE**
   2139 Ash Lane
   Northbrook, Illinois 60062
   ESTADOS UNIDOS DE AMERICA

2. **ANDREW J. SOUERS**
   901 Hinman, 3ª.
   Evanston, Illinois 60202
   ESTADOS UNIDOS DE AMERICA

3. **MILAN BRUNCKO**
   31231 Prairie Ridge
   Green Oaks, Illinois 60048
   ESTADOS UNIDOS DE AMERICA

4. **XIAOHONG SONG**
   34037 Sulkey Drive
   Grayslake, Illinois 60030
   ESTADOS UNIDOS DE AMERICA

5. **XILU WANG**
   34056 Sulkey Drive
   Grayslake, Illinois 60030
   ESTADOS UNIDOS DE AMERICA

6. **LISA A. HASVOLD**
   552 Shakespeare Drive
   Grayslake, Illinois 60030
   ESTADOS UNIDOS DE AMERICA

7. **LE WANG**
   338 East Colonial Drive
   Vernon Hills, Illinois 60061
   ESTADOS UNIDOS DE AMERICA

8. **AARON, R. KUNZER**
   322 Woodbury Court, # A2
   Schaumburg, Illinois 60193-2287
   ESTADOS UNIDOS DE AMERICA

9. **CHEOL-MIN PARK**
   1407 Almaden Lane
   Gurnee, Illinois 60031
   ESTADOS UNIDOS DE AMERICA

10. **MICHAEL, D. WENDT**
    1445 Maidstone Drive
    Vernon Hills, Illinois 60061
    ESTADOS UNIDOS DE AMERICA

11. **ZHI-FU TAO**
    1532 Vineyard Drive
    Gurnee, Illinois 60031
    ESTADOS UNIDOS DE AMERICA

12. **DAVID MADAR**
    4776 East Guadalupe Road
    Apt. 2075
    Gilbert, Arizona 85234
    ESTADOS UNIDOS DE AMERICA

CASTELLANOS & CO LTDA
ABOGADOS
Calle 94 A No. 7 A-09
Bogotá, D.C. – COLOMBIA

Señor

Jefe de la División de Nuevas Creaciones

Superintendencia de Industria y Comercio

Ministerio de Comercio, Desarrollo, Industria y Turismo

E. S. D.

Ref.: **PODER** conferido por **ABBOTT LABORATORIES**

Yo, **XIMENA CASTELLANOS ABONDANO,** mayor de edad, identificada y domiciliada como aparece al pié de mi firma, atentamente manifiesto a Uds. que sustituyo en la Dra. **MARGARITA CASTELLANOS ABONDANO,** el poder que me confirió **ABBOTT LABORATORIES**, con domicilio en **100 Abbott Park Road, Abbott Park, Illinois 60064, ESTADOS UNIDOS DE AMERICA**, debidamente legalizado por Apostilla, el día **26 de Noviembre de 2008**, bajo el número **S08DL14032**, con las mismas facultades que me fueron conferidas, para tramitar la solicitud de Patente PCT Entrada en Fase Nacional en Colombia, para: **INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1**.

De la Señora Jefe,

Acepto

Ximena Castellanos Abondano
C.C. No. **39.773.330** de Usaquén
T.P.A. No. **58.236** del C.S.J.
Calle 94 A No. 7 A-09 – Bogotá
PBX: 7560770

Margarita Castellanos Abondano
C.C. No. **39.779.654** de Usaquén
T.P.A. No. **70.819** del C.S.J.
Calle 94 A No. 7 A-09 – Bogotá
PBX: 7560770

Bogotá, D.C.
XCA/MCA/gcb/ P1827

MEMORIAL SUSTITUCION PODER

El anterior memorial fué presentado personalmente por
Ximena Castellanos Abaunza
quien se identificó con la C. de C. No. 39.773.330
de Usaquén
Tarjeta Profesional No. 58.236 C.S. de la J.
Bogotá, D.C. - 6 OCT. 2009
El Notario Veintiseis
Gustavo Samper Rodríguez

- 6 OCT. 2009

El anterior memorial fué presentado personalmente por
Margarita Castellanos Abaunza
quien se identificó con la C. de C. No. 39.779.654
de Usaquén
Tarjeta Profesional No. 70.817 C.S. de la J.
Bogotá, D.C. - 6 OCT. 2009
El Notario Veintiseis
Gustavo Samper Rodríguez

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

No. 09-111589- -00000-0000

Fecha: 2009-10-08 14:40:14 Dep. 2020 NUECREACIONE
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 597

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 09 - 75,531
FECHA : OCTUBRE 7 DE 2009

***** C O N S I G N A C I O N *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
ALVARO CASTELLANOS	CONSIGNACION	BANCO DE BOGOTA	062754387	105831961	07/10/2009	3,834,000.00

***** C O N C E P T O *****

CANT.	RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-01 SOLICITUDES	1 TRAMITES DE SOL. DE PATENTE DE IN	540,000.00
		TOTAL : $	540,000.00

SON: QUINIENTOS CUARENTA MIL PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL EXPEDIENTE No._____

21661
5

COLOMBIA

PODER

El (los)

ABBOTT LABORATORIES

Domiciliados en

100 Abbott Park Road
Abbott Park
Illinois 60064
E.U.A.

Nombran por el presente a **XIMENA CASTELLANOS A. y/o MARGARITA CASTELLANOS A.** abogadas con oficinas en la Calle 94A No. 7A-09, Bogotá-Colombia para

y para obtener la protección de mi (nuestra) propiedad Industrial y con este fin autorizamos a dichos apoderados para que nos representen ante cualesquiera autoridades o personas de los órdenes administrativo, contencioso –administrativo y judicial en todo lo relacionado con los siguientes actos y gestiones:

a) Obtención de patentes de invención, modelos y dibujos industriales; registro de marcas de fabrica, de servicio, colectivas o defensivas y de denominaciones de origen, depósito de nombres y enseñas comerciales; su renovación, prórroga, inscripción de traspaso y cambio de nombre o domicilio, cancelación voluntaria y el registro de licencias de uso de esos derechos;
b) Para la obtención de registros sanitarios;
c) Acciones de oposición, observación, cancelación, nulidad, medidas cautelares y en general los juicios civiles, penales, administrativos o contencioso - administrativos que promovamos o se nos promuevan.

Pudiendo en todos los actos y gestiones arriba mencionados sustituir éste mandato, transigir, desistir, recibir, cancelar, renunciar, aceptar notificaciones y nombrar apoderados judiciales y extrajudiciales.

Finalmente, este poder ratifica la validez de todos los actos y solicitudes que, a nombre de la poderdante hubieren realizado los apoderados en relación con las facultades anteriormente enumeradas, antes de la suscripción del presente poder

Dado y firmado hoy 19 de Noviembre de 2008

en Abbott Park, Illinois,
ESTADOS UNIDOS DE AMERICA

por ABBOTT LABORATORIES
(firma ilegible) Paul D. Yasger
(El notario debe suscribir el documento en la pagina siguiente)

(Se requiere legalización consular o mediante apostilla)

POWER OF ATTORNEY

I (we) the undersigned

ABBOTT LABORATORIES

Of

100 Abbott Park Road
Abbott Park
Illinois 60064
USA

hereby grant(s) Power of Attorney to **XIMENA CASTELLANOS A. and /or MARGARITA CASTELLANOS** a. attorneys residing at Calle 94A No. 7A-09, Bogotá- Colombia, to

and to obtain the protection of my (our Industrial Property, for which purpose we authorize the said attorneys to represent us before any authorities, or persons, specially those, administrative, contentious and judicial, in all matters concerning the following:

a) Obtainment of patents, models and designs, registration of trademarks, service, collective and defensive marks, and of designations of origin; the deposit of trade names and ensigns; its renewal, extension, recordal of assignments, change of name or domicile, voluntary cancellation, and the registration of licenses of use of the above rights;
b) For the obtainment of Sanitary registrations;
c) Actions of opposition, cancellation, nullity, infringement, granting of licenses; and in general the civil, criminal and administrative suits related to those rights; actions and suits instituted by us or against us;

In all the above matters ~~they~~ may substitute this power of attorney, compromise, desist, cancel, receive, renounce, accept notifications and appoint attorneys in fact, in or out of court.

Finally, this power of attorney ratifies the validity of all acts and applications made by the representatives in the name of the signatory of this power of attorney, with regard to the faculties above given, before the execution of the present power of attorney.

Given and signed this 19 day of November, 2008

in Abbott Park, Illinois, USA 60064

by Paul D. Yasger, Assistant Secretary, DVP, Associate General Counsel
(Notary shall execute on the other side)

(Consular legalization or apostille is required)

CASTELLANOS & CO
ABOGADOS COLOMBIA
Calle 94A No. 7A-09- P.O.Box 6349 - Bogotá, Colombia
Tels.: (571) 610 74 20 / - Fax (571) 610 07 06 - e-mail info@castellanosyco.com

* Abbott at its sole discretion

Esta copia coincide con el original que tuve a la vista
Bogotá, D.C.
- 5 OCT 2009
ALIRIO VIRVIESCAS CALVETE
NOTARIO CUARENTA Y UNO (EN PROP.)

COLOMBIA

CERTIFICADO NOTARIAL (Sociedad)

Hoy 19de Nov. del año 2008
compareció (eron) personalmente
Paul D. Yasger

a quienes conozco como la(s) personas que firma(n) en representación de la Sociedad (Compañía) denominada **ABBOTT LABORATORIES**

Certifico :

a) Que **ABBOTT LABORATORIES**

es una sociedad/Compañía legalmente constituida y existente de acuerdo con las leyes de Estados Unidos de América

b) Que el domicilio de dicha Sociedad/Compañía es

100 Abbott Park Road
Abbott Park
Illinois 60064
EUA

c) Que el objeto u objetos para los cuales se otorga el presente poder están comprendidos dentro del objeto social de la mencionada Sociedad /Compañía.

d) Que el Sr. Paul D. Yasger

esta autorizado para otorgar el presente poder. Lo anterior esta probado por medio de los siguientes documentos, que certifico he visto*

(Ciudad) Abbott Park

(Estado) Illinois

Hoy 19del Noviembre de 2008

(Notario Público)

*Los documentos debe identificarse con fecha y origen.

NOTARIAL CERTIFICATION (Corporation)

On this 19 day of November of 2008
personally appeared Paul D. Yasger,
whom I know to be the person(s) who signed this document as representative(s) of the Corporation /Company named
ABBOTT LABORATORIES

I certify:

a) That **ABBOTT LABORATORIES**

is a corporation (Company legally constituted and in existence in accordance with the laws of United States of America

b) That the domicile of said Corporation/Company is

100 Abbott Park Road
Abbott Park
Illinois 60064
USA

c) That the purpose or purposes for which the present Power of Attorney is granted are comprised within the object set forth in the charter of the mentioned Corporation/Company.

d) That Mr. Paul D. Yasger

is (are) authorized to grant the present Power of Attorney. The aforementioned was duly proven through the following documents and I duly certify having seen them*:Appointment of Corporate Officer dated March 6, 2008 and signed by Mile D. White, Chairman of the Board and Chief Executive Office of Abbott Laboratories

(City) Abbott Park

(State) Illinois

this 19th day of November of the year 2008

(Notary Public)

*Documents must be identified with date and origin

OFFICIAL SEAL
LINDA S LUTZ
NOTARY PUBLIC - STATE OF ILLINOIS
MY COMMISSION EXPIRES

Esta copia coincide con el original que tuve a la vista
Bogotá, D.C.
- 5 OCT 2009
ALIRIO VIRVIESCAS CALVETE
NOTARIO CUARENTA Y UNO (E.P.)

CASTELLANOS & CO
ABOGADOS COLOMBIA
Calle 94A No. 7A-09- P.O.Box 6349 - Bogotá, Colombia
Tels.: (571) 610 74 20 / - Fax (571) 610 07 06 - e-mail info@castellanosyco.com

7

STATE OF ILLINOIS

SECRETARY OF STATE

SPRINGFIELD, ILLINOIS

APOSTILLE

(Convention de La Haye du 5 Octobre 1961)

1. Country: United States of America

This public document

2. has been signed by LINDA S LUTZ

3. acting in the capacity of NOTARY PUBLIC, MCHENRY COUNTY

4. bears the seal/stamp of STATE OF ILLINOIS

Certified

5. Springfield, Illinois

6. NOVEMBER 26, 2008

7. by the Secretary of State, State of Illinois

8. No. S08DL14032

9. Seal/Stamp:

10. Signature:

Jesse White

JESSE WHITE
SECRETARY OF STATE
STATE OF ILLINOIS

Esta copia coincide con el original que tuve a la vista
Bogotá D.C.
OCT 2009
ALIRIO VIRVIESCAS CALVETE
NOTARIO CUARENTA Y UNO (EN PROP.)

Printed on recycled paper. Printed by authority of the State of Illinois. May 2008 — 50M — I 168.2

----------TRADUCCION OFICIAL No. 081205----------

de un documento escrito en INGLES, el cual para su identificación lleva el sello de la Traductora e Intérprete Oficial, Res. 2755/68 y 01144/97 de Minjusticia, al igual que la presente.----------

(Adjunto a un documento de PODER de Abbott Laboratories)

(fdo) ilegible

Notario Público

SELLO OFICIAL

Notario Público – Estado de Illinois

LINDA S. LUTZ

Mi comisión vence 07/23/11



ESTADO DE ILLINOIS

Secretario de Estado

Springfield, Illinois

APOSTILLA

(Convención de La Haya de 5 de Octubre de 1961)

1. País: Estados Unidos de América

Este documento público

2. ha sido firmado por LINDA S. LUTZ
3. actuando en su calidad de Notario Público, Condado de McHenry
4. lleva el sello del Estado de Illinois

CERTIFICADO

5. en Springfield, Illinois
6. El día 26 de Noviembre de 2008
7. Por el Secretario de Estado, Estado de Illinois
8. No. S08DL14032
9. Sello
10. Firma: (fdo) Jesse White

JESSE WHITE

Secretario de Estado

Estado de Illinois



(Sello en oblea dorada)

ES TRADUCCION FIEL Y COMPLETA, a la cual me remito,

Bogotá, D. C., Diciembre 17, 2008

MINISTERIO DE
RELACIONES EXTERIORES

2009 DIC 17 P 12:14

JEFE DE LEGALIZACIONES
BOGOTA D.C.

NO SE ASUME
RESPONSABILIDAD
DEL TEXTO

854400

CUYA FIRMA APARECE EN EL
DOCUMENTO DESEMPEÑA
AS FUNCIONES INDICADAS

RECIBO LEGALIZACIÓN

No. 12644754 1/4

Esta copia coincide con el original que tuvo a la vista

5 OCT 2009

ALBERTO VIRVIESCAS CALVETE
NOTARIO CUARENTA Y UNO (E.N. PROP.)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 October 2008 (30.10.2008)

PCT

(10) International Publication Number
WO 2008/131000 A2

(51) International Patent Classification:
C07D 209/34 (2006.01) *C07D 417/04* (2006.01)
C07D 401/12 (2006.01) *A61P 35/00* (2006.01)
C07D 413/06 (2006.01) *A61K 31/404* (2006.01)

(21) International Application Number:
PCT/US2008/060472

(22) International Filing Date: 16 April 2008 (16.04.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/912,038 16 April 2007 (16.04.2007) US
60/949,650 13 July 2007 (13.07.2007) US

(71) Applicant *(for all designated States except US)*: **ABBOTT LABORATORIES** [US/US]; 100 Abbott Park Road, Abbott Park, Illinois 60064 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ELMORE, Steven, W.** [US/US]; 2139 Ash Lane, Northbrook, Illinois 60062 (US). **SOUERS, Andrew, J.** [US/US]; 901 Hinman, 3a, Evanston, Illinois 60202 (US). **BRUNCKO, Milan** [US/US]; 31231 Prairie Ridge, Green Oaks, Illinois 60048 (US). **SONG, Xiaohong** [CN/US]; 34037 Sulkey Drive, Grayslake, Illinois 60030 (US). **WANG, Xilu** [US/US]; 34056 Sulkey Drive, Grayslake, Illinois 60030 (US). **HASVOLD, Lisa, A.** [US/US]; 552 Shakespeare Drive, Grayslake, Illinois 60030 (US). **WANG, Le** [US/US]; 338 East Colonial Drive, Vernon Hills, Illinois 60061 (US). **KUNZER, Aaron, R.** [US/US]; 322 Woodbury Court, #A2, Schaumburg, Illinois 60193-2287 (US). **PARK, Cheol-min** [KR/US]; 1407 Almaden Lane, Gurnee, Illinois 60031 (US). **WENDT, Michael, D.** [US/US]; 1445 Maidstone Drive, Vernon Hills, Illinois 60061 (US). **TAO, Zhi-fu** [CN/US]; 1532 Vineyard Drive, Gurnee, Illinois 60031 (US).

(74) Agent: **DONNER, B. Gregory**; Abbott Laboratories, Dept. 0377, Bldg. AP6A-1A, 100 Abbott Park Road, Abbott Park, Illinois 60064-6008 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

(54) Title: 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS

(57) Abstract: Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed.

WO 2008/131000 A2

7-SUBSTITUTED INDOLE MCL-1 INHIBITORS

FIELD OF THE INVENTION


This invention pertains to compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein.

BACKGROUND OF THE INVENTION

Mcl-1 protein is associated with a number of diseases. There is therefore an existing need in the therapeutic arts for compounds which bind to and inhibit the activity of Mcl-1 protein.

SUMMARY OF THE INVENTION

One embodiment of this invention, therefore, pertains to compounds which inhibit the activity of Mcl-1 protein, the compounds having Formula I,



(I),

and therapeutically acceptable salts thereof, wherein

A^1 is A^2, OA^2, SA^2, $S(O)A^2$, SO_2A^2, NH_2, NHA^2, $N(A^2)_2$, $C(O)A^2$, $C(O)NH_2$, $C(O)NHA^2$, $C(O)N(A^2)_2$, $NHC(O)A^2$, $NA^2C(O)A^2$, $NHSO_2A^2$, $NA^2SO_2A^2$, $NHC(O)OA^2$, $NA^2C(O)OA^2$, SO_2NH_2, SO_2NHA^2, $SO_2N(A^2)_2$, $NHC(O)NH_2$, $NHC(O)A^2$ $NHC(O)N(A^2)_2$, $NA^2C(O)N(A^2)_2$ F, Cl, Br, or I;

A^2 is R^1, R^2, R^3, or R^4;

R^1 is phenyl which is unfused or fused with benzene, heteroarene or R^{1A}; R^{1A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^2 is heteroaryl which is unfused or fused with benzene, heteroarene or R^{2A}; R^{2A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^3 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{3A}; R^{3A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^4 is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^5, OR^5, SR^5, $S(O)R^5$, SO_2R^5, NH_2, NHR^5, $N(R^5)_2$, $C(O)R^5$, $C(O)NH_2$, $C(O)NHR^5$, $C(O)N(R^5)_2$, $NHC(O)R^5$, $NR^5C(O)R^5$, $NHSO_2R^5$, $NR^5SO_2R^5$, $NHC(O)OR^5$, $NR^5C(O)OR^5$, SO_2NH_2, SO_2NHR^5, $SO_2N(R^5)_2$, $NHC(O)NH_2$, $NHC(O)R^5$, $NHC(O)N(R^5)_2$, $NR^5C(O)N(R^5)_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^5 is R^6, R^7 or R^8;

R^6 is phenyl which is unfused or fused with benzene, heteroarene or R^{6A}; R^{6A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^7 is heteroaryl which is unfused or fused with benzene, heteroarene or R^{7A}; R^{7A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^8 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{8A}; R^{8A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

L^1 is a bond or is alkylene, alkenylene, alkynylene or L^2; and B^1 is C(O)OH or a bioisostere thereof or is $C(O)OR^1$, $C(O)OR^2$, $C(O)OR^3$ or $C(O)OR^4$;

L^2 is C_2-C_6-alkylene, C_4-C_6-alkenylene or C_4-C_6-alkynylene, each of which has one CH_2 moiety replaced with O, S, S(O), SO_2, NH or $N(W^1)$;

W^1 is alkyl, alkenyl or alkynyl;

C^1 and D^1 are independently H, R^9, R^{10}, R^{11}, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, or

one of C^1 and D^1 is H, and the other is R^9, R^{10}, R^{11} R^{12}, $C(O)OR^{12}$, F, Cl, Br, or I;

R^9 is phenyl which is unfused or fused with benzene, heteroarene or R^{9A}; R^{9A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{10} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{10A}; R^{10A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{11} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{11A}; R^{11A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{12} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, NH_2, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHSO_2R^{13}$, $NR^{13}SO_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $NHC(O)NH_2$, $NHC(O)R^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)N(R^{13})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{13} is R^{14}, R^{15} R^{16}, or R^{16A};

R^{14} is phenyl which is unfused or fused with benzene, heteroarene or R^{14A}; R^{14A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused

or fused with R^{14B}; R^{14B} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{15} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{15A}; R^{15A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{16} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{16A}; R^{16A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{16A} is alkyl, alkenyl, or alkynyl; and

one or two or each of E^1 and F^1 and G^1 are independently H, CF_3, F, Cl, Br or I, and the remainder are independently R^{17}, R^{18}, R^{19}, R^{20} or OR^{20};

R^{17} is phenyl which is unfused or fused with benzene, heteroarene or R^{17A}; R^{17A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{18} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{18A}; R^{18A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{19} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{19A}; R^{19A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{20} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{20}, OR^{20}, SR^{20}, $S(O)R^{20}$, SO_2R^{20}, NH_2, NHR^{20}, $N(R^{20})_2$, $C(O)R^{20}$, $C(O)NH_2$, $C(O)NHR^{20}$, $C(O)N(R^{20})_2$, $NHC(O)R^{20}$, $NHC(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NHSO_2R^{20}$, $NR^{20}SO_2R^{20}$, $NHC(O)OR^{20}$, $NR^{20}C(O)OR^{20}$, SO_2NH_2, SO_2NHR^{20}, $SO_2N(R^{20})_2$, $NHC(O)NH_2$, $NHC(O)R^{20}$,

$NHC(O)N(R^{20})_2$, $NR^{20}C(O)N(R^{20})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{20} is R^{21}, R^{22} or R^{23};

R^{21} is phenyl which is unfused or fused with benzene, heteroarene or R^{21A}; R^{21A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

$R^{22}$is heteroaryl which is unfused or fused with benzene, heteroarene or R^{22A}; R^{22A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{23} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{23A}; R^{23A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

wherein each foregoing cyclic moiety is independently unsubstituted or substituted with one or two or three or four or five of independently selected spiroheteroalkyl, R^{30}, OR^{30}, OCH_2R^{30}, SR^{30}, $S(O)R^{30}$, SO_2R^{30}, $C(O)R^{30}$, $CO(O)R^{30}$, $OC(O)R^{30}$, $OC(O)OR^{30}$, NO, NO_2, NH_2, NHR^{30}, $N(R^{30})_2$, CH_2R^{30}, $C(O)NH_2$, $C(O)NHR^{30}$, $C(O)N(R^{30})_2$, $NHC(O)R^{30}$, $NR^{30}C(O)R^{30}$, C(O)NHOH, $C(O)NHOR^{30}$, $C(O)NHSO_2R^{30}$, $C(O)NR^{30}SO_2R^{30}$, SO_2NH_2, SO_2NHR^{30}, $SO_2N(R^{30})_2$, CF_3, CF_2CF_3, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{30}$, $C(N)N(R^{30})_2$, =NO-(alkylene)-$C(O)CF_3$, CNOH, $CNOCH_3$, OH, (O), CN, N_3, CF_3, CF_2CF_3, OCF_3, OCF_2CF_3, F, Cl, Br, or I;

R^{30} is R^{31}, R^{32}, R^{33} or R^{34};

R^{31} is phenyl which is unfused or fused with benzene, heteroarene or R^{31A}; R^{31A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{32} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{32A}; R^{32A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{33} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{33A}; R^{33A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{34} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, NHR^{35}, $N(R^{35})_2$, $C(O)R^{35}$, $C(O)NH_2$, $C(O)NHR^{35}$, $C(O)N(R^{35})_2$, $NHC(O)R^{35}$, $NR^{35}C(O)R^{35}$, $NHSO_2R^{35}$, $NR^{35}SO_2R^{35}$, $NHC(O)OR^{35}$, $NR^{35}C(O)OR^{35}$, SO_2NH_2, SO_2NHR^{35}, $SO_2N(R^{35})_2$, $NHC(O)NH_2$, $NHC(O)R^{35}$ $NHC(O)N(R^{35})_2$, $NR^{35}C(O)N(R^{35})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{35} is R^{36}, R^{37}, R^{38} or R^{39};

R^{36} is phenyl which is unfused or fused with benzene, heteroarene or R^{36A}; R^{36A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{37} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{37A}; R^{37A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{38} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{38A}; R^{38A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{39} is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with NH_2, $N(R^{40})_2$, OR^{40}, or R^{40};

R^{40} is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl;

wherein the moieties represented by R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} and R^{40} are independently unsubstituted or substituted with one or two or three of independently selected R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O) or OH;

R^{50} is R^{51}, R^{52}, R^{53} or R^{54};

R^{51} is phenyl which is unfused or fused with benzene, heteroarene or R^{51A}; R^{51A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{52} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{52A}; R^{52A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;


R^{53} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{53A}; R^{53A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{54} is alkyl, alkenyl, or alkynyl; each of which is unsubstituted or substituted with one, two, three, four or five of independently selected F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O), OH, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl and

wherein the moieties represented by R^{51}, R^{52}, and R^{53} are independently unsubstituted or substituted with one or two or three of independently selected R^{55}, OR^{55}, OCH_2R^{55}, SR^{55}, $S(O)R^{55}$, SO_2R^{55}, $C(O)R^{55}$, $CO(O)R^{55}$, $OC(O)R^{55}$, $OC(O)OR^{55}$, NO_2, NH_2, NHR^{55}, $N(R^{55})_2$, CH_2R^{55}, $C(O)NH_2$, $C(O)NHR^{55}$, $C(O)N(R^{55})_2$, $NHC(O)R^{55}$, $NR^{55}C(O)R^{55}$, C(O)NHOH, $C(O)NHOR^{55}$, $C(O)NHSO_2R^{55}$, $C(O)NR^{55}SO_2R^{55}$, SO_2NH_2, SO_2NHR^{55}, $SO_2N(R^{55})_2$, CF_3, CF_2CF_3, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{55}$, $C(N)N(R^{55})_2$, =NO-(alkylene)-$C(O)CF_3$, CNOH, $CNOCH_3$, OH, (O), CN, N_3, CF_3, CF_2CF_3, OCF_3, OCF_2CF_3, F, Cl, Br or I; and

R^{55} is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl.

Another embodiment pertains to compounds having Formula I,



(I),

and therapeutically acceptable salts thereof, wherein

A^1 is A^2, OA^2, SA^2, $S(O)A^2$, SO_2A^2, NH_2, NHA^2, $N(A^2)_2$, $C(O)A^2$, $C(O)NH_2$, $C(O)NHA^2$, $C(O)N(A^2)_2$, $NHC(O)A^2$, $NA^2C(O)A^2$, $NHSO_2A^2$, $NA^2SO_2A^2$, $NHC(O)OA^2$, $NA^2C(O)OA^2$, SO_2NH_2, SO_2NHA^2, $SO_2N(A^2)_2$, $NHC(O)NH_2$, $NHC(O)A^2$ $NHC(O)N(A^2)_2$, $NA^2C(O)N(A^2)_2$ F, Cl, Br, or I;

A^2 is R^1, R^2, R^3, or R^4;

R^1 is phenyl which is unfused or fused with benzene, heteroarene or R^{1A}; R^{1A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^2 is heteroaryl which is unfused or fused with benzene, heteroarene or R^{2A}; R^{2A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^3 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{3A}; R^{3A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^4 is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^5, OR^5, SR^5, $S(O)R^5$, SO_2R^5, NH_2, NHR^5, $N(R^5)_2$, $C(O)R^5$, $C(O)NH_2$, $C(O)NHR^5$, $C(O)N(R^5)_2$, $NHC(O)R^5$, $NR^5C(O)R^5$, $NHSO_2R^5$,

$NR^5SO_2R^5$, $NHC(O)OR^5$, $NR^5C(O)OR^5$, SO_2NH_2, SO_2NHR^5, $SO_2N(R^5)_2$, $NHC(O)NH_2$, $NHC(O)R^5$, $NHC(O)N(R^5)_2$, $NR^5C(O)N(R^5)_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^5 is R^6, R^7 or R^8;

R^6 is phenyl which is unfused or fused with benzene, heteroarene or R^{6A}; R^{6A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^7 is heteroaryl which is unfused or fused with benzene, heteroarene or R^{7A}; R^{7A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^8 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{8A}; R^{8A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

L^1 is a bond or is alkylene, alkenylene, alkynylene or L^2; and B^1 is C(O)OH or a bioisostere thereof or is $C(O)OR^1$, $C(O)OR^2$, $C(O)OR^3$ or $C(O)OR^4$;

L^2 is C_2-C_6-alkylene, C_4-C_6-alkenylene or C_4-C_6-alkynylene, each of which has one CH_2 moiety replaced with O, S, S(O), SO_2, NH or $N(W^1)$;

W^1 is alkyl, alkenyl or alkynyl;

C^1 and D^1 are independently H, R^9, R^{10}, R^{11}, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, or

one of C^1 and D^1 is H, and the other is R^9, R^{10}, R^{11} R^{12}, $C(O)OR^{12}$, F, Cl, Br, or I;

R^9 is phenyl which is unfused or fused with benzene, heteroarene or R^{9A}; R^{9A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{10} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{10A}; R^{10A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{11} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{11A}; R^{11A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{12} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, NH_2, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHSO_2R^{13}$, $NR^{13}SO_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $NHC(O)NH_2$, $NHC(O)R^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)N(R^{13})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{13} is R^{14}, R^{15} R^{16}, or R^{16A};

R^{14} is phenyl which is unfused or fused with benzene, heteroarene or R^{14A}; R^{14A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with R^{14B}; R^{14B} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

$R^{15}$is heteroaryl which is unfused or fused with benzene, heteroarene or R^{15A}; R^{15A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{16} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{16A}; R^{16A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{16A} is alkyl, alkenyl, or alkynyl; and

one or two or each of E^1 and F^1 and G^1 are independently H, CF_3, F, Cl, Br or I, and the remainder are independently R^{17}, R^{18}, R^{19}, R^{20} or OR^{20};

R^{17} is phenyl which is unfused or fused with benzene, heteroarene or R^{17A}; R^{17A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{18} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{18A}; R^{18A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{19} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{19A}; R^{19A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{20} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{20}, OR^{20}, SR^{20}, $S(O)R^{20}$, SO_2R^{20}, NH_2, NHR^{20}, $N(R^{20})_2$, $C(O)R^{20}$, $C(O)NH_2$, $C(O)NHR^{20}$, $C(O)N(R^{20})_2$, $NHC(O)R^{20}$, $NHC(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NHSO_2R^{20}$, $NR^{20}SO_2R^{20}$, $NHC(O)OR^{20}$, $NR^{20}C(O)OR^{20}$, SO_2NH_2, SO_2NHR^{20}, $SO_2N(R^{20})_2$, $NHC(O)NH_2$, $NHC(O)R^{20}$, $NHC(O)N(R^{20})_2$, $NR^{20}C(O)N(R^{20})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{20} is R^{21}, R^{22} or R^{23};

R^{21} is phenyl which is unfused or fused with benzene, heteroarene or R^{21A}; R^{21A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

$R^{22}$is heteroaryl which is unfused or fused with benzene, heteroarene or R^{22A}; R^{22A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{23} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{23A}; R^{23A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

wherein each foregoing cyclic moiety is independently unsubstituted or substituted with one or two or three or four or five of independently selected spiroheteroalkyl, R^{30}, OR^{30}, SO_2R^{30}, $C(O)R^{30}$, NO, NO_2, NH_2, $N(R^{30})_2$, $C(O)NH_2$, $C(O)NHR^{30}$, $NHC(O)R^{30}$, $C(O)NHSO_2R^{30}$, SO_2NH_2, C(O)OH, OH, (O), CN, CF_3, OCF_3, F, Cl, Br, or I;

R^{30} is R^{31}, R^{32}, R^{33} or R^{34};

R^{31} is phenyl which is unfused or fused with benzene, heteroarene or R^{31A}; R^{31A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{32} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{32A}; R^{32A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{33} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{33A}; R^{33A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{34} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, NHR^{35}, $N(R^{35})_2$, $C(O)R^{35}$, $C(O)NH_2$, $C(O)NHR^{35}$, $C(O)N(R^{35})_2$, $NHC(O)R^{35}$, $NR^{35}C(O)R^{35}$, $NHSO_2R^{35}$, $NR^{35}SO_2R^{35}$, $NHC(O)OR^{35}$, $NR^{35}C(O)OR^{35}$, SO_2NH_2, SO_2NHR^{35}, $SO_2N(R^{35})_2$, $NHC(O)NH_2$, $NHC(O)R^{35}$ $NHC(O)N(R^{35})_2$, $NR^{35}C(O)N(R^{35})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{35} is R^{36}, R^{37}, R^{38} or R^{39};

R^{36} is phenyl which is unfused or fused with benzene, heteroarene or R^{36A}; R^{36A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{37} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{37A}; R^{37A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{38} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{38A}; R^{38A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{39} is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with NH_2, $N(R^{40})_2$, OR^{40}, or R^{40};

R^{40} is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl;

wherein the moieties represented by R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} and R^{40} are independently unsubstituted or substituted with one or two or three of independently selected R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O) or OH;

R^{50} is R^{51}, R^{52}, R^{53} or R^{54};

R^{51} is phenyl which is unfused or fused with benzene, heteroarene or R^{51A}; R^{51A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{52} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{52A}; R^{52A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;


R^{53} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{53A}; R^{53A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{54} is alkyl, alkenyl, or alkynyl; each of which is unsubstituted or substituted with one, two, three, four or five of independently selected F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O), OH, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl and

wherein the moieties represented by R^{51}, R^{52}, and R^{53} are independently unsubstituted or substituted with one or two or three of independently selected $CO(O)R^{55}$, C(O)OH, (O), F, Cl, Br or I; and

R^{55} is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl.

Still another embodiment pertains to compounds having formula (I)



(I),

and therapeutically acceptable salts thereof, wherein

A^1 is A^2, OA^2, SA^2, $S(O)A^2$, SO_2A^2, NH_2, NHA^2, $N(A^2)_2$, $C(O)A^2$, $C(O)NH_2$, $C(O)NHA^2$, $C(O)N(A^2)_2$, $NHC(O)A^2$, $NA^2C(O)A^2$, $NHSO_2A^2$, $NA^2SO_2A^2$, $NHC(O)OA^2$, $NA^2C(O)OA^2$, SO_2NH_2, SO_2NHA^2, $SO_2N(A^2)_2$, $NHC(O)NH_2$, $NHC(O)A^2$ $NHC(O)N(A^2)_2$, $NA^2C(O)N(A^2)_2$ F, Cl, Br, or I;

A^2 is R^1, R^2, R^3, or R^4;

R^1 is phenyl which is unfused or fused with benzene, heteroarene or R^{1A}; R^{1A} is cycloalkane, heterocycloalkane or heterocycloalkene;

R^2 is heteroaryl which is unfused or fused with benzene or heteroarene;

R^3 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene;

R^4 is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^5, OR^5, SR^5, $S(O)R^5$, SO_2R^5, NH_2, NHR^5, $N(R^5)_2$, $C(O)R^5$, $C(O)NH_2$, $C(O)NHR^5$, $C(O)N(R^5)_2$, $NHC(O)R^5$, $NR^5C(O)R^5$, $NHSO_2R^5$, $NR^5SO_2R^5$, $NHC(O)OR^5$, $NR^5C(O)OR^5$, SO_2NH_2, SO_2NHR^5, $SO_2N(R^5)_2$, $NHC(O)NH_2$, $NHC(O)R^5$, $NHC(O)N(R^5)_2$, $NR^5C(O)N(R^5)_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^5 is R^6, R^7 or R^8;

R^6 is phenyl which is unfused or fused with benzene;

R^7 is heteroaryl;

R^8 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;

L^1 is a bond or is alkylene, alkenylene, alkynylene or L^2; and B^1 is C(O)OH or a bioisostere thereof or is $C(O)OR^1$, $C(O)OR^2$, $C(O)OR^3$ or $C(O)OR^4$;

L^2 is C_2-C_6-alkylene, C_4-C_6-alkenylene or C_4-C_6-alkynylene, each of which has one CH_2 moiety replaced with O, S, S(O), SO_2, NH or $N(W^1)$;

W^1 is alkyl, alkenyl or alkynyl;

C^1 and D^1 are independently H, R^9, R^{10}, R^{11}, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, or

one of C^1 and D^1 is H, and the other is R^9, R^{10}, R^{11} R^{12}, $C(O)OR^{12}$, F, Cl, Br, or I;

R^9 is phenyl;

R^{10} is heteroaryl;

R^{11} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;

R^{12} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, NH_2, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHSO_2R^{13}$, $NR^{13}SO_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $NHC(O)NH_2$, $NHC(O)R^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)N(R^{13})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{13} is R^{14}, R^{15} R^{16}, or R^{16A};

R^{14} is phenyl which is unfused or fused with benzene, heteroarene or R^{14A}; R^{14A} is cycloalkane, or heterocycloalkane; each of which is unfused or fused with R^{14B}; R^{14B} is cycloalkane;

$R^{15}$is heteroaryl which is unfused or fused with benzene or heteroarene;

R^{16} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene;

R^{16A} is alkyl, alkenyl, or alkynyl; and

one or two or each of E^1 and F^1 and G^1 are independently H, CF_3, F, Cl, Br or I, and the remainder are independently R^{17}, R^{18}, R^{19}, R^{20} or OR^{20};

R^{17} is phenyl which is unfused or fused with benzene;

R^{18} is heteroaryl;

R^{19} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;

R^{20} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{20}, OR^{20}, SR^{20}, $S(O)R^{20}$, SO_2R^{20}, NH_2, NHR^{20}, $N(R^{20})_2$, $C(O)R^{20}$, $C(O)NH_2$, $C(O)NHR^{20}$, $C(O)N(R^{20})_2$, $NHC(O)R^{20}$, $NHC(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NHSO_2R^{20}$, $NR^{20}SO_2R^{20}$, $NHC(O)OR^{20}$, $NR^{20}C(O)OR^{20}$, SO_2NH_2, SO_2NHR^{20}, $SO_2N(R^{20})_2$, $NHC(O)NH_2$, $NHC(O)R^{20}$, $NHC(O)N(R^{20})_2$, $NR^{20}C(O)N(R^{20})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{20} is R^{21}, R^{22} or R^{23};

R^{21} is phenyl which is unfused or fused with benzene;

$R^{22}$is heteroaryl;

R^{23} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;

wherein each foregoing cyclic moiety is independently unsubstituted or substituted with one or two or three or four or five of independently selected spiroheteroalkyl, R^{30}, OR^{30}, SO_2R^{30}, $C(O)R^{30}$, NO, NO_2, NH_2, $N(R^{30})_2$, $C(O)NH_2$, $C(O)NHR^{30}$, $NHC(O)R^{30}$, $C(O)NHSO_2R^{30}$, SO_2NH_2, C(O)OH, OH, (O), CN, CF_3, OCF_3, F, Cl, Br, or I;

R^{30} is R^{31}, R^{32}, R^{33} or R^{34};

R^{31} is phenyl which is unfused or fused with benzene;

R^{32} is heteroaryl;

R^{33} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene;

R^{34} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, NHR^{35}, $N(R^{35})_2$, $C(O)R^{35}$, $C(O)NH_2$, $C(O)NHR^{35}$, $C(O)N(R^{35})_2$, $NHC(O)R^{35}$, $NR^{35}C(O)R^{35}$, $NHSO_2R^{35}$, $NR^{35}SO_2R^{35}$, $NHC(O)OR^{35}$, $NR^{35}C(O)OR^{35}$, SO_2NH_2, SO_2NHR^{35}, $SO_2N(R^{35})_2$, $NHC(O)NH_2$, $NHC(O)R^{35}$ $NHC(O)N(R^{35})_2$, $NR^{35}C(O)N(R^{35})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{35} is R^{36}, R^{37}, R^{38} or R^{39};

R^{36} is phenyl which is unfused or fused with benzene or R^{36A}; R^{36A} is cycloalkene;

R^{37} is heteroaryl which is unfused or fused with benzene;

R^{38} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene;

R^{39} is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with NH_2, $N(R^{40})_2$, OR^{40}, or R^{40};

R^{40} is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl;

wherein the moieties represented by R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} and R^{40} are independently unsubstituted or substituted with one or two or three of independently selected R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O) or OH;

R^{50} is R^{51}, R^{52}, R^{53} or R^{54};

R^{51} is phenyl;

R^{52} is heteroaryl;


R^{53} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;

R^{54} is alkyl, alkenyl, or alkynyl; each of which is unsubstituted or substituted with one, two, three, four or five of independently selected F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O), OH, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl and

wherein the moieties represented by R^{51}, R^{52}, and R^{53} are independently unsubstituted or substituted with one or two or three of independently selected $CO(O)R^{55}$, C(O)OH, (O), F, Cl, Br or I; and

R^{55} is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl.

Still another embodiment pertains to compounds having formula (I)



(I),

and therapeutically acceptable salts thereof, wherein

A^1 is A^2, NHA^2, $N(A^2)_2$, F, Cl, Br, or I;

A^2 is R^1, R^2, R^3, or R^4;

R^1 is phenyl which is unfused or fused with benzene, heteroarene or R^{1A}; R^{1A} is cycloalkane, heterocycloalkane or heterocycloalkene;

R^2 is heteroaryl which is unfused or fused with benzene or heteroarene;

R^3 is cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene;

R^4 is alkyl or alkenyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^5, OR^5, SR^5, C(O)OH, F, Cl, Br or I;

R^5 is R^6, R^7 or R^8;

R^6 is phenyl which is unfused or fused with benzene;

R^7 is heteroaryl;

R^8 is cycloalkyl;

L^1 is a bond and B^1 is C(O)OH or a bioisostere thereof or is $C(O)OR^4$;

C^1 and D^1 are independently H, R^9, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, or

one of C^1 and D^1 is H, and the other is R^{12}, F, Cl, Br, or I;

R^9 is phenyl;

R^{12} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{13}, OR^{13}, SR^{13}, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)N(R^{13})_2$, C(O)OH, F, Cl, Br or I;

R^{13} is R^{14}, R^{15} R^{16}, or R^{16A};

R^{14} is phenyl which is unfused or fused with benzene, heteroarene or R^{14A}; R^{14A} is cycloalkane, or heterocycloalkane; each of which is unfused or fused with R^{14B}; R^{14B} is cycloalkane;

$R^{15}$is heteroaryl which is unfused or fused with benzene or heteroarene;

R^{16} is cycloalkyl or heterocycloalkyl, each of which is unfused or fused with benzene;

R^{16A} is alkyl; and

one or two or each of E^1 and F^1 and G^1 are independently H, CF_3, F, Cl, Br or I, and the remainder are independently R^{17}, R^{20} or OR^{20};

R^{17} is phenyl which is unfused or fused with benzene;

R^{18} is heteroaryl;

R^{19} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;

R^{20} is alkyl or alkenyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{20}, OR^{20}, F, Cl, Br or I;

R^{20} is R^{21};

R^{21} is phenyl which is unfused or fused with benzene;

wherein each foregoing cyclic moiety is independently unsubstituted or substituted with one or two or three or four or five of independently selected spiroheteroalkyl, R^{30}, OR^{30}, SO_2R^{30}, $C(O)R^{30}$, NO, NO_2, NH_2, $N(R^{30})_2$, $C(O)NH_2$, $C(O)NHR^{30}$, $NHC(O)R^{30}$, $C(O)NHSO_2R^{30}$, SO_2NH_2, C(O)OH, OH, (O), CN, CF_3, OCF_3, F, Cl, Br, or I;

R^{30} is R^{31}, R^{32}, R^{33} or R^{34};

R^{31} is phenyl which is unfused or fused with benzene;

R^{32} is heteroaryl;

R^{33} is cycloalkyl, cycloalkenyl, or heterocycloalkyl, each of which is unfused or fused with benzene;

R^{34} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, $N(R^{35})_2$, $C(O)NHR^{35}$, OH, C(O)OH, F, Cl, Br or I;

R^{35} is R^{36}, R^{37}, R^{38} or R^{39};

R^{36} is phenyl which is unfused or fused with benzene or R^{36A}; R^{36A} is cycloalkene;

R^{37} is heteroaryl which is unfused or fused with benzene;

R^{38} is cycloalkyl, or heterocycloalkyl, each of which is unfused or fused with benzene;

R^{39} is alkyl, each of which is unsubstituted or substituted with NH_2, $N(R^{40})_2$, or OR^{40};

R^{40} is alkyl or phenyl;

wherein the moieties represented by R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} and R^{40} are independently unsubstituted or substituted with one or two or three of independently selected R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, (O) or OH;

R^{50} is R^{51}, R^{52}, R^{53} or R^{54};

R^{51} is phenyl;

R^{52} is heteroaryl;

R^{53} is heterocycloalkyl;

R^{54} is alkyl; each of which is unsubstituted or substituted with one, two, three, four or five of independently selected OH, phenyl, or heteroaryl;

wherein the moieties represented by R^{51} and R^{53} are independently unsubstituted or substituted with one or two or three of independently selected $CO(O)R^{55}$, C(O)OH, (O), F, Cl, Br or I; and

R^{55} is alkyl.

Still another embodiment pertains to compositions comprising an excipient and a therapeutically effective amount of a compound having Formula I.

Still another embodiment pertains to

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-phenylvinyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-phenyl-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((1E)-3-phenylprop-1-enyl)-1H-indole-2-carboxylic acid;

7-((E)-2-cyclohexylvinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-(benzyloxy)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-fluorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-naphthyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-naphthyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,1'-biphenyl-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-fluoro-1,1'-biphenyl-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(benzyloxy)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-pyridin-3-yl-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-pyridin-4-yl-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((1E)-5-phenylpent-1-enyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-carboxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(benzyloxy)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-ethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-ethylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-isopropoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-phenoxyphenyl)-1H-indole-2-carboxylic acid;

7-(2-carboxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-((5,6,7,8-tetrahydronaphthalen-1-yloxy)methyl)phenyl)-1H-indole-2-carboxylic acid;

7-(4-cyclohexylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-chlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-chloropyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,5-dichlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dichlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,3-dimethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,4-dimethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,5-dimethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,6-dimethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methoxypyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methoxypyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-quinolin-4-yl-1H-indole-2-carboxylic acid;

7-(4-hydroxy-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(4-methylpiperazin-1-yl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,4-dichlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methoxyphenyl)-3-(3-((2-methyl-1-naphthyl)oxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-fluoro-2-isopropoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-ethoxy-1-naphthyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-amino-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(((2-(dimethylamino)ethyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-chloro-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,3-dichlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

7-(3-chloro-2-fluorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,3-difluorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-cyclopent-1-en-1-yl-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-cyclohex-1-en-1-yl-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-phenylcyclohex-1-en-1-yl)-1H-indole-2-carboxylic acid;

7-(2-cyclohexylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(6-carboxypyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-methyl-5-nitropyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,3-benzodioxol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((4-chloro-1-naphthyl)oxy)propyl)-7-(2-methoxyphenyl)-1H-indole-2-carboxylic acid;

3-(3-(2-bromophenoxy)propyl)-7-(2-methoxyphenyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-4-(((2-morpholin-4-ylethyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-methylquinolin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(hydroxymethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-(hydroxymethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

5-chloro-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-methylpyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,6-dimethylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(6-amino-2-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-piperazin-1-ylphenyl)-1H-indole-2-carboxylic acid;

7-(4-(3-chlorophenyl)piperazin-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

5-chloro-3-(3-(1-naphthyloxy)propyl)-7-phenyl-1H-indole-2-carboxylic acid;

5-chloro-7-(4-chloro-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

5-chloro-7-cyclopent-1-en-1-yl-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dichloropyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-(aminocarbonyl)pyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-amino-2-(trifluoromethoxy)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-carboxy-2-methoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-nitrophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-carboxy-2-chlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-benzyl-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-amino-2-(trifluoromethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,4-dioxa-8-azaspiro(4.5)dec-8-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-carboxypiperidin-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxypiperidin-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-pyrrolidin-1-yl-1H-indole-2-carboxylic acid;

7-morpholin-4-yl-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-piperidin-1-yl-1H-indole-2-carboxylic acid;

7-(4-(aminosulfonyl)-2-(trifluoromethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

4-(2-(ethoxycarbonyl)-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoic acid;

7-(2-methyl-4-(morpholin-4-ylcarbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-((4-carboxypiperidin-1-yl)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-((3-carboxypiperidin-1-yl)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(carboxymethylcarbamoyl)-2-methylphenyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3,4-dihydroquinolin-1(2H)-yl)propyl)-7-(2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(3-phenoxyphenoxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(2,3-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylbenzyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3,3'-bis(3-(1-naphthyloxy)propyl)-1H,1'H-7,7'-biindole-2,2'-dicarboxylic acid;

3-(4-(3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(4-(3,4-dihydroquinolin-1(2H)-yl)butyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(4-(1-naphthyl)butyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(4-(1-naphthyloxy)butyl)-1H-indole-2-carboxylic acid;

3-(3-(2,4-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(2,5-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(1,1'-biphenyl-2-yl)-3-(4-(1-naphthyloxy)butyl)-1H-indole-2-carboxylic acid;

7-(4-((2-carboxypiperidin-1-yl)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-((S)-1-carboxy-2-methylpropylcarbamoyl)-2-methylphenyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

N-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-4-chlorophenylalanine;

N-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-L-tryptophan;

(3S)-2-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;

N-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-L-tyrosine;

7-(4-((R)-2-carboxypyrrolidine-1-carbonyl)-2-methylphenyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-((S)-1-carboxyethylcarbamoyl)-2-methylphenyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

N-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-4-nitro-L-phenylalanine;

N-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-L-phenylalanine;

7-(4-((((S)-carboxy(phenyl)methyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2,4,5-trichlorophenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2,3,4-trichlorophenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(2-tert-butylphenoxy)propyl)-7-(4-carboxy-2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2-(trifluoromethyl)phenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(quinolin-8-yloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-((5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)oxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3-benzoylphenoxy)propyl)-7-(4-carboxy-2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-1-(2-morpholin-4-ylethyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(cyclohexyloxy)phenyl)-3-(4-(1-naphthyloxy)butyl)-1H-indole-2-carboxylic acid;

7-(1,1'-biphenyl-2-yl)-1-(2-morpholin-4-ylethyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3,4-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(3,5-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(2,3-dimethoxyphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthylamino)propyl)-1H-indole-2-carboxylic acid;

1-(carboxymethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3-(dimethylamino)phenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(4-(3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(2-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(6-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(ethyl(1-naphthyl)amino)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(2,3-dihydro-1H-indol-1-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(2-methyl-2,3-dihydro-1H-indol-1-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-3-(4-(5-nitro-2,3-dihydro-1H-indol-1-yl)butyl)-1H-indole-2-carboxylic acid;

3-(4-(5-bromo-2,3-dihydro-1H-indol-1-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(2,3,6-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(2,3-dichlorophenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(5-(5,6,7,8-tetrahydronaphthalen-1-yloxy)pentyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(5-(1-naphthyloxy)pentyl)-1H-indole-2-carboxylic acid;

7-(2,3-dimethylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-(4-fluorophenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-(2-(2-oxopyrrolidin-1-yl)ethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(tert-butoxycarbonyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)benzyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)benzyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-((E)-2-phenylvinyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(1-naphthyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(2-naphthyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(3-(2-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(4-(1-naphthyloxy)butyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(4-(2-naphthyloxy)butyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(2-(2-naphthyl)ethyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-thien-3-yl-1H-indole-2-carboxylic acid;

7-((3-(aminocarbonyl)phenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((3-cyanophenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((2-benzylphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,1'-biphenyl-2-ylamino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((2-ethylphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((2-propylphenyl)amino)-1H-indole-2-carboxylic acid;

7-(5-carboxy-3-methylthien-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((2-carboxyphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((3-carboxyphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-morpholin-4-yl-5-nitropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-amino-2-morpholin-4-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((3-chloropyridin-4-yl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((2-isopropylphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-morpholin-4-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-(aminocarbonyl)-1,2-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-cyano-1,2-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-amino-4-chloro-2-morpholin-4-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

2-methyl-3'-(3-(1-naphthyloxy)propyl)-2,3-dihydro-1'H-1,7'-biindole-2'-carboxylic acid;

7-(2-fluoro-5-methylpyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((2-methoxypyridin-3-yl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-oxo-1,2-dihydropyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(2-pyrrolidin-1-ylethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(dimethylamino)-5-nitropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(2-(dimethylamino)ethoxy)-5-methylpyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(2-morpholin-4-ylethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(1,4-dioxa-8-azaspiro(4.5)dec-8-yl)-5-nitropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(5-nitro-2-(4-oxopiperidin-1-yl)pyridin-3-yl)-1H-indole-2-carboxylic acid;

7-(5-amino-2-(dimethylamino)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(4-hydroxypiperidin-1-yl)-5-nitropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(6-methoxy-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-fluoro-5-methylpyridin-4-yl)-1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

7-((2-morpholin-4-ylpyridin-3-yl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(2-phenylethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(2-pyridin-3-ylethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((2-morpholin-4-ylphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((4-carboxypyridin-3-yl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((4-(trifluoromethyl)pyridin-3-yl)amino)-1H-indole-2-carboxylic acid;

7-(2-(3-aminopropoxy)-5-methylpyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(tetrahydrofuran-3-ylmethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(4-phenylbutoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(3-methoxyphenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-(carboxymethyl)-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-benzyl-1H-imidazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(2-methylphenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-(2-morpholin-4-ylethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-nitrophenyl)cyclohex-1-en-1-yl)-1H-indole-2-carboxylic acid;

7-(4,4-dimethyl-2-phenylcyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-ethyl-7-(ethyl(phenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-anilino-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(tetrahydro-2H-pyran-3-ylmethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(2-(2-oxopyrrolidin-1-yl)ethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(2-(4-methylpiperazin-1-yl)ethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(2-oxocyclohexyl)pyridin-3-yl)-1H-indole-2-carboxylic acid;

7-(2-fluoro-5-methylpyridin-4-yl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5,5-dimethyl-2-phenylcyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(pyridin-3-ylamino)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(phenyl(propyl)amino)-1-propyl-1H-indole-2-carboxylic acid;

7-(3-cyclohex-1-en-1-ylpyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-pyridin-3-ylcyclohex-1-en-1-yl)-1H-indole-2-carboxylic acid;

3-(3-((8-chloroquinazolin-4-yl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

1-butyl-7-(butyl(phenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(7-chloro-1H-pyrrolo(2,3-c)pyridin-1-yl)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(3-cyclohexylpyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1-(1,3-thiazol-5-ylmethyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)-1H-indole-2-carboxylic acid;

7-(1-(3,3-dimethyl-2-oxobutyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-cyclohex-1-en-1-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-(3,5-difluorobenzyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1-phenylvinyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1H-pyrrolo(2,3-c)pyridin-7-yl)-1H-indole-2-carboxylic acid;

7-(4-cyclohexylpyridin-3-yl)-3-(3-phenoxypropyl)-1H-indole-2-carboxylic acid;

7-(2,4-dimethyl-1,3-thiazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-(carboxymethyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1-phenylethyl)-1H-indole-2-carboxylic acid;

7-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(2-chlorophenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-1H,1'H-7,7'-biindole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1-(2-(2-oxopyrrolidin-1-yl)ethyl)-1H-pyrrolo(2,3-c)pyridin-7-yl)-1H-indole-2-carboxylic acid;

7-(5-methyl-3-phenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(2-(1-naphthyloxy)ethyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(2-(2-naphthyloxy)ethyl)-1H-indole-2-carboxylic acid;

4-(2-(2,3-dichlorophenoxy)ethyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(1H-indol-4-yloxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

4-(2-(2-chloro-3-(trifluoromethyl)phenoxy)ethyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

1-methyl-3-(3-((1-methyl-1H-indol-4-yl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-(4-ethylphenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(4-isopropylphenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-((3-methyloxetan-3-yl)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-tetrahydrofuran-3-yl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-pyridin-2-yl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-chloro-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-(2-(2-oxopyrrolidin-1-yl)ethoxy)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-(tetrahydrofuran-3-ylmethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-cyclopentyl-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-(2-morpholin-4-ylethoxy)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-morpholin-4-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-chloro-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-(2,3-dihydroxypropyl)-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(3-phenyl-5-(2-phenylethyl)-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-phenylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-vinylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-((1E)-prop-1-enyl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-(pyridin-3-ylmethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-isopropenyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-pentylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-propylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-isopropyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-diisopropyl-1-methyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-carboxy-1,3-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-(2-methylprop-1-enyl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-1-phenyl-1H-pyrazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-isobutyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2,3'-bipyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(4-methoxyphenyl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-(hydroxymethyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-bromo-7-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

7-(1,3-dimethyl-5-(phenoxymethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-methyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-bromo-7-(2-((E)-2-cyclohexylvinyl)-4-methylpyridin-3-yl)-1H-indole-2-carboxylic acid;

7-(3-isopropyl-1-methyl-5-(phenoxymethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,5-dimethyl-3-(phenoxymethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(anilinocarbonyl)-1-phenyl-1H-pyrazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-((3-chlorophenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,5-dimethyl-3-((3-phenoxyphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-bromo-4-(2-((4-bromo-1-naphthyl)oxy)ethyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(1,5-dimethyl-3-((4-morpholin-4-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-(((5-chloropyridin-3-yl)oxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-(2-nitrophenyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((2-(phenylthio)ethyl)amino)-1H-indole-2-carboxylic acid;

7-(3-((2-cyanophenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-((4-(4-acetylpiperazin-1-yl)phenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-bromo-7-(2-methylphenyl)-4-(2-(1-naphthyloxy)ethyl)-1H-indole-2-carboxylic acid;

7-(1-(2-aminophenyl)-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-(1H-imidazol-1-ylmethyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(2-(1-naphthyloxy)ethyl)-3-vinyl-1H-indole-2-carboxylic acid;

7-(4-((benzylamino)carbonyl)-1-phenyl-1H-pyrazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1-phenyl-4-(((3-pyrrolidin-1-ylpropyl)amino)carbonyl)-1H-pyrazol-5-yl)-1H-indole-2-carboxylic acid;

7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(1,3-thiazol-4-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-chloro-4-((4-morpholin-4-ylphenoxy)methyl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-isopropyl-1-methyl-3-((4-morpholin-4-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-isopropyl-1-methyl-5-((4-morpholin-4-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-isopropenyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid;

7-(1,5-dimethyl-3-((4-morpholin-4-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-((4-morpholin-4-ylphenoxy)methyl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-pyrimidin-5-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-6'-morpholin-4-yl-2,3'-bipyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid;

7-(4,6-dimethylpyrimidin-5-yl)-1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)-2-oxoethyl)-7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-((4-(1,1-dioxidothiomorpholin-4-yl)phenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4,6-dimethylpyrimidin-5-yl)-1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,5-dimethyl-3-((4-piperazin-1-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-((4-(4-acetylpiperazin-1-yl)phenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid;

7-(4,6-dimethylpyrimidin-5-yl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-((4-(4-(tert-butoxycarbonyl)piperazin-1-yl)phenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)ethyl)-7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(4-(1H-pyrazol-1-yl)phenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2,3,4-trifluorophenyl)-1H-indole-2-carboxylic acid;

7-(4-hydroxy-3-methoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(3,4,5-trimethoxyphenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(4-(trifluoromethoxy)phenyl)-1H-indole-2-carboxylic acid;

7-(2-methoxy-5-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-fluoro-4-methoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(4-(5-oxo-2,5-dihydro-1H-pyrazol-3-yl)phenyl)-1H-indole-2-carboxylic acid;

7-(3-(morpholin-4-ylmethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(morpholin-4-ylmethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-isopropoxy-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(4-(1H-pyrazol-5-yl)phenyl)-1H-indole-2-carboxylic acid;

7-(2,5-dimethylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2,4,5-trimethylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(3-(trifluoromethoxy)phenyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-4-propoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-cyanophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2,3,5,6-tetramethylphenyl)-1H-indole-2-carboxylic acid;

7-(3-cyano-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-ethynyl-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-(((3-(dimethylamino)propyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-isopropylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-(((2-(dimethylamino)ethyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-5-(((2-morpholin-4-ylethyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-5-(((3-morpholin-4-ylpropyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-5-(((2-phenylethyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1H-indazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-((((1S,4R)-bicyclo(2.2.1)hept-2-ylmethyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-5-(((3-phenylpropyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-((2-isopropyl-5-methylphenoxy)methyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-chloro-6-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-benzylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2,4,6-triisopropylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1-oxo-2,3-dihydro-1H-inden-4-yl)-1H-indole-2-carboxylic acid;

7-(2-cyclopentylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2',6'-dimethoxy-1,1'-biphenyl-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(5,6,7,8-tetrahydronaphthalen-1-yl)-1H-indole-2-carboxylic acid;

7-(4'-tert-butyl-1,1'-biphenyl-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-fluoro-2-methyl-3-((methylsulfonyl)methyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-(((2-hydroxy-1,1-dimethylethyl)amino)carbonyl)-2,3,4-trimethylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(4-(ethoxycarbonyl)piperazin-1-yl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-6-nitrophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-propionylpiperazin-1-yl)phenyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-6-thien-2-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-(1,3-thiazol-4-ylmethyl)piperazin-1-yl)phenyl)-1H-indole-2-carboxylic acid;

7-(2-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(4-(methylsulfonyl)piperazin-1-yl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-((4-(tert-butoxycarbonyl)piperazin-1-yl)sulfonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-((4-ethylpiperazin-1-yl)sulfonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-((4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)sulfonyl)phenyl)-1H-indole-2-carboxylic acid;

7-(3-((1S,4R)-2-hydroxybicyclo(2.2.1)hept-2-yl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((1E)-1-ethylbut-1-enyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((Z)-2-carboxy-1-pentylvinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5,7-dimethylpyrazolo(1,5-a)pyrimidin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)thien-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-7-(2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

7-(5-(((2-(dimethylamino)ethyl)(pyridin-2-yl)amino)methyl)thien-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-morpholin-4-yl-6-(trifluoromethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methoxy-2-phenyl-1-benzofuran-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

4-fluoro-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

4-fluoro-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-((2-adamantylamino)carbonyl)-6-methylimidazo(1,2-a)pyridin-8-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-(1-adamantyl)-3-carboxy-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(1-hydroxy-4-methoxycyclohexyl)-1-benzothien-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-chloro-3-methyl-1-tetrahydro-2H-pyran-2-yl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2,2,4-trimethyl-1-(phenylsulfonyl)-1,2-dihydroquinolin-3-yl)-1H-indole-2-carboxylic acid;

7-(7,8-dimethyl-2-(1-methyl-1-phenylethyl)imidazo(1,2-a)pyridin-6-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-(4-((2-fluorobenzoyl)amino)phenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-amino-3-(piperidin-1-ylcarbonyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-methyl-1-(2-nitrophenyl)-5-phenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-1-(2-oxo-2-((2-phenylethyl)amino)ethyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(1-adamantyl)imidazo(1,2-a)pyridin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,1-dioxido-1-benzothien-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-cyclohexyl-6-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-methyl-3,5-diphenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((Z)-2-(1H-imidazol-1-yl)-1-phenylvinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-benzyl-2-methyl-4-nitro-1H-imidazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-prop-1-ynylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(phenylethynyl)phenyl)-1H-indole-2-carboxylic acid;

3,7-bis(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)-2-oxoethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-methylbenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(3-methylbenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(4-methylbenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-1-(3-morpholin-4-ylpropyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(1,1'-biphenyl-2-ylmethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(1,1'-biphenyl-3-ylmethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(1,1'-biphenyl-4-ylmethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2,4-dimethylbenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(4-carboxybenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(1,1'-biphenyl-2-ylmethyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(1,1'-biphenyl-3-ylmethyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(1,1'-biphenyl-4-ylmethyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2,4-dimethylbenzyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2,6-dichlorobenzyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(4-carboxybenzyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(6,6-dimethylcyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5,5-dimethylcyclopent-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(7-phenylcyclohept-1-en-1-yl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-tricyclo(4.3.1.1^{3,8})undec-4-en-4-yl-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-phenylcyclohept-1-en-1-yl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2,6,6-trimethylcyclohex-1-en-1-yl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((1R,4R)-1,7,7-trimethylbicyclo(2.2.1)hept-2-en-2-yl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-4-(trifluoromethyl)-1H-indole-2-carboxylic acid;

7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-4-(trifluoromethyl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)ethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,1'-biphenyl-2-ylmethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,1'-biphenyl-3-ylmethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-(2-(1-naphthyloxy)ethyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(phenoxymethyl)benzyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(2-phenoxyethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(3-(2-phenoxyethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(3-phenoxypropyl)phenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(3-(3-phenoxypropyl)phenyl)-1H-indole-2-carboxylic acid;

3-(3-(3-hydroxy-2-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(3-(2-methoxyethoxy)-2-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(1,2-dimethylprop-1-enyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(2-methyl-3-(2-morpholin-4-ylethoxy)phenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(2,3-dichlorophenoxy)propyl)-7-(2-morpholin-4-ylphenyl)-1H-indole-2-carboxylic acid;

1-(2-morpholin-4-ylethyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthylthio)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3-(2-methoxyethoxy)-5-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-morpholin-4-ylphenyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3-methyl-5-(3-morpholin-4-ylpropoxy)phenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(3-(3-cyclohexylpropoxy)-5-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(3-(3-(2-carboxy-1H-indol-3-yl)propoxy)-5-methylphenoxy)propyl)-7-(2-morpholin-4-ylphenyl)-1H-indole-2-carboxylic acid;

7-bromo-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-1H-indole-2-carboxylic acid;

7-(1,1'-bi(cyclohexan)-2-en-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(2,3-dichlorophenoxy)propyl)-7-(1,2-dimethylprop-1-enyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-4-(trifluoromethyl)phenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-fluoro-2-methylphenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methoxy-2-methylphenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid;

6-methyl-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(2,3-dichlorophenoxy)propyl)-7-(2-methylphenyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3,5-dichlorophenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

1-methyl-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-methyl-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(3-(aminomethyl)benzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(3-(aminomethyl)benzyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(2-((E)-2-cyclohexylvinyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(3-carboxyphenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(2-pyridin-3-ylphenyl)vinyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(3-(((phenylsulfonyl)amino)carbonyl)phenyl)ethyl)-1H-indole-2-carboxylic acid;

7-(2-(3-((4-methylpiperidin-1-yl)carbonyl)phenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(3-(((2-pyrrolidin-1-ylethyl)amino)carbonyl)phenyl)ethyl)-1H-indole-2-carboxylic acid;

7-(2-(3-(((2-morpholin-4-ylethyl)amino)carbonyl)phenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(3-(((2-(dimethylamino)ethyl)amino)carbonyl)phenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-(((phenylsulfonyl)amino)carbonyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(2-pyridin-4-ylphenyl)vinyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(3-chlorophenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(3-((cyclohexylamino)carbonyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-(((2-phenoxyethyl)amino)carbonyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(3-(((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)carbonyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(3-((4-benzylpiperidin-1-yl)carbonyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-((4-phenylpiperazin-1-yl)carbonyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(3-((3-methylpiperidin-1-yl)carbonyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(3-(((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)carbonyl)phenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-((E)-2-phenylvinyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(1,1'-biphenyl-3-yl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-((1E)-3-phenylprop-1-enyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(4-((E)-2-phenylvinyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(4-((1E)-3-phenylprop-1-enyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(1,1'-biphenyl-4-yl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(1,1'-biphenyl-3-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(3-(3-phenylpropyl)phenyl)ethyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(2-chlorophenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(1,1'-biphenyl-2-yl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(2-((E)-2-phenylvinyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-phenylethyl)-1H-indole-2-carboxylic acid;

7-(2-(2-chlorophenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(1,1'-biphenyl-4-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-(2-phenylethyl)phenyl)ethyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-(3-phenylpropyl)phenyl)ethyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-((2-cyanoquinolin-8-yl)oxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((2-acetyl-1-benzofuran-7-yl)oxy)propyl)-7-(4-carboxy-2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-((2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)oxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2,3-difluorophenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(3-methyl-2-nitrophenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2-methyl-3-nitrophenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2-chloro-3-(trifluoromethyl)phenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2-fluoro-3-(trifluoromethyl)phenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-chlorophenyl)-3-(3-(ethyl(1-naphthyl)amino)propyl)-1H-indole-2-carboxylic acid;

7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-3-(4-(5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)butyl)-1H-indole-2-carboxylic acid;

7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-3-(4-(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)butyl)-1H-indole-2-carboxylic acid;

3-(4-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(4-(2-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(4-(6-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(4-(8-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(4-(2-methyl-2,3-dihydro-1H-indol-1-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(4-(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)butyl)-1H-indole-2-carboxylic acid;

3-(4-(3-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(4-(3-(hydroxymethyl)-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(4-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

4-methoxy-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(((1R,4S)-8-hydroxy-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-((1R,4S)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((4-methoxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-((2-nitro-1-naphthyl)oxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((3-hydroxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethylisoxazol-4-yl)-3-(3-(2,3,6,7-tetrahydro-1H,5H-pyrido(3,2,1-ij)quinolin-8-yloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(2,3,6,7-tetrahydro-1H,5H-pyrido(3,2,1-ij)quinolin-8-yloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-((2-nitroso-1-naphthyl)oxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((5-hydroxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(2,3,4-trifluorophenoxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3-chloro-2-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-((8-hydroxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(3-chloro-2-cyanophenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(2-bromo-3-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(3-methyl-2-vinylphenoxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3-methyl-2-nitrophenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(2-amino-3-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((6-amino-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1,2,3,4-tetrahydronaphthalen-1-yloxy)prop-1-ynyl)-1H-indole-2-carboxylic acid;

3-(3-((6-(acryloylamino)-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-((6-(propionylamino)-1-naphthyl)oxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1,2,3,4-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((6-methoxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

1-(4-methoxybenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)prop-1-ynyl)-1H-indole-2-carboxylic acid;

3-(3-((2,3,4,5,6,7,8-heptafluoro-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-benzothien-7-yloxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-((4-fluoro-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-((8-fluoro-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-((5-fluoro-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-fluoro-3-(2-isopropylphenyl)-1-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-fluoro-3-(2-methylphenyl)-1-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((5-fluoro-1-naphthyl)oxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-2-(1H-tetraazol-5-yl)-1H-indole;

1-(4-methoxybenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-2-(1H-tetraazol-5-yl)-1H-indole;

7-(1-methyl-1H-imidazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

7-(4,6-dimethylpyrimidin-5-yl)-1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)ethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

7-(2-methylimidazo(1,2-a)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-((1-(pyridin-4-ylmethyl)pyridinium-4-yl)methyl)-1H-indole-2-carboxylate;

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)-2-oxoethyl)-7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)ethyl)-7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-((4-(4-carboxyphenyl)piperazin-1-yl)methyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-piperazin-1-ylpyridin-3-yl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)-2-oxoethyl)-7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;


7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(2-oxo-2-piperazin-1-ylethyl)-1H-indole-2-carboxylic acid;

and therapeutically acceptable salts, prodrugs, esters, amides, salts of prodrugs, salts of esters, and salts of amides thereof.

Still another embodiment pertains to methods for treating mammals having a disease characterized by overexpression or unregulation of Mcl-1 protein comprising administering thereto a therapeutically effective amount of a compound having Formula I,



(I),

and therapeutically acceptable salts thereof, wherein

A^1 is A^2, OA^2, SA^2, $S(O)A^2$, SO_2A^2, NH_2, NHA^2, $N(A^2)_2$, $C(O)A^2$, $C(O)NH_2$, $C(O)NHA^2$, $C(O)N(A^2)_2$, $NHC(O)A^2$, $NA^2C(O)A^2$, $NHSO_2A^2$, $NA^2SO_2A^2$, $NHC(O)OA^2$, $NA^2C(O)OA^2$, SO_2NH_2, SO_2NHA^2, $SO_2N(A^2)_2$, $NHC(O)NH_2$, $NHC(O)A^2$ $NHC(O)N(A^2)_2$, $NA^2C(O)N(A^2)_2$;

A^2 is R^1, R^2, R^3, R^4,

R^1 is phenyl which is unfused or fused with benzene, heteroarene or R^{1A}; R^{1A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^2 is heteroaryl which is unfused or fused with benzene, heteroarene or R^{2A}; R^{2A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^3 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{3A}; R^{3A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^4 is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^5, OR^5, SR^5, $S(O)R^5$, SO_2R^5, NH_2, NHR^5, $N(R^5)_2$, $C(O)R^5$, $C(O)NH_2$, $C(O)NHR^5$, $C(O)N(R^5)_2$, $NHC(O)R^5$, $NR^5C(O)R^5$, $NHSO_2R^5$, $NR^5SO_2R^5$, $NHC(O)OR^5$, $NR^5C(O)OR^5$, SO_2NH_2, SO_2NHR^5, $SO_2N(R^5)_2$, $NHC(O)NH_2$, $NHC(O)R^5$, $NHC(O)N(R^5)_2$, $NR^5C(O)N(R^5)_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^5 is R^6, R^7 or R^8;

R^6 is phenyl which is unfused or fused with benzene, heteroarene or R^{6A}; R^{6A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^7 is heteroaryl which is unfused or fused with benzene, heteroarene or R^{7A}; R^{7A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^8 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{8A}; R^{8A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

L^1 is a bond or is alkylene, alkenylene, alkynylene or L^2; and B^1 is C(O)OH or a bioisostere thereof or is $C(O)OR^1$, $C(O)OR^2$, $C(O)OR^3$ or $C(O)OR^4$;

L^2 is C_2-C_6-alkylene, C_4-C_6-alkenylene or C_4-C_6-alkynylene, each of which has one CH_2 moiety replaced with O, S, S(O), SO_2, NH or $N(W^1)$;

W^1 is alkyl, alkenyl or alkynyl:

C^1 and D^1 are independently H, R^9, R^{10}, R^{11} or R^{12}; or

one of C^1 and D^1 is H, and the other is R^9, R^{10}, R^{11} or R^{12};

R^9 is phenyl which is unfused or fused with benzene, heteroarene or R^{9A}; R^{9A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{10} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{10A}; R^{10A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{11} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{11A}; R^{11A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{12} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, NH_2, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHSO_2R^{13}$, $NR^{13}SO_2R^{13}$, $NHC(O)OR^{13}$,

$NR^{13}C(O)OR^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $NHC(O)NH_2$, $NHC(O)R^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)N(R^{13})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{13} is R^{14}, R^{15} or R^{16};

R^{14} is phenyl which is unfused or fused with benzene, heteroarene or R^{14A}; R^{14A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

$R^{15}$is heteroaryl which is unfused or fused with benzene, heteroarene or R^{15A}; R^{15A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{16} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{16A}; R^{16A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and

one or two or each of E^1 and F^1 and G^1 are independently H, F, Cl, Br or I, and the remainder are independently R^{17}, R^{18}, R^{19} or R^{20};

R^{17} is phenyl which is unfused or fused with benzene, heteroarene or R^{17A}; R^{17A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{18} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{18A}; R^{18A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{19} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{19A}; R^{19A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{20} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{21}, OR^{20}, SR^{20}, $S(O)R^{20}$, SO_2R^{20},

NH_2, NHR^{20}, $N(R^{20})_2$, $C(O)R^{20}$, $C(O)NH_2$, $C(O)NHR^{20}$, $C(O)N(R^{20})_2$, $NHC(O)R^{20}$, $NHC(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NHSO_2R^{20}$, $NR^{20}SO_2R^{20}$, $NHC(O)OR^{20}$, $NR^{20}C(O)OR^{20}$, SO_2NH_2, SO_2NHR^{20}, $SO_2N(R^{20})_2$, $NHC(O)NH_2$, $NHC(O)R^{20}$, $NHC(O)N(R^{20})_2$, $NR^{20}C(O)N(R^{20})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{20} is R^{21}, R^{22} or R^{23};

R^{21} is phenyl which is unfused or fused with benzene, heteroarene or R^{21A}; R^{21A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

$R^{22}$is heteroaryl which is unfused or fused with benzene, heteroarene or R^{22A}; R^{22A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{23} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{23A}; R^{23A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

wherein each foregoing cyclic moiety is independently unsubstituted or substituted with one or two or three or four or five of independently selected spiroheteroalkyl, R^{30}, OR^{30}, OCH_2R^{30}, SR^{30}, $S(O)R^{30}$, SO_2R^{30}, $C(O)R^{30}$, $CO(O)R^{30}$, $OC(O)R^{30}$, $OC(O)OR^{30}$, NO_2, NH_2, NHR^{30}, $N(R^{30})_2$, CH_2R^{30}, $C(O)NH_2$, $C(O)NHR^{30}$, $C(O)N(R^{30})_2$, $NHC(O)R^{30}$, $NR^{30}C(O)R^{30}$, C(O)NHOH, $C(O)NHOR^{30}$, $C(O)NHSO_2R^{30}$, $C(O)NR^{30}SO_2R^{30}$, SO_2NH_2, SO_2NHR^{30}, $SO_2N(R^{30})_2$, CF_3, CF_2CF_3, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{30}$, $C(N)N(R^{30})_2$, =NO-(alkylene)-$C(O)CF_3$, CNOH, $CNOCH_3$, OH, (O), N_3, CF_3, CF_2CF_3, OCF_3, OCF_2CF_3, F, Cl, Br or I;

R^{30} is R^{31}, R^{32}, R^{33} or R^{34};

R^{31} is phenyl which is unfused or fused with benzene, heteroarene or R^{31A}; R^{31A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{32} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{32A}; R^{32A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{33} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{33A}; R^{33A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{34} is alkyl, alkenyl, or alkenyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, NHR^{35}, $N(R^{35})_2$, $C(O)R^{35}$, $C(O)NH_2$, $C(O)NHR^{35}$, $C(O)N(R^{35})_2$, $NHC(O)R^{35}$, $NR^{35}C(O)R^{35}$, $NHSO_2R^{35}$, $NR^{35}SO_2R^{35}$, $NHC(O)OR^{35}$, $NR^{35}C(O)OR^{35}$, SO_2NH_2, SO_2NHR^{35}, $SO_2N(R^{35})_2$, $NHC(O)NH_2$, $NHC(O)R^{35}$ $NHC(O)N(R^{35})_2$, $NR^{35}C(O)N(R^{35})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{35} is R^{36}, R^{37}, R^{38} or R^{39};

R^{36} is phenyl which is unfused or fused with benzene, heteroarene or R^{36A}; R^{36A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{37} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{37A}; R^{37A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{38} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{38A}; R^{38A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{39} is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with R^{40};

R^{40} is phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl;

wherein the moieties represented by R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} and R^{40} are independently unsubstituted or substituted with one or two or three of independently selected R^{50}, F, Cl, Br, I, C(O)OH, NO_2, NH_2, CF_3, (O) or OH;

R^{50} is R^{51}, R^{52}, R^{53} or R^{54};

R^{51} is phenyl which is unfused or fused with benzene, heteroarene or R^{51A}; R^{51A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{52} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{52A}; R^{52A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{53} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{53A}; R^{53A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and

R^{54} is alkyl, alkenyl, or alkynyl,

with or without administering one or more than one additional therapeutic agents and with or without also administering radiotherapy thereto.

Still another embodiment comprises methods of treating mammals having a disease characterized by overexpression or unregulation of Mcl-1 protein comprising administering thereto therapeutically effective amounts of a compound having Formula I and one or more than one additional therapeutic agents, with or without also administering radiotherapy thereto.

DETAILED DESCRIPTION OF THE INVENTION

Variable moieties of compounds herein are represented by identifiers (capital letters with numerical and/or alphabetical superscripts) and may be specifically embodied.

It is meant to be understood that proper valences are maintained for all combinations herein, that monovalent moieties having more than one atom are attached through their left ends, and that divalent moieties are drawn from left to right.

It is also meant to be understood that a specific embodiment of a variable moiety may be the same or different as another specific embodiment having the same identifier.

The term "alkenyl," as used herein, means monovalent, straight or branched chain hydrocarbon moieties having one or more than one carbon-carbon double bonds, such as C_2-alkenyl, C_3-alkenyl, C_4-alkenyl, C_5-alkenyl, C_6-alkenyl and the like.

The term "alkenylene," as used herein, means divalent, straight or branched chain hydrocarbon moieties having one or more than one carbon-carbon double bonds, such as C_2-alkenylene, C_3-alkenylene, C_4-alkenylene, C_5-alkenylene, C_6-alkenylene and the like.

The term "alkyl," as used herein, means monovalent, saturated, straight or branched chain hydrocarbon moieties, such as C_1-alkyl, C_2-alkyl, C_3-alkyl, C_4-alkyl, C_5-alkyl, C_6-alkyl and the like.

The term "alkylene," as used herein, means divalent, saturated, straight or branched chain hydrocarbon moieties, such as C_1-alkylene, C_2-alkylene, C_3-alkylene, C_4-alkylene, C_5-alkylene, C_6-alkylene and the like.

The term "alkynyl," as used herein, means monovalent, straight or branched chain hydrocarbon moieties having one or more than one carbon-carbon triple bonds, such as C_2-alkynyl, C_3-alkynyl, C_4-alkynyl, C_5-alkynyl, C_6-alkynyl and the like.

The term "alkynylene," as used herein, means divalent, straight or branched chain hydrocarbon moieties having one or more than one carbon-carbon triple bonds, such as C_2-alkynylene, C_3-alkynylene, C_4-alkynylene, C_5-alkynylene, C_6-alkynylene and the like.

The term "C(O)OH bioisostere, as used herein, means a moiety with a substantially similar physical or chemical property that imparts similar biological properties to the compound having Formula (I). Examples of C(O)OH bioisosteres include monovalent radicals derived from removal of one hydrogen atom from a molecule such as isothiazol-3(2H)-one 1,1-dioxide, isothiazolidin-3-one 1,1-dioxide, 1,2,4-oxadiazol-5(2H)-one, 1,2,5-thiadiazolidin-3-one 1,1-dioxide, 1,2,5-thiadiazol-3-ol, 1,2,4-oxadiazolidine-3,5-dione, 2H-tetraazole and the like.

The term "cycloalkane," as used herein, means saturated cyclic or bicyclic hydrocarbon moieties, such as C_4-cycloalkane, C_5-cycloalkane, C_6-cycloalkane, C_7-cycloalkane, C_8-cycloalkane, C_9-cycloalkane, C_{10}-cycloalkane, C_{11}-cycloalkane, C_{12}-cycloalkane and the like.

The term "cycloalkyl," as used herein, means monovalent, saturated cyclic and bicyclic hydrocarbon moieties, such as C_3-cycloalkyl, C_4-cycloalkyl, C_5-cycloalkyl, C_6-cycloalkyl, C_7- cycloalkyl, C_8-cycloalkyl, C_9-cycloalkyl, C_{10}-cycloalkyl, C_{11}-cycloalkyl, C_{12}-cycloalkyl and the like.

The term "cycloalkene," as used herein, means cyclic and bicyclic hydrocarbon moieties having one or more than one carbon-carbon double bonds, such as C_5-cycloalkene, C_6-cycloalkene, C_7-cycloalkene, C_8-cycloalkene, C_9-cycloalkene, C_{10}-cycloalkene, C_{11}-cycloalkene, C_{12}-cycloalkene and the like.

The term "cycloalkenyl," as used herein, means monovalent, cyclic hydrocarbon moieties having one or more than one carbon-carbon double bonds, such as C_4-cycloalkenyl, C_5-cycloalkenyl, C_6-cycloalkenyl, C_7-cycloalkenyl, C_8-cycloalkenyl, C_9-cycloalkenyl, C_{10}-cycloalkenyl, C_{11}-cycloalkenyl, C_{12}-cycloalkenyl and the like.

The term "heteroarene," as used herein, means furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, 1,3,4-thiadiazole, thiophene, triazine and 1,2,3-triazole.

The term "heteroaryl," as used herein, means furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, 1,2,3-thiadiazoyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thiophenyl, triazinyl and 1,2,3-triazolyl.

The term "heterocycloalkane," as used herein, means cycloalkane having one or two or three CH_2 moieties replaced with independently selected O, S, S(O), SO_2 or NH and one or two CH moieties unreplaced or replaced with N and also means cycloalkane having one or two or three CH_2 moieties unreplaced or replaced with independently selected O, S, S(O), SO_2 or NH and one or two CH moieties replaced with N.

The term "heterocycloalkene," as used herein, means cycloalkene having one or two or three CH_2 moieties replaced with independently selected O, S, S(O), SO_2 or NH and one or two CH moieties unreplaced or replaced with N and also means cycloalkene having one or two or three CH_2 moieties unreplaced or replaced with independently selected O, S, S(O), SO_2 or NH and one or two CH moieties replaced with N.

The term "heterocycloalkyl," as used herein, means cycloalkyl having one or two or three CH_2 moieties replaced with independently selected O, S, S(O), SO_2 or NH and one or two CH moieties unreplaced or replaced with N and also means cycloalkyl having one or two or three CH_2 moieties unreplaced or replaced with independently selected O, S, S(O), SO_2 or NH and one or two CH moieties replaced with N.

The term "heterocycloalkenyl," as used herein, means cycloalkenyl having one or two or three CH_2 moieties replaced with independently selected O, S, S(O), SO_2 or NH and one

or two CH moieties unreplaced or replaced with N and also means cycloalkenyl having one or two or three CH_2 moieties unreplaced or replaced with independently selected O, S, S(O), SO_2 or NH and one or two CH moieties replaced with N.

The term "spiroalkyl," as used herein, means saturated, divalent hydrocarbon moieties having both ends attached to the same carbon atom, such as C_2-spiroalkyl, C_3-spiroalkyl, four C_4- spiroalkyl, C_5-spiroalkyl and the like.

The term "cyclic moiety," as used herein, means benzene, cycloalkane, cycloalkyl, cycloalkene, cycloalkenyl, heteroarene, heteroaryl, heterocycloalkane, heterocycloalkyl, heterocycloalkene, heterocycloalkenyl, phenyl and spiroalkyl.

Compounds of this invention may contain asymmetrically substituted carbon atoms in the R or S configuration, wherein the terms "R" and "S" are as defined in Pure Appl. Chem. (1976) 45, 13-10. Compounds having asymmetrically substituted carbon atoms with equal amounts of R and S configurations are racemic at those atoms. Atoms having excess of one configuration over the other are assigned the configuration in excess, preferably an excess of about 85%-90%, more preferably an excess of about 95%-99%, and still more preferably an excess greater than about 99%. Accordingly, this invention is meant to embrace racemic mixtures, relative and absolute diastereoisomers and the compounds thereof.

Compounds of this invention may also contain carbon-carbon double bonds or carbon-nitrogen double bonds in the Z or E configuration, in which the term "Z" represents the larger two substituents on the same side of a carbon-carbon or carbon-nitrogen double bond and the term "E" represents the larger two substituents on opposite sides of a carbon-carbon or carbon-nitrogen double bond. The compounds of this invention may also exist as a mixture of "Z" and "E" isomers.

Compounds of this invention containing NH, C(O)H, C(O)OH, $C(O)NH_2$, OH or SH moieties may have attached thereto prodrug-forming moieties. The prodrug-forming moieties are removed by metabolic processes and release the compounds having the freed NH, C(O)H, C(O)OH, $C(O)NH_2$, OH or SH in vivo. Prodrugs are useful for adjusting such

pharmacokinetic properties of the compounds as solubility and/or hydrophobicity, absorption in the gastrointestinal tract, bioavailability, tissue penetration, and rate of clearance.

Metabolites of compounds having Formula I, produced by in vitro or in vivo metabolic processes, may also have utility for treating diseases caused or exacerbated by overexpressed or unregulated Mcl-1 protein.

Certain precursor compounds of compounds having Formula I may be metabolized in vitro or in vivo to form compounds having Formula I and may thereby also have utility for treating diseases caused or exacerbated by overexpressed or unregulated Mcl-1 protein.

Compounds having Formula I may exist as acid addition salts, basic addition salts or zwitterions. Salts of compounds having Formula I are prepared during their isolation or following their purification. Acid addition salts are those derived from the reaction of a compound having Formula I with acid. Accordingly, salts including the acetate, adipate, alginate, bicarbonate, citrate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsufonate, digluconate, formate, fumarate, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, phosphate, picrate, propionate, succinate, tartrate, thiocyanate, trichloroacetic, trifluoroacetic, para-toluenesulfonate and undecanoate salts of the compounds having Formula I are meant to be embraced by this invention. Basic addition salts of compounds are those derived from the reaction of the compounds having Formula I with the bicarbonate, carbonate, hydroxide, or phosphate of cations such as lithium, sodium, potassium, calcium and magnesium.

Compounds having Formula I may be administered, for example, bucally, ophthalmically, orally, osmotically, parenterally (intramuscularly, intraperintoneally intrasternally, intravenously, subcutaneously), rectally, topically, transdermally and vaginally.

Therapeutically effective amounts of a compound having Formula I depend on recipient of treatment, disease treated and severity thereof, composition comprising it, time of administration, route of administration, duration of treatment, potency, rate of clearance and

whether or not another drug is co-administered. The amount of a compound having Formula I used to make a composition to be administered daily to a patient in a single dose or in divided doses is from about 0.001 to about 200 mg/kg body weight. Single dose compositions contain these amounts or a combination of submultiples thereof.

Compounds having Formula I may be administered with or without an excipient. Excipients include, for example, encapsulators and additives such as absorption accelerators, antioxidants, binders, buffers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents and mixtures thereof.

Compounds having Formula I may be radiolabeled with a radioactive isotope such as carbon (i.e. ^{13}C), hydrogen (i.e. ^{3}H), nitrogen (i.e. ^{15}N), phosphorus (i.e. ^{32}P), sulfur (i.e. ^{35}S), iodide (i.e. ^{125}I) and the like. Radioactive isotopes may be incorporated into the compounds having Formula I by reacting the same and a radioactive derivitizing agent or by incorporating a radiolabeled intermediate into their syntheses. The radiolabeled compounds of Formula I are useful for both prognostic and diagnostic applications and for in vivo and in vitro imaging.

Compounds having Formula I may be incorporated into devices such as, but not limited to, arterio-venous grafts, billiary stents, by-pass grafts, catheters, central nervous system shunts, coronary stents, drug delivery balloons, peripheral stents and ureteural stents, each of which may be used in areas such as, but not limited to, the vasculature for introduction of a compound having Formula I into selected tissues or organs in the body. One measure of the effectivness of compounds having Formula I is reduction or elimination of device-associated thrombi and complications associated therewith.

Compounds having Formula I can used as a radiosensitizers which enhance the efficacy of radiotherapy. Examples of radiotherapy include, but are not limited to, external beam radiotherapy, teletherapy, brachtherapy and sealed and unsealed source radiotherapy.

Excipients for preparation of compositions comprising a compound having Formula I to be administered orally include, for example, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, carbomers, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, cross-povidone, diglycerides, ethanol, ethyl cellulose, ethyl laureate, ethyl oleate, fatty acid esters, gelatin, germ oil, glucose, glycerol, groundnut oil, hydroxypropylmethyl celluose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate salts, potato starch, povidone, propylene glycol, Ringer's solution, safflower oil, sesame oil, sodium carboxymethyl cellulose, sodium phosphate salts, sodium lauryl sulfate, sodium sorbitol, soybean oil, stearic acids, stearyl fumarate, sucrose, surfactants, talc, tragacanth, tetrahydrofurfuryl alcohol, triglycerides, water and mixtures thereof. Excipients for preparation of compositions comprising a compound having Formula I to be administered ophthalmically or orally include, for example, 1,3-butylene glycol, castor oil, corn oil, cottonseed oil, ethanol, fatty acid esters of sorbitan, germ oil, groundnut oil, glycerol, isopropanol, olive oil, polyethylene glycols, propylene glycol, sesame oil, water and mixtures thereof. Excipients for preparation of compositions comprising a compound having Formula I to be administered osmotically include, for example, chlorofluoro-hydrocarbons, ethanol, water and mixtures thereof. Excipients for preparation of compositions comprising a compound having Formula I to be administered parenterally include, for example, 1,3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, germ oil, groundnut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, U.S.P. or isotonic sodium chloride solution, water and mixtures thereof. Excipients for preparation of compositions comprising a compound having Formula I to be administered rectally or vaginally include, for example, cocoa butter, polyethylene glycol, wax and mixtures thereof.

ASSAY

(Fam)-NoxaCF (6-FAM)-GELEVEFATQLRRFGDKLNF-amide) (SEQ.ID NO. 1) was made on a 433A automated synthesizer (Applied Biosystems, Foster City, CA) using standard Fastmoc™ deprotection/coupling cycles with 0.25 mmol MBHA Rink amide resin (SynPep, Dublin, CA). Cartridges containing N^{α}-Fmoc-amino acids (1 mmol) with side-chain protection (Arg: 2,2,5,7,8-pentamethylchroman-6-sulfonyl; Asp and Glu: tert-butyl ester; Asn, Cys, Gln, and His: trityl; Lys and Trp: tert-butyloxycarbonyl; Ser, Thr,

and Tyr: tert-butyl ether were activated with O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (1 mmol), 1-hydroxybenzotriazole (1 mmol) and diisopropylethylamine (2 mmol) in N-methylpyrrolidone (NMP). The activated amino acid was coupled for 30 minutes following removal of the N-terminal Fmoc group with 20% piperidine in NMP. Labeling was accomplished by suspending the resin-bound, N-terminally deprotected side-chain protected peptide resin (0.04 mmol) and 6-carboxyfluorescein-NHS ester (57 mg) in anhydrous dimethylformamide (2 mL) containing 0.02 mL diisopropylethylamine (DIEA) and shaking at ambient temperature overnight. The resin was drained, washed 3 times with 1:1 dichloromethane/methanol and dried. The labeled resin was cleaved and deprotected by mixing with TFA:water:thioanisole:phenol:3,6-dioxa-1,8-octanedithiol:triisopropylsilane, 80:5:5:5:2.5:2.5 for 3 hours at ambient temperature. Following evaporation under reduced pressure, the crude peptide was recovered by precipitation with ether. The product was purified on a preparative HPLC running Unipoint® analysis software (Gilson, Inc., Middleton, WI) on a 25mm×200mm radial compression column containing Delta-Pak® C_{18} packing (Waters, Inc., Taunton, MA) with a flow rate of 20 mL/min. The peptides were eluted with a linear gradient of 0.1% TFA/water and acetonitrile. Fractions containing the pproduct were combined and lyophilized. The purity of the final products were confirmed by reverse-phase analytical HPLC on a Hewlett-Packard 1050 series system with diode-array and fluorescence detection (Agilent Technologies, Palo Alto, CA) eluted with a linear gradient of 0.1% trifluoroacetic acid/water and acetonitrile on a 4.6 × 250 mm YMC ODS-AQ, 5 μm, 120 Å column (Waters Inc.) to give the product (45.6 mg) as a yellow powder following lyophilization. The identity of the product was confirmed by matrix-assisted laser desorption ionization mass spectrography (MALDI-MS) on a Voyager DE-PRO (Applied Biosystems), m/z 1470.00 and 1448.01 $(M+H)^+$.

A fluorescence polarization assay was used for IC_{50} determination of representative compounds having Formula I against recombinant Mcl-1 protein. Compounds were series diluted in DMSO starting at 10 μM and transferred (5 μL) into a 96 well plate. Then, 120 μL of a mixture containing 10 nM fluorescent Noxa BH3 peptide and 80 nM Mcl-1 protein was added to each well. For each assay, free peptide controls (fluorescent peptide only) and bound peptide controls (fluorescent peptide in the presence of Mcl-1) were included on each assay plate. The plate was mixed on a shaker for 1 minute and incubated at room temperature for an additional 15 minutes. The polarization (in mP) was measured at room

temperature with excitation wavelength at 485 nm and emission wavelength at 530 nm using an Analyst (LJL, Molecular Dynamic, Sunnyvale, CA). The percentage inhibition was calculated by % inhibition = 100 × (1-(mP-mP_f)/ (mP_b-mP_f)) in which mP_f is the free peptide control and mP_b is the bound peptide control. Based on percentage of inhibition, the IC_{50} (inhibitor concentration at which 50% of bound peptide is displaced), obtained by fitting the inhibition data using Prism 3.0 software (Graphpad Software Inc, San Diego, CA). The results are shown in TABLE 1.

TABLE 1

IC_{50}'s (in μM) For Representative Compounds Having Formula I For Inhibition of Mcl-1 protein

< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030

< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	< 0.030
< 0.030	< 0.030	< 0.030	< 0.030	0.030
0.030	0.030	0.030	0.031	0.031
0.031	0.031	0.031	0.031	0.031
0.032	0.032	0.032	0.032	0.032
0.032	0.033	0.033	0.033	0.033
0.033	0.033	0.034	0.034	0.035
0.035	0.035	0.036	0.036	0.037
0.037	0.037	0.037	0.037	0.038
0.038	0.038	0.038	0.038	0.039
0.039	0.039	0.039	0.040	0.040
0.040	0.041	0.041	0.041	0.042
0.042	0.043	0.043	0.043	0.044
0.044	0.044	0.044	0.044	0.044
0.045	0.045	0.045	0.045	0.045
0.045	0.045	0.045	0.046	0.046
0.047	0.047	0.047	0.047	0.047
0.048	0.048	0.048	0.049	0.050
0.050	0.050	0.050	0.051	0.051
0.051	0.051	0.051	0.052	0.052
0.052	0.052	0.052	0.053	0.053
0.053	0.053	0.053	0.054	0.054
0.054	0.054	0.054	0.055	0.056
0.057	0.057	0.057	0.057	0.058
0.058	0.058	0.058	0.058	0.059
0.059	0.059	0.060	0.060	0.060
0.061	0.061	0.062	0.062	0.062
0.063	0.063	0.063	0.064	0.065
0.065	0.065	0.067	0.067	0.067

0.068	0.068	0.069	0.069	0.070
0.071	0.072	0.072	0.072	0.073
0.074	0.074	0.074	0.075	0.076
0.077	0.077	0.078	0.078	0.079
0.079	0.079	0.080	0.080	0.081
0.082	0.083	0.084	0.085	0.085
0.085	0.086	0.086	0.087	0.088
0.089	0.089	0.089	0.090	0.090
0.090	0.090	0.090	0.091	0.091
0.093	0.093	0.095	0.096	0.096
0.097	0.097	0.097	0.098	0.100
0.101	0.101	0.101	0.101	0.103
0.104	0.104	0.105	0.105	0.106
0.106	0.107	0.108	0.108	0.110
0.111	0.112	0.114	0.118	0.119
0.121	0.121	0.122	0.123	0.125
0.127	0.128	0.130	0.132	0.132
0.133	0.134	0.136	0.137	0.137
0.138	0.139	0.143	0.145	0.145
0.148	0.148	0.151	0.154	0.155
0.156	0.156	0.156	0.157	0.163
0.163	0.165	0.165	0.166	0.166
0.168	0.169	0.170	0.173	0.173
0.173	0.174	0.175	0.175	0.176
0.179	0.180	0.180	0.182	0.183
0.185	0.186	0.186	0.186	0.186
0.186	0.187	0.191	0.197	0.200
0.200	0.201	0.203	0.206	0.207
0.208	0.209	0.210	0.212	0.212
0.213	0.215	0.216	0.218	0.219
0.220	0.220	0.222	0.222	0.223
0.224	0.224	0.227	0.228	0.229

0.230	0.232	0.234	0.235	0.235
0.240	0.240	0.241	0.242	0.244
0.245	0.256	0.257	0.261	0.265
0.268	0.271	0.272	0.273	0.273
0.277	0.277	0.279	0.279	0.282
0.282	0.283	0.283	0.288	0.288
0.293	0.300	0.301	0.301	0.316
0.318	0.320	0.322	0.326	0.334
0.338	0.338	0.340	0.340	0.350
0.363	0.370	0.373	0.378	0.378
0.379	0.381	0.383	0.391	0.398
0.399	0.400	0.409	0.430	0.439
0.440	0.440	0.447	0.449	0.459
0.475	0.480	0.482	0.489	0.497
0.502	0.505	0.514	0.525	0.532
0.540	0.545	0.547	0.553	0.558
0.562	0.565	0.566	0.573	0.598
0.601	0.611	0.623	0.628	0.630
0.633	0.635	0.684	0.704	0.716
0.738	0.751	0.757	0.782	0.814
0.820	0.851	0.885	0.886	0.910
0.952	0.973	1.002	1.003	1.026
1.030	1.053	1.085	1.097	1.123
1.145	1.175	1.193	1.246	1.256
1.326	1.349	1.353	1.359	1.364
1.385	1.386	1.491	1.557	1.576
1.591	1.765	1.992	2.019	2.054
2.058	2.121	2.186	2.242	2.336
2.449	2.483	2.570	2.682	2.683
2.694	2.727	2.734	2.757	2.759
2.929	2.962	2.982	3.156	3.373
3.388	3.557	3.586	3.763	3.846

4.743	4.890	4.900	4.946	5.105
5.184	5.199	5.448	5.480	5.539
6.283	6.610	6.760	7.270	7.302
8.638				

These data demonstrate the utility of representative compounds having Formula I as inhibitors of the activity of Mcl-1 protein.

5

These data demonstrate the utility of representative compounds having Formula I as inhibitors of the activity of Mcl-1 protein.

Accordingly, compounds having Formula I are expected to have utility in treatment of 10 diseases during which anti-apopotic Mcl-1 is expressed and also utility in treatment of diseases in which anti-apopotic family protein members having close structural homology to Mcl-1 such as, for example, Bcl-X_L protein, Bcl-2 protein and Bcl-w protein are expressed.

Overexpression of Mcl-1 correlates with resistance to chemotherapy, clinical 15 outcome, disease progression, overall prognosis or a combination thereof in various hematologic and solid tumor types such as acoustic neuroma, acute leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyclocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast 20 cancer (including estrogen-receptor positive breast cancer), bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myleogencous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, 25 endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, gastric carcinoma, germ cell testicular cancer, gestational trophobalstic disease, glioblastoma, head and neck cancer, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate

cancer, leiomyosarcoma, liposarcoma, lung cancer (including small cell lung cancer and non-small cell lung cancer), lymphagioendothelio-sarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (lymphoma, including Diffuse Large B-cell lymphoma, follicular lymphoma Hodgkin's lymphoma and non-Hodgkin's lymphoma), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, peripheral T-cell lymphoma, pinealoma, polycythemia vera, prostate cancer (including hormone-insensitive (refractory) prostate cancer), rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, testicular cancer (including germ cell testicular cancer) thyroid cancer, Waldenström's macroglobulinemia, testicular tumors, uterine cancer, Wilms' tumor and the like.

It is also expected that compounds having Formula I would inhibit growth of cells derived from a pediatric cancer or neoplasm including embryonal rhabdomyosarcoma, pediatric acute lymphoblastic leukemia, pediatric acute myelogenous leukemia, pediatric alveolar rhabdomyosarcoma, pediatric anaplastic ependymoma, pediatric anaplastic large cell lymphoma, pediatric anaplastic medulloblastoma, pediatric atypical teratoid/rhabdoid tumor of the central nervous syatem, pediatric biphenotypic acute leukemia, pediatric Burkitts lymphoma, pediatric cancers of Ewing's family of tumors such as primitive neuroectodermal rumors, pediatric diffuse anaplastic Wilm's tumor, pediatric favorable histology Wilm's tumor, pediatric glioblastoma, pediatric medulloblastoma, pediatric neuroblastoma, pediatric neuroblastoma-derived myelocytomatosis, pediatric pre-B-cell cancers (such as leukemia), pediatric psteosarcoma, pediatric rhabdoid kidney tumor, pediatric rhabdomyosarcoma, and pediatric T-cell cancers such as lymphoma and skin cancer and the like.

Involvement of Mcl-1 in acute lymphoblastic leukemia is reported in Blood 1998, 91, 991-1000.

Involvement of Mcl-1 in acute myelogenous leukemia is also reported in Blood 1998, 91, 991-1000.

Involvement of Mcl-1 in cervical cancer is reported in Cancer Letters (Shannon, Ireland) 2002, 180, 63-68.

Involvement of Mcl-1 in chronic lymphocytic leukemia is reported in Journal of the National Cancer Institute 2004, 96, 673-682 and Immunology 2005, 114, 441-449.

Involvement of Mcl-1 in colorectal cancer, is reported in Annals of oncology: Official Journal of the European Society for Medical Oncology/ESMO 2001, 12, 779-785.

Involvement of Mcl-1 in gastric carcinoma, is reported in Gastric Cancer 2004, 7, 78-84.

Involvement of Mcl-1 in gestational trophobalstic disease is reported in Cancer 2005, 103, 268-276.

Involvement of Mcl-1 in glioblastoma is reported in Journal of Neurology, Neurosurgery, and Psychiatry 1999, 67, 763-768.

Involvement of Mcl-1 in head and neck cancer is reported in Archives of Otolaryngology-Head and Neck Surgery 1999, 125, 417-422.

Involvement of Mcl-1 in lung cancer is reported in Pathology Oncology Research: POR 1999, 5, 179-186.

Involvement of Mcl-1 in mesothioloma, is reported in Clinical Cancer Research 1999, 5, 3508-3515.

Involvement of Mcl-1 in multiple myeloma is reported in European Journal of Immunology 2004, 34, 3156-3164.

Involvement of Mcl-1 in non-Hodgkin's lymphoma is reported in British Journal of Haematology 2002, 116, 158-161.

Involvement of Mcl-1 in oligodenroglioma is reported in Cancer (New York) 1999, 86, 1832-1839.

Involvement of Mcl-1 in ovarian cancer is reported in Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2000, 18, 3775-3781.

Involvement of Mcl-1 in pancreatic cancer is reported in Oncology 2002, 62, 354-362.

Involvement of Mcl-1 in peripheral T-cell lymphoma is reported in Journal of Pathology 2003, 200, 240-248.

Compounds having Formula I are expected to be useful when used with alkylating agents, angiogenesis inhibitors, antibodies, antimetabolites, antimitotics, antiproliferatives, aurora kinase inhibitors, Bcl-2 family protein (for example, Bcl-xL, Bcl-2, Bcl-w, Bfl-1) inhibitors, Bcr-Abl kinase inhibitors, biologic response modifiers, cyclin-dependent kinase inhibitors, cell cycle inhibitors, cyclooxygenase-2 inhibitors, leukemia viral oncogene homolog (ErbB2) receptor inhibitors, growth factor inhibitors, heat shock protein (HSP)-90 inhibitors, histone deacetylase (HDAC) inhibitors inhibitors, hormonal therapies, immunologicals, intercalating antibiotics, kinase inhibitors, mammalian target of rapomycin inhibitors, mitogen-activated extracellular signal-regulated kinase inhibitors, non-steroidal anti-inflammatory drugs (NSAID's), platinum chemotherapeutics, polo-like kinase inhibitors, proteasome inhibitors, purine analogs, pyrimidine analogs, receptor tyrosine kinase inhibitors, retinoids/deltoids plant alkaloids, topoisomerase inhibitors and the like.

Alkylating agents include altretamine, AMD-473, AP-5280, apaziquone, bendamustine, brostallicin, busulfan, carboquone, carmustine (BCNU), chlorambucil, Cloretazine™ (VNP 40101M), cyclophosphamide, decarbazine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, lomustine (CCNU), mafosfamide, melphalan, mitobronitol, mitolactol, nimustine, nitrogen mustard N-oxide, ranimustine, temozolomide, thiotepa, treosulfan, trofosfamide and the like.

Angiogenesis inhibitors include endothelial-specific receptor tyrosine kinase (Tie-2) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, insulin growth factor-2 receptor (IGFR-2) inhibitors, matrix metalloproteinase-2 (MMP-2) inhibitors, matrix metalloproteinase-9 (MMP-9) inhibitors, platelet-derived growth factor receptor (PDGFR) inhibitors, thrombospondin analogs vascular endothelial growth factor receptor tyrosine kinase (VEGFR) inhibitors and the like.

Aurora kinase inhibitors include AZD-1152, MLN-8054, VX-680 and the like.

Bcl protein family member inhibitors include AT-101 ((-)gossypol), GENASENSE® (G3139 or oblimersen (Bcl-2-targeting antisense oglionucleotide)), IPI-194, IPI-565, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide) (ABT-737), N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (ABT-263), GX-070 (obatoclax) and the like.

Bcr-Abl kinase inhibitors include DASATINIB® (BMS-354825), GLEEVEC® (imatinib) and the like.

CDK inhibitors include AZD-5438, BMI-1040, BMS-032, BMS-387, CVT-2584, flavopyridol, GPC-286199, MCS-5A, PD0332991, PHA-690509, seliciclib (CYC-202, R-roscovitine), ZK-304709 and the like.

COX-2 inhibitors include ABT-963, ARCOXIA® (etoricoxib), BEXTRA® (valdecoxib), BMS347070, CELEBREX™ (celecoxib), COX-189 (lumiracoxib), CT-3, DERAMAXX® (deracoxib), JTE-522, 4-methyl-2-(3,4-dimethylphenyl)-1-(4-sulfamoylphenyl-1H-pyrrole), MK-663 (etoricoxib), NS-398, parecoxib, RS-57067, SC-58125, SD-8381, SVT-2016, S-2474, T-614, VIOXX® (rofecoxib) and the like.

EGFR inhibitors include ABX-EGF, anti-EGFr immunoliposomes, EGF-vaccine, EMD-7200, ERBITUX® (cetuximab), HR3, IgA antibodies, IRESSA® (gefitinib), TARCEVA® (erlotinib or OSI-774), TP-38, EGFR fusion protein, TYKERB® (lapatinib) and the like.

ErbB2 receptor inhibitors include CP-724-714, CI-1033 (canertinib), Herceptin® (trastuzumab), TYKERB® (lapatinib), OMNITARG® (2C4, petuzumab), TAK-165, GW-572016 (ionafarnib), GW-282974, EKB-569, PI-166, dHER2 (HER2 vaccine), APC-8024 (HER-2 vaccine), anti-HER/2neu bispecific antibody, B7.her2IgG3, AS HER2 trifunctional bispecfic antibodies, mAB AR-209, mAB 2B-1 and the like.

Histone deacetylase inhibitors include depsipeptide, LAQ-824, MS-275, trapoxin, suberoylanilide hydroxamic acid (SAHA), TSA, valproic acid and the like.

HSP-90 inhibitors include 17-AAG-nab, 17-AAG, CNF-101, CNF-1010, CNF-2024, 17-DMAG, geldanamycin, IPI-504, KOS-953, MYCOGRAB®, NCS-683664, PU24FCl, PU-3, radicicol, SNX-2112, STA-9090 VER49009 and the like.

MEK inhibitors include ARRY-142886, ARRY-438162 PD-325901, PD-98059 and the like.

mTOR inhibitors include AP-23573, CCI-779, everolimus, RAD-001, rapamycin, temsirolimus and the like.

Non-steroidal anti-inflammatory drugs include AMIGESIC® (salsalate), DOLOBID® (diflunisal), MOTRIN® (ibuprofen), ORUDIS® (ketoprofen), RELAFEN® (nabumetone), FELDENE® (piroxicam) ibuprofin cream, ALEVE® and NAPROSYN® (naproxen), VOLTAREN® (diclofenac), INDOCIN® (indomethacin), CLINORIL® (sulindac), TOLECTIN® (tolmetin), LODINE® (etodolac), TORADOL® (ketorolac), DAYPRO® (oxaprozin) and the like.

PDGFR inhibitors include C-451, CP-673, CP-868596 and the like.

Platinum chemotherapeutics include cisplatin, ELOXATIN® (oxaliplatin) eptaplatin, lobaplatin, nedaplatin, PARAPLATIN® (carboplatin), satraplatin and the like.

Polo-like kinase inhibitors include BI-2536 and the like.

Thrombospondin analogs include ABT-510, ABT-567, ABT-898, TSP-1 and the like.

VEGFR inhibitors include AVASTIN® (bevacizumab), ABT-869, AEE-788, ANGIOZYME™, axitinib (AG-13736), AZD-2171, CP-547,632, IM-862, Macugen (pegaptamib), NEXAVAR® (sorafenib, BAY43-9006), pazopanib (GW-786034), (PTK-787, ZK-222584), SUTENT® (sunitinib, SU-11248), VEGF trap, vatalanib, ZACTIMA™ (vandetanib, ZD-6474) and the like.

Antimetabolites include ALIMTA® (premetrexed disodium, LY231514, MTA), 5-azacitidine, XELODA® (capecitabine), carmofur, LEUSTAT® (cladribine), clofarabine, cytarabinc, cytarabine ocfosfate, cytosine arabinoside, decitabine, deferoxamine, doxifluridine, eflornithine, EICAR, enocitabine, ethnylcytidine, fludarabine, hydroxyurea, 5-fluorouracil (5-FU) alone or in combination with leucovorin, GEMZAR® (gemcitabine), hydroxyurea, ALKERAN®(melphalan), mercaptopurine, 6-mercaptopurine riboside, methotrexate, mycophenolic acid, nelarabine, nolatrexed, ocfosate, pelitrexol, pentostatin, raltitrexed, Ribavirin, triapine, trimetrexate, S-1, tiazofurin, tegafur, TS-1, vidarabine, UFT and the like.

Antibiotics include intercalating antibiotics aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, BLENOXANE® (bleomycin), daunorubicin, CAELYX® or MYOCET® (doxorubicin), elsamitrucin, epirbucin, glarbuicin, ZAVEDOS® (idarubicin), mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocin, VALSTAR® (valrubicin), zinostatin and the like.

Topoisomerase inhibitors include aclarubicin, 9-aminocamptothecin, amonafide, amsacrine, becatecarin, belotecan, BN-80915, CAMPTOSAR® (irinotecan hydrochloride),

camptothecin, CARDIOXANE® (dexrazoxine), diflomotecan, edotecarin, ELLENCE® or PHARMORUBICIN® (epirubicin), etoposide, exatecan, 10-hydroxycamptothecin, gimatecan, lurtotecan, mitoxantrone, orathecin, pirarbucin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluposide, topotecan and the like.

Antibodies include AVASTIN® (bevacizumab), CD40-specific antibodies, chTNT-1/B, denosumab, ERBITUX® (cetuximab), HUMAX-CD4® (zanolimumab), IGF1R-specific antibodies, lintuzumab, PANOREX® (edrecolomab), RENCAREX® (WX G250), RITUXAN® (rituximab), ticilimumab, trastuzimab and and the like.

Hormonal therapies include ARIMIDEX® (anastrozole), AROMASIN® (exemestane), arzoxifene, CASODEX® (bicalutamide), CETROTIDE® (cetrorelix), degarelix, deslorelin, DESOPAN® (trilostane), dexamethasone, DROGENIL®, (flutamide), EVISTA® (raloxifene), fadrozole, FARESTON® (toremifene), FASLODEX® (fulvestrant),FEMARA®, (letrozole), formestane, glucocorticoids, HECTOROL® or RENAGEL® (doxercalciferol), lasofoxifene, leuprolide acetate, MEGACE® (megesterol), MIFEPREX® (mifepristone), NILANDRON™ (nilutamide), NOLVADEX® (tamoxifen citrate), PLENAXIS™ (abarelix), predisone, PROPECIA® (finasteride), rilostane, SUPREFACT® (buserelin), TRELSTAR® (luteinizing hormone releasing hormone (LHRH)), vantas, VETORYL®, (trilostane or modrastane), ZOLADEX® (fosrelin, goserelin) and the like.

Deltoids and retinoids include seocalcitol (EB1089, CB1093), lexacalcitrol (KH1060), fenretinide, PANRETIN® (aliretinoin), ATRAGEN® (liposomal tretinoin), TARGRETIN®(bexarotene), LGD-1550 and the like.

Plant alkaloids include, but are not limited to, vincristine, vinblastine, vindesine, vinorelbine and the like.

Proteasome inhibitors include VELCADE® (bortezomib), MG132, NPI-0052, PR-171 and the like.

Examples of immunologicals include interferons and other immune-enhancing agents. Interferons include interferon alpha, interferon alpha-2a, interferon alpha-2b, interferon beta, interferon gamma-1a, ACTIMMUNE® (interferon gamma-1b), or interferon gamma-n1, combinations thereof and the like. Other agents include ALFAFERONE®, BAM-002, BEROMUN® (tasonermin), BEXXAR® (tositumomab), CamPath® (alemtuzumab), CTLA4 (cytotoxic lymphocyte antigen 4), decarbazine, denileukin, epratuzumab, GRANOCYTE® (lenograstim), lentinan, leukocyte alpha interferon, imiquimod, MDX-010, melanoma vaccine, mitumomab, molgramostim, MYLOTARG™ (gemtuzumab ozogamicin), NEUPOGEN® (filgrastim), OncoVAC-CL, OvaRex® (oregovomab), pemtumomab (Y-muHMFG1), PROVENGE®, sargaramostim, sizofilan, teceleukin, TheraCys®, ubenimex, VIRULIZIN®, Z-100, WF-10, PROLEUKIN® (aldesleukin), ZADAXIN® (thymalfasin), ZENAPAX® (daclizumab), ZEVALIN® (90Y-Ibritumomab tiuxetan) and the like.

Biological response modifiers are agents that modify defense mechanisms of living organisms or biological responses, such as survival, growth, or differentiation of tissue cells to direct them to have anti-tumor activity and include include krestin, lentinan, sizofiran, picibanil PF-3512676 (CpG-8954), ubenimex and the like.

Pyrimidine analogs include cytarabine (ara C or Arabinoside C), cytosine arabinoside, doxifluridine, FLUDARA® (fludarabine), 5-FU (5-fluorouracil), floxuridine, GEMZAR® (gemcitabine), TOMUDEX® (ratitrexed), TROXATYL™ (triacetyluridine troxacitabine) and the like.

Purine analogs include LANVIS® (thioguanine) and PURI-NETHOL® (mercaptopurine).

Antimitotic agents include batabulin, epothilone D (KOS-862), N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, ixabepilone (BMS

247550), paclitaxel, TAXOTERE® (docetaxel), PNU100940 (109881), patupilone, XRP-9881, vinflunine, ZK-EPO and the like.

Compounds of the present invention are also intended to be used as a radiosensitizer that enhances the efficacy of radiotherapy. Examples of radiotherapy include, but are not limited to, external beam radiotherapy, teletherapy, brachtherapy and sealed and unsealed source radiotherapy.

Additionally, compounds having Formula I may be combined with other chemptherapeutic agents such as ABRAXANE™ (ABI-007), ABT-100 (farnesyl transferase inhibitor), ADVEXIN®, ALTOCOR® or MEVACOR® (lovastatin), AMPLIGEN® (poly I:poly C12U, a synthetic RNA), APTOSYN™ (exisulind), AREDIA® (pamidronic acid), arglabin, L-asparaginase, atamestane (1-methyl-3,17-dione-androsta-1,4-diene), AVAGE® (tazarotne), AVE-8062, BEC2 (mitumomab), cachectin or cachexin (tumor necrosis factor), canvaxin (vaccine), CeaVac™ (cancer vaccine), CELEUK® (celmoleukin), CEPLENE® (histamine dihydrochloride), CERVARIX™ (human papillomavirus vaccine), CHOP® (C: CYTOXAN® (cyclophosphamide); H: ADRIAMYCIN® (hydroxydoxorubicin); O: Vincristine (ONCOVIN®); P: prednisone), CyPat™, combrestatin A4P, DAB(389)EGF or TransMID-107R™ (diphtheria toxins), dacarbazine, dactinomycin, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), eniluracil, EVIZON™ (squalamine lactate), DIMERICINE® (T4N5 liposome lotion), discodermolide, DX-8951f (exatecan mesylate), enzastaurin, EPO906, GARDASIL® (quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine), gastrimmune, genasense, GMK (ganglioside conjugate vaccine), GVAX® (prostate cancer vaccine), halofuginone, histerelin, hydroxycarbamide, ibandronic acid, IGN-101, IL-13-PE38, IL-13-PE38QQR (cintredekin besudotox), IL-13-pseudomonas exotoxin, interferon-α, interferon-γ, JUNOVAN™ or MEPACT™ (mifamurtide), lonafarnib, 5,10-methylenetetrahydrofolate, miltefosine (hexadecylphosphocholine), NEOVASTAT®(AE-941), NEUTREXIN® (trimetrexate glucuronate), NIPENT® (pentostatin), ONCONASE® (a ribonuclease enzyme), ONCOPHAGE® (melanoma vaccine treatment), OncoVAX (IL-2 Vaccine), ORATHECIN™ (rubitecan), OSIDEM® (antibody-based cell drug), OvaRex® MAb (murine monoclonal antibody), paditaxel, PANDIMEX™ (aglycone saponins from

ginseng comprising 20(S)protopanaxadiol (aPPD) and 20(S)protopanaxatriol (aPPT)), panitumumab, PANVAC®-VF (investigational cancer vaccine), pegaspargase, PEG Interferon A, phenoxodiol, procarbazine, rebimastat, REMOVAB® (catumaxomab), REVLIMID® (lenalidomide), RSR13 (efaproxiral), SOMATULINE® LA (lanreotide), SORIATANE® (acitretin), staurosporine (Streptomyces staurospores), talabostat (PT100), TARGRETIN® (bexarotene), Taxoprexin® (DHA-paclitaxel), TELCYTA™ (TLK286), temilifene, TEMODAR® (temozolomide), tesmilifene, thalidomide, THERATOPE® (STn-KLH), thymitaq (2-amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)quinazoline dihydrochloride), TNFerade™ (adenovector: DNA carrier containing the gene for tumor necrosis factor-α), TRACLEER® or ZAVESCA® (bosentan), tretinoin (Retin-A), tetrandrine, TRISENOX® (arsenic trioxide), VIRULIZIN®, ukrain (derivative of alkaloids from the greater celandine plant), vitaxin (anti-alphavbeta3 antibody), XCYTRIN® (motexafin gadolinium), XINLAY™ (atrasentan), XYOTAX™ (paclitaxel poliglumex), YONDELIS™ (trabectedin), ZD-6126, ZINECARD® (dexrazoxane), zometa (zolendronic acid), zorubicin and the like.

It is also expected that compounds having Formula I would inhibit growth of cells derived from a pediatric cancer or neoplasm including embryonal rhabdomyosarcoma, pediatric acute lymphoblastic leukemia, pediatric acute myelogenous leukemia, pediatric alveolar rhabdomyosarcoma, pediatric anaplastic ependymoma, pediatric anaplastic large cell lymphoma, pediatric anaplastic medulloblastoma, pediatric atypical teratoid/rhabdoid tumor of the central nervous syatem, pediatric biphenotypic acute leukemia, pediatric Burkitts lymphoma, pediatric cancers of Ewing's family of tumors such as primitive neuroectodermal rumors, pediatric diffuse anaplastic Wilm's tumor, pediatric favorable histology Wilm's tumor, pediatric glioblastoma, pediatric medulloblastoma, pediatric neuroblastoma, pediatric neuroblastoma-derived myelocytomatosis, pediatric pre-B-cell cancers (such as leukemia), pediatric psteosarcoma, pediatric rhabdoid kidney tumor, pediatric rhabdomyosarcoma, and pediatric T-cell cancers such as lymphoma and skin cancer and the like (commonly-owned United States Application Serial No. 10/988,338), Cancer Res., 2000, 60, 6101-10); and autoimmune disorders include, acquired immunodeficiency disease syndrome, autoimmune lymphoproliferative syndrome, hemolytic anemia, inflammatory diseases, thrombocytopenia and the like (Current Allergy and Asthma Reports 2003, 3:378-384; Br. J. Haematol. 2000

Sep; 110(3): 584-90; Blood 2000 Feb 15;95(4):1283-92; and New England Journal of Medicine 2004 Sep; 351(14): 1409-1418).

Compounds having Formula I may be made by synthetic chemical processes, examples of which are shown hereinbelow. It is meant to be understood that the order of the steps in the processes may be varied, that reagents, solvents and reaction conditions may be substituted for those specifically mentioned, and that vulnerable moieties such as C(O)OH, C(O) and C(O)H, NH, $C(O)NH_2$, OH and SH moieties may be protected and deprotected, as necessary.

Protecting groups for C(O)OH moieties include, but are not limited to, acetoxymethyl, allyl, benzoylmethyl, benzyl, benzyloxymethyl, tert-butyl, tert-butyldiphenylsilyl, diphenylmethyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropyl, diphenylmethylsilyl, ethyl, para-methoxybenzyl, methoxymethyl, methoxyethoxymethyl, methyl, methylthiomethyl, naphthyl, para-nitrobenzyl, phenyl, n-propyl, 2,2,2-trichloroethyl, triethylsilyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, triphenylmethyl and the like.

Protecting groups for C(O) and C(O)H moieties include, but are not limited to, 1,3-dioxylketal, diethylketal, dimethylketal, 1,3-dithianylketal, O-methyloxime, O-phenyloxime and the like.

Protecting groups for NH moieties include, but are not limited to, acetyl, alanyl, benzoyl, benzyl (phenylmethyl), benzylidene, benzyloxycarbonyl (Cbz), tert-butoxycarbonyl (Boc), 3,4-dimethoxybenzyloxycarbonyl, diphenylmethyl, diphenylphosphoryl, formyl, methanesulfonyl, para-methoxybenzyloxycarbonyl, phenylacetyl, phthaloyl, succinyl, trichloroethoxycarbonyl, triethylsilyl, trifluoroacetyl, trimethylsilyl, triphenylmethyl, triphenylsilyl, para-toluenesulfonyl and the like.

Protecting groups for OH and SH moieties include, but are not limited to, acetyl, allyl, allyloxycarbonyl, benzyloxycarbonyl (Cbz), benzoyl, benzyl, tert-butyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, 3,4-dimethoxybenzyl, 3,4-dimethoxybenzyloxycarbonyl, 1,1-dimethyl-2-propenyl, diphenylmethyl, formyl,


methanesulfonyl, methoxyacetyl, 4-methoxybenzyloxycarbonyl, para-methoxybenzyl, methoxycarbonyl, methyl, para-toluenesulfonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-trichloroethyl, triethylsilyl, trifluoroacetyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-trimethylsilylethyl, triphenylmethyl, 2-(triphenylphosphonio)ethoxycarbonyl and the like.

A discussion protecting groups is provided in T.H. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York (1999).

The following abbreviations have the meanings indicated.

ADDP means 1,1'-(azodicarbonyl)dipiperidine; AD-mix-β means a mixture of $(DHQD)_2PHAL$, $K_3Fe(CN)_6$, K_2CO_3 and K_2SO_4); 9-BBN means 9-borabicyclo(3.3.1)nonane; $(DHQD)_2PHAL$ means hydroquinidine 1,4-phthalazinediyl diethyl ether; DBU means 1,8-diazabicyclo(5.4.0)undec-7-ene; DIBAL means diisobutylaluminum hydride; DIEA means diisopropylethylamine; DMAP means N,N-dimethylaminopyridine; DMF means N,N-dimethylformamide; dmpe means 1,2-bis(dimethylphosphino)ethane; DMSO means dimethylsulfoxide; dppb means 1,4-bis(diphenylphosphino)butane; dppe means 1,2-bis(diphenylphosphino)ethane; dppf means 1,1'-bis(diphenylphosphino)ferrocene; d means 1,1-bis(diphenylphosphino)methane; EDAC means 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide; Fmoc means fluorenylmethoxycarbonyl; HATU means O-(7-azabenzotriazol-1-yl)-N,N'N'N'-tetramethyluronium hexafluorophosphate; HMPA means hexamethylphosphoramide; IPA means isopropyl alcohol; MP-BH_3 means macroporus triethylammonium methylpolystyrene cyanoborohydride; PyBOP means benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate; TEA means triethylamine; TFA means trifluoroacetic acid; THF means tetrahydrofuran; NCS means N-chlorosuccinimide; NMM means N-methylmorpholine; NMP means N-methylpyrrolidine and PPh_3 means triphenylphosphine.

SCHEME 1



As shown in SCHEME 1, compounds of Formula (1) can be converted to compounds of Formula (2) by reacting the former with sodium nitrate and an aqueous acid followed by the addition of aqueous sodium acetate and an appropriate 2-oxocycloalkylester.

Examples of acids include hydrochloric acid and the like.

Examples of appropriate 2-oxocycloalkylesters include ethyl 2-oxocyclohexanecarboxylate, ethyl 2-oxocyclopentanecarboxylate and the like.

The reaction is initially conducted at about 0°C, over about 30 minutes to about one hour, and then warmed to between about 15°C and 25°C for about one to four hours, in water.

Compounds of Formula (2) can be converted to compounds of Formula (3) by reacting the former with a solution of borane.


The reaction is typically conducted at ambient temperature over about 8 hours to about 20 hours in a solvent such as but not limited to THF.

Compounds of Formula (3) can be converted to compounds of Formula (4) by reacting the former with R^5OH, triphenylphosphine, and a reagent such as but not limited to DEAD or TBAD.

The addition is typically conducted below room temperature before warming to ambient temperature for about 8-72 hours in a solvent such as but not limited to THF.

Introduction of moieties represented by E^1, F^1, G^1, and A^1 can be accomplished by reacting substituted anilines of Formula (1) as shown in SCHEME (1). Alternatively, bromoanilines of Formula (1) can be reacted as shown in SCHEME (1) and then subsequently reacted using methods described in the literature (such as those described in Palladium Reagents And Catalysts: New Perspectives For The 21st Century, By J. Tsuji, John Wiley & Sons, Ltd., Chichester, 2004, 1-670) and known by those skilled in the art for palladium catalyzed carbon cross coupling reactions.

SCHEME 2



As shown in SCHEME 2, compounds of Formula (4) can be converted to compounds of Formula (5) by reacting the former with a base followed by an appropriate compound of Formula C^1Br (5a) or C^1Cl (5b).

Examples of a base include sodium hydride, potassium carbonate and the like.

Examples of appropriate compounds of Formula (5a) include 1-(3-

bromopropoxy)naphthalene and the like.

Examples of appropriate compounds of Formula (5b) include 2-chloro-1-morpholinoethanone and the like.

The reaction is typically conducted at or below ambient temperature for about 15 minutes to one hour during the addition of the base, and then from about 20°C to 80°C for about one to eight hours after the addition of the compound of Formula (5a) or (5b) in a solvent such as but not limited to DMF.

Compounds of Formula (5) can be converted to compounds of Formula (6) by reacting the former with a base.

Examples of bases include lithium hydroxide, sodium hydroxide, potassium hydroxide and the like.


The reaction is typically conducted over about 1 hour to about 48 hours, between about 0°C and 35°C, in solvents such as water, methanol, ethanol, isopropanol, mixtures thereof and the like.

Compounds of Formula (4), wherein C^1 is H, can be converted to compounds of Formula (6) by reacting the former with a base.

Examples of bases include lithium hydroxide, sodium hydroxide, potassium hydroxide and the like.

The reaction is typically conducted over about 1 hour to about 48 hours, between about 0°C and 35°C, in solvents such as water, methanol, ethanol, isopropanol, mixtures thereof and the like.

SCHEME 3



As shown in SCHEME 3, compounds of Formula (3) can be converted to compounds of Formula (7) by reacting the former with a base followed by methanesulfonyl chloride.

Examples of bases include TEA, pyridine and the like.

The reaction is typically conducted over about 30 minutes to about three hours, between about 0°C and 20°C, in acetonitrile.


Compounds of Formula (7) can be converted to compounds of Formula (8) by reacting the former with a compound of Formula R^5SH, and a base.

Examples of bases include potassium carbonate and sodium carbonate.

The reaction is typically conducted over one to five days between about 50°C and 100°C, in a solvent such as but not limited to acetonitrile.

Compounds of Formula (8) can be converted to compounds of Formula (9) as described in SCHEME 2 for the conversion of compounds of Formula (4) to compounds of Formula (6).

SCHEME 4




(10) (11) (12)

As shown in SCHEME 4, compounds of Formula (10) can be converted to compounds of Formula (12) by reacting the former with compounds of Formula (11), triphenylphosphine, and a reagent such as but not limited to DEAD or TBAD.

The addition may be conducted below room temperature before warming to ambient temperature for about 8-72 hours in a solvent such as but not limited to THF.

SCHEME 5



(12) (13) (14) (15) (16)

As shown in SCHEME 5, compounds of Formula (12) can be converted to compounds of Formula (14) by reacting the former, a compound of Formula (13) and a base.


Examples of bases include sodium hydride and postasium carbonate and the like.

The reaction is typically conducted at or below ambient temperature for about 15 minutes to one hour during the addition of the base, and then from about 20°C to 80°C for about one to eight hours after the addition of the compound of Formula (13) in a solvent such as but not limited to DMF.

Compounds of Formula (14) can be converted to compounds of Formula (15) using methods described in the literature (such as those described in Palladium Reagents And Catalysts: New Perspectives For The 21st Century, By J. Tsuji, John Wiley & Sons, Ltd., Chichester, 2004, 1-670) and known by those skilled in the art for palladium catalyzed carbon cross coupling reactions.

Compounds of Formula (15) can be converted to compounds of Formula (16) as described in SCHEME 2 for the conversion of compounds of Formula (4) to compounds of Formula (6).

SCHEME 6



As shown in SCHEME 6, compounds of Formula (3) can be converted to compounds of Formula (16) by reacting the former, iodine, triphenyphosphine and imidazole, followed by a base.

Examples of bases include sodium carbonate and the like.

The reaction is typically conducted from about –10 °C to about 10 °C for about 15 minutes to one hour and then continued for an additional 30 minutes to one hour after addition of the base, in a solvent such as but not limited to dichloromethane.

Compounds of Formula (16) can be converted to compounds of Formula (17) by reacting the former and triphenyphosphine.

The reaction is typically conducted over about 8 to about 48 hours at reflux, in a solvent such as but not limited to acetonitrile or dichloromethane.

Compounds of Formula (17) can be converted to compounds of Formula (18) by reacting the former, a base, and a compound of Formula $R^5C(O)H$.

Examples of bases include sodium hydride and n-butyllithium.

The reaction is initially conducted over about one hour at about 60°C to about 100 °C after the addition of the base and then cooled to about 10°C to about 25 °C and treated with a compounds of Formula (17). After about 10 minutes to about 20 minutes, the compound of Formula $R^5C(O)H$ is added and the mixture is again heated at about 60°C to about 100 °C for about one to eight hours.

Compounds of Formula (18) can be converted to compounds of Formula (19) by reacting the former with a hydrogen source and a catalyst.


Examples of hydrogen sources include hydrazine and hydrogen gas.

Examples of catalysts include Pd/C and Raney Nickel and the like.

Temperature and pressure vary depending on the hydrogenation method and the substrates employed. Typical solvents include methanol, ethanol, ethyl acetate, and the like.

Compounds of Formula (19) can be converted to compounds of Formula (20) as described in SCHEME 2 for the conversion of compounds of Formula (4) to compounds of Formula (6).

SCHEME 7



As shown in SCHEME 7, compounds of Formula (3) can be converted to compounds of Formula (21) by reacting the former, DMSO, a base, and a dehydration agent.

Examples of bases include triethylamine, diisopropylamine, and the like.

Examples of dehydration agents include oxalyl chloride, trifluoroacetic anhydride, and pyridine sulfate.

The reaction is typically conducted over about one to about eight hours at about –60 °C to about 0 °C depending on the substrate and method employed.

The following examples are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention.

EXAMPLE 1A

ethyl 7-bromo-3-(3-ethoxy-3-oxopropyl)-1H-indole-2-carboxylate

A mixture of 2-bromoaniline (34.2 g) in 5M HCl (50 mL) and water (250 mL) at 0°C was treated with $NaNO_2$ (13.8 g) in water (200 mL). After addition, sodium acetate (92.3 g) in water (250 mL) and 2-oxo-cyclopentanecarboxylic acid ethyl ester (30 mL) were added. The mixture was stirred for 15 minutes, warmed to 19°C over two hours and extracted with

dichloromethane. The extract was dried ($MgSO_4$), filtered and concentrated. The concentrate was dissolved in 1.1:1 H_2SO_4:ethanol (30 mL), refluxed overnight, cooled to room temperature, quenched with water (1.5L), and filtered. The filtrant was dissolved in dichloromethane (200 mL) and filtered through a Flash 75 cartridge with dichloromethane. After concentration, the product was recrystallized from hexane.

EXAMPLE 1B

ethyl 7-bromo-3-(3-hydroxypropyl)-1H-indole-2-carboxylate

To a mixture of EXAMPLE 1A (1.85 g) in THF (50 mL) was added 1M borane·THF (30 mL). The mixture was stirred at room temperature for 16 hours, quenched with methanol (10 mL) and concentrated. The concentrate was purified by flash column chromatography on silica gel with 5-25 % ethyl acetate/hexanes.

EXAMPLE 1C

ethyl 7-bromo-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

To a mixture of Example 1B (10.87 g), 1-naphthol (5.77 g) and triphenylphosphine (10.5 g) in THF (100 mL) was added di-tert-butyl azodicarboxylate (9.21 g). The mixture was stirred for 3 days, concentrated, redissolved in dichloromethane, washed with water and brine and dried (MgSO4), filtered and concentrated. The concentrate was purified by flash column chromatography on silica gel with 0-10% ethyl acetate in hexanes. The product was recrystallized from hexanes.

EXAMPLE 1D

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-phenylvinyl)-1H-indole-2-carboxylic acid

A mixture of EXAMPLE 1C (0.034 g), (E)-styrylboronic acid (0.1 g), bis(triphenylphosphine)palladium(II) dichloride (4 mg), and 2M Na_2CO_3 (0.5 mL) in 7:2:3 dimethoxyethane/ethanol/water (3 mL) was heated under microwave (CEM Discover) at 150°C for 30 minutes, quenched with 1M HCl (0.4 mL) and extracted with ethyl acetate. The extract was filtered through a drying cartridge ($MgSO_4$, Alltech Assoc., 2 g) and concentrated. The concentrate was purified by reverse phase HPLC (Zorbax SB-C18, 20-100% acetonitrile/ water/0.1% TFA). ^{1}H NMR (400 MHz, DMSO-d_6) δ 13.03 (brs, 1H), 11.68 (s, 1H), 8.23 (m, 1H), 8.14 (d, 1H), 7.86 (m, 1H), 7.76 (d, 1H), 7.68 (d, 1H), 7.61 (d, 1H), 7.52 (m, 2H), 7.41 (m, 4H), 7.29 (m, 2H), 7.01 (t, 1H), 6.88 (d, 1H), 4.17 (t, 2H), 2.22

(m, 2H).

EXAMPLE 2

3-(3-(1-naphthyloxy)propyl)-7-phenyl-1H-indole-2-carboxylic acid

This example was prepared by substituting phenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (400 MHz, DMSO-d_6) δ 12.97 (s, 1H), 10.29 (s, 1H), 8.23 (m, 1H), 7.86 (m, 1H), 7.69 (d, 1H), 7.64 (m, 2H), 7.52 (m, 4H), 7.41 (m, 3H), 7.25 (m, 1H), 7.10 (t, 1H), 6.89 (d, 1H), 4.20 (t, 2H), 3.37 (m, 2H), 2.24 (m, 2H).

EXAMPLE 3

3-(3-(1-naphthyloxy)propyl)-7-((1E)-3-phenylprop-1-enyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting (E)-3-phenylprop-1-enylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (400 MHz, DMSO-d_6) δ 13.02 (brs, 1H), 11.38 (s, 1H), 8.20 (m, 1H), 7.85 (m, 1H), 7.36 (m, 12H), 6.93 (t, 1H), 6.86 (d, 1H), 6.44 (m, 1H), 4.15 (t, 2H), 3.58 (d, 2H), 2.20 (m, 2H).

EXAMPLE 4

7-((E)-2-cyclohexylvinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting (E)-2-cyclohexyl-vinylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (400 MHz, DMSO-d_6) δ 13.02 (brs, 1H), 11.37 (s, 1H), 8.21 (m, 1H), 7.85 (m, 1H), 7.51 (m, 3H), 7.44 (m, 1H), 7.36 (m, 2H), 7.19 (d, 1H), 6.89 (m, 2H), 6.30 (m, 1H), 4.15 (t, 2H), 2.19 (m, 3H), 1.77 (m, 5H), 1.27 (m, 5H).

EXAMPLE 5

7-(3-(benzyloxy)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 3-(benzyloxy)-phenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (400 MHz, DMSO-d_6) δ 12.99 (brs, 1H), 10.34 (s, 1H), 8.22 (m, 1H), 7.86 (m, 1H), 7.69 (d, 1H), 7.36 (m, 13H), 7.07 (m, 2H), 6.89 (d, 1H), 5.19 (s, 2H), 4.20 (t, 2H), 3.37 (t, 2H), 2.24 (m, 2H).

EXAMPLE 6

7-(4-fluorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 4-fluorophenyl-boronic acid for (E)-

styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (400 MHz, DMSO-d_6) δ 13.00 (brs, 1H), 10.54 (s, 1H), 8.22 (m, 1H), 7.86 (m, 1H), 7.70 (d, 1H), 7.64 (m, 2H), 7.49 (m, 3H), 7.34 (m, 3H), 7.21 (d, 1H), 7.08 (t, 1H), 6.89 (d, 1H), 4.19 (t, 2H), 3.37 (t, 2H), 2.24 (m, 2H).

EXAMPLE 7

7-(2-naphthyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-naphthylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.01 (brs, 1H), 10.69 (s, 1H), 8.25 (m, 1H), 8.17 (s, 1H), 8.01 (m, 3H), 7.87 (m, 1H), 7.74 (m, 2H), 7.55 (m, 4H), 7.45 (d, 1H), 7.36 (m, 2H), 7.13 (t, 1H), 6.90 (d, 1H), 4.21 (t, 2H), 3.39 (t, 2H), 2.26 (m, 2H).

EXAMPLE 8

7-(1-naphthyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 1-naphthylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.90 (brs, 1H), 10.54 (s, 1H), 8.27 (m, 1H), 8.01 (m, 2H), 7.88 (m, 1H), 7.79 (d, 1H), 7.61 (t, 1H), 7.50 (m, 5H), 7.40 (m, 3H), 7.20 (d, 1H), 7.15 (t, 1H), 6.92 (d, 1H), 4.23 (s, 2H), 3.40 (m, 2H), 2.27 (m, 2H).

EXAMPLE 9

7-(1,1'-biphenyl-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting biphenyl-2-ylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.90 (brs, 1H), 10.22 (s, 1H), 8.24 (m, 1H), 7.86 (m, 1H), 7.50 (m, 8H), 7.38 (t, 1H), 7.09 (m, 5H), 6.86 (m, 3H), 4.14 (t, 2H), 2.18 (m, 2H).

EXAMPLE 10

7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-morpholinophenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.11 (brs, 1H), 10.07 (s, 1H), 8.24 (d, 1H), 7.85 (m, 1H), 7.74 (d, 1H), 7.44 (m, 7H), 7.14 (m, 3H), 6.86 (d, 1H), 4.18 (t, 2H), 3.25 (m, 4H), 2.78 (m, 4H), 2.26 (m, 2H).

EXAMPLE 11

7-(2-fluoro-1,1'-biphenyl-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-fluorobiphenyl-4-ylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.07 (brs, 1H), 10.86 (s, 1H), 8.23 (m, 1H), 7.87 (m, 1H), 7.74 (d, 1H), 7.65 (m, 3H), 7.53 (m, 6H), 7.41 (m, 3H), 7.32 (d, 1H), 7.11 (t, 1H), 6.90 (d, 1H), 4.20 (t, 2H), 3.38 (t, 2H), 2.24 (m, 2H).

EXAMPLE 12

7-(4-(benzyloxy)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 4-(benzyloxy)-phenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.04 (brs, 1H), 10.27 (s, 1H), 8.23 (m, 1H), 7.87 (m, 1H), 7.65 (d, 1H), 7.54 (m, 6H), 7.39 (m, 5H), 7.18 (m, 3H), 7.07 (t, 1H), 6.90 (d, 1H), 5.19 (s, 2H), 4.19 (t, 2H), 2.23 (m, 2H).

EXAMPLE 13

7-(3-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 3-morpholinophenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.03 (brs, 1H), 10.21 (s, 1H), 8.22 (m, 1H), 7.86 (m, 1H), 7.68 (d, 1H), 7.52 (m, 2H), 7.45 (d, 1H), 7.38 (d, 2H), 7.25 (d, 1H), 7.06 (m, 4H), 6.89 (d, 1H), 4.19 (t, 2H), 3.76 (t, 4H), 3.19 (t, 4H), 2.23 (m, 2H).

EXAMPLE 14

3-(3-(1-naphthyloxy)propyl)-7-pyridin-3-yl-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting 3-pyridylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.13 (brs, 1H), 11.30 (s, 1H), 8.96 (s, 1H), 8.76 (m, 1H), 8.31 (d, 1H), 8.22 (d, 1H), 7.84 (m, 3H), 7.52 (m, 2H), 7.45 (d, 1H), 7.38 (t, 1H), 7.29 (d, 1H), 7.14 (t, 1H), 6.89 (d, 1H), 4.19 (t, 2H), 3.38 (t, 2H), 2.24 (m, 2H).

EXAMPLE 15

3-(3-(1-naphthyloxy)propyl)-7-pyridin-4-yl-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting 4-pyridylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.18 (brs, 1H), 11.18 (s, 1H), 8.84 (m, 2H), 8.21 (d, 1H), 7.98 (m, 2H), 7.86 (d, 2H), 7.45 (m, 5H), 7.16 (m, 1H), 6.89 (d, 1H), 4.19 (t, 2H), 3.39 (t, 2H), 2.24 (m, 2H).

EXAMPLE 16

3-(3-(1-naphthyloxy)propyl)-7-((1E)-5-phenylpent-1-enyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting (E)-5-phenylpent-1-enylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.00 (brs, 1H), 11.38 (s, 1H), 8.22 (m, 1H), 7.85 (m, 1H), 7.52 (m, 3H), 7.40 (m, 3H), 7.23 (m, 6H), 6.94 (t, 1H), 6.85 (d, 1H), 6.37 (m, 1H), 4.15 (t, 2H), 2.66 (t, 2H), 2.28 (m, 2H), 2.19 (m, 2H), 1.82 (m, 2H).

EXAMPLE 17

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methylphenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.95 (brs, 1H), 10.49 (s, 1H), 8.26 (d, 1H), 7.87 (d, 1H), 7.69 (d, 1H), 7.53 (m, 2H), 7.45 (d, 1H), 7.39 (t, 1H), 7.26 (m, 4H), 7.06 (m, 2H), 6.90 (d, 1H), 4.21 (t, 2H), 2.24 (m, 2H), 2.06 (s, 3H).

EXAMPLE 18

7-(3-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 3-methylphenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.02 (brs, 1H), 10.32 (s, 1H), 8.22 (m, 1H), 7.87 (m, 1H), 7.68 (d, 1H), 7.52 (m, 2H), 7.41 (m, 5H), 7.23 (m, 2H), 7.09 (t, 1H), 6.89 (d, 1H), 4.19 (t, 2H), 2.41 (s, 3H), 2.24 (m, 2H).

EXAMPLE 19

7-(4-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 4-methylphenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.05 (brs, 1H), 10.25 (s, 1H), 8.22 (m, 1H), 7.86 (m, 1H), 7.67 (d, 1H), 7.50 (m, 5H), 7.36 (m, 3H), 7.22 (d, 1H), 7.08 (t, 1H), 6.89 (d, 1H), 4.19 (t, 2H), 2.39 (s, 3H), 2.23 (m, 2H).

EXAMPLE 20

7-(4-carboxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 4-(methoxycarbonyl)-phenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.01 (brs, 2H), 10.73 (s, 1H), 8.23 (m, 1H), 8.06 (d, 2H), 7.87 (m, 1H), 7.74 (m, 3H), 7.50 (m, 3H), 7.38 (t, 1H), 7.11 (t, 1H), 6.89 (d, 1H), 4.19 (t, 2H), 2.24 (m, 2H).

EXAMPLE 21

7-(3-carboxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 3-(methoxycarbonyl)-phenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.02 (brs, 2H), 10.84 (s, 1H), 8.23 (m, 1H), 8.12 (m, 1H), 7.98 (m, 1H), 7.85 (m, 2H), 7.72 (d, 1H), 7.63 (t, 1H), 7.52 (m, 2H), 7.45 (d, 1H), 7.39 (t, 1H), 7.24 (d, H), 7.10 (t, 1H), 6.90 (d, 1H), 4.19 (t, 2H), 3.38 (t, 2H), 2.24 (m, 2H).

EXAMPLE 22

7-(2-(benzyloxy)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-(benzyloxy)-phenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.95 (brs, 1H), 10.35 (s, 1H), 8.27 (m, 1H), 7.87 (m, 1H), 7.67 (d, 1H), 7.53 (m, 2H), 7.40 (m, 4H), 7.24 (d, 1H), 7.10 (m, 8H), 6.87 (d, 1H), 5.09 (s, 2H), 4.17 (t, 2H), 2.24 (m, 2H).

EXAMPLE 23

7-(2-ethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-ethoxyphenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.01 (brs, 1H), 9.93 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.70 (d, 1H), 7.44 (m, 6H), 7.17 (m, 2H), 7.06 (m, 2H), 6.89 (d, 1H), 4.19 (t, 2H), 4.09 (q, 2H), 2.24 (m, 2H), 1.15 (t, 3H).

EXAMPLE 24

7-(2-ethylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-ethylphenylboronic acid for (E)-

styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.93 (brs, 1H), 10.40 (s, 1H), 8.26 (m, 1H), 7.87 (m, 1H), 7.69 (d, 1H), 7.53 (m, 2H), 7.45 (d, 1H), 7.38 (m, 3H), 7.26 (m, 1H), 7.18 (d, 1H), 7.05 (m, 2H), 6.91 (d, 1H), 4.21 (t, 2H), 2.33 (m, 4H), 0.94 (t, 3H).

EXAMPLE 25

7-(2-methoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methoxyphenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.97 (brs, 1H), 10.09 (s, 1H), 8.26 (m, 1H), 7.87 (m, 1H), 7.68 (d, 1H), 7.53 (m, 2H), 7.42 (m, 3H), 7.29 (m, 1H), 7.15 (m, 2H), 7.06 (m, 2H), 6.91 (d, 1H), 4.20 (t, 2H), 3.74 (s, 3H), 2.24 (m, 2H).

EXAMPLE 26

7-(2-isopropoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-isopropoxyphenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.04 (brs, 1H), 9.73 (s, 1H), 8.24 (m, 1H), 7.86 (m, 1H), 7.70 (d, 1H), 7.52 (m, 2H), 7.45 (d, 1H), 7.38 (m, 3H), 7.20 (m, 2H), 7.08 (m, 2H), 6.89 (d, 1H), 4.62 (m, 1H), 4.19 (t, 2H), 3.37 (t, 2H), 2.24 (m, 2H), 1.13 (d, 6H).

EXAMPLE 27

3-(3-(1-naphthyloxy)propyl)-7-(2-phenoxyphenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-phenoxyphenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.00 (brs, 1H), 10.56 (s, 1H), 8.25 (m, 1H), 7.86 (m, 1H), 7.64 (d, 1H), 7.45 (m, 6H), 7.23 (m, 4H), 6.94 (m, 6H), 4.17 (t, 2H), 2.21 (m, 2H).

EXAMPLE 28

7-(2-carboxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-(diethylcarbamoyl)phenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.90 (brs, 1H), 12.42 (brs, 1H), 10.56 (s, 1H), 8.27 (m, 1H), 7.87 (m, 2H), 7.52 (m, 8H), 7.03 (m, 2H), 6.92 (d, 1H), 4.21 (t, 2H), 2.23 (m, 2H).

EXAMPLE 30

3-(3-(1-naphthyloxy)propyl)-7-(2-((5,6,7,8-tetrahydronaphthalen-1-yloxy)methyl)phenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-((5,6,7,8-tetrahydronaphthalen-1-yloxy)methyl)phenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.94 (brs, 1H), 10.49 (s, 1H), 8.24 (m, 1H), 7.86 (m, 1H), 7.66 (m, 2H), 7.44 (m, 7H), 7.08 (m, 2H), 6.85 (m, 2H), 6.56 (d, 1H), 6.37 (d, 1H), 4.80 (brs, 2H), 4.18 (t, 2H), 2.60 (m, 2H), 2.39 (m, 2H), 2.24 (m, 2H), 1.62 (m, 4H).

EXAMPLE 31

7-(4-cyclohexylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 4-cyclohexylphenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.04 (brs, 1H), 10.26 (s, 1H), 8.23 (m, 1H), 7.86 (m, 1H), 7.67 (d, 1H), 7.45 (m, 8H), 7.23 (m, 1H), 7.08 (t, 1H), 6.89 (d, 1H), 4.19 (t, 2H), 3.37 (t, 2H), 2.59 (m, 1H), 2.24 (m, 2H), 1.80 (m, 5H), 1.39 (m, 5H).

EXAMPLE 32

7-(2-chlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-chlorophenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.97 (brs, 1H), 10.91 (s, 1H), 8.27 (m, 1H), 7.87 (m, 1H), 7.73 (m, 1H), 7.54 (m, 3H), 7.42 (m, 5H), 7.08 (m, 2H), 6.91 (d, 1H), 4.21 (t, 2H), 3.37 (t, 2H), 2.23 (m, 2H).

EXAMPLE 33

7-(3-chloropyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting 2-chloropyrid-4-yl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.03 (brs, 1H), 11.28 (s, 1H), 8.72 (s, 1H), 8.57 (d, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.79 (d, 1H), 7.53 (m, 2H), 7.45 (m, 2H), 7.39 (t, 1H), 7.11 (m, 2H), 6.91 (d, 1H), 4.20 (t, 2H), 2.23 (m, 2H).

EXAMPLE 34

7-(2,5-dichlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2,5-dichlorophenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.96 (brs, 1H), 11.43 (s, 1H), 8.24 (m, 1H), 7.86 (m, 1H), 7.65 (d, 1H), 7.52 (m, 2H), 7.45 (d, 1H), 7.38 (m, 2H), 7.21 (t, 1H), 6.95 (t, 1H), 6.87 (d, 1H), 4.16 (t, 2H), 2.21 (m, 2H).

EXAMPLE 35

7-(3,5-dichlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 3,5-dichlorophenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.94 (brs, 1H), 11.02 (s, 1H), 8.27 (m, 1H), 7.86 (m, 2H), 7.67 (m, 2H), 7.53 (m, 2H), 7.46 (d, 1H), 7.39 (m, 2H), 7.03 (m, 2H), 6.91 (d, 1H), 4.21 (t, 2H), 2.24 (m, 2H).

EXAMPLE 36

7-(2,3-dimethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2,3-dimethoxyphenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.05 (brs, 1H), 10.03 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.71 (d, 1H), 7.52 (m, 2H), 7.45 (d, 1H), 7.39 (t, 1H), 7.14 (m, 4H), 6.92 (m, 2H), 4.20 (t, 2H), 3.88 (s, 3H), 3.43 (s, 3H), 2.24 (m, 2H).

EXAMPLE 37

7-(2,4-dimethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2,4-dimethoxyphenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.96 (brs, 1H), 9.99 (s, 1H), 8.27 (m, 1H), 7.87 (m, 1H), 7.64 (d, 1H), 7.53 (m, 2H), 7.46 (d, 1H), 7.39 (t, 1H), 7.21 (m, 1H), 7.10 (m, 1H), 7.03 (m, 1H), 6.90 (m, 1H), 6.71 (m, 1H), 6.65 (m, 1H), 4.19 (t, 2H), 3.84 (s, 3H), 3.74 (s, 3H), 2.24 (m, 2H).

EXAMPLE 38

7-(2,5-dimethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2,5-dimethoxyphenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.99 (brs, 1H),

10.08 (s, 1H), 8.26 (m, 1H), 7.87 (m, 1H), 7.68 (d, 1H), 7.53 (m, 2H), 7.46 (d, 1H), 7.39 (t, 1H), 7.17 (d, 1H), 7.07 (m, 2H), 6.98 (m, 1H), 6.90 (d, 1H), 6.87 (d, 1H), 4.20 (t, 2H), 3.75 (s, 3H), 3.68 (s, 3H), 2.24 (m, 2H).

EXAMPLE 39

7-(2,6-dimethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2,6-dimethoxyphenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.87 (brs, 1H), 10.18 (s, 1H), 8.30 (m, 1H), 7.88 (m, 1H), 7.62 (m, 1H), 7.53 (m, 2H), 7.46 (d, 1H), 7.38 (m, 2H), 7.01 (m, 2H), 6.93 (d, 1H), 6.76 (d, 2H), 4.22 (s, 2H), 3.62 (s, 6H), 2.23 (m, 2H).

EXAMPLE 40

7-(4-methoxypyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting 4-methoxypyrid-3-yl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.02 (brs, 1H), 10.94 (s, 1H), 8.37 (m, 1H), 8.24 (m, 1H), 7.88 (m, 2H), 7.70 (d, 1H), 7.52 (m, 2H), 7.45 (d, 1H), 7.38 (t, 1H), 7.19 (d, 1H), 7.07 (t, 1H), 6.94 (d, 1H), 6.89 (d, 1H), 4.19 (t, 2H), 3.93 (s, 3H), 2.23 (m, 2H).

EXAMPLE 41

7-(2-methoxypyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting 2-methoxypyrid-3-yl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (400 MHz, DMSO-d_6) δ 13.00 (brs, 1H), 10.85 (s, 1H), 8.25 (m, 2H), 7.87 (m, 1H), 7.68 (m, 2H), 7.53 (m, 2H), 7.46 (d, 1H), 7.39 (t, 1H), 7.08 (m, 3H), 6.90 (m, 1H), 4.20 (t, 2H), 3.83 (s, 3H), 2.22 (m, 2H).

EXAMPLE 42

3-(3-(1-naphthyloxy)propyl)-7-quinolin-4-yl-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting quinolin-4-ylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (400 MHz, DMSO-d_6) δ 12.96 (brs, 1H), 11.01 (s, 1H), 9.06 (d, 1H), 8.25 (m, 1H), 8.18 (d, 1H), 7.86 (m, 3H), 7.64 (d, 1H), 7.47 (m, 6H), 7.22 (m, 2H), 6.92 (m, 1H), 4.23 (t, 2H), 2.27 (m, 2H).

EXAMPLE 43A

ethyl 3-(3-(naphthalen-1-yloxy)propyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-2-carboxylate

A mixture of EXAMPLE 1C (1.0 g), bis(pinacolato)diboron (674 mg), potassium acetate (998 mg) and (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium(II) (81 mg) in DMF (10 mL) was heated at 60 °C overnight and concentrated. The concentrate was partitioned between dichloromethane and water. The extract washed with water and brine and dried (Na_2SO_4), filtered and concentrated. The concentrate was loaded on a silica gel cartridge and eluted with 5% ethyl acetate/hexanes.

EXAMPLE 43B

7-(4-hydroxy-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

To a mixture of EXAMPLE 43A (50 mg) and 4-bromo-3-methylphenol (22 mg) in THF (2 mL) was added tris(dibenzylideneacetone)dipalladium(0) (4.6 mg), and tri-tert-butylphosphine tetrafluoroborate (1.45 mg). The mixture was stirred at ambient temperature overnight and partitioned between ethyl acetate (150 mL) and water (50 mL). The extract was washed with brine, dried over sodium sulfate, and filtered. The filtrate was concentrated, and the concentrate was loaded on a silica gel cartridge and eluted with ethyl acetate (5%) in hexanes to provide a product which was dissolved in THF (2 mL), methanol (1 mL) and water (1 mL) and hydrolyzed with LiOH (100 mg) overnight. The mixture was acidified with 5% aqueous HCl and extracted with ethyl acetate. The exteact was washed with water and brine and and dried (Na_2SO_4), filtered and concentrated. The concentrate was purified by reverse phase HPLC as described in Example 1D. ^{1}H NMR (300 MHz, $CDCl_3$) δ 8.39 (d, 1H), 8.35 (d, 1H), 7.77 (d, 1H), 7.72 (dd, 1H), 7.13-7.50 (m, 6H), 6.85 (d, 1H), 6.76 (t, 2H), 4.21 (t, 2H), 3.47 (t, 2H), 2.38 (m, 2H), 2.13 (s, 3H).

EXAMPLE 44

7-(2-(4-methylpiperazin-1-yl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting EXAMPLE 43A for (E)-styrylboronic acid and 1-(2-bromophenyl)-4-methylpiperazine for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.10 (brs, 1H), 10.43 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.74 (d, 1H), 7.46 (m, 6H), 7.31 (dd, 1H), 7.15 (m, 3H), 6.90 (m, 1H),

4.19 (t, 2H), 3.19 (m, 4H), 2.82 (m, 2H), 2.59 (s, 3H), 2.25 (m, 2H).

EXAMPLE 45

7-(2,4-dichlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2,4-dichlorophenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.06 (brs, 1H), 10.70 (s, 1H), 8.22 (m, 1H), 7.87 (m, 1H), 7.71 (d, 1H), 7.62 (m, 2H), 7.53 (m, 3H), 7.45 (d, 1H), 7.38 (t, 1H), 7.22 (d, 1H), 7.09 (t, 1H), 6.89 (d, 1H), 4.19 (t, 2H), 2.23 (m, 2H).

EXAMPLE 46

7-(4-carboxy-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 4-(methoxycarbonyl)-2-methylphenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.02 (brs, 2H), 10.87 (s, 1H), 8.25 (m, 1H), 7.86 (m, 3H), 7.73 (d, 1H), 7.53 (m, 2H), 7.46 (d, 1H), 7.39 (m, 1H), 7.32 (d, 1H), 7.07 (m, 2H), 6.91 (d, 1H), 4.21 (t, 2H), 2.24 (m, 2H), 2.10 (s, 3H).

EXAMPLE 47A

ethyl 3-(3-hydroxypropyl)-7-(2-methoxyphenyl)-1H-indole-2-carboxylate

A smixture of EXAMPLE 1B (456 mg) and 2-methoxyphenylboronic acid (182.4 mg) in THF (10 mL), tris(dibenzylideneacetone)dipalladium(0) (46 mg), tri-tert-butylphosphine tetrafluoroborate (15 mg) and CsF (456 mg) was stirred at ambient temperature, diluted with ethyl acetate (200 mL), washed with water and brine, and dried (Na_2SO_4), filtered and concentrated. The concentrate was purified by flash column chromatography on silica gel with 20% ethyl acetate in hexanes.

EXAMPLE 47B

7-(2-methoxyphenyl)-3-(3-((2-methyl-1-naphthyl)oxy)propyl)-1H-indole-2-carboxylic acid

To a mixture of EXAMPLE 47A (71 mg), 2-methyl-1-naphthol (35 mg), triphenylphosphine (58 mg) in THF (2 mL) and di-tert-butyl azodicarboxylate (55 mg) was stirred at ambient temperature overnight and partitioned between ethyl acetate (150 mL) and water (50 mL). The organic layer was washed with brine and a dried (Na_2SO_4), filtered and concentrated. The concentrate was purified by flash chromatography on silica gel with 5%

ethyl acetate in hexanes to provide an intermediate which was dissolved in THF (2 mL), methanol (1 mL) and water (1 mL) and hydrolyzed with LiOH (100 mg) overnight. The mixture was acidified with 5% HCl and extracted with ethyl acetate. The extract was washed with water and brine and dried (Na_2SO_4), filtered and concentrated. Theconcentrate was purified by reverse phase HPLC (C-18, 30 to 100 % acetonitrile/water/0.1 % TFA). ^{1}H NMR (300 MHz, $CDCl_3$) δ 8.74 (s, 1H), 8.12 (dd, 1H), 7.82 (d, 1H), 7.77 (d, 1H), 7.52 (d, 1H), 7.36-7.47 (m, 5H), 7.27 (d, 1H), 7.09 (t, 2H), 4.10 (t, 2H), 3.83 (s, 3H), 3.48 (t, 2H), 2.46 (s, 3H), 2.38 (m, 2H).

EXAMPLE 48

7-(4-fluoro-2-isopropoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 4-fluoro-2-isopropoxyphenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.98 (brs, 1H), 10.03 (s, 1H), 8.24 (m, 1H), 7.87 (m, 1H), 7.68 (d, 1H), 7.43 (m, 5H), 7.15 (d, 1H), 7.04 (m, 2H), 6.86 (m, 2H), 4.66 (m, 1H), 4.18 (t, 2H), 2.23 (m, 2H), 1.14 (s, 3H), 1.12 (s, 3H).

EXAMPLE 49

7-(2-ethoxy-1-naphthyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-ethoxynaphthalen-1-ylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.81 (brs, 1H), 10.42 (brs, 1H), 8.29 (m, 1H), 8.00 (d, 1H), 7.89 (m, 2H), 7.75 (m, 1H), 7.41 (m, 7H), 7.13 (m, 3H), 6.91 (m, 1H), 4.24 (t, 2H), 4.10 (q, 2H), 3.39 (t, 2H), 2.27 (m, 2H), 1.02 (m, 3H).

EXAMPLE 50

7-(4-amino-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 4-bromo-3-methylaniline for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 10.48 (s, 1H), 8.25 (dd, 1H), 7.88 (dd, 1H), 7.71 (d, 1H), 7.37-7.57 (m, 6H), 7.27 (d, 1H), 7.09 (m, 3H), 6.92 (d, 1H), 4.21 (t, 2H), 2.26 (m, 2H), 2.01 (s, 3H).

EXAMPLE 51A

4-bromo-N-(2-(dimethylamino)ethyl)-3-methylbenzamide

A mixture of 4-bromo-3-methylbenzoic acid (430 mg), N,N-dimethylethylenediamine

(180 mg), 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride (600 mg) and 4-dimethylaminopyridine (244 mg) in dichloromethane (20 mL) was stirred at ambient temperature for 4 hours, diluted with ethyl acetate (200mL), washed with water and brine, and dried (Na_2SO_4), filtered and concentrated. The concentrate was purified by flash column chromatography with 10% ethyl acetate in ammonia saturated dichloromethane.

EXAMPLE 51B

7-(4-(((2-(dimethylamino)ethyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting EXAMPLE 51A for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 10.65 (s, 1H), 9.32 (m, 1H), 8.69 (t, 1H), 8.25 (dd, 1H), 7.88 (dd, 1H), 7.72 (dt, 1H), 7.33-7.57 (m, 6H), 7.06 (dd, 2H), 6.91 (d, 1H), 4.21 (t, 2H), 3.63 (m, 2H), 2.50 (s, 6H), 2.26 (m, 2H), 2.12 (s, 3H).

EXAMPLE 52

7-(4-chloro-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 4-chloro-2-methylphenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.93 (brs, 1H), 10.88 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.70 (d, 1H), 7.46 (m, 5H), 7.30 (m, 1H), 7.21 (d, 1H), 7.05 (m, 2H), 6.90 (d, 1H), 4.20 (t, 2H), 2.23 (m, 2H), 2.03 (s, 3H).

EXAMPLE 53

7-(2,3-dichlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2,3-dichlorophenyl-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.98 (brs, 1H), 11.20 (s, 1H), 8.26 (m, 1H), 7.87 (m, 1H), 7.74 (m, 1H), 7.68 (m, 1H), 7.53 (m, 2H), 7.39 (m, 4H), 7.06 (m, 2H), 6.91 (d, 1H), 4.21 (t, 2H), 2.24 (m, 2H).

EXAMPLE 54

3-(3-(1-naphthyloxy)propyl)-7-(2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-trifluoromethyl-phenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.93 (brs, 1H),

11.04 (s, 1H), 8.27 (m, 1H), 7.86 (m, 2H), 7.71 (m, 2H), 7.64 (t, 1H), 7.53 (m, 2H), 7.46 (d, 1H), 7.39 (t, 2H), 7.04 (t, 2H), 6.91 (d, 1H), 4.21 (t, 2H), 2.24 (m, 2H).

EXAMPLE 55

7-(3-chloro-2-fluorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 3-chloro-2-fluoro-phenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.02 (brs, 1H), 11.28 (s, 1H), 8.26 (m, 1H), 7.87 (m, 1H), 7.76 (d, 1H), 7.62 (m, 1H), 7.53 (m, 2H), 7.41 (m, 3H), 7.30 (t, 1H), 7.12 (m, 2H), 6.90 (d, 1H), 4.20 (t, 2H), 3.37 (t, 2H), 2.23 (m, 2H).

EXAMPLE 56

7-(2,3-difluorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2,3-difluoro-phenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.04 (brs, 1H), 11.24 (s, 1H), 8.26 (d, 1H), 7.87 (d, 1H), 7.77 (d, 1H), 7.47 (m, 5H), 7.28 (m, 2H), 7.19 (m, 1H), 7.09 (t, 1H), 6.90 (d, 1H), 4.20 (t, 2H), 3.38 (t, 2H), 2.24 (m, 2H).

EXAMPLE 57

7-cyclopent-1-en-1-yl-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 1-cyclopentene-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.10 (brs, 1H), 10.12 (s, 1H), 8.22 (m, 1H), 7.85 (m, 1H), 7.60 (d, 1H), 7.51 (m, 2H), 7.45 (d, 1H), 7.37 (t, 1H), 7.17 (d, 1H), 6.98 (t, 1H), 6.87 (d, 1H), 6.33 (t, 1H), 4.16 (t, 2H), 2.79 (m, 2H), 2.60 (m, 2H), 2.21 (m, 2H), 1.98 (m, 2H).

EXAMPLE 58

7-cyclohex-1-en-1-yl-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 1-cyclohexene-boronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.03 (brs, 1H), 10.44 (s, 1H), 8.22 (m, 1H), 7.86 (m, 1H), 7.46 (m, 5H), 7.05 (m, 1H), 6.95 (t, 1H), 6.88 (d, 1H), 5.96 (m, 1H), 4.17 (t, 2H), 2.38 (m, 2H), 2.20 (m, 4H), 1.73 (m, 4H).

EXAMPLE 59A

2-phenylcyclohex-1-enyl trifluoromethanesulfonate

2-Phenylcyclohexanone (0.2 g) was added to the mixture of 60% oily NaH (0.17g) in DMF (3 mL) at 0°C. The mixture was warmed to room temperature and stirred for 30 minutes, treated with 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (0.7 g), stirred for 6 hours and treated with water (20 mL) and ethyl acetate (50 mL). The extract was washed with brine (20 mL) and water (20 mL), and dried (Na_2SO_4), filtered and concentrated. The concentrate was purified by flash chromotography on silica gel with 0-30% ethyl acetate/hexane.

EXAMPLE 59B

3-(3-(1-naphthyloxy)propyl)-7-(2-phenylcyclohex-1-en-1-yl)-1H-indole-2-carboxylic acid

This example was prepared by substituting EXAMPLE 43A for (E)-styrylboronic acid and EXAMPLE 59A for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.92 (brs, 1H), 10.69 (s, 1H), 8.23 (m, 1H), 7.86 (m, 1H), 7.51 (m, 2H), 7.44 (d, 1H), 7.38 (m, 2H), 6.89 (m, 8H), 4.11 (t, 2H), 3.24 (t, 2H), 2.41 (m, 4H), 2.15 (m, 2H), 1.86 (m, 4H).

EXAMPLE 60

7-(2-cyclohexylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting EXAMPLE 43A for (E)-styrylboronic acid and 1-bromo-2-cyclohexylbenzene for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.95 (brs, 1H), 10.28 (s, 1H), 8.26 (m, 1H), 7.87 (m, 1H), 7.70 (d, 1H), 7.53 (m, 2H), 7.41 (m, 4H), 7.24 (t, 1H), 7.17 (d, 1H), 7.07 (t, 1H), 7.00 (d, 1H), 6.89 (d, 1H), 4.20 (t, 2H), 2.29 (m, 4H), 1.55 (m, 7H), 1.18 (m, 2H), 0.86 (m, 2H).

EXAMPLE 61

7-(6-carboxypyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting methyl 5-bromopicolinate for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 11.30 (s, 1H), 8.88 (s, 1H), 8.22 (dd, 1H), 8.15 (s, 1H), 7.87 (dd, 1H), 7.79 (d, 1H), 7.29-7.56 (m, 6H), 7.13 (t, 1H), 6.90 (d, 1H), 4.19 (t, 2H), 2.26 (m, 2H).

EXAMPLE 62

7-(3-methyl-5-nitropyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-bromo-3-methyl-5-nitropyridine for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, $CDCl_3$) δ 9.90 (m, 1H), 9.43 (d, 1H), 8.52 (d,1H), 8.39 (d, 1H), 7.95 (m, 1H), 7.80 (dd, 1H), 7.68 (dd, 1H), 7.13-7.60 (m, 8H), 7.00 (d, 1H), 6.68 (t, 2H), 4.21 (t, 2H), 3.10 (t, 2H), 2.67 (s, 3H), 2.18 (m, 2H).

EXAMPLE 63

7-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting EXAMPLE 1C for 4-bromo-3-methylphenol and 2,3-dihydrobenzo(b)(1,4)dioxin-6-ylboronic acid for EXAMPLE 43A in EXAMPLE 43B. ^{1}H NMR (300 MHz, $CDCl_3$) δ 8.87 (s, 1H), 8.35 (dd, 1H), 7.76 (dd, 1H), 7.70 (dd, 1H), 7.30-7.49 (m, 5H), 7.15 (m,2H), 7.02 (d, 1H), 6.75 (d, 1H), 4.33 (s, 4H), 4.21 (t, 2H),3.84 (t, 2H), 2.38 (m, 2H).

EXAMPLE 64

7-(1,3-benzodioxol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting EXAMPLE 1C for 4-bromo-3-methylphenol and benzo(d)(1,3)dioxol-5-ylboronic acid for EXAMPLE 43A in EXAMPLE 43B.

^{1}H NMR (300 MHz, $CDCl_3$) δ 8.84 (s, 1H), 8.35 (dd, 1H), 7.78 (dd, 1H), 7.70 (d, 1H), 7.30-7.49 (m, 5H), 7.17 (d, 2H), 7.09 (s, 1H), 6.97 (d, 1H), 6.75 (dd, 1H), 6.05 (s, 2H), 4.21 (t, 2H), 3.49 (t, 2H), 2.38 (m, 2H).

EXAMPLE 65A

ethyl 3-(3-(4-chloronaphthalen-1-yloxy)propyl)-7-(2-methoxyphenyl)-1H-indole-2-carboxylate

This example was prepared by substituting EXAMPLE 47A for EXAMPLE 1B and 4-chloro-1-naphthol for 1-naphthol in EXAMPLE 1D.

EXAMPLE 65B

3-(3-(4-chloronaphthalen-1-yloxy)propyl)-7-(2-methoxyphenyl)-1H-indole-2-carboxylic acid

A mixture of EXAMPLE 65A (70 mg) in THF (2 mL), methanol (1 mL) and water (1

mL) was treated with $LiOH \cdot H_2O$ (100 mg) and stirred at ambient temperature overnight. The mixture was acidified with 5% aqueous HCl and extracted with ethyl acetate. The extract was washed with water, brine and dried (Na_2SO_4), filtered and concentrated. The concentrate was dissolved in 1:1DMSO/methanol and purified by reverse phase HPLC (C18, 20 to 100% acetonitrile/water/0.1% TFA). ^1H NMR (300 MHz, $CDCl_3$) δ 8.72 (s, 1H), 8.38 (dd, 1H), 8.15 (dd, 1H), 7.72 (d, 1H), 7.35-7.57 (m, 5H), 7.08-7.21 (m, 3H), 6.65 (d, 1H), 4.18 (t, 2H), 3.82 (s, 3H), 3.47 (t, 2H), 2.37 (m, 2H).

EXAMPLE 66A

ethyl 3-(3-(2-bromophenoxy)propyl)-7-(2-methoxyphenyl)-1H-indole-2-carboxylate

This example was prepared by substituting EXAMPLE 47A for EXAMPLE 1B and 2-bromophenol for 1-naphthol in EXAMPLE 1C.

EXAMPLE 66B

3-(3-(2-bromophenoxy)propyl)-7-(2-methoxyphenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting EXAMPLE 66A for EXAMPLE 65A in EXAMPLE 65B. ^1H NMR (300 MHz, $CDCl_3$) δ 8.72 (s, 1H), 7.79 (d, 1H), 7.55 (dd, 1H), 7.43 (t, 1H), 7.35 (dd, 1H), 7.22 (m, 3H), 7.10 (d, 1H), 6.85 (d, 1H), 6.77 (d, 1H), 4.11 (t, 2H), 3.84 (s, 3H), 3.43 (t, 2H), 2.29 (m, 2H).

EXAMPLE 67A

4-bromo-3-methyl-N-(2-morpholinoethyl)benzamide

This example was prepared by substituting 2-morpholinoethanamine for N1,N1-dimethylethane-1,2-diamine in EXAMPLE 51A.

EXAMPLE 67B

7-(2-methyl-4-(((2-morpholin-4-ylethyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting EXAMPLE 67A for 4-bromo-3-methylphenol in EXAMPLE 43B. ^1H NMR (300 MHz, DMSO-d_6) δ 12.94 (m, 1H), 10.68 (s, 1H), 9.82 (m, 1H), 8.74 (m, 1H), 8.24 (dd, 2H), 7.88 (dd, 1H), 7.82 (d, 1H), 7.72 (t, 1H), 7.34-7.55 (m, 5H), 7.07 (m, 2H), 6.91 (d, 1H), 4.11 (t, 2H), 4.00 (m, 2H), 3.17-3.67 (m, 8H), 2.26 (m, 2H), 2.12 (S, 3H).

EXAMPLE 68

7-(3-methylquinolin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting 2-bromo-3-methyl-quinoline for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.05 (m, 1H), 11.19 (m, 1H), 8.42 (m, 1H), 8.28 (dd, 1H), 8.05 (d, 1H), 7.37-7.89 (m, 9H), 7.16 (t, 1H), 6.91 (d, 1H), 4.22 (t, 2H), 2.36 (s, 3H), 2.26 (m, 2H).

EXAMPLE 69

7-(4-(hydroxymethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 4-(hydroxymethyl)-phenylboronic acid for EXAMPLE 43A and EXAMPLE 1C for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.05 (m, 1H), 10.28 (m, 1H), 8.22 (dd, 1H), 7.87 (dd, 1H), 7.68 (d, 1H), 7.36-7.61 (m, 6H), 7.26 (d, 1H), 7.09 (t, 1H), 6.90 (d, 1H), 5.25 (t, 1H), 4.59 (d, 2H), 4.19 (t, 2H), 2.26 (m, 2H).

EXAMPLE 70

7-(3-(hydroxymethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 3-(hydroxymethyl)-phenylboronic acid for EXAMPLE 43A and EXAMPLE 1C for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.05 (m, 1H), 10.26 (m, 1H), 8.22 (dd, 1H), 7.87 (dd, 1H), 7.69 (d, 1H), 7.36-7.61 (m, 8H), 7.26 (d, 1H), 7.09 (t, 1H), 6.90 (d, 1H), 5.22 (t, 1H), 4.59 (d, 2H), 4.20 (t, 2H), 2.25 (m, 2H).

EXAMPLE 71A

ethyl 7-bromo-5-chloro-3-(3-ethoxy-3-oxopropyl)-1H-indole-2-carboxylate

This example was prepared by substituting 2-bromo-4-chloroaniline for 2-bromoaniline in EXAMPLE 1A.

EXAMPLE 71B

ethyl 7-bromo-5-chloro-3-(3-hydroxypropyl)-1H-indole-2-carboxylate

This example was prepared by substituting EXAMPLE 71A for EXAMPLE 1A in EXAMPLE 1B.

EXAMPLE 71C

ethyl 7-bromo-5-chloro-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting EXAMPLE 71B for EXAMPLE 1B in EXAMPLE 1C.

EXAMPLE 71D

5-chloro-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting EXAMPLE 71C for EXAMPLE 1C and 2-methylphenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (400 MHz, DMSO-d_6) δ 10.92 (s, 1H), 8.27 (m, 1H), 7.87 (m, 1H), 7.74 (d, 1H), 7.51 (m, 3H), 7.30 (m, 5H), 6.99 (d, 1H), 6.91 (d, 1H), 4.20 (t, 2H), 2.22 (m, 2H), 2.05 (s, 3H).

EXAMPLE 72

7-(3-methylpyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting 2-bromo-3-methylpyridine for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 11.20 (s, 1H), 8.71 (d, 1H), 8.26 (m, 2H), 7.88 (m, 3H), 7.37-7.56 (m, 5H), 7.17 (t, 1H), 6.90 (d, 1H), 4.20 (t, 2H), 2.27 (s, 3H), 2.24 (m, 2H).

EXAMPLE 73

7-(2,6-dimethylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting 3-bromo-2,6-dimethylpyridine for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.10 (m, 1H), 11.31 (s, 1H), 8.23 (m, 2H), 7.88 (m, 3H), 7.36-7.54 (m, 4H), 7.15 (t, 2H), 6.90 (d, 1H), 4.20 (t, 2H), 2.76 (s, 3H), 2.36 (s, 3H), 2.24 (m, 2H).

EXAMPLE 74

7-(6-amino-2-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared TFA salt by substituting 6-amino-3-bromo-2-methylpyridine for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.72 (m, 1H), 13.05 (m, 1H), 11.24 (s, 1H), 8.24 (dd, 1H), 7.88 (dd, 1H), 7.73

(m, 4H), 7.36-7.56 (m, 4H), 7.10 (d, 2H), 6.88 (t, 2H), 4.19 (t, 2H), 2.25 (m, 2H), 2.13 (s, 3H).

EXAMPLE 75

3-(3-(1-naphthyloxy)propyl)-7-(2-piperazin-1-ylphenyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting EXAMPLE 43A for (E)-styrylboronic acid and 1-(2-bromophenyl)-piperazine for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.12 (brs, 1H), 10.36 (s, 1H), 8.42 (brs, 2H), 8.25 (m, 1H), 7.88 (m, 1H), 7.75 (d, 1H), 7.46 (m, 6H), 7.29 (m, 1H), 7.15 (m, 3H), 6.89 (m, 1H), 4.20 (t, 2H), 2.96 (m, 4H), 2.25 (m, 2H).

EXAMPLE 76A

ethyl 7-bromo-1-(methoxymethyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

To an ice bath cooled mixture of EXAMPLE 1C (2.0 g) in THF (20 mL) was added 60% oily NaH (265 mg). The mixture was stirred for 30 minutes before adding chloromethyl methyl ether (0.54 mL). The mixture was stirred for 3 hours and overnight at room temperature, quenched by adding saturated NH_4Cl mixture and extracted with diethylether. The extract was washed with water and brine and dried (Na_2SO_4), filtered and concentrated. The concentrate was purified with flash column chromotography on silica gel with 5% ethyl acetate/hexanes.

EXAMPLE 76B

7-(4-(3-chlorophenyl)piperazin-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

A mixture of EXAMPLE 76A (100 mg), 1-(3-chlorophenyl)piperazine (48 mg), tris(dibenzylideneacetone)dipalladium(0) (9.2 mg), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (13.1 mg) and Cs_2CO_3 (195 mg) in toluene (5 mL) was heated at reflux overnight. The mixture was partitioned between ethyl acetate (200 mL) and water (50 mL). The organic layer was washed with brine and dried (Na_2SO_4), filtered and concentrated. The concentrate was purified by column chromatography on silica gel with 1:4ethyl acetate:hexanes to provide the ethyl ester. The ester was treated with 2M HCl in diethylether (5 mL), concentrated, and treated with $LiOH \cdot H_2O$ (100 mg) in 2/1/2 THF/methanol/water, stirred

overnight at room temperature and concentrated. The product was purified by reverse phase HPLC (C-18, 20 to 100 % acetonitrile/water/0.1% TFA). ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.98 (m, 1H), 10.90 (s, 1H), 8.24 (dd, 1H), 7.86 (dd, 1H), 7.35-7.54 (m, 5H), 7.25 (t, 1H), 6.82-7.03 (m, 6H), 4.18 (t, 2H), 3.45 (m, 4H), 3.15 (m, 4H), 2.20 (m, 2H).

EXAMPLE 77A

ethyl 7-bromo-1-(2-morpholino-2-oxoethyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

To a mixture of 60% oily NaH (0.03 g) in DMF (5 mL) was added EXAMPLE 1C (0.25 g) in DMF (10 mL). After stirring at room temperature for 30 minutes, 2-chloro-1-morpholinoethanone (0.1 g) was added, and the mixture was stirred for three hours. Water (20 mL) and dichloromethane were added, and the organic layer was washed with water and brineand concentrated. The concentrate was purified by preparative reverse phase HPLC (Zorbax SB, C-18 with 30%-100% acetonitrile/ water/0.1% TFA).

EXAMPLE 77B

ethyl 7-bromo-1-(2-morpholinoethyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

To a mixture of EXAMPLE 77A (0.15 g) in THF (10 mL) was added 1M BH_3·THF (1.8 mL). The mixture was stirred at room temperature for 16 hours, quenched with methanol (5 mL) and concentrated. The concentrate was dissolved in ethanol (40 mL) and treated with 12N HCl (0.5 mL). After stirring for three hours, the mixture was concentrated, and the concentrate was purified by preparative reverse phase HPLC (Zorbax SB, C-18, 30% to 100% acetonitrile/water/0.1% TFA).

EXAMPLE 77C

7-(2-methylphenyl)-1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting EXAMPLE 77B for EXAMPLE 1C and 2-methylphenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.23 (m, 1H), 7.88 (m, 1H), 7.81 (d, 1H), 7.45 (m, 8H), 7.15 (t, 1H), 7.01 (d, 1H), 6.92 (d, 1H), 4.64 (m, 1H), 4.24 (t, 2H), 4.02 (m,

1H), 3.61 (m, 4H), 2.23 (m, 2H), 2.00 (s, 3H).

EXAMPLE 78A

ethyl 7-bromo-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting 5,6,7,8-tetrahydronaphthalen-1-ol for 1-naphthol in EXAMPLE 1C.

EXAMPLE 78B

7-(2-methylphenyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic

This example was prepared by substituting EXAMPLE 78A for EXAMPLE 1C and 2-methylphenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 10.41 (brs, 1H), 7.65 (m, 1H), 7.27 (m, 4H), 7.11 (t, 1H), 7.04 (d, 1H), 6.99 (t, 1H), 6.64 (t, 2H), 3.98 (t, 2H), 3.25 (t, 2H), 2.66 (m, 4H), 2.08 (m, 5H), 1.71 (m, 4H).

EXAMPLE 79

5-chloro-3-(3-(1-naphthyloxy)propyl)-7-phenyl-1H-indole-2-carboxylic acid

This example was prepared by substituting EXAMPLE 71C for EXAMPLE 1C and phenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 10.41 (s, 1H), 7.65 (m, 1H), 7.27 (m, 4H), 7.11 (t, 1H), 7.04 (d, 1H), 6.99 (t, 1H), 6.64 (t, 2H), 3.98 (t, 2H), 3.25 (t, 2H), 2.66 (m, 4H), 2.08 (m, 5H), 1.71 (m, 4H).

EXAMPLE 80

5-chloro-7-(4-chloro-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting EXAMPLE 71C for EXAMPLE 1C and 4-chloro-2-methylphenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 11.24 (s, 1H), 8.26 (m, 1H), 7.87 (m, 1H), 7.75 (d, 1H), 7.46 (m, 5H), 7.31 (m, 1H), 7.21 (d, 1H), 7.00 (d, 1H), 6.91 (d, 1H), 4.19 (t, 2H), 2.21 (m, 2H), 2.03 (s, 3H).

EXAMPLE 81

5-chloro-7-cyclopent-1-en-1-yl-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting EXAMPLE 71C for EXAMPLE 1C and 1-cyclopenteneboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 10.49 (s, 1H), 8.22 (m, 1H), 7.86 (m, 1H), 7.62 (d, 1H), 7.49 (m, 3H), 7.38 (t, 1H), 7.09 (d, 1H), 6.87 (d, 1H), 6.39 (m, 1H), 4.15 (t, 2H), 2.77 (m, 2H), 2.59 (m, 2H), 2.19 (m, 2H), 1.98 (m, 2H).

EXAMPLE 82

7-(3,5-dichloropyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting 2-bromo-3,5-dichloropyridine for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.05 (m, 1H), 11.10 (s, 1H), 8.70 (s, 1H), 8.35 (s, 1H), 8.26 (dd, 1H), 7.87 (dd, 1H), 7.79 (d, 1H), 7.53 (m, 2H), 7.40 (d, 1H), 7.36 (t, 1H), 7.30 (d, 1H), 7.09 (t, 1H), 6.90 (d, 1H), 4.20 (t, 2H), 3.35 (m, 2H), 2.24 (m, 2H).

EXAMPLE 83

7-(5-(aminocarbonyl)pyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting 6-bromonicotinamide for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.30 (m, 1H), 11.47 (s, 1H), 9.27 (s, 1H), 8.36 (s, 2H), 8.20 (d, 2H), 8.13 (d, 1H), 7.87 (t, 2H), 7.63 (s, 1H), 7.50 (m, 3H), 7.37 (t, 1H), 7.18 (t, 1H), 6.88 (d, 1H), 4.20 (t, 2H), 3.39 (m, 2H), 2.27 (m, 2H).

EXAMPLE 84

7-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting 2-bromo-3-chloro-5-trifluoromethylpyridine for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.10 (m, 1H), 11.17 (s, 1H), 9.04 (s, 1H), 8.57 (s, 1H), 8.26 (m, 1H), 7.85 (m, 2H), 7.36-7.57 (m, 5H), 7.11 (t, 1H), 6.89 (d, 1H), 4.20 (t, 2H), 3.39 (m, 2H), 2.25 (m, 2H).

EXAMPLE 85

7-(5-amino-2-(trifluoromethoxy)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 3-bromo-4-trifluoromethoxyaniline for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 10.47 (s, 1H), 8.26 (dd, 1H), 7.86 (dd, 1H), 7.70 (d, 1H), 7.54 (m, 2H), 7.41 (d, 1H), 8.37 (t, 1H), 7.10 (m, 3H), 6.89 (d, 1H), 6.69 (d, 1H), 6.66 (s, 1H), 4.19 (t, 2H), 2.23 (m, 2H).

EXAMPLE 86

7-(5-carboxy-2-methoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting methyl 3-bromo-4-methoxybenzoate for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.80 (m, 1H), 10.65 (s, 1H), 8.26 (m, 1H), 8.02 (dd, 1H), 7.89 (m, 1H), 7.81 (s, 1H), 7.70 (d, 1H), 7.53 (m, 3H), 7.40 (d, 1H), 7.36 (t, 1H), 7.22 (d, 1H), 7.12 (d, 1H), 7.05 (t, 1H), 6.91 (d, 1H), 4.21 (t, 2H),3.80 (t, 3H), 2.25 (m, 2H).

EXAMPLE 87

7-(4-carboxy-2-nitrophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting methyl 4-bromo-3-nitrobenzoate for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.60 (m, 1H), 13.00 (m, 1H), 11.31 (s, 1H), 8.56 (s, 1H), 8.26 (dd, 1H), 7.88 (m, 1H), 7.74 (m, 1H), 7.65 (d, 1H), 7.53 (m, 3H), 7.40 (d, 1H), 7.36 (t, 1H), 7.22 (d, 1H), 7.12 (d, 1H), 7.05 (m, 1H), 6.91 (d, 1H), 4.21 (t, 2H), 3.37 (t, 2H), 2.25 (m, 2H).

EXAMPLE 88

7-(5-carboxy-2-chlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting methyl 3-bromo-4-chlorobenzoate for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.00 (m, 1H), 11.18 (s, 1H), 8.26 (m, 1H), 7.98 (d, 1H), 7.88 (m, 1H), 7.74 (m, 1H), 7.68 (d, 1H), 7.53 (m, 3H), 7.40 (d, 1H), 7.36 (t, 1H), 7.09 (m, 2H), 6.91 (d, 1H), 4.21 (t, 2H), 3.37 (t, 2H), 2.25 (m, 2H).

EXAMPLE 89A

1-benzyl-3-methyl-1,2,3,6-tetrahydropyridin-4-yl trifluoromethanesulfonate

This example was prepared by substituting 1-benzyl-3-methylpiperidin-4-one for 2-phenylcyclohexanone in EXAMPLE 59A.

EXAMPLE 89B

7-(1-benzyl-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting EXAMPLE 43A for (E)-styrylboronic acid and EXAMPLE 89A for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.22 (s, 1H), 10.77 (10.55) (s, 1H), 9.99 (9.54) (s, 1H), 8.22 (d, 1H), 7.86 (d, 1H), 7.63 (m, 3H), 7.45 (m, 8H), 7.03 (m, 2H), 6.88 (d, 1H), 5.82 (m, 1H), 4.51 (m, 2H), 4.18 (t, 2H), 3.80 (m, 2H), 2.98 (m, 1H), 2.20 (m, 2H), 0.92 (0.78) (d, 3H).

EXAMPLE 90

7-(4-amino-2-(trifluoromethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 4-bromo-3-trifluoromethylaniline for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.90 (m, 1H), 10.62 (s, 1H), 8.26 (m, 1H), 7.87 (m, 1H), 7.65 (d, 1H), 7.53 (m, 3H), 7.40 (d, 1H), 7.36 (t, 1H), 7.09 (m, 3H), 6.89 (d, 1H), 6.82 (d, 1H), 4.20 (t, 2H), 3.35 (t, 2H), 2.20 (m, 2H).

EXAMPLE 91

7-(1,4-dioxa-8-azaspiro(4.5)dec-8-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 1,4-dioxa-8-azaspiro(4.5)decane for 1-(3-chlorophenyl)piperazine in EXAMPLE 76B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 10.88 (s, 1H), 8.24 (m, 1H), 7.86 (m, 1H), 7.35-7.54 (m, 5H), 6.86 (m, 3H), 4.16 (t, 2H), 3.93 (s, 4H), 3.33 (t, 2H), 3.17 (m, 4H), 2.19 (m, 2H), 1.94 (m, 4H).

EXAMPLE 92

7-(3-carboxypiperidin-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting methyl piperidine-3-carboxylate for 1-(3-chlorophenyl)piperazine in EXAMPLE 76B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.00 (m,

1H), 11.10 (s, 1H), 8.24 (m, 1H), 7.86 (m, 1H), 7.30-7.55 (m, 5H), 6.86 (m, 2H), 6.74 (d, 1H), 4.16 (t, 2H), 3.70 (m, 1H), 2.72-3.06 (m, 5H), 2.20 (m, 4H), 1.72 (m, 3H).

EXAMPLE 93

7-(4-carboxypiperidin-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting methyl piperidine-4-carboxylate for 1-(3-chlorophenyl)piperazine in EXAMPLE 76B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 11.00 (m, 1H), 8.22 (m, 1H), 7.86 (m, 1H), 7.35-7.54 (m, 5H), 6.97 (m, 2H), 6.86 (d, 1H), 4.16 (t, 2H), 3.45 (m, 4H), 3.29 (t, 2H), 2.90 (m, 1H), 2.19 (t, 2H), 2.00 (m, 4H).

EXAMPLE 94

3-(3-(1-naphthyloxy)propyl)-7-pyrrolidin-1-yl-1H-indole-2-carboxylic acid

This example was prepared by substituting pyrrolidine for 1-(3-chlorophenyl)piperazine in EXAMPLE 76B.^{1}H NMR (300 MHz, DMSO-d_6) δ 10.40 (m, 1H), 8.22 (m, 1H), 7.86 (m, 1H), 7.35-7.54 (m, 5H), 7.21 (d, 1H), 6.90 (m, 2H), 6.86 (d, 1H), 6.70 (m, 1H), 4.16 (t, 2H), 3.30 (t, 2H), 2.19 (t, 2H), 1.99 (m, 4H).

EXAMPLE 95

7-morpholin-4-yl-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting morpholine for 1-(3-chlorophenyl)piperazine in EXAMPLE 76B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 10.91 (m, 1H), 8.22 (m, 1H), 7.86 (m, 1H), 7.34-7.53 (m, 5H), 6.92 (m, 2H), 6.80 (d, 1H), 4.16 (t, 2H), 3.86 (m, 4H), 3.30 (t, 2H), 2.98 (m, 4H), 2.19 (t, 2H).

EXAMPLE 96

3-(3-(1-naphthyloxy)propyl)-7-piperidin-1-yl-1H-indole-2-carboxylic acid

This example was prepared by substituting piperidine for 1-(3-chlorophenyl)piperazine in EXAMPLE 76B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 8.21 (m, 1H), 7.86 (m, 1H), 7.35-7.56 (m, 6H), 7.09 (m, 1H), 6.88 (d, 1H), 4.16 (t, 2H), 3.35 (t, 2H), 2.19 (m, 2H), 1.87 (m, 4H), 1.63 (m, 2H).

EXAMPLE 97

7-(4-(aminosulfonyl)-2-(trifluoromethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-

carboxylic acid

This example was prepared by substituting 4-bromo-3-(trifluoromethyl)benzenesulfonamide for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.98 (m, 1H), 11.31 (s, 1H), 8.26 (m, 1H), 8.23 (s, 1H), 8.08 (d, 1H), 7.86 (m, 1H), 7.76 (dd, 1H), 7.36-7.63 (m, 7H), 7.05 (m, 2H), 6.90 (d, 1H), 4.21 (t, 2H), 3.40 (t, 2H), 2.23 (m, 2H).

EXAMPLE 98A

tert-butyl 4-bromo-3-methylbenzoate

To a mixture of methyl 4-bromo-3-methylbenzoate (4.85 g) and tert-butyl acetate (3 mL) was added 1M potassium tert-butoxide in THF (0.3 mL). The mixture was stirred under vacuum for 10 minutes and treated with another equivalent of tert-butyl acetate and 1 mol % of (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium(II) dichloromethane. This procedure was repeated three times. The mixture was diluted with ethyl acetate (40 mL) and washed with 5% aqueous HCl, water and brine. After drying over Na_2SO_4, the mixture was concentrated.

EXAMPLE 98B

tert-butyl 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate

This example was prepared by substituting EXAMPLE 98A for EXAMPLE 1C in EXAMPLE 43A.

EXAMPLE 98C

ethyl 7-(4-(tert-butoxycarbonyl)-2-methylphenyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting EXAMPLE 98B for 2-methoxyphenylboronic acid and EXAMPLE 1C for EXAMPLE 1B in EXAMPLE 47A.

EXAMPLE 98D

4-(2-(ethoxycarbonyl)-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoic acid

A mixture of EXAMPLE 98C in dichoromethane (5 mL) and TFA (5 mL) was stirred at room temperature overnight and concentrated. The concentrate was partitioned between water (50 mL) and ethyl acetate (200 mL), and the organic phase was washed with brine and

dried (Na_2SO_4), filtered and concentrated. ^1H NMR (300 MHz, DMSO-d_6) δ 12.88 (m, 1H), 11.00 (s, 1H), 8.22 (m, 1H), 7.85 (m, 3H), 7.86 (m, 1H), 7.73 (d, 1H), 7.32-7.55 (m, 5H), 7.08 (m, 2H), 6.92 (d, 1H), 4.25 (m, 4H), 3.36 (t, 2H), 2.24 (t, 2H), 2.10 (s, 3H), 1.26 (t, 3H).

EXAMPLE 99

7-(2-methyl-4-(morpholin-4-ylcarbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

To a mixture of EXAMPLE 98D (75 mg) and morpholine (32 mg) in dichloromethane (2 mL) was added 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride (58 mg) and DMAP (38 mg). The mixture was stirred at room temperature overnight and concentrated. The concentrate was diluted with ethyl acetate (150 mL), washed with 5% HCl, water and brine and dried (Na_2SO_4), filtered and concentrated. The concentrate was dissolved in THF (4 mL), methanol (2 mL) and water (2 mL). $LiOH \cdot H_2O$ (100 mg) was added to the mixture and the mixture was stirred overnight. The mixture was concentrated, the concentrate was acidified with 5% HCl and extracted with ethyl acetate. The extract was washed with brine and dried (Na_2SO_4), filtered and concentrated. The concentrate was purified by reverse phase HPLC (C-18, 30 to 100 % acetonitrile/ water/0.1% TFA) . ^1H NMR (300 MHz, DMSO-d_6) δ 12.95 (m, 1H), 10.79 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.71 (d, 1H), 7.35-7.57 (m, 6H), 7.27 (s, 1H), 7.08 (m, 2H), 6.90 (d, 1H), 4.21 (t, 1H), 3.64 (m, 8H), 3.37 (t, 2H), 2.26 (t, 2H), 2.07 (s, 3H).

EXAMPLE 100

7-(4-((4-carboxypiperidin-1-yl)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting methyl piperidine-4-carboxylate for morpholine in EXAMPLE 99. ^1H NMR (300 MHz, DMSO-d_6) δ 10.78 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.71 (d, 1H), 7.32-7.54 (m, 5H), 7.25 (s, 1H), 7.08 (m, 2H), 6.91 (d, 1H), 4.21 (t, 2H), 3.39 (t, 2H), 3.00 (m, 4H), 2.26 (t, 2H), 2.08 (s, 3H), 1.90 (m, 1H), 1.65 (m, 4H).

EXAMPLE 101

7-(4-((3-carboxypiperidin-1-yl)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting methyl piperidine-3-carboxylate for morpholine in EXAMPLE 99. ^{1}H NMR (300 MHz, DMSO-d_6) δ 10.82 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.71 (d, 1H), 7.32-7.54 (m, 5H), 7.26 (s, 1H), 7.08 (m, 2H), 6.91 (d, 1H), 4.21 (t, 2H), 3.38 (t, 2H), 3.05 (m, 4H), 2.26 (t, 2H), 2.08 (s, 3H), 1.86 (m, 5H).

EXAMPLE 102

7-(4-(carboxymethylcarbamoyl)-2-methylphenyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting methyl 2-aminoacetate for morpholine in EXAMPLE 99. ^{1}H NMR (300 MHz, DMSO-d_6) δ 10.83 (s, 1H),8.83 (t, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.85 (s, 1H), 7.71 (m, 2H), 7.32-7.54 (m, 4H), 7.29 (d, 1H), 7.08 (m, 2H), 6.91 (d, 1H), 4.21 (t, 2H), 3.96 (d, 2H), 3.37 (t, 2H), 2.24 (m, 2H), 2.11 (s, 3H).

EXAMPLE 103A

ethyl 7-bromo-3-(3-oxopropyl)-1H-indole-2-carboxylate

To a cooled (0°C) mixture of EXAMPLE 1B (3.26 g) in dichloromethane (5 mL) was added DMSO (1 mL) and triethylamine (0.835 mL) followed by pyridine sulfate (636 mg). The mixture was stirred for 2 hours, diluted with ethyl acetate (150 mL), and washed with 5% HCl, saturated $NaHCO_3$, water and brine and dried (Na_2SO_4), filtered and concentrated.

EXAMPLE 103B

ethyl 7-bromo-3-(3-(3,4-dihydroquinolin-1 (2H)-yl)propyl)-1H-indole-2-carboxylate

To a mixture of EXAMPLE 103A (325 mg) and 1,2,3,4-tetrahydroquinoline (160 mg) in dichloroethane (10 mL) was added sodium acetate (310 mg). The mixture was stirred at ambient temperature overnight, diluted with ethyl acetate (200 mL) and washed with 1N NaOH, water, and brine. After drying over sodium sulfate and concentration, the concentrate was loaded on a silica gel cartridge and eluted with 5% ethyl acetate in hexane.

EXAMPLE 103C

3-(3-(3,4-dihydroquinolin-1 (2H)-yl)propyl)-7-(2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-trifluoromethyl-phenylboronic acid for

EXAMPLE 43A and EXAMPLE 103B for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, $CDCl_3$) δ 8.43 (t, 1H), 7.85 (dd, 1H), 7.57-7.67 (m, 3H), 7.44 (d, 1H), 7.01-7.26 (m, 4H), 3.43 (m, 4H), 3.26 (t, 2H), 2.85 (t, 2H), 2.10 (m, 4H).

EXAMPLE 104A

ethyl 7-bromo-3-(3-(3-phenoxyphenoxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting 3-phenoxyphenol for 1-naphthol in EXAMPLE 1C.

EXAMPLE 104B

7-(2-methylphenyl)-3-(3-(3-phenoxyphenoxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting EXAMPLE 104A for EXAMPLE 1C and 2-methylphenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 10.45 (s, 1H), 7.64 (d, 1H), 7.30 (m, 7H), 7.05 (m, 5H), 6.70 (m, 1H), 6.53 (m, 2H), 3.97 (t, 2H), 3.21 (t, 2H), 2.06 (s, 5H).

EXAMPLE 105A

ethyl 7-bromo-3-(3-(2,3-dimethylphenoxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting 2,3-dimethylphenol for 1-naphthol in EXAMPLE 1C.

EXAMPLE 105B

3-(3-(2,3-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting EXAMPLE 105A for EXAMPLE 1C and 2-methylphenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.96 (brs, 1H), 10.46 (s, 1H), 7.66 (d, 1H), 7.27 (m, 4H), 7.11 (t, 1H), 7.01 (m, 2H), 6.73 (t, 2H), 3.98 (t, 2H), 3.27 (t, 2H), 2.22 (s, 3H), 2.13 (s, 3H), 2.10 (m, 2H), 2.06 (s, 3H)

EXAMPLE 106

7-(4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting 4-methyl-3-pyridylboronic

acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.98 (brs, 1H), 11.18 (s, 1H), 8.56 (d, 1H), 8.47 (s, 1H), 8.25 (m, 1H), 7.86 (m, 1H), 7.77 (m, 1H), 7.52 (m, 3H), 7.42 (m, 2H), 7.10 (m, 2H), 6.91 (m, 1H), 4.21 (t, 2H), 2.24 (m, 2H), 2.12 (s, 3H).

EXAMPLE 107

7-(2-methylbenzyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methylbenzylbromide for EXAMPLE 1C and EXAMPLE 43A for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.00 (brs, 1H), 11.30 (s, 1H), 8.24 (m, 1H), 7.86 (m, 1H), 7.45 (m, 5H), 7.13 (m, 3H), 6.89 (m, 3H), 6.68 (d, 1H), 4.27 (s, 2H), 4.18 (t, 2H), 2.22 (m, 5H).

EXAMPLE 108

3,3'-bis(3-(1-naphthyloxy)propyl)-1H,1'H-7,7'-biindole-2,2'-dicarboxylic acid

This example was prepared as a side product by substituting EXAMPLE 43A for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.94 (brs, 2H), 10.26 (s, 2H), 8.27 (m, 2H), 7.87 (m, 2H), 7.76 (d, 2H), 7.43 (m, 10H), 7.14 (t, 2H), 6.92 (d, 2H), 4.23 (t, 4H), 3.40 (t, 4H), 2.27 (m, 4H).

EXAMPLE 109A

ethyl 7-bromo-3-(4-ethoxy-4-oxobutyl)-1H-indole-2-carboxylate

This example was prepared by substituting ethyl 2-oxocyclohexanecarboxylate for ethyl 2-oxocyclopentanecarboxylate in EXAMPLE 1A.

EXAMPLE 109B

ethyl 7-bromo-3-(4-hydroxybutyl)-1H-indole-2-carboxylate

This example was prepared by substituting EXAMPLE 109A for EXAMPLE 1A in EXAMPLE 1B.

EXAMPLE 109C

ethyl 7-bromo-3-(4-oxobutyl)-1H-indole-2-carboxylate

This example was prepared by substituting EXAMPLE 109B for EXAMPLE 1B in EXAMPLE 103A.

EXAMPLE 109D

ethyl 7-bromo-3-(4-(3,4-dihydroquinolin-1 (2H)-yl)butyl)-1H-indole-2-carboxylate

This example was prepared by substituting EXAMPLE 109C for EXAMPLE 103A in EXAMPLE 103B.

EXAMPLE 109E

3-(4-(3,4-dihydroquinolin-1 (2H)-yl)butyl)-7-(2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-trifluoromethyl-phenylboronic acid for EXAMPLE 43A and EXAMPLE 109D for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 10.93 (s, 1H), 7.83 (dd, 1H), 7.63 (m, 3H), 7.39 (d, 1H), 7.10 (t, 1H), 7.02 (d, 1H), 6.95 (t, 1H), 6.85 (d, 1H), 6.52 (d, 1H), 6.42 (t, 1H), 3.21 (m, 4H), 2.63 (t, 2H), 1.84 (m, 2H), 1.62 (m, 4H).

EXAMPLE 110

7-(4-carboxy-2-methylphenyl)-3-(4-(3,4-dihydroquinolin-1 (2H)-yl)butyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 4-(methoxycarbonyl)-2-methylphenylboronic acid for EXAMPLE 43A and EXAMPLE 109D for 4-bromo-3-methylphenol in EXAMPLE 43B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 10.76 (s, 1H), 7.89 (s, 1H), 7.82 (dd, 1H), 7.71 (dd, 1H), 7.32 (d, 1H), 7.15 (t, 1H), 7.06 (d, 1H), 6.91 (t, 1H), 6.83 (d, 1H), 6.50 (d, 1H), 6.43 (t, 1H), 3.22 (m, 4H), 3.64 (t, 2H), 2.09 (s, 3H), 1.81 (m, 2H), 1.61 (m, 4H).

EXAMPLE 111A

ethyl 7-bromo-3-(3-iodopropyl)-1H-indole-2-carboxylate

To a mixture of EXAMPLE 1B (1.116 g) in dichloromethane (30 mL) at 0°C was added iodine (1.01 g), triphenyl phosphine (1.03 g) and imidazole (0.535 g). The mixture was stirred at 0°C for 1 hour and treated with saturated $NaHCO_3$ (50 mL). Stirring was continued for 30 minutes, and the organic layer was washed with a saturated aqueous $Na_2S_2O_3$ (50 mL), water (20 mL), and brine (50 mL) and dried (Na_2SO_4), filtered and concentrated. The concentrate was purified by column chromatography on silica gel (with 0-20% ethyl acetate

in hexanes.

EXAMPLE 111B

(3-(7-bromo-2-(ethoxycarbonyl)-1H-indol-3-yl)propyl)triphenylphosphonium iodide

To a mixture of EXAMPLE 111A (0.136 g) in CH_3CN (5 mL) was added triphenylphosphine (157 mg). The mixture was refluxed for 48 hours, cooled to room temperature, washed with hexanes and concentrated.

EXAMPLE 111C

ethyl 7-bromo-3-(4-(naphthalen-1-yl)but-3-enyl)-1H-indole-2-carboxylate

A mixture of 60% oily sodium hydride (40 mg) in DMSO (5 mL) was heated for 1 hour at 80 °C, cooled to 15 °C and treated with Example 111B (0. 797 g). The mixture was stirred for 10 minutes, treated with 1-napthalaldehyde (0. 156 g) and heated for 3 hours at 80°C. After standing overnight at room temperature, the mixture was poured into saturated $NaHSO_4$ mixture and extracted with diethylether. The extract was washed with water and brine and dried ($MgSO_4$), filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel chromatography with 0-20% ethyl acetate in hexanes.

EXAMPLE 111D

3-(4-(naphthalen-1-yl)but-3-enyl)-7-o-tolyl-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methylphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 111C for EXAMPLE 1C in EXAMPLE 1D.

EXAMPLE 111E

7-(2-methylphenyl)-3-(4-(1-naphthyl)butyl)-1H-indole-2-carboxylic acid

A mixture of EXAMPLE 111D and Pd/C (catalytic) in ethyl acetate/ethanol was stirred at room temperature under hydrogen (balloon) overnight. The mixture was filtered, washed with ethyl acetate/ethanol and concentrated. The concentrate was purified on reverse phase HPLC (Zorbax SB-C18, 20100 % acetonitrile / water / 0.1% TFA) . ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.82 (brs, 1H), 10.36 (s, 1H), 8.03 (m, 1H), 7.90(m, 1H), 7.75 (d, 1H), 7.66 (d, 1H), 7.51 (m, 2H), 7.31 (m, 6H), 7.12 (t, 1H), 7.03 (m, 1H), 3.17 (m, 2H), 3.09 (m, 2H), 2.05 (s, 3H), 1.78 (m, 4H).

EXAMPLE 112A

ethyl 7-bromo-3-(4-(naphthalen-1-yloxy)butyl)-1H-indole-2-carboxylate

This example was prepared by substituting EXAMPLE 109B for EXAMPLE 1B in EXAMPLE 1C.

EXAMPLE 112B

7-(2-methylphenyl)-3-(4-(1-naphthyloxy)butyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methylphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 112A for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.87 (brs, 1H), 10.42 (s, 1H), 8.12 (d, 1H), 7.85 (d, 1H), 7.70 (d, 1H), 7.37 (m, 8H), 7.12 (t, 1H), 7.05 (m, 1H), 6.94 (d, 1H), 4.19 (m, 2H), 3.22 (m, 2H), 2.06 (s, 3H), 1.93 (m, 4H).

EXAMPLE 113A

ethyl 7-bromo-3-(3-(2,4-dimethylphenoxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting 2,4-dimethylphenol for 1-naphthol in EXAMPLE 1C.

EXAMPLE 113B

3-(3-(2,4-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methylphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 113A for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.88 (brs, 1H), 10.45 (s, 1H), 7.65 (d, 1H), 7.27 (m, 4H), 7.10 (t, 1H), 7.04 (dd, 1H), 6.92 (m, 2H), 6.73 (d, 1H), 3.97 (t, 2H), 3.25 (t, 2H), 2.19 (s, 3H), 2.17 (s, 3H), 2.07 (m, 5H).

EXAMPLE 114A

ethyl 7-bromo-3-(3-(2,5-dimethylphenoxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting 2,5-dimethylphenol for 1-napthol in EXAMPLE 1C.

EXAMPLE 114B

3-(3-(2,5-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting methyl 2-amino-3-(4-chlorophenyl)propanoate for morpholine in EXAMPLE 99. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.84 (m, 1H), 10.84 (s, 1H), 8.70 (d, 1H), 8.25 (m, 1H), 7.86 (m, 1H), 7.78 (s, 1H), 7.71 (d, 1H), 7.29-7.54 (m, 8H), 7.26 (d, 1H), 7.06 (m, 2H), 6.90 (d, 1H), 4.70 (m, 1H), 4.20 (t, 2H), 3.36 (t, 2H), 3.21 (dd, 2H), 2.23 (m, 2H), 2.08 (s, 3H).

EXAMPLE 119

N-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-L-tryptophan

This example was prepared by substituting methyl ester (L)-tryptophan for morpholine in EXAMPLE 99. ^{1}H NMR (300 MHz, DMSO-d_6) δ 10.81 (d, 1H), 8.60 (d, 1H), 8.25 (m, 1H), 7.86 (m, 1H), 7.79 (s, 1H), 7.70 (t, 1H), 7.64 (d, 1H), 7.22-7.54 (m, 9H), 7.04 (m, 4H), 6.90 (d, 1H), 4.75 (m, 1H), 4.20 (t, 2H), 3.36 (t, 2H), 2.23 (m, 2H), 2.08 (s, 3H).

EXAMPLE 120

(3S)-2-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

This example was prepared by substituting (3S)-methyl 1,2,3,4-tetrahydroisoquinolinecarboxylate for morpholine in EXAMPLE 99. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.94 (m, 1H), 10.84 (d, 1H), 8.26 (m, 1H), 7.88 (m, 1H), 7.76 (m, 1H), 7.09-7.55 (m, 13H), 6.91 (d, 1H), 5.20 (t, 1H), 5.05 (d, 1H), 4.90 (m, 1H), 4.70 (dd, 1H), 4.50 (d, 1H), 4.22 (t, 2H), 3.38 (t, 2H), 2.27 (m, 2H), 2.08 (s, 3H).

EXAMPLE 121

N-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-L-tyrosine

This example was prepared by substituting methyl ester L-tyrosine for morpholine in EXAMPLE 99. ^{1}H NMR (300 MHz, DMSO-d_6) δ 10.84 (s, 1H), 9.17 (s, 1H), 8.60 (d, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.79 (s, 1H), 7.74 (m, 1H), 7.53 (m, 2H), 7.40 (d, 1H), 7.36 (d, 1H), 7.26 (d, 1H), 7.08 (m, 4H), 6.90 (d, 1H), 6.66 (d, 2H), 4.60 (m, 1H), 4.20 (t, 2H), 3.36 (t, 2H), 3.00 (m, 3H), 2.23 (m, 2H), 2.08 (s, 3H).

EXAMPLE 122

7-(4-((R)-2-carboxypyrrolidine-1-carbonyl)-2-methylphenyl)-3-(3-(naphthalen-1-

yloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting methyl ester L-proline for morpholine in EXAMPLE 99. ^{1}H NMR (300 MHz, DMSO-d_6) δ 10.80 (s, 1H), 8.25 (m, 1H), 7.86 (m, 1H), 7.71 (d, 1H), 7.36-7.54 (m, 6H), 7.28 (d, 1H), 7.08 (m, 2H), 6.91 (d, 1H), 4.45 (m, 1H), 4.20 (t, 2H), 3.64 (t, 2H), 2.25 (m, 2H), 2.08 (s, 3H), 1.92 (m, 3H).

EXAMPLE 123

7-(4-((S)-1-carboxyethylcarbamoyl)-2-methylphenyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting methyl ester L-alanine for morpholine in EXAMPLE 99. ^{1}H NMR (300 MHz, DMSO-d_6) δ 10.81 (s, 1H), 8.66 (d, 1H), 8.25 (m, 1H), 7.87 (m, 2H), 7.78 (d, 1H), 7.71 (d, 1H), 7.36-7.54 (m, 4H), 7.30 (d, 1H), 7.06 (m, 2H), 6.91 (d, 1H), 4.47 (m, 1H), 4.21 (t, 2H), 3.37 (t, 2H), 2.25 (m, 2H), 2.08 (s, 3H), 1.42 (d, 3H).

EXAMPLE 124

N-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-4-nitro-L-phenylalanine

This example was prepared by substituting methyl 2-amino-3-(4-nitrophenyl)propanoate for morpholine in EXAMPLE 99. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.90 (s, 1H), 10.83 (s, 1H), 8.78 (d, 1H), 8.25 (m, 1H), 8.17 (d, 2H), 7.87 (m, 2H), 7.71 (s, 1H), 7.70 (d, 1H), 7.63 (d, 2H), 7.36-7.54 (m, 4H), 7.26 (d, 1H), 7.06 (m, 2H), 6.91 (d, 1H), 4.80 (m, 1H), 4.20 (t, 2H), 3.36 (t, 2H), 2.23 (m, 2H), 2.08 (s, 3H).

EXAMPLE 125

N-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-L-phenylalanine

This example was prepared by substituting methyl ester L-phenylalanine for morpholine in EXAMPLE 99. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.80 (m, 1H), 10.84 (s, 1H), 8.68 (d, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.78 (s, 1H), 7.72 (d, 1H), 7.22-7.54 (m, 10H), 7.06 (m, 2H), 6.91 (d, 1H), 4.70 (m, 1H), 4.20 (t, 2H), 3.36 (t, 2H), 3.21 (m, 3H), 2.23 (m, 2H), 2.08 (s, 3H).

EXAMPLE 126

7-(4-((((S)-carboxy(phenyl)methyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting (S)-methyl 2-amino-2-phenylacetate for morpholine in EXAMPLE 99. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.92 (s, 1H), 10.79 (s, 1H), 9.02 (d, 1H), 8.25 (m, 1H), 7.93 (s, 1H), 7.85 (m, 2H), 7.70 (d, 1H), 7.31-7.54 (m, 9H), 7.28 (d, 1H), 7.06 (m, 2H), 6.90 (d, 1H), 5.66 (d, 1H), 4.70 (m, 1H), 4.20 (t, 2H), 3.36 (t, 2H), 2.23 (m, 2H), 2.10 (s, 3H).

EXAMPLE 127A

3-methyl-4-(4,4,5,5-tetramethyl-(1,3,2)dioxaborolan-2-yl)-benzoic acid methyl ester

This example was prepared by substituting 4-bromo-3-methyl-benzoic acid methyl ester for EXAMPLE 1C in EXAMPLE 43A.

EXAMPLE 127B

3-(3-hydroxypropyl)-7-(4-methoxycarbonyl-2-methyl-phenyl)-1H-indole-2-carboxylic acid ethyl ester

This example was prepared by substituting EXAMPLE 1B for EXAMPLE 1C and EXAMPLE 127A for 2-methoxyphenylboronic acid in EXAMPLE 47A.

EXAMPLE 127C

7-(4-methoxycarbonyl-2-methyl-phenyl)-3-(3-(toluene-4-sulfonyloxy)-propyl)-1H-indole-2-carboxylic acid ethyl ester

To a mixture of EXAMPLE 127B (2.0 g), toluene-2-sulfonyl chloride (1.16 g) in dichloromethane (30 mL) was added DMAP (0.305 g). The mixture was stirred at room temperature overnight. The mixture was diluted with ethyl acetate (300 mL) and washed with saturated aqueous sodium bicarbonate mixture, 3% aqueous HCl, water and brine. After drying over Na_2SO_4 and filtering, the mixture was concentrated.

EXAMPLE 127D

7-(4-carboxy-2-methylphenyl)-3-(3-(2,4,5-trichlorophenoxy)propyl)-1H-indole-2-carboxylic acid

To a mixture of EXAMPLE 127C (60 mg) in DMF (1 mL) was added 2,4,5-trichlorophenol (43 mg) and Cs_2CO_3 (500 mg). The mixture was stirred at room temperature

overnight, diluted with ethyl acetate (150 mL), and washed with water and brine. After drying over Na_2SO_4, the combined organic layers were concentrated, and the concentrate was saponified with LiOH as described in EXAMPLE 65B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.92 (m, 1H), 10.88 (s, 1H), 7.89 (s, 1H), 7.82 (m, 2H), 7.38 (s, 1H), 7.32 (d, 1H), 7.10 (m, 2H), 4.13 (t, 2H), 3.25 (t, 2H), 2.13 (m, 2H), 2.10 (s, 3H).

EXAMPLE 128

7-(4-carboxy-2-methylphenyl)-3-(3-(2,3,4-trichlorophenoxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2,3,4-trichlorophenol for 2,4,5-trichlorophenol in EXAMPLE 127D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.86 (m, 1H), 10.87 (s, 1H), 7.89 (s, 1H), 7.82 (dd, 2H), 7.69 (dd, 1H), 7.56 (d, 1H), 7.32 (d, 1H), 7.06 (m, 3H), 4.13 (t, 2H), 3.25 (t, 2H), 2.13 (m, 2H), 2.10 (s, 3H).

EXAMPLE 129

7-(4-carboxy-2-methylphenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2,3,5-trimethylphenol for 2,4,5-trichlorophenol in EXAMPLE 127D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.86 (m, 1H), 10.85 (s, 1H), 7.89 (s, 1H), 7.82 (dd, 1H), 7.69 (dd, 1H), 7.32 (d, 1H), 7.13 (t, 1H), 7.06 (d, 1H), 3.97 (t, 2H), 3.26 (t, 2H), 2.13 (m, 2H), 2.14 (s, 3H), 2.10 (s, 3H), 2.08 (S, 3H).

EXAMPLE 130

3-(3-(2-tert-butylphenoxy)propyl)-7-(4-carboxy-2-methylphenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-tert-butylphenol for 2,4,5-trichlorophenol in EXAMPLE 127D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.88 (m, 1H), 10.88 (s, 1H), 7.90 (s, 1H), 7.82 (dd, 1H), 7.72 (dd, 1H), 7.32 (d, 1H), 7.22 (d, 1H), 7.17 (t, 1H), 7.06 (d, 1H), 6.80 (m, 2H), 4.07 (t, 2H), 2.14 (m, 2H), 2.11 (s, 3H), 1.41 (s, 9H).

EXAMPLE 131

7-(4-carboxy-2-methylphenyl)-3-(3-(2-(trifluoromethyl)phenoxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-trifluoromethylphenol for 2,4,5-trichlorophenol in EXAMPLE 127D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.87 (m, 1H), 10.87 (s, 1H), 7.94 (s, 1H), 7.82 (dd, 1H), 7.61 (m, 4H), 7.32 (d, 1H), 7.20 (d, 1H), 7.06 (m, 4H), 4.15 (t, 2H), 3.24 (t, 2H), 2.10 (s, 3H), 2.07 (m, 2H).

EXAMPLE 132

7-(4-carboxy-2-methylphenyl)-3-(3-(quinolin-8-yloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting quinolin-8-ol for 2,4,5-trichlorophenol in EXAMPLE 127D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.84 (m, 1H), 10.88 (s, 1H), 9.05 (dd, 1H), 8.76 (m, 1H), 7.89 (s, 1H), 7.67-7.83 (m, 5H), 7.32 (m, 2H), 7.03 (m, 2H), 4.27 (t, 2H), 3.35 (t, 2H), 2.28 (m, 2H), 2.09 (s, 3H).

EXAMPLE 133

7-(4-carboxy-2-methylphenyl)-3-(3-((5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)oxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 5-hydroxy-3,4-dihydro-2H-naphthalen-1-one for 2,4,5-trichlorophenol in EXAMPLE 127D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.87 (m, 1H), 10.85 (s, 1H), 7.89 (s, 1H), 7.82 (d, 1H), 7.70 (d, 1H), 7.46 (d, 1H), 7.30 (m, 2H), 7.03 (m, 3H), 4.07 (t, 2H), 3.26 (t, 2H), 2.90 (t, 2H), 2.58 (t, 3H), 2.13 (m, 2H), 2.09 (s, 3H).

EXAMPLE 134

3-(3-(3-benzoylphenoxy)propyl)-7-(4-carboxy-2-methylphenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting (3-hydroxy-phenyl)-phenyl-methanone for 2,4,5-trichlorophenol in EXAMPLE 127D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.86 (m, 1H), 10.84 (s, 1H), 7.89 (s, 1H), 7.82 (d, 1H), 7.68 (m, 3H), 7.50 (t, 2H), 7.44 (t, 1H), 7.32 (d, 2H), 7.25 (t, 2H), 7.06 (m, 2H), 4.06 (t, 2H), 3.24 (t, 2H), 2.13 (m, 2H), 2.09 (s, 3H).

EXAMPLE 135A

ethyl 7-bromo-1-(2-morpholino-2-oxoethyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting EXAMPLE 78A for EXAMPLE 1C in EXAMPLE 77A.

EXAMPLE 135B

ethyl 7-bromo-1-(2-morpholinoethyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting EXAMPLE 135A for EXAMPLE 77A in EXAMPLE 77B.

EXAMPLE 135C

7-(2-methylphenyl)-1-(2-morpholin-4-ylethyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting 2-methylphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 135B for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.43 (brs, 1H), 7.77 (d, 1H), 7.41 (m, 4H), 7.20 (t, 1H), 7.01 (m, 2H), 6.65 (m, 2H), 4.66 (m, 1H), 4.02 (m, 4H), 3.26 (t, 2H), 2.66 (m, 8H), 2.05 (m, 6H), 1.72 (m, 4H).

EXAMPLE 136

7-(4-(cyclohexyloxy)phenyl)-3-(4-(1-naphthyloxy)butyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 4-cyclohexyloxyphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 112A for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.98 (brs, 1H), 10.21 (s, 1H), 8.12 (d, 1H), 7.85 (d, 1H), 7.66 (d, 1H), 7.46 (m, 6H), 7.22 (d, 1H), 7.13 (t, 1H), 7.06 (d, 2H), 6.94 (d, 1H), 4.40 (m, 1H), 4.19 (m, 2H), 3.21 (m, 2H), 1.95 (m, 6H), 1.75 (m, 2H), 1.41 (m, 6H).

EXAMPLE 137

7-(1,1'-biphenyl-2-yl)-1-(2-morpholin-4-ylethyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared as a TFA salt by substituting 2-biphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 135B for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 13.17 (brs, 1H), 7.57 (m, 5H), 7.05 (m, 8H), 6.62 (m, 2H), 4.69 (m, 1H), 4.03 (m, 1H), 3.87 (t, 2H), 3.15 (t, 2H), 2.76 (m, 10H), 1.96 (m, 2H), 1.71 (m, 4H).

EXAMPLE 138A

ethyl 7-bromo-3-(3-(3,4-dimethylphenoxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting 3,4-dimethylphenol for 1-naphthol in EXAMPLE 1C.

EXAMPLE 138B

3-(3-(3,4-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methylphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 138A for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.90 (brs, 1H), 10.47 (s, 1H), 7.66 (d, 1H), 7.27 (m, 4H), 7.05 (m, 3H), 6.66 (m, 2H), 3.95 (t, 2H), 3.22 (t, 2H), 2.17 (s, 3H), 2.13 (s, 3H), 2.05 (m, 5H).

EXAMPLE 139A

ethyl 7-bromo-3-(3-(3,5-dimethylphenoxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting 3,5-dimethylphenol for 1-naphthol in EXAMPLE 1C.

EXAMPLE 139B

3-(3-(3,5-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methylphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 139A for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.88 (brs, 1H), 10.48 (s, 1H), 7.67 (d, 1H), 7.28 (m, 4H), 7.08 (m, 2H), 6.52 (m, 3H), 3.96 (t, 2H), 3.22 (t, 2H), 2.21 (s, 6H), 2.06 (m, 5H).

EXAMPLE 140A

ethyl 7-bromo-3-(3-(2,3-dimethoxyphenoxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting 2,3-dimethoxyphenol for 1-naphthol in EXAMPLE 1C.

EXAMPLE 140B

3-(3-(2,3-dimethoxyphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methylphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 140A for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 9.92 (brs, 1H), 7.65 (m, 1H), 7.28 (m, 4H), 7.09 (m, 1H), 7.01 (d, 1H), 6.94 (m, 1H), 6.61 (m, 2H), 4.02 (t, 2H), 3.77 (s, 3H), 3.73 (s, 3H), 3.25 (t, 2H), 2.08

(m, 5H).

EXAMPLE 141A

ethyl 7-bromo-3-(3-(naphthalen-1-ylamino)-3-oxopropyl)-1H-indole-2-carboxylate

A mixture of 3-(7-bromo-2-(ethoxycarbonyl)-1H-indol-3-yl)propanoic acid (0.68 g), naphthalen-1-amine (0.294 g), DMAP (0.363 g) and 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride (0.576 g) was stirred for 3 days at room temperature. The product precipitated and was filtered, washed with dichloromethane, and dried under vacuum.

EXAMPLE 141B

ethyl 7-bromo-3-(3-(naphthalen-1-ylamino)propyl)-1H-indole-2-carboxylate

To EXAMPLE 141A (0.465 g) was added a mixture of 1M BH_3·THF (4 mL), and the mixture was stirred for 16 hours, quenched with methanol and concentrated. The concentrate was treated with HCl and ethanol, and the mixture was concentrated. The concentrate was partitioned between saturated sodium bicarbonate and dichloromethane. The organic layer was dried (Na_2SO_4), filtered and concentrated. The concentrate was purified by flash column chromatography on silica gel with 0-30 % ethyl acetate/hexanes.

EXAMPLE 141C

7-(2-methylphenyl)-3-(3-(1-naphthylamino)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methylphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 141B for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 12.99 (brs, 1H), 10.46 (s, 1H), 8.14 (d, 1H), 7.73 (m, 2H), 7.25 (m, 10H), 6.47 (d, 1H), 3.26 (m, 4H), 2.09 (m, 5H).

EXAMPLE 142A

ethyl 7-bromo-1-(2-methoxy-2-oxoethyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting methyl 2-chloroacetate for 2-chloro-1-morpholinoethanone in EXAMPLE 77A.

EXAMPLE 142B

1-(carboxymethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methylphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 142A for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (300 MHz, DMSO-d_6) δ 13.15 (brs, 1H), 12.37 (brs, 1H), 8.26 (m, 1H), 7.88 (m, 1H), 7.78 (m, 1H), 7.39 (m, 7H), 7.12 (m, 2H), 6.94 (m, 2H), 4.77 (brs, 1H), 4.49 (brs, 1H), 4.23 (t, 2H), 2.23 (m, 2H), 1.96 (s, 3H).

EXAMPLE 143A

ethyl 7-bromo-3-(3-(3-dimethylaminophenoxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting 3-dimethylaminophenol for 1-naphthol in EXAMPLE 1C.

EXAMPLE 143B

3-(3-(3-(dimethylamino)phenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methylphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 143A for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.90 (brs, 1H), 10.48 (s, 1H), 7.68 (m, 1H), 7.26 (m, 4H), 7.07 (m, 3H), 6.37 (m, 3H), 3.99 (t, 2H), 3.22 (t, 2H), 2.90 (s, 6H), 2.06 (m, 5H).

EXAMPLE 144A

morpholino(4-nitro-3-(trifluoromethyl)phenyl)methanone

To a mixture of 4-nitro-3-trifluoromethylbenzoic acid (10 g), morpholine (3.7 g) in dichloromethane (300 mL) was added DMAP (5.2 g) and 1-ethyl-3-(3-(dimethylamino)propyl)-carbodiimide hydrochloride (12.3 g). The mixture was stirred at room temperature overnight, washed with 5% aqueous HCl, water and brine and concentrated.

EXAMPLE 144B

(4-amino-3-(trifluoromethyl)phenyl)(morpholino)methanone

A mixture of EXAMPLE 144A (13 g) and Pd/C (1.3 g, 10%) in ethanol (300 mL) was stirred under hydrogen at room temperature for two days. The catalyst was filtered off and the solvent was evaporated to provide the final compound.

EXAMPLE 144C

(4-bromo-3-(trifluoromethyl)phenyl)(morpholino)methanone

To a mixture of EXAMPLE 144B (8.3 g) was added water (75 mL) and H_2SO_4 (25 mL). The mixture was stirred at 0°C while $NaNO_2$ (3.13 g) in water (30 mL) was added. After stirring for 1 hour, the mixture was added to CuBr (5.45 g) in 48% HBr (200 mL). This mixture was stirred at 60°C for 3 hours, cooled to room temperature, and partitioned between water and ethyl acetate. The organic layer was washed with aqueous Na_2CO_3 and dried (Na_2SO_4), filtered and concentrated.

EXAMPLE 144D

3-(4-oxo-butyl)-7-(4,4,5,5-tetramethyl-(1,3,2)dioxaborolan-2-yl)-1H-indole-2-carboxylic acid ethyl ester

A mixture of EXAMPLE 109C (2.3 g), bis(pinacolato)diboron (2.1 g), potassium acetate (3.34 g) and (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium(II) (278 mg) in DMF (40 mL) was stirred at 60°C overnight and concentrated. The concentrate was partitioned between dichloromethane and water. The aqueous phase was further extracted with dichloromethane. The extract was washed with water and brine and dried (Na_2SO_4), filtered and concentrated. The concentrate was purified by flash chromatography on silica gel with 5% ethyl acetate in hexanes.

EXAMPLE 144E

ethyl 7-(4-(morpholine-4-carbonyl)-2-(trifluoromethyl)phenyl)-3-(4-oxobutyl)-1H-indole-2-carboxylate

To a mixture of EXAMPLE 144D (1.67 g) and EXAMPLE 144C (1.53 g) in dimethoxyethane (80 mL) was added tris(dibenzylideneacetone)dipalladium(0) (201 mg), tri-tert-butylphosphine tetrafluoroborate (128 mg) and CsF (1.97 g). The mixture was stirred at ambient temperature overnight, diluted with ethyl acetate (200 mL), washed with water and brine and dried (Na_2SO_4), filtered and concentrated. The concentrate was purified on silica gel with 20% ethyl acetate in hexanes.

EXAMPLE 144F

3-(4-(3,4-dihydroquinolin-1 (2H)-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid

To a mixture of EXAMPLE 144E (52 mg) and 1,2,3,4-tetrahydroquinoline (27 mg) in dichloroethane (2 mL) was added sodium triacetoxyborohydride (50 mg). The mixture was stirred at ambient temperature overnight, diluted with ethyl acetate (200 mL), washed with water and brine, and dried over sodium sulfate. Evaporation of the solvent and flash column purification on silica gel with 20% ethyl acetate in hexanes provided the ethyl ester which was saponified with LiOH as described in EXAMPLE 65B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 11.09 (s, 1H), 8.29 (s, 1H), 8.21 (dd, 1H), 7.74 (d, 1H), 7.54 (d, 1H), 7.13 (d, 1H), 7.05 (d, 1H), 6.90 (t, 1H), 6.86 (d, 1H), 6.52 (d, 1H), 6.43 (t, 1H), 3.20 (m, 12H), 2.64 (t, 2H), 1.81 (m, 2H), 1.61 (m, 6H).

EXAMPLE 145

3-(4-(2-methyl-3,4-dihydroquinolin-1 (2H)-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methyl-1,2,3,4-tetrahydroquinoline for 1,2,3,4-tetrahydroquinoline in EXAMPLE 144F. ^{1}H NMR (300 MHz, DMSO-d_6) δ 11.09 (s, 1H), 8.29 (s, 1H), 8.22 (dd, 1H), 7.74 (d, 1H), 7.54 (d, 1H), 7.13 (t, 1H), 7.05 (d, 1H), 6.93 (t, 1H), 6.86 (d, 1H), 6.45 (m, 2H), 3.35 (m, 4H), 3.17 (m, 12H), 2.72 (m, 2H), 1.69 (m, 6H), 1.04 (d, 3H).

EXAMPLE 146

3-(4-(6-methyl-3,4-dihydroquinolin-1 (2H)-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 6-methyl-1,2,3,4-tetrahydroquinoline for 1,2,3,4-tetrahydroquinoline in EXAMPLE 144F. ^{1}H NMR (300 MHz, DMSO-d_6) δ 11.09 (s, 1H), 8.29 (s, 1H), 8.21 (dd, 1H), 7.72 (d, 1H), 7.53 (d, 1H), 7.12 (t, 1H), 7.05 (d, 1H), 6.75 (d, 1H), 6.69 (s, 1H), 6.48 (m, 1H), 3.17 (m, 12H), 2.62 (t, 2H), 2.11 (s, 3H), 1.83 (t, 2H), 1.63 (m, 4H).

EXAMPLE 147

3-(4-(6-methoxy-3,4-dihydroquinolin-1 (2H)-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 6-methoxy-1,2,3,4-tetrahydroquinoline for 1,2,3,4-tetrahydroquinoline in EXAMPLE 144F. ^{1}H NMR (300 MHz, DMSO-d_6) δ 11.11 (s, 1H), 8.29 (s, 1H), 8.21 (dd, 1H), 7.75 (d, 1H), 7.53 (d, 1H), 7.13 (t, 1H), 7.06 (d, 1H), 6.61 (m, 3H), 3.65 (s, 3H), 3.17 (m, 12H), 2.69 (m, 2H), 1.86 (m, 2H), 1.6 (m, 4H).

EXAMPLE 148

3-(4-(ethyl(1-naphthyl)amino)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting ethyl-naphthalen-1-yl-amine for 1,2,3,4-tetrahydroquinoline in EXAMPLE 144F. ^{1}H NMR (300 MHz, DMSO-d_6) δ 11.06 (s, 1H), 8.29 (s, 1H), 8.21 (dd, 1H), 7.20-8.00 (m, 8H), 7.04 (m, 3H), 3.17 (m, 12H), 1.63 (m, 5H), 0.95 (t, 3H).

EXAMPLE 149

3-(4-(2,3-dihydro-1H-indol-1-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2,3-dihydro-1H-indole for 1,2,3,4-tetrahydroquinoline in EXAMPLE 144F. ^{1}H NMR (300 MHz, DMSO-d_6) δ 11.09 (s, 1H), 8.29 (s, 1H), 8.21 (dd, 1H), 7.74 (d, 1H), 7.54 (d, 1H), 6.93-7.14 (m, 4H), 6.55 (t, 1H), 6.47 (d, 1H), 3.14 (m, 12H), 2.85 (m, 3H), 1.67 (m, 5H).

EXAMPLE 150

3-(4-(2-methyl-2,3-dihydro-1H-indol-1-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2,3-dihydro-2-methyl-1H-indole for 1,2,3,4-tetrahydroquinoline in EXAMPLE 144F. ^{1}H NMR (300 MHz, DMSO-d_6) δ 11.09 (s, 1H), 8.29 (s, 1H), 8.21 (dd, 1H), 7.74 (d, 1H), 7.54 (d, 1H), 7.12 (t, 1H), 7.07 (d, 1H), 6.49 (t, 1H), 6.33 (d, 1H), 3.62 (m, 2H), 3.14 (m, 12H), 1.70 (m, 5H), 1.18 (d, 3H).

EXAMPLE 151

7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-3-(4-(5-nitro-2,3-dihydro-1H-indol-1-yl)butyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2,3-dihydro-5-nitro-1H-indole for 1,2,3,4-

tetrahydroquinoline in EXAMPLE 144F. ^{1}H NMR (300 MHz, DMSO-d_6) δ 11.09 (s, 1H), 8.29 (s, 1H), 8.21 (dd, 1H), 7.96 (dd, 1H), 7.79 (s, 1H), 7.74 (d, 1H), 7.53 (d, 1H), 7.06 (m, 3H), 6.42 (d, 1H), 3.61 (t, 3H), 3.14 (m, 10H), 3.04 (t, 2H), 1.67 (m, 5H).

EXAMPLE 152

3-(4-(5-bromo-2,3-dihydro-1H-indol-1-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 5-bromo-2,3-dihydro-1H-indole for 1,2,3,4-tetrahydroquinoline in EXAMPLE 144F. ^{1}H NMR (300 MHz, DMSO-d_6) δ 11.10 (s, 1H), 8.29 (s, 1H), 8.22 (dd, 1H), 7.74 (d, 1H), 7.54 (d, 1H), 7.06 (m, 4H), 6.38 (d, 1H), 3.17 (m, 10H), 3.04 (t, 2H), 2.86 (t, 2H), 1.67 (m, 5H).

EXAMPLE 153

3-(4-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 3,4-dihydro-2H-benzo(1,4)oxazine for 1,2,3,4-tetrahydroquinoline in EXAMPLE 144F. ^{1}H NMR (300 MHz, DMSO-d_6) δ 11.09 (s, 1H), 8.29 (s, 1H), 8.21 (dd, 1H), 7.74 (d, 1H), 7.53 (d, 1H), 7.12 (t, 1H), 7.05 (d, 1H), 6.71 (t, 1H), 6.65 (d, 2H), 6.46 (t, 1H), 4.12 (t, 2H), 3.14 (m, 10H), 1.65 (m, 6H).

EXAMPLE 154A

ethyl 7-bromo-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting 2,3,5-trimethylphenol for 1-naphthol in EXAMPLE 1C.

EXAMPLE 154B

7-(2-methylphenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methylphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 154A for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.89 (brs, 1H), 10.47 (s, 1H), 7.66 (d, 1H), 7.27 (m, 4H), 7.11 (t, 1H), 7.04 (d, 1H), 6.54 (d, 2H), 3.97 (t, 2H), 3.26 (t, 2H), 2.18 (s, 3H), 2.17 (s, 3H), 2.07 (m, 8H).

EXAMPLE 155A

ethyl 7-bromo-3-(3-(2,3,6-trimethylphenoxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting 2,3,6-trimethylphenol for 1-naphthol in EXAMPLE 1C.

EXAMPLE 155B

7-(2-methylphenyl)-3-(3-(2,3,6-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methylphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 155A for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.89 (brs, 1H), 10.47 (s, 1H), 7.71 (d, 1H), 7.28 (m, 4H), 7.15 (t, 1H), 7.05 (d, 1H), 6.89 (d, 1H), 6.80 (d, 1H), 3.76 (t, 2H), 3.27 (t, 2H), 2.16 (s, 3H), 2.16 (s, 3H), 2.11 (m, 5H), 2.06 (s, 3H).

EXAMPLE 156A

ethyl 7-bromo-3-(3-(2,3-dichlorophenoxy)propyl)-1H-indole-2-carboxylate

This example was prepared by substituting 2,3-dichlorophenol for 1-naphthol in EXAMPLE 1C.

EXAMPLE 156B

3-(3-(2,3-dichlorophenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting 2-methylphenylboronic acid for (E)-styrylboronic acid and EXAMPLE 156A for EXAMPLE 1C in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 10.48 (brs, 1 H), 7.66 (d, 1H), 7.30 (m, 4H), 7.21 (m, 2H), 7.06 (m, 3H), 4.12 (t, 2H), 3.27 (t, 2H), 2.12 (m, 2H), 2.05 (s, 3H).

EXAMPLE 157A

7-bromo-3-(4-ethoxycarbonyl-butyl)-1H-indole-2-carboxylic acid ethyl ester

This example was prepared by substituting 2-oxo-cycloheptanecarboxylic acid ethyl ester for 2-oxo-cyclopentanecarboxylic acid ethyl ester in EXAMPLE 1A.

EXAMPLE 157B

7-bromo-3-(5-hydroxy-pentyl)-1H-indole-2-carboxylic acid ethyl ester

This example was prepared by substituting EXAMPLE 157A for EXAMPLE 1A in

EXAMPLE 1B.

EXAMPLE 157C

7-bromo-3-(5-(5,6,7,8-tetrahydro-naphthalen-1-yloxy)-pentyl)-1H-indole-2-carboxylic acid ethyl ester

This example was prepared by substituting EXAMPLE 157A for EXAMPLE 1B and 5,6,7,8-tetrahydronaphthol for 1-naphthol in EXAMPLE 1C.

EXAMPLE 157D

7-(2-methylphenyl)-3-(5-(5,6,7,8-tetrahydronaphthalen-1-yloxy)pentyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting EXAMPLE 157C for EXAMPLE 1C and 2-methylphenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.82 (brs, 1H), 10.35 (s, 1H), 7.66 (d, 1H), 7.28 (m, 4H), 7.13 (t, 1H), 7.01 (m, 2H), 6.67 (d, 1H), 6.61 (d, 1H), 3.91 (t, 2H), 3.11 (t, 2H), 2.66 (m, 2H), 2.06 (s, 3H), 1.72 (m, 8H), 1.53 (m, 2H).

EXAMPLE 158A

7-bromo-3-(5-(naphthalen-1-yloxy)-pentyl)-1H-indole-2-carboxylic acid ethyl ester

This example was prepared by substituting EXAMPLE 157B for EXAMPLE 1B in EXAMPLE 1C.

EXAMPLE 158B

7-(2-methylphenyl)-3-(5-(1-naphthyloxy)pentyl)-1H-indole-2-carboxylic acid

This example was prepared by substituting EXAMPLE 158A for EXAMPLE 1C and 2-methylphenylboronic acid for (E)-styrylboronic acid in EXAMPLE 1D. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.81 (brs, 1H), 10.37 (s, 1H), 8.12 (d, 1H), 7.85 (d, 1H), 7.68 (d, 1H), 7.46 (m, 4H), 7.28 (m, 4H), 7.12 (m, 1H), 7.04 (m, 1H), 6.95 (d, 1H), 4.15 (t, 2H), 3.15 (t, 2H), 2.06 (s, 3H), 1.92 (m, 2H), 1.77 (m, 2H), 1.63 (m, 2H).

EXAMPLE 159

7-(2,3-dimethylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.92 (s, 1H), 10.35 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.69 (dd, 1H), 7.52 (m, 2H), 7.42 (m, 2H), 7.19 (m, 2H), 7.04 (m, 3H), 6.91 (dd, 1H), 4.21 (t, 2H), 3.37 (m, 2H), 2.32 (s, 3H), 2.24 (m, 2H), 1.94 (s, 3H).

EXAMPLE 160

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 8.37-8.45 (m, 2H), 8.19-8.26 (m, 1H), 7.84-7.91 (m, 2H), 7.36-7.57 (m, 4H), 7.13-7.28 (m, 3H), 6.83-7.00 (m, 4H), 6.59-6.67 (m, 2H), 5.52-5.63 (m, 1H), 5.17-5.30 (m, 1H), 4.26 (t, 2H), 2.24-2.35 (m, 2H), 1.76 (s, 3H).

EXAMPLE 162

7-(2-(4-fluorophenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.95 (s, 1H), 10.78 (s, 1H), 8.23-8.24 (m, 1H), 7.85-7.87 (m, 1H), 7.35-7.54 (m, 5H), 7.02-7.05 (m, 2H), 6.84 (d, J = 7.63 Hz, 1H), 6.76-6.79 (m, 4H), 4.42 (t, J = 6.87 Hz, 2H), 4.10-4.13 (m, 2H), 3.25 (br, 2H), 2.39-2.42 (m, 4H), 2.21-2.26 (m, 2H), 1.86 (br, 4H).

EXAMPLE 163

7-(3,5-dimethyl-1-(2-(2-oxopyrrolidin-1-yl)ethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.96 (s, 1H), 10.42 (s, 1H), 8.25-8.27 (m, 1H), 7.86-7.88 (m, 1H), 7.65 (d, J = 7.63 Hz, 1H), 7.38-7.55 (m, 4H), 7.25-7.28 (m, 1H), 7.01-7.07 (m, 2H), 6.91 (d, J = 7.63 Hz, 1H), 4.16-4.22 (m, 4H), 4.03 (br, 4H), 3.34-3.37 (m, 2H), 2.21-2.26 (m, 2H), 2.11-2.14 (m, 2H), 2.05 (s, 3H), 1.98 (s, 3H), 1.87-1.93 (m, 2H).

EXAMPLE 164

1-(tert-butoxycarbonyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)benzyl)-1H-indole-2-carboxylic acid

EXAMPLE 164A

7-bromo-1H-indole

1-bromo-2-nitrobenzene (6.000 g, 29.7 mmol) was added to tetrahydrofuran (65 mL) and cooled to – 40 °C. Vinylmagnesiumbromide (1M in tetrahydrofuran, 89 mL) was added quickly. The solution was stirred for 20 minutes and then poured into a saturated aqueous solution of ammonium chloride. The solution was extracted with diethyl ether and dried with brine and anhydrous sodium sulfate. The solution was concentrated and purified by flash column chromatography on silica gel with 5% ethyl acetate in hexanes to provide the title compound.

EXAMPLE 164B

7-o-tolyl-1H-indole

EXAMPLE 164A (2.500 g), *o*-tolylboronic acid (1.907 g), and sodium carbonate (2M aqueous solution, 19.13 mL) were added to dioxane (43 mL). The solution was degassed and flushed with nitrogen three times. Dichloro(1,1'-bis(diphenylphosphino)ferrocene)palladium (II) dichloromethane adduct (833 mg) was added and the solution was heated at 80 °C overnight. The solution was cooled, added to 1M aqueous HCl, extracted with 20% ethyl acetate / hexanes, and dried with brine and anhydrous sodium sulfate. The solution was concentrated and purified by flash column chromatography on silica gel with 5% ethyl acetate in hexanes to provide the title compound.

EXAMPLE 164C

3-(naphthalen-1-yloxy)benzaldehyde

1-iodonaphthalene (2.000 g) and 3-hydroxybenzaldehyde (1.442 g) were added to dioxane (25 mL). The solution was degassed and flushed with nitrogen three times. Cesium carbonate (5.13 g), N,N-dimethylglycine hydrochloride (82 mg), and copper (I) iodide (30 mg) were added, and the solution was heated at 90°C overnight. The solution was cooled, added to 1M aqueous HCl, extracted with diethyl ether, dried with brine and anhydrous sodium sulfate. The solution was concentrated and purified by flash column chromatography on silica gel with 10% ethyl acetate in hexanes to provide the title compound.

EXAMPLE 164D

3-(3-(naphthalen-1-yloxy)benzyl)-7-o-tolyl-1H-indole

EXAMPLE 164B (133 mg) and EXAMPLE 164C (175 mg) were dissolved in dichloromethane (3 mL) and added drop-wise to a solution of trifluoroacetic acid (0.074 mL,

110 mg) and triethylsilane (0.307 mL, 224 mg) in dichloromethane (3 mL), which had been cooled to 0°C. The solution was mixed for one hour at 0°C, quenched with a saturated aqueous solution of ammonium chloride, extracted with ethyl acetate, and dried with brine and anhydrous sodium sulfate. The solution was concentrated and purified by flash column chromatography on silica gel with 5% increasing to 10% ethyl acetate in hexanes to provide the title compound.

EXAMPLE 164E

tert-butyl 3-(3-(naphthalen-1-yloxy)benzyl)-7-o-tolyl-1H-indole-1-carboxylate

EXAMPLE 164D (158 mg) and 4-dimethylaminopyridine (4.4 mg) were added to acetonitrile (3 mL). Di-tert-butyl dicarbonate (0.088 mL, 82 mg) was added, and the solution was mixed at ambient temperature for 30 minutes. The solution was concentrated and purified by flash column chromatography on silica gel with 5% ethyl acetate in hexanes to provide the title compound.

EXAMPLE 164F

1-tert-butyl 2-methyl 3-(3-(naphthalen-1-yloxy)benzyl)-7-o-tolyl-1H-indole-1,2-dicarboxylate

EXAMPLE 164E (161 mg) was added to tetrahydrofuran (3 mL). The solution was cooled to –78°C, and tert-butyl lithium (1.7M in pentane, 0.193 mL) was added slowly. The solution was mixed at –78°C for 45 minutes, and methyl chloroformate (0.025 mL, 30.5 mg) was added. The solution was mixed at –78°C for 30 minutes and was allowed to warm to ambient temperature. The solution was concentrated and purified by flash column chromatography on silica gel with 5% ethyl acetate in hexanes to provide the title compound.

EXAMPLE 164G

1-(tert-butoxycarbonyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)benzyl)-1H-indole-2-carboxylic acid

EXAMPLE 164F (35 mg, 0.059mmol) was dissolved in a mixture of tetrahydrofuran (0.6 mL), water (0.2 mL), and methanol (0.2 mL). Lithium hydroxide monohydrate (9.8 mg, 0.234 mmol) was added and the solution was mixed overnight at ambient temperature. The solution was made slightly acidic using 1M HCl, extracted with ethyl acetate, and dried with anhydrous sodium sulfate. Solvent was removed under vacuum to provide the title compound. ^{1}H NMR (300MHz, DMSO-d_6) δ 13.72 (br s, 1H), 8.05 (dd, 1H), 7.98 (dd, 1H),

7.73 (d, 1H), 7.66 (dd, 1H), 7.61-7.49 (m, 2H), 7.44 (t, 1H), 7.31-7.18 (m, 5H), 7.12 (dd, 2H), 7.06 (td, 2H), 6.95 (dd, 1H), 6.78 (dd, 1H), 4.35 (s, 2H), 1.99 (d, 3H), 1.17 (s, 9H).

EXAMPLE 165

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)benzyl)-1H-indole-2-carboxylic acid

EXAMPLE 164G (35 mg) was dissolved in dichloromethane (2 mL). Triethylsilane (0.011 mL, 7.7mg) and trifluoroacetic acid (0.018 mL, 27 mg) were added, and the solution was mixed overnight at ambient temperature. The solution was concentrated and purified by flash column chromatography on silica gel with 50% ethyl acetate in hexanes to provide the title compound. ^{1}H NMR (300MHz, DMSO-d_6) δ 12.98 (broad s, 1H), 10.61 (s, 1H), 8.05 (dd, 1H), 7.98 (dd, 1H), 7.71 (d, 1H), 7.63-7.49 (m, 3H), 7.43 (t, 1H), 7.35-7.19 (m, 6H), 7.14-7.07 (m, 2H), 7.04 (dd, 1H), 6.93 (dd, 1H), 6.75 (ddd, 1H), 4.48 (s, 2H), 1.99 (s, 3H).

EXAMPLE 166

7-(2-methylphenyl)-4-((E)-2-phenylvinyl)-1H-indole-2-carboxylic acid

EXAMPLE 166A

(Z)-ethyl 2-azido-3-(5-bromo-2-chlorophenyl)acrylate

To a solution of sodium ethoxide in ethanol (15 mL) cooled to –10 °C was added dropwise a solution of 5-bromo-2- chlorobenzaldehyde (1.0 g) and ethyl 2-azidoacetate (11 mL, 18 mmol) in ethanol-tetrahydrofuran (15 mL-3 mL). The reaction mixture was stirred at –10 °C for 3 hours, allowed to warm to 10 °C over 3 hours and poured onto crushed ice. The solid was collected by filtration and dried in a vacuum oven to provide the title compound.

EXAMPLE 166B

ethyl 7-bromo-4-chloro-1H-indole-2-carboxylate

To a refluxing solution of 1,2-dichlorobenzene (17 mL) was added dropwise EXAMPLE 166A (1.2 g, 3.7 mmol) over 3 hours. The solution was heated under reflux for another 2 hours. The solvent was removed under reduced pressure and the residue was purified by flash chromatography (0-20% ethyl acetate in hexanes) to provide the title compound.

EXAMPLE 166C

ethyl 4-chloro-7-o-tolyl-1H-indole-2-carboxylate

To a solution of EXAMPLE 166B (610 mg), o-tolylboronic acid (330 mg), cesium fluoride (930 mg) in dioxane (5 mL) was added tetrakis(triphenylphosphine)palladium (240 mg). The resulting mixture was heated under reflux overnight and concentrated. The residue was diluted with ethyl acetate and saturated ammonium acetate, and the layers were separated. The aqueous layer was extracted with ethyl acetate (x2) and the combined organic layers were washed with brine, dried over $MgSO_4$, filtered and concentrated. The residue was purified by flash chromatography (0-20% ethyl acetate in hexanes) to provide the title compound.

EXAMPLE 166D

To a solution of EXAMPLE 166C (80 mg), (E)-styryl boronic acid (76 mg), cesium fluoride (120 mg) in dioxane-methanol (0.4 mL-0.1 mL) was added palladium acetate (5.7 mg) and (2-biphenyl)dicyclohexylphosphine (18 mg). The resulting mixture was heated under reflux overnight, treated with aqueous lithium hydroxide (0.5 mL, 2N), heated under reflux for 5 hours and concentrated. The residue was diluted with ethyl acetate and saturated ammonium acetate, and the layers were separated. The aqueous layer was extracted with ethyl acetate (x2) and the combined organic layers were washed with brine, dried over $MgSO_4$, filtered and concentrated. The residue was purified by flash chromatography (0-20% ethyl acetate in hexanes) to provide the title compound. ^{1}H NMR (500 MHz, DMSO-d_6) δ 12.88 (br, 1H), 11.18 (s, 1H), 7.76 (m, 3H), 7.69 (d, 1H), 7.53 (d, 1H), 7.41 (m, 3H), 7.34 (d, 2H), 7.27 (m, 3H), 7.08 (d, 1H), 2.08 (s, 3H).

EXAMPLE 167

7-(2-methylphenyl)-4-(1-naphthyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) δ 11.32 (s, 1H), 8.04 (t, 2H), 7.71 (d, 1H), 7.66 (m, 1H), 7.61 (m, 1H), 7.56 (m, 1H), 7.46 (m, 1H), 7.34 (m, 4H), 7.22 (m, 2H), 6.60 (d, 1H), 2.18 (s, 3H).

EXAMPLE 168

7-(2-methylphenyl)-4-(2-naphthyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) δ 12.93 (br, 1H), 11.35 (s, 1H), 8.25 (s, 1H), 8.08 (m, 2H), 8.00 (m, 1H), 7.90 (dd, 1H), 7.57 (m, 2H), 7.36 (m, 3H), 7.31 (m, 3H), 7.19 (d, 1H), 2.13 (s, 3H).

EXAMPLE 169

7-(2-methylphenyl)-4-(3-(2-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

EXAMPLE 169A

To a solution of 2-(allyloxy)naphthalene (71 mg) in tetrahydrofuran at room temperature was added 9-Borabicyclo(3.3.1)nonane (0.5 M, 1.5 mL). The solution was stirred at 50 °C for 2 hours and cooled to room temperature. EXAMPLE 166C (100 mg), palladium acetate (7.2 mg), (2-biphenyl)dicyclohexylphosphine (22 mg) and potassium fluoride (56 mg) were added, and the resulting mixture was heated under reflux overnight. The reaction mixture was diluted with ethyl acetate and saturated ammonium chloride and the layers were separated. The aqueous layer was extracted with ethyl acetate (x2) and the combined organic layers were washed with brine, dried over $MgSO_4$, filtered and concentrated. The residue was purified by flash chromatography (20% ethyl acetate in hexanes) to provide the title compound.

EXAMPLE 169B

To a solution of EXAMPLE 169A (45 mg) in dioxane (1.0 mL) was added aqueous lithium hydroxide (2 N, 0.15 mL). The resulting mixture was heated at 60 °C overnight and diluted with ethyl acetate and saturated ammonium chloride. The layers were separated and the aqueous layer was extracted with ethyl acetate (x2). The combined organic layers were dried over MgSO4, filtered and concentrated. The residue was purified by flash chromatography (0-5% methanol in dichloromethane) to provide the title compound. ^{1}H NMR (400 MHz, DMSO-d_6) δ 12.82 (br, 1H), 11.10 (s, 1H), 7.83 (d, 2H), 7.78 (d, 1H), 7.45 (m, 1H), 7.35 (m, 1H), 7.31 (m, 4H), 7.27 (m, 1H), 7.22 (m, 2H), 7.02 (m, 1H), 6.97 (m, 1H), 4.20 (t, 2H), 3.12 (t, 2H), 2.24 (m, 2H), 2.05 (s, 3H).

EXAMPLE 170

7-(2-methylphenyl)-4-(4-(1-naphthyloxy)butyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) δ 12.81 (br, 1H), 11.02 (s, 1H), 8.14 (d, 1H), 7.85 (d, 1H), 7.49 (m, 3H), 7.40 (m, 1H), 7.31 (m, 3H), 7.26 (m, 1H), 7.21 (m, 1H), 7.01 (m, 1H), 6.96 (m, 2H), 4.21 (t, 2H), 3.04 (t, 2H), 2.05 (s, 3H), 2.00 (m, 4H).

EXAMPLE 171

7-(2-methylphenyl)-4-(4-(2-naphthyloxy)butyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) δ 12.81 (br, 1H), 11.01 (s, 1H), 7.80 (m, 3H), 7.44 (m, 1H), 7.31 (m, 5H), 7.25 (m, 1H), 7.20 (m, 1H), 7.17 (dd, 1H), 7.00 (m, 1H), 6.96 (m, 1H), 4.16 (t, 2H), 3.00 (t, 2H), 2.05 (s, 3H), 1.91 (m, 4H).

EXAMPLE 172

7-(2-methylphenyl)-4-(2-(2-naphthyl)ethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) δ 12.83 (br, 1H), 11.05 (s, 1H), 7.86 (m, 3H), 7.80 (s, 1H), 7.53 (dd, 1H), 7.46 (m, 2H), 7.37 (d, 1H), 7.31 (d, 2H), 7.26 (m, 1H), 7.21 (m, 1H), 7.01 (m, 1H), 6.95 (d, 1H), 3.29 (m, 2H), 3.19 (m, 2H), 2.06 (s, 3H).

EXAMPLE 173

3-(3-(1-naphthyloxy)propyl)-7-thien-3-yl-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.07 (br, 1H), 10.23 (s, 1H), 8.22-8.24 (m, 1H), 7.93 (dd, J = 2.9, 1.37 Hz, 1H), 7.85-7.87 (m, 1H), 7.72 (dd, J = 4.88, 2.75 Hz, 1H), 7.67 (d, J = 7.93 Hz, 1H), 7.79-7.55 (m, 3H), 7.44-7.46 (m, 1H), 7.36-7.40 (m, 2H), 7.05-7.08 (m, 1H), 6.89 (d, J = 7.02 Hz, 1H), 4.18 (t, J = 6.1 Hz, 2H), 3.75-3.78 (m, 2H), 2.21-2.26 (m, 2H).

EXAMPLE 174

7-((3-(aminocarbonyl)phenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.07 (br, 1H), 11.22 (s, 1H), 10.23 (s, 1H), 8.20-8.24 (m, 2H), 7.92 (s, 1H), 7.85-7.87 (m, 1H), 7.68 (s, 1H), 7.49-7.54 (m, 2H), 7.44-7.46 (m, 1H), 7.30-7.40 (m, 5H), 7.23 (d, J = 8.24 Hz, 1H), 7.13 (d, J = 7.63 Hz, 1H), 6.88-6.93 (m, 2H), 4.18 (t, J = 5.95 Hz, 2H), 3.31 (m, 2H), 2.19-2.25 (m, 2H).

EXAMPLE 175

7-((3-cyanophenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

EXAMPLE 175A

ethyl 7-(3-cyanophenylamino)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

A mixture of ethyl 7-bromo-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate (EXAMPLE 1C) (45.2 mg), 3-aminobenzonitrile (14.2 mg), 2'-(dicyclohexylphosphino)-N,N-dimethylbiphenyl-2-amine (Cy-map) (5.9 mg), tris(dibenzylideneacetone)dipalladium(0) (4.6 mg), and Cs_2CO_3 (46 mg) in dioxane (1 mL) was degassed via vacuum-nitrogen cycle three times. The reaction mixture was heated at 100 °C for 16 hours. The reaction mixture was partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over $MgSO_4$, filtered, and concentrated in vacuo. The residue was purified with flash chromatography (1:9 EtOAc/Hex) to provide the title compound.

EXAMPLE 175B

7-((3-cyanophenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

EXAMPLE 175A (28 mg) was treated with dioxane (3 mL) and 1.0 N LiOH (1 mL). The reaction mixture was heated at 100 °C for 3 hours. The solvents were removed in vacuo, and residue was purified with RP HPLC to give pure EXAMPLE 175B and EXAMPLE 174. ^{1}H NMR (500 MHz, DMSO-d_6): δ 13.12 (s, 1H), 11.21 (s, 1H), 8.33 (s, 1H), 8.20-8.22 (m, 1H), 7.85-7.87 (m, 1H), 7.49-7.54 (m, 2H), 7.37-7.46 (m, 5H), 7.32 (d, J = 7.93 Hz, 1H), 7.23-7.25 (m, 1H), 7.17 (d, J = 7.32 Hz, 1H), 6.95 (t, J = 7.78 Hz, 1H), 6.88 (d, J = 7.63 Hz, 1H), 4.18 (t, J = 6.1 Hz, 2H), 3.31 (m, 2H), 2.20-2.24 (m, 2H).

EXAMPLE 176

7-((2-benzylphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.01 (s, 1H), 11.31 (s, 1H), 8.21- 8.23 (m, 1H), 7.84 -7.86 (m, 1H), 7.36 -7.54 (m, 5H), 7.07-7.29 (m, 9H), 6.96-7.00 (m, 1H), 6.89 (d, J = 7.36 Hz, 1H), 6.79 (t, J = 7.83 Hz, 1H), 6.57 (d, J = 7.67 Hz, 1H), 4.19 (t, J = 6.14 Hz, 2H), 4.05 (s, 2H), 3.31 (m, 2H), 2.20-2.25 (m, 2H).

EXAMPLE 177

7-(1,1'-biphenyl-2-ylamino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.93 (s, 1H), 11.28 (s, 1H), 8.21- 8.24 (m, 1H), 7.28 -7.55 (m, 13H), 7.12 -7.16 (m, 1H), 6.89 (d, J = 7.36 Hz, 1H), 7.01 (d, J = 7.61 Hz, 1H), 6.89 (d, J = 6.75 Hz, 1H), 6.81 (t, J = 7.67 Hz, 1H), 6.74-6.76 (m, 1H), 4.18 (t, J = 6.14 Hz, 2H), 3.31 (m, 2H), 2.17-2.24 (m, 2H).

EXAMPLE 178

7-((2-ethylphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.04 (s, 1H), 11.36 (s, 1H), 8.22- 8.24 (m, 1H), 7.85 -7.88 (m, 1H), 7.15 -7.54 (m, 8H), 7.02-7.09 (m, 2H), 6.89 (d, J = 7.63 Hz, 1H), 6.78 (t, J = 7.78 Hz, 1H), 6.50 (d, J = 7.32 Hz, 1H), 4.19 (t, J = 5.95 Hz, 2H), 3.31 (m, 2H), 2.68 (q, J = 7.53 Hz, 2H), 2.19-2.25 (m, 2H), 1.15 (t, J = 7.48 Hz, 3H).

EXAMPLE 179

3-(3-(1-naphthyloxy)propyl)-7-((2-propylphenyl)amino)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.03 (s, 1H), 11.36 (s, 1H), 8.22- 8.24 (m, 1H), 7.85 -7.87 (m, 1H), 7.50 -7.54 (m, 2H), 7.44-7.46 (m, 1H), 7.39 (t, J = 7.93 Hz, 1H), 7.33 (s, 1H), 7.23-7.27 (m, 1H), 7.16 (t, J = 6.87 Hz, 1H), 7.08 (d, J = 7.93 Hz, 1H), 7.02 (t, J = 7.02 Hz, 1H), 6.89 (d, J = 7.63 Hz, 1H), 6.77 (t, J = 7.78 Hz, 1H), 6.50 (d, J = 7.32 Hz, 1H), 4.19 (t, J = 6.1 Hz, 2H), 3.31 (m, 2H), 2.63-2.66 (m, 2H), 2.19-2.25 (m, 2H), 1.55-1.59 (m, 2H), 0.88 (t, J = 7.32 Hz, 3H).

EXAMPLE 180

7-(5-carboxy-3-methylthien-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.01 (s, 1H), 11.02 (s, 1H), 8.22- 8.24 (m, 1H), 7.86 -7.88 (m, 1H), 7.77 (d, J = 7.93 Hz, 1H), 7.65 (s, 1H), 7.45-7.53 (m, H), 7.39 (t, J = 7.78 Hz, 1H), 7.21 (d, J = 6.81 Hz, 1H), 7.08 (t, J = 7.63 Hz, 1H), 6.90 (d, J = 7.63 Hz, 1H), 4.20 (t, J = 6.1 Hz, 2H), 3.34-3.38 (m, 2H), 2.21-2.26 (m, 2H).

EXAMPLE 181

7-((2-carboxyphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.89 (s, 1H), 11.57 (s, 1H), 9.22 (s, 1H), 8.22-8.24 (m, 1H), 7.90 -7.91 (m, 1H), 7.85-7.87 (m, 1H), 7.50 -7.54 (m, 2H), 7.44-7.46 (m, 2H),

7.38 (t, J = 7.93 Hz, 1H), 7.29-7.32 (m, 1H), 7.14 (d, J = 7.32 Hz, 1H), 6.93-6.97 (m, 2H), 6.89 (d, J = 7.63 Hz, 1H), 6.76 (t, J = 7.32 Hz, 1H), 4.18 (t, J = 5.95 Hz, 2H), 3.34-3.38 (m, 2H), 2.21-2.25 (m, 2H).

EXAMPLE 182

7-((3-carboxyphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.99 (s, 1H), 11.22 (s, 1H), 8.26 (s, 1H), 8.22-8.23 (m, 1H), 7.85 -7.87 (m, 1H), 7.76 (s, 1H), 7.49-7.54 (m, 2H), 7.37-7.46 (m, 5H), 7.26 (d, J = 8.06 Hz, 1H), 7.14 (d, J = 7.33 Hz, 1H), 6.94 (t, J = 7.69 Hz, 1H), 4.18 (t, J = 5.95 Hz, 2H), 3.34-3.38 (m, 2H), 2.21-2.25 (m, 2H).

EXAMPLE 183

7-(2-morpholin-4-yl-5-nitropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.03 (s, 1H), 11.27 (s, 1H), 9.09 (d, J = 2.76 Hz, 1H), 8.22- 8.24 (m, 1H), 8.16 (d, J = 2.76 Hz, 1H), 7.85-7.87 (m, 1H), 7.77 (d, J = 7.98 Hz, 1H), 7.44-7.55 (m, 3H), 7.37 (t, J = 7.98 Hz, 1H), 7.30 (d, J = 7.06 Hz, 1H), 7.09 (t, J = 7.67 Hz, 1H), 6.86 (d, J = 7.36 Hz, 1H), 4.17 (t, J = 6.14 Hz, 2H), 3.05-3.35 (m, 10H), 2.23-2.26 (m, 2H).

EXAMPLE 184

7-(5-amino-2-morpholin-4-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.96 (s, 1H), 8.23- 8.25 (m, 1H), 7.86-7.88 (m, 1H), 7.79 (d, J = 7.93 Hz, 1H), 7.75 (s, 1H), 7.49-7.55 (m, 2H), 7.43-7.46 (m, 2H), 7.37 (t, J = 7.93 Hz, 1H), 7.30 (d, J = 7.32 Hz, 1H), 7.10-7.13 (m, 1H), 6.86 (d, J = 7.32 Hz, 1H), 4.17 (t, J = 6.14 Hz, 2H), 3.05-3.35 (m, 10H), 2.23-2.26 (m, 2H).

EXAMPLE 185

7-((3-chloropyridin-4-yl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.20 (s, 1H), 11.72 (s, 1H), 9.77 (s, 1H), 8.73 (s, 1H), 8.24- 8.27 (m, 1H), 8.10 (d, J = 6.71 Hz, 1H), 7.86-7.88 (m, 1H), 7.76 (d, J = 7.93 Hz, 1H), 7.51-7.56 (m, 2H), 7.45-7.47 (m, 1H), 7.39 (t, J = 7.93 Hz, 1H),

7.22 (d, J = 7.32 Hz, 1H), 7.10 (t, J = 7.78 Hz, 1H), 6.89 (d, J = 7.32 Hz, 1H), 6.45 (d, J = 6.71 Hz, 1H), 4.19 (t, J = 6.1 Hz, 2H), 3.36-3.39 (m, 2H), 2.23-2.25 (m, 2H).

EXAMPLE 186

7-((2-isopropylphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.99 (s, 1H), 11.32 (s, 1H), 8.21- 8.23 (m, 1H), 7.85-7.87 (m, 1H), 7.37-7.52 (m, 6H), 7.03-7.22 (m, 4H), 6.89 (d, J = 7.36 Hz, 1H), 6.75 (t, J = 7.83 Hz, 1H), 6.35 (d, J = 7.67 Hz, 1H), 4.19 (t, J = 6.1 Hz, 2H), 3.29-3.35 (m, 2H), 2.23-2.25 (m, 3H), 1.17 (d, J = 6.44 Hz, 6H).

EXAMPLE 187

7-(2-morpholin-4-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.16 (s, 1H), 11.02 (s, 1H), 8.31(dd, J = 5.19, 1.83 Hz, 1H), 8.23-8.25 (m, 1H), 7.86-7.89 (m, 2H), 7.78 (d, J = 7.93 Hz, 1H), 7.49-7.55 (m, 2H), 7.44-7.46 (m, 1H), 7.38 (d, J = 7.93 Hz, 1H), 7.35 (t, J = 7.32 Hz, 1H), 7.18-7.20 (m, 1H), 7.11-7.14 (m, 1H), 6.86 (d, J = 7.63 Hz, 1H), 4.17 (t, J = 6.1 Hz, 2H), 3.39 (t, J = 7.32 Hz, 2H), 3.2 (br, 4H), 2.97 (br, 4H), 2.21-2.27 (m, 2H).

EXAMPLE 188

7-(5-(aminocarbonyl)-1,2-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.03 (s, 1H), 11.18 (s, 1H), 9.21(d, J = 4.58 Hz, 1H), 8.22-8.24 (m, 1H), 8.06 (s, 1H), 7.86-7.88 (m, 1H), 7.72-7.74 (m, 1H), 7.49-7.55 (m, 4H), 7.44-7.46 (m, 1H), 7.69 (t, J = 7.93 Hz, 1H), 7.06-7.10 (m, 2H), 6.90 (d, J = 7.32 Hz, 1H), 4.20 (t, J = 6.1 Hz, 2H), 3.63 (s, 3H), 3.32-3.37 (m, 2H), 2.21-2.26 (m, 2H), 2.17 (s, 3H).

EXAMPLE 189

7-(5-cyano-1,2-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.07 (s, 1H), 11.23 (s, 1H), 8.22-8.24 (m, 1H), 7.93 (s, 1H), 7.86-7.88 (m, 1H), 7.74 (dd, J = 7.02, 2.14 Hz, 1H), 7.49-7.55 (m, 2H), 7.44-

7.46 (m, 1H), 7.39 (t, J = 7.39 Hz, 1H), 7.06-7.10 (m, 2H), 6.89 (d, J = 7.32 Hz, 1H), 4.19 (t, J = 6.1 Hz, 2H), 3.56 (s, 3H), 3.32-3.37 (m, 2H), 2.21-2.26 (m, 2H), 2.13 (s, 3H).

EXAMPLE 190

7-(5-amino-4-chloro-2-morpholin-4-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.07 (s, 1H), 10.65 (s, 1H), 8.24 d, J = 7.63 Hz, 1H), 7.86 (d, J = 7.32 Hz, 1H), 7.74 (d, J = 7.93 Hz, 1H), 7.49-7.54 (m, 2H), 7.45 (d, J = 8.24 Hz, 1H), 7.37 (t, J = 7.93 Hz, 1H), 7.28 (d, J = 7.02 Hz, 1H), 7.25 (s, 1H), 7.09 (t, J = 7.48 Hz, 1H), 6.86 (d, J = 7.63 Hz, 1H), 4.17 (t, J = 6.1 Hz, 2H), 3.39 (t, J = 7.32 Hz, 2H), 3.24 (br, 4H), 2.75 (br, 4H), 2.23-2.25 (m, 2H).

EXAMPLE 191

2-methyl-3'-(3-(1-naphthyloxy)propyl)-2,3-dihydro-1'H-1,7'-biindole-2'-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.01 (s, 1H), 10.89 (s, 1H), 8.25- 8.27 (m, 1H), 7.86-7.88 (m, 1H), 7.58 (d, J = 7.93 Hz, 1H), 7.50-7.55 (m, 2H), 7.45-7.47 (m, 1H), 7.39 (t, J = 7.93 Hz, 1H), 7.17 (d, J = 7.02 Hz, 1H), 7.12 (d, J = 7.02 Hz, 1H), 7.05 (t, J = 7.78 Hz, 1H), 6.91 (d, J = 7.63 Hz, 1H), 6.86 (t, J = 7.63 Hz, 1H), 6.60 (t, J = 7.32 Hz, 1H), 5.97 (d, J = 7.93 Hz, 1H), 4.51-4.54 (m, 1H), 4.21 (t, J = 6.1 Hz, 2H), 3.38 (t, J = 7.32 Hz, 2H), 2.79 (dd, J = 15.1, 8.09 Hz, 1H), 2.21-2.27 (m, 2H).

EXAMPLE 192

7-(2-fluoro-5-methylpyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

EXAMPLE 192A

methyl 7-(2-fluoro-5-methylpyridin-4-yl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

A mixture of EXAMPLE 43A (0.40 g), 2-fluoro-4-iodo-5-methylpyridine (0.209 g), tetrakis(triphenylphosphine)palladium (46 mg) and cesium fluoride (0.365 g) in dimethoxyethane (3 mL) and methanol (1.5 mL) was heated at 120 °C for 20 minutes under microwave conditions (CEM Discovery). After cooling to room temperature, the reaction

mixture was loaded onto a silica gel cartridge. The cartridge was dried in vacuum oven for 1 hour and eluted with 1:4 ethyl acetate/hexanes to give the desired product. ^{1}H NMR (500 MHz, DMSO-d_6): 11.33 (s, 1H), 8.23- 8.25 (m, 1H), 8.17 (s, 1H), 7.86-7.88 (m, 1H), 7.79-7.81 (m, 1H), 7.45-7.56 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.12-7.14 (m, 2H), 7.04 (d, J = 2.14 Hz, 1H), 6.91 (d, J = 7.32 Hz, 1H), 4.20 (t, J = 5.95 Hz, 2H), 3.78 (s, 3H), 3.37 (t, J = 7.48 Hz, 2H), 2.20-2.26 (m, 2H), 2.00 (s, 3H).

EXAMPLE 192B

7-(2-fluoro-5-methylpyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

The title compound was synthesized according to the procedure for EXAMPLE 175B by substituting EXAMPLE 175A with EXAMPLE 192A. ^{1}H NMR (500 MHz, DMSO-d6): 13.00 (s, 1H), 11.21 (s, 1H), 8.23- 8.25 (m, 1H), 8.16 (s, 1H), 7.86-7.88 (m, 1H), 7.76-7.79 (m, 1H), 7.50-7.55 (m, 2H), 7.45-7.47 (m, 1H), 7.39 (t, J = 7.93 Hz, 1H), 7.09-7.11 (m, 2H), 7.03 (d, J = 1.83 Hz, 1H), 6.90 (d, J = 7.63 Hz, 1H), 4.20 (t, J = 6.1 Hz, 2H), 3.37 (t, J = 7.32 Hz, 2H), 2.21-2.27 (m, 2H).

EXAMPLE 193

7-((2-methoxypyridin-3-yl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.04 (br, 1H), 11.58 (s, 1H), 8.22- 8.24 (m, 1H), 7.85-7.87 (m, 1H), 7.70 (dd, J = 4.88, 1.53 Hz, 1H), 7.50-7.55 (m, 3H), 7.44-7.46 (m, 1H), 7.38 (t, J = 7.93 Hz, 1H), 7.23 (d, J = 7.93 Hz, 1H), 6.94 (d, J = 7.02 Hz, 1H), 6.68-6.91 (m, 3H), 4.18 (t, J = 6.1 Hz, 2H), 3.98 (s, 3H), 3.33 (t, J = 7.32 Hz, 2H), 2.19-2.24 (m, 2H).

EXAMPLE 194

7-(5-methyl-2-oxo-1,2-dihydropyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

EXAMPLE 192 (50 mg) in acetic acid (10 ml) and water (1 mL) was heated at 100 °C for 16 hours. The solvents were removed, and the residue was purified with reverse phase (RP) HPLC to provide the title compound. ^{1}H NMR (500 MHz, DMSO-d_6): δ 13.04 (br, 1H), 11.73 (br, 1H), 11.16 (s, 1H), 8.23- 8.25 (m, 1H), 7.86-7.88 (m, 1H), 7.72 (d, J = 6.1 Hz, 1H), 7.50-7.55 (m, 2H), 7.45-7.46 (m, 1H), 7.39 (t, J = 7.93 Hz, 1H), 7.32 (s, 1H), 7.04-7.08 (m, 2H), 6.90 (d, J = 7.32 Hz, 1H), 6.24 (s, 1H), 4.20 (t, J = 5.95 Hz, 2H), 3.36 (t, J = 7.32 Hz, 2H), 2.20-2.25 (m, 2H), 1.71 (s, 3H).

EXAMPLE 195

7-(5-methyl-2-(2-pyrrolidin-1-ylethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

2-(Pyrrolidin-1-yl)ethanol (36.9 mg) in dioxane (2 mL) in a 4-mL vial was treated with 60% NaH (12.8 mg) at room temperature. After the bubbling ceased, EXAMPLE 192 (50 mg) was added to the solution. The vial was capped and heated at 105 °C for 3 hours. The solvent was removed, and the residue was purified with RP HPLC to provide the title compound. ^{1}H NMR (500 MHz, DMSO-d_6): δ 11.00 (s, 1H), 11.16 (s, 1H), 9.78 (s, 1H), 8.23- 8.25 (m, 1H), 8.12 (s, 1H), 7.86-7.88 (m, 1H), 7.76 (d, J = 7.32 Hz, 1H), 7.50-7.55 (m, 2H), 7.45-7.47 (m, 1H), 7.39 (t, J = 7.93 Hz, 1H), 7.06-7.12 (m, 2H), 6.90 (d, J = 7.63 Hz, 1H), 6.76 (s, 1H), 4.58 (s, 2H), 4.20 (t, J = 5.95 Hz, 2H), 3.60-3.61 (m, 4H), 3.36 (t, J = 7.32 Hz, 2H), 3.13 (br, 2H), 2.20-2.25 (m, 2H), 1.97-2.01 (m, 5H), 1.87-1.91 (m, 2H).

EXAMPLE 196

7-(2-(dimethylamino)-5-nitropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.07 (s, 1H), 11.00 (s, 1H), 11.32 (s, 1H), 9.04 (d, J = 2.44 Hz, 1H), 8.21- 8.23 (m, 1H), 8.00 (d, J = 2.75 Hz, 1H), 7.86-7.87 (m, 1H), 7.74 (d, J = 7.63 Hz, 1H), 7.49-7.55 (m, 2H), 7.44-7.46 (m, 1H), 7.38 (t, J = 7.78 Hz, 1H), 7.11-7.13 (m, 1H), 7.04-7.08 (m, 1H), 6.88 (d, J = 7.63 Hz, 1H), 4.19 (t, J = 5.95 Hz, 2H), 3.36 (t, J = 7.32 Hz, 2H), 2.75 (s, 6H), 2.21-2.27 (m, 2H).

EXAMPLE 197

7-(2-(2-(dimethylamino)ethoxy)-5-methylpyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.93 (br, 1H), 11.01 (s, 1H), 9.69 (s, 1H), 8.23-8.25 (m, 1H), 8.12 (s, 1H), 7.86-7.88 (m, 1H), 7.76 (d, J = 7.32 Hz, 1H), 7.45-7.55 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.06-7.12 (m, 2H), 6.90 (d, J = 7.63 Hz, 1H), 6.74 (s, 1H), 4.60 (br, 2H), 4.20 (t, J = 6.1 Hz, 2H), 3.60 (br, 2H), 3.36 (t, J = 7.32 Hz, 2H), 2.88 (s, 6H), 2.21-2.26 (m, 2H), 1.97 (s, 3H).

EXAMPLE 198

7-(5-methyl-2-(2-morpholin-4-ylethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.00 (s, 1H), 10.24 (s, 1H), 8.24- 8.26 (m, 1H), 8.13 (s, 1H), 7.86-7.88 (m, 1H), 7.76 (d, J = 6.71 Hz, 1H), 7.45-7.55 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.06-7.12 (m, 2H), 6.90 (d, J = 7.32 Hz, 1H), 6.77 (s, 1H), 4.64 (br, 2H), 4.20 (t, J = 6.1 Hz, 2H), 3.97 (br, 2H), 3.72 (br, 2H), 3.60 (t, J = 4.88 Hz, 2H), 3.60 (br, 2H), 3.37 (t, J = 7.32 Hz, 2H), 3.22 (br, 2H), 2.21-2.26 (m, 2H), 1.98 (s, 3H).

EXAMPLE 199

7-(2-(1,4-dioxa-8-azaspiro(4.5)dec-8-yl)-5-nitropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.02 (s, 1H), 11.25 (s, 1H), 9.07 (d, J = 2.75 Hz, 1H), 8.22- 8.24 (m, 1H), 8.13 (d, J = 2.75 Hz, 1H), 7.85-7.87 (m, 1H), 7.76 (d, J = 7.93 Hz, 1H), 7.44-7.54 (m, 3H), 7.37 (t, J = 7.78 Hz, 1H), 7.29 (d, J = 7.32 Hz, 1H), 7.09-7.12 (m 1H), 6.85 (d, J = 7.32 Hz, 1H), 4.17 (t, J = 6.1 Hz, 2H), 3.72 (s, 4H), 3.37 (m, 2H), 3.14 (br, 2H), 2.21-2.26 (m, 2H), 1.35 (br, 2H), 1.10 (br, 2H).

EXAMPLE 200

3-(3-(1-naphthyloxy)propyl)-7-(5-nitro-2-(4-oxopiperidin-1-yl)pyridin-3-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.39 (s, 1H), 9.12 (d, J = 2.75 Hz, 1H), 8.22- 8.24 (m, 1H), 8.17 (d, J = 2.75 Hz, 1H), 7.85-7.87 (m, 1H), 7.78 (d, J = 7.93 Hz, 1H), 7.44-7.54 (m, 3H), 7.37 (t, J = 7.93 Hz, 1H), 7.31 (d, J = 6.41 Hz, 1H), 7.09-7.12 (m 1H), 6.86 (d, J = 7.32 Hz, 1H), 4.17 (t, J = 6.1 Hz, 2H), 3.61 (br, 2H), 3.37 (m, 2H), 2.17-2.26 (m, 4H), 1.93 (br, 2H).

EXAMPLE 201

7-(5-amino-2-(dimethylamino)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.15 (br, 1H), 8.24- 8.26 (m, 1H), 7.86-7.88 (m, 1H), 7.78 (d, J = 7.93 Hz, 1H), 7.44-7.54 (m, 3H), 7.38 (t, J = 7.93 Hz, 1H), 7.22 (d, J = 7.02 Hz, 1H), 7.08-7.12 (m 1H), 6.88 (d, J = 7.02 Hz, 1H), 4.18 (t, J = 6.1 Hz, 2H), 3.37 (m, 2H), 2.57 (br, 6H), 2.21-2.27 (m, 2H).

EXAMPLE 202

7-(2-(4-hydroxypiperidin-1-yl)-5-nitropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.00 (s, 1H), 11.19 (br, 1H), 9.05 (d, J = 2.44 Hz, 1H), 8.23- 8.25 (m, 1H), 8.09 (d, J = 2.45 Hz, 1H), 7.86-7.88 (m, 1H), 7.75 (d, J = 7.93 Hz, 1H), 7.44-7.54 (m, 3H), 7.37 (t, J = 7.78 Hz, 1H), 7.25 (d, J = 6.41 Hz, 1H), 7.06-7.10 (m 1H), 6.86 (d, J = 7.32 Hz, 1H), 4.17 (t, J = 6.1 Hz, 2H), 3.75 (br, 6H), 3.49-3.52 (m, 1H), 3.40 (br, 2H) 2.90 (br, 2H), 2.21-2.27 (m, 2H).

EXAMPLE 203

7-(6-methoxy-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.05 (s, 1H), 8.24- 8.26 (m, 1H), 7.94 (d, J = 2.45 Hz, 1H), 7.86-7.88 (m, 1H), 7.71 (d, J = 7.63 Hz, 1H), 7.45-7.55 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.03-7.09 (m, 2H), 6.91 (d, J = 7.63 Hz, 1H), 6.80 (s, 1H), 4.20 (t, J = 6.1 Hz, 2H), 3.90 (s, 3H), 3.35(m, 2H), 2.21-2.27 (m, 2H), 2.00 (s, 3H).

EXAMPLE 204

7-(2-fluoro-5-methylpyridin-4-yl)-1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 8.22- 8.24 (m, 1H), 7.87-7.91 (m, 2H), 7.46-7.56 (m, 3H), 7.39-7.42 (m, 2H), 7.19-7.22 (m, 1H), 7.08 (d, J = 6.41 Hz, 1H), 6.91 (d, J = 7.32 Hz, 1H), 4.77 (br, 1H), 4.23 (t, J = 5.95 Hz, 2H), 3.91 (br, 1H), 3.36-3.39 (m, 2H), 2.80 (br, 4H), 2.20-2.26 (m, 2H), 1.94 (s, 3H).

EXAMPLE 205

3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.56 (s, 1H), 8.24- 8.26 (m, 1H), 7.86-7.88 (m, 1H), 7.66 (d, J = 7.32 Hz, 1H), 7.46-7.55 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.02-7.07 (m, 2H), 6.91 (d, J = 7.32 Hz, 1H), 4.21 (t, J = 6.1 Hz, 2H), 3.75 (s, 3H), 3.34-3.37 (m, 2H), 2.21-2.26 (m, 2H), 2.05 (s, 3H), 2.01 (s, 3H).

EXAMPLE 206

7-((2-morpholin-4-ylpyridin-3-yl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.05 (br, 1H), 11.14 (s, 1H), 8.22- 8.24 (m, 1H), 7.92 (d, J = 3.66 Hz, 1H), 7.86-7.87 (m, 1H), 7.44-7.56 (m, 5H), 7.38 (t, J = 7.93 Hz, 1H), 7.24 (d, J = 7.93 Hz, 1H), 7.00 (dd, J = 7.78, 5.03 Hz, 1H), 6.85-6.88 (m, 2H), 6.74 (d, J = 7.32 Hz, 1H), 4.18 (t, J = 5.95 Hz, 2H), 3.63-3.64 (m, 4H), 3.33 (t, J = 7.32 Hz, 2H), 3.23 (m, 4H), 2.20-2.24 (m, 2H).

EXAMPLE 207

7-(5-methyl-2-(2-phenylethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.98 (s, 1H), 8.17 (d, J = 7.63 Hz, 1H), 8.02 (s, 1H), 7.90 (d, J = 7.02 Hz, 1H), 7.67 (d, J = 7.02 Hz, 1H), 7.22-7.47 (m, 8H), 7.15 (t, J = 6.41 Hz, 1H), 6.98-7.03 (m, 2H), 6.83 (d, J = 7.32 Hz, 1H), 6.59 (s, 1H), 4.42 (t, J = 6.41 Hz, 2H), 4.13 (t, J = 5.64 Hz, 2H), 3.28-3.31 (m, 2H), 2.99 (t, J = 6.71 Hz, 2H), 2.20-2.24 (m, 2H), 1.86 (s, 3H).

EXAMPLE 208

7-(5-methyl-2-(2-pyridin-3-ylethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.98 (s, 1H), 8.17 (d, J = 7.63 Hz, 1H), 8.02 (s, 1H), 7.90 (d, J = 7.02 Hz, 1H), 7.68 (d, J = 7.02 Hz, 1H), 7.22-7.47 (m, 7H), 7.14 (t, J = 6.41 Hz, 1H), 6.98-7.03 (m, 2H), 6.82 (d, J = 7.32 Hz, 1H), 6.59 (s, 1H), 4.42 (t, J = 6.41 Hz, 2H), 4.13 (t, J = 5.64 Hz, 2H), 3.28-3.31 (m, 2H), 2.99 (t, J = 6.71 Hz, 2H), 2.20-2.24 (m, 2H), 1.86 (s, 3H).

EXAMPLE 209

7-((2-morpholin-4-ylphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.50 (s, 1H), 8.17 (s, 1H), 7.79 (s, 1H), 6.75-7.45(m, 12H), 4.41 (br, 2H), 2.81 (br, 4H), 2.44 (m, 5H), 2.15 (br, 2H).

EXAMPLE 210

7-((4-carboxypyridin-3-yl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.53 (br, 1H), 13.04 (br, 1H), 11.68 (s, 1H), 8.87 (s, 1H), 8.23 (s, 1H), 8.20-8.22 (m, 1H), 8.00 (d, J = 4.88 Hz, 1H), 7.85-7.87 (m, 1H), 7.69 (d, J = 5.19 Hz, 1H), 7.44-7.54 (m, 4H), 7.38 (t, J = 7.93 Hz, 1H), 7.17 (d, J = 7.32 Hz, 1H), 6.98 (t, J = 7.78 Hz, 1H), 6.89 (d, J = 7.32 Hz, 1H), 4.19 (t, J = 6.41 Hz, 2H), 3.34-3.37 (m, 2H), 2.20-2.25 (m, 2H).

EXAMPLE 211

3-(3-(1-naphthyloxy)propyl)-7-((4-(trifluoromethyl)pyridin-3-yl)amino)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.11 (br, 1H), 11.59 (s, 1H), 8.55 (s, 1H), 8.37 (d, J = 5.19 Hz, 1H), 8.21-8.23 (m, 1H), 7.85-7.87 (m, 1H), 7.68 (d, J = 5.19 Hz, 1H), 7.66 (s,1 H), 7.44-7.54 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.33 (d, J = 7.93 Hz, 1H), 6.86-6.90 (m, 2H), 6.73 (d, J = 7.32 Hz, 1H), 4.19 (t, J = 6.1 Hz, 2H), 3.34-3.37 (m, 2H), 2.20-2.25 (m, 2H).

EXAMPLE 212

7-(2-(3-aminopropoxy)-5-methylpyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.01 (s, 1H), 8.23-8.25 (m, 1H), 8.08 (s, 1H), 7.86-7.88 (m, 1H), 7.74-7.76 (m, 4H), 7.45-7.55 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.05-7.11 (m, 2H), 6.90 (d, J = 7.32 Hz, 1H), 6.68 (s, 1H), 4.35 (t, J = 6.1 Hz, 2H), 4.20 (t, J = 6.1 Hz, 2H), 3.37 (t, J = 7.48 Hz, 2H), 2.94-3.01 (m, 2H), 2.52 (m, 2H), 2.20-2.26 (m, 2H), 2.00-2.06 (m, 2H), 1.95 (s, 3H).

EXAMPLE 213

7-(5-methyl-2-(tetrahydrofuran-3-ylmethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.07 (s, 1H), 8.24 (d, J = 7.32 Hz, 1H), 8.07 (s, 1H), 7.86-7.88 (m, 1H), 7.74 (d, J = 7.32 Hz, 1H), 7.45-7.54 (m, 3H), 7.39 (t, J = 7.78 Hz, 1H), 7.05-7.10 (m, 2H), 6.90 (d, J = 7.32 Hz, 1H), 6.67 (s, 1H), 4.16-4.27 (m, 2H), 3.75-3.80

(m, 2H), 3.67 (q, J = 7.83 Hz, 1H), 3.55 (dd, J = 8.54, 5.49 Hz, 1H), 3.36 (t, J = 7.32 Hz, 2H), 2.67-2.71 (m, 1H), 2.21-2.26 (m, 2H), 1.99-2.04 (m, 1H), 1.93 (s, 3H), 1.64-1.70 (m, 1H).

EXAMPLE 214

7-(5-methyl-2-(4-phenylbutoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.96 (s, 1H), 11.05 (s, 1H), 8.23-8.25 (m, 1H), 8.05 (s, 1H), 7.86-7.87 (m, 1H), 7.73 (d, J = 7.02 Hz, 1H), 7.45-7.54 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.15-7.29 (m, 5H), 7.04-7.09 (m, 2H), 6.90 (d, J = 7.63 Hz, 1H), 6.63 (s, 1H), 4.29 (t, J = 5.95 Hz, 2H), 4.20 (t, J = 5.95 Hz, 2H), 3.36 (t, J = 7.32 Hz, 2H), 2.65 (d, J = 6.87 Hz, 1H), 2.21-2.26 (m, 2H), 1.92 (s, 3H), 1.70-1.78 (m, 4H).

EXAMPLE 215

7-(2-(3-methoxyphenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.92 (s, 1H), 10.74 (s, 1H), 8.23-8.25 (m, 1H), 7.85-7.87 (m, 1H), 7.48-7.54 (m, 2H), 7.36-7.45 (m, 3H), 6.78-6.89 (m, 4H), 6.61 (d, J = 7.63 Hz, 1H), 6.58 (d, J = 7.63 Hz, 1H), 6.44 (dd, J = 8.24, 1.83 Hz, 1H), 4.11 (t, J = 6.1 Hz, 2H), 3.34 (s, 3H), 3.25 (t, J = 7.32 Hz, 2H), 2.23-2.45 (m, 4H), 2.11-2.17 (m, 2H), 1.86 (m, 4H).

EXAMPLE 216

7-(1-(carboxymethyl)-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.98 (s, 1H), 10.32 (s, 1H), 8.24-8.26 (m, 1H), 7.86-7.88 (m, 1H), 7.66 (dd, J = 7.32, 1.83 Hz, 1H), 7.45-7.55 (m, 3H), 7.39 (d, J = 7.93 Hz, 1H), 7.05-7.09 (m, 2H), 6.91 (d, J = 7.32 Hz, 1H), 4.88 (s, 2H), 4.21 (t, J = 6.1 Hz, 2H), 3.34-3.37 (m, 2H), 2.21-2.26 (m, 2H), 2.03 (s, 3H), 2.01 (s, 3H).

EXAMPLE 217

7-(1-benzyl-1H-imidazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.23 (s, 1H), 11.54 (s, 1H), 9.35 (s, 1H), 8.24-8.26 (m, 1H), 7.83-7.88 (m, 3H), 7.60-7.64 (m, 1H), 7.45-7.57 (m, 4H), 7.38 (d, J = 7.93 Hz,

1H), 7.14-7.20 (m, 3H), 7.04-7.05 (m, 1H), 6.97-7.01 (m, 1H), 6.85-6.89 (m, 3H), 5.14 (s, 2H), 4.17 (t, J = 6.1 Hz, 2H), 3.37 (t, J = 7.32 Hz, 2H), 2.20-2.26 (m, 2H).

EXAMPLE 218

7-(2-(2-methylphenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.94 (s, 1H), 10.91&10.68 (s, 1H), 8.20-8.24 (m, 1H), 7.85-7.86 (m, 1H), 7.33-7.45 (m, 5H), 6.70-7.06 (m, 7H), 4.10-4.13 (m, 2H), 3.21-3.25 (m, 2H), 2.24-2.44 (m, 4H), 2.21-2.26 (m, 5H), 1.87 (br, 4H).

EXAMPLE 219

7-(3,5-dimethyl-1-(2-morpholin-4-ylethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.98 (s, 1H), 10.46 (s, 1H), 8.24-8.26 (m, 1H), 7.86-7.88 (m, 1H), 7.67 (d, J = 7.63 Hz, 1H), 7.45-7.55 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.08 (t, J = 7.48 Hz, 1H), 7.03-7.04 (m, 1H), 6.91 (d, J = 7.63 Hz, 1H), 4.42 (t, J = 6.87 Hz, 2H), 4.21 (t, J = 6.1 Hz, 2H), 3.87 (br, 4H), 3.61 (t, J = 6.87 Hz, 2H), 3.34-3.37 (m, 2H), 2.21-2.26 (m, 2H), 2.09 (s, 3H), 2.04 (s, 3H).

EXAMPLE 221

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-nitrophenyl)cyclohex-1-en-1-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.04(s, 1H), 8.21-8.22 (m, 1H), 7.81-7.85 (m, 3H), 7.40-7.52 (m, 4H), 7.32-7.35 (m, 1H), 7.25 (d, J = 8.85 Hz, 2H), 6.81 (d, J = 7.63 Hz, 2H), 6.73-6.75 (m, 2H), 4.08 (t, J = 5.95 Hz, 2H), 3.23 (br, 2H), 2.45 (br, 2H), 210-2.15 (m, 2H), 1.87 (br, 4H).

EXAMPLE 222

7-(4,4-dimethyl-2-phenylcyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.97 (s, 1H), 10.58 (s, 1H), 8.22-8.24 (m, 1H), 7.85-7.87 (m, 1H), 7.35-7.54 (m, 5H), 6.89-7.00 (m, 5H), 6.84 (d, J = 7.63 Hz, 2H), 6.77 (d, J

= 4.27 Hz, 2H), 4.11 (t, J = 6.1 Hz, 2H), 3.25 (t, J = 7.32 Hz, 2H), 2.37 (br, 2H), 2.25 (br, 2H), 2.12-2.17 (m, 2H), 1.64 (br, 2H), 1.09 (s, 6H).

EXAMPLE 223

1-ethyl-7-(ethyl(phenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

EXAMPLE 223A

ethyl 1-ethyl-7-(ethyl(phenyl)amino)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

EXAMPLE 224 (139 mg) in N,N-dimethylformamide (2 mL) was treated 60% NaH (36 mg, 0.9 mmol) at room temperature. After bubbling ceased, iodomethane (140 mg, 0.9 mmol) was added. The reaction was stirred for 3 hours. The reaction mixture was portioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified with flash chromatography on silica gel (ethyl acetate in hexanes) to give EXAMPLE 223A.

EXAMPLE 223B

1-ethyl-7-(ethyl(phenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

The title compound was synthesized as described in EXAMPLE 175B, substituting EXAMPLE 223A for EXAMPLE 175A. ^{1}H NMR (500 MHz, DMSO-d_6): δ 13.20 (s, 1H), 8.22-8.24 (m, 1H), 7.86-7.88 (m, 1H), 7.72 (dd, J = 7.17, 1.98 Hz, 1H), 7.45-7.55 (m, 3H), 7.40 (t, J = 7.78 Hz, 1H), 7.08-7.14 (m, 4H), 6.91 (d, J = 7.32 Hz, 1H), 6.64 (t, J = 7.32 Hz, 1H), 6.53 (d, J = 8.24 Hz, 2H), 4.48-4.62 (m, 2H), 4.22 (t, J = 6.1 Hz, 2H), 3.88-3.95 (m, 1H), 3.44-3.51 (m, 1H), 2.19-2.24 (m, 2H), 1.18 (t, J = 7.02 Hz, 3H), 0.94 (t, J = 6.87 Hz, 3H).

EXAMPLE 224

7-anilino-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.07 (s, 1H), 11.22 (s, 1H), 8.22-8.24 (m, 1H), 8.06 (s, 1H), 7.85-7.87 (m, 1H), 7.44-7.54 (m, 3H), 7.38 (t, J = 7.93 Hz, 1H), 7.27-7.30 (m, 2H), 7.18-7.20 (m, 3H), 7.09 (d, J = 7.32 Hz, 1H), 6.86-6.90 (m, 3H), 4.18 (t, J = 5.95 Hz, 2H), 3.32 (m, 2H), 2.19-2.24 (m, 2H).

EXAMPLE 225

7-(5-methyl-2-(tetrahydro-2H-pyran-3-ylmethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.95 (s, 1H), 11.07 (s, 1H), 8.23-8.25 (m, 1H), 8.06 (s, 1H), 7.86-7.88 (m, 1H), 7.74 (d, J = 6.71 Hz, 1H), 7.45-7.54 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.05-7.11 (m, 2H), 7.18-7.20 (m, 3H), 7.09 (d, J = 7.32 Hz, 1H), 6.90 (d, J = 7.32 Hz, 1H), 6.65 (s, 1H), 4.09-4.21 (m, 4H), 3.87-3.90 (m, 2H), 3.73-3.75 (m, 2H), 3.24-3.37 (m, 4H), 2.21-2.26 (m, 2H), 2.01-2.05 (m, 1H), 1.93 (s, 3H), 1.93-1.95 (m, 1H), 1.59-1.60 (m, 1H), 1.51-1.53 (m, 1H), 1.36-1.39 (m 1H).

EXAMPLE 226

7-(5-methyl-2-(2-(2-oxopyrrolidin-1-yl)ethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.03 (br, 1H), 11.06 (s, 1H), 8.23-8.25 (m, 1H), 8.09 (s, 1H), 7.86-7.88 (m, 1H), 7.74 (dd, J = 7.17, 1.68 Hz, 1H), 7.45-7.54 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.06-7.10 (m, 2H), 6.90 (d, J = 7.32 Hz, 1H), 6.68 (s, 1H), 4.38 (t, J = 5.49 Hz, 2H), 4.20 (t, J = 6.1 Hz, 2H), 3.56 (t, J = 5.64 Hz, 2H), 3.46 (t, J = 7.02 Hz, 2H), 3.37 (t, J = 7.48 Hz, 2H), 2.19-2.25 (m, 4H), 1.89-1.95 (m, 5H).

EXAMPLE 227

7-(5-methyl-2-(2-(4-methylpiperazin-1-yl)ethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.01 (s, 1H), 8.24-8.25 (m, 1H), 8.09 (s, 1H), 7.86-7.88 (m, 1H), 7.75 (d, J = 7.63 Hz, 1H), 7.45-7.54 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.05-7.11 (m, 2H), 6.90 (d, J = 7.32 Hz, 1H), 6.69 (s, 1H), 4.47 (s, 2H), 4.20 (t, J = 6.1 Hz, 2H), 3.77 (br, 8H), 3.35-3.38 (m, 2H), 3.09 (m, 2H), 2.78 (s, 3H), 2.21-2.26 (m, 2H), 1.96 (s, 3H).

EXAMPLE 228

3-(3-(1-naphthyloxy)propyl)-7-(2-(2-oxocyclohexyl)pyridin-3-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.13 (s, 1H), 8.72-8.73 (m, 1H), 8.24-8.26 (m, 1H), 7.86-7.88 (m, 2H), 7.76 (d, J = 8.24 Hz, 1H), 7.45-7.54 (m, 4H), 7.37-7.41 (m, 1H), 7.05 (t, J = 7.48 Hz, 1H), 6.87-6.91(m, 2H), 4.20 (t, J = 5.8 Hz, 2H), 3.30-3.55 (br, 6H), 1.40-2.24 (m, 7H),

EXAMPLE 229

7-(2-fluoro-5-methylpyridin-4-yl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 9.37 (s, 1H), 8.19-8.21 (m, 2H), 7.87 (t, J = 7.02 Hz, 1H), 7.45-7.56 (m, 4H), 7.40 (t, J = 7.93 Hz, 1H), 7.32 (d, J = 1.83 Hz, 1H), 7.15-7.18 (m 1H), 7.04 (d, J = 6.1 Hz, 1H), 6.90 (d, J = 7.32 Hz, 1H), 4.46-4.50 (m, 1H), 4.21 (t, J = 6.1 Hz, 2H), 3.59-3.61 (m, 1H), 2.75 (br, 2H), 2.71 (s, 3H), 2.09-2.25 (m, 6H), 1.95 (s, 3H),

EXAMPLE 230

7-(5,5-dimethyl-2-phenylcyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.95 (s, 1H), 10.24 (s, 1H), 8.21-8.23 (m, 2H), 7.85-7.86 (m, 1H), 7.35-7.54 (m, 5H), 7.01-7.03 (m, 2H), 6.95 (t, J = 7.48 Hz, 1H), 6.88-6.91 (m 1H), 6.83 (d, J = 7.02 Hz, 1H), 6.80-6.81 (m, 2H), 4.10 (t, J = 6.1 Hz, 2H), 3.22-3.25 (m, 2H), 2.11-2.25 (m, 6H), 1.6 (br, 2H), 1.06 (s, 6H).

EXAMPLE 231

3-(3-(1-naphthyloxy)propyl)-7-(pyridin-3-ylamino)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.18 (s, 1H), 11.27 (s, 1H), 8.67 (s, 1H), 8.36 (d, J = 2.44 Hz, 1H), 8.21-8.23 (m, 1H), 8.17 (d, J = 4.58 Hz, 1H), 7.86-7.87 (m, 1H), 7.77 (dd, J = 8.54, 1.83 Hz, 1H), 7.61 (dd, J = 8.54, 5.19 Hz, 1H), 7.43-7.54 (m, 4H), 7.39 (t, J = 7.78 Hz, 1H), 7.20 (d, J = 7.32 Hz, 1H), 7.00 (t, J = 7.78 Hz, 1H), 6.89 (d, J = 7.32 Hz, 1H), 4.18 (t, J = 6.1 Hz, 2H), 3.24 (t, J = 7.32 Hz, 2H), 2.20-2.25 (m, 2H).

EXAMPLE 232

3-(3-(1-naphthyloxy)propyl)-7-(phenyl(propyl)amino)-1-propyl-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.20 (s, 1H), 8.22 (d, J = 7.63 Hz, 1H), 7.87 (d, J = 7.02 Hz, 1H), 7.70-7.72 (m, 1H), 7.45-7.54 (m, 3H), 7.08-7.13 (m, 4H), 6.90 (d, J = 7.63

Hz, 1H), 6.64 (t, J = 7.17 Hz, 1H), 6.53 (d, J = 7.93 Hz, 2H), 4.44-4.50 (m, 1H), 4.32-4.37 (m, 1H), 4.21 (t, J = 5.95 Hz, 2H), 3.76-3.82 (m, 1H), 2.19-2.23 (m, 2H), 1.74 (m, 1H), 1.58-1.60 (m, 1H), 1.38-1.40 (m, 1H), 1.18-1.23 (m, 1H), 0.88 (t, J = 7.32 Hz, 3H), 0.45 (t, J = 7.17 Hz, 3H).

EXAMPLE 233

7-(3-cyclohex-1-en-1-ylpyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.21 (s, 1H), 11.12 (s, 1H), 8.76 (d, J = 5.19 Hz, 1H), 8.27-8.29 (m, 1H), 8.15 (s, 1H), 7.85-7.88 (m, 2H), 7.78 (s, 1H), 7.45-7.55 (m, 4H), 7.38 (t, J = 7.93 Hz, 1H), 7.11 (t, J = 7.63 Hz, 1H), 6.86 (d, J = 7.63 Hz, 1H), 5.72 (s, 1H), 4.44-4.50 (m, 1H), 4.16 (t, J = 6.1 Hz, 2H), 3.40 (t, J = 7.32 Hz, 2H), 2.22-2.27 (m, 2H), 1.92 (br, 2H), 1.82 (br, 2H), 1.34-1.35 (m, 4H).

EXAMPLE 234

3-(3-(1-naphthyloxy)propyl)-7-(2-pyridin-3-ylcyclohex-1-en-1-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.07 (s, 1H), 8.33-8.35 (m, 2H), 8.22-8.23 (m, 1H), 7.93 (d, J = 7.93 Hz, 1H), 7.85-7.87 (m, 1H), 7.44-7.54 (m, 5H), 7.38 (t, J = 7.78 Hz, 1H), 6.89-6.90 (m, 1H), 6.82-6.86 (m, 2H), 4.11 (t, J = 6.1 Hz, 2H), 3.27 (br, 2H), 2.10-2.16 (m, 2H), 1.91 (br, 4H).

EXAMPLE 235

3-(3-((8-chloroquinazolin-4-yl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.95 (s, 1H), 10.48 (s, 1H), 8.85 (s, 1H), 8.13 (dd, J = 7.63, 1.22 Hz, 1H), 8.10 (dd, J = 8.24, 1.22 Hz, 1H), 7.70 (d, J = 7.93 Hz, 1H), 7.64 (t, J = 7.93 Hz, 1H), 7.25-7.34 (m, 3H), 7.19 (d, J = 7.32 Hz, 1H), 7.07-7.10 (m, 1H), 7.02-7.02 (m, 1H), 4.60 (t, J = 6.1 Hz, 2H), 3.34 (t, J = 7.02 Hz, 2H), 2.23-2.29 (m, 2H), 2.04 (s, 3H).

EXAMPLE 236

1-butyl-7-(butyl(phenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 8.21 (d, J = 7.67 Hz, 1H), 7.86 (d, J = 7.67 Hz, 1H), 7.69-7.71 (m, 1H), 7.36-7.55 (m, 4H), 7.09-7.13 (m, 4H), 6.89 (d, J = 7.67 Hz, 1H), 6.63

(t, J = 7.06 Hz, 1H), 6.52 (d, J = 7.98 Hz, 2H), 4.49-4.53 (m, 1H), 4.37 (m, 1H), 4.21 (t, J = 5.52 Hz, 2H), 3.61 (m, 1H), 2.17-2.25 (m, 2H), 0.78-1.72 (m, 9H), 0.54 (t, J = 7.36 Hz, 3H).

EXAMPLE 237

3-(3-(7-chloro-1H-pyrrolo(2,3-c)pyridin-1-yl)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.46 (s, 1H), 7.87 (d, J = 5.22 Hz, 1H), 7.78 (d, J = 3.07 Hz, 1H), 7.54-7.57 (m, 2H), 7.20-7.33 (m, 4H), 7.10-7.13 (m, 1H), 7.03-7.05 (m, 1H), 6.62 (d, J = 3.07 Hz, 1H), 4.57-4.61 (m, 2H), 3.16 (t, J = 7.36 Hz, 2H), 2.12-2.20 (m, 2H), 2.06 (s, 3H).

EXAMPLE 238

7-(3-cyclohexylpyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.27 (s, 1H), 8.70 (d, J = 4.91 Hz, 1H), 8.41 (s, 1H), 8.28-8.30 (m, 1H), 7.86-7.91 (m, 3H), 7.45-7.57 (m, 3H), 7.39 (t, J = 7.98 Hz, 1H), 7.29 (d, J = 7.06 Hz, 1H), 7.16-7.18 (m, 1H), 6.89 (d, J = 7.36 Hz, 1H), 4.20 (t, J = 6.14 Hz, 2H), 3.39-3.42 (m, 2H), 2.46 (m, 2H), 2.21-2.28 (m, 2H), 0.91-1.78 (m, 10H).

EXAMPLE 239

3-(3-(1-naphthyloxy)propyl)-7-(1-(1,3-thiazol-5-ylmethyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.14 (s, 1H), 10.95 (s, 1H), 9.61 (s, 1H), 9.10 (s, 1H), 8.78 (s, 1H), 8.38 (d, J = 6.41 Hz, 1H), 8.22-8.24 (m, 1H), 8.15 (s, 1H), 7.93 (t, J = 6.41 Hz, 1H), 7.86-7.88 (m, 1H), 7.78 (d, J= 7.93 Hz, 1H), 7.35-7.54 (m, 5H), 7.12-7.16 (m, 1H), 6.90 (d, J = 7.63 Hz, 1H), 6.12 (s, 2H), 4.21 (t, J = 5.95 Hz, 2H), 3.40 (t, J = 7.32 Hz, 2H), 2.23-2.28 (m, 2H).

EXAMPLE 240

7-(1-(3,3-dimethyl-2-oxobutyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.14 (s, 1H), 10.74 (s, 1H), 9.18 (s, 1H), 8.39 (s, 1H), 8.34 (d, J = 6.1 Hz, 1H), 8.22-8.24 (m, 1H), 7.93 (d, J = 6.1 Hz, 1H), 7.86-7.88 (m, 1H),

7.76 (d, J= 8.24 Hz, 1H), 7.35-7.53 (m, 5H), 7.14-7.18 (m, 1H), 6.90 (d, J = 7.32 Hz, 1H), 5.81 (s, 2H), 4.21 (t, J = 5.95 Hz, 2H), 3.39-3.41 (m, 2H), 2.23-2.28 (m, 2H), 1.30 (s, 9H).

EXAMPLE 241

7-(4-cyclohex-1-en-1-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.07 (s, 1H), 11.09 (s, 1H), 8.76-8.78 (m, 2H), 8.26-8.28 (m, 1H), 7.86-7.88 (m, 1H), 7.78 (d, J= 7.93 Hz, 1H), 7.74 (d, J = 5.8 Hz, 1H), 7.36-7.56 (m, 5H), 7.14 (d, J = 6.1 Hz, 1H), 7.06-7.09 (m, 1H), 6.84-6.85 (m, 1H), 5.76 (s, 1H), 4.15 (t, J = 6.1 Hz, 2H), 3.38 (t, J = 7.32 Hz, 2H), 2.21-2.27 (m, 2H), 1.76-1.85 (m, 4H), 1.25-1.26 (m, 4H).

EXAMPLE 242

7-(1-(3,5-difluorobenzyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.95 (s, 1H), 9.46 (s, 1H), 8.75 (s, 1H), 8.36 (d, J = 6.41 Hz, 1H), 8.23-8.25 (m, 1H), 7.91 (d, J = 6.41 Hz, 1H), 7.86-7.88 (m, 1H), 7.78 (d, J= 8.24 Hz, 1H), 7.37-7.54 (m, 5H), 7.13-7.25 (m, 4H), 6.90 (d, J = 7.63 Hz, 1H), 5.83 (s, 2H), 4.21 (t, J = 6.1 Hz, 2H), 3.39-3.41(m, 2H), 2.24-2.29 (m, 2H).

EXAMPLE 243

3-(3-(1-naphthyloxy)propyl)-7-(1-phenylvinyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.03 (s, 1H), 9.82 (s, 1H), 8.22-8.24 (m, 1H), 7.91 (d, J = 6.41 Hz, 1H), 7.86-7.88 (m, 1H), 7.45-7.55 (m, 3H), 7.30-7.40 (m, 6H), 7.09-7.11 (m, 1H), 7.04-7.07 (m, 1H), 6.90 (d, J = 7.32 Hz, 1H), 5.85 (s, 1H), 5.51 (s, 1H), 4.19 (t, J = 6.1 Hz, 2H), 3.34-3.36 (m, 2H), 2.20-2.25 (m, 2H).

EXAMPLE 244

3-(3-(1-naphthyloxy)propyl)-7-(1H-pyrrolo(2,3-c)pyridin-7-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.58 (s, 1H), 11.65 (s, 1H), 8.31-8.32 (m, 2H), 8.13-8.16 (m, 2H), 8.04 (d, J = 7.93 Hz, 1H), 7.88-7.90 (m, 1H), 7.63 (d, J= 7.62 Hz, 1H), 7.45-7.57 (m, 3H), 7.39-7.43 (m 1H), 7.26-7.29 (m, 1H), 7.03 (s, 1H), 6.92 (d, J = 7.32 Hz, 1H), 4.22 (t, J = 6.1 Hz, 2H), 3.43-3.45 (m, 2H), 2.24-2.30 (m, 2H).

EXAMPLE 245

7-(4-cyclohexylpyridin-3-yl)-3-(3-phenoxypropyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.09 (s, 1H), 11.33 (s, 1H), 8.81 (d, J = 6.1 Hz, 1H), 8.72 (s, 1H), 8.26-8.28 (m, 1H), 7.90 (d, J = 5.8 Hz, 1H), 7.83-7.98 (m, 2H), 7.45-7.54 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.12-7.16 (m, 1H), 6.89 (d, J = 7.63 Hz, 1H), 4.19 (t, J = 6.26 Hz, 2H), 3.42-3.46 (m, 2H), 3.32-3.37 (m, 2H), 2.37-2.45 (m, 1H), 2.22-2.27 (m, 2H), 1.45-1.76 (m, 7H), 1.15-1.20 (m 1H), 0.81-0.99 (m, 2H).

EXAMPLE 246

7-(2,4-dimethyl-1,3-thiazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.95 (s, 1H), 8.21-8.23 (m, 1H), 7.85-7.97 (m, 2H), 7.75 (d, J = 7.98 Hz, 1H), 7.36-7.55 (m, 4H), 7.19 (t, J = 6.44 Hz, 1H), 7.06-7.09 (m, 1H), 6.89 (d, J = 7.37 Hz, 1H), 4.19 (t, J = 6.14 Hz, 2H), 3.37 (t, J = 7.52 Hz, 2H), 2.70 (s, 3H), 2.20-2.27 (m, 2H), 2.17 (s, 3H).

EXAMPLE 247

7-(1-(carboxymethyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.22 (s, 1H), 8.90 (s, 1H), 8.20-8.23 (m, 2H), 8.06 (s, 1H), 7.85-7.87 (m, 1H), 7.66-7.68 (m, 1H), 7.58-7.60 (m, 1H), 7.36-7.55 (m, 5H), 7.12-7.15 (m, 1H), 6.90 (d, J = 7.67 Hz, 1H), 5.22 (s, 2H), 4.21 (t, J = 6.1 Hz, 2H), 3.28 (t, J = 7.52 Hz, 2H), 2.20-2.27 (m, 2H).

EXAMPLE 248

3-(3-(1-naphthyloxy)propyl)-7-(1-phenylethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.09 (s, 1H), 8.23 (d, J = 7.67 Hz, 1H), 7.85-7.87 (m, 1H), 7.66-7.68 (m, 1H), 7.35-7.53 (m, 7H), 7.26 (t, J = 7.52 Hz, 2H), 7.10-7.17 (m, 2H), 6.96 (t, J = 7.67 Hz, 1H), 6.78 (d, J = 7.37 Hz, 1H), 5.00 (d, J = 7.06 Hz, 1H), 4.16 (t, J = 5.98 Hz, 2H), 3.28 (t, J = 7.52 Hz, 2H), 2.15-2.22 (m, 2H), 1.85 (m, 1H), 1.60 (d, J = 7.06 Hz, 3H).

EXAMPLE 249

7-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.57 (s, 1H), 8.24-8.26 (m, 1H), 7.85-7.87 (m, 1H), 7.65 (dd, J = 7.06, 1.53 Hz, 1H), 7.26-7.52 (m, 8H), 7.03-7.08 (m, 2H), 6.90 (d, J = 7.67 Hz, 1H), 5.31 (d, J = 7.06 Hz, 1H), 4.21 (t, J = 5.98 Hz, 2H), 3.34-3.37 (m, 2H), 2.18-2.27 (m, 2H), 2.04 (s, 6H).

EXAMPLE 250

7-(2-(2-chlorophenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.93 (s, 1H), 8.21-8.23 (m, 1H), 7.84-7.86 (m, 1H), 7.34-7.54 (m, 8H), 7.20-7.22 (m, 1H), 7.09 (dd, J = 7.36, 1.84 Hz, 1H), 6.82-6.98 (m, 4H), 6.71-6.75 (m, 1H), 5.31 (d, J = 7.06 Hz, 1H), 4.12 (t, J = 6.14 Hz, 2H), 3.20-3.26 (m, 4H), 2.21-2.28 (m, 4H), 1.82-1.96 (m, 4H).

EXAMPLE 251

3-(3-(1-naphthyloxy)propyl)-1H,1'H-7,7'-biindole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.02 (s, 1H), 10.70 (s, 1H), 9.88 (s, 1H), 8.27-8.29 (m, 1H), 7.87-7.89 (m, 1H), 7.76 (d, J = 7.93 Hz, 1H), 7.62 (d, J = 7.63 Hz, 1H), 7.37-7.56 (m, 5H), 7.27 (t, J = 2.9 Hz, 1H), 7.21 (d, J = 7.02 Hz, 1H), 7.13-7.18 (m, 2H), 6.92 (d, J = 7.63 Hz, 1H), 6.55 (dd, J = 3.05, 1.83 Hz, 1H), 4.23 (t, J = 6.26 Hz, 2H), 3.39-3.42 (m, 2H), 2.25-2.30 (m, 2H).

EXAMPLE 252

3-(3-(1-naphthyloxy)propyl)-7-(1-(2-(2-oxopyrrolidin-1-yl)ethyl)-1H-pyrrolo(2,3-c)pyridin-7-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 15.03 (s, 1H), 11.85 (s, 1H), 8.35 (d, J = 6.1 Hz, 1H), 8.31-8.32 (m, 1H), 8.22 (d, J = 6.41 Hz, 1H), 8.20 (d, J = 3.05 Hz, 1H), 8.08 (d, J = 7.93 Hz, 1H), 7.88-7.90 (m, 1H), 7.61 (d, J = 7.02 Hz, 1H), 7.39-7.55 (m, 5H), 7.25-7.28 (m, 1H), 7.07 (d, J = 3.05 Hz, 1H), 6.92 (d, J = 7.32 Hz, 1H), 4.20 (t, J = 6.1 Hz, 2H), 3.83-3.88 (m,

2H), 3.56-3.60 (m, 2H), 3.42-3.45 (m, 2H), 2.23-2.28 (m, 2H), 1.94-1.98 (m, 2H), 1.64-1.71 (m, 2H).

EXAMPLE 254

7-(5-methyl-3-phenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.53 (s, 1H), 8.26-8.28 (m, 1H), 7.86-7.88 (m, 1H), 7.68 (dd, J = 6.87, 2.29 Hz, 1H), 7.45-7.54 (m, 3H), 7.39 (t, J = 7.78 Hz, 1H), 7.29-7.31 (m, 2H), 7.15-7.17 (m, 3H), 7.01-7.05 (m, 2H), 6.90 (d, J = 7.32 Hz, 1H), 4.20 (t, J = 6.1 Hz, 2H), 3.33-3.36 (m, 2H), 2.21-2.26 (m, 2H), 2.03 (s, 3H).

EXAMPLE 255

7-(2-methylphenyl)-4-(2-(1-naphthyloxy)ethyl)-1H-indole-2-carboxylic acid

EXAMPLE 255A

ethyl 4-(1-ethoxy-1,3-dioxobutan-2-yl)-7-o-tolyl-1H-indole-2-carboxylate

A mixture of ethyl 4-chloro-7-o-tolyl-1H-indole-2-carboxylate (EXAMPLE 166C) (0.93 g), ethyl 3-oxobutanoate (0.849 g), *di*-tert-butyl(2'-methylbiphenyl-2-yl)phosphine (0.093 mg), K_3PO_4 (3.46 g), and palladium(II) acetate (0.033 g) in toluene (8 mL) was degassed via vacuum/nitrogen cycle three times. The reaction mixture was heated at 93 °C for 14 hours. The reaction mixture was partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The residue was purified with flash chromatography on silica gel (ethyl acetate in hexanes) to give the title compound.

EXAMPLE 255B

methyl 4-(2-methoxy-2-oxoethyl)-7-o-tolyl-1H-indole-2-carboxylate

EXAMPLE 255A (crude) in ethanol (35 mL) was treated with 20% KOH (15 mL). The mixture was heated at 100 C for 1 hour. The solvent was removed and the residue dissolved in ethyl acetate. After addition of concentrated HCl, the organic layer was separated and the aqueous layer was extracted with additional ethyl acetate. The combined organic layers were dried, and concentrated. The residue was treated with diazomethane in

CH_2Cl_2 and a few drops of methanol. After bubbling ceased, the solvents were evaporated and the compound purified via flash chromatography (15:85 EtOAc/Hex) to give pure EXAMPLE 255B. ^{1}H NMR (500 MHz, DMSO-d_6): δ 11.14 (s, 1H), 7.26-7.34 (m, 4H), 7.21 (d, J = 7.32 Hz, 1H), 7.00-7.05 (m, 2H), 3.99 (s, 2H), 3.83 (s, 3H), 3.64 (s, 3H), 2.05 (s, 3H).

EXAMPLE 255C

7-(2-methylphenyl)-4-(2-(1-naphthyloxy)ethyl)-1H-indole-2-carboxylic acid

The title compound was prepared according to the procedure for EXAMPLE 164G, substituting EXAMPLE 255B for EXAMPLE 164F. ^{1}H NMR (500 MHz, DMSO-d_6): δ 11.05 (s, 1H), 8.13 (d, J = 7.98 Hz, 1H), 7.84 (d, J = 7.98 Hz, 1H), 7.31-7.51 (m, 7H), 7.18-7.27 (m, 3H), 7.01 (d, J = 6.75 Hz, 1H), 4.50 (t, J = 6.44 Hz, 2H), 3.52 (t, J = 6.44 Hz, 2H), 2.05 (s, 3H).

EXAMPLE 256

7-(2-methylphenyl)-4-(2-(2-naphthyloxy)ethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.06 (s, 1H), 7.78-7.83 (m, 3H), 7.13-7.46 (m, 10H), 7.01 (d, J = 7.06 Hz, 1H), 4.46 (t, J = 6.9 Hz, 2H), 3.45 (t, J = 6.75 Hz, 2H), 2.06 (s, 3H).

EXAMPLE 257

4-(2-(2,3-dichlorophenoxy)ethyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.02 (s, 1H), 7.36 (d, J = 1.84 Hz, 1H), 7.17-7.32 (m, 7H), 7.12 (d, J = 7.06 Hz, 1H), 7.00 (d, J = 7.36 Hz, 1H), 4.40 (t, J = 6.6 Hz, 2H), 3.28-3.34 (m, 2H), 2.21-2.29 (m, 2H), 2.06 (s, 3H).

EXAMPLE 258

3-(3-(1H-indol-4-yloxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.02 (s, 1H), 10.41 (s, 1H), 7.71 (d, J = 7.98 Hz, 1H), 7.20-7.33 (m, 5H), 6.93-7.11 (m, 4H), 6.47-6.49 (m, 1H), 6.42 (d, J = 6.44 Hz, 1H), 4.12 (t, J = 6.44 Hz, 2H), 3.40-3.42 (m, 2H), 2.06 (s, 3H).

EXAMPLE 259

4-(2-(2-chloro-3-(trifluoromethyl)phenoxy)ethyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.03 (s, 1H), 7.45-7.53 (m, 2H), 7.19-7.39 (m, 6H), 7.13 (d, J = 7.36 Hz, 1H), 6.99 (d, J = 7.06 Hz, 1H), 4.49 (t, J = 6.75 Hz, 2H), 3.41-3.44 (m, 2H), 2.05 (s, 3H).

EXAMPLE 260

1-methyl-3-(3-((1-methyl-1H-indol-4-yl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.07 (s, 1H), 7.74 (d, J = 7.98 Hz, 1H), 7.27-7.37 (m, 4H), 7.20 (d, J = 3.07 Hz, 1H), 7.09 (t, J = 7.52 Hz, 1H), 6.98-7.05 (m, 3H), 6.49 (d, J = 1.43 Hz, 1H), 6.47 (d, J = 2.76 Hz, 1H), 4.13 (t, J = 6.14 Hz, 2H), 3.76 (s, 3H), 3.24-3.27 (m, 2H), 2.10-2.17 (m, 2H), 2.00 (s, 3H).

EXAMPLE 261

7-(2-(4-ethylphenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.56 (s, 1H), 8.22-8.24 (m, 1H), 7.84-7.86 (m, 1H), 7.34-7.54 (m, 5H), 6.92 (d, J = 8.29 Hz, 1H), 6.84 (d, J = 7.67 Hz, 2H), 6.67-6.80 (m, 4H), 4.11 (t, J = 6.14 Hz, 2H), 3.23-3.27 (m, 2H), 2.31-2.43 (m, 6H), 2.11-2.18 (m, 2H), 1.85 (br, 4H), 0.98 (t, J = 7.52 Hz, 3H).

EXAMPLE 262

7-(2-(4-isopropylphenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.43 (s, 1H), 8.22-8.24 (m, 1H), 7.84-7.86 (m, 1H), 7.34-7.54 (m, 5H), 6.93 (d, J = 7.98 Hz, 1H), 6.79-6.84 (m, 5H), 4.10 (t, J = 6.14 Hz, 2H), 3.22-3.26 (m, 2H), 2.57-2.64 (m, 1H), 2.11-2.44 (m, 6H), 1.85 (br, 4H), 0.99 (d, J = 6.75 Hz, 6H).

EXAMPLE 263

7-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.85 (s, 1H), 10.42 (s, 1H), 8.25 (d, J = 7.63 Hz, 1H), 7.85-7.87 (m, 1H), 7.44-7.58 (m, 4H), 7.38 (t, J = 7.93 Hz, 1H), 7.25-7.30 (m, 5H), 6.93-6.97 (m, 2H), 6.88 (d, J = 7.63 Hz, 1H), 4.17 (t, J = 6.1 Hz, 2H), 3.73 (s, 3H), 3.27-3.30 (m, 2H), 2.16-2.20 (m, 2H), 2.00 (s, 3H).

EXAMPLE 264

7-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.87 (s, 1H), 10.60 (s, 1H), 8.26-8.28 (m, 1H), 7.86-7.88 (m, 1H), 7.69 (d, J = 7.63 Hz, 1H), 7.45-7.55 (m, 3H), 7.39 (t, J = 7.78 Hz, 1H), 7.28 (dd, J = 7.32, 2.44 Hz, 2H), 7.11-7.13 (m, 3H), 6.97-7.04 (m, 2H), 6.90 (d, J = 7.63 Hz, 1H), 4.20 (t, J = 6.1 Hz, 2H), 3.85 (s, 3H), 3.36 (br, 2H), 2.21-2.27 (m, 2H), 2.01 (s, 3H).

EXAMPLE 265

7-(3,5-dimethyl-1-((3-methyloxetan-3-yl)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.24 (s, 1H), 11.06 (s, 1H), 8.23 (d, J = 7.63 Hz, 1H), 7.81-7.88 (m, 2H), 7.39-7.55 (m, 4H), 7.13-7.17 (m, 2H), 6.91 (d, J = 7.32 Hz, 1H), 5.50 (m, 1H), 4.41-4.49 (m, 2H), 4.22-4.29 (m, 4H), 3.56 (s, 3H), 2.20-2.26 (m, 8H), 1.93 (s, 3H).

EXAMPLE 266

7-(3,5-dimethyl-1-tetrahydrofuran-3-yl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.98 (s, 1H), 10.59 (s, 1H), 8.25-8.26 (m, 1H), 7.86-7.88 (m, 1H), 7.65 (d, J = 7.93 Hz, 1H), 7.45-7.55 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.07-7.07 (m, 2H), 6.91 (d, J = 7.63 Hz, 1H), 4.96-5.01 (m, 1H), 4.21 (t, J = 6.1 Hz, 2H), 4.03-4.07 (m, 2H), 3.83-3.88 (m, 2H), 3.34-3.37 (m, 2H), 2.31-2.41 (m, 4H), 2.21-2.26 (m 2H), 2.07 (s, 3H), 2.02 (s, 3H).

EXAMPLE 267

7-(3,5-dimethyl-1-pyridin-2-yl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.98 (s, 1H), 8.48 (d, J = 4.58 Hz, 1H), 8.25-8.28 (m, 1H), 7.86-8.00 (m, 3H), 7.70 (dd, J = 7.17, 1.68 Hz, 1H), 7.45-7.55 (m, 3H), 7.38-7.41 (m, 1H), 7.31-7.33 (m, 1H), 7.07-7.12 (m, 2H), 6.91 (d, J = 7.32 Hz, 1H), 4.22 (t, J = 5.95 Hz, 2H), 3.37 (t, J = 7.63 Hz, 2H), 2.43 (s, 3H), 2.21-2.27 (m, 2H), 2.09 (s, 3H).

EXAMPLE 268

7-(2-chloro-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.99 (s, 1H), 11.40 (s, 1H), 8.26-8.31 (m, 2H), 8.25-8.28 (m, 2H), 7.86-7.88 (m, 1H), 7.76 (d, J = 7.93 Hz, 1H), 7.38-7.55 (m, 5H), 7.09-7.12 (m, 1H), 7.03 (d, J = 7.02 Hz, 1H), 6.91 (d, J = 7.63 Hz, 1H), 4.22 (t, J = 6.1 Hz, 2H), 3.37 (t, J = 7.63 Hz, 2H), 2.22-2.27 (m, 2H), 1.96 (s, 3H).

EXAMPLE 269

7-(4-methyl-2-(2-(2-oxopyrrolidin-1-yl)ethoxy)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.10 (s, 1H), 8.27-8.30 (m, 1H), 8.05 (d, J = 5.22 Hz, 1H), 7.86-7.88 (m, 1H), 7.68 (d, J = 7.98 Hz, 1H), 7.37-7.55 (m, 4H), 7.03-7.07 (m, 1H), 6.96-6.98 (m, 1H), 6.90 (d, J = 7.36 Hz, 1H), 4.15-4.30 (m, 4H), 3.34 (m, 2H), 3.24 (t, J = 4.91 Hz, 1H), 2.55-2.65 (m, 2H), 2.22-2.27 (m, 2H), 1.96 (s, 3H), 1.90 (t, J = 8.13 Hz, 2H), 1.43-1.49 (m, 2H).

EXAMPLE 270

7-(3,5-dimethyl-1-(tetrahydrofuran-3-ylmethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.51 (s, 1H), 8.24-8.26 (m, 1H), 7.86-7.88 (m, 1H), 7.85-7.88 (m, 1H), 7.64-7.66 (m, 1H), 7.44-7.55 (m, 3H), 7.39 (t, J = 7.83 Hz, 1H), 7.02-7.08 (m, 2H), 6.91 (d, J = 7.36 Hz, 1H), 4.21 (t, J = 5.98 Hz, 2H), 3.95-4.05 (m, 2H), 3.80-3.86 (m, 2H), 3.64-3.74 (m, 4H), 3.35 (t, J = 7.52 Hz, 1H), 2.74-2.81 (m, 1H), 2.20-2.27 (m, 2H), 1.96-2.03 (m, 6H), 1.69-1.75 (m, 1H).

EXAMPLE 271

7-(1-cyclopentyl-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.47 (s, 1H), 8.24-8.26 (m, 1H), 7.85-7.88 (m, 1H), 7.85-7.88 (m, 1H), 7.65 (d, J = 6.75 Hz, 1H), 7.45-7.55 (m, 3H), 7.39 (t, J = 7.83 Hz, 1H), 7.01-7.07 (m, 2H), 6.91 (d, J = 7.36 Hz, 1H), 4.64-4.70 (m, 1H), 4.21 (t, J = 6.14 Hz, 2H), 3.33-3.37 (m, 2H), 2.21-2.26 (m, 2H), 2.02-2.08 (m, 10H), 1.85-1.88 (m, 2H), 1.64-1.66 (m, 2H).

EXAMPLE 272

7-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.34 (s, 1H), 8.23-8.26 (m, 1H), 7.85-7.88 (m, 1H), 7.65 (d, J = 7.67 Hz, 1H), 7.37-7.55 (m, 4H), 7.02-7.08 (m, 2H), 6.91 (d, J = 7.36 Hz, 1H), 4.44-4.47 (m, 1H), 4.09-4.23 (m, 5H), 3.87-3.91 (m, 1H), 3.34-3.37 (m, 2H), 2.21-2.27 (m, 2H), 2.09 (s, 3H), 2.01 (s, 3H), 1.33 (s, 3H), 1.29 (s, 3H).

EXAMPLE 273

7-(4-methyl-2-(2-morpholin-4-ylethoxy)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.11 (s, 1H), 8.91 (s, 1H), 8.26-8.28 (m, 1H), 8.10 (d, J = 5.22 Hz, 1H), 7.85-7.88 (m, 1H), 7.71 (d, J = 7.98 Hz, 1H), 7.45-7.55 (m, 4H), 7.39 (t, J = 7.83 Hz, 1H), 7.05-7.09 (m, 1H), 6.91 (d, J = 7.36 Hz, 1H), 4.55-4.59 (m, 1H), 4.40-4.46 (m, 1H), 4.21 (t, J = 5.98 Hz, 2H), 3.33-3.37 (m, 2H), 2.93 (br, 2H), 2.73 (br, 2H), 2.20-2.25 (m, 2H), 1.98 (s, 3H).

EXAMPLE 274

7-(4-methyl-2-morpholin-4-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.28 (s, 1H), 8.27-8.29 (m, 1H), 8.20 (d, J = 5.83 Hz, 1H), 7.86-7.88 (m, 1H), 7.79 (d, J = 7.98 Hz, 1H), 7.45-7.55 (m, 4H), 7.37 (t, J = 7.98 Hz, 1H), 7.20-7.24 (m, 2H), 7.09-7.13 (m, 1H), 6.86 (d, J = 7.37 Hz, 1H), 4.18 (t, J = 6.14 Hz, 2H), 3.39 (t, J = 6.14 Hz, 2H), 2.87-3.17 (m, 8H), 2.21-2.28 (m, 2H), 2.12 (s, 3H).

EXAMPLE 275

7-(2-chloro-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 8.51 (d, J = 4.3 Hz, 1H), 8.25-8.29 (m, 2H), 7.93 (d, J = 7.98 Hz, 1H), 7.87-7.89 (m, 1H), 7.74 (s, 1H), 7.39-7.56 (m, 5H), 7.19-7.24 (m, 2H), 7.10 (d, J = 7.98 Hz, 1H), 6.99 (d, J = 7.36 Hz, 1H), 6.94 (d, J = 6.75 Hz, 1H), 5.29-5.46 (m, 2H), 4.28 (t, J = 5.98 Hz, 2H), 3.42-3.45 (m, 2H), 2.27-2.33 (m, 2H), 1.66 (s, 3H).

EXAMPLE 276

7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.37 (s, 1H), 8.75 (s, 1H), 8.60 (d, J = 5.22 Hz, 1H), 8.25-8.28 (m, 1H), 7.86-7.88 (m, 1H), 7.74 (d, J = 7.98 Hz, 1H), 7.70 (d, J = 5.22 Hz, 1H), 7.45-7.54 (m, 3H), 7.39 (t, J = 7.98 Hz, 1H), 7.30 (d, J = 7.36 Hz, 2H), 7.02-7.09 (m, 2H), 6.88 (d, J = 7.36 Hz, 1H), 4.17 (t, J = 6.14 Hz, 2H), 3.27-3.39 (m, 2H), 2.18-2.25 (m, 2H), 2.06 (s, 3H).

EXAMPLE 277

7-(1-(2,3-dihydroxypropyl)-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.47 (s, 1H), 8.24-8.26 (m, 1H), 7.86-7.88 (m, 1H), 7.67 (d, J = 7.36 Hz, 1H), 7.37-7.53 (m, 4H), 7.03-7.09 (m, 2H), 6.91 (d, J = 7.67 Hz, 1H), 4.15-4.23 (m, 4H), 3.34-3.46 (m, 2H), 2.21-2.26 (m, 2H), 2.07 (s, 3H), 2.03 (s, 3H).

EXAMPLE 278

3-(3-(1-naphthyloxy)propyl)-7-(3-phenyl-5-(2-phenylethyl)-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.40 (s, 1H), 8.26-8.29 (m, 1H), 7.85-7.88 (m, 1H), 7.68 (d, J = 8.29 Hz, 1H), 7.44-7.55 (m, 3H), 7.31-7.39 (m, 3H), 7.00-7.17 (m, 7H), 6.89-6.95 (m, 4H), 4.19 (t, J = 6.14 Hz, 2H), 3.34-3.46 (m, 2H), 2.65-2.74 (m 4H), 2.21-2.26 (m, 2H).

EXAMPLE 279

7-(4-methyl-2-phenylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.29 (s, 1H), 8.81 (d, J = 5.52 Hz, 1H), 8.24-8.26 (m, 1H), 7.85-7.90 (m, 2H), 7.64-7.66 (m, 1H), 7.31-7.39 (m, 3H), 7.35-7.45 (m, 4H), 7.15-7.28 (m, 5H), 6.92-6.97 (m, 2H), 6.84 (d, J = 7.67 Hz, 1H), 4.12 (t, J = 6.14 Hz, 2H), 3.28-3.34 (m, 2H), 2.17-2.21 (m, 2H), 2.15 (s, 3H).

EXAMPLE 280

7-(4-methyl-2-vinylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.22 (s, 1H), 8.65 (d, J = 5.83 Hz, 1H), 8.25-8.27 (m, 1H), 7.86-7.88 (m, 1H), 7.81 (d, J = 7.98 Hz, 1H), 7.62-7.64 (m, 1H), 7.45-7.54 (m, 3H), 7.39 (t, J = 7.98 Hz, 1H), 7.04 (d, J = 6.44 Hz, 1H), 6.91 (d, J = 7.67 Hz, 1H), 6.16-6.29 (m, 2H), 5.47-5.49 (m, 1H), 4.22 (t, J = 6.14 Hz, 2H), 3.28-3.34 (m, 2H), 2.21-2.28 (m, 2H), 2.04 (s, 3H).

EXAMPLE 281

7-(4-methyl-2-((1E)-prop-1-enyl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.24 (s, 1H), 8.65 (d, J = 5.83 Hz, 1H), 8.25-8.28 (m, 1H), 7.82-7.88 (m, 2H), 7.70 (d, J = 5.83 Hz, 1H), 7.45-7.55 (m, 3H), 7.39 (t, J = 7.98 Hz, 1H), 7.14-7.18 (m, 1H), 7.05 (d, J = 7.14 Hz, 1H), 6.90 (d, J = 7.36 Hz, 1H), 6.16-6.29 (m, 2H), 6.82 (dd, J = 15.65, 6.75 Hz, 1H), 5.92 (dd, J = 15.65, 1.53 Hz, 1H), 4.22 (t, J = 6.14 Hz, 2H), 3.36-3.40 (m, 2H), 2.22-2.28 (m, 2H), 2.04 (s, 3H), 1.69-1.71 (m, 3H).

EXAMPLE 282

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.30 (s, 1H), 8.76 (d, J = 5.83 Hz, 1H), 8.25-8.27 (m, 1H), 7.84-7.88 (m, 2H), 7.45-7.56 (m, 3H), 7.39 (t, J = 7.83 Hz, 1H), 7.12-7.20 (m, 2H), 6.90 (d, J = 7.67 Hz, 1H), 4.22 (t, J = 6.14 Hz, 2H), 3.36-3.40 (m, 2H), 2.59-2.65 (m, 1H), 2.42-2.48 (m, 1H), 2.21-2.27 (m, 2H), 2.10 (s, 3H).

EXAMPLE 283

7-(3,5-dimethyl-1-(pyridin-3-ylmethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.95 (s, 1H), 8.60-8.65 (m, 2H), 8.24-8.26 (m, 1H), 7.94 (d, J = 7.98 Hz, 1H), 7.85-7.87 (m, 1H), 7.62-7.67 (m, 2H), 7.44-7.53 (m, 3H), 7.39 (t, J = 7.98 Hz, 1H), 7.03-7.08 (m, 2H), 6.91 (d, J = 7.36 Hz, 1H), 5.41 (s, 2H), 4.21 (t, J = 5.98 Hz, 2H), 3.34-3.38 (m, 2H), 2.21-2.26 (m, 2H), 2.08 (s, 3H), 2.02 (s, 3H).

EXAMPLE 284

7-(2-isopropenyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.26 (s, 1H), 8.71 (d, J = 5.52 Hz, 1H), 8.26-8.28 (m, 1H), 7.80-7.88 (m, 2H), 7.77 (d, J = 7.67 Hz, 1H), 7.45-7.55 (m, 3H), 7.38 (t, J = 7.83 Hz, 1H), 7.04-7.11 (m, 2H), 6.88 (d, J = 7.37 Hz, 1H), 5.15 (s, 1H), 5.13 (s, 1H), 4.20 (t, J = 6.14 Hz, 2H), 3.33-3.37 (m, 2H), 2.21-2.26 (m, 2H), 2.10 (s, 3H), 1.67 (s, 3H).

EXAMPLE 285

7-(4-methyl-2-pentylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.23 (s, 1H), 8.74 (d, J = 5.83 Hz, 1H), 8.25-8.28 (m, 1H), 7.83-7.88 (m, 3H), 7.45-7.55 (m, 3H), 7.38 (t, J = 7.83 Hz, 1H), 7.11-7.18 (m, 2H), 6.87 (d, J = 7.67 Hz, 1H), 4.20 (t, J = 6.19 Hz, 2H), 3.33-3.37 (m, 2H), 2.54-2.62 (m, 1H), 2.29-2.46 (m, 1H), 2.22-2.28 (m, 2H), 2.12 (s, 3H), 1.35-1.40 (m, 2H), 0.88-0.99 (m, 4H), 0.58 (t, J = 7.06 Hz, 3H).

EXAMPLE 286

7-(4-methyl-2-propylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.30 (s, 1H), 8.73 (d, J = 5.83 Hz, 1H), 8.26-8.28 (m, 1H), 7.82-7.88 (m, 2H), 7.79 (d, J = 5.83 Hz, 1H), 7.45-7.55 (m, 3H), 7.38 (t, J = 7.83 Hz, 1H), 7.10-7.18 (m, 2H), 6.89 (d, J = 7.36 Hz, 1H), 4.21 (t, J = 5.98 Hz, 2H), 3.37-3.40 (m, 2H), 2.54-2.64 (m, 1H), 2.34-2.42 (m, 1H), 2.22-2.28 (m, 2H), 2.09 (s, 3H), 1.39-1.49 (m, 2H), 0.65 (t, J = 7.36 Hz, 3H).

EXAMPLE 287

7-(2-isopropyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.26 (s, 1H), 8.65 (d, J = 5.83 Hz, 1H), 8.22-8.24 (m, 1H), 7.84-7.86 (m, 1H), 7.80 (d, J = 7.98 Hz, 1H), 7.72 (d, J = 6.14 Hz, 1H), 7.35-7.45 (m, 3H), 7.37 (t, J = 7.98 Hz, 1H), 7.15 (t, J = 7.52 Hz, 1H), 7.07-7.08 (m, 1H), 6.88 (d, J = 7.36 Hz, 1H), 4.20 (t, J = 5.98 Hz, 2H), 3.36 (m, 2H), 2.67-2.70 (m, 2H), 2.22-2.28 (m, 2H), 2.02 (s, 3H), 1.12 (dd, J = 6.75, 5.22 Hz, 6H).

EXAMPLE 288

7-(3,5-diisopropyl-1-methyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.43 (s, 1H), 8.27-8.29 (m, 1H), 7.86-7.88 (m, 1H), 7.66 (d, J = 7.06 Hz, 1H), 7.45-7.55 (m, 3H), 7.36-7.40 (m, 1H), 6.99-7.06 (m, 2H), 6.89 (d, J = 7.06 Hz, 1H), 4.20 (t, J = 6.14 Hz, 2H), 3.82 (s, 3H), 3.32-3.36 (m, 2H), 2.89-2.94 (m, 1H), 2.43-2.50 (m, 1H), 2.19-2.26 (m, 2H), 1.03-1.06 (m, 6H), 0.96 (d, J = 6.75, Hz, 3H), 0.91 (d, J = 7.06 Hz, 3H).

EXAMPLE 289

7-(5-carboxy-1,3-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.61 (s, 1H), 8.28-8.30 (m, 1H), 7.86-7.88 (m, 1H), 7.64 (d, J = 7.06, 2.15 Hz, 1H), 7.45-7.55 (m, 3H), 7.40 (t, J = 7.83 Hz, 1H), 7.00-7.05 (m, 2H), 6.92 (d, J = 7.36 Hz, 1H), 4.22 (t, J = 6.14 Hz, 2H), 4.09 (s, 3H), 3.33-3.36 (m, 2H), 2.21-2.26 (m, 2H), 1.92 (s, 3H).

EXAMPLE 290

7-(4-methyl-2-(2-methylprop-1-enyl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.20 (s, 1H), 8.70 (d, J = 5.83 Hz, 1H), 8.25-8.27 (m, 1H), 7.86-7.88 (m, 1H), 7.80 (d, J = 7.67 Hz, 1H), 7.45-7.55 (m, 3H), 7.38 (t, J = 7.83 Hz, 1H), 7.11-7.14 (m, 1H), 7.04-7.06 (m 1H), 6.88 (d, J = 7.67 Hz, 1H), 5.78 (s, 1H), 4.20 (t, J = 5.98 Hz, 2H), 3.33-3.36 (m, 2H), 2.20-2.28 (m, 2H), 2.11 (s, 3H), 1.78 (s, 3H), 1.60 (s, 3H).

EXAMPLE 291

7-(4-carboxy-1-phenyl-1H-pyrazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.40 (s, 1H), 8.27-8.29 (m, 1H), 8.16 (s, 1H), 7.85-7.88 (m, 1H), 7.69 (d, J = 7.98 Hz, 1H), 7.44-7.55 (m, 3H), 7.38 (t, J = 7.98 Hz, 1H), 7.19-7.23 (m, 5H), 7.02 (d, J = 6.75 Hz, 1H), 6.93 (t, J = 7.67 Hz, 1H), 6.87 (d, J = 7.36 Hz, 1H), 5.78 (s, 1H), 4.16 (t, J = 6.14 Hz, 2H), 3.28-3.34 (m, 2H), 2.16-2.24 (m, 2H).

EXAMPLE 292

7-(2-isobutyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.31 (s, 1H), 8.75 (d, J = 6.14 Hz, 1H), 8.26-8.28 (m, 1H), 7.83-7.88 (m, 1H), 7.44-7.56 (m, 3H), 7.37 (t, J = 7.98 Hz, 1H), 7.12-7.17 (m, 2H), 6.87 (d, J = 7.36 Hz, 1H), 4.19 (t, J = 6.14 Hz, 2H), 3.28-3.34 (m, 2H), 2.54-2.61 (m, 1H), 2.22-2.32 (m, 3H), 2.12 (m, 3H), 1.72-1.78 (m, 1H), 0.66 (d, J = 6.44 Hz, 3H), 0.62 (d, J = 6.75 Hz, 3H).

EXAMPLE 293

7-(4-methyl-2,3'-bipyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.32 (s, 1H), 8.71 (d, J = 5.22 Hz, 1H), 8.43 (s, 1H), 8.36 (d, J = 6.1 Hz, 1H), 8.25-8.27 (m, 1H), 7.85-7.88 (m, 1H), 7.71 (d, J= 7.98 Hz, 1H), 7.61-7.65 (m, 2H), 7.44-7.55 (m, 3H), 7.38 (t, J = 7.98 Hz, 1H), 7.26 (dd, J = 7.98, 5.22 Hz, 1H), 6.93-6.96 (m, 2H), 6.86 (d, J = 7.36 Hz, 1H), 4.14 (t, J = 6.14 Hz, 2H), 3.30-3.34 (m, 2H), 2.16-2.20 (m, 2H), 2.06 (s, 3H).

EXAMPLE 294

7-(2-(4-methoxyphenyl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.28 (s, 1H), 8.75 (d, J = 5.83 Hz, 1H), 8.25-8.27 (m, 1H), 7.83-7.88 (m, 2H), 7.68 (dd, J= 7.06, 2.15 Hz, 1H), 7.44-7.55 (m, 3H), 7.37 (t, J = 7.83 Hz, 1H), 7.20 (d, J = 8.59 Hz, 1H), 6.94-6.99 (m, 2H), 6.85 (d, J = 7.67 Hz, 1H), 6.74 (d, J = 8.59 Hz, 1H), 4.14 (t, J = 6.29 Hz, 2H), 3.63 (s, 3H), 3.31-3.35 (m, 2H), 2.18-2.24 (m, 2H), 2.11 (s, 3H).

EXAMPLE 295

7-(4-methyl-2-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.28 (s, 1H), 8.66 (d, J = 5.19 Hz, 1H), 8.27-8.29 (m, 1H), 7.84-7.88 (m, 2H), 7.86 (s, 1H), 7.45-7.55 (m, 3H), 7.37 (t, J = 7.83 Hz, 1H), 7.37-7.40 (m, 1H), 7.07-7.15 (m, 2H), 6.88 (d, J = 7.63 Hz, 1H), 6.78 (s, 1H), 4.18 (t, J = 6.26 Hz, 2H), 3.63 (s, 3H), 3.29-3.33 (m, 2H), 2.21-2.27 (m, 2H), 2.08 (s, 3H).

EXAMPLE 296

7-(3-(hydroxymethyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

EXAMPLE 296A

Ethyl 4-bromo-5-methyl-1H-pyrazole-3-carboxylate

Ethyl 5-methyl-1H-pyrazole-3-carboxylate (3.24 g) in CH_3CN (25 mL) was treated with N-bromosuccinimide (3.92 g) at 0 °C. The solution was stirred at room temperature for 2 hours. The solvent was removed, and the residue was purified by flash chromatography on silica gel (ethyl acetate in hexanes) to give the title coompound. ^{1}H NMR (500 MHz, DMSO-d6): 13.61 (s, 1H), 4.27 (q, J = 6.75 Hz, 2H), 2.21(s, 3H), 1.28 (t, J = 7.06 Hz, 3H).

EXAMPLE 296B

Ethyl 4-bromo-1,5-dimethyl-1H-pyrazole-3-carboxylate

EXAMPLE 296A (2.33 g) in N,N-dimethylformamide was treated with 60% NaH (0.8 g) at 0°C. After 10 minutes, to this solution was added iodomethane (1.703 g). The solution was stirred at room temperature for 3 hours. Aqueous workup followed by drying, filtering, and flash chromatography (ethyl acetate in hexanes) afforded the title compound. ^{1}H NMR (500 MHz, DMSO-d_6): 4.26 (q, J = 7.06 Hz, 2H), 3.86 (s, 3H), 2.27(s, 3H), 1.28 (t, J = 7.06 Hz, 3H).

EXAMPLE 296C

(4-Bromo-1,5-dimethyl-1H-pyrazol-3-yl)methanol

EXAMPLE 296B (1.43 g) in tetrahydrofuran (10 ml) was treated with 1N $LiAlH_4$ in tetrahydrofuran (5.79 mL) at 0°C. The solution was stirred for 10 minutes. Aqueous workup

followed by flash chromatography (ethyl acetate in hexanes) afforded the title compound. ^{1}H NMR (500 MHz, DMSO-d6): 4.91 (t, J = 5.68 Hz, 1H), 4.30 (d, J = 5.52 Hz, 2H), 3.73 (s, 3H), 2.21(s, 3H).

EXAMPLE 296D

Methyl 7-(3-(hydroxymethyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

The title compound was synthesized according to the procedure for EXAMPLE 192A by substituting 2-fluoro-4-iodo-5-methylpyridine with EXAMPLE 296C. ^{1}H NMR (500 MHz, DMSO-d_6): δ 11.06 (s, 1H), 8.25-8.26 (m, 1H), 7.86-7.88 (m, 1H), 7.65 (dd, J = 7.02, 1.83 Hz, 1H), 7.45-7.55 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.05-7.09 (m, 2H), 6.91 (d, J = 7.63 Hz, 1H), 6.78 (s, 1H), 4.24 (s, 2H), 4.21 (t, J = 6.1 Hz, 2H), 3.83 (s, 3H), 3.34-3.37 (m, 2H), 2.21-2.26 (m, 2H), 2.15 (s, 3H).

EXAMPLE 296E

7-(3-(hydroxymethyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

The title compound was synthesized according to the procedure for EXAMPLE 175B by substituting EXAMPLE 175A with EXAMPLE 296D. ^{1}H NMR (500 MHz, DMSO-d6): 11.06 (s, 1H), 8.25-8.26 (m, 1H), 7.86-7.88 (m, 1H), 7.65 (dd, J = 7.02, 1.83 Hz, 1H), 7.45-7.55 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.05-7.09 (m, 2H), 6.91 (d, J = 7.63 Hz, 1H), 6.78 (s, 1H), 4.24 (s, 2H), 4.21 (t, J = 6.1 Hz, 2H), 3.83 (s, 3H), 3.34-3.37 (m, 2H), 2.21-2.26 (m, 2H), 2.15 (s, 3H).

EXAMPLE 297

3-Bromo-7-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acidEXAMPLE 297A

4-Bromo-1,3-dimethyl-5-phenyl-1H-pyrazole

The title compound was synthesized according to the procedure for EXAMPLE 296B by substituting ethyl 5-methyl-1H-pyrazole-3-carboxylate with 5-methyl-3-phenyl-1H-pyrazole. ^{1}H NMR (500 MHz, DMSO-d6): 7.46-7.56 (m, 5H), 3.70 (s, 3H), 2.18 (s, 3H).

EXAMPLE 297B

7-(4,4,5,5-Tetramethyl-(1,3,2)dioxaborolan-2-yl)-1H-indole-2-carboxylic acid ethyl ester

A mixture of ethyl 1H-indole-2-carboxylate (1.89 g), 5,5'-di-tert-butyl-2,2'-bipyridine (0.081 g), and $(Ir(OMe)(COD))_2$ (0.152 g) in hexanes (30 mL) was treated with 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.66 g) via a syringe. The reaction mixture was degassed via vacuum/nitrogen cycle three times. The reaction mixture was heated at 62°C for 12 hours. After this time, the solvent was removed and the residue was purified by flash chromatography on silica gel eluting with 1:9 ethyl acetate/hexane to give the title compound. ^{1}H NMR (500 MHz, DMSO-d_6): 9.75 (s, 1H), 7.87 (d, J = 7.93 Hz, 1H), 7.64-7.65 (m, 1H), 7.24 (s, 1H), 7.16-7.17 (m, 1H), 4.36 (q, J = 7.02 Hz, 2H), 1.38 (s, 12H), 1.35 (q, J = 7.02 Hz, 3H).

EXAMPLE 297C

7-(1,3-Dimethyl-5-phenyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid methyl ester

The title compound was synthesized according to the procedure for EXAMPLE 192 by substituting EXAMPLE 43A and 2-fluoro-4-iodo-5-methylpyridine with EXAMPLE 297B and EXAMPLE 297A, respectively.

EXAMPLE 297D

3-Bromo-7-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid

A mixture of EXAMPLE 279C (60 mg) and N-bromosuccinimide (32 mg) in acetonitrile (2 mL) was stirred for 3 hours at room temperature. The desired product was purified by flash chromatography on silica gel. It was then hydrolyzed with 1.0 N LiOH, and purified by Prep HPLC to give the title compound. ^{1}H NMR (500 MHz, DMSO-d_6): 13.22 (s, 1H), 11.44 (s, 1H), 7.41 (d, J = 7.93 Hz, 1H), 7.24-7.30 (m, 5H), 7.11-7.14 (m, 2H), 7.04 (d, J = 7.02 Hz, 1H), 3.73 (s, 3H), 1.98 (s, 3H).

EXAMPLE 298

7-(1,3-dimethyl-5-(phenoxymethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.96 (s, 1H), 10.45 (s, 1H), 8.23-8.25 (m, 2H), 7.85-7.87 (m, 2H), 7.65 (d, J = 7.93 Hz, 1H), 7.44-7.54 (m, 3H), 7.38 (t, J = 7.93 Hz, 1H),

7.17-7.20 (m, 3H), 7.10 (d, J = 7.02 Hz, 1H), 7.01-7.04 (m, 1H), 6.85-6.90 (m, 4H), 4.78 (s, 2H), 4.19 (t, J = 6.1 Hz, 2H), 3.82 (s, 3H), 3.32-3.35 (m, 2H), 2.19-2.24 (m 2H), 2.09 (s, 3H).

EXAMPLE 299

7-(1-methyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.21 (s, 1H), 8.29 (s, 1H), 8.22-8.24 (m, 1H), 7.84-7.87 (m, 2H), 7.59 (d, J = 7.98 Hz, 1H), 7.44-7.54 (m, 3H), 7.39 (t, J = 7.67 Hz, 1H), 7.33-7.35 (m, 1H), 7.01-7.04 (m, 1H), 6.88 (d, J = 7.67 Hz, 1H), 4.18 (t, J = 5.98 Hz, 2H), 3.93 (s, 3H), 3.35 (t, J = 7.36 Hz, 2H), 2.19-2.26 (m 2H).

EXAMPLE 300

3-bromo-7-(2-((E)-2-cyclohexylvinyl)-4-methylpyridin-3-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.90 (s, 1H), 8.61 (d, J = 5.52 Hz, 1H), 7.67 (d, J = 7.98 Hz, 1H), 7.62 (s, 1H), 7.33-7.36 (m, 1H), 7.17 (d, J = 7.06 Hz, 1H), 6.70 (dd, J = 15.8, 7.21 Hz, 1H), 5.81 (d, J = 15.65 Hz, 1H), 2.04 (s, 3H), 1.95 (m, 2H), 1.43-1.54 (m 5H), 0.99-1.16 (m, 5H).

EXAMPLE 301

7-(3-isopropyl-1-methyl-5-(phenoxymethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.33 (s, 1H), 8.23-8.25 (m, 1H), 7.85-7.87 (m, 1H), 7.69 (dd, J = 7.32, 1.53 Hz, 1H), 7.44-7.54 (m, 3H), 7.37 (t, J = 7.98 Hz, 1H), 7.18 (t, J = 7.93 Hz, 1H), 7.05-7.09 (m, 2H), 6.89 (t, J = 8.09 Hz, 1H), 6.83 (t, J = 7.93 Hz, 1H), 4.85-4.87 (m, 1H), 4.75-4.77 (m 1H), 4.19 (t, J = 6.26 Hz, 2H), 3.87 (s, 3H), 3.32-3.35 (m, 2H), 2.73-2.79 (m, 1H), 2.19-2.26 (m 2H), 1.09 (d J = 6.71 Hz, 3H), 1.06 (d, J = 7.02 Hz, 3H).

EXAMPLE 302

7-(1,5-dimethyl-3-(phenoxymethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

A mixture of EXAMPLE 296 (0.060 g), phenol (13 mg), and triphenylphosphine (48.8 mg) in tetrahydrofuran (2 mL) was cooled to 0 °C. To this solution was added (E)-di-*tert*-butyl diazene-1,2-dicarboxylate (34.3 mg). The solution was stirred at room temperature for 15 hours. The solvent was removed and the residue was hydrolyzed in 1.0 N

LiOH/dioxane. The crude acid was purified by RP HPLC to give the title compound.^{1}H NMR (500 MHz, DMSO-d_6): δ 10.40 (s, 1H), 8.22-8.24 (m, 1H), 7.85-7.87 (m, 1H), 7.65 (d, J = 7.67 Hz, 1H), 7.44-7.54 (m, 3H), 7.37 (t, J = 7.98 Hz, 1H), 7.16-7.20 (m, 2H), 7.09-7.11 (m, 1H), 7.01-7.05 (m ,1H), 6.84-6.90 (m, 4H), 4.48 (s, 2H), 4.19 (t, J = 6.41 Hz, 2H), 3.82 (s, 3H), 3.31-3.35 (m, 2H), 2.73-2.79 (m, 1H), 2.18-2.25 (m 2H), 2.09 (s, 3H).

EXAMPLE 303

7-(4-(anilinocarbonyl)-1-phenyl-1H-pyrazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.01 (s, 1H), 11.37 (s, 1H), 9.45 (s, 1H), 8.49 (s, 1H), 8.27-8.29 (m, 1H), 7.86-7.88 (m, 1H), 7.73 (d, J = 7.93 Hz, 1H), 7.44-7.54 (m, 5H), 7.21-7.24 (m, 7H), 7.07 (d, J = 7.32 Hz, 1H), 6.94-7.00 (m, 2H), 6.87 (d, J = 7.63 Hz, 1H), 4.16 (t, J = 6.1 Hz, 2H), 3.31-3.35 (m, 2H), 2.18-2.23 (m 2H).

EXAMPLE 304

7-(3-((3-chlorophenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.41 (s, 1H), 8.22-8.24 (m, 1H), 7.85-7.87 (m, 1H), 7.65 (d, J = 7.67 Hz, 1H), 7.44-7.54 (m, 3H), 7.37 (t, J = 7.98 Hz, 1H), 7.19 (t, J = 8.13 Hz, 1H), 7.07-7.09 (m, 1H), 7.01-7.05 (m, 1H), 6.84-6.95 (m, 4H), 4.82 (s, 2H), 4.19 (t, J = 6.14 Hz, 2H), 3.82 (s, 3H), 3.32-3.36 (m, 2H), 2.19-2.25 (m 2H), 2.09 (s, 3H).

EXAMPLE 305

7-(1,5-dimethyl-3-((3-phenoxyphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.43 (s, 1H), 8.23-8.25 (m, 1H), 7.85-7.87 (m, 1H), 7.64 (d, J = 7.98 Hz, 1H), 7.34-7.54 (m, 6H), 6.95-7.18 (m, 6H), 6.89 (d, J = 7.36 Hz, 1H), 6.67 (dd, J = 8.29, 2.46 Hz, 1H), 6.57 (t, J = 2.3 Hz, 1H), 6.46 (dd, J = 8.13, 2.3 Hz, 1H), 4.78 (s, 2H), 4.19 (t, J = 6.14 Hz, 2H), 3.80 (s, 3H), 3.31-3.35 (m, 2H), 2.17-2.25 (m 2H), 2.08 (s, 3H).

EXAMPLE 306

3-bromo-4-(2-((4-bromo-1-naphthyl)oxy)ethyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.29 (s, 1H), 11.32 (s, 1H), 8.22 (d, J = 8.29 Hz, 1H), 8.05 (d, J = 8.59 Hz, 1H), 7.73 (d, J = 8.29 Hz, 1H), 7.67-7.70 (m, 1H), 7.56-7.60 (m, 1H), 7.26-7.33 (m, 3H), 7.23 (d, J = 7.06 Hz, 1H), 7.19 (d, J = 7.36 Hz, 1H), 7.06 (d, J = 7.36 Hz, 1H), 7.00 (d, J = 8.29 Hz, 1H), 4.53 (t, J = 6.9 Hz, 2H), 3.89 (br, 2H), 3.12 (s, 3H).

EXAMPLE 307

7-(1,5-dimethyl-3-((4-morpholin-4-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.39 (s, 1H), 8.22-8.24 (m, 1H), 7.85-7.87 (m, 1H), 7.66 (d, J = 7.67 Hz, 1H), 7.44-7.54 (m, 3H), 7.37 (t, J = 7.98 Hz, 1H), 7.02-7.11 (m, 2H), 6.79-6.89 (m, 5H), 4.73 (s, 2H), 4.19 (t, J = 6.14 Hz, 2H), 3.81 (s, 3H), 3.71-3.73 (m, 4H), 3.34 (t, J = 7.52 Hz, 2H), 3.01-3.02 (m, 4H), 2.18-2.26 (m 2H), 2.09 (s, 3H).

EXAMPLE 308

7-(3-(((5-chloropyridin-3-yl)oxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.38 (s, 1H), 8.16-8.18 (m, 1H), 8.10 (d, J = 2.4 Hz, 1H), 8.06 (d, J = 2.15 Hz, 1H), 7.78-7.80 (m, 1H), 7.58 (d, J = 7.36 Hz, 1H), 7.37-7.47 (m, 4H), 7.29-7.33 (m, 1H), 6.94-7.02 (m, 2H), 6.82 (d, J = 7.06 Hz, 1H), 4.86 (s, 2H), 4.12 (t, J = 6.14 Hz, 2H), 3.75 (s, 3H), 3.25-3.28 (m, 2H), 2.11-2.17 (m 2H), 2.02 (s, 3H).

EXAMPLE 309

7-(3,5-dimethyl-1-(2-nitrophenyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.00 (s, 1H), 10.77 (s, 1H), 8.25-8.27 (m, 1H), 8.11 (d, J = 7.63 Hz, 1H), 7.86-7.95 (m, 3H), 7.71-7.76 (m, 2H), 7.45-7.55 (m, 3H), 7.40 (t, J = 7.78 Hz, 1H), 7.10-7.16 (m, 2H), 6.92 (d, J = 7.63 Hz, 1H), 4.23 (t, J = 6.1 Hz, 2H), 3.36-3.39 (m, 2H), 2.23-2.28 (m 2H), 2.06 (s, 3H), 2.05 (s, 3H).

EXAMPLE 310

3-(3-(1-naphthyloxy)propyl)-7-((2-(phenylthio)ethyl)amino)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.15 (s, 1H), 8.21-8.23 (m, 1H), 7.85-7.87 (m, 1H), 7.43-7.53 (m, 3H), 7.32-7.40 (m, 5H), 7.21 (t, J = 7.32 Hz, 1H), 6.91 (d, J = 7.93 Hz, 1H), 6.86 (d, J = 7.32 Hz, 1H), 6.77 (t, J = 7.63 Hz, 1H), 6.24 (d, J = 7.32 Hz, 1H), 4.14 (t, J = 6.1 Hz, 2H), 3.42 ((t, J = 6.87 Hz, 2H), 3.23-3.29 (m, 4H), 2.15-2.21 (m 2H), 2.06 (s, 3H), 2.05 (s, 3H).

EXAMPLE 311

7-(3-((2-cyanophenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.94 (s, 1H), 10.62 (s, 1H), 8.23-8.24 (m, 1H), 7.86 (d, J = 8.63 Hz, 1H), 7.64-7.66 (m, 2H), 7.44-7.54 (m, 4H), 7.39 (t, J = 7.93 Hz, 1H), 7.22 (d, J = 8.54 Hz, 1H), 7.18 (d, J = 7.02 Hz, 1H), 6.99-7.03 (m, 2H), 6.89 (d, J = 7.32 Hz, 1H), 5.07 (br, 1H), 4.83 (br, 1H), 4.19 (t, J = 6.1 Hz, 2H), 3.83 (s, 3H), 3.35 (t, J = 7.48 Hz, 2H), 2.19-2.14 (m 2H), 2.08 (s, 3H).

EXAMPLE 312

7-(3-((4-(4-acetylpiperazin-1-yl)phenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.39 (s, 1H), 8.22-8.24 (m, 1H), 7.85-7.87 (m, 2H), 7.65 (d, J = 7.98 Hz, 1H), 7.44-7.54 (m, 3H), 7.38 (t, J = 7.83 Hz, 1H), 7.09-7.10 (m, 1H), 7.03 (t, J = 7.52 Hz, 1H), 6.80-7.91 (m, 5H), 4.73 (s, 2H), 4.19 (t, J = 6.14 Hz, 2H), 3.81 (s, 3H), 3.56-3.57 (m 2H), 3.34 (t, J = 7.52 Hz, 2H), 2.99-3.05 (m, 4H), 2.18-2.15 (m 2H), 2.09 (s, 3H), 2.02 (s, 3H).

EXAMPLE 313

3-bromo-7-(2-methylphenyl)-4-(2-(1-naphthyloxy)ethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.36 (s, 1H), 8.15 (d, J = 8.24 Hz, 1H), 7.85 (d, J = 7.93 Hz, 1H), 7.45-7.53 (m, 3H), 7.39 (t, J = 7.83 Hz, 1H), 7.28-7.35 (m, 2H), 7.24-7.28 (m 2H), 7.20 (d, J = 7.32 Hz, 1H), 7.07 (d, J = 7.32 Hz, 1H), 7.01 (d, J = 7.63 Hz, 1H), 4.52 (t, J = 6.87 Hz, 2H), 3.92 (br, 1H), 3.85 (br, 1H), 3.34 (t, J = 7.52 Hz, 2H), 2.03 (s, 3H).

EXAMPLE 314

7-(1-(2-aminophenyl)-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.01 (s, 1H), 8.25-8.27 (m, 1H), 7.86-7.88 (m, 3H), 7.68 (d, J = 7.63 Hz, 1H), 7.45-7.55 (m, 3H), 7.39 (t, J = 7.93 Hz, 1H), 7.07-7.20 (m, 4H), 6.91 (d, J = 7.32 Hz, 1H), 6.96 (d, J = 7.93 Hz, 1H), 6.67 (t, J = 7.48 Hz, 1H), 4.22 (t, J = 6.1 Hz, 2H), 3.37 (t, J = 7.48 Hz, 2H), 2.22-2.29 (m, 2H), 2.09 (s, 3H), 1.88 (s, 3H).

EXAMPLE 315

7-(3-(1H-imidazol-1-ylmethyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.01 (s, 1H), 10.88 (s, 1H), 8.45 (s, 1H), 8.25-8.27 (m, 1H), 7.86-7.88 (m, 1H), 7.68 (d, J = 7.93 Hz, 1H), 7.37-7.55 (m, 6H), 7.96-7.05 (m, 2H), 5.18-5.27 (m, 2H), 4.20 (t, J = 6.1 Hz, 2H), 3.81 (s, 3H), 3.34-3.37 (m, 2H), 2.19-2.26 (m, 2H), 2.05 (s, 3H).

EXAMPLE 316

7-(2-methylphenyl)-4-(2-(1-naphthyloxy)ethyl)-3-vinyl-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 12.92 (s, 1H), 10.66 (s, 1H), 8.04 (d, J = 8.24 Hz, 1H), 7.84 (d, J = 7.93 Hz, 1H), 7.43-7.51 (m, 3H), 7.38 (t, J = 7.78 Hz, 1H), 7.26-7.33 (m, 4H), 7.22 (t, J = 7.48 Hz, 1H), 7.18 (d, J = 7.32 Hz, 1H), 7.03 (d, J = 7.32 Hz, 1H), 6.99 (d, J = 7.32 Hz, 1H), 5.47-5.53 (m, 2H), 4.41 (t, J = 6.87 Hz, 2H), 3.86 (br, 2H), 2.05 (s, 3H).

EXAMPLE 317

7-(4-((benzylamino)carbonyl)-1-phenyl-1H-pyrazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.22 (s, 1H), 8.22 (s, 1H), 8.20 (d, J = 4.3 Hz, 1H), 7.88 (t, J = 6.14 Hz, 1H), 7.78-7.81 (m, 1H), 7.61 (d, J = 7.98 Hz, 1H), 7.37-7.48 (m, 3H), 7.30 (t, J = 7.83 Hz, 1H), 7.09-7.17 (m, 8H), 7.00 (d, J = 7.06 Hz, 1H), 6.96 (d, J = 7.36 Hz, 1H), 6.92-6.96 (m, 1H), 6.78 (d, J = 7.67 Hz, 1H), 4.21-4.23 (m, 2H), 4.07 (t, J = 6.14 Hz, 2H), 3.24 (m, 2H), 2.18-2.25 (m, 2H).

EXAMPLE 318

3-(3-(1-naphthyloxy)propyl)-7-(1-phenyl-4-(((3-pyrrolidin-1-ylpropyl)amino)carbonyl)-1H-pyrazol-5-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.26 (s, 1H), 9.24 (s, 1H), 8.27-8.29 (m, 1H), 8.10 (t, J = 5.98 Hz, 1H), 7.86-7.88 (m, 5H), 7.70 (d, J = 7.36 Hz, 1H), 7.45-7.56 (m, 3H), 7.39 (t, J = 7.98 Hz, 1H), 7.16-7.25 (m, 8H), 6.87-6.99 (m, 3H), 4.18 (t, J = 5.98 Hz, 2H), 3.17-3.19 (m, 2H), 3.00 (t, J = 6.9 Hz, 1H), 2.82 (br, 1H), 2.17-2.23 (m, 2H), 1.72-2.08 (m, 6H).

EXAMPLE 319

7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.37 (s, 1H), 8.95 (s, 1H), 8.26-8.28 (m, 1H), 7.86-7.88 (m, 1H), 7.77 (d, J = 7.67 Hz, 1H), 7.45-7.56 (m, 3H), 7.39 (t, J = 7.98 Hz, 1H), 7.06-7.14 (m, 2H), 6.90 (d, J = 7.67 Hz, 1H), 4.22 (t, J = 6.14 Hz, 2H), 3.35-3.39 (m, 2H), 2.22-2.28 (m, 2H), 2.08 (s, 6H).

EXAMPLE 320

7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 8.86 (s, 1H), 8.48 (d, J = 4.6 Hz, 1H), 8.26-8.28 (m, 1H), 7.94 (d, J = 7.98 Hz, 1H), 7.87-7.89 (m, 1H), 7.67 (s, 1H), 7.46-7.56 (m, 3H), 7.42 (t, J = 7.67 Hz, 1H), 7.35-7.39 (m, 1H), 7.19-7.23 (m, 1H), 7.02 (d, J = 7.36 Hz, 1H), 6.97 (d, J = 7.67 Hz, 1H), 6.94 (d, J = 7.36 Hz, 1H), 5.31 (s, 2H), 4.29 (t, J = 5.98 Hz, 2H), 3.42-3.46 (m, 2H), 2.28-2.35 (m, 2H), 1.78 (s, 6H).

EXAMPLE 321

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 8.61 (d, J = 4.6 Hz, 1H), 8.43 (s, 1H), 8.25-8.27 (m, 1H), 7.96 (d, J = 7.98 Hz, 1H), 7.87-7.89 (m, 1H), 7.61 (s, 1H), 7.46-7.56 (m, 4H), 7.41 (t, J = 7.83 Hz, 1H), 7.20-7.26 (m, 1H), 7.02 (d, J = 6.44 Hz, 1H), 6.93 (d, J = 7.36 Hz, 1H), 6.86 (d, J = 8.29 Hz, 1H), 5.13-5.37 (m, 2H), 4.28 (t, J = 6.14 Hz, 2H), 3.42-3.46 (m, 2H), 2.19-2.25 (m, 2H), 1.92-2.08 (m, 2H), 1.81 (s, 3H), 0.87 (t, J = 7.52 Hz, 3H).

EXAMPLE 322

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(1,3-thiazol-4-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 8.82 (d, J = 1.84 Hz, 1H), 8.61 (d, J = 5.52 Hz, 1H), 8.22-8.25 (m, 1H), 7.93 (d, J = 7.67 Hz, 1H), 7.86-7.88 (m, 1H), 7.46-7.56 (m, 4H), 7.40 (t, J = 7.83 Hz, 1H), 7.21 (t, J = 7.52 Hz, 1H), 7.02 (d, J = 6.75 Hz, 1H), 6.91 (d, J = 7.36 Hz, 1H), 6.47 (s, 1H), 5.21-5.36 (m, 2H), 4.27 (t, J = 5.98 Hz, 2H), 3.39-3.43 (m, 2H), 2.25-2.33 (m, 2H), 2.15-2.21 (m, 2H), 1.87 (s, 3H), 0.94 (t, J = 7.52 Hz, 3H).

EXAMPLE 323

7-(2-chloro-4-((4-morpholin-4-ylphenoxy)methyl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.50 (s, 1H), 8.47 (d, J = 4.91 Hz, 1H), 8.26-8.29 (m, 1H), 7.85-7.88 (m, 1H), 7.77 (dd, J = 7.06, 1.84, Hz, 1H), 7.57 (d, J = 7.22, Hz, 1H), 7.44-7.55 (m, 3H), 7.37 (t, J = 7.83 Hz, 1H), 7.07-7.12 (m, 2H), 6.87 (d, J = 7.36 Hz, 1H), 6.77 (d, J = 8.9 Hz, 2H), 6.63 (d, J = 8.9 Hz, 2H), 4.72 (d, J = 14.12 Hz, 1H), 4.50 (d, J = 13.81 Hz, 1H), 4.20 (t, J = 6.29 Hz, 2H), 3.65-3.68 (m, 4H), 3.35-3.39 (m, 2H), 2.90-2.92 (m, 4H), 2.21-2.27 (m, 2H).

EXAMPLE 324

7-(5-isopropyl-1-methyl-3-((4-morpholin-4-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ10.20 (s, 1H), 8.25-8.27 (m, 1H), 7.85-7.87 (m, 1H), 7.65 (dd, J = 7.06, 2.15, Hz, 1H), 7.44-7.55 (m, 3H), 7.36 (t, J = 7.98 Hz, 1H), 7.00-7.05 (m, 2H), 6.85 (d, J = 7.67 Hz, 1H), 6.81 (d, J = 8.59 Hz, 2H), 6.65 (d, J = 8.9 Hz, 2H), 4.54-4.60 (m, 2H), 4.17 (t, J = 6.29 Hz, 1H), 3.89 (s, 3H), 3.66-3.69 (m, 4H), 3.28-3.37 (m, 2H), 2.96-3.04 (m, 5H), 2.18-2.25 (m, 2H), 1.12 (d, J = 7.06 Hz, 3H), 0.96 (d, J = 7.06 Hz, 3H).

EXAMPLE 325

7-(3-isopropyl-1-methyl-5-((4-morpholin-4-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ10.20 (s, 1H), 8.23-8.25 (m, 1H), 7.85-7.87 (m, 1H), 7.69 (d, J = 6.44, Hz, 1H), 7.44-7.55 (m, 3H), 7.37 (t, J = 7.83 Hz, 1H), 7.03-7.10 (m,

2H), 6.88 (d, J = 7.36 Hz, 1H), 6.81-6.83 (m, 2H), 6.72-6.75 (m, 2H), 4.69-4.82 (m, 2H), 4.19 (t, J = 6.29 Hz, 1H), 3.87 (s, 3H), 3.69-3.72 (m, 4H), 3.32-3.36 (m, 2H), 2.97-2.99 (m, 4H), 2.72-2.79 (m, 1H), 2.18-2.25 (m, 2H), 1.08 (d, J = 6.75 Hz, 3H), 1.06 (d, J = 7.06 Hz, 3H).

EXAMPLE 326

7-(2-isopropenyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 8.56 (d, J = 5.22 Hz, 1H), 8.25-8.28 (m, 2H), 7.86-7.88 (m, 2H), 7.44-7.55 (m, 3H), 7.39 (t, J = 7.98 Hz, 1H), 7.33 (d, J = 4.6 Hz, 2H), 7.12-7.16 (m, 2H), 7.00 (d, J = 7.06 Hz, 1H), 6.89 (d, J = 7.36 Hz, 1H), 6.27 (d, J = 7.98 Hz, 1H), 5.75 (d, J = 17.8 Hz, 1H), 4.83-5.05 (m, 3H), 4.23 (t, J = 6.29 Hz, 2H), 3.40 (t, J = 7.52 Hz, 2H), 2.25-2.34 (m, 2H), 1.64 (s, 3H), 1.58 (s, 3H).

EXAMPLE 327

7-(1,5-dimethyl-3-((4-morpholin-4-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 8.50 (d, J = 4.6 Hz, 1H), 8.24-8.27 (m, 1H), 7.86-7.88 (m, 1H), 7.79-7.84 (m, 2H), 7.44-7.54 (m, 4H), 7.38-7.40 (m, 1H), 7.06-7.10 (m, 2H), 6.93-6.94 (m, 1H), 6.88 (d, J = 7.36 Hz, 1H), 6.77 (d, J = 9.21 Hz, 2H), 6.60 (d, J = 9.21 Hz, 2H), 5.50-5.69 (m, 2H), 4.51 (s 2H), 4.22 (t, J = 6.44 Hz, 2H), 3.64-3.66 (m, 7H), 3.35-3.43 (m, 2H), 2.90-2.92 (m, 4H), 2.23-2.29 (m, 2H), 1.47 (s, 3H).

EXAMPLE 328

7-(2-ethyl-4-((4-morpholin-4-ylphenoxy)methyl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.40 (s, 1H), 8.84 (d, J = 5.83 Hz, 1H), 8.25-8.27 (m, 1H), 7.84-7.89 (m, 4H), 7.44-7.55 (m, 3H), 7.37 (t, J = 7.98 Hz, 1H), 7.14-7.21 (m, 2H), 6.87 (d, J = 7.67 Hz, 1H), 6.77 (d, J = 8.9 Hz, 2H), 6.64 (d, J = 9.21 Hz, 2H), 4.87 (d, J = 15.65 Hz, 1H), 4.52 (d, J = 15.34 Hz, 1H), 4.20 (t, J = 6.14 Hz, 2H), 3.66-3.68 (m, 7H), 3.36-3.39 (m, 2H), 2.89-2.92 (m, 4H), 2.59-2.62 (m 1H), 2.24-2.48 (m, 1H), 2.21-2.28 (m, 2H), 1.03 (t, J = 7.52 Hz, 3H).

EXAMPLE 329

7-(4-methyl-2-pyrimidin-5-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 11.36 (s, 1H), 8.99 (s, 1H), 8.72 (d, J = 5.19 Hz, 1H), 8.54 (s, 2H), 8.26-8.28 (m, 1H), 7.86-7.88 (m, 1H), 7.68 (dd, J = 7.32, 1.53 Hz, 1H), 7.60 (d, J = 5.19 Hz, 1H), 7.45-7.55 (m, 3H), 7.38 (t, J = 7.93 Hz, 1H), 6.96-7.01 (m, 2H), 6.86 (d, J = 7.32 Hz, 1H), 4.14 (t, J = 6.26 Hz, 2H), 3.26-3.37 (m, 2H), 2.16-2.22 (m, 2H), 2.06 (s, 3H).

EXAMPLE 330

7-(4-methyl-6'-morpholin-4-yl-2,3'-bipyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.11 (s, 1H), 11.33 (s, 1H), 8.78 (d, J = 5.8 Hz, 1H), 8.25-8.27 (m, 1H), 8.01 (d, J = 2.14 Hz, 1H), 7.82-7.86 (m, 2H), 7.72-7.75 (m, 1H), 7.45-7.55 (m, 3H), 7.34-7.39 (m, 2H), 7.03 (d, J = 4.88 Hz, 2H), 6.86 (d, J = 7.32 Hz, 1H), 6.61 (d, J = 9.15 Hz, 1H), 4.16 (t, J = 6.41 Hz, 2H), 3.32-3.39 (m, 10H), 2.18-2.24 (m, 2H), 2.10 (s, 3H).

EXAMPLE 331

7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 8.84 (s, 1H), 8.26-8.30 (m, 2H), 7.87-7.92 (m, 2H), 7.46-7.62 (m, 4H), 7.40 (t, J = 7.93 Hz, 1H), 7.17-7.24 (m, 2H), 6.99 (d, J = 6.1 Hz, 1H), 6.93 (d, J = 7.63 Hz, 1H), 6.34 (d, J = 7.93 Hz, 1H), 5.36 (s, 2H), 4.27 (t, J = 6.1 Hz, 2H), 3.42-3.45 (m, 10H), 2.29-2.33 (m, 2H), 1.79 (s, 6H).

EXAMPLE 332

7-(4,6-dimethylpyrimidin-5-yl)-1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 13.27 (s, 1H), 9.94 (s, 1H), 9.02 (s, 1H), 8.26-8.28 (m, 1H), 7.86-7.89 (m, 2H), 7.46-7.56 (m, 3H), 7.40 (t, J = 7.78 Hz, 1H), 7.16-7.19 (m, 1H), 7.03 (d, J = 6.41 Hz, 1H), 6.92 (d, J = 7.63 Hz, 1H), 6.34 (d, J = 7.93 Hz, 1H), 4.24 (t, J = 6.26 Hz, 2H), 3.42-3.45 (m, 2H), 2.64-2.81 (m, 7H), 2.07-2.11 (m, 6H).

EXAMPLE 333

1-(2-(dimethylamino)-2-oxoethyl)-7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 8.98 (s, 1H), 8.27-8.29 (m, 1H), 7.84-7.89 (m, 2H), 7.46-7.55 (m, 3H), 7.40 (t, J = 7.93 Hz, 1H), 7.14-7.17 (m, 1H), 7.01 (d, J = 7.02 Hz, 1H), 6.92 (d, J = 7.32 Hz, 1H), 4.92 (s, 2H), 4.24 (t, J = 6.1 Hz, 2H), 3.36-3.39 (m, 2H), 2.63 (s, 3H), 2.41 (s, 3H), 2.21-2.27 (m, 2H), 2.08 (s, 6H).

EXAMPLE 334

7-(3-((4-(1,1-dioxidothiomorpholin-4-yl)phenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.43 (s, 1H), 8.98 (s, 1H), 8.24 (d, J = 7.93 Hz, 1H), 7.85-7.87 (m, 2H), 7.65 (d, J = 7.93 Hz, 1H), 7.44-7.54 (m, 3H), 7.38 (t, J = 7.93 Hz, 1H), 7.02-7.11 (m, 2H), 6.85-6.90 (m, 3H), 6.87-6.90 (m, 2H), 4.72 (s, 2H), 4.19 (t, J = 6.1 Hz, 2H), 3.81 (s, 3H), 3.54-3.56 (m, 2H), 3.32-3.35 (m, 2H), 3.38-3.10 (m, 4H), 2.18-2.25 (m, 2H), 2.09 (s, 3H).

EXAMPLE 335

7-(4,6-dimethylpyrimidin-5-yl)-1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 9.04 (s, 1H), 8.23-8.25 (m, 1H), 7.86-7.91 (m, 2H), 7.45-7.56 (m, 3H), 7.40 (t, J = 7.83 Hz, 1H), 7.22 (t, J = 7.67 Hz, 1H), 7.11 (d, J = 7.37 Hz, 1H), 6.92 (d, J = 7.36 Hz, 1H), 4.23-4.33 (m, 4H), 3.36-3.40 (m, 2H), 2.84 (br, 4H), 2.18-2.25 (m, 2H), 2.20-2.26 (m, 8H).

EXAMPLE 336

7-(1,5-dimethyl-3-((4-piperazin-1-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.40 (s, 1H), 8.69 (s, 2H), 8.22-8.24 (m, 1H), 7.85-7.87 (m, 1H), 7.65 (d, J = 7.98 Hz, 1H), 7.44-7.55 (m, 3H), 7.38 (t, J = 7.83 Hz, 1H), 7.01-7.11 (m, 2H), 6.89 (d, J = 7.06 Hz, 1H), 6.79-6.85 (m, 4H), 4.72 (s, 2H), 4.20 (t, J = 6.14 Hz, 2H), 3.81 (s, 3H), 3.34 (t, J = 7.52 Hz, 2H), 3.15-3.19 (m, 8H), 2.19-2.25 (m, 2H), 2.09 (s, 3H).

EXAMPLE 337

7-(3-((4-(4-acetylpiperazin-1-yl)phenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 8.51 (d, J = 4.91 Hz, 1H), 8.24-8.27 (m, 1H), 7.79-7.89 (m, 3H), 7.45-7.55 (m, 4H), 7.38 (t, J = 7.83 Hz, 1H), 7.06-7.12 (m, 2H), 6.93 (d, J = 6.75 Hz, 1H), 6.88 (d, J = 7.36 Hz, 1H), 6.80 (d, J = 9.21 Hz, 2H), 6.61 (d, J = 9.21 Hz, 2H), 5.50-5.65 (m, 2H), 4.52 (s, 2H), 4.22 (t, J = 6.44 Hz, 2H), 3.66 (s, 3H), 3.37-3.53 (m, 6H), 2.86-2.95 (m, 4H), 2.23-2.30 (m, 2H), 1.99 (s, 3H), 1.47 (s, 3H).

EXAMPLE 338

7-(4,6-dimethylpyrimidin-5-yl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.06 (s, 1H), 9.00 (s, 1H), 8.23-8.25 (m, 1H), 7.84-7.88 (m, 2H), 7.45-7.56 (m, 3H), 7.40 (t, J = 7.83 Hz, 1H), 7.17-7.21 (m, 1H), 7.08 (d, J = 7.06 Hz, 1H), 6.91 (d, J = 7.67 Hz, 1H), 4.23 (t, J = 5.98 Hz, 2H), 4.00-4.04 (m, 2H), 3.25-3.36 (m, 4H), 2.85 (br, 2H), 2.70 (s, 3H), 2.18-2.25 (m, 10H).

EXAMPLE 339

7-(3-((4-(4-(tert-butoxycarbonyl)piperazin-1-yl)phenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 10.38 (s, 1H), 9.00 (s, 1H), 8.22-8.24 (m, 1H), 7.85-7.87 (m, 1H), 7.65 (d, J = 7.98 Hz, 1H), 7.45-7.56 (m, 3H), 7.37 (t, J = 7.98 Hz, 1H), 7.01-7.10 (m, 2H), 6.78-6.89 (m, 5H), 4.72 (s, 2H), 4.19 (t, J = 6.14 Hz, 2H), 3.81 (s, 3H), 3.42-3.45 (m, 4H), 3.34 (t, J = 7.36 Hz, 2H), 2.94-2.97 (m, 2H), 2.18-2.26 (m, 2H), 2.09 (s, 3H), 1.41 (s, 9H).

EXAMPLE 340

1-(2-(dimethylamino)ethyl)-7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6): δ 8.96 (s, 1H), 8.16-8.18 (m, 1H), 7.79-7.84 (m, 2H), 7.38-7.49 (m, 3H), 7.33 (t, J = 7.83 Hz, 1H), 7.16 (t, J = 7.52 Hz, 1H), 7.04 (d, J = 7.06

Hz, 1H), 6.85 (d, J = 7.67 Hz, 1H), 4.16-4.23 (m, 4H), 3.51 (br, 6H), 3.30-3.34 (m, 2H), 2.77-2.81 (m, 2H), 2.43 (m, 2H), 2.13-2.26 (m, 8H).

EXAMPLE 341

3-(3-(1-naphthyloxy)propyl)-7-(4-(1H-pyrazol-1-yl)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.03 (s, 1H), 10.59 (s, 1H), 8.58 (d, 1H), 8.23 (m, 1H), 7.98 (ddd, 2H), 7.86 (m, 1H), 7.75 (m, 4H), 7.51 (m, 3H), 7.39 (m, 1H), 7.28 (m, 1H), 7.11 (m, 1H), 6.89 (m, 1H), 6.58 (m, 1H), 4.20 (t, 2H), 3.38 (t, 2H), 2.24 (m, 2H).

EXAMPLE 342

3-(3-(1-naphthyloxy)propyl)-7-(2,3,4-trifluorophenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.05 (s, 1H), 11.23 (s, 1H), 8.25 (m, 1H), 7.86 (m, 1H), 7.77 (d, 1H), 7.51 (m, 2H), 7.38 (m, 3H), 7.28 (m, 1H), 7.18 (m, 1H), 7.08 (m, 1H), 6.89 (m, 1H), 4.19 (t, 2H), 3.37 (t, 2H), 2.24 (m, 2H).

EXAMPLE 343

7-(4-hydroxy-3-methoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.01 (s, 1H), 10.23 (s, 1H), 9.10 (s, 1H), 8.23 (td, 7.87 (m, 1H), 7.63 (d, 1H), 7.51 (m, 3H), 7.38 (m, 1H), 7.21 (dd, 1H), 7.12 (d, 1H), 7.05 (m, 2H), 6.90 (m, 2H), 4.18 (t, 2H), 3.83 (s, 3H), 3.36 (m, 2H), 2.23 (m, 2H).

EXAMPLE 344

3-(3-(1-naphthyloxy)propyl)-7-(3,4,5-trimethoxyphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.00 (s, 1H), 10.58 (s, 1H), 8.24 (m, 1H), 7.87 (m, 1H), 7.67 (d, 1H), 7.52 (m, 2H), 7.41 (m, 2H), 7.26 (dd, 1H), 7.07 (dd, 1H), 6.89 (dd, 1H), 6.85 (s, 2H), 4.19 (t, 2H), 3.84 (s, 6H), 3.73 (s, 3H), 3.37 (m, 2H), 2.24 (m, 2H).

EXAMPLE 345

3-(3-(1-naphthyloxy)propyl)-7-(4-(trifluoromethoxy)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.05 (s, 1H), 10.78 (s, 1H), 8.23 (m, 1H), 7.87 (m, 1H), 7.72 (m, 3H), 7.51 (m, 5H), 7.38 (m, 1H), 7.24 (dd, 1H), 7.09 (m, 1H), 6.89 (m, 1H), 4.19 (t, 2H), 3.37 (m, 2H), 2.24 (m, 2H).

EXAMPLE 346

7-(2-methoxy-5-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.97 (s, 1H), 9.97 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.67 (d, 1H), 7.51 (m, 3H), 7.40 (d, 1H), 7.21 (m, 1H), 7.12 (m, 2H), 7.04 (m, 2H), 6.90 (dd, 1H), 4.20 (t, 2H), 3.70 (s, 3H), 3.35 (m, 2H), 2.30 (s, 3H), 2.24 (m, 2H).

EXAMPLE 347

7-(3-fluoro-4-methoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.05 (s, 1H), 10.61 (s, 1H), 8.23 (m, 1H), 7.87 (m, 1H), 7.67 (d, 1H), 7.51 (m, 2H), 7.40 (m, 4H), 7.29 (t, 1H), 7.21 (dd, 1H), 7.06 (m, 1H), 6.89 (dd, 1H), 4.18 (t, 2H), 3.91 (s, 3H), 3.36 (m, 2H), 2.24 (m, 2H).

EXAMPLE 348

3-(3-(1-naphthyloxy)propyl)-7-(4-(5-oxo-2,5-dihydro-1H-pyrazol-3-yl)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) □ 12.94 (s, 1H), 12.22 (s, 1H), 10.55 (s, 1H), 9.74 (s, 1H), 8.23 (m, 1H), 7.87 (m, 1H), 7.81 (d, 2H), 7.70 (d, 1H), 7.66 (d, 2H), 7.52 (m, 2H), 7.45 (m, 1H), 7.39 (t, 1H), 7.28 (dd, 1H), 7.10 (m, 1H), 6.90 (d, 1H), 5.96 (s, 1H), 4.19 (t, 2H), 3.39 (m, 2H), 2.24 (m, 2H).

EXAMPLE 349

7-(3-(morpholin-4-ylmethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 10.58 (s, 1H), 8.24 (m, 1H), 7.87 (m, 1H), 7.73 (m, 3H), 7.62 (t, 1H), 7.51 (m, 4H), 7.39 (m, 1H), 7.27 (dd, 1H), 7.12 (m, 1H), 6.89 (dd, 1H), 4.45 (s, 2H), 4.19 (t, 2H), 3.97 (m, 2H), 3.63 (t, 2H), 3.41 (m, 2H), 3.38 (m, 3H), 3.17 (m, 3H), 2.24 (m, 2H).

EXAMPLE 350

7-(4-(morpholin-4-ylmethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.12 (s, 1H), 10.39 (s, 1H), 8.22 (m, 1H), 7.87 (m, 1H), 7.74 (d, 3H), 7.62 (d, 2H), 7.51 (m, 2H), 7.46 (m, 1H), 7.38 (m, 1H), 7.27 (dd, 1H),

7.12 (m, 1H), 6.89 (dd, 1H), 4.44 (s, 2H), 4.20 (t, 2H), 4.00 (m, 2H), 3.66 (t, 2H), 3.38 (m, 3H), 3.21 (m, 3H), 2.24 (m, 2H).

EXAMPLE 351

7-(4-isopropoxy-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.92 (s, 1H), 10.37 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.66 (dd, 1H), 7.52 (m, 2H), 7.42 (m, 2H), 7.04 (m, 3H), 6.88 (m, 2H), 6.81 (dd, 1H), 4.65 (septet, 1H), 4.20 (t, 2H), 3.36 (m, 2H), 2.23 (m, 2H), 2.02 (s, 3H), 1.31 (d, 6H).

EXAMPLE 352

3-(3-(1-naphthyloxy)propyl)-7-(4-(1H-pyrazol-5-yl)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.01 (s, 1H), 10.46 (s, 1H), 8.24 (m, 1H), 7.94 (d, 2H), 7.87 (m, 1H), 7.71 (m, 4H), 7.50 (m, 3H), 7.39 (m, 1H), 7.28 (m, 1H), 7.10 (m, 1H), 6.89 (m, 1H), 6.78 (d, 1H), 4.20 (t, 2H), 3.38 (t, 2H), 2.25 (m, 2H).

EXAMPLE 354

7-(2,5-dimethylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.93 (s, 1H), 10.36 (s, 1H), 8.24 (m, 1H), 7.87 (m, 1H), 7.68 (dd, 1H), 7.50 (m, 3H), 7.40 (d, 1H), 7.16 (m, 2H), 7.04 (m, 3H), 6.90 (d, 1H), 4.20 (t, 2H), 3.36 (m, 2H), 2.31 (s, 3H), 2.23 (m, 2H), 2.01 (s, 3H).

EXAMPLE 355

3-(3-(1-naphthyloxy)propyl)-7-(2,4,5-trimethylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.91 (s, 1H), 10.25 (s, 1H), 8.24 (m, 1H), 7.87 (m, 1H), 7.66 (dd, 1H), 7.52 (m, 2H), 7.41 (m, 2H), 7.04 (m, 4H), 6.90 (m, 1H), 4.20 (t, 2H), 3.36 (m, 2H), 2.26 (s, 3H), 2.24 (m, 2H), 2.22 (s, 3H), 1.99 (s, 3H).

EXAMPLE 356

3-(3-(1-naphthyloxy)propyl)-7-(3-(trifluoromethoxy)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.05 (s, 1H), 10.80 (s, 1H), 8.21 (m, 1H), 7.86 (m, 1H), 7.73 (d, 1H), 7.62 (m, 2H), 7.47 (m, 6H), 7.26 (d, 1H), 7.10 (t, 1H), 6.89 (d, 1H), 4.19 (t, 2H), 3.37 (m, 2H), 2.22 (m, 2H).

EXAMPLE 357

7-(2-methyl-4-propoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.92 (s, 1H), 10.38 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.66 (dd, 1H), 7.52 (m, 2H), 7.41 (m, 2H), 7.04 (m, 3H), 6.91 (m, 2H), 6.82 (dd, 1H), 4.20 (t, 2H), 3.98 (t, 2H), 3.36 (m, 2H), 2.23 (m, 2H), 2.03 (s, 3H), 1.76 (m, 2H), 1.01 (t, 3H).

EXAMPLE 358

7-(3-cyanophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 11.07 (s, 1H), 8.22 (m, 1H), 8.02 (t, 1H), 7.87 (m, 3H), 7.71 (ddd, 2H), 7.51 (m, 3H), 7.40 (d, 1H), 7.26 (dd, 1H), 7.10 (m, 1H), 6.89 (dd, 1H), 4.19 (t, 2H), 3.37 (m, 2H), 2.24 (m, 2H).

EXAMPLE 359

3-(3-(1-naphthyloxy)propyl)-7-(2,3,5,6-tetramethylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 10.22 (s, 1H), 8.28 (m, 1H), 7.87 (m, 1H), 7.68 (d, 1H), 7.53 (m, 2H), 7.42 (m, 2H), 7.08 (dd, 1H), 7.03 (s, 1H), 6.89 (ddd, 2H), 4.22 (t, 2H), 3.39 (m, 2H), 2.25 (m, 2H), 2.22 (s, 6H), 1.73 (s, 6H).

EXAMPLE 360

7-(3-cyano-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 11.04 (s, 1H), 8.24 (m, 1H), 7.85 (m, 2H), 7.74 (m, 1H), 7.47 (m, 6H), 7.06 (m, 2H), 6.90 (d, 1H), 4.20 (t, 2H), 3.38 (m, 2H), 2.23 (m, 2H), 2.19 (s, 3H).

EXAMPLE 361

7-(3-ethynyl-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.93 (s, 1H), 10.87 (s, 1H), 8.26 (m, 1H), 7.87 (m, 1H), 7.70 (dd, 1H), 7.51 (m, 4H), 7.40 (d, 1H), 7.24 (m, 2H), 7.04 (m, 2H), 6.90 (dd, 1H), 4.38 (s, 1H), 4.20 (t, 2H), 3.37 (m, 2H), 2.23 (m, 2H), 2.12 (s, 3H).

EXAMPLE 362

7-(5-(((3-(dimethylamino)propyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 10.79 (s, 1H), 9.21 (s, 1H), 8.53 (t, 1H), 8.27 (m, 1H), 7.86 (m, 2H), 7.73 (m, 2H), 7.49 (m, 4H), 7.07 (m, 2H), 6.90 (m, 1H), 4.21 (t, 2H), 3.30 (m, 4H), 3.06 (m, 2H), 2.76 (d, 6H), 2.24 (m, 2H), 2.11 (s, 3H), 1.85 (m, 2H).

EXAMPLE 363

7-(2-isopropylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.93 (s, 1H), 10.35 (s, 1H), 8.26 (m, 1H), 7.87 (m, 1H), 7.69 (d, 1H), 7.53 (m, 2H), 7.41 (m, 4H), 7.25 (td, 1H), 7.15 (m, 1H), 7.04 (m, 2H), 6.91 (dd, 1H), 4.22 (t, 2H), 3.39 (m, 2H), 2.69 (m, 1H), 2.26 (m, 2H), 1.06 (dd, 6H).

EXAMPLE 364

7-(5-(((2-(dimethylamino)ethyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.97 (s, 1H), 10.77 (s, 1H), 9.24 (s, 1H), 8.59 (m, 1H), 8.27 (m, 1H), 7.87 (m, 2H), 7.74 (m, 2H), 7.50 (m, 4H), 7.07 (m, 2H), 6.90 (m, 1H), 4.20 (t, 2H), 3.58 (m, 2H), 3.38 (m, 2H), 3.23 (m, 2H), 2.82 (d, 6H), 2.25 (m, 2H), 2.12 (s, 3H).

EXAMPLE 365

7-(2-methyl-5-(((2-morpholin-4-ylethyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.98 (s, 1H), 10.77 (s, 1H), 9.54 (s, 1H), 8.61 (m, 1H), 8.27 (m, 1H), 7.87 (m, 2H), 7.74 (m, 2H), 7.53 (m, 2H), 7.43 (m, 2H), 7.08 (m, 2H), 6.91 (dd, 1H), 4.21 (t, 2H), 3.98 (m, 2H), 3.55 (m, 5H), 3.39 (m, 7H), 2.26 (m, 2H), 2.12 (s, 3H).

EXAMPLE 366

7-(2-methyl-5-(((3-morpholin-4-ylpropyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.97 (s, 1H), 10.79 (s, 1H), 9.50 (s, 1H), 8.55 (t, 1H), 8.27 (m, 1H), 7.86 (m, 2H), 7.73 (m, 2H), 7.53 (m, 2H), 7.42 (m, 2H), 7.07 (m, 2H), 6.91 (dd, 1H), 4.20 (t, 2H), 3.95 (m, 2H), 3.61 (td, 2H), 3.38 (m, 2H), 3.32 (m, 4H), 3.09 (m, 4H), 2.23 (m, 2H), 2.11 (s, 3H), 1.88 (m, 2H).

EXAMPLE 367

7-(2-methyl-5-(((2-phenylethyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.94 (s, 1H), 10.83 (s, 1H), 8.49 (t, 1H), 8.28 (m, 1H), 7.87 (m, 1H), 7.81 (dd, 1H), 7.71 (m, 2H), 7.53 (m, 2H), 7.46 (m, 1H), 7.39 (ddd, 2H), 7.22 (m, 5H), 7.08 (m, 2H), 6.91 (dd, 1H), 4.20 (t, 2H), 3.46 (m, 2H), 3.37 (m, 2H), 2.82 (t, 2H), 2.24 (m, 2H), 2.09 (s, 3H).

EXAMPLE 368

7-(1H-indazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.11 (s, 1H), 13.02 (s, 1H), 10.44 (s, 1H), 8.24 (m, 1H), 8.15 (d, 1H), 8.00 (dd, 1H), 7.87 (m, 1H), 7.67 (m, 2H), 7.58 (dd, 1H), 7.52 (m, 2H), 7.39 (m, 1H), 7.27 (dd, 1H), 7.10 (dd, 1H), 6.90 (dd, 1H), 4.20 (t, 2H), 3.38 (m, 2H), 2.25 (m, 2H).

EXAMPLE 369

7-(5-((((1S,4R)-bicyclo(2.2.1)hept-2-ylmethyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.92 (s, 1H), 10.82 (s, 1H), 8.34 (m, 2H), 7.85 (m, 2H), 7.72 (m, 2H), 7.53 (m, 2H), 7.41 (m, 3H), 7.06 (m, 2H), 6.91 (d, 1H), 4.21 (t, 2H), 3.39 (m, 2H), 3.23 (m, 2H), 3.02 (m, 1H), 2.26 (m, 2H), 2.14 (m, 2H), 2.09 (m, 3H), 2.04 (m, 1H), 1.65 (m, 3H), 1.27 (m, 2H), 1.07 (m, 2H).

Example 370

7-(2-methyl-5-(((3-phenylpropyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.93 (s, 1H), 10.83 (s, 1H), 8.41 (t, 1H), 8.27 (m, 1H), 7.85 (m, 2H), 7.73 (td, 2H), 7.53 (m, 2H), 7.41 (m, 3H), 7.21 (m, 5H), 7.07 (m, 2H), 6.90 (dd, 1H), 4.21 (m, 2H), 3.43 (m, 2H), 3.27 (m, 2H), 2.60 (m, 2H), 2.24 (m, 2H), 2.09 (s, 3H), 1.81 (m, 2H).

EXAMPLE 371

7-(2-((2-isopropyl-5-methylphenoxy)methyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.97 (s, 1H), 10.56 (s, 1H), 8.24 (m, 1H), 7.86 (m, 1H), 7.71 (d, 1H), 7.65 (dd, 1H), 7.49 (m, 5H), 7.37 (m, 2H), 7.14 (m, 1H), 7.06 (m, 1H), 6.97 (d, 1H), 6.88 (dd, 1H), 6.61 (d, 1H), 6.38 (d, 1H), 4.82 (m, 2H), 4.19 (t, 2H), 3.37 (m, 2H), 3.07 (septet, 1H), 2.23 (m, 2H), 2.07 (s, 3H), 1.04 (d, 6H).

EXAMPLE 372

7-(2-chloro-6-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.92 (s, 1H), 11.00 (s, 1H), 8.29 (m, 1H), 7.87 (m, 1H), 7.71 (d, 1H), 7.53 (m, 2H), 7.37 (m, 5H), 7.09 (dd, 1H), 6.96 (dd, 1H), 6.91 (dd, 1H), 4.22 (t, 2H), 3.37 (m, 2H), 2.25 (m, 2H), 1.94 (s, 3H).

EXAMPLE 373

7-(2-benzylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.94 (s, 1H), 10.41 (s, 1H), 8.26 (m, 1H), 7.87 (m, 1H), 7.69 (dd, 1H), 7.52 (m, 2H), 7.38 (m, 4H), 7.24 (m, 2H), 7.05 (m, 5H), 6.90 (dd, 1H), 6.83 (m, 2H), 4.20 (t, 2H), 3.81 (m, 1H), 3.66 (m, 1H), 3.37 (m, 2H), 2.25 (m, 2H).

EXAMPLE 374

3-(3-(1-naphthyloxy)propyl)-7-(2,4,6-triisopropylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.92 (s, 1H), 10.23 (s, 1H),8.28 (m, 1H), 7.87 (m, 1H), 7.67 (d, 1H), 7.51 (m, 3H), 7.39 (m, 1H), 7.08 (m, 3H), 6.93 (m, 2H), 4.23 (t, 2H), 3.37 (m, 2H), 2.95 (m, 1H), 2.33 (m, 2H), 2.25 (m, 2H), 1.29 (d, 6H), 0.99 (dd, 12H).

EXAMPLE 375

3-(3-(1-naphthyloxy)propyl)-7-(1-oxo-2,3-dihydro-1H-inden-4-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.98 (s, 1H), 10.99 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.75 (dd, 1H), 7.71 (dd, 1H), 7.63 (m, 1H), 7.50 (m, 5H), 7.14 (m, 2H), 6.91 (dd, 1H), 4.21 (t, 2H), 3.38 (m, 2H), 2.82 (m, 2H), 2.58 (m, 2H), 2.24 (m, 2H).

EXAMPLE 376

7-(2-cyclopentylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.95 (s, 1H), 10.24 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.69 (d, 1H), 7.52 (m, 2H), 7.40 (m, 4H), 7.24 (td, 1H), 7.16 (m, 1H), 7.05 (m, 2H),

6.90 (d, 1H), 4.21 (m, 2H), 3.38 (m, 2H), 2.74 (m, 1H), 2.25 (m, 2H), 1.72 (m, 4H), 1.37 (m, 4H).

EXAMPLE 377

7-(2',6'-dimethoxy-1,1'-biphenyl-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.07 (s, 1H), 8.93 (s, 1H), 8.22 (m, 1H), 7.86 (m, 1H), 7.45 (m, 8H), 7.25 (m, 1H), 6.94 (m, 3H), 6.82 (m, 1H), 6.41 (d, 2H), 4.07 (t, 2H), 3.42 (s, 6H), 3.24 (m, 2H), 2.14 (m, 2H).

EXAMPLE 378

3-(3-(1-naphthyloxy)propyl)-7-(5,6,7,8-tetrahydronaphthalen-1-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.91 (s, 1H), 10.43 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.67 (m, 1H), 7.52 (m, 2H), 7.42 (m, 2H), 7.14 (m, 2H), 7.02 (m, 3H), 6.91 (dd, 1H), 4.21 (t, 2H), 3.38 (td, 2H), 2.82 (t, 2H), 2.29 (m, 4H), 1.73 (m, 2H), 1.60 (m, 2H).

EXAMPLE 379

7-(4'-tert-butyl-1,1'-biphenyl-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.85 (s, 1H), 9.87 (s, 1H), 8.23 (m, 1H), 7.86 (m, 1H), 7.50 (m, 9H), 7.06 (ddd, 4H), 6.91 (m, 2H), 6.85 (m, 1H), 4.13 (t, 2H), 3.25 (m, 2H), 2.18 (m, 2H), 1.12 (s, 9H).

EXAMPLE 380

7-(5-fluoro-2-methyl-3-((methylsulfonyl)methyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.95 (s, 1H), 10.76 (s, 1H), 8.24 (m, 1H), 7.87 (m, 1H), 7.71 (dd, 1H), 7.52 (m, 2H), 7.41 (m, 2H), 7.28 (dd, 1H), 7.05 (m, 3H), 6.90 (dd, 1H), 4.64 (s, 2H), 4.21 (t, 2H), 3.40 (m, 2H), 3.06 (s, 3H), 2.24 (m, 2H), 2.04 (s, 3H).

EXAMPLE 381

7-(5-(((2-hydroxy-1,1-dimethylethyl)amino)carbonyl)-2,3,4-trimethylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 8.24 (m, 1H), 7.86 (m, 1H), 7.63 (d, 1H), 7.51 (m, 4H), 7.38 (m, 1H), 7.03 (m, 1H), 6.95 (m, 2H), 6.89 (d, 1H), 4.87 (s, 1H), 4.20 (t, 2H), 3.46 (s, 2H), 3.39 (m, 2H), 2.29 (s, 3H), 2.26 (m, 2H), 2.24 (s, 3H), 1.99 (s, 3H), 1.26 (s, 6H).

EXAMPLE 382

7-(2-(4-(ethoxycarbonyl)piperazin-1-yl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.08 (s, 1H), 10.05 (s, 1H), 8.25 (m, 1H), 7.86 (m, 1H), 7.74 (d, 1H), 7.43 (m, 7H), 7.15 (m, 3H), 6.84 (m, 1H), 4.16 (t, 2H), 3.93 (q, 2H), 3.39 (m, 2H), 2.97 (m, 4H), 2.76 (m, 4H), 2.24 (m, 2H), 1.08 (t, 3H).

EXAMPLE 383

7-(2-methyl-6-nitrophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.01 (s, 1H), 11.04 (s, 1H), 8.28 (m, 1H), 7.86 (m, 2H), 7.65 (m, 2H), 7.54 (m, 3H), 7.41 (m, 2H), 7.02 (m, 1H), 6.89 (ddd, 2H), 4.22 (t, 2H), 3.38 (m, 2H), 2.24 (m, 2H), 1.94 (s, 3H).

EXAMPLE 384

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-propionylpiperazin-1-yl)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.10 (s, 1H), 10.09 (s, 1H), 8.24 (m, 1H), 7.86 (m, 1H), 7.75 (d, 1H), 7.51 (m, 2H), 7.39 (m, 5H), 7.15 (td, 3H), 6.85 (dd, 1H), 4.16 (t, 2H), 3.39 (m, 2H), 3.17 (m, 2H), 2.94 (m, 2H), 2.75 (m, 4H), 2.24 (m, 2H), 2.12 (q, 2H), 0.85 (t, 3H).

EXAMPLE 385

7-(2-methyl-6-thien-2-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.89 (s, 1H), 10.76 (s, 1H), 8.29 (m, 1H), 7.86 (m, 1H), 7.66 (d, 1H), 7.51 (m, 4H), 7.35 (m, 3H), 7.16 (dd, 1H), 6.96 (dd, 1H), 6.86 (ddd, 2H), 6.72 (m, 1H), 6.67 (m, 1H), 4.17 (t, 2H), 3.38 (m, 2H), 2.23 (m, 2H), 1.93 (s, 3H).

EXAMPLE 386

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-(1,3-thiazol-4-ylmethyl)piperazin-1-yl)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.00 (s, 1H), 10.21 (s, 1H), 9.12 (d, 1H), 8.27 (m, 1H), 7.87 (m, 1H), 7.79 (s, 1H), 7.72 (d, 1H), 7.53 (m, 2H), 7.40 (m, 4H), 7.28 (dd, 1H), 7.17 (t, 2H), 7.10 (dd, 1H), 6.90 (dd, 1H), 4.29 (s, 2H), 4.21 (t, 2H), 3.39 (m, 6H), 3.16 (m, 2H), 2.90 (m, 2H), 2.25 (m, 2H).

EXAMPLE 387

7-(2-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.02 (s, 1H), 9.91 (s, 1H), 8.24 (td, 1H), 7.86 (m, 1H), 7.73 (d, 1H), 7.51 (m, 2H), 7.38 (m, 5H), 7.14 (m, 3H), 6.85 (dd, 1H), 4.30 (s, 1H), 4.17 (t, 2H), 3.40 (m, 6H), 2.76 (m, 4H), 2.21 (m, 6H).

EXAMPLE 388

7-(2-(4-(methylsulfonyl)piperazin-1-yl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.21 (s, 1H), 10.13 (s, 1H), 8.24 (m, 1H), 7.86 (m, 1H), 7.73 (d, 1H), 7.52 (m, 2H), 7.41 (m, 4H), 7.33 (m, 1H), 7.14 (m, 3H), 6.87 (dd, 1H), 4.18 (t, 2H), 3.39 (m, 3H), 2.85 (m, 4H), 2.72 (m, 3H), 2.64 (s, 3H), 2.23 (m, 2H).

EXAMPLE 389

7-(2-((4-(tert-butoxycarbonyl)piperazin-1-yl)sulfonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 10.33 (s, 1H), 8.28 (m, 1H), 8.07 (dd, 1H), 7.87 (m, 1H), 7.73 (td, 1H), 7.65 (td, 2H), 7.53 (m, 2H), 7.42 (m, 3H), 7.09 (dd, 1H), 6.97 (m, 1H), 6.89 (d, 1H), 4.17 (m, 2H), 3.42 (m, 2H), 3.18 (m, 2H), 2.82 (m, 2H), 2.58 (m, 2H), 2.42 (m, 2H), 2.20 (m, 2H), 1.28 (s, 9H).

EXAMPLE 390

7-(2-((4-ethylpiperazin-1-yl)sulfonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.04 (s, 1H), 11.19 (s, 1H), 8.27 (m, 1H), 8.08 (m, 1H), 7.89 (m, 1H), 7.75 (m, 3H), 7.54 (m, 2H), 7.45 (m, 3H), 7.11 (m, 2H), 6.93 (d, 1H), 4.23 (t, 2H), 3.47 (m, 2H), 3.18 (m, 3H), 2.72 (m, 4H), 2.36 (m, 2H), 2.23 (m, 2H), 1.49 (m, 1H), 1.00 (t, 3H).

EXAMPLE 391

3-(3-(1-naphthyloxy)propyl)-7-(2-((4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)sulfonyl)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.95 (s, 1H), 11.08 (s, 1H), 8.27 (m, 1H), 8.07 (dd, 1H), 7.87 (m, 1H), 7.67 (m, 3H), 7.53 (m, 2H), 7.41 (m, 3H), 7.17 (dd, 1H), 7.03 (dd, 1H), 6.89 (dd, 1H), 4.19 (m, 2H), 3.45 (m, 3H), 2.95 (m, 4H), 2.25 (m, 4H), 2.09 (m, 2H), 1.77 (dq, 2H), 1.10 (m, 3H), 0.31 (m, 1H).

EXAMPLE 392

7-(3-((1S,4R)-2-hydroxybicyclo(2.2.1)hept-2-yl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) □ 12.97 (m, 1H), 10.55 (s, 0.5H), 9.78 (s, 0.5H), 8.24 (m, 1H), 7.87 (d, 1H), 7.69 (m, 1H), 7.48 (m, 4H), 7.39 (t, 1H), 7.19 (m, 1H), 7.07 (m, 2.5H), 6.92 (m, 1.5H), 4.75 (d, 1H), 4.21 (t, 2H), 3.38 (m, 2H), 2.83 (m, 1H), 2.24 (m, 4H), 2.15 (d, 3H), 1.98 (m, 1H), 1.50 (m, 6H).

EXAMPLE 393

7-((1E)-1-ethylbut-1-enyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.01 (s, 1H), 10.41 (s, 1H), 8.23 (m, 1H), 7.86 (m, 1H), 7.51 (m, 4H), 7.39 (d, 1H), 6.98 (m, 2H), 6.89 (dd, 1H), 5.50 (t, 1H), 4.18 (t, 2H), 3.39 (m, 2H), 2.53 (m, 2H), 2.22 (m, 4H), 1.05 (t, 3H), 0.83 (t, 3H).

EXAMPLE 394

7-((Z)-2-carboxy-1-pentylvinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.97 (s, 1H), 12.13 (s, 1H), 11.07 (s, 1H), 8.23 (m, 1H), 7.86 (m, 1H), 7.66 (d, 1H), 7.51 (m, 2H), 7.41 (m, 2H), 7.12 (m, 1H), 6.99 (m, 1H), 6.89 (m, 1H), 5.90 (s, 1H), 4.18 (t, 2H), 3.40 (m, 2H), 3.07 (m, 2H), 2.21 (m, 2H), 1.23 (m, 6H), 0.76 (m, 3H).

EXAMPLE 395

7-(5,7-dimethylpyrazolo(1,5-a)pyrimidin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.56 (s, 1H), 13.08 (s, 1H), 8.92 (s, 1H), 8.25 (m, 1H), 7.86 (m, 2H), 7.59 (d, 1H), 7.52 (m, 2H), 7.41 (m, 2H), 7.03 (m, 2H), 6.89 (dd, 1H), 4.19 (t, 2H), 3.39 (m, 2H), 2.75 (s, 3H), 2.72 (s, 3H), 2.25 (m, 2H).

EXAMPLE 396

7-(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)thien-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.17 (s, 1H), 10.87 (s, 1H), 8.22 (m, 1H), 7.89 (m, 3H), 7.76 (d, 1H), 7.71 (s, 1H), 7.48 (m, 8H), 7.26 (ddd, 2H), 7.11 (m, 1H), 6.90 (dd, 1H), 4.20 (t, 2H), 3.40 (m, 2H), 3.24 (s, 3H), 2.24 (m, 2H).

EXAMPLE 397

3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-7-(2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.29 (s, 1H), 8.40 (d, 2H), 8.23 (m, 1H), 7.90 (m, 2H), 7.77 (d, 1H), 7.53 (m, 5H), 7.31 (t, 1H), 7.16 (dd, 1H), 7.03 (t, 2H), 6.93 (dd, 1H), 6.63 (d, 2H), 5.61 (d, 1H), 5.01 (d, 1H), 4.26 (t, 2H), 3.42 (m, 2H), 2.29 (m, 2H).

EXAMPLE 398

7-(5-(((2-(dimethylamino)ethyl)(pyridin-2-yl)amino)methyl)thien-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) □ 9.77 (s, 1H), 8.16 (m, 2H), 7.82 (d, 1H), 7.68 (m, 1H), 7.59 (m, 1H), 7.44 (m, 4H), 7.35 (dd, 2H), 7.14 (t, 1H), 7.07 (td, 1H), 6.91 (d, 1H), 6.87 (m, 1H), 6.72 (m, 1H), 4.94 (s, 1H), 4.77 (s, 1H), 4.21 (m, 2H), 3.94 (t, 1H), 3.36 (m, 4H), 2.89 (s, 6H), 2.24 (m, 3H).

EXAMPLE 399

7-(2-morpholin-4-yl-6-(trifluoromethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.81 (s, 1H), 10.77 (s, 1H), 8.31 (m, 1H), 7.87 (m, 1H), 7.69 (dd, 1H), 7.55 (m, 4H), 7.40 (m, 3H), 7.00 (m, 2H), 6.83 (d, 1H), 4.16 (m, 2H), 3.40 (d, 2H), 2.92 (m, 2H), 2.75 (m, 2H), 2.62 (m, 4H), 2.24 (m, 2H).

EXAMPLE 400

7-(4-methoxy-2-phenyl-1-benzofuran-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.81 (s, 1H), 10.99 (s, 1H), 8.31 (m, 1H), 7.87 (m, 1H), 7.75 (d, 1H), 7.53 (m, 2H), 7.46 (m, 1H), 7.34 (m, 5H), 7.21 (m, 4H), 7.06 (m, 1H), 6.88 (d, 1H), 6.73 (m, 1H), 4.19 (t, 2H), 3.42 (s, 3H), 3.38 (d, 2H), 2.26 (m, 2H).

EXAMPLE 401

4-fluoro-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.29 (s, 1H), 10.36 (s, 1H), 8.17 (dd, 1H), 7.85 (m, 1H), 7.43 (m, 6H), 7.30 (dd, 1H), 7.14 (m, 2H), 6.96 (dd, 1H), 6.89 (dd, 1H), 4.22 (t, 2H), 3.48 (m, 2H), 3.23 (m, 4H), 2.75 (m, 4H), 2.25 (m, 2H).

EXAMPLE 402

4-fluoro-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

EXAMPLE 402A

ethyl 7-bromo-3-(3-ethoxy-3-oxopropyl)-4-fluoro-1H-indole-2-carboxylate

A mixture of 2-bromo-5-fluoroaniline (5 g) in ethanol (17.5 ml) and 1.6M HCl (50 mL) at -5 °C was treated with 2.5M $NaNO_2$ (10.5 ml). 4.5M potassium acetate (29.2 ml) was then added, followed by ethyl 2-oxocyclopentanecarboxylate (3.8 ml). The reaction mixture was stirred at 0 °C for 15 minutes, warmed to 20 °C over 1.5 hours, extracted with dichloromethane, concentrated and dried in vacuo. The residue was dissolved in 67 ml of (H_2SO_4/ethanol, 17:50), refluxed for 2 days, cooled to room temperature, quenched with water and extracted with dichloromethane. The combined extracts were washed with brine, dried ($MgSO_4$), filtered and concentrated. The concentrate was purified by column chromatography on silica gel with 5-20% ethyl acetate in hexanes. The product was purified further by trituration with ethanol.

EXAMPLE 402B

3-(7-bromo-2-(ethoxycarbonyl)-4-fluoro-1H-indol-3-yl)propanoic acid

To a mixture of EXAMPLE 402A (2.3 g) in acetic acid (40 ml) was added concentrated hydrochloric acid (3 ml). The mixture was heated at 80 °C for 4 hours. After

cooling to room temperature, precipitation of the product occurred. Water (50mL) was added to further induce precipitation. The solid was filtered, rinsed with water and dried in vacuo.

EXAMPLE 402C

7-bromo-4-fluoro-3-(3-hydroxypropyl)-1H-indole-2-carboxylate

To a suspension of EXAMPLE 402B (1.9 g) in tetrahydrofuran (10 ml) was added 1M borane•tetrahydrofuran (5.8 ml). The reaction mixture was stirred at ambient temperature overnight. Additional 1M borane•tetrahydrofuran (2.0 ml) was added and stirring was continued for 3 hours. The reaction was quenched with methanol and concentrated. The concentrate was dissolved in hot ethanol (30 ml) and 1 ml of concentrated HCl, and was stirred for 1 hour. Precipitation of the product occurred. Water (20 ml) was added to further induce precipitation. The solid was filtered, rinsed with water and dried.

EXAMPLE 402D

ethyl 7-bromo-4-fluoro-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

To a mixture of EXAMPLE 402C (1.03 g), naphthalen-1-ol (519 mg), and triphenylphosphine (905 mg) in tetrahydrofuran (15 ml) at -10 °C was added di-tert-butyl azodicarboxylate (794 mg) slowly. After one hour, the reaction was allowed to warm to room temperature. Stirring was continued for two hours at room temperature. The reaction mixture was concentrated. The concentrate was purified by column chromatography on silica gel with 0-4% ethyl acetate in hexanes.

EXAMPLE 402E

4-fluoro-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

A mixture of EXAMPLE 402D (47 mg), o-tolylboronic acid (19 mg), tris(dibenzylidineacetone)dipalladium(0) (4.6 mg), tri-t-butyl-phosphonium tetrafluoroborate (3.5 mg), cesium fluoride (45.6 mg) and tetrahydrofuran (1.5 ml) was stirred at ambient temperature under a nitrogen atmosphere overnight. Additional o-tolylboronic acid (9.5 mg), tris(dibenzylidineacetone)dipalladium(0) (2.3 mg), tri-t-butyl-phosphonium tetrafluoroborate (1.8 mg) and cesium fluoride (23 mg) were added and stirring was continued at ambient temperature overnight. $LiOH\text{-}H_2O$ (42 mg) and water (0.5 ml) were added and the mixture was heated overnight at 60 °C. The reaction mixture was acidified with 1 M HCl (aq), extracted (3 x 5 ml) with ethyl acetate, dried ($MgSO_4$), filtered and concentrated. The

concentrate was slurried in methanol and filtered through a syringe filter. The filtrate was concentrated. The concentrate was purified by reverse phase HPLC (50-95% acetonitrile/ water/0.1% trifluoroacetic acid). ^{1}H NMR (300 MHz, DMSO-d_6) □ 13.10 (s, 1H), 10.86 (s, 1H), 8.20 (m, 1H), 7.86 (m, 1H), 7.48 (m, 4H), 7.28 (m, 4H), 6.99 (m, 1H), 6.90 (m, 2H), 4.23 (t, 2H), 3.45 (t, 2H), 2.25 (m, 2H), 2.05 (s, 3H).

EXAMPLE 403

7-(2-((2-adamantylamino)carbonyl)-6-methylimidazo(1,2-a)pyridin-8-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.03 (s, 1H), 10.76 (s, 1H), 8.48 (d, 2H), 8.22 (m, 1H), 7.85 (m, 2H), 7.59 (m, 1H), 7.49 (m, 5H), 7.37 (m, 1H), 7.16 (dd, 1H), 6.87 (dd, 1H), 4.19 (t, 2H), 3.95 (m, 1H), 3.41 (m, 2H), 2.39 (d, 3H), 2.26 (m, 2H), 1.86 (m, 2H), 1.78 (m, 6H), 1.62 (m, 4H), 1.43 (m, 2H).

EXAMPLE 404

7-(1-(1-adamantyl)-3-carboxy-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.86 (s, 1H), 12.22 (s, 1H), 10.59 (s, 1H), 8.26 (m, 1H), 7.99 (s, 1H), 7.87 (m, 1H), 7.62 (d, 1H), 7.51 (m, 3H), 7.40 (d, 1H), 7.10 (d, 1H), 6.98 (t, 1H), 6.90 (d, 1H), 4.19 (t, 2H), 3.37 (m, 2H), 2.24 (m, 2H), 2.20 (s, 9H), 1.75 (s, 6H).

EXAMPLE 405

7-(2-(1-hydroxy-4-methoxycyclohexyl)-1-benzothien-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.93 (s, 1H), 10.63 (s, 1H), 8.29 (m, 1H), 7.91 (m, 2H), 7.76 (m, 1H), 7.51 (m, 2H), 7.42 (m, 2H), 7.28 (ddd, 1H), 7.11 (m, 2H), 6.88 (m, 1H), 6.64 (d, 1H), 6.07 (s, 1H), 5.57 (s, 1H), 4.21 (m, 2H), 3.40 (s, 2H), 3.06 (s, 3H), 2.64 (m, 1H), 2.26 (m, 2H), 1.62 (m, 6H).

EXAMPLE 406

7-(5-chloro-3-methyl-1-tetrahydro-2H-pyran-2-yl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 10.71 (s, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.69 (dt, 1H), 7.52 (m, 2H), 7.41 (dt, 2H), 7.05 (m, 2H), 6.91 (d, 1H), 5.44 (dd, 1H), 4.20 (t, 2H), 3.94

(d, 1H), 3.69 (m, 1H), 3.46 (m, 2H), 2.25 (m, 3H), 2.13 (s, 3H), 1.99 (m, 2H), 1.73 (m, 1H), 1.55 (m, 2H).

EXAMPLE 407

3-(3-(1-naphthyloxy)propyl)-7-(2,2,4-trimethyl-1-(phenylsulfonyl)-1,2-dihydroquinolin-3-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.01 (s, 1H), 11.27 (s, 1H), 8.23 (m, 1H), 7.86 (m, 1H), 7.67 (m, 1H), 7.52 (m, 7H), 7.34 (m, 6H), 6.85 (m, 2H), 6.43 (m, 1H), 4.95 (s, 1H), 4.17 (t, 2H), 3.76 (s, 2H), 3.37 (m, 2H), 2.20 (m, 2H), 1.33 (s, 6H).

EXAMPLE 408

7-(7,8-dimethyl-2-(1-methyl-1-phenylethyl)imidazo(1,2-a)pyridin-6-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.50 (s, 1H), 11.16 (s, 1H), 8.67 (s, 1H), 8.26 (m, 1H), 8.16 (s, 1H), 7.85 (m, 2H), 7.53 (m, 2H), 7.38 (m, 7H), 7.16 (m, 2H), 6.91 (dd, 1H), 4.21 (t, 2H), 3.42 (m, 2H), 2.56 (s, 3H), 2.25 (m, 2H), 2.07 (s, 3H), 1.81 (s, 6H).

EXAMPLE 409

7-(1-(4-((2-fluorobenzoyl)amino)phenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) □ 11.33 (s, 1H), 10.48 (s, 1H), 8.23 (d, 1H), 7.85 (d, 1H), 7.74 (d, 1H), 7.62 (m, 3H), 7.53 (m, 3H), 7.44 (m, 1H), 7.33 (m, 5H), 7.09 (m, 2H), 6.98 (t, 1H), 6.87 (d, 1H), 4.16 (t, 2H), 3.38 (m, 2H), 2.20 (m, 2H).

EXAMPLE 410

7-(5-amino-3-(piperidin-1-ylcarbonyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) □ 13.03 (s, 1H), 10.30 (s, 1H), 8.27 (m, 1H), 7.86 (m, 1H), 7.61 (d, 1H), 7.53 (m, 2H), 7.45 (d, 1H), 7.38 (t, 1H), 7.10 (m, 1H), 7.00 (m, 1H), 6.86 (d, 1H), 5.17 (s, 2H), 4.16 (t, 2H), 3.59 (m, 4H), 3.01 (m, 2H), 2.22 (ddd, 2H), 1.28 (m, 4H), 0.76 (m, 2H).

EXAMPLE 411

7-(3-methyl-1-(2-nitrophenyl)-5-phenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.99 (s, 1H), 10.72 (s, 1H), 8.26 (m, 1H), 8.04 (dd, 1H), 7.87 (m, 1H), 7.65 (s, 3H), 7.50 (m, 3H), 7.37 (m, 2H), 7.13 (m, 3H), 7.04 (m, 2H), 6.98 (m, 2H), 6.90 (dd, 1H), 4.20 (t, 2H), 3.41 (m, 2H), 2.22 (m, 2H), 2.03 (s, 3H).

EXAMPLE 412

7-(5-methyl-1-(2-oxo-2-((2-phenylethyl)amino)ethyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) □ 10.80 (s, 1H), 8.26 (m, 1H), 8.22 (t, 1H), 7.87 (td, 1H), 7.73 (m, 1H), 7.52 (m, 2H), 7.46 (m, 1H), 7.39 (t, 1H), 7.24 (m, 4H), 7.16 (m, 1H), 7.08 (m, 2H), 6.91 (d, 1H), 4.89 (s, 2H), 4.22 (t, 2H), 3.49 (m, 4H), 2.79 (m, 2H), 2.23 (m, 2H), 1.84 (s, 3H).

EXAMPLE 413

7-(2-(1-adamantyl)imidazo(1,2-a)pyridin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) □ 11.30 (s, 1H), 8.17 (dd, 1H), 8.01 (d, 1H), 7.94 (m, 2H), 7.87 (m, 1H), 7.49 (m, 5H), 7.39 (m, 1H), 7.25 (dd, 1H), 7.02 (s, 1H), 6.90 (d, 1H), 4.22 (t, 2H), 3.80 (m, 2H), 2.27 (qd, 2H), 2.01 (m, 3H), 1.88 (m, 6H), 1.70 (m, 6H).

EXAMPLE 414

7-(1,1-dioxido-1-benzothien-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) □ 11.54 (s, 1H), 8.24 (m, 1H), 7.92 (d, 1H), 7.87 (m, 2H), 7.61 (m, 2H), 7.52 (m, 2H), 7.46 (m, 2H), 7.39 (m, 1H), 7.32 (d, 1H), 7.11 (m, 2H), 6.90 (d, 1H), 4.20 (t, 2H), 3.40 (m, 2H), 2.25 (m, 2H).

EXAMPLE 415

7-(2-cyclohexyl-6-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.87 (s, 1H), 10.39 (s, 1H), 8.29 (m, 1H), 7.87 (m, 1H), 7.69 (d, 1H), 7.53 (m, 2H), 7.45 (m, 1H), 7.37 (m, 1H), 7.25 (m, 2H), 7.09 (m, 2H), 6.88 (m, 2H), 4.19 (t, 2H), 3.38 (m, 2H), 2.25 (m, 2H), 2.02 (m, 1H), 1.83 (s, 3H), 1.54 (m, 5H), 1.33 (m, 2H), 1.09 (m, 1H), 0.82 (m, 1H), 0.71 (m, 1H).

EXAMPLE 416

7-(4-(((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.94 (s, 1H), 10.71 (s, 1H), 8.51 (t, 1H), 8.24 (m, 1H), 7.87 (ddd, 1H), 7.74 (m, 5H), 7.52 (m, 3H), 7.40 (d, 1H), 7.30 (d, 1H), 7.06 (m, 2H), 6.90 (m, 1H), 4.21 (t, 2H), 3.59 (m, 8H), 3.47 (m, 2H), 3.39 (m, 2H), 2.98 (m, 2H), 2.24 (m, 2H), 2.10 (s, 3H).

EXAMPLE 417

7-(1-methyl-3,5-diphenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.85 (s, 1H), 10.75 (s, 1H), 8.26 (m, 1H), 7.86 (m, 1H), 7.60 (d, 1H), 7.50 (m, 3H), 7.31 (m, 8H), 7.11 (m, 3H), 7.05 (dd, 1H), 6.93 (dd, 1H), 6.84 (m, 1H), 4.13 (t, 2H), 3.82 (s, 3H), 3.25 (m, 2H), 2.18 (m, 2H).

EXAMPLE 418

7-((Z)-2-(1H-imidazol-1-yl)-1-phenylvinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.20 (m, 1H), 11.04 (m, 1H), 8.25 (m, 1H), 7.87 (m, 1H), 7.76 (m, 1H), 7.52 (m, 4H), 7.35 (m, 6H), 7.22 (m, 2H), 7.11 (m, 1H), 7.00 (m, 2H), 6.89 (d, 1H), 4.19 (t, 2H), 3.54 (m, 2H), 2.23 (m, 2H).

EXAMPLE 419

7-(1-benzyl-2-methyl-4-nitro-1H-imidazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 13.05 (s, 1H), 11.61 (s, 1H), 8.26 (m, 1H), 7.87 (m, 1H), 7.80 (d, 1H), 7.51 (m, 2H), 7.41 (m, 2H), 7.20 (m, 4H), 7.03 (m, 1H), 6.92 (m, 3H), 5.07 (d, 1H), 4.75 (d, 1H), 4.19 (t, 2H), 3.39 (m, 2H), 2.30 (s, 3H), 2.20 (m, 2H).

EXAMPLE 420

3-(3-(1-naphthyloxy)propyl)-7-(2-prop-1-ynylphenyl)-1H-indole-2-carboxylic acid

EXAMPLE 420A

1-bromo-2-(prop-1-ynyl)benzene

1M Lithium hexamethyldisilazide solution (6 mL) was added to 1-bromo-2-ethynylbenzene (1 g) in 20 mL tetrahydrofuran at room temperature, and the reaction was stirred 30 minutes. $(CH_3)_2SO_4$ (0.58 mL) was added and the reaction was stirred 30 minutes. The reaction was poured into 20 mL water, extracted with 2x 50 mL ether, and the combined organic layers were dried over Na_2SO_4, filtered, and the filtrate was concentrated.

EXAMPLE 420B

2-(prop-1-ynyl)phenylboronic acid

2.5M n-butyllithium (1.92 mL) was added to EXAMPLE 420A (850 mg) in 15 mL tetrahydrofuran at -78 °C. The reaction was stirred 1 minute, trimethylborate (0.974 mL) was added, and the reaction was allowed to warm to room temperature. The reaction was poured into 20 mL 1M HCl, extracted with 3x 50 mL ether, and the organic layers were concentrated. The crude material was taken up in 50 mL 1M NaOH, and rinsed with 2x 50 mL ether. The aqueous layer was acidified with concentrated HCl, extracted with 3x 50 mL ether, and the combined extracts were washed with brine, dried over Na_2SO_4, and concentrated. The crude product was triturated from ether/hexane.

EXAMPLE 420C

3-(3-(1-naphthyloxy)propyl)-7-(2-prop-1-ynylphenyl)-1H-indole-2-carboxylic acid

A suspension of EXAMPLE 1C (0.034 g, 0.075 mmol), EXAMPLE 420B (0.1 g, 0.68 mmol), tetrakis(triphenylphosphine)palladium (0.004 g, 0.006 mmol), and solution of Na_2CO_3 (2M, 0.5 ml, 1 mmol) in dimethoxyethane/EtOH/H_2O (7/2/3) 3 mL was heated under microwave conditions at 150 C for 30 min. The reaction mixture was quenched with aq. HCl (1M, 0.4 mL) and product extracted with ethyl acetate (3 x 7 mL). The organic phases were filtered through a drying cartridge ($MgSO_4$, Alltech Asoc., 2g) and concentrated under reduced pressure. The crude product was purified by chromatography on SiO2 using 1% AcOH in EtOAc as eluent. ^{1}H NMR (300 MHz, DMSO-d_6) □12.39 (br s, 1H), 10.28 (s, 1H), 8.25 (dd, 1H), 7.87 (d, 1H), 7.71 (d, 1H), 7.38-7.56 (m, 8H), 7.21 (d, 1H), 7.09 (dd, 1H), 6.89 (d, 1H), 4.20 (m, 2H), 3.38 (m, 2H), 2.24 (m, 2H), 1.91 (s, 3H).

EXAMPLE 421

3-(3-(1-naphthyloxy)propyl)-7-(2-(phenylethynyl)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □12.85 (br s, 1H), 10.66 (s, 1H), 8.28 (dd, 1H), 7.87 (d, 1H), 7.78 (d, 1H), 7.68 (d, 1H), 7.40-7.58 (m, 8H), 7.18-7.26 (m, 3H), 7.08 (dd, 1H), 6.89 (m, 3H), 4.21 (t, 2H), 3.40 (t, 2H), 2.26 (m, 2H).

EXAMPLE 422

3,7-bis(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □12.80 (br s, 1H), 11.35 (s, 1H), 8.21 (dd, 2H), 7.86 (d, 2H), 7.35-7.55 (m, 8H), 7.08 (d, 1H), 6.86-6.96 (m, 4H), 4.18 (m, 4H), 3.37 (m, 4H), 2.21 (m, 4H).

EXAMPLE 423

1-(2-(dimethylamino)-2-oxoethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.02 (s, 1H), 8.24-8.31 (m, 1H), 7.84-7.91 (m, 1H), 7.75 (dd, J=8.1, 1.4 Hz, 1H), 7.50-7.56 (m, 2H), 7.46 (d, J=8.1, 1H), 7.41 (d, J=7.1 Hz, 1H), 7.31-7.39 (m, 2H), 7.20-7.28 (m, 1H), 7.02-7.12 (m, 2H), 6.91 (dd, J=6.8, 4.4 Hz, 2H), 5.05 (d, J=17.3 Hz, 1H), 4.70 (d, J=17.6 Hz, 1H), 4.23 (t, J=6.1 Hz, 2H), 3.32-3.40 (m, 2H), 2.63 (s, 3H), 2.28 (s, 3H), 2.18-2.27 (m, 2H), 1.95 (s, 3H).

EXAMPLE 424

1-(2-methylbenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.13 (s, 1H), 8.22-8.30 (m, 1H), 7.81-7.91 (m, 2H), 7.49-7.56 (m, 1H), 7.44-7.49 (m, 1H), 7.36-7.44 (m, 1H), 7.23-7.31 (m, 1H), 7.07-7.19 (m, 2H), 6.99-7.04 (m, 1H), 6.92-6.99 (m, 3H), 6.84-6.92 (m, 2H), 6.74-6.82 (m, 2H), 5.50 (d, J=7.8 Hz, 1H), 5.34 (d, J=17.6 Hz, 1H), 5.17 (d, J=17.6 Hz, 1H), 4.26 (t, J=6.1 Hz, 2H), 3.37-3.49 (m, 2H), 2.22-2.36 (m, 2H), 1.61 (s, 3H), 1.57 (s, 3H).

EXAMPLE 425

1-(3-methylbenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.18 (s, 1H), 8.20-8.29 (m, 1H), 7.83-7.91 (m, 1H), 7.80 (d, J=8.3 Hz, 1H), 7.48-7.58 (m, 2H), 7.43-7.48 (m, 1H), 7.34-7.42 (m, 1H), 7.30 (t, J=7.3 Hz, 1H), 7.21 (d, J=7.1 Hz, 1H), 7.06-7.17 (m, 2H), 7.00 (d, J=7.5 Hz, 1H), 6.82-6.96

(m, 4H), 6.04 (s, 1H), 5.98 (d, *J*=6.7 Hz, 1H), 5.29 (d, *J*=16.6 Hz, 1H), 5.19 (d, *J*=16.6 Hz, 1H), 4.22 (t, *J*=6.1 Hz, 2H), 3.34-3.43 (m, 2H), 2.19-2.33 (m, 2H), 2.06 (s, 3H), 1.70 (s, 3H).

EXAMPLE 426

1-(4-methylbenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.13 (s, 1H), 8.21-8.29 (m, 1H), 7.84-7.92 (m, 2H), 7.80 (d, *J*=6.7 Hz, 1H), 7.50-7.58 (m, 2H), 7.47 (d, *J*=8.7 Hz, 2H), 7.35-7.42 (m, 1H), 7.26-7.33 (m, 1H), 7.23 (d, *J*=7.1 Hz, 1H), 7.08-7.16 (m, 2H), 7.03 (d, *J*=6.7 Hz, 1H), 6.95 (d, *J*=5.9 Hz, 1H), 6.89 (d, *J*=6.7 Hz, 1H), 6.83 (d, *J*=7.9 Hz, 2H), 6.14 (d, *J*=8.3 Hz, 2H), 5.29 (d, *J*=16.7 Hz, 1H), 5.11 (d, *J*=16.7 Hz, 1H), 4.21 (t, *J*=6.1 Hz, 2H), 3.34-3.42 (m, 2H), 2.18-2.32 (m, 2H), 2.14 (s, 3H), 1.76 (s, 3H).

EXAMPLE 427

7-(2-methylphenyl)-1-(3-morpholin-4-ylpropyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.31 (s, 1H), 9.43 (s, 1H), 8.19-8.27 (m, 1H), 7.83-7.91 (m, 1H), 7.79 (dd, *J*=8.1, 1.4 Hz, 1H), 7.49-7.58 (m, 2H), 7.47 (d, *J*=8.4 Hz, 1H), 7.34-7.44 (m, 5H), 7.10-7.18 (m, 1H), 7.00 (d, *J*=5.8 Hz, 1H), 6.92 (d, *J*=6.4 Hz, 1H), 4.26-4.40 (m, 1H), 4.23 (t, *J*=5.9 Hz, 2H), 3.88 (bs, 2H), 3.48-3.65 (m, 4H), 3.29-3.39 (m, 4H), 2.85 (bs, 2H), 1.99 (s, 3H), 1.60 (bs, 2H).

EXAMPLE 428

7-(2-methylphenyl)-1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.07 (s, 1H), 9.69 (s, 1H), 8.22-8.32 (m, 1H), 7.84-7.92 (m, 1H), 7.77 (dd, *J*=8.1, 1.4 Hz, 1H), 7.50-7.58 (m, 2H), 7.47 (d, *J*=8.1 Hz, 1H), 7.33-7.43 (m, 4H), 7.23-7.32 (m, 1H), 7.05-7.13 (m, 1H), 6.92 (d, *J*=7.5 Hz, 2H), 5.39 (bs, 1H), 4.93 (bs, 1H), 4.23 (t, *J*=6.1 Hz, 2H), 3.36-3.44 (m, 4H), 2.72-2.86 (m, 4H), 2.17-2.30 (m, 2H), 1.93 (s, 3H).

EXAMPLE 429

7-(2-methylphenyl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.17 (s, 1H), 9.20 (s, 1H), 8.17-8.25 (m, 1H), 7.84-7.90 (m, 1H), 7.76 (dd, *J*=8.1, 1.4 Hz, 1H), 7.49-7.58 (m, 1H), 7.46 (d, *J*=8.4 Hz, 1H), 7.37-7.43 (m, 1H), 7.25-7.36 (m, 4H), 7.07-7.16 (m, 1H), 6.96 (dd, *J*=7.1, 1.4 Hz, 1H), 4.27-4.40 (m, 1H), 4.22 (t, *J*=5.9 Hz, 2H), 3.70-3.85 (m, 1H), 3.27-3.40 (m, 2H), 3.21 (d, *J*=12.5 Hz, 2H), 2.70-2.88 (m, 2H), 2.69 (s, 3H), 2.39 (d, *J*=14.6 Hz, 2H), 2.14-2.30 (m, 2H), 2.06 (m, 4H), 2.00 (s, 3H).

EXAMPLE 430

1-(1,1'-biphenyl-2-ylmethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.97 (s, 1H), 8.18-8.26 (m, 1H), 7.82-7.91 (m, 2H), 7.43-7.58 (m, 3H), 7.35-7.43 (m, 1H), 7.29-7.36 (m, 4H), 7.26 (d, *J*=7.1 Hz, 1H), 7.03-7.19 (m, 3H), 6.87-7.02 (m, 5H), 6.65-6.75 (m, 2H), 5.52 (d, *J*=7.5 Hz, 1H), 5.29 (d, *J*=17.8 Hz, 1H), 5.10 (d, *J*=17.8 Hz, 1H), 4.23 (t, *J*=6.1 Hz, 2H), 3.36-3.45 (m, 2H), 2.27 (qt, *J*=7.3 Hz, 2H), 1.76 (s, 3H).

EXAMPLE 431

1-(1,1'-biphenyl-3-ylmethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.23 (s, 1H), 8.20-8.30 (m, 1H), 7.84-7.91 (m, 1H), 7.81 (d, *J*=7.8 Hz, 1H), 7.48-7.59 (m, 2H), 7.46 (d, *J*=8.1 Hz, 1H), 7.32-7.41 (m, 6H), 7.22-7.32 (m, 2H), 7.06-7.20 (m, 4H), 7.01 (d, *J*=6.8 Hz, 1H), 6.94 (d, *J*=7.1 Hz, 1H), 6.87 (d, *J*=7.5 Hz, 1H), 6.44 (s, 1H), 6.22 (d, *J*=8.1 Hz, 1H), 5.39 (d, *J*=16.6 Hz, 1H), 5.27 (d, *J*=16.6 Hz, 1H), 4.23 (t, *J*=6.3 Hz, 2H), 3.39 (t, *J*=7.5 Hz, 2H), 2.21-2.36 (m, 2H), 1.70 (s, 3H).

EXAMPLE 432

1-(1,1'-biphenyl-4-ylmethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.20 (s, 1H), 8.17-8.27 (m, 1H), 7.80-7.90 (m, 2H), 7.48-7.57 (m, 4H), 7.46 (d, *J*=8.1 Hz, 1H), 7.34-7.43 (m, 3H), 7.26-7.34 (m, 4H), 7.23 (d, *J*=7.1 Hz, 1H), 7.08-7.18 (m, 2H), 7.03 (d, *J*=6.8 Hz, 1H), 6.96 (d, *J*=6.1 Hz, 1H), 6.90 (d, *J*=6.8 Hz, 1H), 6.31 (d, *J*=8.1 Hz, 2H), 5.38 (d, *J*=17.3 Hz, 1H), 5.25 (d, *J*=17.3 Hz, 1H), 4.23 (t, *J*=6.1 Hz, 2H), 3.35-3.45 (m, 2H), 2.21-2.35 (m, 2H), 1.75 (s, 3H).

EXAMPLE 433

1-(2,4-dimethylbenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.07 (s, 1H), 8.21-8.30 (m, 1H), 7.85-7.91 (m, 1H), 7.83 (d, J=7.9 Hz, 1H), 7.49-7.57 (m, 2H), 7.48 (d, J=8.1 Hz, 1H), 7.36-7.44 (m, 1H), 7.27 (t, J=7.3 Hz, 1H), 7.17 (d, J=7.1 Hz, 1H), 7.07-7.14 (m, 1H), 7.02 (t, J=7.3 Hz, 1H), 6.91 (d, J=7.5 Hz, 1H), 6.88 (d, J=7.1 Hz, 1H), 6.81 (d, J=7.5 Hz, 1H), 6.76 (s, 1H), 6.56 (d, J=7.9 Hz, 1H), 5.38 (d, J=7.9 Hz, 1H), 5.28 (d, J=17.4 Hz, 1H), 5.09 (d, J=17.4 Hz, 1H), 4.25 (t, J=6.1 Hz, 2H), 3.41 (t, J=7.3 Hz, 2H), 2.22-2.36 (m, 2H), 2.11 (s, 3H), 1.64 (s, 3H), 1.54 (s, 3H).

EXAMPLE 434

1-(4-carboxybenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.09 (s, 1H), 12.79 (s, 1H), 8.19-8.30 (m, 1H), 7.85-7.91 (m, 1H), 7.83 (d, J=7.9 Hz, 1H), 7.62 (d, J=8.3 Hz, 2H), 7.49-7.58 (m, 2H), 7.46 (d, J=8.3 Hz, 1H), 7.35-7.43 (m, 1H), 7.28 (t, J=7.5 Hz, 1H), 7.19 (d, J=7.5 Hz, 1H), 7.09-7.16 (m, 1H), 7.06 (t, J=7.5 Hz, 1H), 6.89 – 7.01 (m, 3H), 6.33 (d, J=8.3 Hz, 2H), 5.43 (d, J=17.1 Hz, 1H), 5.25 (d, J=17.1 Hz, 1H), 4.23 (t, J=6.1 Hz, 2H), 3.36-3.46 (m, 2H), 2.19-2.35 (m, 2H), 1.71 (s, 3H).

EXAMPLE 435

1-(1,1'-biphenyl-2-ylmethyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.90 (s, 1H), 8.23-8.31 (m, 1H), 7.85-7.89 (m, 1H), 7.82 (dd, J=7.5, 2.0 Hz, 1H), 7.48-7.58 (m, 2H), 7.42-7.48 (m, 2H), 7.32-7.42 (m, 5H), 7.04-7.15 (m, 4H), 6.96-7.04 (m, 2H), 6.88-6.96 (m, 1H), 6.86 (d, J=7.5 Hz, 1H), 6.62-6.72 (m, 2H), 5.55 (d, J=18.0 Hz, 1H), 5.47 (d, J=7.8 Hz, 1H), 5.16 (d, J=18.0 Hz, 1H), 4.19 (t, J=6.1 Hz, 2H), 3.31-3.51 (m, 4H), 3.00-3.10 (m, 2H), 2.73-2.84 (m, 2H), 2.20-2.31 (m, 4H).

EXAMPLE 436

1-(1,1'-biphenyl-3-ylmethyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.23 (s, 1H), 8.21-8.33 (m, 1H), 7.83-7.91 (m, 1H), 7.77 (dd, J=7.1, 2.4 Hz, 1H), 7.49-7.57 (m, 2H), 7.45 (d, J=8.3 Hz, 1H), 7.26-7.41 (m, 8H), 7.18 (dd, J=7.5, 1.6 Hz, 1H), 7.05-7.14 (m, 4H), 7.00 (t, J=7.3 Hz, 1H), 6.81 (d, J=7.5 Hz, 1H), 6.60 (s, 1H), 6.30 (d, J=7.9 Hz, 1H), 5.82 (d, J=16.7 Hz, 1H), 5.02 (d, J=16.7 Hz, 1H), 4.16 (t, J=5.9 Hz, 2H), 3.33-3.45 (m, 2H), 3.15-3.26 (m, 4H), 2.89 (s, 2H), 2.53-2.70 (m, 2H), 2.13-2.31 (m, 2H).

EXAMPLE 437

1-(1,1'-biphenyl-4-ylmethyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.20 (s, 1H), 8.22-8.31 (m, 1H), 7.83-7.91 (m, 1H), 7.75-7.82 (m, 1H), 7.50-7.57 (m, 2H), 7.33-7.50 (m, 6H), 7.24-7.33 (m, 3H), 7.21 (dd, J=7.5, 1.7 Hz, 1H), 6.97-7.15 (m, 4H), 6.83 (d, J=6.8 Hz, 1H), 6.40 (d, J=8.1 Hz, 2H), 5.79 (d, J=16.3 Hz, 1H), 4.99 (d, J=16.3 Hz, 1H), 4.17 (t, J=6.1 Hz, 2H), 3.29-3.52 (m, 2H), 3.15-3.28 (m, 2H), 2.90 (s, 2H), 2.53-2.71 (m, 4H), 2.18-2.30 (m, 2H).

EXAMPLE 438

1-(2,4-dimethylbenzyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.05 (s, 1H), 8.23-8.34 (m, 1H), 7.84-7.92 (m, 1H), 7.80 (dd, J=7.5, 1.7 Hz, 1H), 7.49-7.59 (m, 2H), 7.46 (d, J=8.5 Hz, 1H), 7.30-7.41 (m, 2H), 7.00-7.13 (m, 3H), 6.88-6.98 (m, 2H), 6.86 (d, J=6.4 Hz, 1H), 6.52 (d, J=8.1 Hz, 1H), 5.65 (d, J=17.0 Hz, 1H), 5.41 (d, J=8.1 Hz, 1H), 4.99 (d, J=17.0 Hz, 1H), 4.20 (t, J=6.3 Hz, 2H), 3.38-3.53 (m, 2H), 3.12-3.25 (m, 2H), 2.79-3.01 (m, 2H), 2.51-2.60 (m, 4H), 2.17-2.35 (m, 2H), 2.02-2.10 (m, 3H), 1.59 (s, 3H).

EXAMPLE 439

1-(2,6-dichlorobenzyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.90 (s, 1H), 8.23-8.31 (m, 1H), 7.83-7.90 (m, 1H), 7.74 (dd, J=7.5, 1.7 Hz, 1H), 7.48-7.57 (m, 2H), 7.45 (d, J=8.5 Hz, 1H), 7.30-7.42 (m, 2H), 7.27 (dd, J=7.6, 1.5 Hz, 1H), 7.15-7.23 (m, 3H), 6.98-7.14 (m, 4H), 6.80 (d, J=6.8 Hz, 1H), 5.80 (d, J=16.3 Hz, 1H), 4.97 (d, J=15.9 Hz, 1H), 4.06-4.18 (m, 2H), 3.19-3.34 (m, 4H), 2.95 (bs, 2H), 2.60-2.70 (m, 4H), 2.10-2.24 (m, 2H).

EXAMPLE 440

1-(4-carboxybenzyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.14 (s, 1H), 12.79 (s, 1H), 8.23-8.32 (m, 1H), 7.83-7.91 (m, 1H), 7.79 (dd, J=5.8, 3.4 Hz, 1H), 7.55-7.61 (m, 2H), 7.49-7.55 (m, 2H), 7.45 (d, J=8.5 Hz, 2H), 7.32-7.41 (m, 2H), 7.01-7.14 (m, 4H), 6.95 (t, J=8.0 Hz, 1H), 6.84 (d, J=6.8 Hz, 1H), 6.37 (d, J=8.5 Hz, 2H), 5.86 (d, J=17.3 Hz, 1H), 5.02 (d, J=17.0 Hz, 1H), 4.16 (t, J=6.1 Hz, 2H), 3.38-3.50 (m, 2H), 3.13-3.27 (m, 2H), 2.81-2.97 (m, 2H), 2.52-2.70 (m, 4H), 2.16-2.31 (m, 2H).

EXAMPLE 441

7-(6,6-dimethylcyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.98 (s, 1H), 10.41 (s, 1H), 8.15-8.33 (m, 1H), 7.78-7.95 (m, 1H), 7.34-7.58 (m, 5H), 6.86-6.99 (m, 3H), 5.46 (t, J=3.6 Hz, 1H), 4.19 (t, J=6.1 Hz, 2H), 3.33-3.38 (m, 2H), 2.10-2.28 (m, 4H), 1.62-1.82 (m, 4H), 0.97 (s, 6H).

EXAMPLE 442

7-(5,5-dimethylcyclopent-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.04 (s, 1H), 10.19 (s, 1H), 8.16-8.30 (m, 1H), 7.79-7.92 (m, 1H), 7.42-7.63 (m, 4H), 7.34-7.42 (m, 1H), 6.93-7.08 (m, 2H), 6.90 (d, J=6.4 Hz, 1H), 5.78 (t, J=2.4 Hz, 1H), 4.19 (t, J=6.1 Hz, 2H), 3.33-3.42 (m, 2H), 2.42-2.49 (m, 2H), 2.13-2.29 (m, 2H), 1.90 (t, J=7.0 Hz, 2H), 1.11 (s, 6H).

EXAMPLE 443

3-(3-(1-naphthyloxy)propyl)-7-(7-phenylcyclohept-1-en-1-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.02 (s, 1H), 10.25 (s, 1H), 8.13-8.24 (m, 1H), 7.80-7.90 (m, 1H), 7.32-7.58 (m, 7H), 7.24 (t, J=7.6 Hz, 2H), 7.10 (t, J=7.1 Hz, 1H), 6.97 (d, J=6.1 Hz, 1H), 6.80-6.90 (m, 2H), 6.29 (t, J=6.3 Hz, 1H), 4.21 (t, J=4.7 Hz, 1H), 4.14 (t, J=5.9 Hz, 2H), 3.21-3.32 (m, 2H), 2.31-2.45 (m, 2H), 2.10-2.24 (m, 4H), 1.50-1.85 (m, 3H), 1.30-1.49 (m, 1H).

EXAMPLE 444

3-(3-(1-naphthyloxy)propyl)-7-tricyclo(4.3.1.1^{3,8})undec-4-en-4-yl-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.15 (s, 1H), 9.53 (s, 1H), 8.12-8.32 (m, 1H), 7.72-7.93 (m, 1H), 7.27-7.62 (m, 5H), 7.01-7.07 (m, 1H), 6.93-7.01 (m, 1H), 6.87 (d, *J*=6.4 Hz, 1H), 6.30-6.42 (m, 1H), 4.17 (t, *J*=6.1 Hz, 2H), 3.33-3.41 (m, 2H), 2.63-2.71 (m, 1H), 2.11-2.26 (m, 4H), 1.70-2.06 (m, 11H).

EXAMPLE 445

3-(3-(1-naphthyloxy)propyl)-7-(2-phenylcyclohept-1-en-1-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.94 (s, 1H), 10.53 (s, 1H), 8.17-8.26 (m, 1H), 7.81-7.89 (m, 1H), 7.47-7.56 (m, 2H), 7.32-7.47 (m, 3H), 6.87-6.98 (m, 5H), 6.85 (d, *J*=6.4 Hz, 1H), 6.65-6.77 (m, 2H), 4.13 (t, *J*=6.1 Hz, 2H), 3.18-3.30 (m, 2H), 2.73-3.07 (m, 2H), 2.24-2.44 (m, 2H), 2.16 (t, *J*=6.6 Hz, 2H), 1.38-2.05 (m, 6H).

EXAMPLE 446

3-(3-(1-naphthyloxy)propyl)-7-(2,6,6-trimethylcyclohex-1-en-1-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.96 (s, 1H), 10.46 (s, 1H), 8.19-8.36 (m, 1H), 7.77-7.97 (m, 1H), 7.48-7.60 (m, 3H), 7.46 (d, *J*=8.1 Hz, 1H), 7.34-7.42 (m, 1H), 6.94-7.01 (m, 1H), 6.89 (d, *J*=6.8 Hz, 1H), 6.83 (d, *J*=6.1 Hz, 1H), 4.20 (t, *J*=6.1 Hz, 2H), 3.22-3.33 (m, 2H), 2.12-2.31 (m, 3H), 1.91-2.05 (m, 1H), 1.69-1.84 (m, 3H), 1.45-1.59 (m, 1H), 1.17 (s, 3H), 1.05 (s, 3H), 0.74 (s, 3H).

EXAMPLE 447

3-(3-(1-naphthyloxy)propyl)-7-((1R,4R)-1,7,7-trimethylbicyclo(2.2.1)hept-2-en-2-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.18 (s, 1H), 9.34 (s, 1H), 8.16-8.27 (m, 1H), 7.81-7.90 (m, 1H), 7.47-7.59 (m, 3H), 7.45 (d, *J*=8.1 Hz, 1H), 7.33-7.41 (m, 1H), 7.07 (d, *J*=7.3 Hz, 1H), 7.00 (t, *J*=7.5 Hz, 1H), 6.89 (d, *J*=7.5 Hz, 1H), 6.38 (d, *J*=3.6 Hz, 1H), 4.18 (t, *J*=5.9 Hz, 2H), 3.32-3.39 (m, 2H), 2.54 (t, *J*=3.4 Hz, 1H), 2.15-2.28 (m, 2H), 1.89-2.04 (m, 1H), 1.64-1.78 (m, 1H), 1.30-1.45 (m, 1H), 1.07-1.19 (m, 1H), 1.04 (s, 3H), 0.98 (s, 3H), 0.86 (s, 3H).

EXAMPLE 448

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-4-(trifluoromethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.23 (s, 1H), 11.20 (s, 1H), 8.21-8.37 (m, 1H), 7.83-7.90 (m, 1H), 7.62 (d, J=7.8 Hz, 1H), 7.22-7.58 (m, 8H), 7.20 (d, J=7.5 Hz, 1H), 6.99 (d, J=7.1 Hz, 1H), 4.25 (t, J=5.8 Hz, 2H), 3.35-3.48 (m, 2H), 2.09-2.23 (m, 2H), 2.05 (s, 3H).

EXAMPLE 449

7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-4-(trifluoromethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.51 (s, 1H), 10.79 (s, 1H), 8.23-8.38 (m, 1H), 7.82-7.91 (m, 1H), 7.67 (d, J=7.8 Hz, 1H), 7.35-7.57 (m, 7H), 7.15-7.27 (m, 2H), 6.94-7.04 (m, 1H), 4.25 (t, J=5.9 Hz, 2H), 3.37-3.51 (m, 2H), 3.07-3.36 (m, 4H), 2.71-2.87 (m, 4H), 2.17 (s, 2H).

EXAMPLE 450

1-(2-(dimethylamino)ethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 8.14-8.30 (m, 1H), 7.84-7.92 (m, 1H), 7.80 (d, J=7.9 Hz, 1H), 7.32-7.59 (m, 8H), 7.15 (t, J=7.7 Hz, 1H), 6.99 (d, J=5.9 Hz, 1H), 6.92 (d, J=6.3 Hz, 1H), 4.45-4.78 (m, 1H), 4.23 (t, J=5.6 Hz, 2H), 3.42 (s, 3H), 3.35-3.41 (m, 2H), 3.19-3.23 (m, 3H), 2.70-2.75 (m, 2H), 2.17-2.35 (m, 4H), 2.00 (s, 3H).

EXAMPLE 451

7-(1,1'-biphenyl-2-ylmethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.99 (s, 1H), 11.25 (s, 1H), 8.15-8.33 (m, 1H), 7.76-7.95 (m, 1H), 7.47-7.57 (m, 2H), 7.23-7.47 (m, 11H), 7.05-7.11 (m, 1H), 6.80-6.91 (m, 2H), 6.58 (d, J=6.7 Hz, 1H), 4.26 (s, 2H), 4.17 (t, J=5.9 Hz, 2H), 3.28-3.36 (m, 2H), 2.15-2.26 (m, 2H).

EXAMPLE 452

7-(1,1'-biphenyl-3-ylmethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.05 (s, 1H), 11.39 (s, 1H), 8.06-8.34 (m, 1H), 7.81-7.89 (m, 1H), 7.68 (s, 1H), 7.61 (d, J=7.1 Hz, 2H), 7.30-7.56 (m, 12H), 7.23-7.30 (m,

1H), 7.07 (d, *J*=6.3 Hz, 1H), 6.89-6.97 (m, 1H), 6.87 (d, *J*=7.5 Hz, 1H), 4.38 (s, 2H), 4.16 (t, *J*=5.9 Hz, 2H), 3.27-3.31 (m, 2H), 2.14 – 2.23 (m, 2H).

EXAMPLE 453

7-(1-(2-(1-naphthyloxy)ethyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.03 (s, 1H), 10.51 (s, 1H), 8.14-8.30 (m, 1H), 7.92 (d, *J*=7.5 Hz, 1H), 7.83-7.89 (m, 1H), 7.81 (d, *J*=7.5 Hz, 1H), 7.62 (d, *J*=8.1 Hz, 1H), 7.28-7.54 (m, 8H), 7.18 (d, *J*=6.1 Hz, 1H), 6.94-7.03 (m, 1H), 6.87 (d, *J*=7.5 Hz, 2H), 5.51 (s, 1H), 5.37 (d, *J*=1.7 Hz, 1H), 4.11-4.26 (m, 4H), 3.32-3.37 (m, 2H), 3.16 (t, *J*=6.1 Hz, 2H), 2.15-2.26 (m, 2H).

EXAMPLE 454

3-(3-(1-naphthyloxy)propyl)-7-(2-(phenoxymethyl)benzyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.01 (s, 1H), 11.24 (s, 1H), 8.09-8.34 (m, 1H), 7.72-7.94 (m, 1H), 7.41-7.58 (m, 5H), 7.32-7.41 (m, 1H), 7.17-7.30 (m, 4H), 7.00 (dd, *J*=6.6, 2.5 Hz, 1H), 6.87-6.96 (m, 5H), 6.79-6.87 (m, 1H), 5.13 (s, 2H), 4.39 (s, 2H), 4.17 (t, *J*=6.1 Hz, 2H), 3.32-3.40 (m, 2H), 2.15-2.25 (m, 2H).

EXAMPLE 455

3-(3-(1-naphthyloxy)propyl)-7-(2-(2-phenoxyethyl)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.95 (s, 1H), 10.60 (s, 1H), 10.60 (s, 1H), 8.17-8.32 (m, 1H), 7.82-7.91 (m, 1H), 7.70-7.78 (m, 1H), 7.29-7.58 (m, 7H), 7.20-7.27 (m, 1H), 7.04-7.15 (m, 4H), 6.89 (d, *J*=6.4 Hz, 1H), 6.79 (t, *J*=7.5 Hz, 1H), 6.52 (d, *J*=7.8 Hz, 2H), 4.21 (t, *J*=6.1 Hz, 2H), 3.93 (t, *J*=7.6 Hz, 2H), 3.36-3.45 (m, 2H), 2.70-2.95 (m, 2H), 2.16-2.31 (m, 2H).

EXAMPLE 456

3-(3-(1-naphthyloxy)propyl)-7-(3-(2-phenoxyethyl)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.06 (s, 1H), 10.34 (s, 1H), 8.10-8.33 (m, 1H), 7.80-7.98 (m, 1H), 7.70 (d, *J*=7.8 Hz, 1H), 7.59 (s, 1H), 7.34-7.56 (m, 8H), 7.22-7.31 (m, 3H), 7.05-7.13 (m, 1H), 6.95 (d, *J*=8.8 Hz, 2H), 6.85-6.93 (m, 2H), 4.26 (t, *J*=6.8 Hz, 2H), 4.19 (t, *J*=5.9 Hz, 2H), 3.35-3.43 (m, 2H), 3.14 (t, *J*=6.8 Hz, 2H), 2.16-2.32 (m, 2H).

EXAMPLE 457

3-(3-(1-naphthyloxy)propyl)-7-(2-(3-phenoxypropyl)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.92 (s, 1H), 10.50 (s, 1H), 8.09-8.41 (m, 1H), 7.82-8.01 (m, 1H), 7.70 (dd, J=6.4, 2.7 Hz, 1H), 7.47-7.57 (m, 2H), 7.45 (d, J=8.5 Hz, 1H), 7.33-7.42 (m, 2H), 7.25-7.32 (m, 1H), 7.18-7.24 (m, 2H), 7.12-7.18 (m, 2H), 7.01-7.09 (m, 2H), 6.88 (d, J=7.5 Hz, 1H), 6.83 (t, J=7.3 Hz, 1H), 6.66 (d, J=7.8 Hz, 2H), 4.20 (t, J=6.1 Hz, 2H), 3.56-3.75 (m, 2H), 3.29-3.41 (m, 2H), 2.63 (d, J=6.1 Hz, 2H), 2.18-2.31 (m, 2H), 1.68-1.84 (m, 2H).

EXAMPLE 458

3-(3-(1-naphthyloxy)propyl)-7-(3-(3-phenoxypropyl)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.03 (s, 1H), 10.32 (s, 1H), 8.05-8.32 (m, 1H), 7.80-7.98 (m, 1H), 7.69 (d, J=7.8 Hz, 1H), 7.34-7.56 (m, 7H), 7.22-7.32 (m, 3H), 7.20 (d, J=6.1 Hz, 1H), 7.03-7.11 (m, 1H), 6.86-6.97 (m, 4H), 4.19 (t, J=6.1 Hz, 2H), 4.01 (t, J=6.4 Hz, 2H), 3.37 (t, J=7.5 Hz, 2H), 2.80-2.90 (m, 2H), 2.16-2.32 (m, 2H), 2.01-2.16 (m, 2H).

EXAMPLE 459

3-(3-(3-hydroxy-2-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.88 (br. s, 1H), 10.44 (br. s, 1H), 9.17 (s, 1H), 7.66 (d, 1H), 7.20-7.36 (m, 4H), 7.11 (t, 1H), 7.02-7.06 (m, 1H), 6.88 (t, 1H), 6.42 (d, 1H), 6.35 (d, 1H), 3.96 (t, 2H), 3.25 (t, 2H), 2.04-2.12 (m, 5H), 2.02 (s, 3H).

EXAMPLE 460

3-(3-(3-(2-methoxyethoxy)-2-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.91 (br. s, 1H), 10.46 (s, 1H), 7.65 (d, 1H), 7.19-7.37 (m, 4H), 7.01-7.14 (m, 3H), 6.51-6.61 (m, 2H), 4.05-4.09 (m, 2H), 4.00 (t, 2H), 3.65-3.69 (m, 2H), 3.33 (s, 3H), 3.23-3.29 (m, 2H), 2.02-2.15 (m, 8H).

EXAMPLE 461

7-(1,2-dimethylprop-1-enyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.95 (br. s, 1H), 10.63 (s, 1H), 8.22-8.29 (m, 1H), 7.83-7.90 (m, 1H), 7.33-7.59 (m, 5H), 6.84-7.00 (m, 3H), 4.18 (t, 2H), 3.27-3.37 (m, 2H), 2.16-2.26 (m, 2H), 1.94 (s, 3H), 1.84 (s, 3H), 1.40 (s, 3H).

EXAMPLE 462

3-(3-(2-methyl-3-(2-morpholin-4-ylethoxy)phenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.88 (br. s, 1H), 10.50 (s, 1H), 7.65 (d, 1H), 7.16-7.36 (m, 4H), 7.02-7.16 (m, 3H), 6.58-6.68 (m, 2H), 4.33 (t, 2H), 3.99-4.04 (m, 4H), 3.49-3.75 (m, 6H), 3.23-3.28 (m, 4H), 2.07-2.14 (m, 5H), 2.05 (s, 3H).

EXAMPLE 463

3-(3-(2,3-dichlorophenoxy)propyl)-7-(2-morpholin-4-ylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.04 (br. s, 1H), 10.04 (s, 1H), 7.71 (d, 1H), 7.31-7.45 (m, 3H), 7.27 (t, 1H), 7.09-7.22 (m, 4H), 7.00-7.07 (m, 1H), 4.09 (t, 2H), 3.18-3.34 (m, 6H), 2.73-2.81 (m, 4H), 2.09-2.19 (m, 2H).

EXAMPLE 464

1-(2-morpholin-4-ylethyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.31 (br. s, 1H), 7.71-7.80 (m, 1H), 7.50-7.56 (m, 1H), 7.40-7.46 (m, 1H), 7.14-7.23 (m, 3H), 7.07 (d, 1H), 6.99 (t, 1H), 6.59-6.65 (m, 2H), 3.96 (t, 2H), 3.19-3.35 (m, 10H), 3.08-3.18 (m, 4H), 2.55-2.89 (m, 10H), 2.00-2.14 (m, 3H), 1.56-1.85 (m, 5H).

EXAMPLE 465

7-(2-methylphenyl)-3-(3-(1-naphthylthio)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.89 (br. s, 1H), 10.48 (s, 1H), 8.23-8.28 (m, 1H), 7.92-7.97 (m, 1H), 7.78 (d, 1H), 7.54-7.64 (m, 3H), 7.46-7.50 (m, 1H), 7.42 (t, 1H), 7.30-7.35 (m, 2H), 7.24-7.29 (m, 1H), 7.19-7.23 (m, 1H), 7.08 (t, 1H), 7.01-7.05 (m, 1H), 3.24 (t, 2H), 3.11 (t, 2H), 2.04 (s, 3H), 1.94-2.02 (m, 2H).

EXAMPLE 466

3-(3-(3-(2-methoxyethoxy)-5-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.86 (br. s, 1H), 10.41 (s, 1H), 7.67 (d, 1H), 7.31-7.34 (m, 2H), 7.20-7.30 (m, 2H), 7.11 (t, 1H), 7.02-7.06 (m, 1H), 6.30-6.35 (m, 2H), 6.25-

6.28 (m, 1H), 4.00-4.05 (m, 2H), 3.96 (t, 2H), 3.59-3.65 (m, 2H), 3.21 (t, 2H), 2.21 (s, 3H), 2.00-2.11 (m, 5H).

EXAMPLE 467

7-(2-morpholin-4-ylphenyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.04 (br. s, 1H), 10.02 (s, 1H), 7.70 (d, 1H), 7.33-7.45 (m, 3H), 7.12-7.22 (m, 3H), 6.97 (t, 1H), 6.61 (t, 2H), 3.96 (t, 2H), 3.20-3.30 (m, 6H), 2.73-2.82 (m, 4H), 2.69 (t, 2H), 2.62 (t, 2H), 2.04-2.16 (m, 2H), 1.63-1.80 (m, 4H).

EXAMPLE 468

3-(3-(3-methyl-5-(3-morpholin-4-ylpropoxy)phenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, $CDCl_3$) δ 8.41 (s, 1H), 7.71 (s, 1H), 7.27-7.40 (m, 4H), 7.16-7.24 (m, 2H), 6.34 (s, 1H), 6.21-6.29 (m, 2H), 3.99-4.09 (m, 6H), 3.93 (t, 2H), 3.65-3.74 (m, 2H), 3.23-3.39 (m, 4H), 2.85-2.98 (m, 2H), 2.11-2.30 (m, 10H).

EXAMPLE 469

3-(3-(3-(3-cyclohexylpropoxy)-5-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

EXAMPLE 469A

ethyl 7-bromo-3-(3-(3-hydroxy-5-methylphenoxy)propyl)-1H-indole-2-carboxylate

A suspension of ethyl 7-bromo-3-(3-hydroxypropyl)-1H-indole-2-carboxylate (EXAMPLE 1C) (0.9 g), 5-methylbenzene-1,3-diol (1.028 g), triphenylphosphine (0.868 g), dibenzylazodicarboxylate (0.762 g) and tetrahydrofuran (40 ml) was stirred at room temperature for 19 hours. After removal of the solvent, the crude product was purified by flash chromatography silica gel, (Analogix, SF65-200g) eluting with 0-10% ethyl acetate in hexane.

EXAMPLE 469B

ethyl 7-bromo-3-(3-(3-hydroxy-5-methylphenoxy)propyl)-1H-indole-2-carboxylate

A suspension of EXAMPLE 469A (0.067 g), 3-cyclohexylpropan-1-ol (0.22 g), triphenylphosphine (0.081 g), dibenzylazodicarboxylate (0.071 g) in tetrahydrofuran (3 ml) was stirred at room temperature for 2 hours. The sample was directly purified by flash chromatography, silica gel, (Analogix, SF25-40g) eluting with 0 to 20% ethyl acetate in hexane.

EXAMPLE 469C

3-(3-(3-(3-cyclohexylpropoxy)-5-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

The title compound was prepared according to the procedure for EXAMPLE 164G, substituting EXAMPLE 164F with EXAMPLE 469B. ^{1}H NMR (500 MHz, $CDCl_3$) δ 8.41 (s, 1H), 7.68-7.76 (m, 1H), 7.28-7.39 (m, 4H), 7.16-7.23 (m, 2H), 6.24-6.35 (m, 3H), 4.00 (t, 2H), 3.88 (t, 2H), 3.33 (t, 2H), 2.15-2.28 (m, 8H), 1.61-1.79 (m, 7H), 1.09-1.35 (m, 6H), 0.83-0.96 (m, 2H).

EXAMPLE 470

3-(3-(3-(3-(2-carboxy-1H-indol-3-yl)propoxy)-5-methylphenoxy)propyl)-7-(2-morpholin-4-ylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 11.42 (s, 1H), 10.04 (s, 1H), 7.71 (d, 1H), 7.63 (d, 1H), 7.31-7.44 (m, 4H), 7.12-7.23 (m, 4H), 6.96-7.01 (m, 1H), 6.15-6.32 (m, 3H), 3.86-3.94 (m, 4H), 3.22-3.28 (m, 5H), 3.14-3.20 (m, 4H), 2.71-2.81 (m, 4H), 2.18 (s, 3H), 1.97-2.10 (m, 4H).

EXAMPLE 471

7-bromo-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 8.66-8.77 (m, 2H), 8.12 (d, 1H), 7.88 (t, 2H), 7.36-7.56 (m, 7H), 7.01 (t, 1H), 6.89 (d, 1H), 6.34 (s, 2H), 4.21 (t, 2H), 3.38 (t, 2H), 2.20-2.29 (m, 2H).

EXAMPLE 473

7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 13.47 (br. s, 1H), 8.46 (d, 2H), 8.25-8.31 (m, 1H), 7.83-7.91 (m, 2H), 7.50-7.58 (m, 2H), 7.47 (d, 1H), 7.39 (t, 1H), 7.29-7.34 (m, 1H), 7.15 (t, 1H), 7.02-7.10 (m, 2H), 6.88 (d, 1H), 6.69-6.81 (m, 4H), 6.20 (d, 1H), 5.25 (d, 1H), 4.22 (t, 2H), 3.38-3.53 (m, 2H), 3.19-3.26 (m, 2H), 2.88-3.05 (m, 2H), 2.60-2.76 (m, 4H), 2.22-2.33 (m, 2H).

EXAMPLE 474

7-(1,1'-bi(cyclohexan)-2-en-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 13.04 (br. s, 1H), 10.39 (s, 1H), 8.22-8.28 (m, 1H), 7.84-7.89 (m, 1H), 7.48-7.57 (m, 3H), 7.44 (d, 1H), 7.37 (t, 1H), 6.92-7.02 (m, 2H), 6.87 (d, 1H), 5.90-5.97 (m, 1H), 4.16 (t, 2H), 2.77-2.86 (m, 1H), 2.02-2.26 (m, 4H), 1.58-1.82 (m, 4H), 1.38-1.57 (m, 4H), 1.12-1.37 (m, 3H), 0.80-1.11 (m, 5H), 0.58-0.71 (m, 1H).

EXAMPLE 475

3-(3-(2,3-dichlorophenoxy)propyl)-7-(1,2-dimethylprop-1-enyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 12.88 (br. s, 1H), 10.63 (s, 1H), 7.50 (s, 1H), 7.28 (t, 1H), 7.17-7.21 (m, 1H), 7.04-7.08 (m, 1H), 6.97 (t, 1H), 6.88-6.92 (m, 1H), 4.09 (t, 2H), 3.22 (t, 2H), 2.05-2.14 (m, 2H), 1.94 (s, 3H), 1.83 (s, 3H), 1.40 (s, 3H).

EXAMPLE 476

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 13.26 (br. s, 1H), 8.30-8.35 (m, 1H), 8.22-8.27 (m, 1H), 7.81-7.91 (m, 2H), 7.64-7.70 (m, 1H), 7.37-7.58 (m, 4H), 7.08-7.34 (m, 4H), 6.80-6.99 (m, 4H), 6.24-6.33 (m, 1H), 5.52 (d, 1H), 5.22 (d, 1H), 4.25 (t, 2H), 3.35-3.49 (m, 2H), 2.24-2.33 (m, 2H), 1.78 (s, 3H).

EXAMPLE 477

7-(2-methyl-4-(trifluoromethyl)phenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.74 (br. s, 1H), 10.96 (s, 1H), 7.65-7.73 (m, 2H), 7.57-7.62 (m, 1H), 7.42 (d, 1H), 7.13 (t, 1H), 7.06 (d, 1H), 6.54 (d, 2H), 3.97 (t, 2H), 3.23-3.30 (m, 2H), 2.15-2.20 (m, 6H), 2.05-2.14 (m, 8H).

EXAMPLE 478

7-(4-fluoro-2-methylphenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 12.89 (br. s, 1H), 10.69 (s, 1H), 7.66 (d, 1H), 7.13 (d, 5H), 6.54 (d, 2H), 3.97 (t, 2H), 3.25 (t, 2H), 2.14-2.20 (m, 6H), 2.00-2.13 (m, 8H).

EXAMPLE 479

7-(4-methoxy-2-methylphenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 10.30 (s, 1H), 7.60-7.66 (m, 1H), 7.05-7.17 (m, 2H), 6.99-7.03 (m, 1H), 6.89-6.92 (m, 1H), 6.82-6.87 (m, 1H), 6.51-6.57 (m, 2H), 3.97 (t, 2H), 3.81 (s, 3H), 2.15-2.20 (m, 6H), 2.02-2.10 (m, 8H).

EXAMPLE 480

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 8.39-8.44 (m, 1H), 8.21-8.28 (m, 1H), 7.80-7.92 (m, 2H), 7.36-7.65 (m, 5H), 7.23-7.34 (m, 2H), 7.11-7.20 (m, 2H), 7.05 (t, 1H), 6.86-6.99 (m, 4H), 5.45 (d, 1H), 5.22 (d, 1H), 4.25 (t, 2H), 2.23-2.32 (m, 2H), 1.73 (s, 3H).

EXAMPLE 481

6-methyl-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.82 (br. s, 1H), 9.78 (s, 1H), 8.22-8.28 (m, 1H), 7.84-7.90 (m, 1H), 7.49-7.62 (m, 3H), 7.45 (d, 1H), 7.25-7.42 (m, 4H), 7.09 (d, 1H), 6.99 (d, 1H), 6.90 (d, 1H), 4.20 (t, 2H), 2.18-2.28 (m, 2H), 2.02 (s, 3H), 1.92 (s, 3H).

EXAMPLE 482

3-(3-(2,3-dichlorophenoxy)propyl)-7-(2-methylphenyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.96 (br. s, 1H), 8.22-8.27 (m, 1H), 7.76-7.84 (m, 1H), 7.50-7.57 (m, 1H), 7.30 (t, 1H), 7.05-7.26 (m, 6H), 6.99 (t, 1H), 6.91-6.95 (m, 1H), 6.83-6.88 (m, 1H), 6.06-6.12 (m, 1H), 5.46 (d, 1H), 5.19 (d, 1H), 4.16 (t, 2H), 2.09-2.21 (m, 2H), 1.76 (s, 3H).

EXAMPLE 483

7-(2-methylphenyl)-1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 8.23-8.30 (m, 1H), 7.84-7.90 (m, 1H), 7.76 (d, 1H), 7.49-7.59 (m, 2H), 7.31-7.49 (m, 4H), 7.22-7.30 (m, 1H), 7.02-7.15 (m, 2H), 6.88-6.95 (m, 2H), 5.00-5.13 (m, 1H), 4.66-4.81 (m, 1H), 4.23 (t, 2H), 3.07-3.30 (m, 2H), 2.65-2.86 (m, 2H), 2.16-2.29 (m, 2H), 1.95 (s, 3H).

EXAMPLE 484

3-(3-(3,5-dichlorophenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 10.33 (s, 1H), 7.64 (d, 1H), 7.17-7.33 (m, 4H), 6.99-7.13 (m, 3H), 6.93-6.96 (m, 2H), 4.02 (t, 2H), 3.20 (t, 2H), 2.00-2.10 (m, 5H).

EXAMPLE 485

1-methyl-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 8.22-8.25 (m, 1H), 7.85-7.89 (m, 1H), 7.74 (d, 1H), 7.49-7.58 (m, 2H), 7.46 (d, 1H), 7.22-7.43 (m, 5H), 7.05-7.10 (m, 1H), 6.98 (d, 1H), 6.91 (d, 1H), 4.21 (t, 2H), 3.32 (s, 3H), 2.19-2.26 (m, 2H), 1.99 (s, 3H).

EXAMPLE 486

1-methyl-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 8.22-8.29 (m, 1H), 7.84-7.89 (m, 1H), 7.71 (d, 1H), 7.50-7.57 (m, 2H), 7.45 (d, 1H), 7.34-7.42 (m, 3H), 7.08-7.16 (m, 2H), 7.03 (t, 2H), 6.86 (d, 1H), 4.17 (t, 2H), 3.34-3.40 (m, 5H), 3.09-3.16 (m, 2H), 2.78-2.88 (m, 2H), 2.52-2.63 (m, 4H), 2.18-2.27 (m, 2H).

EXAMPLE 487

1-(3-(aminomethyl)benzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.15 (br. s, 1H), 8.21-8.29 (m, 1H), 8.01 (s, 2H), 7.76-7.92 (m, 2H), 7.34-7.59 (m, 3H), 7.23-7.32 (m, 1H), 7.02-7.23 (m, 4H), 6.86-7.01 (m, 2H), 6.45 (s, 1H), 6.10 (d, 1H), 5.42 (d, 1H), 5.19 (d, 1H), 4.24 (t, 2H), 3.83 (dd, 2H), 3.40 (t, 2H), 2.20-2.33 (m, 2H).

EXAMPLE 488

1-(3-(aminomethyl)benzyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 8.26-8.31 (m, 1H), 7.91-8.09 (m, 2H), 7.85-7.90 (m, 1H), 7.76-7.83 (m, 1H), 7.49-7.59 (m, 2H), 7.46 (d, 1H), 7.38 (t, 2H), 6.93-7.19 (m, 7H), 6.84 (d, 1H), 6.50 (s, 1H), 6.13 (d, 1H), 5.81 (d, 1H), 4.97 (d, 1H), 4.17 (t, 2H), 3.76-3.82 (m, 2H), 3.30-3.38 (m, 2H), 3.18-3.25 (m, 2H), 2.80-2.99 (m, 2H), 2.53-2.66 (m, 4H), 2.16-2.29 (m, 2H).

EXAMPLE 489

7-((E)-2-(2-((E)-2-cyclohexylvinyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 11.66 (s, 1H), 8.18-8.23 (m, 1H), 7.92-8.03 (m, 2H), 7.81-7.88 (m, 1H), 7.68 (d, 1H), 7.32-7.63 (m, 7H), 7.17-7.32 (m, 2H), 7.01 (t, 1H), 6.80-6.90 (m, 2H), 6.02-6.12 (m, 1H), 4.16 (t, 2H), 2.15-2.29 (m, 2H), 1.57-1.85 (m, 5H), 1.11-1.37 (m, 6H).

EXAMPLE 490

7-(2-(3-carboxyphenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 11.42 (s, 1H), 8.20-8.25 (m, 1H), 7.95 (s, 1H), 7.82-7.88 (m, 1H), 7.77 (d, 1H), 7.58 (d, 1H), 7.47-7.55 (m, 3H), 7.32-7.46 (m, 3H), 7.06 (d, 1H), 6.84-6.92 (m, 1H), 4.16 (t, 2H), 2.93-3.01 (m, 2H), 2.14-2.25 (m, 2H).

EXAMPLE 491

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(2-pyridin-3-ylphenyl)vinyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 11.74 (s, 1H), 8.72-8.76 (m, 2H), 8.04-8.25 (m, 4H), 7.82-7.88 (m, 1H), 7.71-7.78 (m, 1H), 7.26-7.62 (m, 9H), 7.06 (d, 1H), 6.93 (t, 1H), 6.86 (d, 1H), 4.16 (t, 2H), 3.34 (t, 2H), 2.16-2.25 (m, 2H).

EXAMPLE 492

3-(3-(1-naphthyloxy)propyl)-7-(2-(3-(((phenylsulfonyl)amino)carbonyl)phenyl)ethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.52 (br. s, 1H), 11.43 (s, 1H), 8.21-8.26 (m, 1H), 7.99-8.06 (m, 2H), 7.90 (s, 1H), 7.84-7.88 (m, 1H), 7.62-7.77 (m, 4H), 7.48-7.60 (m, 4H), 7.34-7.47 (m, 3H), 7.06 (d, 1H), 6.85-6.93 (m, 2H), 4.16 (t, 2H), 3.19-3.25 (m, 2H), 2.92-2.98 (m, 2H), 2.16-2.24 (m, 2H).

EXAMPLE 493

7-(2-(3-((4-methylpiperidin-1-yl)carbonyl)phenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.95 (br. s, 1H), 11.37 (s, 1H), 7.83-7.89 (m, 1H), 7.42-7.57 (m, 4H), 7.30-7.42 (m, 3H), 7.27 (s, 1H), 7.14 (d, 1H), 7.03 (d, 1H), 6.85-6.91 (m, 2H), 4.17 (t, 2H), 3.32 (t, 2H), 3.22-3.28 (m, 2H), 2.94-3.00 (m, 2H), 2.63-2.92 (m, 2H), 2.14-2.25 (m, 2H), 1.39-1.75 (m, 3H), 0.93-1.13 (m, 2H), 0.90 (d, 3H).

EXAMPLE 494

3-(3-(1-naphthyloxy)propyl)-7-(2-(3-(((2-pyrrolidin-1-ylethyl)amino)carbonyl)phenyl)ethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.96 (br. s, 1H), 11.42 (s, 1H), 9.36 (s, 1H), 8.60-8.66 (m, 1H), 8.20-8.26 (m, 1H), 7.81-7.91 (m, 2H), 7.67-7.72 (m, 1H), 7.48-7.59 (m, 4H), 7.33-7.48 (m, 3H), 7.06 (d, 1H), 6.85-6.93 (m, 2H), 4.17 (t, 2H), 3.56-3.69 (m, 4H), 2.95-3.12 (m, 4H), 2.15-2.25 (m, 2H), 1.97-2.07 (m, 2H), 1.80-1.92 (m, 2H).

EXAMPLE 495

7-(2-(3-(((2-morpholin-4-ylethyl)amino)carbonyl)phenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.98 (br. s, 1H), 11.42 (s, 1H), 9.55 (s, 1H), 8.62-8.69 (m, 1H), 8.20-8.25 (m, 1H), 7.81-7.90 (m, 2H), 7.69 (d, 1H), 7.47-7.59 (m, 4H), 7.33-7.47 (m, 3H), 7.06 (d, 1H), 6.85-6.94 (m, 2H), 4.17 (t, 2H), 3.97-4.05 (m, 2H), 3.50-3.71 (m, 6H), 3.06-3.21 (m, 4H), 2.95-3.04 (m, 2H), 2.16-2.25 (m, 2H).

EXAMPLE 496

7-(2-(3-(((2-(dimethylamino)ethyl)amino)carbonyl)phenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.94 (br. s, 1H), 11.41 (s, 1H), 9.26 (s, 1H), 8.58-8.64 (m, 1H), 8.19-8.27 (m, 1H), 7.81-7.88 (m, 2H), 7.68 (d, 1H), 7.47-7.58 (m, 4H), 7.33-

7.47 (m, 3H), 7.06 (d, 1H), 6.84-6.94 (m, 2H), 4.17 (t, 2H), 3.33 (t, 2H), 3.21-3.30 (m, 4H), 2.95-3.04 (m, 2H), 2.85 (s, 6H), 2.16-2.26 (m, 2H).

EXAMPLE 497

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-(((phenylsulfonyl)amino)carbonyl)phenyl)vinyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.10 (br. s, 1H), 12.59 (br. s, 1H), 11.71 (s, 1H), 8.13-8.27 (m, 3H), 7.95-8.07 (m, 3H), 7.82-7.89 (m, 1H), 7.60-7.77 (m, 6H), 7.47-7.57 (m, 3H), 7.44 (d, 1H), 7.29-7.41 (m, 2H), 7.02 (t, 1H), 6.88 (d, 1H), 4.17 (t, 2H), 3.35 (t, 2H), 2.17-2.27 (m, 2H).

EXAMPLE 498

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(2-pyridin-4-ylphenyl)vinyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.13 (br. s, 1H), 11.75 (s, 1H), 8.81-8.88 (m, 2H), 8.15-8.27 (m, 3H), 7.83-7.89 (m, 1H), 7.76-7.80 (m, 2H), 7.56-7.64 (m, 2H), 7.42-7.55 (m, 5H), 7.32-7.40 (m, 2H), 7.10 (d, 1H), 6.94 (t, 1H), 6.86 (d, 1H), 4.16 (t, 2H), 3.34 (t, 2H), 2.16-2.26 (m, 2H).

EXAMPLE 499

7-((E)-2-(3-chlorophenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.11 (br. s, 1H), 11.68 (s, 1H), 8.12-8.27 (m, 2H), 7.83-7.89 (m, 2H), 7.60-7.72 (m, 3H), 7.48-7.57 (m, 2H), 7.26-7.47 (m, 5H), 6.99-7.08 (m, 1H), 6.88 (d, 1H), 4.18 (t, 2H), 3.35 (t, 2H), 2.17-2.28 (m, 2H).

EXAMPLE 500

7-((E)-2-(3-((cyclohexylamino)carbonyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.08 (br. s, 1H), 11.73 (s, 1H), 8.13-8.26 (m, 3H), 8.05-8.09 (m, 1H), 7.92-7.97 (m, 1H), 7.83-7.89 (m, 1H), 7.69 (d, 2H), 7.62 (d, 1H), 7.48 (d, 4H), 7.36 (d, 2H), 7.03 (t, 1H), 6.88 (d, 1H), 4.18 (t, 2H), 3.73-3.85 (m, 1H), 2.16-2.28 (m, 2H), 1.81-1.91 (m, 2H), 1.71-1.79 (m, 2H), 1.26-1.38 (m, 6H).

EXAMPLE 501

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-(((2-phenoxyethyl)amino)carbonyl)phenyl)vinyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.08 (br. s, 1H), 8.69-8.74 (m, 1H), 8.10-8.27 (m, 3H), 7.95 (d, 1H), 7.82-7.89 (m, 1H), 7.67-7.76 (m, 2H), 7.62 (d, 1H), 7.43-7.56 (m, 4H), 7.22-7.41 (m, 4H), 6.85-7.07 (m, 5H), 4.11-4.21 (m, 4H), 3.63-3.71 (m, 2H), 2.17-2.27 (m, 2H).

EXAMPLE 502

7-((E)-2-(3-(((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)carbonyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.12 (br. s, 1H), 11.70 (s, 1H), 8.52 (t, 1H), 8.13-8.27 (m, 2H), 8.10 (s, 1H), 7.98 (d, 1H), 7.83-7.90 (m, 1H), 7.58-7.83 (m, 5H), 7.42-7.57 (m, 4H), 7.28-7.41 (m, 2H), 7.03 (t, 1H), 6.88 (d, 1H), 4.17 (t, 2H), 3.44-3.50 (m, 2H), 3.35 (t, 2H), 2.90-3.02 (m, 2H), 2.15-2.28 (m, 2H).

EXAMPLE 503

7-((E)-2-(3-((4-benzylpiperidin-1-yl)carbonyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.10 (br. s, 1H), 11.70 (s, 1H), 8.12-8.28 (m, 2H), 7.82-7.90 (m, 1H), 7.59-7.81 (m, 4H), 7.41-7.57 (m, 4H), 7.13-7.40 (m, 8H), 7.03 (t, 1H), 6.88 (d, 1H), 4.41-4.59 (m, 1H), 4.18 (t, 2H), 3.51-3.69 (m, 1H), 3.35 (t, 2H), 2.92-3.10 (m, 1H), 2.67-2.82 (m, 1H), 2.55 (d, 2H), 2.17-2.28 (m, 2H), 1.63-1.90 (m, 3H), 1.08-1.29 (m, 2H).

EXAMPLE 504

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-((4-phenylpiperazin-1-yl)carbonyl)phenyl)vinyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 11.72 (s, 1H), 8.17-8.25 (m, 2H), 7.80-7.90 (m, 3H), 7.71 (d, 1H), 7.62 (d, 1H), 7.42-7.56 (m, 4H), 7.30-7.41 (m, 3H), 7.24 (t, 2H), 7.03 (t, 1H), 6.98 (s, 2H), 6.88 (d, 1H), 6.82 (t, 1H), 4.17 (t, 2H), 3.75-3.86 (m, 2H), 3.50-3.58 (m, 2H), 3.12-3.26 (m, 4H), 2.18-2.26 (m, 2H).

EXAMPLE 505

7-((E)-2-(3-((3-methylpiperidin-1-yl)carbonyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 11.72 (s, 1H), 8.21-8.24 (m, 1H), 8.18 (d, 1H), 7.85-7.88 (m, 1H), 7.74-7.81 (m, 2H), 7.71 (d, 1H), 7.62 (d, 1H), 7.43-7.56 (m, 4H), 7.32-7.40 (m, 2H), 7.24 (d, 1H), 7.03 (t, 1H), 6.88 (d, 1H), 4.17 (t, 2H), 2.19-2.26 (m, 2H), 1.11-1.85 (m, 5H), 0.84 (d, 3H).

EXAMPLE 506

7-(2-(3-(((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)carbonyl)phenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 12.97 (br. s, 1H), 11.45 (s, 1H), 8.47 (t, 1H), 8.21-8.27 (m, 1H), 7.83-7.90 (m, 2H), 7.77 (br. s, 2H), 7.66 (d, 1H), 7.29-7.58 (m, 7H), 7.07 (d, 1H), 6.86-6.94 (m, 2H), 4.17 (t, 2H), 3.59 (t, 6H), 3.55 (t, 2H), 3.41-3.47 (m, 2H), 3.34 (t, 2H), 3.23-3.29 (m, 2H), 2.92-3.03 (m, 4H), 2.16-2.26 (m, 2H).

EXAMPLE 507

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-((E)-2-phenylvinyl)phenyl)vinyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 13.13 (br. s, 1H), 11.69 (s, 1H), 8.21-8.25 (m, 1H), 8.18 (d, 1H), 7.85-7.92 (m, 2H), 7.69-7.75 (m, 2H), 7.61-7.66 (m, 3H), 7.49-7.56 (m, 3H), 7.35-7.47 (m, 6H), 7.27-7.34 (m, 3H), 7.04 (t, 1H), 6.89 (d, 1H), 4.18 (t, 2H), 3.36 (t, 2H), 2.18-2.27 (m, 2H).

EXAMPLE 508

7-((E)-2-(1,1'-biphenyl-3-yl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 11.68 (s, 1H), 8.18-8.27 (m, 2H), 8.04 (s, 1H), 7.85-7.91 (m, 1H), 7.71-7.82 (m, 4H), 7.65 (d, 1H), 7.49-7.61 (m, 6H), 7.34-7.49 (m, 4H), 7.06 (t, 1H), 6.90 (d, 1H), 4.20 (t, 2H), 2.20-2.30 (m, 2H).

EXAMPLE 509

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-((1E)-3-phenylprop-1-enyl)phenyl)vinyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 13.09 (br. s, 1H), 11.64 (s, 1H), 8.00-8.27 (m, 2H), 7.81-7.89 (m, 1H), 7.47-7.76 (m, 6H), 7.09-7.46 (m, 10H), 7.02 (t, 1H), 6.88 (d, 1H), 6.52 (s, 1H), 4.17 (t, 2H), 2.62-2.70 (m, 2H), 2.17-2.27 (m, 2H).

EXAMPLE 510

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(4-((E)-2-phenylvinyl)phenyl)vinyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.09 (s, 1H), 11.71 (s, 1H), 8.20-8.25 (m, 1H), 8.17 (d, 1H), 7.83-7.89 (m, 1H), 7.78 (d, 2H), 7.70 (d, 1H), 7.58-7.67 (m, 5H), 7.22-7.56 (m, 10H), 7.03 (t, 1H), 6.88 (d, 1H), 4.18 (t, 2H), 3.35 (t, 2H), 2.17-2.28 (m, 2H).

EXAMPLE 511

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(4-((1E)-3-phenylprop-1-enyl)phenyl)vinyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.04 (br. s, 1H), 11.68 (s, 1H), 8.19-8.27 (m, 1H), 8.06-8.16 (m, 1H), 7.83-7.89 (m, 1H), 7.64-7.75 (m, 3H), 7.56-7.62 (m, 1H), 7.18-7.55 (m, 12H), 7.01 (t, 1H), 6.87 (d, 1H), 6.41-6.56 (m, 2H), 4.17 (t, 2H), 3.53-3.58 (m, 2H), 2.15-2.28 (m, 2H).

EXAMPLE 512

7-((E)-2-(1,1'-biphenyl-4-yl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) □ 13.07 (br. s, 1H), 11.73 (s, 1H), 8.15-8.26 (m, 2H), 7.82-7.90 (m, 3H), 7.68-7.76 (m, 5H), 7.62 (d, 1H), 7.32-7.56 (m, 8H), 7.03 (t, 1H), 6.88 (d, 1H), 4.18 (t, 2H), 3.36 (t, 2H), 2.18-2.28 (m, 2H).

EXAMPLE 513

7-(2-(1,1'-biphenyl-3-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.95 (br. s, 1H), 11.36 (s, 1H), 8.21-8.26 (m, 1H), 7.83-7.89 (m, 1H), 7.56-7.66 (m, 3H), 7.30-7.56 (m, 11H), 7.10 (d, 1H), 6.84-6.95 (m, 2H), 4.17 (t, 2H), 2.97-3.05 (m, 2H), 2.15-2.26 (m, 2H).

EXAMPLE 514

3-(3-(1-naphthyloxy)propyl)-7-(2-(3-(3-phenylpropyl)phenyl)ethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.91 (br. s, 1H), 11.33 (s, 1H), 8.21-8.26 (m, 1H), 7.83-7.89 (m, 1H), 7.41-7.56 (m, 4H), 7.37 (t, 1H), 6.83-7.32 (m, 12H), 4.16 (t, 2H), 3.19-3.26 (m, 2H), 2.87-2.94 (m, 2H), 2.52-2.63 (m, 4H), 2.14-2.26 (m, 2H), 1.79-1.91 (m, 2H).

EXAMPLE 515

7-((E)-2-(2-chlorophenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.07 (br. s, 1H), 11.75 (s, 1H), 8.13-8.24 (m, 3H), 7.82-7.88 (m, 1H), 7.67 (t, 2H), 7.28-7.57 (m, 8H), 7.04 (t, 1H), 6.88 (d, 1H), 4.17 (t, 2H), 3.35 (t, 2H), 2.17-2.28 (m, 2H).

EXAMPLE 516

7-((E)-2-(1,1'-biphenyl-2-yl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.08 (br. s, 1H), 11.73 (s, 1H), 8.06-8.24 (m, 3H), 7.82-7.89 (m, 1H), 7.28-7.62 (m, 13H), 7.21 (d, 1H), 7.10 (d, 1H), 6.92 (t, 1H), 6.86 (d, 1H), 4.16 (t, 2H), 2.14-2.27 (m, 2H).

EXAMPLE 517

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(2-((E)-2-phenylvinyl)phenyl)vinyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.08 (br. s, 1H), 11.76 (s, 1H), 8.21-8.25 (m, 1H), 8.02-8.10 (m, 2H), 7.81-7.89 (m, 2H), 7.68-7.80 (m, 5H), 7.63 (d, 1H), 7.48-7.56 (m, 2H), 7.45 (d, 1H), 7.26-7.42 (m, 6H), 7.14 (d, 1H), 7.04 (t, 1H), 6.88 (d, 1H), 4.17 (t, 2H), 2.18-2.26 (m, 2H).

EXAMPLE 518

3-(3-(1-naphthyloxy)propyl)-7-(2-phenylethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.93 (br. s, 1H), 11.37 (s, 1H), 8.21-8.26 (m, 1H), 7.83-7.89 (m, 1H), 7.48-7.56 (m, 3H), 7.44 (d, 1H), 7.24-7.41 (m, 4H), 7.14-7.21 (m, 1H), 7.06 (d, 1H), 6.85-6.93 (m, 2H), 4.17 (t, 2H), 3.34 (t, 2H), 3.21-3.27 (m, 2H), 2.89-2.97 (m, 2H), 2.16-2.26 (m, 2H).

EXAMPLE 519

7-(2-(2-chlorophenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.95 (br. s, 1H), 11.34 (s, 1H), 8.20-8.25 (m, 1H), 7.84-7.88 (m, 1H), 7.34-7.56 (m, 7H), 7.20-7.32 (m, 2H), 7.02 (d, 1H), 6.85-6.93 (m, 2H), 4.17 (t, 2H), 3.19-3.25 (m, 2H), 2.99-3.07 (m, 2H), 2.16-2.26 (m, 2H).

EXAMPLE 520

7-(2-(1,1'-biphenyl-4-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.93 (br. s, 1H), 11.38 (s, 1H), 8.21-8.26 (m, 1H), 7.84-7.88 (m, 1H), 7.62-7.67 (m, 2H), 7.56-7.61 (m, 2H), 7.31-7.55 (m, 10H), 7.10 (d, 1H), 6.85-6.95 (m, 2H), 4.17 (t, 2H), 2.94-3.01 (m, 2H), 2.16-2.26 (m, 2H).

EXAMPLE 521

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-(2-phenylethyl)phenyl)ethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.93 (br. s, 1H), 11.33 (s, 1H), 8.20-8.26 (m, 1H), 7.84-7.88 (m, 1H), 7.42-7.57 (m, 4H), 7.37 (t, 1H), 7.09-7.30 (m, 9H), 7.04 (d, 1H), 6.85-6.93 (m, 2H), 4.17 (t, 2H), 2.82-2.93 (m, 6H), 2.15-2.25 (m, 2H).

EXAMPLE 522

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-(3-phenylpropyl)phenyl)ethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.92 (br. s, 1H), 11.33 (s, 1H), 8.20-8.25 (m, 1H), 7.84-7.88 (m, 1H), 7.47-7.56 (m, 3H), 7.44 (d, 1H), 7.37 (t, 1H), 7.08-7.31 (m, 9H), 7.05 (d, 1H), 6.84-6.93 (m, 2H), 4.16 (t, 2H), 3.16-3.25 (m, 2H), 2.85-2.93 (m, 2H), 2.53-2.63 (m, 4H), 2.15-2.25 (m, 2H), 1.81-1.92 (m, 2H).

EXAMPLE 523

7-(4-carboxy-2-methylphenyl)-3-(3-((2-cyanoquinolin-8-yl)oxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 10.85 (s, 1H), 8.51 (d, 1H), 8.18 (d, 1H), 8.04 (s, 1H), 7.89 (s, 1H), 7.80 (m, 3H), 7.58 (m, 2H), 7.32 (d, 1H), 7.24 (m, 1H), 7.04 (m, 2H), 4.26 (t, 2H), 2.26 (m, 2H), 2.10 (s, 3H).

EXAMPLE 524

3-(3-((2-acetyl-1-benzofuran-7-yl)oxy)propyl)-7-(4-carboxy-2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.87 (s, 2H), 10.87 (s, 1H), 7.89 (s, 2H), 7.82 (dd, 1H), 7.73 (dd, 1H), 7.34 (m, 2H), 7.24 (t, 1H), 7.07 (m, 3H), 4.24 (t, 2H), 2.58 (s, 2H), 2.19 (m, 2H), 2.09 (s, 3H).

EXAMPLE 525

7-(4-carboxy-2-methylphenyl)-3-(3-((2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)oxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.86 (s, 2H), 10.85 (s, 1H), 7.89 (m, 1H), 7.82 (m, 1H), 7.71 (m, 1H), 7.32 (d, 1H), 7.06 (m, 2H), 6.71 (m, 3H), 3.98 (t, 2H), 3.20 (t, 2H), 3.00 (s, 2H), 2.07 (m, 5H), 1.43 (s, 6H).

EXAMPLE 526

7-(4-carboxy-2-methylphenyl)-3-(3-(2,3-difluorophenoxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.86 (m, 2H), 10.85 (s, 1H), 7.89 (m, 1H), 7.82 (m, 1H), 7.69 (m, 1H), 7.32 (d, 1H), 7.09 (m, 3H), 6.96 (m, 2H), 4.12 (t, 2H), 3.24 (m, 5H).

EXAMPLE 527

7-(4-carboxy-2-methylphenyl)-3-(3-(3-methyl-2-nitrophenoxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.88 (m, 2H), 10.88 (s, 1H), 7.89 (m, 1H), 7.82 (m, 1H), 7.63 (m, 1H), 7.40 (t, 1H), 7.32 (d, 1H), 7.08 (m, 3H), 6.99 (m, 1H), 4.13 (t, 2H), 3.16 (t, 2H), 2.26 (m, 3H), 2.10 (m, 3H), 2.03 (m, 2H).

EXAMPLE 528

7-(4-carboxy-2-methylphenyl)-3-(3-(2-methyl-3-nitrophenoxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.86 (m, 2H), 10.86 (m, 1H), 7.89 (m, 1H), 7.82 (m, 1H), 7.69 (m, 1H), 7.45 (m, 3H), 7.31 (d, 1H), 7.07 (m, 2H), 4.17 (t, 2H), 3.27 (t, 2H), 2.15 (m, 2H), 2.09 (s, 3H).

EXAMPLE 529

7-(4-carboxy-2-methylphenyl)-3-(3-(2-chloro-3-(trifluoromethyl)phenoxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.86 (m, 2H), 10.86 (m, 1H), 7.90 (m, 1H), 7.82 (m, 1H), 7.69 (m, 1H), 7.34 (m, 4H), 7.10 (m, 2H), 4.12 (t, 2H), 2.29 (m, 3H), 2.14 (m, 2H), 2.10 (m, 3H).

EXAMPLE 530

7-(4-carboxy-2-methylphenyl)-3-(3-(2-fluoro-3-(trifluoromethyl)phenoxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.87 (m, 1H), 7.89 (m, 1H), 7.89 (m, 1H), 7.82 (m, 1H), 7.82 (m, 1H), 7.68 (m, 1H), 7.46 (m, 1H), 7.29 (m, 3H), 7.08 (m, 2H), 4.15 (t, 2H), 3.25 (t, 2H), 2.14 (m, 2H), 2.09 (m, 3H)

EXAMPLE 531

7-(2-chlorophenyl)-3-(3-(ethyl(1-naphthyl)amino)propyl)-1H-indole-2-carboxylic acid

EXAMPLE 531A

ethyl 7-bromo-3-(3-oxopropyl)-1H-indole-2-carboxylate

To a solution of ethyl 7-bromo-3-(4-hydroxypropyl)-1H-indole-2-carboxylate (EXAMPLE 1C) (3.4 g) and triethylamine (8.5 ml) in dichloromethane (100 ml) and dimethylsulfoxide (10 mL), cooled to 0 °C, was added pyridine-2-sulfonate (9.54 g). The mixture was stirred for 3 hours and diluted with ethyl acetate (300 ml) and washed with 5% HCl, water, and brine. After drying the combined organic layers over Na_2SO_4, the filtrate was concentrated and the crude product was purified by flash chromatography on a silica gel, eluting with 10% ethyl acetate in hexane.

EXAMPLE 531B

ethyl 7-bromo-3-(3-(ethyl(naphthalen-1-yl)amino)propyl)-1H-indole-2-carboxylate

To a solution of EXAMPLE 531A (130 mg) and N-ethylnaphthalen-1-amine (82 mg) in dichloromethane (3 mL) was added sodium triacetoxyborohydride (2.35 g). The mixture was stirred at room temperature overnight. After this time the mixture was diluted with ethyl acetate (1500 mL) and washed with1N NaOH, water, brine, and dried over Na_2SO_4. After

filtration and concentration of the filtrate, the residue was purified by flash chromatography using silica gel and eluenting with 5% ethyl acetate in hexane.

EXAMPLE 531C

7-(2-chlorophenyl)-3-(3-(ethyl(1-naphthyl)amino)propyl)-1H-indole-2-carboxylic acid

To a mixture of EXAMPLE 531B (192 mg) and 2-chlorophenylboronic acid (76 mg) in tetrahydrofuran (6 ml) was added tris(dibenzylideneacetone)dipalladium(0) (19 mg), tri-t-butyl-phosphonium tetrafluoroborate (12 mg) and cesium fluoride (200 mg). The mixture was purged with argon and stirred at room temperature for 24 hours. The mixture was diluted with ethyl acetate (200 mL) and washed with water, and brine and dried over Na_2SO_4. Concentration of the mixture and column purification of the crude material (5% ethyl acetate in hexane) provided the title compound. A portion of this material (50 mg) was dissolved in 1:1 tetrahydrofuran/methanol with a few drops of water and hydrolyzed with LiOH. Subsequent purification via RP HPLC afforded the title compound. ^{1}H NMR (300 MHz, DMSO-d_6) □ 10.80 (m, 1H), 8.27 (m, 1H), 7.90 (m, 1H), 7.55 (m, 1H), 7.53 (m, 1H), 7.42 (m, 3H), 7.34 (m, 3H), 7.21 (m, 2H), 7.03 (m, 1H), 6.98 (m, 2H), 3.21 (m, 4H), 3.08 (t, 2H), 1.79 (m, 2H), 0.96 (t, 3H).

EXAMPLE 532

7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-3-(4-(5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)butyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 11.11 (m, 1H), 8.29 (m, 1H), 8.21 (m, 1H), 7.75 (m, 1H), 7.53 (m, 2H), 7.27 (m, 1H), 7.09 (m, 2H), 6.96 (m, 1H), 6.70 (m, 1H), 3.74 (m, 6 H), 3.49 (t, 2H), 3.16 (t, 4H), 2.55 (t, 2H), 2.07 (m, 3H).

EXAMPLE 533

7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-3-(4-(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)butyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 11.09 (m, 1H), 8.29 (m, 1H), 8.20 (dd, 2H), 7.68 (dd, 1H), 7.52 (dd, 1H), 7.08 (m, 4H), 6.83 (m, 2H), 4.36 (m, 6 H), 3.13 (m, 4H), 2.76 (m, 3H), 1.59 (m, 8H).

EXAMPLE 534

3-(4-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 11.10 (m, 1H), 8.29 (m, 1H), 8.21 (m, 1H), 7.74 (m, 1H), 7.54 (m, 1H), 7.10 (m, 2H), 6.89 (m, 2H), 6.64 (m, 1H), 6.49 (m, 1H), 3.52 (m, 2H), 3.30 (m, 8H), 3.14 (m, 2H), 1.68 (m, 4H).

EXAMPLE 535

3-(4-(3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 10.41 (m, 1H), 7.68 (m, 1H), 7.28 (m, 4H), 7.08 (m, 2H), 6.88 (m, 2H), 6.46 (m, 2H), 3.18 (m, 6H), 2.64 (m, 2H), 2.05 (m, 3H), 1.68 (m, 6H).

EXAMPLE 536

3-(4-(2-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 10.38 (s, 1H), 7.69 (m, 1H), 7.29 (m, 4H), 7.09 (m, 2H), 6.90 (m, 2H), 6.44 (m, 2H), 3.38 (m, 3H), 3.14 (m, 3H), 2.69 (m, 2H), 2.05 (m, 3H), 1.65 (m, 6H), 1.02 (d, 3H).

EXAMPLE 537

3-(4-(6-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 10.38 (s, 1H), 7.68 (m, 1H), 7.28 (m, 5 H), 7.10 (m, 2H), 6.72 (m, 2H), 6.45 (m, 1H), 3.15 (m, 7 H), 2.61 (m, 2H), 2.11 (s, 3H), 2.05 (s, 3H), 1.69 (m, 5H).

EXAMPLE 538

3-(4-(8-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 10.41 (m, 1H), 7.70 (m, 1H), 7.24 (m, 8H), 7.03 (m, 2H), 3.13 (m, 4H), 2.78 (m, 4H), 2.25 (m, 4H), 2.03 (s, 3H), 1.75 (m, 5H).

EXAMPLE 539

3-(4-(2-methyl-2,3-dihydro-1H-indol-1-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 10.37 (m, 1H), 7.68 (m, 1H), 7.32 (m, 2H), 7.24 (m, 2H), 7.15 (m, 1H), 7.05 (m, 1H), 6.93 (m, 2H), 6.49 (m, 1H), 6.32 (m, 1H), 3.08 (m, 6 H), 2.06 (s, 3H), 1.63 (m, 4H), 1.18 (d, 3H).

EXAMPLE 540

7-(2-methylphenyl)-3-(4-(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)butyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 10.35 (m, 1H), 7.62 (m, 1H), 7.27 (m, 4H), 7.07 (m, 4H), 6.83 (m, 2H), 3.07 (m, 5H), 2.77 (m, 4H), 2.08 (s, 3H), 1.63 (m, 8H).

EXAMPLE 541

3-(4-(3-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 10.36 (m, 1H), 7.67 (m, 1H), 7.27 (m, 4H), 7.09 (m, 2H), 6.86 (m, 2H), 6.47 (m, 2H), 3.22 (m, 6 H), 2.75 (m, 1H), 2.31 (m, 2H), 2.06 (m, 3H), 1.91 (m, 1H), 1.65 (m, 4H), 0.96 (d, 3H).

EXAMPLE 542

3-(4-(3-(hydroxymethyl)-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 10.39 (m, 1H), 7.68 (m, 1H), 7.28 (m, 4H), 7.09 (m, 2H), 6.89 (m, 2H), 6.44 (m, 2H), 3.25 (m, 8 H), 2.93 (m, 1H), 2.67 (m, 1H), 2.36 (m, 1H), 2.06 (s, 3H), 1.92 (m, 1H), 1.66 (m, 4H).

EXAMPLE 543

3-(4-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 10.40 (m, 1H), 7.68 (m, 1H), 7.29 (m, 4H), 7.09 (m, 2H), 6.88 (m, 2H), 6.55 (m, 2H), 3.54 (m, 2H), 3.29 (m, 3H), 3.13 (m, 2H), 2.98 (m, 2H), 2.05 (m, 3H), 1.67 (m, 4H).

EXAMPLE 544

4-methoxy-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 10.23 (m, 1H), 8.23 (m, 1H), 7.86 (m, 1H), 7.47 (m, 4H), 7.23 (m, 4H), 6.94 (m, 2H), 6.59 (m, 2H), 4.23 (t, 2H), 3.87 (s, 3H), 3.49 (m, 2H), 2.24 (m, 2H), 2.06 (m, 3H).

EXAMPLE 545

3-(3-(((1R,4S)-8-hydroxy-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 10.45 (m, 1H), 8.57 (m, 1H), 7.65 (m, 1H), 7.27 (m, 4H), 7.07 (m, 2H), 6.43 (m, 2H), 3.90 (m, 2H), 3.48 (m, 2H), 3.22 (m, 2H), 2.06 (s, 3H), 1.79 (m, 2H), 1.28 (m, 5 H).

EXAMPLE 546

7-(2-methylphenyl)-3-(3-((1R,4S)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yloxy)propyl)-1H-indole-2-carboxylic acid

EXAMPLE 546A

To a solution of 3',6'-Dihydroxybenzonorbomane (3.52 g) and imidazole (1.36 g) in N,N-dimethylformamide (150 ml) was added a solution of t-Butylchlorodimethylsilane (3.01 g) in N,N-dimethylformamide (30 ml) dropwise. After the addition, the mixture was stirred overnight at room temperature. After concentration of the solvent under vacuum, the residue was dissolved in ethyl acetate (300 ml) and washed with 5% HCl, water, and brine and dried over Na_2SO_4. After evaporation of the solvent, the residue was loaded on a silica gel column and eluted with 20% ethyl acetate in hexane to give the product.

EXAMPLE 546B

To a cooled (0 ^oC) solution of ethyl 7-bromo-3-(3-hydroxypropyl)-1H-indole-2-carboxylate (326 mg) and EXAMPLE 546A (290 mg) and triphenylphosphine (315 mg) in tetrahydrofuran (10 ml) was added di-tert-butyl azodicarboxylate (276 mg). The mixture was stirred at 0 ^oC for 1 hour and then stirred at room temperature for 14 hours. After this time, the mixture was diluted with ethyl acetate (200 ml) and washed with water, brine and dried over Na_2SO_4. Concentration of the solvent and column purification (10% ethyl acetate in hexane) gave the product.

EXAMPLE 546C

To a mixture of the EXAMPLE 1C (310 mg) and 2-toluneboronic acid (84 mg) in dimethoxyethane (20 ml) and ethanol (10 ml) was added tetrakis(triphenylphosphine)palladium(0) (30 mg), and cesium fluoride (236 mg). The mixture was stirred under nitrogen at reflux for 4 hours. After this time the solvent was concentrated under vacuum and the residue was partitioned between ethyl acetate (300 mL) and water (100 ml). The organic phase was washed with water, brine and dried over Na_2SO_4. Evaporation of solvent and column purification (5% ethyl acetate in hexane) afforded the product.

EXAMPLE 546D

ethyl 7-(2-methylphenyl)-3-(3-((8-(((trifluoromethyl)sulfonyl)oxy)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl)oxy)propyl)-1*H*-indole-2-carboxylate

To a mixture of EXAMPLE 546C (85 mg) in pyridine (2 ml) at 0°C was added triflic anhydride (120 mg). The mixture was stirred at room temperature overnight. The mixture was partitioned between ethyl ether (300 mL) and 5% aqueous HCl (50 ml). The organic phase was washed with water and brine and dried over Na_2SO_4. After filtration and concentration of the filtrate the crude product was used in the next step without further purification.

EXAMPLE 546E

ethyl 7-(2-methylphenyl)-3-(3-(1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yloxy)propyl)-1*H*-indole-2-carboxylate

To a solution of EXAMPLE 546D (80 mg) in tetrahydrofuran and methanol (40 ml, 1:1) was added 10% palladium hydroxide (40 mg). The mixture was shaken under 30 psi of hydrogen for 4 hours. The catalyst was filtered off, the filtrate was concentrated and the residue was hydrolyzed with LiOH/tetrahydrofuran/methanol/H_2O. The product was purified by reverse phase HPLC.

EXAMPLE 546F

7-(2-methylphenyl)-3-(3-((1R,4S)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yloxy)propyl)-1H-indole-2-carboxylic acid

The title compound was prepared according to the procedure for EXAMPLE 164G, substituting EXAMPLE 546E for EXAMPLE 164F. ^{1}H NMR (300 MHz, DMSO-d_6) 10.45 (m, 1H), 7.65 (m, 1H), 7.28 (m, 4H), 7.02 (m, 3H), 6.78 (m, 1H), 6.63 (m, 1H), 4.00 (m, 2H), 2.07 (m, 5H), 1.87 (m, 2H), 1.30 (m, 7H).

EXAMPLE 547

3-(3-((4-methoxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 10.47 (m, 1H), 8.22 (m, 1H), 8.11 (m, 1H), 7.69 (m, 1H), 7.54 (m, 2H), 7.26 (m, 4H), 7.05 (m, 2H), 6.82 (m, 2H), 4.14 (m, 2H), 3.91 (s, 3H), 3.36 (m, 2H), 2.22 (m, 2H), 2.05 (s, 3H).

EXAMPLE 548

7-(2-methylphenyl)-3-(3-((2-nitro-1-naphthyl)oxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.92 (m, 1H), 10.51 (m, 1H), 8.30 (m, 1H), 8.08 (m, 1H), 7.90 (m, 2H), 7.74 (m, 3H), 7.19 (m, 4H), 4.27 (m, 2H), 2.23 (m, 2H), 2.07 (s, 3H).

EXAMPLE 549

3-(3-((3-hydroxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.92 (m, 1H), 10.50 (m, 1H), 9.65 (m, 1H), 8.08 (m, 1H), 7.64 (m, 2H), 7.30 (m, 4H), 7.05 (m, 2H), 6.68 (m, 1H), 6.48 (m, 1H), 4.13 (m, 2H), 2.23 (m, 2H), 2.05 (s, 3H).

EXAMPLE 550

7-(3,5-dimethylisoxazol-4-yl)-3-(3-(2,3,6,7-tetrahydro-1H,5H-pyrido(3,2,1-ij)quinolin-8-yloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 11.25 (m, 1H), 7.67 (m, 1H), 7.11 (m, 2H), 6.62 (d, 1H), 6.08 (d, 1H), 3.22 (m, 2H), 3.04 (m, 4H), 2.62 (m, 4H), 2.22 (s, 3H), 2.05 (s, 3H), 2.04 (m, 4H), 1.86 (m, 4H).

EXAMPLE 551

7-(2-methylphenyl)-3-(3-(2,3,6,7-tetrahydro-1H,5H-pyrido(3,2,1-ij)quinolin-8-yloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 10.46 (m, 1H), 7.65 (m, 1H), 7.27 (m, 4H), 7.08 (m, 2H), 6.63 (d, 1H), 6.10 (d, 1H), 3.93 (m, 2H), 3.23 (m, 2H), 3.05 (m, 4H), 2.64 (m, 4H), 2.05 (m, 5H), 1.86 (m, 4H).

EXAMPLE 552

7-(2-methylphenyl)-3-(3-((2-nitroso-1-naphthyl)oxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 10.64 (m, 1H), 8.13 (m, 2H), 7.72 (m, 5H), 7.27 (m, 4H), 7.04 (m, 2H), 3.71 (m, 2H), 2.03 (s, 3H), 1.40 (m, 2H).

EXAMPLE 553

3-(3-((5-hydroxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.92 (m, 1H), 10.46 (m, 1H), 9.99 (m, 1H), 7.69 (m, 3H), 7.28 (m, 6H), 7.06 (m, 2H), 6.88 (m, 2H), 4.17 (t, 2H), 3.35 (t, 2H), 2.22 (m, 2H), 2.06 (s, 3H).

EXAMPLE 554

7-(2-methylphenyl)-3-(3-(2,3,4-trifluorophenoxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.85 (m, 1H), 10.47 (m, 1H), 7.66 (d, 1H), 7.12 (m, 8H), 4.10 (t, 2H), 3.23 (t, 2H), 2.11 (m, 2H), 2.06 (s, 3H).

Example 555

3-(3-(3-chloro-2-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) □ 12.87 (m, 1H), 10.45 (m, 1H), 7.65 (d, 1H), 7.27 (m, 4H), 7.07 (m, 2H), 6.88 (d, 1H), 4.04 (t, 2H), 3.27 (t, 2H), 2.24 (s, 3H), 2.12 (m, 2H), 2.06 (s, 3H).

EXAMPLE 556

3-(3-((8-hydroxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 10.53 (m, 1H), 9.56 (m, 1H), 7.68 (d, 1H), 7.44 (d, 1H), 7.34 (m, 6H), 7.24 (m, 2H), 7.07 (m, 2H), 6.93 (d, 1H), 6.81 (dd, 1H), 4.33 (t, 2H), 2.24 (m, 2H), 2.06 (s, 3H).

EXAMPLE 557

3-(3-(3-chloro-2-cyanophenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.88 (m, 1H), 10.48 (m, 1H), 7.70 (d, 1H), 7.63 (t, 1H), 7.27 (m, 5H), 7.18 (d, 1H), 7.07 (m, 2H), 4.20 (t, 2H), 3.26 (t, 2H), 2.13 (m, 2H), 2.05 (s, 3H).

EXAMPLE 558

3-(3-(2-bromo-3-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.88 (m, 1H), 10.46 (m, 1H), 7.70 (d, 1H), 7.32 (m, 2H), 7.25 (m, 2H), 7.18 (d, 1H), 7.06 (m, 2H), 6.93 (d, 1H), 6.86 (d, 1H), 4.06 (t, 2H), 3.27 (t, 2H), 2.38 (s, 3H), 2.11 (m, 2H), 2.05 (s, 3H).

EXAMPLE 559

7-(2-methylphenyl)-3-(3-(3-methyl-2-vinylphenoxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.88 (m, 1H), 10.47 (m, 1H), 7.65 (d, 1H), 7.32 (m, 2H), 7.24 (m, 3H), 7.08 (m, 3H), 6.80 (d, 2H), 5.81 (dd, 1H), 5.53 (dd, 1H), 4.02 (t, 2H), 3.25 (m, 2H), 2.32 (m, 3H), 2.11 (m, 2H), 2.06 (s, 3H).

EXAMPLE 560

3-(3-(3-methyl-2-nitrophenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 12.89 (m, 1H), 10.51 (m, 1H), 7.60 (d, 1H), 7.40 (t, 1H), 7.32 (m, 2H), 7.24 (m, 3H), 4.13 (t, 2H), 3.15 (t, 2H), 2.26 (s, 3H), 2.05 (s, 3H), 2.03 (m, 2H).

EXAMPLE 561

3-(3-(2-amino-3-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 10.49 (m, 1H), 7.69 (d, 1H), 7.33 (m, 2H), 7.25 (m, 3H), 7.08 (m, 3H), 6.73 (m, 3H), 4.04 (t, 2H), 3.26 (t, 2H), 2.18 (s, 3H), 2.12 (m, 2H), 2.06 (s, 3H).

EXAMPLE 562

7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) 11.10 (m, 1H), 8.25 (m, 2H), 7.86 (m, 2H), 7.73 (m, 3H), 7.53 (m, 3H), 7.43 (m, 4H), 7.07 (m, 3H), 6.90 (d, 1H), 4.21 (t, 2H), 3.61 (m, 6H), 2.24 (m, 2H).

EXAMPLE 563

3-(3-((6-amino-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

EXAMPLE 563A

ethyl 3-(3-(6-aminonaphthalen-1-yloxy)propyl)-7-bromo-1H-indole-2-carboxylate

To a mixture of ethyl 7-bromo-3-(3-hydroxypropyl)-1H-indole-2-carboxylate (EXAMPLE 1C) (100 mg), 6-aminonaphthalen-1-ol (98 mg) and triphenylphosphine, polymer supported (204 mg 0.613 mmol) in tetrahydrofuran (4 ml) was added di-tert-butyl diazene-1,2-dicarboxylate (141 mg). The reaction mixture was stirred at room temperature for 3 hours. The insoluble material was filtered off and the filtrate was concentrated. The residue was purified by flash chromatography (ethyl acetate in hexanes) to provide the title compound.

EXAMPLE 563B

3-(3-((6-amino-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

A mixture of EXAMPLE 563A (45 mg), o-tolylboronic acid (15.7 mg), K_2CO_3 (1 M, 0.17 ml) and bis(triphenylphosphine)palladium(II) dichloride (7.2 mg, 0.01 mmol) in a mixture of dimethoxyethane (2.2 ml), ethanol (0.6 ml) and water (0.9 ml) was heated at 160 °C in a microwave reactor (CEM Discover) for 10 minutes. The reaction mixture was acidified with a diluted trifluoroacetic acid methanol solution and concentrated. The residue was suspended in a mixture of DMSO and methanol (1:1) and filtered. The filtrate was purified by RP HPLC to provide the desired product. ^{1}H NMR (400 MHz, DMSO-D_6) □ 10.43 (s, 1 H), 8.08 (d, *J*=8.90 Hz, 1 H), 7.69 (d, *J*=6.75 Hz, 1 H), 7.31-7.34 (m, 2 H), 7.18-7.29 (m, 5 H), 7.02-7.11 (m, 5 H), 6.64 (d, *J*=7.67 Hz, 1 H), 4.15 (t, *J*=5.98 Hz, 2 H), 2.49-2.53 (m, 2 H), 2.17-2.25 (m, 2 H), 2.06 (s, 3 H).

EXAMPLE 564

7-(2-methylphenyl)-3-(3-(1,2,3,4-tetrahydronaphthalen-1-yloxy)prop-1-ynyl)-1H-indole-2-carboxylic acid

EXAMPLE 564A

ethyl 7-o-tolyl-1H-indole-2-carboxylate

To a mixture of ethyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-2-carboxylate (Paul et al. *J. Am. Chem. Soc.* 2006, *128*, 15552-15553) (1.6 g), tri-(t-butyl)phosphonium tetrafluoroborate (0.074 g), tris(dibenzylideneacetone)dipalladium(0) (0.116 g) and cesium fluoride (2.313 g) was added ortho-iodotoluene (0.781 ml), then dioxane (200 ml) and methanol (20 ml). The reaction mixture was immediately purged with nitrogen and stirred at room temperature for 2 hours. Additional amounts of (dibenzylideneacetone)dipalladium(0) (0.116 g), ortho-iodotoluene (0.781 ml), CsF (2.313 g), and tri-(t-butyl)phosphonium tetrafluoroborate (0.074 g) were added at the same time. The resulting solution was stirred at room temperature overnight. The insoluble material was filtered off and the filtrate was concentrated and the residue was purified by flash chromatography, eluting with 0-100% dichloromethane in hexane to provide the title compound.

EXAMPLE 564B

ethyl 3-iodo-7-o-tolyl-1H-indole-2-carboxylate

To a solution of EXAMPLE 564A (944mg, 3.38 mmol) in dichloromethane (10 mL) was added 1-iodopyrrolidine-2,5-dione (798 mg, 3.55 9 mmol). The reaction mixture was stirred at room temperature for 3 hours and directly loaded on a flash column, eluting with hexane first and then with 0-50% hexane in dichloromethane. The title compound was obtained as a white solid.

EXAMPLE 564C

7-(2-methylphenyl)-3-(3-(1,2,3,4-tetrahydronaphthalen-1-yloxy)prop-1-ynyl)-1H-indole-2-carboxylic acid

To a solution of EXAMPLE 564B (180 mg) and 1-(prop-2-ynyloxy)-1,2,3,4-tetrahydronaphthalene (165 mg) in triethylamine (5 ml) was added bis(triphenylphosphine)palladium(II) dichloride (18.71 mg) and copper(I) iodide (4.23 mg). The reaction mixture was stirred at 70°C for 3 hours, cooled and concentrated. The residue was dissolved in dichloromethane and purified by flash chromatography, eluting with dichloromethane, to provide ethyl 3-(3-(1,2,3,4-tetrahydronaphthalen-1-yloxy)prop-1-ynyl)-7-o-tolyl-1H-indole-2-carboxylate. This ester was hydrolyzed with aqueous NaOH in tetrahydrofuran and methanol to provide the title compound. ^{1}H NMR (400 MHz, methanol-d_4) 7.76 (dd, *J*=7.98, 1.23 Hz, 1 H), 7.52 (dd, *J*=6.75, 2.46 Hz, 1 H), 7.34-7.40 (m, 2 H),

7.27-7.31 (m, 2 H), 7.26 (d, *J*=7.98 Hz, 1 H), 7.13-7.19 (m, 3 H), 7.07-7.12 (m, 1 H), 4.97 (t, *J*=3.99 Hz, 1 H), 4.52-4.71 (m, 2 H), 2.79-2.90 (m, 1 H), 2.68-2.78 (m, 1 H), 2.14-2.21 (m, 1 H), 2.12 (s, 3 H), 1.91-2.06 (m, 2 H), 1.73-1.84 (m, 1 H).

EXAMPLE 565

3-(3-((6-(acryloylamino)-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

EXAMPLE 565A

To a mixture of ethyl 7-bromo-3-(3-hydroxypropyl)-1H-indole-2-carboxylate (1 g mmol), 6-aminonaphthalen-1-ol (0.732 g), triphenylphosphine, polymer supported (1.230 g) in tetrahydrofuran (4 ml) was added di-t-butyl azodicarboxylate (1.059 g, 4.60 mmol). The reaction was stirred at room temperature for 3 h. The insoluble material was removed by filtration and extensively washed with ethyl acetate. The combined filtrate was concentrated. The residue was purified by flash chromatography, eluting with CH2Cl2/ethyl acetate (20:1) to provide the title compound.

EXAMPLE 565B

The title compound was prepared according to the procedure for EXAMPLE 564A by substituting ethyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-2-carboxylate with o-tolylboronic acid, and ortho-iodotoluene with EXAMPLE 565A, respectively.

EXAMPLE 565C

3-(3-((6-(acryloylamino)-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

To a mixture of EXAMPLE 565B (62.8 mg), acrylic acid (9.91 µl) and 2-(1H-7-azabenzotriazol-1-yl)--1,1,3,3-tetramethyl uronium hexafluorophosphate Methanaminium (HATU, 54.9 mg) in tetrahydrofuran (3 ml) was added triethylamine (36.6 µl). The reaction was stirred at room temperature overnight, diluted with ethyl acetate and washed with water. The organic layer was dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography, eluting with dichloromethane, to provide ethyl 3-(3-(6-acrylamidonaphthalen-1-yloxy)propyl)-7-o-tolyl-1H-indole-2-carboxylate. This ester was hydrolyzed with aqueous NaOH in tetrahydrofuran and methanol to provide the title compound. ^{1}H NMR (500 MHz, methanol -d_4) □ 8.22-8.25 (m, 2 H), 7.68 (dd, *J*=5.95, 3.20

Hz, 1 H), 7.59 (dd, *J*=9.15, 2.14 Hz, 1 H), 7.25-7.37 (m, 6 H), 7.05-7.08 (m, 2 H), 6.74 (dd, *J*=6.10, 2.44 Hz, 1 H), 6.46-6.55 (m, 1 H), 6.38-6.44 (m, 1 H), 5.80 (dd, *J*=10.07, 1.83 Hz, 1 H), 4.20 (t, *J*=5.95 Hz, 2 H), 3.40-3.56 (m, 2 H), 2.34 (t, *J*=6.71 Hz, 2 H), 2.11 (s, 3 H).

EXAMPLE 566

7-(2-methylphenyl)-3-(3-((6-(propionylamino)-1-naphthyl)oxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, methanol -d_4) 8.21 (d, *J*=9.15 Hz, 1 H), 8.14 (d, *J*=1.83 Hz, 1 H), 7.67 (dd, *J*=6.26, 2.90 Hz, 1 H), 7.53 (dd, *J*=9.15, 2.14 Hz, 1 H), 7.24-7.37 (m, 6 H), 7.04-7.07 (m, 2 H), 6.71 (dd, *J*=5.03, 3.51 Hz, 1 H), 4.19 (t, *J*=5.95 Hz, 2 H), 3.42-3.49 (m, 2 H), 2.45 (q, *J*=7.63 Hz, 2 H), 2.29-2.37 (m, 2 H), 2.11 (s, 3 H), 1.25 (t, *J*=7.63 Hz, 3 H).

EXAMPLE 567

7-(2-methylphenyl)-3-(3-(1,2,3,4-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid

A mixture of EXAMPLE 564 (50 mg) and Raney-Ni (wet, 240 mg) in tetrahydrofuran (5 ml) and methanol (3 ml) was stirred under hydrogen at 30 °C for 1 hour. The insoluble material was filtered off. To the filtrate was added 10% NaOH (1 ml) and the resulting mixture was stirred overnight and acidified with HCl. The mixture was concentrated and the residue was purified by reverse phase HPLC (mobile phase: 10%-100% acetonitrile in 0.1% TFA aqueous solution during 60 min) to provide the title compound. ^{1}H NMR (400 MHz, methanol -d_4) □ 7.69 (dd, *J*=7.98, 1.23 Hz, 1 H), 7.31-7.38 (m, 3 H), 7.27-7.30 (m, 2 H), 7.13-7.17 (m, 3 H), 7.07-7.12 (m, 2 H), 4.43 (t, *J*=4.60 Hz, 1 H), 3.71-3.76 (m, 1 H), 3.59-3.65 (m, 1 H), 3.23-3.27 (m, 2 H), 2.79-2.86 (m, 1 H), 2.67-2.75 (m, 1 H), 2.12 (s, 3 H), 1.94-2.06 (m, 4 H), 1.85-1.93 (m, 1 H), 1.69-1.77 (m, 1 H).

EXAMPLE 568

3-(3-((6-methoxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, dichloromethane-d_2) 8.49 (s, 1 H), 8.22 (d, *J*=9.76 Hz, 1 H), 7.75 (d, *J*=7.32 Hz, 1 H), 7.27-7.38 (m, 7 H), 7.16-7.21 (m, 2 H), 7.12 (s, 2 H), 6.64 (dd, *J*=5.80, 2.75 Hz, 1 H), 4.19 (t, *J*=6.10 Hz, 2 H), 3.89 (s, 3 H), 3.46 (t, *J*=7.48 Hz, 2 H), 2.32-2.38 (m, 2 H), 2.15 (s, 3 H).

EXAMPLE 569

1-(4-methoxybenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)prop-1-ynyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.50 (s, 1 H), 8.21-8.24 (m, 1 H), 7.89-7.92 (m, 1 H), 7.63 (dd, *J*=7.98, 1.23 Hz, 1 H), 7.49-7.57 (m, 4 H), 7.28-7.33 (m, 2 H), 7.24 (t, *J*=7.67 Hz, 2 H), 7.14 (t, *J*=7.52 Hz, 1 H), 7.01-7.04 (m, 2 H), 6.61-6.65 (m, 2 H), 6.18 (s, 1 H), 6.16 (s, 1 H), 5.39 (s, 2 H), 5.29 (d, *J*=15.96 Hz, 1 H), 5.11 (d, *J*=16.26 Hz, 1 H), 3.62 (s, 3 H), 1.72 (s, 3 H).

EXAMPLE 570

3-(3-((2,3,4,5,6,7,8-heptafluoro-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 12.84 (s, 1 H), 10.51 (s, 1 H), 7.70 (d, *J*=7.93 Hz, 1 H), 7.33 (d, *J*=3.97 Hz, 2 H), 7.25-7.30 (m, 1 H), 7.21-7.23 (m, 1 H), 7.13-7.16 (m, 1 H), 7.05 (d, *J*=6.71 Hz, 1 H), 4.29 (t, *J*=6.41 Hz, 2 H), 3.25-3.29 (m, 2 H), 2.14-2.20 (m, 2 H), 2.05 (s, 3 H).

EXAMPLE 571

3-(3-(1-benzothien-7-yloxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 12.91 (s, 1 H), 10.50 (s, 1 H), 7.75 (d, *J*=5.49 Hz, 1 H), 7.69 (d, *J*=7.93 Hz, 1 H), 7.45-7.48 (m, 2 H), 7.25-7.33 (m, 4 H), 7.21-7.23 (m, 1 H), 7.08 (t, *J*=7.48 Hz, 1 H), 7.02-7.04 (m, 1 H), 6.87 (d, *J*=7.93 Hz, 1 H), 4.23 (t, *J*=6.10 Hz, 2 H), 3.27-3.32 (m, 2 H), 2.14-2.20 (m, 2 H), 2.06 (s, 3 H).

EXAMPLE 572

3-(3-((4-fluoro-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 12.97 (s, 1 H), 10.46 (s, 1 H), 8.28 (d, *J*=7.93 Hz, 1 H), 8.00 (d, *J*=7.63 Hz, 1 H), 7.61-7.69 (m, 3 H), 7.33 (d, *J*=3.66 Hz, 2 H), 7.24-7.29 (m, 1 H), 7.19-7.23 (m, 2 H), 7.02-7.08 (m, 2 H), 6.84 (dd, *J*=8.54, 3.97 Hz, 1 H), 4.19 (t, *J*=6.10 Hz, 2 H), 3.32-3.37 (m, 2 H), 2.20-2.26 (m, 2 H), 2.06 (s, 3 H).

EXAMPLE 573

3-(3-((8-fluoro-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 10.46 (s, 1 H), 7.69-7.72 (m, 2 H), 7.42-7.52 (m, 3 H), 7.33 (d, *J*=3.66 Hz, 2 H), 7.21-7.29 (m, 3 H), 7.02-7.07 (m, 2 H), 6.97 (d, *J*=7.63 Hz, 1 H), 4.15 (t, *J*=6.10 Hz, 2 H), 3.32-3.36 (m, 2 H), 2.16-2.22 (m, 2 H), 2.06 (s, 3 H).

EXAMPLE 574

3-(3-((5-fluoro-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, DMSO-d_6) 10.43 (s, 1 H), 8.07 (d, *J*=8.54 Hz, 1 H), 7.68 (d, *J*=7.32 Hz, 1 H), 7.57-7.59 (m, 1 H), 7.48-7.52 (m, 2 H), 7.36 (dd, *J*=10.98, 7.63 Hz, 1 H), 7.33 (d, *J*=3.66 Hz, 2 H), 7.25-7.29 (m, 1 H), 7.21-7.23 (m, 1 H), 7.05-7.09 (m, 1 H), 7.01-7.04 (m, 2 H), 4.23 (t, *J*=6.10 Hz, 2 H), 3.22-3.31 (m, 2 H), 2.21-2.27 (m, 2 H), 2.06 (s, 3 H).

EXAMPLE 575

7-fluoro-3-(2-isopropylphenyl)-1-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.87 (s, 1 H), 8.06 (d, *J*=8.29 Hz, 1 H), 7.84 (d, *J*=7.98 Hz, 1 H), 7.50 (t, *J*=6.90 Hz, 1 H), 7.32-7.47 (m, 5 H), 7.12-7.20 (m, 2 H), 6.99-7.05 (m, 2 H), 6.88 (d, *J*=8.59 Hz, 2 H), 5.03 (t, *J*=8.13 Hz, 2 H), 4.18 (t, *J*=5.83 Hz, 2 H), 2.63-2.70 (m, 1 H), 2.38-2.46 (m, 2 H), 1.00 (d, *J*=6.75 Hz, 3 H), 0.93 (d, *J*=6.75 Hz, 3 H).

EXAMPLE 576

7-fluoro-3-(2-methylphenyl)-1-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 8.09 (d, *J*=8.90 Hz, 1 H), 7.85 (d, *J*=8.29 Hz, 1 H), 7.49-7.53 (m, 1 H), 7.36-7.47 (m, 3 H), 7.09-7.31 (m, 5 H), 6.99-7.04 (m, 1 H), 6.88-6.91 (m, 2 H), 5.02 (t, *J*=7.21 Hz, 2 H), 4.20 (t, *J*=5.68 Hz, 2 H), 2.38-2.45 (m, 2 H), 1.99 (s, 3 H).

EXAMPLE 577

3-(3-((5-fluoro-1-naphthyl)oxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 10.51 (s, 1 H), 8.07 (d, *J*=8.59 Hz, 1 H), 7.65 (d, *J*=6.75 Hz, 1 H), 7.56-7.60 (m, 1 H), 7.46-7.53 (m, 2 H), 7.36 (dd, *J*=11.05, 6.75 Hz, 1 H), 7.04-7.08 (m, 1 H), 7.01-7.03 (m, 2 H), 4.23 (t, *J*=6.14 Hz, 2 H), 3.75 (s, 3 H), 3.33-3.37 (m, 2 H), 2.19-2.27 (m, 2 H), 2.05 (s, 3 H), 2.00 (s, 3 H).

EXAMPLE 578

3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 8.62 (d, *J*=6.44 Hz, 2 H), 8.23-8.28 (m, 1 H), 7.83-7.90 (m, 2 H), 7.45-7.57 (m, 3 H), 7.38-7.44 (m, 1 H), 7.12-7.18 (m, 1 H), 6.90-6.96 (m, 4 H), 5.79 (d, *J*=18.41 Hz, 1 H), 5.58 (d, *J*=18.10 Hz, 1 H), 4.28 (t, *J*=5.98 Hz, 2 H), 3.59 (s, 3 H), 3.39-3.46 (m, 2 H), 2.25-2.33 (m, 2 H), 1.65 (s, 3 H), 1.58 (s, 3 H).

EXAMPLE 579

3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 8.43 (d, *J*=4.30 Hz, 1 H), 8.24-8.27 (m, 1 H), 7.86-7.89 (m, 1 H), 7.81 (d, *J*=7.06 Hz, 1 H), 7.74 (t, *J*=8.29 Hz, 1 H), 7.49-7.56 (m, 2 H), 7.44-7.48 (m, 1 H), 7.38-7.42 (m, 1 H), 7.30-7.35 (m, 1 H), 7.09-7.14 (m, 1 H), 6.92 (d, *J*=7.36 Hz, 1 H), 6.89 (dd, *J*=7.06, 0.92 Hz, 1 H), 6.31 (d, *J*=7.67 Hz, 1 H), 5.73 (d, *J*=18.10 Hz, 1 H), 5.49 (d, *J*=17.49 Hz, 1 H), 4.26 (t, *J*=6.14 Hz, 2 H), 3.59 (s, 3 H), 3.36-3.44 (m, 2 H), 2.24-2.31 (m, 2 H), 1.67 (s, 3 H), 1.56 (s, 3 H).

EXAMPLE 580

3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid

EXAMPLE 580A

ethyl 3-(3-(naphthalen-1-yloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylate

To a mixture of ethyl 7-bromo-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate (EXAMPLE 1C) (1.605 g) and 1,3,5-trimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.838 g) in toluene (25 ml) was added diacetoxypalladium (0.080 g), dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (0.291 g), and K_3PO_4 (2.259 g). The resulting mixture was stirred at 110°C overnight. Silica gel (25 g) was added and the mixture was carefully dried on house vacumn overnight. The gel powder was loaded onto a flash column and eluted with 0-50% ethyl acetate in dichloromethane to provide the title compound.

EXAMPLE 580B

3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid

A mixture of EXAMPLE 580A (90 mg), 3-(bromomethyl)pyridine hydrobromide (47.3 mg) and cesium carbonate (183 mg) in N,N-dimethylformamide (3.5 ml) was stirred at room temperature overnight. The insoluble material was filtered off and the filtrate was concentrated. The residue was suspended in tetrahydrofuran-methanol, and 10% NaOH was added. The resulting mixture was stirred at room temperature overnight and concentrated. The residue was dissolved in a mixture of DMSO and methanol. The solution was purified by reverse phase HPLC (mobile phase: 10%-100% acetonitrile in 0.1% TFA aqueous solution during 60 minutes) to provide the title compound. ^{1}H NMR (400 MHz, DMSO-d_6) □ 8.55 (d, *J*=5.22 Hz, 1 H), 8.23-8.28 (m, 1 H), 7.85-7.90 (m, 1 H), 7.80-7.85 (m, 2 H), 7.49-7.57 (m, 3 H), 7.45-7.49 (m, 1 H), 7.38-7.43 (m, 1 H), 7.19 (d, *J*=7.67 Hz, 1 H), 7.10-7.15 (m, 1 H), 6.92 (t, *J*=7.67 Hz, 2 H), 5.65 (d, *J*=17.49 Hz, 1 H), 5.44 (d, *J*=17.80 Hz, 1 H), 4.26 (t, *J*=5.98 Hz, 2 H), 3.62 (s, 3 H), 3.35-3.49 (m, 2 H), 2.24-2.32 (m, 2 H), 1.67 (s, 3 H), 1.59 (s, 3 H).

Example 581

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-2-(1H-tetraazol-5-yl)-1H-indole

Example 581A

ethyl 7-bromo-1-(4-methoxybenzyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate

To a solution of ethyl 7-bromo-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylate (2.39 g, prepared in a similar manner as described herein) in N,N-dimethylamide (20 mL) was added 1-(chloromethyl)-4-methoxybenzene (1.0 g) and Cs_2CO_3 (5.16 g). The mixture was stirred overnight at room temperature. The mixture was diluted with ether (300 mL) and water (200 mL). The aqueous layer was extracted with ether. The combined extracts were washed with water (x3), brine and dried over Na_2SO_4. Concentration gave Example 581A.

Example 581B

7-bromo-1-(4-methoxybenzyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxamide

To a solution of EXAMPLE 581A (1 g) in oxalyl chloride (10 mL) was added a few drops of N,N-dimethylamide. The mixture was stirred for 3 hours at room temperature. The mixture was concentrated under vacuum and the residue was dissolved in dichloromethane (20 ml) and added to cooled (0°C) concentrated NH_3H_2O (30 ml). After the addition, the mixture was stirred for 2 hours before extraction with ethyl acetate (200 ml). The organic extract was washed with water , brine and dried over Na_2SO_4. After filtration, evaporation of solvent gave Example 581B.

Example 581C

7-bromo-1-(4-methoxybenzyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carbonitrile

To a cooled (0 °C) solution of EXAMPLE 581B (545 mg) in tetrahydrofuran (5 mL) and dichloromethane (1 ml) was added triethylamine (1 ml) followed by trifluoroacetic acid (1ml) dropwise. After the addition, the mixture was stirred for 3 hours at 0°C. The mixture was diluted with ethyl acetate (200 mL) and water (80 mL). The aqueous layer was extracted with ether. The combined organic extracts were washed with water (x3), brine and dried over Na_2SO_4. After filtration, concentration of the solvent gave Example 581C.

Example 581D

1-(4-methoxybenzyl)-3-(3-(naphthalen-1-yloxy)propyl)-7-o-tolyl-1H-indole-2-carbonitrile

To a mixture of EXAMPLE 581C (300 mg) and o-tolylboronic acid (93 mg) in 1,2-dimethoxyethane (10 ml)and methanol (5 ml) was added tetrakis(triphenylphosphine)palladium(0) (33 mg) and CsF (260 mg). The mixture was stirred at reflux under nitrogen for 4 hours. The mixture was concentrated under vacuum and the residue was partitioned between ethyl acetate (300 mL) and water (100 ml). The aqueous layer was further extracted with ehtyl acetate and the combined extracts were washed with water, brine and dried over Na_2SO_4. . After filtration, concentration of the solvent and column purification (5 to 10% ethyl acetate in hexane) gave Example 581D.

Example 581E

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-2-(1H-tetraazol-5-yl)-1H-indole

To a mixture of EXAMPLE 581D (232 mg)in N,N-dimethylamide (10 ml) was added NaN_3 (281 mg) and NH_4Cl (231 mg). The mixture was stirred at reflux overnight. The

mixture was concentrated under vacuum and the residue was partitioned between ethyl acetate (200 ml) and water (60 ml). The organic phase was washed with brine and dried over Na_2SO_4. Concentration of the solvent gave crude product which was dissolved in dichloromethane/trifluoroacetic acid (1:1, 4 ml) and heated to 125°C in a microwave (CEM Discover) for 20 minutes. The mixture was concentrated and the residue was dissolved in dimehtylsulfoxide/methanol (1/1, 2 ml) and loaded on HPLC for purification. ^{1}H NMR (300 MHz, DMSO-d_6) δ 10.63 (m, 1H), 8.26 (m, 1H), 7.86 (m, 1H), 7.74 (d, 1H), 7.53 (m, 2H), 7.42 (m, 5 H), 7.33 (m, 2H), 7.11 (m, 3H), 6.90 (d, 1H), 4.23 (t, 2H), 2.29 (m, 2H), 2.13 (s, 3H).

Example 582

1-(4-methoxybenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-2-(1H-tetraazol-5-yl)-1H-indole

^{1}H NMR (300 MHz, DMSO-d_6) δ 8.08 (d, 1H), 7.84 (m, 2H), 7.52 (m, 2H), 7.45 (d, 1H), 7.39 (d, 1H), 7.32 (m, 1H), 7.25 (d, 1H), 7.17 (m, 2H), 7.10 (d, 1H), 6.96 (d, 1H), 6.85 (d, 1H), 6.51 (d, 2H), 6.02 (d, 2H), 4.89 (dd, 2H), 4.14 (t, 2H), 3.57 (s, 3H), 3.16 (m, 2H), 2.20 (m, 2H), 1.80 (s, 3H).

Example 585

7-(1-methyl-1H-imidazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) δ 14.39 (s, 1H), 13.21 (s, 1H), 11.52 (s, 1H), 9.23 (s, 1H), 8.12-8.32 (m, 1H), 7.83-7.97 (m, 2H), 7.80 (d, *J*=1.7 Hz, 1H), 7.33-7.69 (m, 5H), 7.30 (d, *J*=6.1 Hz, 1H), 7.07-7.22 (m, 1H), 6.89 (d, *J*=6.4 Hz, 1H), 4.19 (t, *J*=6.1 Hz, 2H), 3.55 (s, 3H), 3.38 (t, *J*=7.3 Hz, 2H), 2.11-2.34 (m, 2H).

Example 586

1-(2-(dimethylamino)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.01 (s, 1 H), 8.26-8.30 (m, 1 H), 7.84-7.90 (m, 1 H), 7.73 (d, *J*=7.06 Hz, 1 H), 7.50-7.55 (m, 2 H), 7.44-7.48 (m, 1 H), 7.40 (t, *J*=7.98 Hz, 1 H), 7.03-7.08 (m, 1 H), 6.92 (d, *J*=7.36 Hz, 1 H), 6.88 (d, *J*=6.14 Hz, 1 H), 5.07-5.24 (m, 2 H), 4.23 (t, *J*=6.14 Hz, 2 H), 3.74 (s, 3 H), 3.31-3.38 (m, 2 H), 2.69 (s, 3 H), 2.56 (s, 3 H), 2.19-2.26 (m, 2 H), 1.91 (s, 3 H), 1.84 (s, 3 H).

Example 587

1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, pyridine-d_5) 8.64-8.68 (m, 1 H), 8.01 (d, *J*=7.02 Hz, 1 H), 7.87-7.90 (m, 1 H), 7.48-7.53 (m, 3 H), 7.36-7.40 (m, 1 H), 7.30-7.33 (m, 1 H), 7.19-7.21 (m, 1 H), 6.87 (d, *J*=7.32 Hz, 1 H), 6.05 (s, br, 1 H), 5.79 (s, br, 1 H), 4.28 (t, *J*=6.26 Hz, 2 H), 3.74-3.87 (m, 6 H), 3.24-3.52 (m, 3 H), 2.40-2.56 (m, 5 H), 2.35 (s, br, 1 H), 2.31 (s, 3 H), 2.22 (s, 3 H), 2.02 (s, 3 H).

Example 588

7-(4,6-dimethylpyrimidin-5-yl)-1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 9.01 (s, 1H), 8.27-8.29 (m, 1H), 7.84-7.88 (m, 2H), 7.45-7.56 (m, 3H), 7.39 (t, J = 7.98 Hz, 1H), 7.16 (t, J = 7.67 Hz, 1H), 7.01 (d, J = 6.44 Hz, 1H), 6.92 (d, J = 7.67 Hz, 1H), 4.92 (br, 2H), 4.24 (t, J = 6.14 Hz, 2H), 3.07 (br, 2H), 3.35-3.40 (m, 4H), 3.22 (br, 2H), 2.93 (br, 2H), 2.15-2.28 (m, 2H), 2.09 (s, 6H).

Example 589

1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, pyridine-d_5) 8.66 (d, *J*=7.93 Hz, 1 H), 8.01 (dd, *J*=8.09, 1.07 Hz, 1 H), 7.89-7.91 (m, 1 H), 7.48-7.55 (m, 3 H), 7.32-7.42 (m, 2 H), 7.18-7.21 (m, 1 H), 6.91 (d, *J*=7.63 Hz, 1 H), 4.96-5.03 (m, 1 H), 4.71-4.78 (m, 1 H), 4.33 (t, *J*=6.10 Hz, 2 H), 3.84 (s, 3 H), 3.77 (t, *J*=7.48 Hz, 2 H), 2.98 (s, 3 H), 2.58 (s, 3 H), 2.42-2.58 (m, 6 H), 2.23 (s, 3 H), 2.21-2.27 (m, 1 H), 2.14 (s, 3 H), 2.10 (d, *J*=7.93 Hz, 1 H).

Example 590

1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, pyridine-d_5) 8.66-8.69 (m, 1 H), 8.00-8.03 (m, 1 H), 7.89 (d, *J*=7.32 Hz, 1 H), 7.47-7.55 (m, 3 H), 7.31-7.43 (m, 2 H), 7.21 (m, 1 H), 6.92 (d, *J*=7.63 Hz, 1 H), 4.95-5.03 (m, 1 H), 4.83-4.89 (m, 1 H), 4.34 (t, *J*=6.26 Hz, 2 H), 3.76-3.81 (m, 2 H), 3.76

(s, 3 H), 3.61 (t, *J*=4.73 Hz, 4 H), 2.55-2.61 (m, 2 H), 2.39-2.44 (m, 1 H), 2.27 (s, 3 H), 2.20-2.30 (m, 5 H), 2.09 (s, 3 H).

Example 591

1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, methanol-d_4) 8.31-8.37 (m, 1 H), 7.74-7.81 (m, 2 H), 7.46-7.50 (m, 2 H), 7.36-7.41 (m, 1 H), 7.33 (t, *J*=7.93 Hz, 1 H), 7.01-7.07 (m, 1 H), 6.91-6.97 (m, 1 H), 6.80-6.83 (m, 1 H), 5.27 (s, 2 H), 4.20-4.24 (m, 2 H), 3.85-3.88 (m, 1 H), 3.85-3.90 (m, 1 H), 3.82-3.85 (m, 3 H), 3.82-3.84 (m, 3 H), 3.55-3.62 (m, 4 H), 3.44-3.50 (m, 3 H), 3.34-3.40 (m, 2 H), 3.16-3.24 (m, 3 H), 2.31-2.37 (m, 2 H), 1.93 – 2.03 (m, 6 H).

Example 592

1-(2-(dimethylamino)ethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (500 MHz, pyridine-d_5) 8.65-8.69 (m, 1 H), 8.01 (d, *J*=7.02 Hz, 1 H), 7.89-7.91 (m, 1 H), 7.49-7.55 (m, 3 H), 7.40 (t, *J*=7.93 Hz, 1 H), 7.30-7.36 (m, 1 H), 7.19 (m, 1 H), 6.91 (d, *J*=7.63 Hz, 1 H), 5.01 (t, *J*=7.93 Hz, 2 H), 4.33 (t, *J*=6.10 Hz, 2 H), 3.81 (s, 3 H), 3.75-3.79 (m, 2 H), 2.86-2.99 (m, 2 H), 2.50-2.58 (m, 2 H), 2.47 (s, 6 H), 2.21 (s, 3 H), 2.12 (s, 3 H).

Example 593

7-(2-methylimidazo(1,2-a)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.16 (s, 1H), 11.35 (s, 1H), 8.14-8.36 (m, 1H), 7.91-8.08 (m, 4H), 7.84-7.90 (m, 1H), 7.37-7.57 (m, 5H), 7.34 (t, *J*=6.3 Hz, 1H), 7.22-7.29 (m, 1H), 6.92 (d, *J*=7.1 Hz, 1H), 4.23 (t, *J*=6.1 Hz, 2H), 3.37-3.46 (m, 2H), 2.37 (s, 3H), 2.21-2.31 (m, 2H),

Example 594

7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 13.31 (s, 1H), 8.72 (s, 1H), 8.55 (d, *J*=4.7 Hz, 1H), 8.22-8.33 (m, 1H), 8.19 (d, *J*=4.1 Hz, 1H), 7.83-7.96 (m, 2H), 7.44-7.59 (m, 5H), 7.35-7.43

(m, 1H), 7.32 (s, 1H), 7.19 (s, 1H), 7.06-7.16 (m, 3H), 6.89 (d, *J*=6.8 Hz, 1H), 6.40 (d, *J*=7.8 Hz, 1H), 5.44 (d, *J*=17.3 Hz, 1H), 5.22 (d, *J*=17.3 Hz, 1H), 4.20 (t, *J*=6.1 Hz, 2H), 3.26-3.43 (m, 2H), 2.17-2.30 (m, 2H), 1.83 (s, 3H).

Example 595

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 8.63-8.67 (m, 1H) 8.22-8.28 (m, 2H) 7.96 (d, 1H) 7.85-7.90 (m, 1H) 7.34-7.72 (m, 6H) 7.15-7.27 (m, 2H) 7.03 (d, 1H) 6.92 (d, 1H) 6.37 (d, 1H) 5.40 (d, 1H) 5.18 (d, 1H) 4.27 (t, 2H) 2.26-2.35 (m, 2H) 1.97-2.15 (m, 2H) 1.86 (s, 3H) 0.90 (t, 3H).

Example 596

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-((1-(pyridin-4-ylmethyl)pyridinium-4-yl)methyl)-1H-indole-2-carboxylate

^{1}H NMR (400 MHz, DMSO-d_6) 8.88-8.92 (m, 2H) 8.69-8.72 (m, 2H) 8.39-8.43 (m, 1H) 8.23-8.28 (m, 1H) 7.95-7.99 (m, 1H) 7.85-7.90 (m, 1H) 7.37-7.58 (m, 6H) 7.22-7.35 (m, 3H) 7.10-7.21 (m, 1H) 6.91-7.06 (m, 2H) 5.85 (s, 2H) 5.24-5.61 (m, 2H) 4.30 (t, 2H) 3.45 (t, 2H) 2.26-2.38 (m, 2H) 1.87-2.13 (m, 2H) 1.70-1.82 (m, 3H) 0.82 (t, 3H).

Example 597

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 8.60 (d, 1H) 8.43 (d, 2H) 8.22-8.28 (m, 1H) 7.99 (d, 1H) 7.85-7.91 (m, 1H) 7.37-7.59 (m, 5H) 7.25 (t, 1H) 7.02-7.07 (m, 1H) 6.94 (d, 1H) 6.69 (d, 2H) 5.38-5.51 (m, 1H) 5.14-5.28 (m, 1H) 4.29 (t, 2H) 3.46 (t, 2H) 2.27-2.37 (m, 2H) 1.92-2.13 (m, 2H) 1.85 (s, 3H) 0.88 (t, 3H).

Example 598

7-(2-ethyl-4-methylpyridin-3-yl)-1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 12.96 (br. s, 1H) 8.60-8.67 (m, 1H) 8.24-8.29 (m, 1H) 7.84-7.90 (m, 2H) 7.49-7.59 (m, 3H) 7.46 (d, 1H) 7.39 (t, 1H) 7.19 (t, 1H) 7.03 (d, 1H) 6.91 (d, 1H) 4.24 (t, 2H) 2.18-2.40 (m, 4H) 2.01 (s, 3H) 1.02 (t, 3H).

Example 599

1-(2-(dimethylamino)-2-oxoethyl)-7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 8.51-8.56 (m, 1H) 8.25-8.31 (m, 1H) 7.79-7.90 (m, 2H) 7.26-7.58 (m, 5H) 7.10-7.22 (m, 1H) 6.89-7.02 (m, 2H) 4.24 (t, 2H) 2.63 (s, 2H) 2.20-2.39 (m, 7H) 1.85-1.97 (m, 3H) 1.01 (t, 3H).

Example 600

7-(2-ethyl-4-methylpyridin-3-yl)-1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 10.19 (s, 1H) 8.62-8.77 (m, 1H) 8.21-8.32 (m, 1H) 7.82-7.95 (m, 2H) 7.33-7.74 (m, 5H) 7.18 (t, 1H) 7.02 (d, 1H) 6.90 (d, 1H) 4.23 (t, 2H) 3.34-3.40 (m, 6H) 2.61-2.97 (m, 6H) 2.15-2.41 (m, 3H) 2.01 (s, 3H) 1.02 (t, 3H).

Example 601

7-(2-ethyl-4-methylpyridin-3-yl)-1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 8.53-8.57 (m, 1H) 8.21-8.26 (m, 1H) 7.83-7.89 (m, 2H) 7.35-7.58 (m, 5H) 7.20 (t, 1H) 7.02 (d, 1H) 6.91 (d, 1H) 4.25 (t, 2H) 2.18-2.40 (m, 8H) 2.03 (s, 3H) 1.07 (t, 3H).

Example 602

1-(2-(dimethylamino)ethyl)-7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 9.78 (s, 1H) 8.63 (d, 1H) 8.17-8.25 (m, 1H) 7.81-7.91 (m, 2H) 7.31-7.60 (m, 5H) 7.20 (t, 1H) 7.04 (d, 1H) 6.89 (d, 1H) 4.22 (t, 2H) 3.36 (t, 2H) 2.74-2.89 (m, 2H) 2.49 (s, 6H) 2.30-2.43 (m, 2H) 2.16-2.27 (m, 2H) 2.06 (s, 3H) 1.05 (t, 3H).

Example 603

7-(2-ethyl-4-methylpyridin-3-yl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (400 MHz, DMSO-d_6) 8.69 (d, 1H) 8.20-8.26 (m, 1H) 7.84-7.91 (m, 2H) 7.66 (d, 1H) 7.44-7.57 (m, 3H) 7.39 (t, 1H) 7.20 (t, 1H) 7.06 (d, 1H) 6.91 (d, 1H) 4.23 (t, 2H)

3.91-3.98 (m, 2H) 3.34 (t, 2H) 3.23-3.30 (m, 2H) 2.75-2.87 (m, 2H) 2.72 (s, 3H) 2.53-2.62 (m, 2H) 2.00-2.31 (m, 10H) 1.08 (t, 3H).

Example 604

7-(2-((4-(4-carboxyphenyl)piperazin-1-yl)methyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) δ 12.96 (s, 1H), 12.37 (s, 1H), 11.05 (s, 1H), 9.46 (s, 1H), 8.14-8.30 (m, 1H), 7.82-7.90 (m, 1H), 7.69-7.78 (m, 4H), 7.55-7.63 (m, 2H), 7.47-7.55 (m, 2H), 7.45 (d, *J*=8.1 Hz, 1H), 7.32-7.42 (m, 3H), 7.08-7.12 (m, 2H), 6.83-6.91 (m, 4H), 4.39 (d, *J*=16.7 Hz, 1H), 4.19 (t, *J*=5.9 Hz, 2H), 4.08 (d, *J*=16.7 Hz, 1H), 3.62-3.76 (m, 2H), 3.29-3.42 (m, 2H), 3.13-3.26 (m, 1H), 2.93-3.10 (m, 1H), 2.75-2.87 (m, 2H), 2.16-2.26 (m, 2H).

Example 605

3-(3-(1-naphthyloxy)propyl)-7-(2-piperazin-1-ylpyridin-3-yl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) δ 13.12 (s, 1H), 10.87 (s, 1H), 8.44 (s, 2H), 8.32 (dd, *J*=4.7, 1.7 Hz, 1H), 8.22-8.29 (m, 1H), 7.84-7.90 (m, 1H), 7.70-7.80 (m, 2H), 7.48-7.58 (m, 2H), 7.46 (d, *J*=8.1 Hz, 1H), 7.35-7.43 (m, 1H), 7.31 (d, *J*=6.1 Hz, 1H), 7.07-7.16 (m, 2H), 6.89 (d, *J*=6.4 Hz, 1H), 4.19 (t, *J*=6.1 Hz, 2H), 3.12 (s, 4H), 2.59-2.71 (m, 2H), 2.16-2.31 (m, 2H).

Example 606

1-(2-(dimethylamino)-2-oxoethyl)-7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) δ 13.23 (s, 1H), 8.61 (d, *J*=4.7 Hz, 1H), 8.24-8.39 (m, 1H), 8.16-8.25 (m, 1H), 7.76-7.95 (m, 2H), 7.64 (d, *J*=5.1 Hz, 1H), 7.49-7.57 (m, 2H), 7.46 (d, *J*=8.1 Hz, 1H), 7.36-7.43 (m, 1H), 7.26 (s, 1H), 6.99-7.12 (m, 3H), 6.90 (d, *J*=7.5 Hz, 1H), 4.94 (s, 1H), 4.20 (t, *J*=6.3 Hz, 2H), 3.39-3.52 (m, 2H), 2.57 (s, 3H), 2.16-2.25 (m, 2H), 2.07 (s, 3H).

Example 607

7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) δ 13.44 (s, 1H), 8.55 (d, *J*=4.7 Hz, 1H), 8.14-8.37 (m, 3H), 7.90-7.98 (m, 1H), 7.84-7.90 (m, 1H), 7.36-7.58 (m, 6H), 7.08-7.21 (m, 4H), 6.98 (s, 1H), 6.91 (d, *J*=7.5 Hz, 1H), 6.69 (d, *J*=8.5 Hz, 1H), 5.52 (d, *J*=17.3 Hz, 1H), 4.97 (d, *J*=17.3 Hz, 1H), 4.21 (t, *J*=6.3 Hz, 2H), 3.38 (t, 2H), 3.11-3.21 (m, 2H), 2.16-2.30 (m, 2H), 1.68 (s, 3H).

Example 608

7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) δ 13.26 (s, 1H), 8.66 (d, *J*=5.1 Hz, 1H), 8.41 (s, 1H), 8.23-8.31 (m, 1H), 7.80-7.91 (m, 2H), 7.71 (d, *J*=5.1 Hz, 1H), 7.49-7.57 (m, 2H), 7.46 (d, *J*=8.1 Hz, 1H), 7.36-7.43 (m, 1H), 7.31 (s, 1H), 7.15-7.23 (m, 1H), 7.00-7.10 (m, 2H), 6.90 (d, *J*=7.5 Hz, 1H), 4.88 (d, 2H), 4.20 (t, *J*=6.1 Hz, 2H), 3.34 (s, 4H), 3.17 (s, 2H), 3.04 (s, 2H), 2.14-2.25 (m, 2H), 2.09 (s, 3H).

Example 609


7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(2-oxo-2-piperazin-1-ylethyl)-1H-indole-2-carboxylic acid

^{1}H NMR (300 MHz, DMSO-d_6) δ 13.22 (s, 1H), 8.69 (s, 2H), 8.57 (d, *J*=4.7 Hz, 1H), 8.24-8.31 (m, 1H), 7.82-7.91 (m, 2H), 7.49-7.61 (m, 3H), 7.47 (d, *J*=8.1 Hz, 1H), 7.35-7.44 (m, 1H), 7.10 (t, *J*=7.6 Hz, 3H), 6.89 (d, *J*=6.8 Hz, 2H), 6.47 (s, 1H), 5.01 (s, 1H), 4.21 (t, *J*=5.8 Hz, 2H), 3.12-3.29 (m, 4H), 2.81-3.06 (m, 4H), 2.16-2.25 (m, 2H), 2.03 (s, 3H).

The foregoing is meant to illustrate the invention but not to limit it. Variations and changes obvious to one skilled in the art are intended to be within the scope of the invention as defined in the appended claims.

WE CLAIM:

1. A compound having Formula I,



(I),

or a therapeutically acceptable salt thereof, wherein

A^1 is A^2, OA^2, SA^2, $S(O)A^2$, SO_2A^2, NH_2, NHA^2, $N(A^2)_2$, $C(O)A^2$, $C(O)NH_2$, $C(O)NHA^2$, $C(O)N(A^2)_2$, $NHC(O)A^2$, $NA^2C(O)A^2$, $NHSO_2A^2$, $NA^2SO_2A^2$, $NHC(O)OA^2$, $NA^2C(O)OA^2$, SO_2NH_2, SO_2NHA^2, $SO_2N(A^2)_2$, $NHC(O)NH_2$, $NHC(O)A^2$ $NHC(O)N(A^2)_2$, $NA^2C(O)N(A^2)_2$ F, Cl, Br, or I;

A^2 is R^1, R^2, R^3, or R^4;

R^1 is phenyl which is unfused or fused with benzene, heteroarene or R^{1A}; R^{1A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^2 is heteroaryl which is unfused or fused with benzene, heteroarene or R^{2A}; R^{2A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^3 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{3A}; R^{3A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^4 is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^5, OR^5, SR^5, $S(O)R^5$, SO_2R^5, NH_2, NHR^5, $N(R^5)_2$, $C(O)R^5$, $C(O)NH_2$, $C(O)NHR^5$, $C(O)N(R^5)_2$, $NHC(O)R^5$, $NR^5C(O)R^5$, $NHSO_2R^5$,

$NR^5SO_2R^5$, $NHC(O)OR^5$, $NR^5C(O)OR^5$, SO_2NH_2, SO_2NHR^5, $SO_2N(R^5)_2$, $NHC(O)NH_2$, $NHC(O)R^5$, $NHC(O)N(R^5)_2$, $NR^5C(O)N(R^5)_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^5 is R^6, R^7 or R^8;

R^6 is phenyl which is unfused or fused with benzene, heteroarene or R^{6A}; R^{6A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^7 is heteroaryl which is unfused or fused with benzene, heteroarene or R^{7A}; R^{7A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^8 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{8A}; R^{8A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

L^1 is a bond or is alkylene, alkenylene, alkynylene or L^2; and B^1 is C(O)OH or a bioisostere thereof or is $C(O)OR^1$, $C(O)OR^2$, $C(O)OR^3$ or $C(O)OR^4$;

L^2 is C_2-C_6-alkylene, C_4-C_6-alkenylene or C_4-C_6-alkynylene, each of which has one CH_2 moiety replaced with O, S, S(O), SO_2, NH or $N(W^1)$;

W^1 is alkyl, alkenyl or alkynyl;

C^1 and D^1 are independently H, R^9, R^{10}, R^{11}, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, or

one of C^1 and D^1 is H, and the other is R^9, R^{10}, R^{11} R^{12}, $C(O)OR^{12}$, F, Cl, Br, or I;

R^9 is phenyl which is unfused or fused with benzene, heteroarene or R^{9A}; R^{9A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{10} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{10A}; R^{10A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{11} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{11A}; R^{11A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{12} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, NH_2, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHSO_2R^{13}$, $NR^{13}SO_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $NHC(O)NH_2$, $NHC(O)R^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)N(R^{13})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{13} is R^{14}, R^{15} R^{16}, or R^{16A};

R^{14} is phenyl which is unfused or fused with benzene, heteroarene or R^{14A}; R^{14A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused or fused with R^{14B}; R^{14B} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

$R^{15}$is heteroaryl which is unfused or fused with benzene, heteroarene or R^{15A}; R^{15A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{16} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{16A}; R^{16A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{16A} is alkyl, alkenyl, or alkynyl; and

one or two or each of E^1 and F^1 and G^1 are independently H, CF_3, F, Cl, Br or I, and the remainder are independently R^{17}, R^{18}, R^{19}, R^{20} or OR^{20};

R^{17} is phenyl which is unfused or fused with benzene, heteroarene or R^{17A}; R^{17A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{18} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{18A}; R^{18A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{19} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{19A}; R^{19A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{20} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{20}, OR^{20}, SR^{20}, $S(O)R^{20}$, SO_2R^{20}, NH_2, NHR^{20}, $N(R^{20})_2$, $C(O)R^{20}$, $C(O)NH_2$, $C(O)NHR^{20}$, $C(O)N(R^{20})_2$, $NHC(O)R^{20}$, $NHC(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NHSO_2R^{20}$, $NR^{20}SO_2R^{20}$, $NHC(O)OR^{20}$, $NR^{20}C(O)OR^{20}$, SO_2NH_2, SO_2NHR^{20}, $SO_2N(R^{20})_2$, $NHC(O)NH_2$, $NHC(O)R^{20}$, $NHC(O)N(R^{20})_2$, $NR^{20}C(O)N(R^{20})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{20} is R^{21}, R^{22} or R^{23};

R^{21} is phenyl which is unfused or fused with benzene, heteroarene or R^{21A}; R^{21A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

$R^{22}$is heteroaryl which is unfused or fused with benzene, heteroarene or R^{22A}; R^{22A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{23} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{23A}; R^{23A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

wherein each foregoing cyclic moiety is independently unsubstituted or substituted with one or two or three or four or five of independently selected spiroheteroalkyl, R^{30}, OR^{30}, OCH_2R^{30}, SR^{30}, $S(O)R^{30}$, SO_2R^{30}, $C(O)R^{30}$, $CO(O)R^{30}$, $OC(O)R^{30}$, $OC(O)OR^{30}$, NO, NO_2, NH_2, NHR^{30}, $N(R^{30})_2$, CH_2R^{30}, $C(O)NH_2$, $C(O)NHR^{30}$, $C(O)N(R^{30})_2$, $NHC(O)R^{30}$, $NR^{30}C(O)R^{30}$, C(O)NHOH, $C(O)NHOR^{30}$, $C(O)NHSO_2R^{30}$, $C(O)NR^{30}SO_2R^{30}$, SO_2NH_2, SO_2NHR^{30}, $SO_2N(R^{30})_2$, CF_3, CF_2CF_3, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{30}$, $C(N)N(R^{30})_2$, =NO-(alkylene)-$C(O)CF_3$, CNOH, $CNOCH_3$, OH, (O), CN, N_3, CF_3, CF_2CF_3, OCF_3, OCF_2CF_3, F, Cl, Br, or I;

R^{30} is R^{31}, R^{32}, R^{33} or R^{34};

R^{31} is phenyl which is unfused or fused with benzene, heteroarene or R^{31A}; R^{31A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{32} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{32A}; R^{32A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{33} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{33A}; R^{33A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{34} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, NHR^{35}, $N(R^{35})_2$, $C(O)R^{35}$, $C(O)NH_2$, $C(O)NHR^{35}$, $C(O)N(R^{35})_2$, $NHC(O)R^{35}$, $NR^{35}C(O)R^{35}$, $NHSO_2R^{35}$, $NR^{35}SO_2R^{35}$, $NHC(O)OR^{35}$, $NR^{35}C(O)OR^{35}$, SO_2NH_2, SO_2NHR^{35}, $SO_2N(R^{35})_2$, $NHC(O)NH_2$, $NHC(O)R^{35}$ $NHC(O)N(R^{35})_2$, $NR^{35}C(O)N(R^{35})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{35} is R^{36}, R^{37}, R^{38} or R^{39};

R^{36} is phenyl which is unfused or fused with benzene, heteroarene or R^{36A}; R^{36A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{37} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{37A}; R^{37A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{38} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{38A}; R^{38A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{39} is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with NH_2, $N(R^{40})_2$, OR^{40}, or R^{40};

R^{40} is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl;

wherein the moieties represented by R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} and R^{40} are independently unsubstituted or substituted with one or two or three of independently selected R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O) or OH;

R^{50} is R^{51}, R^{52}, R^{53} or R^{54};

R^{51} is phenyl which is unfused or fused with benzene, heteroarene or R^{51A}; R^{51A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{52} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{52A}; R^{52A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{53} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{53A}; R^{53A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{54} is alkyl, alkenyl, or alkynyl; each of which is unsubstituted or substituted with one, two, three, four or five of independently selected F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O), OH, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl and

wherein the moieties represented by R^{51}, R^{52}, and R^{53} are independently unsubstituted or substituted with one or two or three of independently selected R^{55}, OR^{55}, OCH_2R^{55}, SR^{55}, $S(O)R^{55}$, SO_2R^{55}, $C(O)R^{55}$, $CO(O)R^{55}$, $OC(O)R^{55}$, $OC(O)OR^{55}$, NO_2, NH_2, NHR^{55}, $N(R^{55})_2$, CH_2R^{55}, $C(O)NH_2$, $C(O)NHR^{55}$, $C(O)N(R^{55})_2$, $NHC(O)R^{55}$, $NR^{55}C(O)R^{55}$, C(O)NHOH, $C(O)NHOR^{55}$, $C(O)NHSO_2R^{55}$, $C(O)NR^{55}SO_2R^{55}$, SO_2NH_2, SO_2NHR^{55}, $SO_2N(R^{55})_2$, CF_3, CF_2CF_3, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{55}$, $C(N)N(R^{55})_2$, =NO-(alkylene)-$C(O)CF_3$, CNOH, $CNOCH_3$, OH, (O), CN, N_3, CF_3, CF_2CF_3, OCF_3, OCF_2CF_3, F, Cl, Br or I; and

R^{55} is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl.

2. A compound of claim 1 or a therapeutically acceptable salt thereof, wherein

A^1 is A^2, OA^2, SA^2, $S(O)A^2$, SO_2A^2, NH_2, NHA^2, $N(A^2)_2$, $C(O)A^2$, $C(O)NH_2$, $C(O)NHA^2$, $C(O)N(A^2)_2$, $NHC(O)A^2$, $NA^2C(O)A^2$, $NHSO_2A^2$, $NA^2SO_2A^2$, $NHC(O)OA^2$, $NA^2C(O)OA^2$, SO_2NH_2, SO_2NHA^2, $SO_2N(A^2)_2$, $NHC(O)NH_2$, $NHC(O)A^2$ $NHC(O)N(A^2)_2$, $NA^2C(O)N(A^2)_2$ F, Cl, Br, or I;

A^2 is R^1, R^2, R^3, or R^4;

R^1 is phenyl which is unfused or fused with benzene, heteroarene or R^{1A}; R^{1A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^2 is heteroaryl which is unfused or fused with benzene, heteroarene or R^{2A}; R^{2A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^3 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{3A}; R^{3A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^4 is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^5, OR^5, SR^5, $S(O)R^5$, SO_2R^5, NH_2, NHR^5, $N(R^5)_2$, $C(O)R^5$, $C(O)NH_2$, $C(O)NHR^5$, $C(O)N(R^5)_2$, $NHC(O)R^5$, $NR^5C(O)R^5$, $NHSO_2R^5$, $NR^5SO_2R^5$, $NHC(O)OR^5$, $NR^5C(O)OR^5$, SO_2NH_2, SO_2NHR^5, $SO_2N(R^5)_2$, $NHC(O)NH_2$, $NHC(O)R^5$, $NHC(O)N(R^5)_2$, $NR^5C(O)N(R^5)_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^5 is R^6, R^7 or R^8;

R^6 is phenyl which is unfused or fused with benzene, heteroarene or R^{6A}; R^{6A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^7 is heteroaryl which is unfused or fused with benzene, heteroarene or R^{7A}; R^{7A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^8 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{8A}; R^{8A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

L^1 is a bond or is alkylene, alkenylene, alkynylene or L^2; and B^1 is C(O)OH or a bioisostere thereof or is $C(O)OR^1$, $C(O)OR^2$, $C(O)OR^3$ or $C(O)OR^4$;

L^2 is C_2-C_6-alkylene, C_4-C_6-alkenylene or C_4-C_6-alkynylene, each of which has one CH_2 moiety replaced with O, S, S(O), SO_2, NH or N(W^1);

W^1 is alkyl, alkenyl or alkynyl;

C^1 and D^1 are independently H, R^9, R^{10}, R^{11}, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, or

one of C^1 and D^1 is H, and the other is R^9, R^{10}, R^{11} R^{12}, $C(O)OR^{12}$, F, Cl, Br, or I;

R^9 is phenyl which is unfused or fused with benzene, heteroarene or R^{9A}; R^{9A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{10} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{10A}; R^{10A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{11} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{11A}; R^{11A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{12} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, NH_2, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHSO_2R^{13}$, $NR^{13}SO_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $NHC(O)NH_2$, $NHC(O)R^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)N(R^{13})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{13} is R^{14}, R^{15} R^{16}, or R^{16A};

R^{14} is phenyl which is unfused or fused with benzene, heteroarene or R^{14A}; R^{14A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is unfused

or fused with R^{14B}; R^{14B} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

$R^{15}$is heteroaryl which is unfused or fused with benzene, heteroarene or R^{15A}; R^{15A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{16} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{16A}; R^{16A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{16A} is alkyl, alkenyl, or alkynyl; and

one or two or each of E^1 and F^1 and G^1 are independently H, CF_3, F, Cl, Br or I, and the remainder are independently R^{17}, R^{18}, R^{19}, R^{20} or OR^{20};

R^{17} is phenyl which is unfused or fused with benzene, heteroarene or R^{17A}; R^{17A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{18} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{18A}; R^{18A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{19} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{19A}; R^{19A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{20} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{20}, OR^{20}, SR^{20}, $S(O)R^{20}$, SO_2R^{20}, NH_2, NHR^{20}, $N(R^{20})_2$, $C(O)R^{20}$, $C(O)NH_2$, $C(O)NHR^{20}$, $C(O)N(R^{20})_2$, $NHC(O)R^{20}$, $NHC(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NHSO_2R^{20}$, $NR^{20}SO_2R^{20}$, $NHC(O)OR^{20}$, $NR^{20}C(O)OR^{20}$, SO_2NH_2, SO_2NHR^{20}, $SO_2N(R^{20})_2$, $NHC(O)NH_2$, $NHC(O)R^{20}$,

$NHC(O)N(R^{20})_2$, $NR^{20}C(O)N(R^{20})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{20} is R^{21}, R^{22} or R^{23};

R^{21} is phenyl which is unfused or fused with benzene, heteroarene or R^{21A}; R^{21A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

$R^{22}$is heteroaryl which is unfused or fused with benzene, heteroarene or R^{22A}; R^{22A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{23} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{23A}; R^{23A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

wherein each foregoing cyclic moiety is independently unsubstituted or substituted with one or two or three or four or five of independently selected spiroheteroalkyl, R^{30}, OR^{30}, SO_2R^{30}, $C(O)R^{30}$, NO, NO_2, NH_2, $N(R^{30})_2$, $C(O)NH_2$, $C(O)NHR^{30}$, $NHC(O)R^{30}$, $C(O)NHSO_2R^{30}$, SO_2NH_2, C(O)OH, OH, (O), CN, CF_3, OCF_3, F, Cl, Br, or I;

R^{30} is R^{31}, R^{32}, R^{33} or R^{34};

R^{31} is phenyl which is unfused or fused with benzene, heteroarene or R^{31A}; R^{31A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{32} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{32A}; R^{32A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{33} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{33A}; R^{33A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{34} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, NHR^{35}, $N(R^{35})_2$, $C(O)R^{35}$, $C(O)NH_2$, $C(O)NHR^{35}$, $C(O)N(R^{35})_2$, $NHC(O)R^{35}$, $NR^{35}C(O)R^{35}$, $NHSO_2R^{35}$, $NR^{35}SO_2R^{35}$, $NHC(O)OR^{35}$, $NR^{35}C(O)OR^{35}$, SO_2NH_2, SO_2NHR^{35}, $SO_2N(R^{35})_2$, $NHC(O)NH_2$, $NHC(O)R^{35}$ $NHC(O)N(R^{35})_2$, $NR^{35}C(O)N(R^{35})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{35} is R^{36}, R^{37}, R^{38} or R^{39};

R^{36} is phenyl which is unfused or fused with benzene, heteroarene or R^{36A}; R^{36A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{37} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{37A}; R^{37A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{38} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{38A}; R^{38A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{39} is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with NH_2, $N(R^{40})_2$, OR^{40}, or R^{40};

R^{40} is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl;

wherein the moieties represented by R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} and R^{40} are independently unsubstituted or substituted with one or two or three of independently selected R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O) or OH;

R^{50} is R^{51}, R^{52}, R^{53} or R^{54};

R^{51} is phenyl which is unfused or fused with benzene, heteroarene or R^{51A}; R^{51A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{52} is heteroaryl which is unfused or fused with benzene, heteroarene or R^{52A}; R^{52A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{53} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R^{53A}; R^{53A} is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;

R^{54} is alkyl, alkenyl, or alkynyl; each of which is unsubstituted or substituted with one, two, three, four or five of independently selected F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O), OH, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl and

wherein the moieties represented by R^{51}, R^{52}, and R^{53} are independently unsubstituted or substituted with one or two or three of independently selected $CO(O)R^{55}$, C(O)OH, (O), F, Cl, Br or I; and

R^{55} is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl.

3. A compound of claim 2 or a therapeutically acceptable salt thereof, wherein

A^1 is A^2, OA^2, SA^2, $S(O)A^2$, SO_2A^2, NH_2, NHA^2, $N(A^2)_2$, $C(O)A^2$, $C(O)NH_2$, $C(O)NHA^2$, $C(O)N(A^2)_2$, $NHC(O)A^2$, $NA^2C(O)A^2$, $NHSO_2A^2$, $NA^2SO_2A^2$, $NHC(O)OA^2$, $NA^2C(O)OA^2$, SO_2NH_2, SO_2NHA^2, $SO_2N(A^2)_2$, $NHC(O)NH_2$, $NHC(O)A^2$ $NHC(O)N(A^2)_2$, $NA^2C(O)N(A^2)_2$ F, Cl, Br, or I;

A^2 is R^1, R^2, R^3, or R^4;

R^1 is phenyl which is unfused or fused with benzene, heteroarene or R^{1A}; R^{1A} is cycloalkane, heterocycloalkane or heterocycloalkene;

R^2 is heteroaryl which is unfused or fused with benzene or heteroarene;

R^3 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene;

R^4 is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^5, OR^5, SR^5, $S(O)R^5$, SO_2R^5, NH_2, NHR^5, $N(R^5)_2$, $C(O)R^5$, $C(O)NH_2$, $C(O)NHR^5$, $C(O)N(R^5)_2$, $NHC(O)R^5$, $NR^5C(O)R^5$, $NHSO_2R^5$, $NR^5SO_2R^5$, $NHC(O)OR^5$, $NR^5C(O)OR^5$, SO_2NH_2, SO_2NHR^5, $SO_2N(R^5)_2$, $NHC(O)NH_2$, $NHC(O)R^5$, $NHC(O)N(R^5)_2$, $NR^5C(O)N(R^5)_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^5 is R^6, R^7 or R^8;

R^6 is phenyl which is unfused or fused with benzene;

R^7 is heteroaryl;

R^8 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;

L^1 is a bond or is alkylene, alkenylene, alkynylene or L^2; and B^1 is C(O)OH or a bioisostere thereof or is $C(O)OR^1$, $C(O)OR^2$, $C(O)OR^3$ or $C(O)OR^4$;

L^2 is C_2-C_6-alkylene, C_4-C_6-alkenylene or C_4-C_6-alkynylene, each of which has one CH_2 moiety replaced with O, S, S(O), SO_2, NH or $N(W^1)$;

W^1 is alkyl, alkenyl or alkynyl;

C^1 and D^1 are independently H, R^9, R^{10}, R^{11}, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, or

one of C^1 and D^1 is H, and the other is R^9, R^{10}, R^{11} R^{12}, $C(O)OR^{12}$, F, Cl, Br, or I;

R^9 is phenyl;

R^{10} is heteroaryl;

R^{11} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;

R^{12} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, NH_2, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHSO_2R^{13}$, $NR^{13}SO_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $NHC(O)NH_2$, $NHC(O)R^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)N(R^{13})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{13} is R^{14}, R^{15} R^{16}, or R^{16A};

R^{14} is phenyl which is unfused or fused with benzene, heteroarene or R^{14A}; R^{14A} is cycloalkane, or heterocycloalkane; each of which is unfused or fused with R^{14B}; R^{14B} is cycloalkane;

$R^{15}$is heteroaryl which is unfused or fused with benzene or heteroarene;

R^{16} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene;

R^{16A} is alkyl, alkenyl, or alkynyl; and

one or two or each of E^1 and F^1 and G^1 are independently H, CF_3, F, Cl, Br or I, and the remainder are independently R^{17}, R^{18}, R^{19}, R^{20} or OR^{20};

R^{17} is phenyl which is unfused or fused with benzene;

R^{18} is heteroaryl;

R^{19} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;

R^{20} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{20}, OR^{20}, SR^{20}, $S(O)R^{20}$, SO_2R^{20}, NH_2, NHR^{20}, $N(R^{20})_2$, $C(O)R^{20}$, $C(O)NH_2$, $C(O)NHR^{20}$, $C(O)N(R^{20})_2$, $NHC(O)R^{20}$, $NHC(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NHSO_2R^{20}$, $NR^{20}SO_2R^{20}$, $NHC(O)OR^{20}$, $NR^{20}C(O)OR^{20}$, SO_2NH_2, SO_2NHR^{20}, $SO_2N(R^{20})_2$, $NHC(O)NH_2$, $NHC(O)R^{20}$, $NHC(O)N(R^{20})_2$, $NR^{20}C(O)N(R^{20})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{20} is R^{21}, R^{22} or R^{23};

R^{21} is phenyl which is unfused or fused with benzene;

$R^{22}$is heteroaryl;

R^{23} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;

wherein each foregoing cyclic moiety is independently unsubstituted or substituted with one or two or three or four or five of independently selected spiroheteroalkyl, R^{30}, OR^{30}, SO_2R^{30}, $C(O)R^{30}$, NO, NO_2, NH_2, $N(R^{30})_2$, $C(O)NH_2$, $C(O)NHR^{30}$, $NHC(O)R^{30}$, $C(O)NHSO_2R^{30}$, SO_2NH_2, C(O)OH, OH, (O), CN, CF_3, OCF_3, F, Cl, Br, or I;

R^{30} is R^{31}, R^{32}, R^{33} or R^{34};

R^{31} is phenyl which is unfused or fused with benzene;

R^{32} is heteroaryl;

R^{33} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene;

R^{34} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, NHR^{35}, $N(R^{35})_2$, $C(O)R^{35}$, $C(O)NH_2$, $C(O)NHR^{35}$, $C(O)N(R^{35})_2$, $NHC(O)R^{35}$, $NR^{35}C(O)R^{35}$, $NHSO_2R^{35}$, $NR^{35}SO_2R^{35}$, $NHC(O)OR^{35}$, $NR^{35}C(O)OR^{35}$, SO_2NH_2, SO_2NHR^{35}, $SO_2N(R^{35})_2$, $NHC(O)NH_2$, $NHC(O)R^{35}$ $NHC(O)N(R^{35})_2$, $NR^{35}C(O)N(R^{35})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br or I;

R^{35} is R^{36}, R^{37}, R^{38} or R^{39};

R^{36} is phenyl which is unfused or fused with benzene or R^{36A}; R^{36A} is cycloalkene;

R^{37} is heteroaryl which is unfused or fused with benzene;

R^{38} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene;

R^{39} is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with NH_2, $N(R^{40})_2$, OR^{40}, or R^{40};

R^{40} is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl;

wherein the moieties represented by R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} and R^{40} are independently unsubstituted or substituted with one or two or three of independently selected R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O) or OH;

R^{50} is R^{51}, R^{52}, R^{53} or R^{54};

R^{51} is phenyl;

R^{52} is heteroaryl;

R^{53} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;

R^{54} is alkyl, alkenyl, or alkynyl; each of which is unsubstituted or substituted with one, two, three, four or five of independently selected F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O), OH, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl and

wherein the moieties represented by R^{51}, R^{52}, and R^{53} are independently unsubstituted or substituted with one or two or three of independently selected $CO(O)R^{55}$, C(O)OH, (O), F, Cl, Br or I; and

R^{55} is alkyl, alkenyl, alkynyl, phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl.

4. A compound of claim 3 or a therapeutically acceptable salt thereof, wherein

A^1 is A^2, NHA^2, $N(A^2)_2$, F, Cl, Br, or I;

A^2 is R^1, R^2, R^3, or R^4;

R^1 is phenyl which is unfused or fused with benzene, heteroarene or R^{1A}; R^{1A} is cycloalkane, heterocycloalkane or heterocycloalkene;

R^2 is heteroaryl which is unfused or fused with benzene or heteroarene;

R^3 is cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene;

R^4 is alkyl or alkenyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^5, OR^5, SR^5, C(O)OH, F, Cl, Br or I;

R^5 is R^6, R^7 or R^8;

R^6 is phenyl which is unfused or fused with benzene;

R^7 is heteroaryl;

R^8 is cycloalkyl;

L^1 is a bond and B^1 is C(O)OH or a bioisostere thereof or is $C(O)OR^4$;

C^1 and D^1 are independently H, R^9, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, or

one of C^1 and D^1 is H, and the other is R^{12}, F, Cl, Br, or I;

R^9 is phenyl;

R^{12} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{13}, OR^{13}, SR^{13}, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)N(R^{13})_2$, C(O)OH, F, Cl, Br or I;

R^{13} is R^{14}, R^{15} R^{16}, or R^{16A};

R^{14} is phenyl which is unfused or fused with benzene, heteroarene or R^{14A}; R^{14A} is cycloalkane, or heterocycloalkane; each of which is unfused or fused with R^{14B}; R^{14B} is cycloalkane;

$R^{15}$is heteroaryl which is unfused or fused with benzene or heteroarene;

R^{16} is cycloalkyl or heterocycloalkyl, each of which is unfused or fused with benzene;

R^{16A} is alkyl; and

one or two or each of E^1 and F^1 and G^1 are independently H, CF_3, F, Cl, Br or I, and the remainder are independently R^{17}, R^{20} or OR^{20};

R^{17} is phenyl which is unfused or fused with benzene;

R^{18} is heteroaryl;

R^{19} is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;

R^{20} is alkyl or alkenyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{20}, OR^{20}, F, Cl, Br or I;

R^{20} is R^{21};

R^{21} is phenyl which is unfused or fused with benzene;

wherein each foregoing cyclic moiety is independently unsubstituted or substituted with one or two or three or four or five of independently selected spiroheteroalkyl, R^{30}, OR^{30},

SO_2R^{30}, $C(O)R^{30}$, NO, NO_2, NH_2, $N(R^{30})_2$, $C(O)NH_2$, $C(O)NHR^{30}$, $NHC(O)R^{30}$, $C(O)NHSO_2R^{30}$, SO_2NH_2, C(O)OH, OH, (O), CN, CF_3, OCF_3, F, Cl, Br, or I;

R^{30} is R^{31}, R^{32}, R^{33} or R^{34};

R^{31} is phenyl which is unfused or fused with benzene;

R^{32} is heteroaryl;

R^{33} is cycloalkyl, cycloalkenyl, or heterocycloalkyl, each of which is unfused or fused with benzene;

R^{34} is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, $N(R^{35})_2$, $C(O)NHR^{35}$, OH, C(O)OH, F, Cl, Br or I;

R^{35} is R^{36}, R^{37}, R^{38} or R^{39};

R^{36} is phenyl which is unfused or fused with benzene or R^{36A}; R^{36A} is cycloalkene;

R^{37} is heteroaryl which is unfused or fused with benzene;

R^{38} is cycloalkyl, or heterocycloalkyl, each of which is unfused or fused with benzene;

R^{39} is alkyl, each of which is unsubstituted or substituted with NH_2, $N(R^{40})_2$, or OR^{40};

R^{40} is alkyl or phenyl;

wherein the moieties represented by R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} and R^{40} are independently unsubstituted or substituted with one or two or three of independently selected

R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, (O) or OH;

R^{50} is R^{51}, R^{52}, R^{53} or R^{54};

R^{51} is phenyl;

R^{52} is heteroaryl;

R^{53} is heterocycloalkyl;

R^{54} is alkyl; each of which is unsubstituted or substituted with one, two, three, four or five of independently selected OH, phenyl, or heteroaryl;

wherein the moieties represented by R^{51} and R^{53} are independently unsubstituted or substituted with one or two or three of independently selected $CO(O)R^{55}$, C(O)OH, (O), F, Cl, Br or I; and

R^{55} is alkyl.

5. The compound

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-phenylvinyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-phenyl-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((1E)-3-phenylprop-1-enyl)-1H-indole-2-carboxylic acid;

7-((E)-2-cyclohexylvinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-(benzyloxy)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-fluorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-naphthyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-naphthyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,1'-biphenyl-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-fluoro-1,1'-biphenyl-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(benzyloxy)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-pyridin-3-yl-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-pyridin-4-yl-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((1E)-5-phenylpent-1-enyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-carboxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(benzyloxy)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-ethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-ethylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-isopropoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-phenoxyphenyl)-1H-indole-2-carboxylic acid;

7-(2-carboxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-((5,6,7,8-tetrahydronaphthalen-1-yloxy)methyl)phenyl)-1H-indole-2-carboxylic acid;

7-(4-cyclohexylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-chlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-chloropyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,5-dichlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dichlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,3-dimethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,4-dimethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,5-dimethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,6-dimethoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methoxypyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methoxypyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-quinolin-4-yl-1H-indole-2-carboxylic acid;

7-(4-hydroxy-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(4-methylpiperazin-1-yl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,4-dichlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methoxyphenyl)-3-(3-((2-methyl-1-naphthyl)oxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-fluoro-2-isopropoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-ethoxy-1-naphthyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-amino-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(((2-(dimethylamino)ethyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-chloro-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,3-dichlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

7-(3-chloro-2-fluorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,3-difluorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-cyclopent-1-en-1-yl-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-cyclohex-1-en-1-yl-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-phenylcyclohex-1-en-1-yl)-1H-indole-2-carboxylic acid;

7-(2-cyclohexylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(6-carboxypyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-methyl-5-nitropyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,3-benzodioxol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((4-chloro-1-naphthyl)oxy)propyl)-7-(2-methoxyphenyl)-1H-indole-2-carboxylic acid;

3-(3-(2-bromophenoxy)propyl)-7-(2-methoxyphenyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-4-(((2-morpholin-4-ylethyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-methylquinolin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(hydroxymethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-(hydroxymethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

5-chloro-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-methylpyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2,6-dimethylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(6-amino-2-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-piperazin-1-ylphenyl)-1H-indole-2-carboxylic acid;

7-(4-(3-chlorophenyl)piperazin-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

5-chloro-3-(3-(1-naphthyloxy)propyl)-7-phenyl-1H-indole-2-carboxylic acid;

5-chloro-7-(4-chloro-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

5-chloro-7-cyclopent-1-en-1-yl-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dichloropyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-(aminocarbonyl)pyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-amino-2-(trifluoromethoxy)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-carboxy-2-methoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-nitrophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-carboxy-2-chlorophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-benzyl-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-amino-2-(trifluoromethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,4-dioxa-8-azaspiro(4.5)dec-8-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-carboxypiperidin-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxypiperidin-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-pyrrolidin-1-yl-1H-indole-2-carboxylic acid;

7-morpholin-4-yl-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-piperidin-1-yl-1H-indole-2-carboxylic acid;

7-(4-(aminosulfonyl)-2-(trifluoromethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

4-(2-(ethoxycarbonyl)-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoic acid;

7-(2-methyl-4-(morpholin-4-ylcarbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-((4-carboxypiperidin-1-yl)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-((3-carboxypiperidin-1-yl)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(carboxymethylcarbamoyl)-2-methylphenyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3,4-dihydroquinolin-1(2H)-yl)propyl)-7-(2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(3-phenoxyphenoxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(2,3-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylbenzyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3,3'-bis(3-(1-naphthyloxy)propyl)-1H,1'H-7,7'-biindole-2,2'-dicarboxylic acid;

3-(4-(3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(4-(3,4-dihydroquinolin-1(2H)-yl)butyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(4-(1-naphthyl)butyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(4-(1-naphthyloxy)butyl)-1H-indole-2-carboxylic acid;

3-(3-(2,4-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(2,5-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(1,1'-biphenyl-2-yl)-3-(4-(1-naphthyloxy)butyl)-1H-indole-2-carboxylic acid;

7-(4-((2-carboxypiperidin-1-yl)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-((S)-1-carboxy-2-methylpropylcarbamoyl)-2-methylphenyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

N-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-4-chlorophenylalanine;

N-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-L-tryptophan;

(3S)-2-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;

N-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-L-tyrosine;

7-(4-((R)-2-carboxypyrrolidine-1-carbonyl)-2-methylphenyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-((S)-1-carboxyethylcarbamoyl)-2-methylphenyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

N-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-4-nitro-L-phenylalanine;

N-(4-(2-carboxy-3-(3-(1-naphthyloxy)propyl)-1H-indol-7-yl)-3-methylbenzoyl)-L-phenylalanine;

7-(4-((((S)-carboxy(phenyl)methyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2,4,5-trichlorophenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2,3,4-trichlorophenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(2-tert-butylphenoxy)propyl)-7-(4-carboxy-2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2-(trifluoromethyl)phenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(quinolin-8-yloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-((5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)oxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3-benzoylphenoxy)propyl)-7-(4-carboxy-2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-1-(2-morpholin-4-ylethyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(cyclohexyloxy)phenyl)-3-(4-(1-naphthyloxy)butyl)-1H-indole-2-carboxylic acid;

7-(1,1'-biphenyl-2-yl)-1-(2-morpholin-4-ylethyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3,4-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(3,5-dimethylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(2,3-dimethoxyphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthylamino)propyl)-1H-indole-2-carboxylic acid;

1-(carboxymethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3-(dimethylamino)phenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(4-(3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(2-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(6-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(ethyl(1-naphthyl)amino)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(2,3-dihydro-1H-indol-1-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(2-methyl-2,3-dihydro-1H-indol-1-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-3-(4-(5-nitro-2,3-dihydro-1H-indol-1-yl)butyl)-1H-indole-2-carboxylic acid;

3-(4-(5-bromo-2,3-dihydro-1H-indol-1-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(2,3-dihydro-4H-1,4-benzoxazin-4-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(2,3,6-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(2,3-dichlorophenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(5-(5,6,7,8-tetrahydronaphthalen-1-yloxy)pentyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(5-(1-naphthyloxy)pentyl)-1H-indole-2-carboxylic acid;

7-(2,3-dimethylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-(4-fluorophenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-(2-(2-oxopyrrolidin-1-yl)ethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(tert-butoxycarbonyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)benzyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)benzyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-((E)-2-phenylvinyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(1-naphthyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(2-naphthyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(3-(2-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(4-(1-naphthyloxy)butyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(4-(2-naphthyloxy)butyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(2-(2-naphthyl)ethyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-thien-3-yl-1H-indole-2-carboxylic acid;

7-((3-(aminocarbonyl)phenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((3-cyanophenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((2-benzylphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,1'-biphenyl-2-ylamino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((2-ethylphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((2-propylphenyl)amino)-1H-indole-2-carboxylic acid;

7-(5-carboxy-3-methylthien-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((2-carboxyphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((3-carboxyphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-morpholin-4-yl-5-nitropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-amino-2-morpholin-4-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((3-chloropyridin-4-yl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((2-isopropylphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-morpholin-4-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-(aminocarbonyl)-1,2-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-cyano-1,2-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-amino-4-chloro-2-morpholin-4-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

2-methyl-3'-(3-(1-naphthyloxy)propyl)-2,3-dihydro-1'H-1,7'-biindole-2'-carboxylic acid;

7-(2-fluoro-5-methylpyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((2-methoxypyridin-3-yl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-oxo-1,2-dihydropyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(2-pyrrolidin-1-ylethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(dimethylamino)-5-nitropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(2-(dimethylamino)ethoxy)-5-methylpyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(2-morpholin-4-ylethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(1,4-dioxa-8-azaspiro(4.5)dec-8-yl)-5-nitropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(5-nitro-2-(4-oxopiperidin-1-yl)pyridin-3-yl)-1H-indole-2-carboxylic acid;

7-(5-amino-2-(dimethylamino)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(4-hydroxypiperidin-1-yl)-5-nitropyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(6-methoxy-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-fluoro-5-methylpyridin-4-yl)-1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

7-((2-morpholin-4-ylpyridin-3-yl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(2-phenylethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(2-pyridin-3-ylethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((2-morpholin-4-ylphenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((4-carboxypyridin-3-yl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((4-(trifluoromethyl)pyridin-3-yl)amino)-1H-indole-2-carboxylic acid;

7-(2-(3-aminopropoxy)-5-methylpyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(tetrahydrofuran-3-ylmethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(4-phenylbutoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(3-methoxyphenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-(carboxymethyl)-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-benzyl-1H-imidazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(2-methylphenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-(2-morpholin-4-ylethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-nitrophenyl)cyclohex-1-en-1-yl)-1H-indole-2-carboxylic acid;

7-(4,4-dimethyl-2-phenylcyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-ethyl-7-(ethyl(phenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-anilino-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(tetrahydro-2H-pyran-3-ylmethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

Organización y
Digitalización CSA Ltda.

PATENTE DE INVENCIÓN

09-11589

2/2

7-(5-methyl-2-(2-(2-oxopyrrolidin-1-yl)ethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-2-(2-(4-methylpiperazin-1-yl)ethoxy)pyridin-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(2-oxocyclohexyl)pyridin-3-yl)-1H-indole-2-carboxylic acid;

7-(2-fluoro-5-methylpyridin-4-yl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5,5-dimethyl-2-phenylcyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(pyridin-3-ylamino)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(phenyl(propyl)amino)-1-propyl-1H-indole-2-carboxylic acid;

7-(3-cyclohex-1-en-1-ylpyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-pyridin-3-ylcyclohex-1-en-1-yl)-1H-indole-2-carboxylic acid;

3-(3-((8-chloroquinazolin-4-yl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

1-butyl-7-(butyl(phenyl)amino)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(7-chloro-1H-pyrrolo(2,3-c)pyridin-1-yl)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(3-cyclohexylpyridin-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1-(1,3-thiazol-5-ylmethyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)-1H-indole-2-carboxylic acid;

7-(1-(3,3-dimethyl-2-oxobutyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-cyclohex-1-en-1-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-(3,5-difluorobenzyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1-phenylvinyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1H-pyrrolo(2,3-c)pyridin-7-yl)-1H-indole-2-carboxylic acid;

7-(4-cyclohexylpyridin-3-yl)-3-(3-phenoxypropyl)-1H-indole-2-carboxylic acid;

7-(2,4-dimethyl-1,3-thiazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-(carboxymethyl)-1H-pyrrolo(2,3-c)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1-phenylethyl)-1H-indole-2-carboxylic acid;

7-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(2-chlorophenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-1H,1'H-7,7'-biindole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1-(2-(2-oxopyrrolidin-1-yl)ethyl)-1H-pyrrolo(2,3-c)pyridin-7-yl)-1H-indole-2-carboxylic acid;

7-(5-methyl-3-phenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(2-(1-naphthyloxy)ethyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(2-(2-naphthyloxy)ethyl)-1H-indole-2-carboxylic acid;

4-(2-(2,3-dichlorophenoxy)ethyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(1H-indol-4-yloxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

4-(2-(2-chloro-3-(trifluoromethyl)phenoxy)ethyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

1-methyl-3-(3-((1-methyl-1H-indol-4-yl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-(4-ethylphenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(4-isopropylphenyl)cyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-((3-methyloxetan-3-yl)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-tetrahydrofuran-3-yl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-pyridin-2-yl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-chloro-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-(2-(2-oxopyrrolidin-1-yl)ethoxy)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-(tetrahydrofuran-3-ylmethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-cyclopentyl-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-(2-morpholin-4-ylethoxy)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-morpholin-4-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-chloro-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-(2,3-dihydroxypropyl)-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(3-phenyl-5-(2-phenylethyl)-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-phenylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-vinylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-((1E)-prop-1-enyl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-(pyridin-3-ylmethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-isopropenyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-pentylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-propylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-isopropyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-diisopropyl-1-methyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-carboxy-1,3-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-(2-methylprop-1-enyl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-1-phenyl-1H-pyrazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-isobutyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2,3'-bipyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(4-methoxyphenyl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-(hydroxymethyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-bromo-7-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

7-(1,3-dimethyl-5-(phenoxymethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-methyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-bromo-7-(2-((E)-2-cyclohexylvinyl)-4-methylpyridin-3-yl)-1H-indole-2-carboxylic acid;

7-(3-isopropyl-1-methyl-5-(phenoxymethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,5-dimethyl-3-(phenoxymethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(anilinocarbonyl)-1-phenyl-1H-pyrazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-((3-chlorophenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,5-dimethyl-3-((3-phenoxyphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-bromo-4-(2-((4-bromo-1-naphthyl)oxy)ethyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(1,5-dimethyl-3-((4-morpholin-4-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-(((5-chloropyridin-3-yl)oxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethyl-1-(2-nitrophenyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((2-(phenylthio)ethyl)amino)-1H-indole-2-carboxylic acid;

7-(3-((2-cyanophenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-((4-(4-acetylpiperazin-1-yl)phenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-bromo-7-(2-methylphenyl)-4-(2-(1-naphthyloxy)ethyl)-1H-indole-2-carboxylic acid;

7-(1-(2-aminophenyl)-3,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-(1H-imidazol-1-ylmethyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-4-(2-(1-naphthyloxy)ethyl)-3-vinyl-1H-indole-2-carboxylic acid;

7-(4-((benzylamino)carbonyl)-1-phenyl-1H-pyrazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1-phenyl-4-(((3-pyrrolidin-1-ylpropyl)amino)carbonyl)-1H-pyrazol-5-yl)-1H-indole-2-carboxylic acid;

7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(1,3-thiazol-4-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-chloro-4-((4-morpholin-4-ylphenoxy)methyl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-isopropyl-1-methyl-3-((4-morpholin-4-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-isopropyl-1-methyl-5-((4-morpholin-4-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-isopropenyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid;

7-(1,5-dimethyl-3-((4-morpholin-4-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-((4-morpholin-4-ylphenoxy)methyl)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-2-pyrimidin-5-ylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methyl-6'-morpholin-4-yl-2,3'-bipyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid;

7-(4,6-dimethylpyrimidin-5-yl)-1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)-2-oxoethyl)-7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-((4-(1,1-dioxidothiomorpholin-4-yl)phenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4,6-dimethylpyrimidin-5-yl)-1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,5-dimethyl-3-((4-piperazin-1-ylphenoxy)methyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-((4-(4-acetylpiperazin-1-yl)phenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid;

7-(4,6-dimethylpyrimidin-5-yl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-((4-(4-(tert-butoxycarbonyl)piperazin-1-yl)phenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)ethyl)-7-(4,6-dimethylpyrimidin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(4-(1H-pyrazol-1-yl)phenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2,3,4-trifluorophenyl)-1H-indole-2-carboxylic acid;

7-(4-hydroxy-3-methoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(3,4,5-trimethoxyphenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(4-(trifluoromethoxy)phenyl)-1H-indole-2-carboxylic acid;

7-(2-methoxy-5-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-fluoro-4-methoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(4-(5-oxo-2,5-dihydro-1H-pyrazol-3-yl)phenyl)-1H-indole-2-carboxylic acid;

7-(3-(morpholin-4-ylmethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(morpholin-4-ylmethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-isopropoxy-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(4-(1H-pyrazol-5-yl)phenyl)-1H-indole-2-carboxylic acid;

7-(2,5-dimethylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2,4,5-trimethylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(3-(trifluoromethoxy)phenyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-4-propoxyphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-cyanophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2,3,5,6-tetramethylphenyl)-1H-indole-2-carboxylic acid;

7-(3-cyano-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-ethynyl-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-(((3-(dimethylamino)propyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-isopropylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-(((2-(dimethylamino)ethyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-5-(((2-morpholin-4-ylethyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-5-(((3-morpholin-4-ylpropyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-5-(((2-phenylethyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1H-indazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-((((1S,4R)-bicyclo(2.2.1)hept-2-ylmethyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-5-(((3-phenylpropyl)amino)carbonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-((2-isopropyl-5-methylphenoxy)methyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-chloro-6-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-benzylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2,4,6-triisopropylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(1-oxo-2,3-dihydro-1H-inden-4-yl)-1H-indole-2-carboxylic acid;

7-(2-cyclopentylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2',6'-dimethoxy-1,1'-biphenyl-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(5,6,7,8-tetrahydronaphthalen-1-yl)-1H-indole-2-carboxylic acid;

7-(4'-tert-butyl-1,1'-biphenyl-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-fluoro-2-methyl-3-((methylsulfonyl)methyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-(((2-hydroxy-1,1-dimethylethyl)amino)carbonyl)-2,3,4-trimethylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(4-(ethoxycarbonyl)piperazin-1-yl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-6-nitrophenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-propionylpiperazin-1-yl)phenyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-6-thien-2-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-(1,3-thiazol-4-ylmethyl)piperazin-1-yl)phenyl)-1H-indole-2-carboxylic acid;

7-(2-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(4-(methylsulfonyl)piperazin-1-yl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-((4-(tert-butoxycarbonyl)piperazin-1-yl)sulfonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-((4-ethylpiperazin-1-yl)sulfonyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-((4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)sulfonyl)phenyl)-1H-indole-2-carboxylic acid;

7-(3-((1S,4R)-2-hydroxybicyclo(2.2.1)hept-2-yl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((1E)-1-ethylbut-1-enyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((Z)-2-carboxy-1-pentylvinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5,7-dimethylpyrazolo(1,5-a)pyrimidin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)thien-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-7-(2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

7-(5-(((2-(dimethylamino)ethyl)(pyridin-2-yl)amino)methyl)thien-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-morpholin-4-yl-6-(trifluoromethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methoxy-2-phenyl-1-benzofuran-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

4-fluoro-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

4-fluoro-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-((2-adamantylamino)carbonyl)-6-methylimidazo(1,2-a)pyridin-8-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-(1-adamantyl)-3-carboxy-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(1-hydroxy-4-methoxycyclohexyl)-1-benzothien-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-chloro-3-methyl-1-tetrahydro-2H-pyran-2-yl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2,2,4-trimethyl-1-(phenylsulfonyl)-1,2-dihydroquinolin-3-yl)-1H-indole-2-carboxylic acid;

7-(7,8-dimethyl-2-(1-methyl-1-phenylethyl)imidazo(1,2-a)pyridin-6-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-(4-((2-fluorobenzoyl)amino)phenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-amino-3-(piperidin-1-ylcarbonyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(3-methyl-1-(2-nitrophenyl)-5-phenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5-methyl-1-(2-oxo-2-((2-phenylethyl)amino)ethyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(1-adamantyl)imidazo(1,2-a)pyridin-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,1-dioxido-1-benzothien-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-cyclohexyl-6-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-(((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)carbonyl)-2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-methyl-3,5-diphenyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((Z)-2-(1H-imidazol-1-yl)-1-phenylvinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-benzyl-2-methyl-4-nitro-1H-imidazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-prop-1-ynylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(phenylethynyl)phenyl)-1H-indole-2-carboxylic acid;

3,7-bis(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)-2-oxoethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-methylbenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(3-methylbenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(4-methylbenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-1-(3-morpholin-4-ylpropyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(1,1'-biphenyl-2-ylmethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(1,1'-biphenyl-3-ylmethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(1,1'-biphenyl-4-ylmethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2,4-dimethylbenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(4-carboxybenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(1,1'-biphenyl-2-ylmethyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(1,1'-biphenyl-3-ylmethyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(1,1'-biphenyl-4-ylmethyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2,4-dimethylbenzyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2,6-dichlorobenzyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(4-carboxybenzyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(6,6-dimethylcyclohex-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(5,5-dimethylcyclopent-1-en-1-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(7-phenylcyclohept-1-en-1-yl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-tricyclo(4.3.1.$1^{3,8}$)undec-4-en-4-yl-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-phenylcyclohept-1-en-1-yl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2,6,6-trimethylcyclohex-1-en-1-yl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((1R,4R)-1,7,7-trimethylbicyclo(2.2.1)hept-2-en-2-yl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-4-(trifluoromethyl)-1H-indole-2-carboxylic acid;

7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-4-(trifluoromethyl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)ethyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,1'-biphenyl-2-ylmethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1,1'-biphenyl-3-ylmethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(1-(2-(1-naphthyloxy)ethyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(phenoxymethyl)benzyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(2-phenoxyethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(3-(2-phenoxyethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(3-phenoxypropyl)phenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(3-(3-phenoxypropyl)phenyl)-1H-indole-2-carboxylic acid;

3-(3-(3-hydroxy-2-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(3-(2-methoxyethoxy)-2-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(1,2-dimethylprop-1-enyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(2-methyl-3-(2-morpholin-4-ylethoxy)phenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(2,3-dichlorophenoxy)propyl)-7-(2-morpholin-4-ylphenyl)-1H-indole-2-carboxylic acid;

1-(2-morpholin-4-ylethyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthylthio)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3-(2-methoxyethoxy)-5-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-morpholin-4-ylphenyl)-3-(3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3-methyl-5-(3-morpholin-4-ylpropoxy)phenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(3-(3-cyclohexylpropoxy)-5-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(3-(3-(2-carboxy-1H-indol-3-yl)propoxy)-5-methylphenoxy)propyl)-7-(2-morpholin-4-ylphenyl)-1H-indole-2-carboxylic acid;

7-bromo-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-1H-indole-2-carboxylic acid;

7-(1,1'-bi(cyclohexan)-2-en-2-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(2,3-dichlorophenoxy)propyl)-7-(1,2-dimethylprop-1-enyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-methyl-4-(trifluoromethyl)phenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-fluoro-2-methylphenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-methoxy-2-methylphenyl)-3-(3-(2,3,5-trimethylphenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid;

6-methyl-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(2,3-dichlorophenoxy)propyl)-7-(2-methylphenyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3,5-dichlorophenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

1-methyl-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-methyl-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(3-(aminomethyl)benzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(3-(aminomethyl)benzyl)-7-(2-morpholin-4-ylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(2-((E)-2-cyclohexylvinyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(3-carboxyphenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(2-pyridin-3-ylphenyl)vinyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(3-(((phenylsulfonyl)amino)carbonyl)phenyl)ethyl)-1H-indole-2-carboxylic acid;

7-(2-(3-((4-methylpiperidin-1-yl)carbonyl)phenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(3-(((2-pyrrolidin-1-ylethyl)amino)carbonyl)phenyl)ethyl)-1H-indole-2-carboxylic acid;

7-(2-(3-(((2-morpholin-4-ylethyl)amino)carbonyl)phenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(3-(((2-(dimethylamino)ethyl)amino)carbonyl)phenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-(((phenylsulfonyl)amino)carbonyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(2-pyridin-4-ylphenyl)vinyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(3-chlorophenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(3-((cyclohexylamino)carbonyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-(((2-phenoxyethyl)amino)carbonyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(3-(((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)carbonyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(3-((4-benzylpiperidin-1-yl)carbonyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-((4-phenylpiperazin-1-yl)carbonyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(3-((3-methylpiperidin-1-yl)carbonyl)phenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(3-(((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)carbonyl)phenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-((E)-2-phenylvinyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(1,1'-biphenyl-3-yl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(3-((1E)-3-phenylprop-1-enyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(4-((E)-2-phenylvinyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(4-((1E)-3-phenylprop-1-enyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(1,1'-biphenyl-4-yl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(1,1'-biphenyl-3-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(3-(3-phenylpropyl)phenyl)ethyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(2-chlorophenyl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-((E)-2-(1,1'-biphenyl-2-yl)vinyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-((E)-2-(2-((E)-2-phenylvinyl)phenyl)vinyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-phenylethyl)-1H-indole-2-carboxylic acid;

7-(2-(2-chlorophenyl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(1,1'-biphenyl-4-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-(2-phenylethyl)phenyl)ethyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-(4-(3-phenylpropyl)phenyl)ethyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-((2-cyanoquinolin-8-yl)oxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((2-acetyl-1-benzofuran-7-yl)oxy)propyl)-7-(4-carboxy-2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-((2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)oxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2,3-difluorophenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(3-methyl-2-nitrophenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2-methyl-3-nitrophenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2-chloro-3-(trifluoromethyl)phenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(4-carboxy-2-methylphenyl)-3-(3-(2-fluoro-3-(trifluoromethyl)phenoxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-chlorophenyl)-3-(3-(ethyl(1-naphthyl)amino)propyl)-1H-indole-2-carboxylic acid;

7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-3-(4-(5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)butyl)-1H-indole-2-carboxylic acid;

7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-3-(4-(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)butyl)-1H-indole-2-carboxylic acid;

3-(4-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)butyl)-7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-1H-indole-2-carboxylic acid;

3-(4-(3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(4-(2-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(4-(6-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(4-(8-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(4-(2-methyl-2,3-dihydro-1H-indol-1-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(4-(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)butyl)-1H-indole-2-carboxylic acid;

3-(4-(3-methyl-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(4-(3-(hydroxymethyl)-3,4-dihydroquinolin-1(2H)-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(4-(2,3-dihydro-4H-1,4-benzothiazin-4-yl)butyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

4-methoxy-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(((1R,4S)-8-hydroxy-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-((1R,4S)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((4-methoxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-((2-nitro-1-naphthyl)oxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((3-hydroxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(3,5-dimethylisoxazol-4-yl)-3-(3-(2,3,6,7-tetrahydro-1H,5H-pyrido(3,2,1-ij)quinolin-8-yloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(2,3,6,7-tetrahydro-1H,5H-pyrido(3,2,1-ij)quinolin-8-yloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-((2-nitroso-1-naphthyl)oxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((5-hydroxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(2,3,4-trifluorophenoxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3-chloro-2-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-((8-hydroxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(3-chloro-2-cyanophenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(2-bromo-3-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(3-methyl-2-vinylphenoxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(3-methyl-2-nitrophenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(2-amino-3-methylphenoxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((6-amino-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1,2,3,4-tetrahydronaphthalen-1-yloxy)prop-1-ynyl)-1H-indole-2-carboxylic acid;

3-(3-((6-(acryloylamino)-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-((6-(propionylamino)-1-naphthyl)oxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1,2,3,4-tetrahydronaphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((6-methoxy-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

1-(4-methoxybenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)prop-1-ynyl)-1H-indole-2-carboxylic acid;

3-(3-((2,3,4,5,6,7,8-heptafluoro-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-(1-benzothien-7-yloxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-((4-fluoro-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-((8-fluoro-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

3-(3-((5-fluoro-1-naphthyl)oxy)propyl)-7-(2-methylphenyl)-1H-indole-2-carboxylic acid;

7-fluoro-3-(2-isopropylphenyl)-1-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-fluoro-3-(2-methylphenyl)-1-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-((5-fluoro-1-naphthyl)oxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-2-(1H-tetraazol-5-yl)-1H-indole;

1-(4-methoxybenzyl)-7-(2-methylphenyl)-3-(3-(1-naphthyloxy)propyl)-2-(1H-tetraazol-5-yl)-1H-indole;

7-(1-methyl-1H-imidazol-5-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

7-(4,6-dimethylpyrimidin-5-yl)-1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)ethyl)-3-(3-(1-naphthyloxy)propyl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carboxylic acid;

7-(2-methylimidazo(1,2-a)pyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-2-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-((1-(pyridin-4-ylmethyl)pyridinium-4-yl)methyl)-1H-indole-2-carboxylate;

7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-4-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)-2-oxoethyl)-7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-1-(2-morpholin-4-ylethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)ethyl)-7-(2-ethyl-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-ethyl-4-methylpyridin-3-yl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-((4-(4-carboxyphenyl)piperazin-1-yl)methyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

3-(3-(1-naphthyloxy)propyl)-7-(2-piperazin-1-ylpyridin-3-yl)-1H-indole-2-carboxylic acid;

1-(2-(dimethylamino)-2-oxoethyl)-7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid;

7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(pyridin-3-ylmethyl)-1H-indole-2-carboxylic acid;

7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-1-(2-morpholin-4-yl-2-oxoethyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid; or

7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(2-oxo-2-piperazin-1-ylethyl)-1H-indole-2-carboxylic acid;

or a therapeutically acceptable salt thereof.

6. A composition comprising an excipient and a therapeutically effective amount of a compound having Formula I.

INDOLES SUSTITUIDOS EN LA POSICIÓN 7 INHIBIDORES DE Mcl-1

CAMPO DE LA INVENCIÓN


La presente invención se refiere a compuestos que inhiben la actividad de la proteína antiapoptótica Mcl-1, composiciones que contienen los compuestos, y métodos para tratar enfermedades relacionadas con la proteína Mcl-1 sobreexpresada o no regulada.

ANTECEDENTES DE LA INVENCIÓN

La proteína Mcl-1 está asociada con una cantidad de enfermedades. Por lo tanto, en la técnica terapéutica existe la necesidad de compuestos que se unan a la proteína Mcl-1 e inhiban su actividad .

SÍNTESIS DE LA INVENCIÓN

Por lo tanto, una forma de realización de la presente invención, se refiere a compuestos que inhiben la actividad de la proteína Mcl-1: los compuestos con la Fórmula I,



(I),

y las sales terapéuticamente aceptables de los mismos, donde

A^1 es A^2, OA^2, SA^2, $S(O)A^2$, SO_2A^2, NH_2, NHA^2, $N(A^2)_2$, $C(O)A^2$, $C(O)NH_2$, $C(O)NHA^2$, $C(O)N(A^2)_2$, $NHC(O)A^2$, $NA^2C(O)A^2$, $NHSO_2A^2$, $NA^2SO_2A^2$, $NHC(O)OA^2$, $NA^2C(O)OA^2$, SO_2NH_2, SO_2NHA^2, $SO_2N(A^2)_2$, $NHC(O)NH_2$, $NHC(O)A^2$ $NHC(O)N(A^2)_2$, $NA^2C(O)N(A^2)_2$ F, Cl, Br, o I;

A^2 es R^1, R^2, R^3, o R^4;

R^1 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{1A}; R^{1A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^2 es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{2A}; R^{2A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^3 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{3A}; R^{3A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^4 es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^5, OR^5, SR^5, $S(O)R^5$, SO_2R^5, NH_2, NHR^5, $N(R^5)_2$, $C(O)R^5$, $C(O)NH_2$, $C(O)NHR^5$, $C(O)N(R^5)_2$, $NHC(O)R^5$, $NR^5C(O)R^5$, $NHSO_2R^5$, $NR^5SO_2R^5$, $NHC(O)OR^5$, $NR^5C(O)OR^5$, SO_2NH_2, SO_2NHR^5, $SO_2N(R^5)_2$, $NHC(O)NH_2$, $NHC(O)R^5$, $NHC(O)N(R^5)_2$, $NR^5C(O)N(R^5)_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^5 es R^6, R^7 o R^8;

R^6 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{6A}; R^{6A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^7 es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{7A}; R^{7A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^8 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{8A}; R^{8A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

L^1 es un enlace o es alquileno, alquenileno, alquinileno o L^2; y B^1 es C(O)OH o un bioisóstero del mismo o es $C(O)OR^1$, $C(O)OR^2$, $C(O)OR^3$ o $C(O)OR^4$;

L^2 es C_2-C_6-alquileno, C_4-C_6-alquenileno o C_4-C_6-alquinileno, en cada uno de los cuales una porción CH_2 se reemplaza por O, S, S(O), SO_2, NH o $N(W^1)$;

W^1 es alquilo, alquenilo o alquinilo;

C^1 y D^1 son en forma independiente H, R^9, R^{10}, R^{11}, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, o uno de C^1 y D^1 es H, y el otro es R^9, R^{10}, R^{11} R^{12}, $C(O)OR^{12}$, F, Cl, Br, o I;

R^9 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{9A}; R^{9A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{10} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{10A}; R^{10A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{11} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{11A}; R^{11A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{12} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, NH_2, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHSO_2R^{13}$, $NR^{13}SO_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $NHC(O)NH_2$, $NHC(O)R^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)N(R^{13})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{13} es R^{14}, R^{15} R^{16}, o R^{16A};

R^{14} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{14A}; R^{14A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; donde cada uno de los cuales no está fusionado o está fusionado con R^{14B}; R^{14B} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{15} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{15A}; R^{15A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{16} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o

R^{16A}; R^{16A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{16A} es alquilo, alquenilo, o alquinilo; y

uno o dos o cada uno de E^1 y F^1 y G^1 son en forma independiente H, CF_3, F, Cl, Br o I, y los demás son en forma independiente R^{17}, R^{18}, R^{19}, R^{20} o OR^{20};

R^{17} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{17A}; R^{17A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{18} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{18A}; R^{18A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{19} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{19A}; R^{19A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{20} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{20}, OR^{20}, SR^{20}, $S(O)R^{20}$, SO_2R^{20}, NH_2, NHR^{20}, $N(R^{20})_2$, $C(O)R^{20}$, $C(O)NH_2$, $C(O)NHR^{20}$, $C(O)N(R^{20})_2$, $NHC(O)R^{20}$, $NHC(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NHSO_2R^{20}$, $NR^{20}SO_2R^{20}$, $NHC(O)OR^{20}$, $NR^{20}C(O)OR^{20}$, SO_2NH_2, SO_2NHR^{20}, $SO_2N(R^{20})_2$, $NHC(O)NH_2$, $NHC(O)R^{20}$, $NHC(O)N(R^{20})_2$, $NR^{20}C(O)N(R^{20})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{20} es R^{21}, R^{22} o R^{23};

R^{21} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{21A}; R^{21A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{22} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{22A}; R^{22A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{23} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{23A}; R^{23A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

donde cada porción cíclica que se ha mencionado en forma independiente no está sustituida o está sustituida con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre espiroheteroalquilo, R^{30}, OR^{30}, OCH_2R^{30}, SR^{30}, $S(O)R^{30}$, SO_2R^{30}, $C(O)R^{30}$, $CO(O)R^{30}$, $OC(O)R^{30}$, $OC(O)OR^{30}$, NO, NO_2, NH_2, NHR^{30}, $N(R^{30})_2$, CH_2R^{30}, $C(O)NH_2$, $C(O)NHR^{30}$, $C(O)N(R^{30})_2$, $NHC(O)R^{30}$, $NR^{30}C(O)R^{30}$, C(O)NHOH, $C(O)NHOR^{30}$, $C(O)NHSO_2R^{30}$, $C(O)NR^{30}SO_2R^{30}$, SO_2NH_2, SO_2NHR^{30}, $SO_2N(R^{30})_2$, CF_3, CF_2CF_3, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{30}$, $C(N)N(R^{30})_2$, =NO-(alquilen)-$C(O)CF_3$, CNOH, $CNOCH_3$, OH, (O), CN, N_3, CF_3, CF_2CF_3, OCF_3, OCF_2CF_3, F, Cl, Br, o I;

R^{30} es R^{31}, R^{32}, R^{33} o R^{34};

R^{31} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{31A}; R^{31A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{32} es heteroarilo que no está fusionado o está fusionado con benceno,

heteroareno o R^{32A}; R^{32A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{33} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{33A}; R^{33A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{34} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, NHR^{35}, $N(R^{35})_2$, $C(O)R^{35}$, $C(O)NH_2$, $C(O)NHR^{35}$, $C(O)N(R^{35})_2$, $NHC(O)R^{35}$, $NR^{35}C(O)R^{35}$, $NHSO_2R^{35}$, $NR^{35}SO_2R^{35}$, $NHC(O)OR^{35}$, $NR^{35}C(O)OR^{35}$, SO_2NH_2, SO_2NHR^{35}, $SO_2N(R^{35})_2$, $NHC(O)NH_2$, $NHC(O)R^{35}$ $NHC(O)N(R^{35})_2$, $NR^{35}C(O)N(R^{35})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{35} es R^{36}, R^{37}, R^{38} o R^{39};

R^{36} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{36A}; R^{36A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{37} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{37A}; R^{37A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{38} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{38A}; R^{38A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{39} es alquilo, alquenilo o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con NH_2, $N(R^{40})_2$, OR^{40}, o R^{40};

R^{40} es alquilo, alquenilo, alquinilo, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo;

donde las porciones representadas por R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} y R^{40} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O) o OH;

R^{50} es R^{51}, R^{52}, R^{53} o R^{54};

R^{51} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{51A}; R^{51A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{52} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{52A}; R^{52A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{53} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{53A}; R^{53A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;


R^{54} es alquilo, alquenilo, o alquinilo; donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados

en forma independiente entre F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O), OH, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo y

donde las porciones representadas por R^{51}, R^{52}, y R^{53} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre R^{55}, OR^{55}, OCH_2R^{55}, SR^{55}, $S(O)R^{55}$, SO_2R^{55}, $C(O)R^{55}$, $CO(O)R^{55}$, $OC(O)R^{55}$, $OC(O)OR^{55}$, NO_2, NH_2, NHR^{55}, $N(R^{55})_2$, CH_2R^{55}, $C(O)NH_2$, $C(O)NHR^{55}$, $C(O)N(R^{55})_2$, $NHC(O)R^{55}$, $NR^{55}C(O)R^{55}$, C(O)NHOH, $C(O)NHOR^{55}$, $C(O)NHSO_2R^{55}$, $C(O)NR^{55}SO_2R^{55}$, SO_2NH_2, SO_2NHR^{55}, $SO_2N(R^{55})_2$, CF_3, CF_2CF_3, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{55}$, $C(N)N(R^{55})_2$, =NO-(alquilen)-$C(O)CF_3$, CNOH, $CNOCH_3$, OH, (O), CN, N_3, CF_3, CF_2CF_3, OCF_3, OCF_2CF_3, F, Cl, Br o I; y

R^{55} es alquilo, alquenilo, alquinilo, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo.

Otra realización hace referencia a compuestos de la Fórmula I,



(I),

y sales aceptables para terapia de los mismos, donde

A^1 es A^2, OA^2, SA^2, $S(O)A^2$, SO_2A^2, NH_2, NHA^2, $N(A^2)_2$, $C(O)A^2$, $C(O)NH_2$, $C(O)NHA^2$, $C(O)N(A^2)_2$, $NHC(O)A^2$, $NA^2C(O)A^2$, $NHSO_2A^2$, $NA^2SO_2A^2$, $NHC(O)OA^2$, $NA^2C(O)OA^2$, SO_2NH_2, SO_2NHA^2, $SO_2N(A^2)_2$, $NHC(O)NH_2$, $NHC(O)A^2$ $NHC(O)N(A^2)_2$, $NA^2C(O)N(A^2)_2$ F, Cl, Br, o I;

A^2 es R^1, R^2, R^3, o R^4;

R^1 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{1A}; R^{1A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^2 es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{2A}; R^{2A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^3 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{3A}; R^{3A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^4 es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^5, OR^5, SR^5, $S(O)R^5$, SO_2R^5, NH_2, NHR^5, $N(R^5)_2$, $C(O)R^5$, $C(O)NH_2$, $C(O)NHR^5$, $C(O)N(R^5)_2$, $NHC(O)R^5$, $NR^5C(O)R^5$, $NHSO_2R^5$, $NR^5SO_2R^5$, $NHC(O)OR^5$, $NR^5C(O)OR^5$, SO_2NH_2, SO_2NHR^5, $SO_2N(R^5)_2$, $NHC(O)NH_2$, $NHC(O)R^5$, $NHC(O)N(R^5)_2$, $NR^5C(O)N(R^5)_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^5 es R^6, R^7 o R^8;

R^6 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o

R^{6A}; R^{6A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^7 es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{7A}; R^{7A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^8 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{8A}; R^{8A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

L^1 es un enlace o es alquileno, alquenileno, alquinileno o L^2; y B^1 es C(O)OH o un bioisóstero del mismo o es $C(O)OR^1$, $C(O)OR^2$, $C(O)OR^3$ o $C(O)OR^4$;

L^2 es C_2-C_6-alquileno, C_4-C_6-alquenileno o C_4-C_6-alquinileno, en cada uno de los cuales una porción CH_2 se reemplaza por O, S, S(O), SO_2, NH o $N(W^1)$;

W^1 es alquilo, alquenilo o alquinilo;

C^1 y D^1 son en forma independiente H, R^9, R^{10}, R^{11}, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, o uno de C^1 y D^1 es H, y el otro es R^9, R^{10}, R^{11} R^{12}, $C(O)OR^{12}$, F, Cl, Br, o I;

R^9 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{9A}; R^{9A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{10} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{10A}; R^{10A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{11} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{11A}; R^{11A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{12} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, NH_2, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHSO_2R^{13}$, $NR^{13}SO_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $NHC(O)NH_2$, $NHC(O)R^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)N(R^{13})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{13} es R^{14}, R^{15} R^{16}, o R^{16A};

R^{14} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{14A}; R^{14A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; donde cada uno de los cuales no está fusionado o está fusionado con R^{14B}; R^{14B} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{15} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{15A}; R^{15A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{16} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{16A}; R^{16A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{16A} es alquilo, alquenilo, o alquinilo; y

uno o dos o cada uno de E^1 y F^1 y G^1 son en forma independiente H, CF_3, F, Cl, Br o I, y los demás son en forma independiente R^{17}, R^{18}, R^{19}, R^{20} o OR^{20};

R^{17} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{17A}; R^{17A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{18} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{18A}; R^{18A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{19} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{19A}; R^{19A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{20} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{20}, OR^{20}, SR^{20}, $S(O)R^{20}$, SO_2R^{20}, NH_2, NHR^{20}, $N(R^{20})_2$, $C(O)R^{20}$, $C(O)NH_2$, $C(O)NHR^{20}$, $C(O)N(R^{20})_2$, $NHC(O)R^{20}$, $NHC(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NHSO_2R^{20}$, $NR^{20}SO_2R^{20}$, $NHC(O)OR^{20}$, $NR^{20}C(O)OR^{20}$, SO_2NH_2, SO_2NHR^{20}, $SO_2N(R^{20})_2$, $NHC(O)NH_2$, $NHC(O)R^{20}$, $NHC(O)N(R^{20})_2$, $NR^{20}C(O)N(R^{20})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{20} es R^{21}, R^{22} o R^{23};

R^{21} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{21A}; R^{21A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{22} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{22A}; R^{22A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{23} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{23A}; R^{23A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

donde cada porción cíclica que se ha mencionado en forma independiente no está sustituida o está sustituida con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre espiroheteroalquilo, R^{30}, OR^{30}, SO_2R^{30}, $C(O)R^{30}$, NO, NO_2, NH_2, $N(R^{30})_2$, $C(O)NH_2$, $C(O)NHR^{30}$, $NHC(O)R^{30}$, $C(O)NHSO_2R^{30}$, SO_2NH_2, C(O)OH, OH, (O), CN, CF_3, OCF_3, F, Cl, Br, o I;

R^{30} es R^{31}, R^{32}, R^{33} o R^{34};

R^{31} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{31A}; R^{31A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{32} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{32A}; R^{32A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{33} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o

R^{33A}; R^{33A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{34} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, NHR^{35}, $N(R^{35})_2$, $C(O)R^{35}$, $C(O)NH_2$, $C(O)NHR^{35}$, $C(O)N(R^{35})_2$, $NHC(O)R^{35}$, $NR^{35}C(O)R^{35}$, $NHSO_2R^{35}$, $NR^{35}SO_2R^{35}$, $NHC(O)OR^{35}$, $NR^{35}C(O)OR^{35}$, SO_2NH_2, SO_2NHR^{35}, $SO_2N(R^{35})_2$, $NHC(O)NH_2$, $NHC(O)R^{35}$ $NHC(O)N(R^{35})_2$, $NR^{35}C(O)N(R^{35})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{35} es R^{36}, R^{37}, R^{38} o R^{39};

R^{36} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{36A}; R^{36A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{37} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{37A}; R^{37A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{38} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{38A}; R^{38A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{39} es alquilo, alquenilo o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con NH_2, $N(R^{40})_2$, OR^{40}, o R^{40};

R^{40} es alquilo, alquenilo, alquinilo, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo;

donde las porciones representadas por R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} y R^{40} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O) o OH;

R^{50} es R^{51}, R^{52}, R^{53} o R^{54};

R^{51} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{51A}; R^{51A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{52} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{52A}; R^{52A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{53} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{53A}; R^{53A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;


R^{54} es alquilo, alquenilo, o alquinilo; donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O), OH, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo y

donde las porciones representadas por R^{51}, R^{52}, y R^{53} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en

forma independiente entre $CO(O)R^{55}$, C(O)OH, (O), F, Cl, Br o I; y

R^{55} es alquilo, alquenilo, alquinilo, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo.

Aún otra realización hace referencia a compuestos de la Fórmula (I)



(I),

y sales aceptables para terapia de los mismos, donde

A^1 es A^2, OA^2, SA^2, $S(O)A^2$, SO_2A^2, NH_2, NHA^2, $N(A^2)_2$, $C(O)A^2$, $C(O)NH_2$, $C(O)NHA^2$, $C(O)N(A^2)_2$, $NHC(O)A^2$, $NA^2C(O)A^2$, $NHSO_2A^2$, $NA^2SO_2A^2$, $NHC(O)OA^2$, $NA^2C(O)OA^2$, SO_2NH_2, SO_2NHA^2, $SO_2N(A^2)_2$, $NHC(O)NH_2$, $NHC(O)A^2$ $NHC(O)N(A^2)_2$, $NA^2C(O)N(A^2)_2$ F, Cl, Br, o I;

A^2 es R^1, R^2, R^3, o R^4;

R^1 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{1A}; R^{1A} es cicloalcano, heterocicloalcano o heterocicloalqueno;

R^2 es heteroarilo que no está fusionado o está fusionado con benceno o heteroareno;

R^3 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^4 es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^5, OR^5, SR^5, $S(O)R^5$, SO_2R^5, NH_2, NHR^5, $N(R^5)_2$, $C(O)R^5$, $C(O)NH_2$, $C(O)NHR^5$, $C(O)N(R^5)_2$, $NHC(O)R^5$, $NR^5C(O)R^5$, $NHSO_2R^5$, $NR^5SO_2R^5$, $NHC(O)OR^5$, $NR^5C(O)OR^5$, SO_2NH_2, SO_2NHR^5, $SO_2N(R^5)_2$, $NHC(O)NH_2$, $NHC(O)R^5$, $NHC(O)N(R^5)_2$, $NR^5C(O)N(R^5)_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^5 es R^6, R^7 o R^8;

R^6 es fenilo que no está fusionado o está fusionado con benceno;

R^7 es heteroarilo;

R^8 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo;

L^1 es un enlace o es alquileno, alquenileno, alquinileno o L^2; y B^1 es C(O)OH o un bioisóstero del mismo o es $C(O)OR^1$, $C(O)OR^2$, $C(O)OR^3$ o $C(O)OR^4$;

L^2 es C_2-C_6-alquileno, C_4-C_6-alquenileno o C_4-C_6-alquinileno, en cada uno de los cuales una porción CH_2 se reemplaza por O, S, S(O), SO_2, NH o $N(W^1)$;

W^1 es alquilo, alquenilo o alquinilo;

C^1 y D^1 son en forma independiente H, R^9, R^{10}, R^{11}, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, o uno de C^1 y D^1 es H, y el otro es R^9, R^{10}, R^{11} R^{12}, $C(O)OR^{12}$, F, Cl, Br, o I;

R^9 es fenilo;

R^{10} es heteroarilo;

R^{11} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo;

R^{12} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, NH_2, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHSO_2R^{13}$, $NR^{13}SO_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $NHC(O)NH_2$, $NHC(O)R^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)N(R^{13})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{13} es R^{14}, R^{15} R^{16}, o R^{16A};

R^{14} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{14A}; R^{14A} es cicloalcano, o heterocicloalcano; donde cada uno de los cuales no está fusionado o está fusionado con R^{14B}; R^{14B} es cicloalcano;

R^{15} es heteroarilo que no está fusionado o está fusionado con benceno o heteroareno;

R^{16} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^{16A} es alquilo, alquenilo, o alquinilo; y

uno o dos o cada uno de E^1 y F^1 y G^1 son en forma independiente H, CF_3, F, Cl, Br o I, y los demás son en forma independiente R^{17}, R^{18}, R^{19}, R^{20} o OR^{20};

R^{17} es fenilo que no está fusionado o está fusionado con benceno;

R^{18} es heteroarilo;

R^{19} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo;

R^{20} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{20}, OR^{20}, SR^{20}, $S(O)R^{20}$, SO_2R^{20}, NH_2, NHR^{20}, $N(R^{20})_2$, $C(O)R^{20}$, $C(O)NH_2$, $C(O)NHR^{20}$, $C(O)N(R^{20})_2$, $NHC(O)R^{20}$, $NHC(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NHSO_2R^{20}$, $NR^{20}SO_2R^{20}$, $NHC(O)OR^{20}$, $NR^{20}C(O)OR^{20}$, SO_2NH_2, SO_2NHR^{20}, $SO_2N(R^{20})_2$, $NHC(O)NH_2$, $NHC(O)R^{20}$, $NHC(O)N(R^{20})_2$, $NR^{20}C(O)N(R^{20})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{20} es R^{21}, R^{22} o R^{23};

R^{21} es fenilo que no está fusionado o está fusionado con benceno;

R^{22} es heteroarilo;

R^{23} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo;

donde cada porción cíclica que se ha mencionado en forma independiente no está sustituida o está sustituida con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre espiroheteroalquilo, R^{30}, OR^{30}, SO_2R^{30}, $C(O)R^{30}$, NO, NO_2, NH_2, $N(R^{30})_2$, $C(O)NH_2$, $C(O)NHR^{30}$, $NHC(O)R^{30}$, $C(O)NHSO_2R^{30}$, SO_2NH_2, C(O)OH, OH, (O), CN, CF_3, OCF_3, F, Cl, Br, o I;

R^{30} es R^{31}, R^{32}, R^{33} o R^{34};

R^{31} es fenilo que no está fusionado o está fusionado con benceno;

R^{32} es heteroarilo;

R^{33} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^{34} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, NHR^{35}, $N(R^{35})_2$, $C(O)R^{35}$, $C(O)NH_2$, $C(O)NHR^{35}$, $C(O)N(R^{35})_2$, $NHC(O)R^{35}$, $NR^{35}C(O)R^{35}$, $NHSO_2R^{35}$, $NR^{35}SO_2R^{35}$, $NHC(O)OR^{35}$, $NR^{35}C(O)OR^{35}$, SO_2NH_2, SO_2NHR^{35}, $SO_2N(R^{35})_2$, $NHC(O)NH_2$, $NHC(O)R^{35}$ $NHC(O)N(R^{35})_2$, $NR^{35}C(O)N(R^{35})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{35} es R^{36}, R^{37}, R^{38} o R^{39};

R^{36} es fenilo que no está fusionado o está fusionado con benceno o R^{36A}; R^{36A} es cicloalqueno;

R^{37} es heteroarilo que no está fusionado o está fusionado con benceno;

R^{38} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^{39} es alquilo, alquenilo o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con NH_2, $N(R^{40})_2$, OR^{40}, o R^{40};

R^{40} es alquilo, alquenilo, alquinilo, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo;

donde las porciones representadas por R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} y R^{40} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O) o OH;

R^{50} es R^{51}, R^{52}, R^{53} o R^{54};

R^{51} es fenilo;

R^{52} es heteroarilo;


R^{53} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo;

R^{54} es alquilo, alquenilo, o alquinilo; donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O), OH, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo y

donde las porciones representadas por R^{51}, R^{52}, y R^{53} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre $CO(O)R^{55}$, C(O)OH, (O), F, Cl, Br o I; y

R^{55} es alquilo, alquenilo, alquinilo, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo.

Aún otra realización hace referencia a compuestos de la Fórmula (I)



(I),

y sales aceptables para terapia de los mismos, donde

A^1 es A^2, NHA^2, $N(A^2)_2$, F, Cl, Br, o I;

A^2 es R^1, R^2, R^3, o R^4;

R^1 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{1A}; R^{1A} es cicloalcano, heterocicloalcano o heterocicloalqueno;

R^2 es heteroarilo que no está fusionado o está fusionado con benceno o heteroareno;

R^3 es cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^4 es alquilo o alquenilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^5, OR^5, SR^5, C(O)OH, F, Cl, Br o I;

R^5 es R^6, R^7 o R^8;

R^6 es fenilo que no está fusionado o está fusionado con benceno;

R^7 es heteroarilo;

R^8 es cicloalquilo;

L^1 es un enlace y B^1 es C(O)OH o un bioisóstero del mismo o es $C(O)OR^4$;

C^1 y D^1 son en forma independiente H, R^9, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, o

uno de C^1 y D^1 es H, y el otro es R^{12}, F, Cl, Br, o I;

R^9 es fenilo;

R^{12} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{13}, OR^{13}, SR^{13}, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)N(R^{13})_2$, C(O)OH, F, Cl, Br o I;

R^{13} es R^{14}, R^{15} R^{16}, o R^{16A};

R^{14} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{14A}; R^{14A} es cicloalcano, o heterocicloalcano; donde cada uno de los cuales no está fusionado o está fusionado con R^{14B}; R^{14B} es cicloalcano;

R^{15} es heteroarilo que no está fusionado o está fusionado con benceno o heteroareno;

R^{16} es cicloalquilo o heterocicloalquilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^{16A} es alquilo; y

uno o dos o cada uno de E^1 y F^1 y G^1 son en forma independiente H, CF_3, F, Cl, Br o I, y los demás son en forma independiente R^{17}, R^{20} o OR^{20};

R^{17} es fenilo que no está fusionado o está fusionado con benceno;

R^{18} es heteroarilo;

R^{19} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo;

R^{20} es alquilo o alquenilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{20}, OR^{20}, F, Cl, Br o I;

R^{20} es R^{21};

R^{21} es fenilo que no está fusionado o está fusionado con benceno;

donde cada porción cíclica que se ha mencionado en forma independiente no está sustituida o está sustituida con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre espiroheteroalquilo, R^{30}, OR^{30}, SO_2R^{30}, $C(O)R^{30}$, NO, NO_2, NH_2, $N(R^{30})_2$, $C(O)NH_2$, $C(O)NHR^{30}$, $NHC(O)R^{30}$, $C(O)NHSO_2R^{30}$, SO_2NH_2, C(O)OH, OH, (O), CN, CF_3, OCF_3, F, Cl, Br, o I;

R^{30} es R^{31}, R^{32}, R^{33} o R^{34};

R^{31} es fenilo que no está fusionado o está fusionado con benceno;

R^{32} es heteroarilo;

R^{33} es cicloalquilo, cicloalquenilo, o heterocicloalquilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^{34} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, $N(R^{35})_2$, $C(O)NHR^{35}$, OH, C(O)OH, F, Cl, Br o I;

R^{35} es R^{36}, R^{37}, R^{38} o R^{39};

R^{36} es fenilo que no está fusionado o está fusionado con benceno o R^{36A}; R^{36A} es cicloalqueno;

R^{37} es heteroarilo que no está fusionado o está fusionado con benceno;

R^{38} es cicloalquilo, o heterocicloalquilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^{39} es alquilo, donde cada uno de los cuales no está sustituido o está sustituido con NH_2, $N(R^{40})_2$, o OR^{40};

R^{40} es alquilo o fenilo;

donde las porciones representadas por R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} y R^{40} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, (O) o OH;

R^{50} es R^{51}, R^{52}, R^{53} o R^{54};

R^{51} es fenilo;

R^{52} es heteroarilo;

R^{53} es heterocicloalquilo;

R^{54} es alquilo; donde cada uno de los cuales no está sustituido o está sustituido

con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre OH, fenilo, o heteroarilo;

donde las porciones representadas por R^{51} y R^{53} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre $CO(O)R^{55}$, C(O)OH, (O), F, Cl, Br o I; y

R^{55} es alquilo.

Aún otra realización hace referencia a composiciones que comprenden un excipiente y una cantidad eficaz para terapia de un compuesto de la Fórmula I.

Aún otra realización hace referencia a

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-fenilvinil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-fenil-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((1E)-3-fenilprop-1-enil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-ciclohexilvinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-(benciloxi)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-fluorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-naftil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-naftil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,1'-bifenil-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-fluoro-1,1'-bifenil-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(benciloxi)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-piridin-3-il-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-piridin-4-il-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((1E)-5-fenilpent-1-enil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-carboxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(benciloxi)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-etoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-etilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-isopropoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-fenoxifenil)-1H-indol-2-carboxílico;

ácido 7-(2-carboxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-((5,6,7,8-tetrahidronaftalen-1-iloxi)metil)fenil)-1H-indol-2-carboxílico;

ácido 7-(4-ciclohexilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-clorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-cloropiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,5-diclorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-diclorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,3-dimetoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,4-dimetoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,5-dimetoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,6-dimetoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metoxipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metoxipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-quinolin-4-il-1H-indol-2-carboxílico;

ácido 7-(4-hidroxi-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-metilpiperazin-1-il)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,4-diclorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metoxifenil)-3-(3-((2-metil-1-naftil)oxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-fluoro-2-isopropoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-etoxi-1-naftil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-amino-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(((2-(dimetilamino)etil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-cloro-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,3-diclorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 7-(3-cloro-2-fluorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,3-difluorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-ciclopent-1-en-1-il-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-ciclohex-1-en-1-il-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-fenilciclohex-1-en-1-il)-1H-indol-2-carboxílico;

ácido 7-(2-ciclohexilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(6-carboxipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-metil-5-nitropiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,3-dihidro-1,4-benzodioxin-6-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,3-benzodioxol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((4-cloro-1-naftil)oxi)propil)-7-(2-metoxifenil)-1H-indol-2-carboxílico;

ácido 3-(3-(2-bromofenoxi)propil)-7-(2-metoxifenil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-4-(((2-morfolin-4-iletil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-metilquinolin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(hidroximetil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-(hidroximetil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 5-cloro-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-metilpiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,6-dimetilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(6-amino-2-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-piperazin-1-ilfenil)-1H-indol-2-carboxílico;

ácido 7-(4-(3-clorofenil)piperazin-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 5-cloro-3-(3-(1-naftiloxi)propil)-7-fenil-1H-indol-2-carboxílico;

ácido 5-cloro-7-(4-cloro-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 5-cloro-7-ciclopent-1-en-1-il-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dicloropiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-(aminocarbonil)piridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-cloro-5-(trifluorometil)piridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-amino-2-(trifluorometoxi)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-carboxi-2-metoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-nitrofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-carboxi-2-clorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-bencil-3-metil-1,2,3,6-tetrahidropiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-amino-2-(trifluorometil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,4-dioxa-8-azaespiro(4,5)dec-8-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-carboxipiperidin-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxipiperidin-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-pirrolidin-1-il-1H-indol-2-carboxílico;

ácido 7-morfolin-4-il-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-piperidin-1-il-1H-indol-2-carboxílico;

ácido 7-(4-(aminosulfonil)-2-(trifluorometil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 4-(2-(etoxicarbonil)-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoico;

ácido 7-(2-metil-4-(morfolin-4-ilcarbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-((4-carboxipiperidin-1-il)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-((3-carboxipiperidin-1-il)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(carboximetilcarbamoil)-2-metilfenil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3,4-dihidroquinolin-1(2H)-il)propil)-7-(2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(3-fenoxifenoxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,3-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilbencil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3,3'-bis(3-(1-naftiloxi)propil)-1H,1'H-7,7'-biindol-2,2'-dicarboxílico;

ácido 3-(4-(3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(4-(3,4-dihidroquinolin-1(2H)-il)butil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(4-(1-naftil)butil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(4-(1-naftiloxi)butil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,4-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,5-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(1,1'-bifenil-2-il)-3-(4-(1-naftiloxi)butil)-1H-indol-2-carboxílico;

ácido 7-(4-((2-carboxipiperidin-1-il)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-((S)-1-carboxi-2-metilpropilcarbamoil)-2-metilfenil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-4-clorofenilalanina;

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-L-triptofano;

ácido (3S)-2-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-1,2,3,4-tetrahidroisoquinolin-3-carboxílico;

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-L-tirosina;

ácido 7-(4-((R)-2-carboxipirrolidin-1-carbonil)-2-metilfenil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-((S)-1-carboxietilcarbamoil)-2-metilfenil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-4-nitro-L-

fenilalanina;

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-L-fenilalanina;

ácido 7-(4-((((S)-carboxi(fenil)metil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2,4,5-triclorofenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2,3,4-triclorofenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(2-tert-butilfenoxi)propil)-7-(4-carboxi-2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2-(trifluorometil)fenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(quinolin-8-iloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-((5-oxo-5,6,7,8-tetrahidronaftalen-1-il)oxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-benzoilfenoxi)propil)-7-(4-carboxi-2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-1-(2-morfolin-4-iletil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(ciclohexiloxi)fenil)-3-(4-(1-naftiloxi)butil)-1H-indol-2-carboxílico;

ácido 7-(1,1'-bifenil-2-il)-1-(2-morfolin-4-iletil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3,4-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(3,5-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,3-dimetoxifenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftilamino)propil)-1H-indol-2-carboxílico;

ácido 1-(carboximetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-(dimetilamino)fenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(4-(3,4-dihidroquinolin-1(2H)-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(2-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(6-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(6-metoxi-3,4-dihidroquinolin-1(2H)-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(etil(1-naftil)amino)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(2,3-dihidro-1H-indol-1-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-

(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(2-metil-2,3-dihidro-1H-indol-1-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-3-(4-(5-nitro-2,3-dihidro-1H-indol-1-il)butil)-1H-indol-2-carboxílico;

ácido 3-(4-(5-bromo-2,3-dihidro-1H-indol-1-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(2,3-dihidro-4H-1,4-benzoxazin-4-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(2,3,6-trimetilfenoxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,3-diclorofenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(5-(5,6,7,8-tetrahidronaftalen-1-iloxi)pentil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(5-(1-naftiloxi)pentil)-1H-indol-2-carboxílico;

ácido 7-(2,3-dimetilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-fluorofenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-(2-(2-oxopirrolidin-1-il)etil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(tert-butoxicarbonil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)bencil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)bencil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-((E)-2-fenilvinil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(1-naftil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(2-naftil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(3-(2-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(4-(1-naftiloxi)butil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(4-(2-naftiloxi)butil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(2-(2-naftil)etil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-tien-3-il-1H-indol-2-carboxílico;

ácido 7-((3-(aminocarbonil)fenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((3-cianofenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((2-bencilfenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,1'-bifenil-2-ilamino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((2-etilfenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((2-propilfenil)amino)-1H-indol-2-carboxílico;

ácido 7-(5-carboxi-3-metiltien-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((2-carboxifenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((3-carboxifenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-morfolin-4-il-5-nitropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-amino-2-morfolin-4-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((3-cloropiridin-4-il)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((2-isopropilfenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-morfolin-4-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-(aminocarbonil)-1,2-dimetil-6-oxo-1,6-dihidropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-ciano-1,2-dimetil-6-oxo-1,6-dihidropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-amino-4-cloro-2-morfolin-4-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 2-metil-3'-(3-(1-naftiloxi)propil)-2,3-dihidro-1'H-1,7'-biindol-2'-carboxílico;

ácido 7-(2-fluoro-5-metilpiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((2-metoxipiridin-3-il)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-oxo-1,2-dihidropiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(2-pirrolidin-1-iletoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(dimetilamino)-5-nitropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(2-(dimetilamino)etoxi)-5-metilpiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(2-morfolin-4-iletoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(1,4-dioxa-8-azaespiro(4,5)dec-8-il)-5-nitropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(5-nitro-2-(4-oxopiperidin-1-il)piridin-3-il)-1H-indol-2-carboxílico;

ácido 7-(5-amino-2-(dimetilamino)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-hidroxipiperidin-1-il)-5-nitropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(6-metoxi-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-fluoro-5-metilpiridin-4-il)-1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 7-((2-morfolin-4-ilpiridin-3-il)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(2-feniletoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(2-piridin-3-iletoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((2-morfolin-4-ilfenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((4-carboxipiridin-3-il)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((4-(trifluorometil)piridin-3-il)amino)-1H-indol-2-carboxílico;

ácido 7-(2-(3-aminopropoxi)-5-metilpiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(tetrahidrofuran-3-ilmetoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(4-fenilbutoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(3-metoxifenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-(carboximetil)-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-bencil-1H-imidazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(2-metilfenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-(2-morfolin-4-iletil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-nitrofenil)ciclohex-1-en-1-il)-1H-indol-2-carboxílico;

ácido 7-(4,4-dimetil-2-fenilciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-etil-7-(etil(fenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-anilino-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(tetrahidro-2H-piran-3-ilmetoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(2-(2-oxopirrolidin-1-il)etoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(2-(4-metilpiperazin-1-il)etoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(2-oxociclohexil)piridin-3-il)-1H-indol-2-carboxílico;

ácido 7-(2-fluoro-5-metilpiridin-4-il)-1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5,5-dimetil-2-fenilciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(piridin-3-ilamino)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(fenil(propil)amino)-1-propil-1H-indol-2-carboxílico;

ácido 7-(3-ciclohex-1-en-1-ilpiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-piridin-3-ilciclohex-1-en-1-il)-1H-indol-2-carboxílico;

ácido 3-(3-((8-cloroquinazolin-4-il)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 1-butil-7-(butil(fenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(7-cloro-1H-pirrolo(2,3-c)piridin-1-il)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(3-ciclohexilpiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1-(1,3-tiazol-5-ilmetil)-1H-pirrolo(2,3-c)piridin-3-il)-1H-indol-2-carboxílico;

ácido 7-(1-(3,3-dimetil-2-oxobutil)-1H-pirrolo(2,3-c)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-ciclohex-1-en-1-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-(3,5-difluorobencil)-1H-pirrolo(2,3-c)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1-fenilvinil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1H-pirrolo(2,3-c)piridin-7-il)-1H-indol-2-carboxílico;

ácido 7-(4-ciclohexilpiridin-3-il)-3-(3-fenoxipropil)-1H-indol-2-carboxílico;

ácido 7-(2,4-dimetil-1,3-tiazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-(carboximetil)-1H-pirrolo(2,3-c)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1-feniletil)-1H-indol-2-carboxílico;

ácido 7-(1-bencil-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(2-clorofenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-1H,1'H-7,7'-biindol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1-(2-(2-oxopirrolidin-1-il)etil)-1H-pirrolo(2,3-c)piridin-7-il)-1H-indol-2-carboxílico;

ácido 7-(5-metil-3-fenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(2-(1-naftiloxi)etil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(2-(2-naftiloxi)etil)-1H-indol-2-carboxílico;

ácido 4-(2-(2,3-diclorofenoxi)etil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1H-indol-4-iloxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 4-(2-(2-cloro-3-(trifluorometil)fenoxi)etil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 1-metil-3-(3-((1-metil-1H-indol-4-il)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-etilfenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-isopropilfenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,3-dimetil-5-fenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,5-dimetil-3-fenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-((3-metiloxetan-3-il)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-tetrahidrofuran-3-il-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-piridin-2-il-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-cloro-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-(2-(2-oxopirrolidin-1-il)etoxi)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-(tetrahidrofuran-3-ilmetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-ciclopentil-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-((2,2-dimetil-1,3-dioxolan-4-il)metil)-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-(2-morfolin-4-iletoxi)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-morfolin-4-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-cloro-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-(2,3-dihidroxipropil)-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(3-fenil-5-(2-feniletil)-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-fenilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-vinilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-((1E)-prop-1-enil)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-(piridin-3-ilmetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-isopropenil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-pentilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-propilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-isopropil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-diisopropil-1-metil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-carboxi-1,3-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-(2-metilprop-1-enil)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-1-fenil-1H-pirazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-isobutil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2,3'-bipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-metoxifenil)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-(1-metil-1H-pirazol-4-il)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-(hidroximetil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-bromo-7-(1,3-dimetil-5-fenil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 7-(1,3-dimetil-5-(fenoximetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-metil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-bromo-7-(2-((E)-2-ciclohexilvinil)-4-metilpiridin-3-il)-1H-indol-2-carboxílico;

ácido 7-(3-isopropil-1-metil-5-(fenoximetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,5-dimetil-3-(fenoximetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(anilinocarbonil)-1-fenil-1H-pirazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-((3-clorofenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,5-dimetil-3-((3-fenoxifenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-bromo-4-(2-((4-bromo-1-naftil)oxi)etil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(1,5-dimetil-3-((4-morfolin-4-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-(((5-cloropiridin-3-il)oxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-(2-nitrofenil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((2-(feniltio)etil)amino)-1H-indol-2-carboxílico;

ácido 7-(3-((2-cianofenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-((4-(4-acetilpiperazin-1-il)fenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-bromo-7-(2-metilfenil)-4-(2-(1-naftiloxi)etil)-1H-indol-2-carboxílico;

ácido 7-(1-(2-aminofenil)-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-(1H-imidazol-1-ilmetil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(2-(1-naftiloxi)etil)-3-vinil-1H-indol-2-carboxílico;

ácido 7-(4-((bencilamino)carbonil)-1-fenil-1H-pirazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1-fenil-4-(((3-pirrolidin-1-ilpropil)amino)carbonil)-1H-pirazol-5-il)-1H-indol-2-carboxílico;

ácido 7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(1,3-tiazol-4-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-cloro-4-((4-morfolin-4-ilfenoxi)metil)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-isopropil-1-metil-3-((4-morfolin-4-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-isopropil-1-metil-5-((4-morfolin-4-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-isopropenil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(1,5-dimetil-3-((4-morfolin-4-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-((4-morfolin-4-ilfenoxi)metil)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-pirimidin-5-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-6'-morfolin-4-il-2,3'-bipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(4,6-dimetilpirimidin-5-il)-1-(2-(4-metilpiperazin-1-il)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)-2-oxoetil)-7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-((4-(1,1-dioxidotiomorfolin-4-il)fenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4,6-dimetilpirimidin-5-il)-1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,5-dimetil-3-((4-piperazin-1-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-((4-(4-acetilpiperazin-1-il)fenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(4,6-dimetilpirimidin-5-il)-1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-((4-(4-(tert-butoxicarbonil)piperazin-1-il)fenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)etil)-7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(4-(1H-pirazol-1-il)fenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2,3,4-trifluorofenil)-1H-indol-2-carboxílico;

ácido 7-(4-hidroxi-3-metoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(3,4,5-trimetoxifenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(4-(trifluorometoxi)fenil)-1H-indol-2-carboxílico;

ácido 7-(2-metoxi-5-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-fluoro-4-metoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(4-(5-oxo-2,5-dihidro-1H-pirazol-3-il)fenil)-1H-indol-

2-carboxílico;

ácido 7-(3-(morfolin-4-ilmetil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(morfolin-4-ilmetil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-isopropoxi-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(4-(1H-pirazol-5-il)fenil)-1H-indol-2-carboxílico;

ácido 7-(2,5-dimetilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2,4,5-trimetilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(3-(trifluorometoxi)fenil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-4-propoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-cianofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2,3,5,6-tetrametilfenil)-1H-indol-2-carboxílico;

ácido 7-(3-ciano-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-etinil-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-(((3-(dimetilamino)propil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-isopropilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-(((2-(dimetilamino)etil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-5-(((2-morfolin-4-iletil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-5-(((3-morfolin-4-ilpropil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-5-(((2-feniletil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1H-indazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-((((1S,4R)-biciclo(2,2,1)hept-2-ilmetil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-5-(((3-fenilpropil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-((2-isopropil-5-metilfenoxi)metil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-cloro-6-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-bencilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2,4,6-triisopropilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1-oxo-2,3-dihidro-1H-inden-4-il)-1H-indol-2-carboxílico;

ácido 7-(2-ciclopentilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2',6'-dimetoxi-1,1'-bifenil-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(5,6,7,8-tetrahidronaftalen-1-il)-1H-indol-2-

carboxílico;

ácido 7-(4'-tert-butil-1,1'-bifenil-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-fluoro-2-metil-3-((metilsulfonil)metil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-(((2-hidroxi-1,1-dimetiletil)amino)carbonil)-2,3,4-trimetilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-(etoxicarbonil)piperazin-1-il)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-6-nitrofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-propionilpiperazin-1-il)fenil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-6-tien-2-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-(1,3-tiazol-4-ilmetil)piperazin-1-il)fenil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-(2-hidroxietil)piperazin-1-il)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-(metilsulfonil)piperazin-1-il)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-((4-(tert-butoxicarbonil)piperazin-1-il)sulfonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-((4-etilpiperazin-1-il)sulfonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-((4-(2-oxopirrolidin-1-il)piperidin-1-il)sulfonil)fenil)-1H-indol-2-carboxílico;

ácido 7-(3-((1S,4R)-2-hidroxibiciclo(2,2,1)hept-2-il)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((1E)-1-etilbut-1-enil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((Z)-2-carboxi-1-pentilvinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5,7-dimetilpirazolo(1,5-a)pirimidin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(4-fluorofenil)-5-(4-(metilsulfonil)fenil)tien-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-7-(2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 7-(5-(((2-(dimetilamino)etil)(piridin-2-il)amino)metil)tien-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-morfolin-4-il-6-(trifluorometil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metoxi-2-fenil-1-benzofuran-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 4-fluoro-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 4-fluoro-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-((2-adamantilamino)carbonil)-6-metilimidazo(1,2-a)piridin-8-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-(1-adamantil)-3-carboxi-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(1-hidroxi-4-metoxiciclohexil)-1-benzotien-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-cloro-3-metil-1-tetrahidro-2H-piran-2-il-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2,2,4-trimetil-1-(fenilsulfonil)-1,2-dihidroquinolin-3-il)-1H-indol-2-carboxílico;

ácido 7-(7,8-dimetil-2-(1-metil-1-feniletil)imidazo(1,2-a)piridin-6-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-(4-((2-fluorobenzoil)amino)fenil)-3-(trifluorometil)-1H-pirazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-amino-3-(piperidin-1-ilcarbonil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-metil-1-(2-nitrofenil)-5-fenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-1-(2-oxo-2-((2-feniletil)amino)etil)-3-(trifluorometil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(1-adamantil)imidazo(1,2-a)piridin-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,1-dioxido-1-benzotien-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-ciclohexil-6-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(((2-(2-(2-aminoetoxi)etoxi)etil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-metil-3,5-difenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((Z)-2-(1H-imidazol-1-il)-1-fenilvinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-bencil-2-metil-4-nitro-1H-imidazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-prop-1-inilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(feniletinil)fenil)-1H-indol-2-carboxílico;

ácido 3,7-bis(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)-2-oxoetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-metilbencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-

carboxílico;

ácido 1-(3-metilbencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(4-metilbencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-1-(3-morfolin-4-ilpropil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-1-(2-(4-metilpiperazin-1-il)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(1,1'-bifenil-2-ilmetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(1,1'-bifenil-3-ilmetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(1,1'-bifenil-4-ilmetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2,4-dimetilbencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(4-carboxibencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(1,1'-bifenil-2-ilmetil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(1,1'-bifenil-3-ilmetil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(1,1'-bifenil-4-ilmetil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2,4-dimetilbencil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2,6-diclorobencil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(4-carboxibencil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(6,6-dimetilciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5,5-dimetilciclopent-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(7-fenilciclohept-1-en-1-il)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-triciclo(4,3,1,$1^{3,8}$)undec-4-en-4-il-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-fenilciclohept-1-en-1-il)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2,6,6-trimetilciclohex-1-en-1-il)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((1R,4R)-1,7,7-trimetilbiciclo(2,2,1)hept-2-en-2-il)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-4-(trifluorometil)-1H-indol-2-carboxílico;

ácido 7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-4-(trifluorometil)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)etil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,1'-bifenil-2-ilmetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,1'-bifenil-3-ilmetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-(2-(1-naftiloxi)etil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(fenoximetil)bencil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(2-fenoxietil)fenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(3-(2-fenoxietil)fenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(3-fenoxipropil)fenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(3-(3-fenoxipropil)fenil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-hidroxi-2-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-(2-metoxietoxi)-2-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(1,2-dimetilprop-1-enil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(2-metil-3-(2-morfolin-4-iletoxi)fenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,3-diclorofenoxi)propil)-7-(2-morfolin-4-ilfenil)-1H-indol-2-carboxílico;

ácido 1-(2-morfolin-4-iletil)-7-(2-morfolin-4-ilfenil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftiltio)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-(2-metoxietoxi)-5-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-morfolin-4-ilfenil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-metil-5-(3-morfolin-4-ilpropoxi)fenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-(3-ciclohexilpropoxi)-5-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-(3-(2-carboxi-1H-indol-3-il)propoxi)-5-metilfenoxi)propil)-7-(2-morfolin-4-ilfenil)-1H-indol-2-carboxílico;

ácido 7-bromo-3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(1,1'-bi(ciclohexan)-2-en-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,3-diclorofenoxi)propil)-7-(1,2-dimetilprop-1-enil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-4-(trifluorometil)fenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-fluoro-2-metilfenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metoxi-2-metilfenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico;

ácido 6-metil-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,3-diclorofenoxi)propil)-7-(2-metilfenil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3,5-diclorofenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 1-metil-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-metil-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(3-(aminometil)bencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(3-(aminometil)bencil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(2-((E)-2-ciclohexilvinil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(3-carboxifenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(2-piridin-3-ilfenil)vinil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(3-(((fenilsulfonil)amino)carbonil)fenil)etil)-1H-indol-2-carboxílico;

ácido 7-(2-(3-((4-metilpiperidin-1-il)carbonil)fenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(3-(((2-pirrolidin-1-iletil)amino)carbonil)fenil)etil)-1H-indol-2-carboxílico;

ácido 7-(2-(3-(((2-morfolin-4-iletil)amino)carbonil)fenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(3-(((2-(dimetilamino)etil)amino)carbonil)fenil)etil)-3-(3-(1-

naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-(((fenilsulfonil)amino)carbonil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(2-piridin-4-ilfenil)vinil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(3-clorofenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(3-((ciclohexilamino)carbonil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-(((2-fenoxietil)amino)carbonil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(3-(((2-(2-(2-aminoetoxi)etoxi)etil)amino)carbonil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(3-((4-bencilpiperidin-1-il)carbonil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-((4-fenilpiperazin-1-il)carbonil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(3-((3-metilpiperidin-1-il)carbonil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(3-(((2-(2-(2-aminoetoxi)etoxi)etil)amino)carbonil)fenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-((E)-2-fenilvinil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(1,1'-bifenil-3-il)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-((1E)-3-fenilprop-1-enil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(4-((E)-2-fenilvinil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(4-((1E)-3-fenilprop-1-enil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(1,1'-bifenil-4-il)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(1,1'-bifenil-3-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(3-(3-fenilpropil)fenil)etil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(2-clorofenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(1,1'-bifenil-2-il)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(2-((E)-2-fenilvinil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-feniletil)-1H-indol-2-carboxílico;

ácido 7-(2-(2-clorofenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(1,1'-bifenil-4-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-(2-feniletil)fenil)etil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-(3-fenilpropil)fenil)etil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-((2-cianoquinolin-8-il)oxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((2-acetil-1-benzofuran-7-il)oxi)propil)-7-(4-carboxi-2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-((2,2-dimetil-2,3-dihidro-1-benzofuran-7-il)oxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2,3-difluorofenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(3-metil-2-nitrofenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2-metil-3-nitrofenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2-cloro-3-(trifluorometil)fenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2-fluoro-3-(trifluorometil)fenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-clorofenil)-3-(3-(etil(1-naftil)amino)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-3-(4-(5-oxo-2,3,4,5-tetrahidro-1H-1-benzazepin-1-il)butil)-1H-indol-2-carboxílico;

ácido 7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-3-(4-(2,3,4,5-tetrahidro-1H-1-benzazepin-1-il)butil)-1H-indol-2-carboxílico;

ácido 3-(4-(2,3-dihidro-4H-1,4-benzotiazin-4-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(4-(2-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(4-(6-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(4-(8-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(4-(2-metil-2,3-dihidro-1H-indol-1-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(4-(2,3,4,5-tetrahidro-1H-1-benzazepin-1-il)butil)-1H-indol-2-carboxílico;

ácido 3-(4-(3-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(4-(3-(hidroximetil)-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(4-(2,3-dihidro-4H-1,4-benzotiazin-4-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 4-metoxi-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(((1R,4S)-8-hidroxi-1,2,3,4-tetrahidro-1,4-metanonaftalen-5-il)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-((1R,4S)-1,2,3,4-tetrahidro-1,4-metanonaftalen-5-iloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((4-metoxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-((2-nitro-1-naftil)oxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((3-hidroxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetilisoxazol-4-il)-3-(3-(2,3,6,7-tetrahidro-1H,5H-pirido(3,2,1-ij)quinolin-8-iloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(2,3,6,7-tetrahidro-1H,5H-pirido(3,2,1-ij)quinolin-8-iloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-((2-nitroso-1-naftil)oxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((5-hidroxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(2,3,4-trifluorofenoxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-cloro-2-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-((8-hidroxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-cloro-2-cianofenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(2-bromo-3-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(3-metil-2-vinilfenoxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-metil-2-nitrofenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(2-amino-3-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((6-amino-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1,2,3,4-tetrahidronaftalen-1-iloxi)prop-1-inil)-1H-indol-2-carboxílico;

ácido 3-(3-((6-(acriloilamino)-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-((6-(propionilamino)-1-naftil)oxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1,2,3,4-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((6-metoxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 1-(4-metoxibencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)prop-1-inil)-1H-indol-2-carboxílico;

ácido 3-(3-((2,3,4,5,6,7,8-heptafluoro-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-benzotien-7-iloxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-((4-fluoro-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-((8-fluoro-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-((5-fluoro-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-fluoro-3-(2-isopropilfenil)-1-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-fluoro-3-(2-metilfenil)-1-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((5-fluoro-1-naftil)oxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-2-(1H-tetraazol-5-il)-1H-indol;

1-(4-metoxibencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-2-(1H-tetraazol-5-il)-1H-indol;

ácido 7-(1-metil-1H-imidazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 1-(2-(4-metilpiperazin-1-il)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 7-(4,6-dimetilpirimidin-5-il)-1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)etil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 7-(2-metilimidazo(1,2-a)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico;

7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-((1-(piridin-4-ilmetil)piridinio-4-il)metil)-1H-indol-2-carboxilato;

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)-2-oxoetil)-7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-1-(2-(4-metilpiperazin-1-il)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)etil)-7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-((4-(4-carboxifenil)piperazin-1-il)metil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-piperazin-1-ilpiridin-3-il)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)-2-oxoetil)-7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;


ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(2-oxo-2-piperazin-1-iletil)-1H-indol-2-carboxílico;

y sales, prodrogas, ésteres, amidas, sales de prodrogas, sales de ésteres y sales de amidas aceptables para terapia de los mismos.

Aún otra realización hace referencia a métodos para tratar mamíferos que tengan una enfermedad caracterizada por la sobreexpresión o desregulación de la proteina Mcl-1 que comprenden administrar al mismo una cantidad eficaz para terapia de un compuesto de la Fórmula I,



(I),

y sales aceptables para terapia del mismo, donde

A^1 es A^2, OA^2, SA^2, $S(O)A^2$, SO_2A^2, NH_2, NHA^2, $N(A^2)_2$, $C(O)A^2$, $C(O)NH_2$, $C(O)NHA^2$, $C(O)N(A^2)_2$, $NHC(O)A^2$, $NA^2C(O)A^2$, $NHSO_2A^2$, $NA^2SO_2A^2$, $NHC(O)OA^2$, $NA^2C(O)OA^2$, SO_2NH_2, SO_2NHA^2, $SO_2N(A^2)_2$, $NHC(O)NH_2$, $NHC(O)A^2$ $NHC(O)N(A^2)_2$, $NA^2C(O)N(A^2)_2$;

A^2 es R^1, R^2, R^3, R^4,

R^1 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{1A}; R^{1A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^2 es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{2A}; R^{2A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^3 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{3A}; R^{3A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^4 es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^5, OR^5, SR^5, $S(O)R^5$, SO_2R^5, NH_2, NHR^5, $N(R^5)_2$, $C(O)R^5$, $C(O)NH_2$, $C(O)NHR^5$, $C(O)N(R^5)_2$, $NHC(O)R^5$, $NR^5C(O)R^5$, $NHSO_2R^5$, $NR^5SO_2R^5$, $NHC(O)OR^5$, $NR^5C(O)OR^5$, SO_2NH_2, SO_2NHR^5, $SO_2N(R^5)_2$, $NHC(O)NH_2$, $NHC(O)R^5$, $NHC(O)N(R^5)_2$, $NR^5C(O)N(R^5)_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^5 es R^6, R^7 o R^8;

R^6 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{6A}; R^{6A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^7 es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{7A}; R^{7A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^8 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{8A}; R^{8A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

L^1 es un enlace o es alquileno, alquenileno, alquinileno o L^2; y B^1 es C(O)OH o un bioisóstero del mismo o es $C(O)OR^1$, $C(O)OR^2$, $C(O)OR^3$ o $C(O)OR^4$;

L^2 es C_2-C_6-alquileno, C_4-C_6-alquenileno o C_4-C_6-alquinileno, en cada uno de los cuales una porción CH_2 se reemplaza por O, S, S(O), SO_2, NH o $N(W^1)$;

W^1 es alquilo, alquenilo o alquinilo;

C^1 y D^1 son en forma independiente H, R^9, R^{10}, R^{11} o R^{12}; o

uno de C^1 y D^1 es H, y el otro es R^9, R^{10}, R^{11} o R^{12};

R^9 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{9A}; R^{9A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{10} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{10A}; R^{10A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{11} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{11A}; R^{11A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{12} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados

en forma independiente entre R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, NH_2, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHSO_2R^{13}$, $NR^{13}SO_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $NHC(O)NH_2$, $NHC(O)R^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)N(R^{13})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{13} es R^{14}, R^{15} o R^{16};

R^{14} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{14A}; R^{14A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{15} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{15A}; R^{15A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{16} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{16A}; R^{16A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; y

uno o dos o cada uno de E^1 y F^1 y G^1 son en forma independiente H, F, Cl, Br o I, y los demás son en forma independiente R^{17}, R^{18}, R^{19} o R^{20};

R^{17} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{17A}; R^{17A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{18} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{18A}; R^{18A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{19} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{19A}; R^{19A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{20} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{21}, OR^{20}, SR^{20}, $S(O)R^{20}$, SO_2R^{20}, NH_2, NHR^{20}, $N(R^{20})_2$, $C(O)R^{20}$, $C(O)NH_2$, $C(O)NHR^{20}$, $C(O)N(R^{20})_2$, $NHC(O)R^{20}$, $NHC(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NHSO_2R^{20}$, $NR^{20}SO_2R^{20}$, $NHC(O)OR^{20}$, $NR^{20}C(O)OR^{20}$, SO_2NH_2, SO_2NHR^{20}, $SO_2N(R^{20})_2$, $NHC(O)NH_2$, $NHC(O)R^{20}$, $NHC(O)N(R^{20})_2$, $NR^{20}C(O)N(R^{20})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{20} es R^{21}, R^{22} o R^{23};

R^{21} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{21A}; R^{21A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{22} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{22A}; R^{22A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{23} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{23A}; R^{23A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

donde cada porción cíclica que se ha mencionado en forma independiente no está sustituida o está sustituida con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre espiroheteroalquilo, R^{30}, OR^{30}, OCH_2R^{30}, SR^{30}, $S(O)R^{30}$, SO_2R^{30}, $C(O)R^{30}$, $CO(O)R^{30}$, $OC(O)R^{30}$, $OC(O)OR^{30}$, NO_2, NH_2, NHR^{30}, $N(R^{30})_2$, CH_2R^{30}, $C(O)NH_2$, $C(O)NHR^{30}$, $C(O)N(R^{30})_2$, $NHC(O)R^{30}$, $NR^{30}C(O)R^{30}$, C(O)NHOH, $C(O)NHOR^{30}$, $C(O)NHSO_2R^{30}$, $C(O)NR^{30}SO_2R^{30}$, SO_2NH_2, SO_2NHR^{30}, $SO_2N(R^{30})_2$, CF_3, CF_2CF_3, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{30}$, $C(N)N(R^{30})_2$, =NO-(alquilen)-$C(O)CF_3$, CNOH, $CNOCH_3$, OH, (O), N_3, CF_3, CF_2CF_3, OCF_3, OCF_2CF_3, F, Cl, Br o I;

R^{30} es R^{31}, R^{32}, R^{33} o R^{34};

R^{31} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{31A}; R^{31A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{32} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{32A}; R^{32A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{33} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{33A}; R^{33A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{34} es alquilo, alquenilo, o alquenilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, NHR^{35}, $N(R^{35})_2$, $C(O)R^{35}$, $C(O)NH_2$, $C(O)NHR^{35}$, $C(O)N(R^{35})_2$, $NHC(O)R^{35}$, $NR^{35}C(O)R^{35}$, $NHSO_2R^{35}$, $NR^{35}SO_2R^{35}$, $NHC(O)OR^{35}$, $NR^{35}C(O)OR^{35}$, SO_2NH_2, SO_2NHR^{35}, $SO_2N(R^{35})_2$, $NHC(O)NH_2$, $NHC(O)R^{35}$ $NHC(O)N(R^{35})_2$, $NR^{35}C(O)N(R^{35})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{35} es R^{36}, R^{37}, R^{38} o R^{39};

R^{36} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{36A}; R^{36A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{37} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{37A}; R^{37A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{38} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{38A}; R^{38A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{39} es alquilo, alquenilo o alquenilo, donde cada uno de los cuales no está sustituido o está sustituido con R^{40};

R^{40} es fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo;

donde las porciones representadas por R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} y R^{40} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre R^{50}, F, Cl, Br, I, C(O)OH, NO_2, NH_2, CF_3, (O) o OH;

R^{50} es R^{51}, R^{52}, R^{53} o R^{54};

R^{51} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{51A}; R^{51A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{52} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{52A}; R^{52A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{53} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{53A}; R^{53A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; y

R^{54} es alquilo, alquenilo, o alquinilo,

administrando o no un agente terapéutico adicional o más de uno y administrando también al mismo radioterapia o sin administrarla.

Aún otro forma de realización comprende métodos para tratar mamíferos con una enfermedad caracterizada por la sobreexpresión o la falta de regulación de la proteína Mcl-1 que comprende administrar al mismo cantidades terapéuticamente efectivas de un compuesto con la Fórmula I y un agente terapéutico adicional o más de uno, administrando también radioterapia al mismo o no.

DESCRIPCIÓN DETALLADA DE LA INVENCIÓN

Los grupos variables de los compuestos en la presente están representados por identificadores (letras en mayúscula con valores numéricos y/o alfabéticos en superíndice) y se pueden realizar específicamente.

Debe quedar claro que se mantienen las valencias correctas para todas las combinaciones que figuran aquí, que las unidades monovalentes con más de un átomo están unidas a través de sus extremos izquierdos, y que las unidades divalentes se han dibujado de izquierda a derecha.

También se podrá comprender que una realización específica de un grupo variable puede ser igual o diferente de otra realización específica que tiene al mismo identificador.

El término "alquenilo", como se usa en la presente, significa grupos de hidrocarburos monovalentes de cadena lineal o ramificada que contienen uno o más de un doble enlace carbono-carbono, tal como C_2-alquenilo, C_3-alquenilo, C_4-alquenilo, C_5-alquenilo, C_6-alquenilo y semejantes.

El término "alquenileno", según se usa aquí, significa unidades hidrocarburo divalentes, de cadena lineal o ramificada con una o más uniones dobles carbono-carbono, como por ejemplo C_2-alquenileno, C_3-alquenileno, C_4-alquenileno, C_5-alquenileno, C_6-alquenileno, etcétera.

El término "alquilo", como se usa en la presente, significa grupos de hidrocarburos monovalentes, saturados de cadena lineal o ramificada, tal como C1-alquilo, C_2-alquilo, C_3-alquilo, C_4-alquilo, C_5-alquilo, C_6-alquilo y semejantes.

El término "alquileno", según se usa aquí, significa unidades hidrocarburo divalentes, saturadas, de cadena lineal o ramificada, como por ejemplo C_1-alquileno, C_2-

alquileno, C_3-alquileno, C_4-alquileno, C_5-alquileno, C_6-alquileno, etcétera.

El término "alquinilo", como se usa en la presente, significa grupos de hidrocarburos monovalentes de cadena lineal o ramificada que contienen uno o más de un triple enlace carbono-carbono, tal como C_2-alquinilo, C_3-alquinilo, C_4-alquinilo, C_5-alquinilo, C_6-alquinilo y semejantes.

El término "alquinileno", según se usa aquí, significa unidades hidrocarburo divalentes, de cadena lineal o ramificada con una o más uniones triples carbono-carbono, como por ejemplo C_2-alquinileno, C_3-alquinileno, C_4-alquinileno, C_5-alquinileno, C_6-alquinileno, etcétera.

El término "bioisóstero de C(O)OH", según se usa aquí, significa una unidad con una propiedad física o química sustancialmente similar que confiere propiedades biológicas similares a las del compuesto con la Fórmula (I). Los ejemplos de bioisósteros de C(O)OH incluyen radicales monovalentes derivados por eliminación de un átomo de hidrógeno de una molécula tal como isotiazol-3(2H)-ona 1,1-dióxido, isotiazolidin-3-ona 1,1-dióxido, 1,2,4-oxadiazol-5(2H)-ona, 1,2,5-tiadiazolidin-3-ona 1,1-dióxido, 1,2,5-tiadiazol-3-ol, 1,2,4-oxadiazolidina-3,5-diona, 2H-tetraazol, etcétera.

El término "cicloalcano", como se usa en la presente, significa grupos de hidrocarburos saturados cíclicos o bicíclicos, tal como C_4-cicloalcano, C_5-cicloalcano, C_6-cicloalcano, C_7-cicloalcano, C_8-cicloalcano, C_9-cicloalcano, C_{10}-cicloalcano, C_{11}-cicloalcano, C_{12}-cicloalcano y semejantes.

El término "cicloalquilo", como se usa en la presente, significa grupos de hidrocarburos monovalentes, saturados cíclicos y bicíclicos, tal como C3-cicloalquilo, C_4-cicloalquilo, C_5-cicloalquilo, C_6-cicloalquilo, C_7-cicloalquilo, C_8-cicloalquilo, C_9-cicloalquilo, C_{10}-cicloalquilo, C_{11}-cicloalquilo, C_{12}-cicloalquilo y semejantes.

El término "cicloalqueno", como se usa en la presente, significa grupos de hidrocarburos cíclicos y bicíclicos que contienen uno o más de un enlace doble carbono-carbono, tal como C_5-cicloalqueno, C_6-cicloalqueno, C_7-cicloalqueno, C_8-cicloalqueno, C_9-cicloalqueno, C_{10}-cicloalqueno, C_{11}-cicloalqueno, C_{12}-cicloalqueno y semejantes.

El término "cicloalquenilo", como se usa en la presente, significa grupos de hidrocarburos monovalentes, cíclicos, que contienen uno o más de un doble enlace carbono-carbono, tales como C_4-cicloalquenilo, C_5-cicloalquenilo, C_6-cicloalquenilo, C_7-cicloalquenilo, C_8-cicloalquenilo, C_9-cicloalquenilo, C_{10}-cicloalquenilo, C_{11}-cicloalquenilo, C_{12}-cicloalquenilo y semejantes.

El término "heteroareno", como se usa en la presente, significa furano, imidazol, isotiazol, isoxazol, 1,2,3-oxadiazol, 1,2,5-oxadiazol, 1,3,4-oxadiazol, oxazol, pirazina, pirazol, piridazina, piridina, pirimidina, pirrol, tiazol, 1,3,4-tiadiazol, tiofeno, triazina y 1,2,3-triazol.

El término "heteroarilo", como se usa en la presente, significa furanilo, imidazolilo, isotiazolilo, isoxazolilo, 1,2,3-oxadiazolilo, 1,2,5-oxadiazolilo, 1,3,4-oxadiazolilo, oxazolilo, pirazinilo, pirazolilo, piridazinilo, piridinilo, pirimidinilo, pirrolilo, tetrazolilo, tiazolilo, 1,2,3-

tiadiazoilo, 1,2,5-tiadiazolilo, 1,3,4-tiadiazolilo, tiofenilo, triazinilo y 1,2,3-triazolilo.

El término "heterocicloalcano", como se usa en la presente, significa cicloalcano que contiene uno o dos o tres grupos CH_2 reemplazados con O, S, S(O), SO_2 o NH seleccionados de manera independiente y uno o dos grupos CH no sustituidos o sustituidos con N y también significa cicloalcano que tiene uno o dos o tres grupos CH_2 no sustituidos o con O, S, S(O), SO_2 o NH seleccionados de manera independiente y uno o dos grupos CH sustituidos con N.

El término "heterocicloalqueno", como se usa en la presente, significa cicloalqueno que tiene uno o dos o tres grupos CH_2 sustituidos con O, S, S(O), SO_2 o NH seleccionados de manera independiente y uno o dos grupos CH no sustituidos o sustituidos con N y también significa cicloalqueno que tiene uno o dos o tres grupos CH_2 no sustituidos o sustituidos con O, S, S(O), SO_2 o NH seleccionados de manera independiente y uno o dos grupos CH sustituidos con N.

El término "heterocicloalquilo", como se usa en la presente, significa cicloalquilo que contiene uno o dos o tres grupos CH_2 reemplazados con O, S, S(O), SO_2 o NH seleccionados de manera independiente y uno o dos grupos CH no sustituidos o sustituidos con N y también significa cicloalquilo que tiene uno o dos o tres grupos CH_2 no sustituidos o con O, S, S(O), SO_2 o NH seleccionados de manera independiente y uno o dos grupos CH sustituidos con N.

El término "heterocicloalquenilo", como se usa en la presente, significa cicloalquenilo que contiene uno o dos o tres grupos CH_2 reemplazados con O, S, S(O), SO_2 o NH seleccionados de manera independiente y uno o dos grupos CH no sustituidos o sustituidos con N y también significa cicloalquenilo que tiene uno o dos o tres grupos CH_2 no sustituidos o con O, S, S(O), SO_2 o NH seleccionados de manera independiente y uno o dos grupos CH sustituidos con N.

El término "espiroalquilo", según se usa aquí, significa unidades hidrocarburo divalentes saturadas, con ambos extremos unidos al mismo átomo de carbono, como por ejemplo C_2-espiroalquilo, C_3-espiroalquilo, C_4-espiroalquilo, C_5-espiroalquilo, etcétera.

El término "grupo cíclico", como se usa en la presente, significa benceno, cicloalcano, cicloalquilo, cicloalqueno, cicloalquenilo, heteroareno, heteroarilo, heterocicloalcano, heterocicloalquilo, heterocicloalqueno, heterocicloalquenilo, fenilo y espiroalquilo.

Los compuestos de esta invención pueden contener átomos de carbono sustituidos de manera asimétrica en la configuración R o S, en donde los términos "R" y "S" son como se definen en *Pure Appl. Chem.*(1976) 45, 13-10. Los compuestos que contienen átomos de carbono sustituidos de manera asimétrica con cantidades iguales de configuraciones R y S son racémicos en dichos átomos. A los átomos que contienen un exceso de una configuración ante la otra se les asigna la configuración en exceso, preferiblemente un exceso de aproximadamente 85%-90%, más preferiblemente un exceso de aproximadamente 95%99% y aún más preferiblemente un exceso mayor que aproximadamente 99%. Por lo tanto, esta invención pretende abarcar mezclas racémicas,

diastereoisómeros relativos y absolutos y los compuestos de los mismos.

Los compuestos de esta invención también pueden contener enlaces dobles carbono-carbono o enlaces dobles carbono-nitrógeno en la configuración Z o E, en donde el término "Z" representa el mayor de los dos sustituyentes del mismo lado de un enlace doble carbono-carbono o carbono-nitrógeno y el término "E" representa el mayor de los dos sustituyentes en lados opuestos de un enlace doble carbono-carbono o carbono-nitrógeno. Los compuestos de esta invención también pueden existir como una mezcla de isómeros "Z" y "E".

Los compuestos de esta invención que contienen grupos NH, C(O)H, C(O)OH, $C(O)NH_2$, OH o SH pueden estar unidos a grupos formadores de prodrogas. Los grupos formadores de prodrogas son removidos por medio de procesos metabólicos y liberan los compuestos que contienen a los grupos NH, C(O)H, C(O)OH, $C(O)NH_2$, OH o SH liberados *in vivo*. Las prodrogas son de utilidad para ajustar propiedades farmacocinéticas de los compuestos tales como solubilidad y/o hidrofobicidad, absorción en el tracto gastrointestinal, biodisponibilidad, penetración en tejidos y velocidad de depuración.

Los metabolitos de compuestos con la Fórmula I, que se producen por procesos metabólicos in vitro o in vivo, también pueden ser útiles para tratar enfermedades causadas o agravadas por la sobreexpresión o falta de regulación de la proteína Mcl-1.

Ciertos compuestos precursores de los compuestos con la Fórmula I se pueden metabolizar in vitro o in vivo para formar compuestos con la Fórmula I y de esa manera también pueden ser útiles para tratar enfermedades causadas o agravadas por la sobreexpresión o falta de regulación de la proteína Mcl-1.

Los compuestos de la Fórmula I pueden existir como sales de adición ácida, sales de adición básica o zwitteriones. Las sales de los compuestos de la Fórmula I se preparan durante su aislamiento o después de su purificación. Las sales de adición ácida son aquellas que derivan de la reacción de un compuesto de la fórmula I con un ácido. Por consiguiente, se considera que las sales incluyendo las sales acetato, adipato, alginato, bicarbonato, citrato, aspartato, benzoato, bencenosulfonato (besilato), bisulfato, butirato, alcanforato, alcanforsulfonato, digluconato, formiato, fumarato, glicerofosfato, glutamato, hemisulfato, heptanoato, hexanoato, clorhidrato, bromhidrato, yodhidrato, lactobionato, lactato, maleato, mesitilensulfonato, metansulfonato, naftilensulfonato, nicotinato, oxalato, pamoato, pectinato, persulfato, fosfato, picrato, propionato, succinato, tartrato, tiocianato, tricloroacético, trifluoroacético, para-toluensulfonato y undecanoato de los compuestos de la Fórmula I están incluidas en esta invención. Las sales de adición básica de los compuestos son aquellas que derivan de la reacción de los compuestos de la Fórmula I con el bicarbonato, carbonato, hidróxido o fosfato de cationes tales como litio, sodio, potasio, calcio y magnesio.

Los compuestos de la Fórmula I se pueden administrar, por ejemplo, por vía bucal, oftálmica, oral, osmótica, parenteral (intramuscular, intraperitoneal, intraesternal, intravenosa, subcutánea), rectal, tópica, transdérmica y vaginal.

Las cantidades terapéuticamente eficaces de un compuesto de la fórmula I dependen del receptor del tratamiento, de la enfermedad tratada y de la severidad de la misma, la composición que comprende a las mismas, el momento de la administración, la ruta de administración, la duración del tratamiento, potencia, velocidad de depuración y si se coadministra, o no, otra droga. La cantidad de un compuesto de la fórmula I usada para conformarla como una composición que será administrada diariamente a un paciente en una sola dosis o en dosis divididas comprende entre aproximadamente 0,001 y aproximadamente 200 mg/kg peso corporal. Las composiciones de dosis única contienen estas cantidades o una combinación de submúltiplos de las mismas.

Los compuestos de la Fórmula I se pueden administrar con o sin un excipiente. Los excipientes incluyen, por ejemplo, agentes encapsulantes y aditivos tales como aceleradores de la absorción, antioxidantes, aglutinantes, soluciones amortiguadoras, agentes de recubrimiento, agentes colorantes, disolventes, agentes desintegradores, emulsionantes, diluyentes, rellenos, agentes saborizantes, humectantes, lubricantes, perfumes, conservantes, propelentes, agentes de liberación, agentes esterilizantes, edulcorantes, solubilizantes, agentes humectantes y mezclas de los mismos.

Los compuestos de la Fórmula I se pueden marcar radioactivamente con un isótopo radioactivo tal como carbono (es decir, ^{13}C), hidrógeno (es decir, ^{3}H), nitrógeno (es decir, ^{15}N), fósforo (es decir, ^{32}P), azufre (es decir, ^{35}S), ioduro (es decir, ^{125}I) y semejantes. Los isótopos radioactivos se pueden incorporar en los compuestos de la Fórmula I por reacción de los mismos con un agente derivatizante radioactivo o por incorporación de un intermediario radiomarcado en sus síntesis. Los compuestos radiomarcados de la fórmula I son de utilidad para aplicaciones tanto de pronóstico como de diagnóstico y para el diagnóstico por imágenes *in vivo* e *in vitro*.

Los compuestos de la Fórmula I se pueden incorporar en dispositivos tales como, pero en un sentido no limitativo, injertos arterio-venosos, Stents biliares, injertos de derivaciones [*by-pass*], catéteres, derivaciones [*shunts*] del sistema nervioso central, Stents coronarios, balones de distribución de drogas, Stents periféricos y Stents ureterales, cada uno de los cuales se puede usar en áreas tales como, pero en un sentido no limitativo, la vasculatura para la introducción de un compuesto de la fórmula I en tejidos u órganos seleccionados en el cuerpo. Una medida de la efectividad de los compuestos de la Fórmula I es la reducción o eliminación de los trombos asociados con dispositivos y las complicaciones asociadas con los mismos.

Los compuestos de la Fórmula I se pueden usar como radiosensibilizadores que mejora la eficacia de la radioterapia. Los ejemplos de radioterapia incluyen, pero en un sentido no limitativo, una radioterapia de haz externa, teleterapia, braquiterapia y radioterapias de fuente sellada y no sellada.

Los excipientes para la preparación de composiciones que comprenden un compuesto de la fórmula I que serán administradas por vía oral incluyen, por ejemplo, ágar, ácido algínico, hidróxido de aluminio, alcohol bencílico, benzoato de bencilo, 1,3-

butilenglicol, carbómeros, aceite de castor, celulosa, acetato de celulosa, manteca de cacao, almidón de maíz, aceite de maíz, aceite de semillas de algodón, crospovidona, diglicéridos, etanol, etilcelulosa, laurato de etilo, oleato de etilo, ésteres de ácidos grasos, gelatina, aceite de germen, glucosa, glicerol, aceite de cacahuete, hidroxipropilmetilcelulosa, isopropanol, salina isotónica, lactosa, hidróxido de magnesio, estearato de magnesio, malta, manitol, monoglicéridos, aceite de oliva, aceite de maní, sales de fosfato de potasio, almidón de papa, povidona, propilenglicol, solución de Ringer, aceite de alazor, aceite de sésamo, carboximetilcelulosa de sodio, sales de fosfato de sodio, laurilsulfato de sodio, sorbitol sódico, aceite de soja, ácidos esteáricos, fumarato de estearilo, sacarosa, agentes tensioactivos, talco, tragacanto, alcohol tetrahidrofurfurílico, triglicéridos, agua y mezclas de los mismos. Los excipientes para la preparación de composiciones que comprenden un compuesto de la fórmula I que serán administradas por vía oftálmica u oral incluyen, por ejemplo, 1,3-butilenglicol, aceite de castor, aceite de maíz, aceite de semillas de algodón, etanol, ésteres de ácidos grasos de sorbitán, aceite de germen, aceite de cacahuete, glicerol, isopropanol, aceite de oliva, polietilenglicoles, propilenglicol, aceite de sésamo, agua y mezclas de los mismos. Los excipientes para la preparación de composiciones que comprenden un compuesto de la fórmula I que serán administradas osmóticamente incluyen, por ejemplo, clorofluoro-hidrocarburos, etanol, agua y mezclas de los mismos. Los excipientes para la preparación de composiciones que comprenden un compuesto de la fórmula I que serán administradas por vía parenteral incluyen, por ejemplo, 1,3-butanodiol, aceite de castor, aceite de maíz, aceite de semillas de algodón, dextrosa, aceite de germen, aceite de cacahuete, liposomas, ácido oleico, aceite de oliva, aceite de maní, solución de Ringer, aceite de alazor, aceite de sésamo, aceite de soja, solución de cloruro de sodio grado U.S.P. o isotónica, agua y mezclas de los mismos. Los excipientes para la preparación de composiciones que comprenden un compuesto de la fórmula I que serán administradas por vía rectal o vaginal incluyen, por ejemplo, manteca de cacao, polietilenglicol, cera y mezclas de los mismos.

ENSAYO

Se hizo (Fam)-NoxaCF (6-FAM)-GELEVEFATQLRRFGDKLNF-amida) (SEQ.ID NO. 1) en un sintetizador automatizado 433A (Applied Biosystems, Foster City, CA) usando ciclos estándar Fastmoc™ de desprotección/acoplamiento con 0,25 mmol de resina MBHA Rink amida (SynPep, Dublín, CA). Los cartuchos que contenían N^{α}-Fmoc-aminoácidos (1 mmol) con protección de cadena lateral (Arg: 2,2,5,7,8-pentametilcroman-6-sulfonilo; Asp y Glu: éster tert-butílico; Asn, Cys, Gln, y His: tritilo; Lys y Trp: tert-butiloxicarbonilo; Ser, Thr, y Tyr: tert-butil éter) se activaron con hexafluorofosfato de O-benzotriazol-1-il-N,N,N',N'-tetrametiluronio (1 mmol), 1-hidroxibenzotriazol (1 mmol) y diisopropiletilamina (2 mmol) en N-metilpirrolidona (NMP). El aminoácido activado se acopló durante 30 minutos luego de la eliminación del grupo Fmoc N-terminal con piperidina al 20% en NMP. El marcado se realizó suspendiendo la resina de péptido unida

a la resina, desprotegida en el extremo N-terminal con las cadenas laterales protegidas (0,04 mmol) y éster 6-carboxifluorescein-NHS (57 mg) en dimetilformamida anhidra (2 ml) que contenía 0,02 ml diisopropiletilamina (DIEA) y se sacudió a temperatura ambiente durante toda la noche. La resina se drenó, se lavó 3 veces con 1:1 diclorometano/metanol y se secó. La resina marcada se clivó y desprotegió por mezcla con TFA:agua:tioanisol:fenol:3,6-dioxa-1,8-octanoditiol:triisopropilsilano, 80:5:5:5:2,5:2,5 durante 3 horas a temperatura ambiente. Luego de la evaporación a presión reducida, el péptido en bruto se recuperó por precipitación con éter. El producto se purificó en una HPLC preparativa corriendo un software de análisis Unipoint® (Gilson, Inc., Middleton, WI) en una columna de compresión radial de 25mm x 200mm que contenía un relleno Delta-Pak® C_{18} (Waters, Inc., Taunton, MA) con un caudal de 20 ml/min. Los péptidos se eluyeron con un gradiente lineal de 0,1% TFA/agua y acetonitrilo. Las fracciones que contenían el producto se combinaron y se liofilizaron. La pureza de los productos finales se confirmó por HPLC analítica de fase inversa en un sistema Hewlett-Packard serie 1050 con matriz de diodos y detección de fluorescencia (Agilent Technologies, Palo Alto, CA) se eluyó con un gradiente lineal de 0,1% ácido trifluoroacético/agua y acetonitrilo en una columna YMC ODS-AQ, 5 µm, 120 Å de 4,6 x 250 mm (Waters Inc.) para dar el producto (45,6 mg) como un polvo amarillo luego de la liofilización. La identidad del producto se confirmó por espectrografía de masas ionización/desorción por láser asistida por matriz (MALDI-MS) en un Voyager DE-PRO (Applied Biosystems), m/z 1470,00 y 1448,01 $(M+H)^+$.

Se utilizó un ensayo de polarización de la fluorescencia para determinar la IC_{50} de compuestos representativos con la Fórmula I contra proteína Mcl-1 recombinante. Los compuestos se diluyeron en series en DMSO comenzando a 10 µM y se transfirieron (5 µL) a una placa de 96 cavidades. Luego, se agregaron a cada cavidad 120 µL de una mezcla que contenía péptido Noxa BH3 fluorescente 10 nM y proteína Mcl-1 80 nM. Para cada ensayo, en cada placa del ensayo se incluyeron controles de péptido libre (solo péptido fluorescente) y controles de péptido unido (péptido fluorescente en presencia de Mcl-1). La placa se mezcló en una sacudidora durante 1 minuto y se incubó a temperatura ambiente durante otros 15 minutos adicionales. La polarización (en mP) se midió a temperatura ambiente con una longitud de onda de excitación de 485 nm y una longitud de onda de emisión de 530 nm usando un aparato Analyst (LJL, Molecular Dynamic, Sunnyvale, CA). La inhibición porcentual se calculó como % inhibición = 100 × (1-(mP-mP_f)/ (mP_b-mP_f)) donde mP_f es el control de péptido libre y mP_b es el control de péptido unido. En base a la inhibición porcentual, se obtuvo la IC_{50} (concentración de inhibidor con la cual es desplazado el 50% del péptido unido), ajustando los datos de inhibición usando el software Prism 3.0 (Graphpad Software Inc, San Diego, CA). Los resultados se muestran en la tabla 1.

TABLA 1

IC_{50} (en µM) para compuestos representativos con la Fórmula I para Inhibición de

la proteína Mcl-1

< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	< 0,030
< 0,030	< 0,030	< 0,030	< 0,030	0,030
0,030	0,030	0,030	0,031	0,031
0,031	0,031	0,031	0,031	0,031
0,032	0,032	0,032	0,032	0,032
0,032	0,033	0,033	0,033	0,033
0,033	0,033	0,034	0,034	0,035
0,035	0,035	0,036	0,036	0,037
0,037	0,037	0,037	0,037	0,038
0,038	0,038	0,038	0,038	0,039
0,039	0,039	0,039	0,040	0,040
0,040	0,041	0,041	0,041	0,042
0,042	0,043	0,043	0,043	0,044
0,044	0,044	0,044	0,044	0,044

0,045	0,045	0,045	0,045	0,045
0,045	0,045	0,045	0,046	0,046
0,047	0,047	0,047	0,047	0,047
0,048	0,048	0,048	0,049	0,050
0,050	0,050	0,050	0,051	0,051
0,051	0,051	0,051	0,052	0,052
0,052	0,052	0,052	0,053	0,053
0,053	0,053	0,053	0,054	0,054
0,054	0,054	0,054	0,055	0,056
0,057	0,057	0,057	0,057	0,058
0,058	0,058	0,058	0,058	0,059
0,059	0,059	0,060	0,060	0,060
0,061	0,061	0,062	0,062	0,062
0,063	0,063	0,063	0,064	0,065
0,065	0,065	0,067	0,067	0,067
0,068	0,068	0,069	0,069	0,070
0,071	0,072	0,072	0,072	0,073
0,074	0,074	0,074	0,075	0,076
0,077	0,077	0,078	0,078	0,079
0,079	0,079	0,080	0,080	0,081
0,082	0,083	0,084	0,085	0,085
0,085	0,086	0,086	0,087	0,088
0,089	0,089	0,089	0,090	0,090
0,090	0,090	0,090	0,091	0,091
0,093	0,093	0,095	0,096	0,096
0,097	0,097	0,097	0,098	0,100
0,101	0,101	0,101	0,101	0,103
0,104	0,104	0,105	0,105	0,106
0,106	0,107	0,108	0,108	0,110
0,111	0,112	0,114	0,118	0,119
0,121	0,121	0,122	0,123	0,125
0,127	0,128	0,130	0,132	0,132
0,133	0,134	0,136	0,137	0,137
0,138	0,139	0,143	0,145	0,145
0,148	0,148	0,151	0,154	0,155
0,156	0,156	0,156	0,157	0,163
0,163	0,165	0,165	0,166	0,166
0,168	0,169	0,170	0,173	0,173
0,173	0,174	0,175	0,175	0,176

0,179	0,180	0,180	0,182	0,183
0,185	0,186	0,186	0,186	0,186
0,186	0,187	0,191	0,197	0,200
0,200	0,201	0,203	0,206	0,207
0,208	0,209	0,210	0,212	0,212
0,213	0,215	0,216	0,218	0,219
0,220	0,220	0,222	0,222	0,223
0,224	0,224	0,227	0,228	0,229
0,230	0,232	0,234	0,235	0,235
0,240	0,240	0,241	0,242	0,244
0,245	0,256	0,257	0,261	0,265
0,268	0,271	0,272	0,273	0,273
0,277	0,277	0,279	0,279	0,282
0,282	0,283	0,283	0,288	0,288
0,293	0,300	0,301	0,301	0,316
0,318	0,320	0,322	0,326	0,334
0,338	0,338	0,340	0,340	0,350
0,363	0,370	0,373	0,378	0,378
0,379	0,381	0,383	0,391	0,398
0,399	0,400	0,409	0,430	0,439
0,440	0,440	0,447	0,449	0,459
0,475	0,480	0,482	0,489	0,497
0,502	0,505	0,514	0,525	0,532
0,540	0,545	0,547	0,553	0,558
0,562	0,565	0,566	0,573	0,598
0,601	0,611	0,623	0,628	0,630
0,633	0,635	0,684	0,704	0,716
0,738	0,751	0,757	0,782	0,814
0,820	0,851	0,885	0,886	0,910
0,952	0,973	1,002	1,003	1,026
1,030	1,053	1,085	1,097	1,123
1,145	1,175	1,193	1,246	1,256
1,326	1,349	1,353	1,359	1,364
1,385	1,386	1,491	1,557	1,576
1,591	1,765	1,992	2,019	2,054
2,058	2,121	2,186	2,242	2,336
2,449	2,483	2,570	2,682	2,683
2,694	2,727	2,734	2,757	2,759
2,929	2,962	2,982	3,156	3,373

3,388	3,557	3,586	3,763	3,846
4,743	4,890	4,900	4,946	5,105
5,184	5,199	5,448	5,480	5,539
6,283	6,610	6,760	7,270	7,302
8,638				

Dichos datos demuestran la utilidad de los compuestos representativos con la Fórmula I como inhibidores de la actividad de la proteína Mcl-1.

Dichos datos demuestran la utilidad de los compuestos representativos con la Fórmula I como inhibidores de la actividad de la proteína Mcl-1.

Por lo tanto, se espera que los compuestos con la Fórmula I sean útiles para el tratamiento de enfermedades durante las cuales se expresa la Mcl-1 anti-apoptótica y también que sean útiles para el tratamiento de enfermedades donde se expresan miembros de la familia de la proteína anti-apoptótica con estrecha homología estructural con Mcl-1 tales como, por ejemplo, proteína Bcl-X_L, proteína Bcl-2 y proteína Bcl-w.

La sobreexpresión de Mcl-1 está correlacionada con la resistencia a la quimioterapia, resultado clínico, progreso de la enfermedad, prognosis total o una combinación de los mismos en diversas enfermedades hematológicas y tipos de tumores sólidos tales como neuroma acústico, leucemia aguda, leucemia linfoblástica aguda, leucemia mielogénica aguda (monocítica, mieloblástica, adenocarcinoma, angiosarcoma, astrocitoma, mielomonocítica y promielocítica), leucemia aguda de células T, carcinoma de células basales, carcinoma de conducto biliar, cáncer de vejiga, cáncer de cerebro, cáncer de mamas (incluyendo cáncer de mamas con receptor de estrógeno positivo), carcinoma broncogénico, cáncer cervical, condrosarcoma, cordoma, coriocarcinoma, leucemia crónica, leucemia linfocítica crónica, leucemia mielocítica crónica (granulocítica), leucemia mielógena crónica, cáncer de colon, cáncer colorrectal, craneofaringioma, cistadenocarcinoma, linfoma difuso de células B grandes, cambios disproliferativos (displasias y metaplasias), carcinoma embrional, cáncer de endometrio, endoteliosarcoma, ependimoma, carcinoma epitelial, eritroleucemia, cáncer de esófago, cáncer de mamas con receptor de estrógeno positivo, trombocitemia esencial, tumor de Ewing, fibrosarcoma, linfoma folicular, carcinoma gástrico, cáncer testicular de célula germinal, enfermedad trofoblástica gestacional, glioblastoma, cáncer de cabeza y cuello, enfermedades de las cadenas pesadas, hemangioblastoma, hepatoma, cáncer hepatocelular, cáncer de próstata insensible a las hormonas, leiomiosarcoma, liposarcoma, cáncer de pulmón (incluyendo cáncer de pulmón de células pequeñas y cáncer de pulmón de células no pequeñas), linfangioendotelio-sarcoma, linfangiosarcoma, leucemia linfoblástica, linfoma (linfoma, incluyendo linfoma difuso de células B grandes, linfoma folicular, linfoma de Hodgkin y linfoma no de Hodgkin), malignidades y trastornos hiperproliferativos de la vejiga, mamas, colon, pulmón, ovarios, páncreas, próstata, piel y útero, malignidades linfoides con origen en células T o células

B, leucemia, linfoma, carcinoma medular, meduloblastoma, melanoma, meningioma, mesotelioma, mieloma múltiple, leucemia mielogénica, mieloma, mixosarcoma, neuroblastoma, cáncer de pulmón de células no pequeñas, oligodendroglioma, cáncer oral, sarcoma osteogénico, cáncer de ovarios, cáncer pancreático, adenocarcinomas papilares, carcinoma papilar, linfoma periférico de células T, pinealoma, policitemia vera, cáncer de próstata (incluyendo cáncer de próstata insensible a hormonas (refractario)), cáncer rectal, carcinoma de células renales, retinoblastoma, rabdomiosarcoma, sarcoma, carcinoma de glándulas sebáceas, seminoma, cáncer de piel, carcinoma de pulmón de células pequeñas, tumores sólidos (carcinomas y sarcomas), cáncer de pulmón de células pequeñas, cáncer de estómago, carcinoma de células escamosas, sinovioma, carcinoma de glándulas sudoríparas, cáncer testicular (incluyendo cáncer testicular de células germinales), cáncer de tiroides, macroglobulinemia de Waldenström, tumores testiculares, cáncer uterino, tumor de Wilms, etcétera.

También se espera que los compuestos de Fórmula I puedan inhibir el crecimiento de células derivadas de un cáncer o neoplasma pediátricos que incluye rabdomiosarcoma embrionario, leucemia linfoblástica aguda pediátrica, leucemia mielogénica aguda pediátrica, rabdomiosarcoma alveolar pediátrico, ependinoma anaplásico pediátrico, linfoma anaplásico de células grandes pediátrico, meduloblastoma anaplásico pediátrico, tumor atípico teratoide/rabdoide del sistema nervioso central pediátrico, leucemia aguda bifenotípica pediátrica, linfoma de Burkitts pediátrico, cánceres pediátricos de la familia de Ewing de tumores tales como tumores primitivos neuroectodérmico, tumor anaplásico difuso de Wilms pediátrico, tumor de Wilms de histología favorable pediátrico, glioblastoma pediátrico, meduloblastoma pediátrico, neuroblastoma pediátrico, mielocitomatosis pediátrica derivada de neuroblastoma, cánceres pediátricos de células pre-B (tales como leucemia), osteosarcoma pediátrico, tumor de riñón rabdoide pediátrico, rabdomiosarcoma pediátrico, y cánceres pediátricos de células T tales como linfoma y cáncer de piel y similares.

La relación de Mcl-1 con la leucemia linfoblástica aguda se informa en Blood 1998, 91, 991-1000.

La relación de Mcl-1 con la leucemia mielogénica aguda se informa también en Blood 1998, 91, 991-1000.

La relación de Mcl-1 con el cáncer cervical se informa en Cancer Letters (Shannon, Irlanda) 2002, 180, 63-68.

La relación de Mcl-1 con la leucemia linfocítica crónica se informa en el Journal of the National Cancer Institute 2004, 96, 673-682 y en Immunology 2005, 114, 441-449.

La relación de Mcl-1 con el cáncer colorrectal, se informa en Annals of oncology: Official Journal of the European Society for Medical Oncology/ESMO 2001, 12, 779-785.

La relación de Mcl-1 con el carcinoma gástrico, se informa en Gastric Cancer 2004, 7, 78-84.

La relación de Mcl-1 con la enfermedad trofoblástica gestacional se informa en

Cancer 2005, 103, 268-276.

La relación de Mcl-1 con el glioblastoma se informa en el Journal of Neurology, Neurosurgery, and Psychiatry 1999, 67, 763-768.

La relación de Mcl-1 con el cáncer de cabeza y cuello se informa en Archives of Otolaryngology-Head and Neck Surgery 1999, 125, 417-422.

La relación de Mcl-1 con el cáncer de pulmón se informa en Pathology Oncology Research: POR 1999, 5, 179-186.

La relación de Mcl-1 con el mesotelioma, se informa en Clinic Cancer Research 1999, 5, 3508-3515.

La relación de Mcl-1 con el mieloma múltiple se informa en European Journal of Immunology 2004, 34, 3156-3164.

La relación de Mcl-1 con el linfoma no de Hodgkin se informa en British Journal of Haematology 2002, 116, 158-161.

La relación de Mcl-1 con el oligodenroglioma se informa en Cancer (Nueva York) 1999, 86, 1832-1839.

La relación de Mcl-1 con el cáncer de ovarios se informa en el Journal of Clinic Oncology: Official Journal of the American Society of Clinic Oncology 2000, 18, 3775-3781.

La relación de Mcl-1 con el cáncer pancreático se informa en Oncology 2002, 62, 354-362.

La relación de Mcl-1 con el linfoma periférico de células T se informa en el Journal of Pathology 2003, 200, 240-248.

Se espera que los compuestos con la Fórmula I sean útiles para utilizar con agentes alquilantes, inhibidores de angiogénesis, anticuerpos, antimetabolitos, antimitóticos, antiproliferativos, inhibidores de aurora quinasa, inhibidores de proteínas de la familia Bcl-2 (por ejemplo, Bcl-xL, Bcl-2, Bcl-w, Bfl-1), inhibidores de Bcr-Abl quinasa, modificadores de la respuesta biológica, inhibidores de quinasa dependientes de ciclina, inhibidores del ciclo celular, inhibidores de ciclooxigenasa-2, inhibidores del receptor del homólogo del oncogen viral de leucemia (ErbB2), inhibidores del factor de crecimiento, inhibidores de la proteína choque térmico (HSP)-90, inhibidores de inhibidores de histona desacetilasa (HDAC), terapias hormonales, inmunológicas, antibióticos intercalantes, inhibidores de quinasa, inhibidores del objetivo de la rapamicina en mamíferos, inhibidores de quinasas reguladas por señal extracelular y activadas por mitógeno, drogas antiinflamatorias no esteroides (NSAIDs), quimioterapéuticos de platino, inhibidores de quinasa tipo Polo, inhibidores de proteosoma, análogos de purina, análogos de pirimidina, inhibidores de receptores tirosina quinasas, alcaloides vegetales retinoides/deltoides, inhibidores de topoisomerasa, etcétera.

Entre los agentes alquilantes se incluyen altretamina, AMD-473, AP-5280, apazicuona, bendamustina, brostalicina, busulfano, carbocuona, carmustina (BCNU), clorambucilo, Cloretazina™ (VNP 40101M), ciclofosfamida, decarbacina, estramustina, fotemustina,

glufosfamida, ifosfamida, KW-2170, lomustina (CCNU), mafosfamida, melfalano, mitobronitol, mitolactol, nimustina, N-óxido mostaza nitrogenada, ranimustina, temozolomida, tiotepa, treosulfano, trofosfamida y similares.

Entre los inhibidores de angiogénesis se incluyen inhibidores del receptor de tirosina quinasa específico de endotelio (Tie-2), inhibidores del receptor del factor de crecimiento epidérmico (EGFR), inhibidores del receptor del factor de crecimiento insulínico-2 (IGFR-2), inhibidores de metaloproteinasa de matriz-2 (MMP-2), inhibidores de metaloproteinasa de matriz-9 (MMP-9), inhibidores del receptor del factor de crecimiento derivado de plaquetas (PDGFR), análogos de trombospondina, inhibidores del receptor tirosina quinasa del factor de crecimiento de endotelio vascular (VEGFR) y similares.

Los inhibidores de la aurora quinasa incluyen AZD-1152, MLN-8054, VX-680 y semejantes.

Los miembros de inhibidores de proteínas de la familia Bcl incluyen AT-101 ((-)gosipol), GENASENSE® (G3139 o oblimersen (oglionucleótido antisentido dirigido a Bcl-2)), IPI-194, IPI-565, N-(4-(4-((4'-cloro(1,1'-bifenil)-2-il)metil)piperazin-1-il)benzoil)-4-(((1R)-3-(dimetilamino)-1-((fenilsulfanil)metil) propil)amino)-3-nitrobencenosulfonamida) (ABT-737), N-(4-(4-((2-(4-clorofenil)-5,5-dimetil-1-ciclohex-1-en-1-il)metil)piperazin-1-il)benzoil)-4-(((1R)-3-(morfolin-4-il)-1-((fenilsulfanil)metil)propil)amino)-3-((trifluorometil)sulfonil)benceno sulfonamida (ABT-263), GX-070 (obatoclax), etcétera.

Los inhibidores de la quinasa Bcr-Abl incluyen DASATINIB® (BMS-354825), GLEEVEC® (imatinib) y semejantes.

Entre los inhibidores de CDK se incluyen AZD-5438, BMI-1040, BMS-032, BMS-387, CVT-2584, flavopiridol, GPC-286199, MCS-5A, PD0332991, PHA-690509, seliciclib (CYC-202, R-roscovitina), ZK-304709 y similares.

Entre los inhibidores de la COX-2 se incluyen ABT-963, ARCOXIA® (etoricoxib), BEXTRA® (valdecoxib), BMS347070, CELEBREX™ (celecoxib), COX-189 (lumiracoxib), CT-3, DERAMAXX® (deracoxib), JTE-522, 4-metil-2-(3,4-dimetilfenil)-1-(4-sulfamoilfenil-1H-pirrol), MK--663 (etoricoxib), NS-398, parecoxib, RS-57067, SC-58125, SD-8381, SVT-2016, S-2474, T-614, VIOXX® (rofecoxib) y similares.

Los inhibidores de EGFR incluyen ABX-EGF, anti-EGFr inmunoliposomas, vacuna EGF, EMD-7200, ERBITUX® (cetuximab), HR3, anticuerpos IgA, IRESSA® (gefitinib), TARCEVA® (erlotinib o OSI-774), TP-38, proteína de fusión EGFR, TYKERB® (lapatinib) y similares.

Entre los inhibidores de ErbB2 se incluyen CP-724-714, CI-1033 (canertinib), Herceptin® (trastuzumab), TYKERB® (lapatinib), OMNITARG® (2C4, petuzumab), TAK-165, GW-572016 (ionafarnib), GW-282974, EKB-569, PI-166, dHER2 (vacuna HER2), APC-8024 (vacuna HER-2), anticuerpo biespecífico anti-HER/2neu, B7.her2IgG3, anticuerpos biespecíficos trifuncionales AS HER2, anticuerpo monoclonal AR-209, anticuerpo monoclonal 2B-1 y similares.

Los inhibidores de histona desacetilasa incluyen depsipéptido, LAQ-824, MS-275, trapoxina, ácido hidroxámico suberoilanilida (SAHA), TSA, ácido valproico y semejantes.

Entre los inhibidores de HSP-90 se incluyen 17-AAG-nab, 17-AAG, CNF-101, CNF-1010, CNF-2024, 17-DMAG, geldanamicina, IPI-504, KOS-953, MYCOGRAB®, NCS-683664, PU24FCI, PU-3, radicicol, SNX-2112, STA-9090 VER49009 y similares.

Entre los inhibidores de MEK se incluyen ARRY-142886, ARRY-438162 PD-325901, PD-98059 y similares.

Los inhibidores de mTOR incluyen AP-23573, CCI-779, everolimus, RAD-001, rapamicina, temsirolimus y semejantes.

Las drogas antiinflamatorias no esteroides incluyen AMIGESIC® (salsalato), DOLOBID® (diflunisal), MOTRIN® (ibuprofeno), ORUDIS® (ketoprofeno), RELAFEN® (nabumetona), FELDENE® (piroxicam) crema ibuprofeno, ALEVE® y NAPROSYN® (naproxeno), VOLTAREN® (diclofenac), INDOCIN® (indometacina), CLINORIL® (sulindac), TOLECTIN® (tolmetin), LODINE® (etodolac), TORADOL® (ketorolac), DAYPRO® (oxaprozina) y semejantes.

Los inhibidores de PDGFR incluyen C-451, CP-673, CP-868596 y semejantes.

Los quimioterapéuticos de platino incluyen cisplatino, ELOXATIN® (oxaliplatino) eptaplatino, lobaplatino, nedaplatino, PARAPLATIN® (carboplatino), satraplatino y semejantes.

Los inhibidores de quinasa del tipo polo incluyen BI-2536 y semejantes.

Entre los análogos de trombospondina se incluyen ABT-510, ABT-567, ABT-898, TSP-1 y similares.

Entre los inhibidores de VEGFR se incluyen AVASTIN® (bevacizumab), ABT-869, AEE-788, ANGIOZYME™, axitinib (AG-13736), AZD-2171, CP-547.632, IM-862, Macugen (pegaptamib), NEXAVAR® (sorafenib, BAY43-9006), pazopanib (GW-786034), (PTK-787, ZK-222584), SUTENT® (sunitinib, SU-11248), VEGF trap, vatalanib, ZACTIMA™ (vandetanib, ZD-6474) y similares.

Entre los antimetabolitos se incluyen ALIMTA® (premetrexed disódico, LY231514, MTA), 5-azacitidina, XELODA® (capecitabina), carmofur, LEUSTAT® (cladribina), clofarabina, citarabina, ocfosfato de citarabina, arabinósido de citosina, decitabina, deferoxamina, doxifluridina, eflornitina, EICAR, enocitabina, etinilcitidina, fludarabina, hidroxiurea, 5-fluorouracilo (5-FU) sólo o en combinación con leucovorin, GEMZAR® (gemcitabina), hidroxiurea, ALKERAN®(melfalán), mercaptopurina, 6-mercaptopurina ribósido, metotrexato, ácido micofenólico, nelarabina, nolatrexed, ocfosato, pelitrexol, pentostatina, raltitrexed, ribavirina, triapina, trimetrexato, S-1, tiazofurin, tegafur, TS-1, vidarabina, UFT y similares.

Los antibióticos incluyen los antibióticos intercalantes aclarubicina, actinomicina D, amrubicina, anamicina, adriamicina, BLENOXANE® (bleomicina), daunorubicina, CAELYX® o MYOCET® (doxorrubicina), elsamitrucina, epirbucina, glarbuicina, ZAVEDOS®

(idarubicina), mitomicina C, nemorubicina, neocarzinostatina, peplomicina, pirarubicina, rebecamicina, Stimalamer, estreptozocina, VALSTAR® (valrubicina), zinostatina y semejantes.

Entre los inhibidores de topoisomerasa se incluyen aclarubicina, 9-aminocamptotecina, amonafida, amsacrina, becatecarina, belotecan, BN-80915, CAMPTOSAR® (clorhidrato de irinotecan), camptotecina, CARDIOXANE® (dexrazoxina), diflomotecan, edotecarina, ELLENCE® o PHARMORUBICIN® (epirubicina), etopósido, exatecan, 10-hidroxicamptotecina, gimatecan, lurtotecan, mitoxantrona, oratecina, pirarbucin, pixantrona, rubitecan, sobuzoxan, SN-38, taflupósido, topotecan y similares.

Entre los anticuerpos se incluyen AVASTIN® (bevacizumab), anticuerpos específicos para CD40, chTNT-1/B, denosumab, ERBITUX® (cetuximab), HUMAX-CD4® (zanolimumab), anticuerpos específicos para IGF1R, lintuzumab, PANOREX® (edrecolomab), RENCAREX® (WX G250), RITUXAN® (rituximab), ticilimumab, trastuzimab y similares.

Las terapias hormonales incluyen ARIMIDEX® (anastrozol), AROMASIN® (exemestano), arzoxifeno, CASODEX® (bicalutamida), CETROTIDE® (cetrorelix), degarelix, deslorelina, DESOPAN® (trilostano), dexametasona, DROGENIL®, (flutamida), EVISTA® (raloxifeno), fadrozol, FARESTON® (toremifeno), FASLODEX® (fulvestrant),FEMARA®, (letrozol), formestano, glucocorticoides, HECTOROL® o RENAGEL® (doxercalciferol), lasofoxifeno, acetato de leuprolida, MEGACE® (megesterol), MIFEPREX® (mifepristona), NILANDRON™ (nilutamida), NOLVADEX® (citrato de tamoxifen), PLENAXIS™ (abarelix), prednisona, PROPECIA® (finasteride), rilostan, SUPREFACT® (buserelina), TRELSTAR® (hormona de liberación de la hormona luteinizante (LHRH)), VANTAS (implante de histrelina), VETORYL®, (trilostano o modrastano), ZOLADEX® (fosrelina, goserelin) y semejantes.

Los deltoides y retinoides incluyen seocalcitol (EB1089, CB1093), lexacalcitrol (KH1060), fenretinida, PANRETIN® (alitretinoina), ATRAGEN® (tretinoína liposomal), TARGRETIN® (bexaroteno), LGD-1550 y semejantes.

Los alcaloides vegetales incluyen, pero en un sentido no limitativo, vincristina, vinblastina, vindesina, vinorelbina y semejantes.

Entre los inhibidores de proteosoma se incluyen VELCADE® (bortezomib), MG132, NPI-0052, PR-171 y similares.

Los ejemplos de sustancias inmunológicas incluyen interferones y otros agentes mejoradores del sistema inmune. Los interferones incluyen interferón alfa, interferón alfa-2a, interferón alfa-2b, interferón beta, interferón gamma-1a, ACTIMMUNE® (interferón gamma-1b) o interferón gamma-n1, combinaciones de los mismos y semejantes. Entre otros agentes se incluyen ALFAFERONE®, BAM-002, BEROMUN® (tasonermina), BEXXAR® (tositumomab), CamPath® (alemtuzumab), CTLA4 (antígeno linfocítico citotóxico 4), decarbazina, denileuquina, epratuzumab, GRANOCYTE® (lenograstima), lentinano, interferón alfa de leucocitos, imiquimod, MDX-010, vacuna de melanoma,

mitumomab, molgramostim, MYLOTARG™ (gemtuzumab ozogamicina), NEUPOGEN® (filgrastim), OncoVAC-CL, OvaRex® (oregovomab), pemtumomab (Y-muHMFG1), PROVENGE®, sargaramostim, sizofilan, teceleuquina, TheraCys®, ubenimex, VIRULIZIN®, Z--100, WF-10, PROLEUKIN® (aldesleuquina), ZADAXIN® (timalfasina), ZENAPAX® (daclizumab), ZEVALIN® (90Y-Ibritumomab tiuxetano) y similares.

Los modificadores de la respuesta biológica son agentes que modifican los mecanismos de defensa de organismos vivientes o respuestas biológicas, tales como sobrevida, crecimiento o diferenciación de células de tejidos para dirigirlas hacia una actividad antitumoral e incluyen crestina, lentinano, sizofirano, picibanilo PF-3512676 (CpG-8954), ubenimex y similares.

Entre los análogos de pirimidina se incluyen citarabina (ara C o Arabinósido C), arabinósido de citosina, doxifluridina, FLUDARA® (fludarabina), 5-FU (5-fluorouracilo), floxuridina, GEMZAR® (gemcitabina), TOMUDEX® (raltitrexed), TROXATYL™ (triacetiluridina troxacitabina) y similares.

Los análogos de purina incluyen LANVIS® (tioguanina) y PURI-NETHOL® (mercaptopurina).

Entre los agentes antimicóticos se incluyen batabulina, epotilona D (KOS-862), N-(2-((4-hidroxifenil)amino)piridin-3-il)-4-metoxibencensulfonamida, ixabepilona (BMS 247550), paclitaxel, TAXOTERE® (docetaxel), PNU100940 (109881), patupilona, XRP-9881, vinflunina, ZK-EPO y similares.

Se pretende asimismo usar los compuestos de la presente invención como radiosensibilizadores que mejoran la eficacia de la radioterapia. Los ejemplos de radioterapia incluyen, pero en un sentido no limitativo, una radioterapia de haz externa, teleterapia, braquiterapia y radioterapias de fuente sellada y no sellada.

Además, los compuestos de la Fórmula I se pueden combinar con otros agentes quimioterapéuticos tales como ABRAXANE™ (ABI-007), ABT-100 (inhibidor de la farnesiltransferasa), ADVEXIN®, ALTOCOR® o MEVACOR® (lovastatina), AMPLIGEN® (poli I:poli C12U, un ARN sintético), APTOSYN™ (exisulind), AREDIA® (ácido pamidrónico), arglabina, L-asparaginasa, atamestano (1-metil-3,17-diona-androsta-1,4-dieno), AVAGE® (tazaroteno), AVE-8062, BEC2 (mitumomab), caquectina o caquexina (factor de necrosis tumoral), canvaxina (vacuna), CeaVac™ (vacuna para cáncer), CELEUK® (celmoleuquina), CEPLENE® (diclorhidrato de histamina), CERVARIX™ (vacuna para papilomavirus humano), CHOP® (C: CYTOXAN® (ciclofosfamida); H: ADRIAMYCIN® (hidroxidoxorubicina); O: Vincristina (ONCOVIN®); P: prednisona), CyPat™, combrestatina A4P, DAB(389)EGF o TransMID-107R™ (toxinas diftéricas), dacarbazina, dactinomicina, ácido 5,6-dimetilxantenona-4-acético (DMXAA), eniluracilo, EVIZON™ (lactato de escualamina), DIMERICINE® (loción liposomal T4N5), discodermolida, DX-8951f (mesilato de exatecán), enzastaurina, EPO906, GARDASIL® (vacuna recombinante cuadrivalente contra el papilomavirus humano (Tipos 6, 11, 16, 18)), gastrimmune, genasense, GMK (vacuna conjugada con ganglиósido), GVAX®

(vacuna contra cáncer de próstata), halofuginona, histerelina, hidroxicarbamida, ácido ibandrónico, IGN-101, IL-13-PE38, IL-13-PE38QQR (cintredequina besudotox), IL-13-exotoxina de *Pseudomonas*, interferón-α, interferón-γ, JUNOVAN™ o MEPACT™ (mifamurtida), lonafarnib, 5,10-metilentetrahidrofolato, miltefosina (hexadecilfosfocolina), NEOVASTAT®(AE-941), NEUTREXIN® (glucuronato de trimetrexato), NIPENT® (pentostatina), ONCONASE® (una enzima ribonucleasa), ONCOPHAGE® (tratamiento con vacuna para melanoma), OncoVAX (vacuna contra IL-2), ORATHECIN™ (rubitecano), OSIDEM® (droga celular basada en anticuerpos), OvaRex® MAb (anticuerpo monoclonal murino), paclitaxel, PANDIMEX™ (saponinas aglicona de ginseng que comprende 20(*S*)protopanaxadiol (aPPD) y 20(*S*)protopanaxatriol (aPPT)), panitumumab, PANVAC®-VF (vacuna contra el cáncer en investigación), PEGaspargasa, PEG Interferón A, fenoxodiol, procarbazina, rebimastato, REMOVAB® (catumaxomab), REVLIMID® (lenalidomida), RSR13 (efaproxiral), SOMATULINE® LA (lanreotide), SORIATANE® (acitretina), estaurosporina (*Streptomyces staurospores*), talabostat (PT100), TARGRETIN® (bexaroteno), Taxoprexin® (DHA-paclitaxel), TELCYTA™ (TLK286), temilifeno, TEMODAR® (temozolomida), tesmilifeno, talidomida, THERATOPE® (STn-KLH), timitaq (diclorhidrato de 2-amino-3,4-dihidro-6-metil-4-oxo-5-(4-piridiltio)quinazolina), TNFerade™ (adenovector: vehículo de ADN que contiene el gen para el factor de necrosis tumoral-α), TRACLEER® o ZAVESCA® (bosentano), tretinoína (Retin-A), tetrandrina, TRISENOX® (trióxido de arsénico), VIRULIZIN®, ukraína (derivado de alcaloides de la planta *Celidonia*), vitaxina (anticuerpo anti-alfavbeta3), XCYTRIN® (motexafin gadolinio), XINLAY™ (atrasentano), XYOTAX™ (paclitaxel poliglumex), YONDELIS™ (trabectedina), ZD-6126, ZINECARD® (dexrazoxan), zometa (ácido zolendrónico), zorubicina y similares.

También se espera que los compuestos con la Fórmula I puedan inhibir el desarrollo de células derivadas de un cáncer pediátrico o neoplasma incluyendo rabdomiosarcoma embrional, leucemia linfoblástica aguda pediátrica, leucemia mielogénica aguda pediátrica, rabdomiosarcoma alveolar pediátrico, ependimoma anaplástico pediátrico, linfoma anaplástico de células grandes pediátrico, meduloblastoma anaplástico pediátrico, tumor teratoide/rabdoide atípico del sistema nervioso central pediátrico, leucemia aguda bifenotípica pediátrica, linfoma de Burkitts pediátrico, tipos de cáncer pediátrico de la familia de tumores de Ewing tales como tumores neuroectodérmicos primitivos, tumor de Wilm anaplástico difuso pediátrico, tumor de Wilm pediátrico con histología favorable, glioblastoma pediátrico, meduloblastoma pediátrico, neuroblastoma pediátrico, mielocitomatosis derivada de neuroblastoma pediátrico, tipos pediátricos de cáncer pre-células B (tal como leucemia), osteosarcoma pediátrico, tumor renal rabdoide pediátrico, rabdomiosarcoma pediátrico, y tipos de cáncer pediátricos de Células T tales como linfoma y cáncer de piel, etcétera (Solicitud de los EE.UU. Nº de Acta 10/988.338 de propiedad en común), Cancer Res., 2000, 60, 6101-10); y trastornos autoinmunes que incluyen, enfermedad de síndrome de inmunodeficiencia adquirida,

síndrome linfoproliferativo autoinmune, anemia hemolítica, enfermedades inflamatorias, trombocitopenia, etcétera (Current Allergy and Asthma Reports 2003, 3:378-384; Br. J. Haematol. 2000 Sep; 110(3): 584-90; Blood 2000 Feb 15;95(4):1283-92; y New England Journal of Medicine 2004 Sep; 351(14): 1409-1418).

Los compuestos con la Fórmula I se pueden hacer por procesos de síntesis química, algunos de cuyos ejemplos se muestran aquí a continuación. Debe quedar claro que el orden de los pasos en los procesos se puede variar, que los reactivos, solventes y las condiciones de reacción se pueden sustituir por aquellos que se mencionan específicamente, y que las unidades vulnerables tales como las unidades C(O)OH, C(O) y C(O)H, NH, $C(O)NH_2$, OH y SH se pueden proteger y desproteger, según sea necesario.

Los grupos protectores para las unidades C(O)OH incluyen, pero de manera no taxativa, acetoximetilo, alilo, benzoilmetilo, bencilo, benciloximetilo, tert-butilo, tert-butildifenilsililo, difenilmetilo, ciclobutilo, ciclohexilo, ciclopentilo, ciclopropilo, difenilmetilsililo, etilo, para-metoxibencilo, metoximetilo, metoxietoximetilo, metilo, metiltiometilo, naftilo, para-nitrobencilo, fenilo, n-propilo, 2,2,2-tricloroetilo, trietilsililo, 2-(trimetilsilil)etilo, 2-(trimetilsilil)etoximetilo, trifenilmetilo, etcétera.

Los grupos protectores para las unidades C(O) y C(O)H incluyen, pero de manera no taxativa, 1,3-dioxilcetal, dietilcetal, dimetilcetal, 1,3-ditianilcetal, O-metiloxima, O-feniloxima, etcétera.

Los grupos protectores para unidades NH incluyen, pero de manera no taxativa, acetilo, alanilo, benzoilo, bencilo (fenilmetilo), bencilideno, benciloxicarbonilo (Cbz), tert-butoxicarbonilo (Boc), 3,4-dimetoxibenciloxicarbonilo, difenilmetilo, difenilfosforilo, formilo, metanosulfonilo, para-metoxibenciloxicarbonilo, fenilacetilo, ftaloilo, succinilo, tricloroetoxicarbonilo, trietilsililo, trifluoroacetilo, trimetilsililo, trifenilmetilo, trifenilsililo, para-toluensulfonilo, etcétera.

Los grupos protectores para unidades OH y SH incluyen, pero de manera no taxativa, acetilo, alilo, aliloxicarbonilo, benciloxicarbonilo (Cbz), benzoilo, bencilo, tert-butilo, tert-butildimetilsililo, tert-butildifenilsililo, 3,4-dimetoxibencilo, 3,4-dimetoxibenciloxicarbonilo, 1,1-dimetil-2-propenilo, difenilmetilo, formilo, metanosulfonilo, metoxiacetilo, 4-metoxibenciloxicarbonilo, para-metoxibencilo, metoxicarbonilo, metilo, para-toluensulfonilo, 2,2,2-tricloroetoxicarbonilo, 2,2,2-tricloroetilo, trietilsililo, trifluoroacetilo, 2-(trimetilsilil)etoxicarbonilo, 2-trimetilsililetilo, trifenilmetilo, 2-(trifenilfosfonio)etoxicarbonilo, etcétera.


Se provee una exposición sobre grupos protectores en T.H. Greene y P.G.M. Wuts, Protective Groups in Organic Synthesis, 3ª Ed., John Wiley & Sons, Nueva York (1999).

Las siguientes abreviaturas tienen los significados que se indican.

ADDP significa 1,1'-(azodicarbonil)dipiperidina; AD-mix-β significa una mezcla de $(DHQD)_2PHAL$, $K_3Fe(CN)_6$, K_2CO_3 y K_2SO_4); 9-BBN significa 9-borabiciclo(3.3.1)nonano; $(DHQD)_2PHAL$ significa hidroquinidina 1,4-ftalazinadiil dietil éter; DBU significa 1,8-

diazabiciclo(5.4.0)undec-7-eno; DIBAL significa hidruro de diisobutilaluminio; DIEA significa diisopropiletilamina; DMAP significa N,N-dimetilaminopiridina; DMF significa N,N-dimetilformamida; dmpe significa 1,2-bis(dimetilfosfino)etano; DMSO significa dimetilsulfóxido; dppb significa 1,4-bis(difenilfosfino)butano; dppe significa 1,2-bis(difenilfosfino)etano; dppf significa 1,1'-bis(difenilfosfino)ferroceno; d significa 1,1-bis(difenilfosfino)metano; EDAC significa 1-(3-dimetilaminopropil)-3-etilcarbodiimida; Fmoc significa fluorenilmetoxicarbonilo; HATU significa hexafluorofosfato de O-(7-azabenzotriazol-1-il)-N,N'N'N'-tetrametiluronio; HMPA significa hexametilfosforamida; IPA significa alcohol isopropílico; MP-BH_3 significa cianoborohidruro de trietilamonio metilpoliestireno macroporoso; PyBOP significa hexafluorofosfato de benzotriazol-1-iloxitripirrolidinofosfonio; TEA significa trietilamina; TFA significa ácido trifluoroacético; THF significa tetrahidrofurano; NCS significa N-clorosuccinimida; NMM significa N-metilmorfolina; NMP significa N-metilpirrolidina y PPh_3 significa trifenilfosfina.

ESQUEMA 1



Según se muestra en el esquema 1, los compuestos de fórmula (1) se pueden convertir en compuestos de fórmula (2) haciendo reaccionar a los anteriores con nitrato de sodio y un ácido acuoso seguido del agregado de acetato de sodio acuoso y un éster 2-oxocicloalquílico apropiado.

Los ejemplos de ácidos incluyen ácido clorhídrico, etcétera.

Los ejemplos de apropiado ésteres 2-oxocicloalquílicos incluyen 2-oxociclohexanocarboxilato de etilo, 2-oxociclopentanocarboxilato de etilo, etcétera.

La reacción inicialmente se lleva a cabo a aproximadamente 0ºC, durante entre aproximadamente 30 minutos y aproximadamente una hora, y luego se calienta hasta entre aproximadamente 15ºC y 25ºC durante entre aproximadamente una y cuatro horas, en agua.

Los compuestos de fórmula (2) se pueden convertir en compuestos de fórmula (3) haciendo reaccionar a los anteriores con una solución de borano.


La reacción típicamente se lleva a cabo a temperatura ambiente durante entre aproximadamente 8 horas y aproximadamente 20 horas en un solvente tal como THF pero sin limitarse a la misma.

Los compuestos de fórmula (3) se pueden convertir en compuestos de fórmula (4) haciendo reaccionar a los anteriores con R^5OH, trifenilfosfina, y un reactivo tal como DEAD o TBAD pero sin limitarse a los mismos.

El agregado típicamente se lleva a cabo a una temperatura menor que la ambiente antes de calentar hasta la temperatura ambiente durante aproximadamente 8-72 horas en un solvente tal como THF pero sin limitarse a la misma.

La introducción de unidades representadas por E^1, F^1, G^1, y A^1 se puede conseguir haciendo reaccionar anilinas sustituidas con la fórmula (1) según se muestra en el esquema (1). Como alternativa, se pueden hacer reaccionar bromoanilinas de fórmula (1) según se muestra en el esquema (1) y luego subsiguientemente se pueden hacer reaccionar usando métodos descritos en la literatura (tales como los que se describen en Palladium Reagents And Catalysts: New Perspectives For The 21st Century, de J. Tsuji, John Wiley & Sons, Ltd., Chichester, 2004, 1-670) y conocidos por aquellos con experiencia en el arte para las reacciones de acoplamiento cruzado de carbonos catalizadas por paladio.

Esquema 2



Según se muestra en el esquema 2, los compuestos de fórmula (4) se pueden convertir en compuestos de fórmula (5) haciendo reaccionar a los anteriores con una base, seguido de un compuesto de fórmula C^1Br (5a) o C^1Cl (5b) apropiado.

Los ejemplos de bases incluyen hidruro de sodio, carbonato de potasio, etcétera.

Los ejemplos de compuestos de fórmula (5a) incluyen 1-(3-bromopropoxi)naftaleno, etcétera apropiados.

Los ejemplos de compuestos de fórmula (5b) incluyen 2-cloro-1-morfolinoetanona,

etcétera , que son apropiados.

La reacción típicamente se lleva a cabo a una temperatura menor que la ambiente durante aproximadamente 15 minutos a una hora durante el agregado de la base, y luego entre aproximadamente 20°C y 80°C durante entre aproximadamente una y ocho horas luego del agregado del compuesto de fórmula (5a) o (5b) en un solvente tal como DMF pero sin limitarse esta.

Los compuestos de fórmula (5) se pueden convertir en compuestos de fórmula (6) haciendo reaccionar a los anteriores con una base.

Los ejemplos de bases incluyen hidróxido de litio, hidróxido de sodio, hidróxido de potasio, etcétera.


La reacción típicamente se lleva a cabo durante entre aproximadamente 1 hora y aproximadamente 48 horas, a entre aproximadamente 0°C y 35°C, en solventes tales como agua, metanol, etanol, isopropanol, mezclas de los mismos, etcétera.

Los compuestos de fórmula (4), donde C^1 es H, se pueden convertir en compuestos de fórmula (6) haciendo reaccionar a los anteriores con una base.

Los ejemplos de bases incluyen hidróxido de litio, hidróxido de sodio, hidróxido de potasio, etcétera.

La reacción típicamente se lleva a cabo durante entre aproximadamente 1 hora y aproximadamente 48 horas, a entre aproximadamente 0°C y 35°C, en solventes tales como agua, metanol, etanol, isopropanol, mezclas de los mismos, etcétera.

Esquema 3



Según se muestra en el esquema 3, los compuestos de fórmula (3) se pueden convertir en compuestos de fórmula (7) haciendo reaccionar a los anteriores con una base seguida de cloruro de metanosulfonilo.

Los ejemplos de bases incluyen TEA, piridina, etcétera.

La reacción típicamente se lleva a cabo durante entre aproximadamente 30 minutos y aproximadamente tres horas, a entre aproximadamente 0°C y 20°C, en

acetonitrilo.


Los compuestos de fórmula (7) se pueden convertir en compuestos de fórmula (8) haciendo reaccionar a los anteriores con un compuesto de fórmula R^5SH, y una base.

Los ejemplos de bases incluyen carbonato de potasio y carbonato de sodio.

La reacción típicamente se lleva a cabo durante entre uno y cinco días a entre aproximadamente 50°C y 100°C, en un solvente tal como acetonitrilo pero sin limitarse a este.

Los compuestos de fórmula (8) se pueden convertir en compuestos de fórmula (9) según se describe en el esquema 2 para la conversión de compuestos de fórmula (4) a compuestos de fórmula (6).

Esquema 4




(10) (11) (12)

Según se muestra en el esquema 4, los compuestos de fórmula (10) se pueden convertir en compuestos de fórmula (12) haciendo reaccionar a los anteriores con compuestos de fórmula (11), trifenilfosfina, y un reactivo tal como DEAD o TBAD, pero sin limitarse a los mismos.

El agregado se puede llevar a cabo a una temperatura menor que la ambiente antes de calentar hasta la temperatura ambiente durante aproximadamente 8-72 horas en un solvente tal como THF pero sin limitarse a la misma.

Esquema 5



(12) (13) (14) (15) (16)

Según se muestra en el esquema 5, los compuestos de fórmula (12) se pueden convertir en compuestos de fórmula (14) haciendo reaccionar a los anteriores con un compuesto de fórmula (13) y una base.


Los ejemplos de bases incluyen hidruro de sodio y carbonato de potasio, etcétera.

La reacción típicamente se lleva a cabo a una temperatura menor que la ambiente durante aproximadamente 15 minutos a una hora durante el agregado de la base, y luego a entre aproximadamente 20°C y 80°C durante entre aproximadamente una y ocho horas luego del agregado del compuesto de fórmula (13) en un solvente tal como DMF pero sin limitarse a esta.

Los compuestos de fórmula (14) se pueden convertir en compuestos de fórmula (15) usando métodos descritos en la literatura (tal como los que se describen en Palladium Reagents And Catalysts: New Perspectives For The 21st Century, de J. Tsuji, John Wiley & Sons, Ltd., Chichester, 2004, 1-670) y los conocidos por aquellos con experiencia en el arte de las reacciones de acoplamiento cruzado de carbonos catalizadas por paladio.

Los compuestos de fórmula (15) se pueden convertir en compuestos de fórmula (16) según se describe en el esquema 2 para la conversión de compuestos de fórmula (4) a compuestos de fórmula (6).

Esquema 6



Según se muestra en el esquema 6, los compuestos de fórmula (3) se pueden convertir en compuestos de fórmula (16) haciendo reaccionar a los anteriores, con yodo, trifenilfosfina e imidazol, seguido de una base.

Los ejemplos de bases incluyen carbonato de sodio, etcétera.

La reacción típicamente se lleva a cabo entre aproximadamente −10°C y aproximadamente 10°C durante entre aproximadamente 15 minutos y una hora y luego se continúan durante entre otros 30 minutos y una hora adicionales luego del agregado de la

base, en un solvente tal como diclorometano pero sin limitarse a este.

Los compuestos de fórmula (16) se pueden convertir en compuestos de fórmula (17) haciendo reaccionar a los anteriores con trifenilfosfina.

La reacción típicamente se lleva a cabo durante entre aproximadamente 8 y aproximadamente 48 horas a reflujo, en un solvente tal como acetonitrilo o diclorometano pero sin limitarse a los mismos.

Los compuestos de fórmula (17) se pueden convertir en compuestos de fórmula (18) haciendo reaccionar a los anteriores con una base, y un compuesto de fórmula $R^5C(O)H$.

Los ejemplos de bases incluyen hidruro de sodio y n-butil-litio.

La reacción se lleva a cabo inicialmente durante aproximadamente una hora a entre aproximadamente 60°C y aproximadamente 100°C luego del agregado de la base y luego se enfría hasta entre aproximadamente 10°C y aproximadamente 25°C y se trata con un compuesto de fórmula (17). Luego de entre aproximadamente 10 minutos y aproximadamente 20 minutos, se agrega el compuesto de fórmula $R^5C(O)H$ y se vuelve a calentar la mezcla nuevamente hasta entre aproximadamente 60°C y aproximadamente 100°C durante entre aproximadamente una y ocho horas.

Los compuestos de fórmula (18) se pueden convertir en compuestos de fórmula (19) haciendo reaccionar a los anteriores con una fuente de hidrógeno y un catalizador.


Los ejemplos de fuentes de hidrógeno incluyen hidrazina y gas hidrógeno.

Los ejemplos de catalizadores incluyen Pd/C y níquel de Raney, etcétera.

La temperatura y la presión varían dependiendo del método de hidrogenación y de los sustratos que se empleen. Los solventes típicos incluyen metanol, etanol, acetato de etilo, etcétera.

Los compuestos de fórmula (19) se pueden convertir en compuestos de fórmula (20) según se describe en el esquema 2 para convertir a los compuestos de fórmula (4) en compuestos de fórmula (6).

Esquema 7



Según se muestra en el esquema 7, los compuestos de fórmula (3) se pueden convertir en compuestos de fórmula (21) haciendo reaccionar a los anteriores, DMSO, una base, y un agente deshidratante.

Los ejemplos de bases incluyen trietilamina, diisopropilamina, etcétera.

Los ejemplos de agentes deshidratantes incluyen cloruro de oxalilo, anhídrido trifluoroacético, y piridina-sulfato.

La reacción típicamente se lleva a cabo durante entre aproximadamente uno y

aproximadamente ocho horas a entre aproximadamente –60°C y aproximadamente 0°C dependiendo del sustrato y el método que se empleen.

Los siguientes ejemplos se ofrecen para proporcionar lo que se considera la descripción más útil y fácilmente comprensible de los procedimientos y aspectos conceptuales de esta invención.

EJEMPLO 1A

7-bromo-3-(3-etoxi-3-oxopropil)-1H-indol-2-carboxilato de etilo

Una mezcla de 2-bromoanilina (34,2 g) en HCl 5M (50 ml) y agua (250 ml) a 0°C se trató con $NaNO_2$ (13,8 g) en agua (200 ml). Después de la adición, se agregaron acetato de sodio (92,3 g) en agua (250 ml) y etiléster de ácido 2-oxo-ciclopentancarboxílico (30 ml). La mezcla se agitó durante 15 minutos, se calentó a 19°C a lo largo de dos horas y se extrajo con diclorometano. El extracto se secó ($MgSO_4$), se filtró y se concentró. El concentrado se disolvió en 1,1:1 H_2SO_4:etanol (30 ml), se sometió a reflujo durante la noche, se enfrió a temperatura ambiente, se neutralizó con agua (1,5L), y se filtró. La torta filtrante se disolvió en diclorometano (200 ml) y se filtró a través de un cartucho Flash 75 con diclorometano. Después de la concentración, el producto se recristalizó desde hexano.

EJEMPLO 1B

7-bromo-3-(3-hidroxipropil)-1H-indol-2-carboxilato de etilo

A una mezcla del EJEMPLO 1A (1,85 g) en THF (50 ml) se agregó borano·THF 1M (30 ml). La mezcla se agitó a temperatura ambiente durante 16 horas, se neutralizó con metanol (10 ml) y se concentró. El concentrado se purificó por cromatografía flash en columna sobre gel de sílice con 5-25 % acetato de etilo/hexanos.

EJEMPLO 1C

7-bromo-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo

A una mezcla del EJEMPLO 1B (10,87 g), 1-naftol (5,77 g) y trifenilfosfina (10,5 g) en THF (100 ml) se agregó azodicarboxilato de di-tert-butilo (9,21 g). La mezcla se agitó durante 3 días, se concentró, se redisolvió en diclorometano, se lavó con agua y salmuera y se secó ($MgSO_4$), se filtró y se concentró. El concentrado se purificó por cromatografía flash en columna sobre gel de sílice con 0-10% acetato de etilo en hexanos. El producto se recristalizó desde hexanos.

EJEMPLO 1D

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-fenilvinil)-1H-indol-2-carboxílico

Una mezcla del EJEMPLO 1C (0,034 g), ácido (E)-estirilborónico (0,1 g), dicloruro de bis(trifenilfosfin)paladio(II) (4 mg), y Na_2CO_3 2M (0,5 ml) en 7:2:3 dimetoxietano/etanol/agua (3 ml) se calentó bajo microondas (CEM Discover) a 150°C durante 30 minutos, se neutralizó con HCl 1M (0,4 ml) y se extrajo con acetato de etilo. El extracto se filtró a través de un cartucho de secado ($MgSO_4$, Alltech Assoc., 2 g) y se concentró. El concentrado se purificó por HPLC en fase reversa (Zorbax SB-C18, 20-100% acetonitrilo/ agua/0,1% TFA). ^{1}H RMN (400 MHz, DMSO-d_6) □ 13,03 (s ancho, 1H),

11,68 (s, 1H), 8,23 (m, 1H), 8,14 (d, 1H), 7,86 (m, 1H), 7,76 (d, 1H), 7,68 (d, 1H), 7,61 (d, 1H), 7,52 (m, 2H), 7,41 (m, 4H), 7,29 (m, 2H), 7,01 (t, 1H), 6,88 (d, 1H), 4,17 (t, 2H), 2,22 (m, 2H).

EJEMPLO 2

ácido 3-(3-(1-naftiloxi)propil)-7-fenil-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido fenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (400 MHz, DMSO-d_6) □ 12,97 (s, 1H), 10,29 (s, 1H), 8,23 (m, 1H), 7,86 (m, 1H), 7,69 (d, 1H), 7,64 (m, 2H), 7,52 (m, 4H), 7,41 (m, 3H), 7,25 (m, 1H), 7,10 (t, 1H), 6,89 (d, 1H), 4,20 (t, 2H), 3,37 (m, 2H), 2,24 (m, 2H).

EJEMPLO 3

ácido 3-(3-(1-naftiloxi)propil)-7-((1E)-3-fenilprop-1-enil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido (E)-3-fenilprop-1-enilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (400 MHz, DMSO-d_6) □ 13,02 (s ancho, 1H), 11,38 (s, 1H), 8,20 (m, 1H), 7,85 (m, 1H), 7,36 (m, 12H), 6,93 (t, 1H), 6,86 (d, 1H), 6,44 (m, 1H), 4,15 (t, 2H), 3,58 (d, 2H), 2,20 (m, 2H).

EJEMPLO 4

ácido 7-((E)-2-ciclohexilvinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido (E)-2-ciclohexil-vinilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (400 MHz, DMSO-d_6) □ 13,02 (s ancho, 1H), 11,37 (s, 1H), 8,21 (m, 1H), 7,85 (m, 1H), 7,51 (m, 3H), 7,44 (m, 1H), 7,36 (m, 2H), 7,19 (d, 1H), 6,89 (m, 2H), 6,30 (m, 1H), 4,15 (t, 2H), 2,19 (m, 3H), 1,77 (m, 5H), 1,27 (m, 5H).

EJEMPLO 5

ácido 7-(3-(benciloxi)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 3-(benciloxi)-fenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (400 MHz, DMSO-d_6) □ 12,99 (s ancho, 1H), 10,34 (s, 1H), 8,22 (m, 1H), 7,86 (m, 1H), 7,69 (d, 1H), 7,36 (m, 13H), 7,07 (m, 2H), 6,89 (d, 1H), 5,19 (s, 2H), 4,20 (t, 2H), 3,37 (t, 2H), 2,24 (m, 2H).

EJEMPLO 6

ácido 7-(4-fluorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 4-fluorofenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (400 MHz, DMSO-d_6) □ 13,00 (s ancho, 1H), 10,54 (s, 1H), 8,22 (m, 1H), 7,86 (m, 1H), 7,70 (d, 1H), 7,64 (m, 2H), 7,49 (m, 3H), 7,34 (m, 3H), 7,21 (d, 1H), 7,08 (t, 1H), 6,89 (d, 1H), 4,19 (t, 2H), 3,37 (t, 2H), 2,24 (m, 2H).

EJEMPLO 7

ácido 7-(2-naftil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-naftilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,01 (s ancho, 1H), 10,69 (s, 1H), 8,25 (m, 1H), 8,17 (s, 1H), 8,01 (m, 3H), 7,87 (m, 1H), 7,74 (m, 2H), 7,55

(m, 4H), 7,45 (d, 1H), 7,36 (m, 2H), 7,13 (t, 1H), 6,90 (d, 1H), 4,21 (t, 2H), 3,39 (t, 2H), 2,26 (m, 2H).

EJEMPLO 8

ácido 7-(1-naftil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 1-naftilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,90 (s ancho, 1H), 10,54 (s, 1H), 8,27 (m, 1H), 8,01 (m, 2H), 7,88 (m, 1H), 7,79 (d, 1H), 7,61 (t, 1H), 7,50 (m, 5H), 7,40 (m, 3H), 7,20 (d, 1H), 7,15 (t, 1H), 6,92 (d, 1H), 4,23 (s, 2H), 3,40 (m, 2H), 2,27 (m, 2H).

EJEMPLO 9

ácido 7-(1,1'-bifenil-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido bifenil-2-ilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,90 (s ancho, 1H), 10,22 (s, 1H), 8,24 (m, 1H), 7,86 (m, 1H), 7,50 (m, 8H), 7,38 (t, 1H), 7,09 (m, 5H), 6,86 (m, 3H), 4,14 (t, 2H), 2,18 (m, 2H).

EJEMPLO 10

ácido 7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-morfolinofenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,11 (s ancho, 1H), 10,07 (s, 1H), 8,24 (d, 1H), 7,85 (m, 1H), 7,74 (d, 1H), 7,44 (m, 7H), 7,14 (m, 3H), 6,86 (d, 1H), 4,18 (t, 2H), 3,25 (m, 4H), 2,78 (m, 4H), 2,26 (m, 2H).

EJEMPLO 11

ácido 7-(2-fluoro-1,1'-bifenil-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-fluorobifenil-4-ilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,07 (s ancho, 1H), 10,86 (s, 1H), 8,23 (m, 1H), 7,87 (m, 1H), 7,74 (d, 1H), 7,65 (m, 3H), 7,53 (m, 6H), 7,41 (m, 3H), 7,32 (d, 1H), 7,11 (t, 1H), 6,90 (d, 1H), 4,20 (t, 2H), 3,38 (t, 2H), 2,24 (m, 2H).

EJEMPLO 12

ácido 7-(4-(benciloxi)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 4-(benciloxi)-fenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,04 (s ancho, 1H), 10,27 (s, 1H), 8,23 (m, 1H), 7,87 (m, 1H), 7,65 (d, 1H), 7,54 (m, 6H), 7,39 (m, 5H), 7,18 (m, 3H), 7,07 (t, 1H), 6,90 (d, 1H), 5,19 (s, 2H), 4,19 (t, 2H), 2,23 (m, 2H).

EJEMPLO 13

ácido 7-(3-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 3-morfolinofenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,03 (s ancho, 1H), 10,21 (s, 1H), 8,22 (m, 1H), 7,86 (m, 1H), 7,68 (d, 1H), 7,52 (m, 2H), 7,45 (d, 1H), 7,38 (d, 2H), 7,25 (d, 1H), 7,06 (m, 4H), 6,89 (d, 1H), 4,19 (t, 2H), 3,76 (t, 4H), 3,19

(t, 4H), 2,23 (m, 2H).

EJEMPLO 14

ácido 3-(3-(1-naftiloxi)propil)-7-piridin-3-il-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando ácido 3-piridilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,13 (s ancho, 1H), 11,30 (s, 1H), 8,96 (s, 1H), 8,76 (m, 1H), 8,31 (d, 1H), 8,22 (d, 1H), 7,84 (m, 3H), 7,52 (m, 2H), 7,45 (d, 1H), 7,38 (t, 1H), 7,29 (d, 1H), 7,14 (t, 1H), 6,89 (d, 1H), 4,19 (t, 2H), 3,38 (t, 2H), 2,24 (m, 2H).

EJEMPLO 15

ácido 3-(3-(1-naftiloxi)propil)-7-piridin-4-il-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando ácido 4-piridilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,18 (s ancho, 1H), 11,18 (s, 1H), 8,84 (m, 2H), 8,21 (d, 1H), 7,98 (m, 2H), 7,86 (d, 2H), 7,45 (m, 5H), 7,16 (m, 1H), 6,89 (d, 1H), 4,19 (t, 2H), 3,39 (t, 2H), 2,24 (m, 2H).

EJEMPLO 16

ácido 3-(3-(1-naftiloxi)propil)-7-((1E)-5-fenilpent-1-enil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido (E)-5-fenilpent-1-enilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,00 (s ancho, 1H), 11,38 (s, 1H), 8,22 (m, 1H), 7,85 (m, 1H), 7,52 (m, 3H), 7,40 (m, 3H), 7,23 (m, 6H), 6,94 (t, 1H), 6,85 (d, 1H), 6,37 (m, 1H), 4,15 (t, 2H), 2,66 (t, 2H), 2,28 (m, 2H), 2,19 (m, 2H), 1,82 (m, 2H).

EJEMPLO 17

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,95 (s ancho, 1H), 10,49 (s, 1H), 8,26 (d, 1H), 7,87 (d, 1H), 7,69 (d, 1H), 7,53 (m, 2H), 7,45 (d, 1H), 7,39 (t, 1H), 7,26 (m, 4H), 7,06 (m, 2H), 6,90 (d, 1H), 4,21 (t, 2H), 2,24 (m, 2H), 2,06 (s, 3H).

EJEMPLO 18

ácido 7-(3-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 3-metilfenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,02 (s ancho, 1H), 10,32 (s, 1H), 8,22 (m, 1H), 7,87 (m, 1H), 7,68 (d, 1H), 7,52 (m, 2H), 7,41 (m, 5H), 7,23 (m, 2H), 7,09 (t, 1H), 6,89 (d, 1H), 4,19 (t, 2H), 2,41 (s, 3H), 2,24 (m, 2H).

EJEMPLO 19

ácido 7-(4-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 4-metilfenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,05 (s ancho, 1H), 10,25 (s, 1H), 8,22 (m, 1H), 7,86 (m, 1H), 7,67 (d, 1H), 7,50 (m, 5H), 7,36 (m, 3H), 7,22 (d, 1H), 7,08 (t, 1H), 6,89 (d, 1H), 4,19 (t, 2H), 2,39 (s, 3H), 2,23 (m, 2H).

EJEMPLO 20

ácido 7-(4-carboxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 4-(metoxicarbonil)-fenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,01 (s ancho, 2H), 10,73 (s, 1H), 8,23 (m, 1H), 8,06 (d, 2H), 7,87 (m, 1H), 7,74 (m, 3H), 7,50 (m, 3H), 7,38 (t, 1H), 7,11 (t, 1H), 6,89 (d, 1H), 4,19 (t, 2H), 2,24 (m, 2H).

EJEMPLO 21

ácido 7-(3-carboxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 3-(metoxicarbonil)-fenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,02 (s ancho, 2H), 10,84 (s, 1H), 8,23 (m, 1H), 8,12 (m, 1H), 7,98 (m, 1H), 7,85 (m, 2H), 7,72 (d, 1H), 7,63 (t, 1H), 7,52 (m, 2H), 7,45 (d, 1H), 7,39 (t, 1H), 7,24 (d, H), 7,10 (t, 1H), 6,90 (d, 1H), 4,19 (t, 2H), 3,38 (t, 2H), 2,24 (m, 2H).

EJEMPLO 22

ácido 7-(2-(benciloxi)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-(benciloxi)-fenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,95 (s ancho, 1H), 10,35 (s, 1H), 8,27 (m, 1H), 7,87 (m, 1H), 7,67 (d, 1H), 7,53 (m, 2H), 7,40 (m, 4H), 7,24 (d, 1H), 7,10 (m, 8H), 6,87 (d, 1H), 5,09 (s, 2H), 4,17 (t, 2H), 2,24 (m, 2H).

EJEMPLO 23

ácido 7-(2-etoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-etoxifenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,01 (s ancho, 1H), 9,93 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,70 (d, 1H), 7,44 (m, 6H), 7,17 (m, 2H), 7,06 (m, 2H), 6,89 (d, 1H), 4,19 (t, 2H), 4,09 (q, 2H), 2,24 (m, 2H), 1,15 (t, 3H).

EJEMPLO 24

ácido 7-(2-etilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-etilfenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,93 (s ancho, 1H), 10,40 (s, 1H), 8,26 (m, 1H), 7,87 (m, 1H), 7,69 (d, 1H), 7,53 (m, 2H), 7,45 (d, 1H), 7,38 (m, 3H), 7,26 (m, 1H), 7,18 (d, 1H), 7,05 (m, 2H), 6,91 (d, 1H), 4,21 (t, 2H), 2,33 (m, 4H), 0,94 (t, 3H).

EJEMPLO 25

ácido 7-(2-metoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metoxifenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,97 (s ancho, 1H), 10,09 (s, 1H), 8,26 (m, 1H), 7,87 (m, 1H), 7,68 (d, 1H), 7,53 (m, 2H), 7,42 (m, 3H), 7,29 (m, 1H), 7,15 (m, 2H), 7,06 (m, 2H), 6,91 (d, 1H), 4,20 (t, 2H), 3,74 (s, 3H), 2,24 (m, 2H).

EJEMPLO 26

ácido 7-(2-isopropoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-isopropoxifenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,04 (s ancho, 1H), 9,73 (s, 1H), 8,24 (m, 1H), 7,86 (m, 1H), 7,70 (d, 1H), 7,52 (m, 2H), 7,45 (d, 1H), 7,38 (m, 3H), 7,20 (m, 2H), 7,08 (m, 2H), 6,89 (d, 1H), 4,62 (m, 1H), 4,19 (t, 2H), 3,37 (t, 2H), 2,24 (m, 2H), 1,13 (d, 6H).

EJEMPLO 27

ácido 3-(3-(1-naftiloxi)propil)-7-(2-fenoxifenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-fenoxifenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,00 (s ancho, 1H), 10,56 (s, 1H), 8,25 (m, 1H), 7,86 (m, 1H), 7,64 (d, 1H), 7,45 (m, 6H), 7,23 (m, 4H), 6,94 (m, 6H), 4,17 (t, 2H), 2,21 (m, 2H).

EJEMPLO 28

ácido 7-(2-carboxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-(dietilcarbamoil)fenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,90 (s ancho, 1H), 12,42 (s ancho, 1H), 10,56 (s, 1H), 8,27 (m, 1H), 7,87 (m, 2H), 7,52 (m, 8H), 7,03 (m, 2H), 6,92 (d, 1H), 4,21 (t, 2H), 2,23 (m, 2H).

EJEMPLO 30

ácido 3-(3-(1-naftiloxi)propil)-7-(2-((5,6,7,8-tetrahidronaftalen-1-iloxi)metil)fenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-((5,6,7,8-tetrahidronaftalen-1-iloxi)metil)fenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,94 (s ancho, 1H), 10,49 (s, 1H), 8,24 (m, 1H), 7,86 (m, 1H), 7,66 (m, 2H), 7,44 (m, 7H), 7,08 (m, 2H), 6,85 (m, 2H), 6,56 (d, 1H), 6,37 (d, 1H), 4,80 (s ancho, 2H), 4,18 (t, 2H), 2,60 (m, 2H), 2,39 (m, 2H), 2,24 (m, 2H), 1,62 (m, 4H).

EJEMPLO 31

ácido 7-(4-ciclohexilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 4-ciclohexilfenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,04 (s ancho, 1H), 10,26 (s, 1H), 8,23 (m, 1H), 7,86 (m, 1H), 7,67 (d, 1H), 7,45 (m, 8H), 7,23 (m, 1H), 7,08 (t, 1H), 6,89 (d, 1H), 4,19 (t, 2H), 3,37 (t, 2H), 2,59 (m, 1H), 2,24 (m, 2H), 1,80 (m, 5H), 1,39 (m, 5H).

EJEMPLO 32

ácido 7-(2-clorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-clorofenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,97 (s ancho, 1H), 10,91 (s, 1H), 8,27 (m, 1H), 7,87 (m, 1H), 7,73 (m, 1H), 7,54 (m, 3H), 7,42 (m, 5H), 7,08 (m, 2H), 6,91 (d, 1H), 4,21 (t, 2H), 3,37 (t, 2H), 2,23 (m, 2H).

EJEMPLO 33

ácido 7-(3-cloropiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando ácido 2-cloropirid-4-il-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,03 (s ancho, 1H), 11,28 (s, 1H), 8,72 (s, 1H), 8,57 (d, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,79 (d, 1H), 7,53 (m, 2H), 7,45 (m, 2H), 7,39 (t, 1H), 7,11 (m, 2H), 6,91 (d, 1H), 4,20 (t, 2H), 2,23 (m, 2H).

EJEMPLO 34

ácido 7-(2,5-diclorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2,5-diclorofenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,96 (s ancho, 1H), 11,43 (s, 1H), 8,24 (m, 1H), 7,86 (m, 1H), 7,65 (d, 1H), 7,52 (m, 2H), 7,45 (d, 1H), 7,38 (m, 2H), 7,21 (t, 1H), 6,95 (t, 1H), 6,87 (d, 1H), 4,16 (t, 2H), 2,21 (m, 2H).

EJEMPLO 35

ácido 7-(3,5-diclorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 3,5-diclorofenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,94 (s ancho, 1H), 11,02 (s, 1H), 8,27 (m, 1H), 7,86 (m, 2H), 7,67 (m, 2H), 7,53 (m, 2H), 7,46 (d, 1H), 7,39 (m, 2H), 7,03 (m, 2H), 6,91 (d, 1H), 4,21 (t, 2H), 2,24 (m, 2H).

EJEMPLO 36

ácido 7-(2,3-dimetoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2,3-dimetoxifenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,05 (s ancho, 1H), 10,03 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,71 (d, 1H), 7,52 (m, 2H), 7,45 (d, 1H), 7,39 (t, 1H), 7,14 (m, 4H), 6,92 (m, 2H), 4,20 (t, 2H), 3,88 (s, 3H), 3,43 (s, 3H), 2,24 (m, 2H).

EJEMPLO 37

ácido 7-(2,4-dimetoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2,4-dimetoxifenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,96 (s ancho, 1H), 9,99 (s, 1H), 8,27 (m, 1H), 7,87 (m, 1H), 7,64 (d, 1H), 7,53 (m, 2H), 7,46 (d, 1H), 7,39 (t, 1H), 7,21 (m, 1H), 7,10 (m, 1H), 7,03 (m, 1H), 6,90 (m, 1H), 6,71 (m, 1H), 6,65 (m, 1H), 4,19 (t, 2H), 3,84 (s, 3H), 3,74 (s, 3H), 2,24 (m, 2H).

EJEMPLO 38

ácido 7-(2,5-dimetoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2,5-dimetoxifenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,99 (s ancho, 1H), 10,08 (s, 1H), 8,26 (m, 1H), 7,87 (m, 1H), 7,68 (d, 1H), 7,53 (m, 2H), 7,46 (d, 1H), 7,39 (t, 1H), 7,17 (d, 1H), 7,07 (m, 2H), 6,98 (m, 1H), 6,90 (d, 1H), 6,87 (d, 1H), 4,20 (t, 2H), 3,75 (s, 3H), 3,68 (s, 3H), 2,24 (m, 2H).

EJEMPLO 39

ácido 7-(2,6-dimetoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2,6-dimetoxifenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,87 (s ancho, 1H), 10,18 (s, 1H), 8,30 (m, 1H), 7,88 (m, 1H), 7,62 (m, 1H), 7,53 (m, 2H), 7,46 (d, 1H), 7,38 (m, 2H), 7,01 (m, 2H), 6,93 (d, 1H), 6,76 (d, 2H), 4,22 (s, 2H), 3,62 (s, 6H), 2,23 (m, 2H).

EJEMPLO 40

ácido 7-(4-metoxipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando ácido 4-metoxipirid-3-il-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,02 (s ancho, 1H), 10,94 (s, 1H), 8,37 (m, 1H), 8,24 (m, 1H), 7,88 (m, 2H), 7,70 (d, 1H), 7,52 (m, 2H), 7,45 (d, 1H), 7,38 (t, 1H), 7,19 (d, 1H), 7,07 (t, 1H), 6,94 (d, 1H), 6,89 (d, 1H), 4,19 (t, 2H), 3,93 (s, 3H), 2,23 (m, 2H).

EJEMPLO 41

ácido 7-(2-metoxipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando ácido 2-metoxipirid-3-il-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (400 MHz, DMSO-d_6) □ 13,00 (s ancho, 1H), 10,85 (s, 1H), 8,25 (m, 2H), 7,87 (m, 1H), 7,68 (m, 2H), 7,53 (m, 2H), 7,46 (d, 1H), 7,39 (t, 1H), 7,08 (m, 3H), 6,90 (m, 1H), 4,20 (t, 2H), 3,83 (s, 3H), 2,22 (m, 2H).

EJEMPLO 42

ácido 3-(3-(1-naftiloxi)propil)-7-quinolin-4-il-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando ácido quinolin-4-ilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (400 MHz, DMSO-d_6) □ 12,96 (s ancho, 1H), 11,01 (s, 1H), 9,06 (d, 1H), 8,25 (m, 1H), 8,18 (d, 1H), 7,86 (m, 3H), 7,64 (d, 1H), 7,47 (m, 6H), 7,22 (m, 2H), 6,92 (m, 1H), 4,23 (t, 2H), 2,27 (m, 2H).

EJEMPLO 43A

3-(3-(naftalen-1-iloxi)propil)-7-(4,4,5,5-tetrametil-1,3,2-dioxaborolan-2-il)-1H-indol-2-carboxilato de etilo

Una mezcla del EJEMPLO 1C (1,0 g), bis(pinacolato)diboro (674 mg), acetato de potasio (998 mg) y (1,1'-bis(difenilfosfino)ferrocen)dicloropaladio(II) (81 mg) en DMF (10 ml) se calentó a 60 °C durante la noche y se concentró. El concentrado se particionó entre diclorometano y agua. El extracto se lavó con agua y salmuera y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se cargó en un cartucho de gel de sílice y se eluyó con 5% acetato de etilo/hexanos.

EJEMPLO 43B

ácido 7-(4-hidroxi-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

A una mezcla del EJEMPLO 43A (50 mg) y 4-bromo-3-metilfenol (22 mg) en THF (2 ml) se agregó tris(dibencilidenacetona)dipaladio(0) (4,6 mg), y tetrafluoroborato de tri-tert-butilfosfina (1,45 mg). La mezcla se agitó a temperatura ambiente durante la noche y

se particionó entre acetato de etilo (150 ml) y agua (50 ml). El extracto se lavó con salmuera, se secó sobre sulfato de sodio, y se filtró. El filtrado se concentró, y el concentrado se cargó en un cartucho de gel de sílice y se eluyó con acetato de etilo (5%) en hexanos para dar un producto que se disolvió en THF (2 ml), metanol (1 ml) y agua (1 ml) y se hidrolizó con LiOH (100 mg) durante la noche. La mezcla se acidificó con HCl acuoso 5% y se extrajo con acetato de etilo. El extracto se lavó con agua y salmuera y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se purificó por HPLC en fase reversa como se describe en el EJEMPLO 1D. ^{1}H RMN (300 MHz, $CDCl_3$) □ 8,39 (d, 1H), 8,35 (d, 1H), 7,77 (d, 1H), 7,72 (dd, 1H), 7,13-7,50 (m, 6H), 6,85 (d, 1H), 6,76 (t, 2H), 4,21 (t, 2H), 3,47 (t, 2H), 2,38 (m, 2H), 2,13 (s, 3H).

EJEMPLO 44

ácido 7-(2-(4-metilpiperazin-1-il)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando el EJEMPLO 43A en lugar de ácido (E)-estirilborónico y 1-(2-bromofenil)-4-metilpiperazina en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,10 (s ancho, 1H), 10,43 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,74 (d, 1H), 7,46 (m, 6H), 7,31 (dd, 1H), 7,15 (m, 3H), 6,90 (m, 1H), 4,19 (t, 2H), 3,19 (m, 4H), 2,82 (m, 2H), 2,59 (s, 3H), 2,25 (m, 2H).

EJEMPLO 45

ácido 7-(2,4-diclorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2,4-diclorofenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,06 (s ancho, 1H), 10,70 (s, 1H), 8,22 (m, 1H), 7,87 (m, 1H), 7,71 (d, 1H), 7,62 (m, 2H), 7,53 (m, 3H), 7,45 (d, 1H), 7,38 (t, 1H), 7,22 (d, 1H), 7,09 (t, 1H), 6,89 (d, 1H), 4,19 (t, 2H), 2,23 (m, 2H).

EJEMPLO 46

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 4-(metoxicarbonil)-2-metilfenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,02 (s ancho, 2H), 10,87 (s, 1H), 8,25 (m, 1H), 7,86 (m, 3H), 7,73 (d, 1H), 7,53 (m, 2H), 7,46 (d, 1H), 7,39 (m, 1H), 7,32 (d, 1H), 7,07 (m, 2H), 6,91 (d, 1H), 4,21 (t, 2H), 2,24 (m, 2H), 2,10 (s, 3H).

EJEMPLO 47A

3-(3-hidroxipropil)-7-(2-metoxifenil)-1H-indol-2-carboxilato de etilo

Una mezcla del EJEMPLO 1B (456 mg) y ácido 2-metoxifenilborónico (182,4 mg) en THF (10 ml), tris(dibencilidenacetona)dipaladio(0) (46 mg), tetrafluoroborato de tri-tert-butilfosfina (15 mg) y CsF (456 mg) se agitó a temperatura ambiente, se diluyó con acetato de etilo (200 ml), se lavó con agua y salmuera, y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se purificó por cromatografía flash en columna sobre gel de sílice con 20% acetato de etilo en hexanos.

EJEMPLO 47B

ácido 7-(2-metoxifenil)-3-(3-((2-metil-1-naftil)oxi)propil)-1H-indol-2-carboxílico

Una mezcla del EJEMPLO 47A (71 mg), 2-metil-1-naftol (35 mg), trifenilfosfina (58 mg) en THF (2 ml) y azodicarboxilato de di-tert-butilo (55 mg) se agitó a temperatura ambiente durante la noche y se particionó entre acetato de etilo (150 ml) y agua (50 ml). La fase orgánica se lavó con salmuera y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se purificó por cromatografía flash sobre gel de sílice con 5% acetato de etilo en hexanos para dar un intermediario que se disolvió en THF (2 ml), metanol (1 ml) y agua (1 ml) y se hidrolizó con LiOH (100 mg) durante la noche. La mezcla se acidificó con HCl 5% y se extrajo con acetato de etilo. El extracto se lavó con agua y salmuera y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se purificó por HPLC en fase reversa (C-18, 30 a 100 % acetonitrilo/agua/0,1 % TFA). ^{1}H RMN (300 MHz, $CDCl_3$) □ 8,74 (s, 1H), 8,12 (dd, 1H), 7,82 (d, 1H), 7,77 (d, 1H), 7,52 (d, 1H), 7,36-7,47 (m, 5H), 7,27 (d, 1H), 7,09 (t, 2H), 4,10 (t, 2H), 3,83 (s, 3H), 3,48 (t, 2H), 2,46 (s, 3H), 2,38 (m, 2H).

EJEMPLO 48

ácido 7-(4-fluoro-2-isopropoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 4-fluoro-2-isopropoxifenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,98 (s ancho, 1H), 10,03 (s, 1H), 8,24 (m, 1H), 7,87 (m, 1H), 7,68 (d, 1H), 7,43 (m, 5H), 7,15 (d, 1H), 7,04 (m, 2H), 6,86 (m, 2H), 4,66 (m, 1H), 4,18 (t, 2H), 2,23 (m, 2H), 1,14 (s, 3H), 1,12 (s, 3H).

EJEMPLO 49

ácido 7-(2-etoxi-1-naftil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-etoxinaftalen-1-ilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,81 (s ancho, 1H), 10,42 (s ancho, 1H), 8,29 (m, 1H), 8,00 (d, 1H), 7,89 (m, 2H), 7,75 (m, 1H), 7,41 (m, 7H), 7,13 (m, 3H), 6,91 (m, 1H), 4,24 (t, 2H), 4,10 (q, 2H), 3,39 (t, 2H), 2,27 (m, 2H), 1,02 (m, 3H).

EJEMPLO 50

ácido 7-(4-amino-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 4-bromo-3-metilanilina en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,48 (s, 1H), 8,25 (dd, 1H), 7,88 (dd, 1H), 7,71 (d, 1H), 7,37-7,57 (m, 6H), 7,27 (d, 1H), 7,09 (m, 3H), 6,92 (d, 1H), 4,21 (t, 2H), 2,26 (m, 2H), 2,01 (s, 3H).

EJEMPLO 51A

4-bromo-N-(2-(dimetilamino)etil)-3-metilbenzamida

Una mezcla de ácido 4-bromo-3-metilbenzoico (430 mg), N,N-dimetiletilendiamina (180 mg), clorhidrato de 1-etil-3-(3-(dimetilamino)propil)carbodiimida (600 mg) y 4-dimetilaminopiridina (244 mg) en diclorometano (20 ml) se agitó a temperatura ambiente durante 4 horas, se diluyó con acetato de etilo (200mL), se lavó con agua y

salmuera, y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se purificó por cromatografía flash en columna con 10% acetato de etilo en diclorometano saturado con amoníaco.

EJEMPLO 51B

ácido 7-(4-(((2-(dimetilamino)etil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando el EJEMPLO 51A en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,65 (s, 1H), 9,32 (m, 1H), 8,69 (t, 1H), 8,25 (dd, 1H), 7,88 (dd, 1H), 7,72 (dt, 1H), 7,33-7,57 (m, 6H), 7,06 (dd, 2H), 6,91 (d, 1H), 4,21 (t, 2H), 3,63 (m, 2H), 2,50 (s, 6H), 2,26 (m, 2H), 2,12 (s, 3H).

EJEMPLO 52

ácido 7-(4-cloro-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 4-cloro-2-metilfenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,93 (s ancho, 1H), 10,88 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,70 (d, 1H), 7,46 (m, 5H), 7,30 (m, 1H), 7,21 (d, 1H), 7,05 (m, 2H), 6,90 (d, 1H), 4,20 (t, 2H), 2,23 (m, 2H), 2,03 (s, 3H).

EJEMPLO 53

ácido 7-(2,3-diclorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2,3-diclorofenil-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,98 (s ancho, 1H), 11,20 (s, 1H), 8,26 (m, 1H), 7,87 (m, 1H), 7,74 (m, 1H), 7,68 (m, 1H), 7,53 (m, 2H), 7,39 (m, 4H), 7,06 (m, 2H), 6,91 (d, 1H), 4,21 (t, 2H), 2,24 (m, 2H).

EJEMPLO 54

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(trifluorometil)fenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-trifluorometil-fenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,93 (s ancho, 1H), 11,04 (s, 1H), 8,27 (m, 1H), 7,86 (m, 2H), 7,71 (m, 2H), 7,64 (t, 1H), 7,53 (m, 2H), 7,46 (d, 1H), 7,39 (t, 2H), 7,04 (t, 2H), 6,91 (d, 1H), 4,21 (t, 2H), 2,24 (m, 2H).

EJEMPLO 55

ácido 7-(3-cloro-2-fluorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 3-cloro-2-fluoro-fenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,02 (s ancho, 1H), 11,28 (s, 1H), 8,26 (m, 1H), 7,87 (m, 1H), 7,76 (d, 1H), 7,62 (m, 1H), 7,53 (m, 2H), 7,41 (m, 3H), 7,30 (t, 1H), 7,12 (m, 2H), 6,90 (d, 1H), 4,20 (t, 2H), 3,37 (t, 2H), 2,23 (m, 2H).

EJEMPLO 56

ácido 7-(2,3-difluorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2,3-difluoro-fenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,04 (s

ancho, 1H), 11,24 (s, 1H), 8,26 (d, 1H), 7,87 (d, 1H), 7,77 (d, 1H), 7,47 (m, 5H), 7,28 (m, 2H), 7,19 (m, 1H), 7,09 (t, 1H), 6,90 (d, 1H), 4,20 (t, 2H), 3,38 (t, 2H), 2,24 (m, 2H).

EJEMPLO 57

ácido 7-ciclopent-1-en-1-il-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 1-ciclopenten-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,10 (s ancho, 1H), 10,12 (s, 1H), 8,22 (m, 1H), 7,85 (m, 1H), 7,60 (d, 1H), 7,51 (m, 2H), 7,45 (d, 1H), 7,37 (t, 1H), 7,17 (d, 1H), 6,98 (t, 1H), 6,87 (d, 1H), 6,33 (t, 1H), 4,16 (t, 2H), 2,79 (m, 2H), 2,60 (m, 2H), 2,21 (m, 2H), 1,98 (m, 2H).

EJEMPLO 58

ácido 7-ciclohex-1-en-1-il-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 1-ciclohexen-borónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,03 (s ancho, 1H), 10,44 (s, 1H), 8,22 (m, 1H), 7,86 (m, 1H), 7,46 (m, 5H), 7,05 (m, 1H), 6,95 (t, 1H), 6,88 (d, 1H), 5,96 (m, 1H), 4,17 (t, 2H), 2,38 (m, 2H), 2,20 (m, 4H), 1,73 (m, 4H).

EJEMPLO 59A

trifluorometansulfonato de 2-fenilciclohex-1-enilo

Se agregó 2-fenilciclohexanona (0,2 g) a la mezcla de NaH en aceite 60% (0,17g) en DMF (3 ml) a 0°C. La mezcla se calentó a temperatura ambiente y se agitó durante 30 minutos, se trató con 1,1,1-trifluoro-N-fenil-N-(trifluorometilsulfonil)metansulfonamida (0,7 g), se agitó durante 6 horas y se trató con agua (20 ml) y acetato de etilo (50 ml). El extracto se lavó con salmuera (20 ml) y agua (20 ml), y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se purificó por cromatografía flash sobre gel de sílice con 0-30% acetato de etilo/hexano.

EJEMPLO 59B

ácido 3-(3-(1-naftiloxi)propil)-7-(2-fenilciclohex-1-en-1-il)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 43A en lugar de ácido (E)-estirilborónico y el EJEMPLO 59A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,92 (s ancho, 1H), 10,69 (s, 1H), 8,23 (m, 1H), 7,86 (m, 1H), 7,51 (m, 2H), 7,44 (d, 1H), 7,38 (m, 2H), 6,89 (m, 8H), 4,11 (t, 2H), 3,24 (t, 2H), 2,41 (m, 4H), 2,15 (m, 2H), 1,86 (m, 4H).

EJEMPLO 60

ácido 7-(2-ciclohexilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 43A en lugar de ácido (E)-estirilborónico y 1-bromo-2-ciclohexilbenceno en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,95 (s ancho, 1H), 10,28 (s, 1H), 8,26 (m, 1H), 7,87 (m, 1H), 7,70 (d, 1H), 7,53 (m, 2H), 7,41 (m, 4H), 7,24 (t, 1H), 7,17 (d, 1H), 7,07 (t, 1H), 7,00 (d, 1H), 6,89 (d, 1H), 4,20 (t, 2H), 2,29 (m, 4H), 1,55 (m, 7H), 1,18 (m, 2H), 0,86 (m, 2H).

EJEMPLO 61

ácido 7-(6-carboxipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 5-bromopicolinato de metilo en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 11,30 (s, 1H), 8,88 (s, 1H), 8,22 (dd, 1H), 8,15 (s, 1H), 7,87 (dd, 1H), 7,79 (d, 1H), 7,29-7,56 (m, 6H), 7,13 (t, 1H), 6,90 (d, 1H), 4,19 (t, 2H), 2,26 (m, 2H).

EJEMPLO 62

ácido 7-(3-metil-5-nitropiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 2-bromo-3-metil-5-nitropiridina en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, $CDCl_3$) □ 9,90 (m, 1H), 9,43 (d, 1H), 8,52 (d,1H), 8,39 (d, 1H), 7,95 (m, 1H), 7,80 (dd, 1H), 7,68 (dd, 1H), 7,13-7,60 (m, 8H), 7,00 (d, 1H), 6,68 (t, 2H), 4,21 (t, 2H), 3,10 (t, 2H), 2,67 (s, 3H), 2,18 (m, 2H).

EJEMPLO 63

ácido 7-(2,3-dihidro-1,4-benzodioxin-6-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 1C en lugar de 4-bromo-3-metilfenol y ácido 2,3-dihidrobenzo(b)(1,4)dioxin-6-ilborónico en lugar del EJEMPLO 43A en el EJEMPLO 43B. ^{1}H RMN (300 MHz, $CDCl_3$) □ 8,87 (s, 1H), 8,35 (dd, 1H), 7,76 (dd, 1H), 7,70 (dd, 1H), 7,30-7,49 (m, 5H), 7,15 (m,2H), 7,02 (d, 1H), 6,75 (d, 1H), 4,33 (s, 4H), 4,21 (t, 2H),3,84 (t, 2H), 2,38 (m, 2H).

EJEMPLO 64

ácido 7-(1,3-benzodioxol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 1C en lugar de 4-bromo-3-metilfenol y ácido benzo(d)(1,3)dioxol-5-ilborónico en lugar del EJEMPLO 43A en el EJEMPLO 43B.

^{1}H RMN (300 MHz, $CDCl_3$) □ 8,84 (s, 1H), 8,35 (dd, 1H), 7,78 (dd, 1H), 7,70 (d, 1H), 7,30-7,49 (m, 5H), 7,17 (d, 2H), 7,09 (s, 1H), 6,97 (d, 1H), 6,75 (dd, 1H), 6,05 (s, 2H), 4,21 (t, 2H), 3,49 (t, 2H), 2,38 (m, 2H).

EJEMPLO 65A

3-(3-(4-cloronaftalen-1-iloxi)propil)-7-(2-metoxifenil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando el EJEMPLO 47A en lugar del EJEMPLO 1B y 4-cloro-1-naftol en lugar de 1-naftol en el EJEMPLO 1D.

EJEMPLO 65B

ácido 3-(3-(4-cloronaftalen-1-iloxi)propil)-7-(2-metoxifenil)-1H-indol-2-carboxílico

Una mezcla del EJEMPLO 65A (70 mg) en THF (2 ml), metanol (1 ml) y agua (1 ml) se trató con $LiOH{\cdot}H_2O$ (100 mg) y se agitó a temperatura ambiente durante la noche. La mezcla se acidificó con HCl acuoso 5% y se extrajo con acetato de etilo. El extracto se lavó con agua, salmuera y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se disolvió en 1:1DMSO/metanol y se purificó por HPLC en fase reversa (C18, 20 a 100% acetonitrilo/agua/0,1% TFA). ^{1}H RMN (300 MHz, $CDCl_3$) □ 8,72 (s, 1H), 8,38 (dd, 1H), 8,15 (dd, 1H), 7,72 (d, 1H), 7,35-7,57 (m, 5H), 7,08-7,21 (m, 3H), 6,65 (d, 1H), 4,18 (t, 2H), 3,82 (s, 3H), 3,47 (t, 2H), 2,37 (m, 2H).

EJEMPLO 66A

3-(3-(2-bromofenoxi)propil)-7-(2-metoxifenil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando el EJEMPLO 47A en lugar del EJEMPLO 1B y 2-bromofenol en lugar de 1-naftol en el EJEMPLO 1C.

EJEMPLO 66B

ácido 3-(3-(2-bromofenoxi)propil)-7-(2-metoxifenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 66A en lugar del EJEMPLO 65A en el EJEMPLO 65B. ^{1}H RMN (300 MHz, $CDCl_3$) □ 8,72 (s, 1H), 7,79 (d, 1H), 7,55 (dd, 1H), 7,43 (t, 1H), 7,35 (dd, 1H), 7,22 (m, 3H), 7,10 (d, 1H), 6,85 (d, 1H), 6,77 (d, 1H), 4,11 (t, 2H), 3,84 (s, 3H), 3,43 (t, 2H), 2,29 (m, 2H).

EJEMPLO 67A

4-bromo-3-metil-N-(2-morfolinoetil)benzamida

Este ejemplo se preparó utilizando 2-morfolinoetanamina en lugar de N1,N1-dimetiletan-1,2-diamina en el EJEMPLO 51A.

EJEMPLO 67B

ácido 7-(2-metil-4-(((2-morfolin-4-iletil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando el EJEMPLO 67A en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,94 (m, 1H), 10,68 (s, 1H), 9,82 (m, 1H), 8,74 (m, 1H), 8,24 (dd, 2H), 7,88 (dd, 1H), 7,82 (d, 1H), 7,72 (t, 1H), 7,34-7,55 (m, 5H), 7,07 (m, 2H), 6,91 (d, 1H), 4,11 (t, 2H), 4,00 (m, 2H), 3,17-3,67 (m, 8H), 2,26 (m, 2H), 2,12 (S, 3H).

EJEMPLO 68

ácido 7-(3-metilquinolin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando 2-bromo-3-metil-quinolina en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,05 (m, 1H), 11,19 (m, 1H), 8,42 (m, 1H), 8,28 (dd, 1H), 8,05 (d, 1H), 7,37-7,89 (m, 9H), 7,16 (t, 1H), 6,91 (d, 1H), 4,22 (t, 2H), 2,36 (s, 3H), 2,26 (m, 2H).

EJEMPLO 69

ácido 7-(4-(hidroximetil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 4-(hidroximetil)-fenilborónico en lugar del EJEMPLO 43A y el EJEMPLO 1C en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,05 (m, 1H), 10,28 (m, 1H), 8,22 (dd, 1H), 7,87 (dd, 1H), 7,68 (d, 1H), 7,36-7,61 (m, 6H), 7,26 (d, 1H), 7,09 (t, 1H), 6,90 (d, 1H), 5,25 (t, 1H), 4,59 (d, 2H), 4,19 (t, 2H), 2,26 (m, 2H).

EJEMPLO 70

ácido 7-(3-(hidroximetil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 3-(hidroximetil)-fenilborónico en lugar del EJEMPLO 43A y el EJEMPLO 1C en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,05 (m, 1H), 10,26 (m, 1H), 8,22 (dd, 1H), 7,87 (dd,

1H), 7,69 (d, 1H), 7,36-7,61 (m, 8H), 7,26 (d, 1H), 7,09 (t, 1H), 6,90 (d, 1H), 5,22 (t, 1H), 4,59 (d, 2H), 4,20 (t, 2H), 2,25 (m, 2H).

EJEMPLO 71A

7-bromo-5-cloro-3-(3-etoxi-3-oxopropil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 2-bromo-4-cloroanilina en lugar de 2-bromoanilina en el EJEMPLO 1A.

EJEMPLO 71B

7-bromo-5-cloro-3-(3-hidroxipropil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando el EJEMPLO 71A en lugar del EJEMPLO 1A en el EJEMPLO 1B.

EJEMPLO 71C

7-bromo-5-cloro-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando el EJEMPLO 71B en lugar del EJEMPLO 1B en el EJEMPLO 1C.

EJEMPLO 71D

ácido 5-cloro-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 71C en lugar del EJEMPLO 1C y ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (400 MHz, DMSO-d_6) □ 10,92 (s, 1H), 8,27 (m, 1H), 7,87 (m, 1H), 7,74 (d, 1H), 7,51 (m, 3H), 7,30 (m, 5H), 6,99 (d, 1H), 6,91 (d, 1H), 4,20 (t, 2H), 2,22 (m, 2H), 2,05 (s, 3H).

EJEMPLO 72

ácido 7-(3-metilpiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando 2-bromo-3-metilpiridina en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 11,20 (s, 1H), 8,71 (d, 1H), 8,26 (m, 2H), 7,88 (m, 3H), 7,37-7,56 (m, 5H), 7,17 (t, 1H), 6,90 (d, 1H), 4,20 (t, 2H), 2,27 (s, 3H), 2,24 (m, 2H).

EJEMPLO 73

ácido 7-(2,6-dimetilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando 3-bromo-2,6-dimetilpiridina en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,10 (m, 1H), 11,31 (s, 1H), 8,23 (m, 2H), 7,88 (m, 3H), 7,36-7,54 (m, 4H), 7,15 (t, 2H), 6,90 (d, 1H), 4,20 (t, 2H), 2,76 (s, 3H), 2,36 (s, 3H), 2,24 (m, 2H).

EJEMPLO 74

ácido 7-(6-amino-2-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando 6-amino-3-bromo-2-metilpiridina en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,72 (m, 1H), 13,05 (m, 1H), 11,24 (s, 1H), 8,24 (dd, 1H), 7,88 (dd, 1H), 7,73 (m, 4H), 7,36-7,56 (m, 4H), 7,10 (d, 2H), 6,88 (t, 2H), 4,19 (t, 2H), 2,25 (m, 2H), 2,13 (s, 3H).

EJEMPLO 75

ácido 3-(3-(1-naftiloxi)propil)-7-(2-piperazin-1-ilfenil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando el EJEMPLO 43A en lugar de ácido (E)-estirilborónico y 1-(2-bromofenil)-piperazina en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,12 (s ancho, 1H), 10,36 (s, 1H), 8,42 (s ancho, 2H), 8,25 (m, 1H), 7,88 (m, 1H), 7,75 (d, 1H), 7,46 (m, 6H), 7,29 (m, 1H), 7,15 (m, 3H), 6,89 (m, 1H), 4,20 (t, 2H), 2,96 (m, 4H), 2,25 (m, 2H).

EJEMPLO 76A

7-bromo-1-(metoximetil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo

A una mezcla enfriada con baño de hielo del EJEMPLO 1C (2,0 g) en THF (20 ml) se agregó NaH en aceite 60% (265 mg). La mezcla se agitó durante 30 minutos antes de agregar clorometilmetiléter (0,54 ml). La mezcla se agitó durante 3 horas y durante la noche a temperatura ambiente, se neutralizó agregando NH_4Cl saturado y se extrajo con dietiléter. El extracto se lavó con agua y salmuera y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se purificó por cromatografía flash en columna sobre gel de sílice con 5% acetato de etilo/hexanos.

EJEMPLO 76B

ácido 7-(4-(3-clorofenil)piperazin-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Una mezcla del EJEMPLO 76A (100 mg), 1-(3-clorofenil)piperazina (48 mg), tris(dibencilidenacetona)dipaladio(0) (9,2 mg), 2,2'-bis(difenilfosfino)-1,1'-binaftilo (13,1 mg) y Cs_2CO_3 (195 mg) en tolueno (5 ml) se calentó a reflujo durante la noche. La mezcla se particionó entre acetato de etilo (200 ml) y agua (50 ml). La fase orgánica se lavó con salmuera y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se purificó por cromatografía en columna sobre gel de sílice con 1:4 acetato de etilo:hexanos para dar el etiléster. El éster se trató con HCl 2M en dietiléter (5 ml), se concentró, y se trató con $LiOH \cdot H_2O$ (100 mg) en 2/1/2 THF/metanol/agua, se agitó durante la noche a temperatura ambiente y se concentró. El producto se purificó por HPLC en fase reversa (C-18, 20 a 100 % acetonitrilo/agua/0,1% TFA). ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,98 (m, 1H), 10,90 (s, 1H), 8,24 (dd, 1H), 7,86 (dd, 1H), 7,35-7,54 (m, 5H), 7,25 (t, 1H), 6,82-7,03 (m, 6H), 4,18 (t, 2H), 3,45 (m, 4H), 3,15 (m, 4H), 2,20 (m, 2H).

EJEMPLO 77A

7-bromo-1-(2-morfolino-2-oxoetil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo

A una mezcla de NaH en aceite 60% (0,03 g) en DMF (5 ml) se agregó el EJEMPLO 1C (0,25 g) en DMF (10 ml). Después de agitar a temperatura ambiente durante 30 minutos, se agregó 2-cloro-1-morfolinoetanona (0,1 g), y la mezcla se agitó durante tres horas. Se agregaron agua (20 ml) y diclorometano, y la fase orgánica se lavó con agua y salmuera y se concentró. El concentrado se purificó por HPLC preparativa en fase reversa (Zorbax SB, C-18 con 30%-100% acetonitrilo/ agua/0,1% TFA).

EJEMPLO 77B

7-bromo-1-(2-morfolinoetil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo

A una mezcla del EJEMPLO 77A (0,15 g) en THF (10 ml) se agregó BH_3·THF 1M (1,8 ml). La mezcla se agitó a temperatura ambiente durante 16 horas, se neutralizó con metanol (5 ml) y se concentró. El concentrado se disolvió en etanol (40 ml) y se trató con HCl 12N (0,5 ml). Después de agitar durante tres horas, la mezcla se concentró, y el concentrado se purificó por HPLC preparativa en fase reversa (Zorbax SB, C-18, 30% a 100% acetonitrilo/agua/0,1% TFA).

EJEMPLO 77C

ácido 7-(2-metilfenil)-1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando el EJEMPLO 77B en lugar del EJEMPLO 1C y ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 8,23 (m, 1H), 7,88 (m, 1H), 7,81 (d, 1H), 7,45 (m, 8H), 7,15 (t, 1H), 7,01 (d, 1H), 6,92 (d, 1H), 4,64 (m, 1H), 4,24 (t, 2H), 4,02 (m, 1H), 3,61 (m, 4H), 2,23 (m, 2H), 2,00 (s, 3H).

EJEMPLO 78A

7-bromo-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 5,6,7,8-tetrahidronaftalen-1-ol en lugar de 1-naftol en el EJEMPLO 1C.

EJEMPLO 78B

ácido 7-(2-metilfenil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 78A en lugar del EJEMPLO 1C y ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 10,41 (s ancho, 1H), 7,65 (m, 1H), 7,27 (m, 4H), 7,11 (t, 1H), 7,04 (d, 1H), 6,99 (t, 1H), 6,64 (t, 2H), 3,98 (t, 2H), 3,25 (t, 2H), 2,66 (m, 4H), 2,08 (m, 5H), 1,71 (m, 4H).

EJEMPLO 79

ácido 5-cloro-3-(3-(1-naftiloxi)propil)-7-fenil-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 71C en lugar del EJEMPLO 1C y ácido fenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 10,41 (s, 1H), 7,65 (m, 1H), 7,27 (m, 4H), 7,11 (t, 1H), 7,04 (d, 1H), 6,99 (t, 1H), 6,64 (t, 2H), 3,98 (t, 2H), 3,25 (t, 2H), 2,66 (m, 4H), 2,08 (m, 5H), 1,71 (m, 4H).

EJEMPLO 80

ácido 5-cloro-7-(4-cloro-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 71C en lugar del EJEMPLO 1C y ácido 4-cloro-2-metilfenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 11,24 (s, 1H), 8,26 (m, 1H), 7,87 (m, 1H), 7,75 (d, 1H), 7,46 (m, 5H), 7,31 (m, 1H), 7,21 (d, 1H), 7,00 (d, 1H), 6,91 (d, 1H), 4,19 (t, 2H), 2,21 (m, 2H), 2,03 (s, 3H).

EJEMPLO 81

ácido 5-cloro-7-ciclopent-1-en-1-il-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 71C en lugar del EJEMPLO 1C y ácido 1-ciclopentenborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 10,49 (s, 1H), 8,22 (m, 1H), 7,86 (m, 1H), 7,62 (d, 1H), 7,49 (m, 3H), 7,38 (t, 1H), 7,09 (d, 1H), 6,87 (d, 1H), 6,39 (m, 1H), 4,15 (t, 2H), 2,77 (m, 2H), 2,59 (m, 2H), 2,19 (m, 2H), 1,98 (m, 2H).

EJEMPLO 82

ácido 7-(3,5-dicloropiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando 2-bromo-3,5-dicloropiridina en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,05 (m, 1H), 11,10 (s, 1H), 8,70 (s, 1H), 8,35 (s, 1H), 8,26 (dd, 1H), 7,87 (dd, 1H), 7,79 (d, 1H), 7,53 (m, 2H), 7,40 (d, 1H), 7,36 (t, 1H), 7,30 (d, 1H), 7,09 (t, 1H), 6,90 (d, 1H), 4,20 (t, 2H), 3,35 (m, 2H), 2,24 (m, 2H).

EJEMPLO 83

ácido 7-(5-(aminocarbonil)piridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando 6-bromonicotinamida en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,30 (m, 1H), 11,47 (s, 1H), 9,27 (s, 1H), 8,36 (s, 2H), 8,20 (d, 2H), 8,13 (d, 1H), 7,87 (t, 2H), 7,63 (s, 1H), 7,50 (m, 3H), 7,37 (t, 1H), 7,18 (t, 1H), 6,88 (d, 1H), 4,20 (t, 2H), 3,39 (m, 2H), 2,27 (m, 2H).

EJEMPLO 84

ácido 7-(3-cloro-5-(trifluorometil)piridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando 2-bromo-3-cloro-5-trifluorometilpiridina en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,10 (m, 1H), 11,17 (s, 1H), 9,04 (s, 1H), 8,57 (s, 1H), 8,26 (m, 1H), 7,85 (m, 2H), 7,36-7,57 (m, 5H), 7,11 (t, 1H), 6,89 (d, 1H), 4,20 (t, 2H), 3,39 (m, 2H), 2,25 (m, 2H).

EJEMPLO 85

ácido 7-(5-amino-2-(trifluorometoxi)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 3-bromo-4-trifluorometoxianilina en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,47 (s, 1H), 8,26 (dd, 1H), 7,86 (dd, 1H), 7,70 (d, 1H), 7,54 (m, 2H), 7,41 (d, 1H), 8,37 (t, 1H), 7,10 (m, 3H), 6,89 (d, 1H), 6,69 (d, 1H), 6,66 (s, 1H), 4,19 (t, 2H), 2,23 (m, 2H).

EJEMPLO 86

ácido 7-(5-carboxi-2-metoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 3-bromo-4-metoxibenzoato de metilo en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,80 (m, 1H), 10,65 (s, 1H), 8,26 (m, 1H), 8,02 (dd, 1H), 7,89 (m, 1H), 7,81 (s, 1H), 7,70 (d, 1H), 7,53 (m, 3H), 7,40 (d, 1H), 7,36 (t, 1H), 7,22 (d, 1H), 7,12 (d, 1H), 7,05 (t, 1H), 6,91 (d, 1H), 4,21 (t, 2H),3,80 (t, 3H), 2,25 (m, 2H).

EJEMPLO 87

ácido 7-(4-carboxi-2-nitrofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 4-bromo-3-nitrobenzoato de metilo en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,60 (m, 1H), 13,00 (m, 1H), 11,31 (s, 1H), 8,56 (s, 1H), 8,26 (dd, 1H), 7,88 (m, 1H), 7,74 (m, 1H), 7,65 (d, 1H), 7,53 (m, 3H), 7,40 (d, 1H), 7,36 (t, 1H), 7,22 (d, 1H), 7,12 (d, 1H), 7,05 (m, 1H), 6,91 (d, 1H), 4,21 (t, 2H), 3,37 (t, 2H), 2,25 (m, 2H).

EJEMPLO 88

ácido 7-(5-carboxi-2-clorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 3-bromo-4-clorobenzoato de metilo en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,00 (m, 1H), 11,18 (s, 1H), 8,26 (m, 1H), 7,98 (d, 1H), 7,88 (m, 1H), 7,74 (m, 1H), 7,68 (d, 1H), 7,53 (m, 3H), 7,40 (d, 1H), 7,36 (t, 1H), 7,09 (m, 2H), 6,91 (d, 1H), 4,21 (t, 2H), 3,37 (t, 2H), 2,25 (m, 2H).

EJEMPLO 89A

trifluorometansulfonato de 1-bencil-3-metil-1,2,3,6-tetrahidropiridin-4-ilo

Este ejemplo se preparó utilizando 1-bencil-3-metilpiperidin-4-ona en lugar de 2-fenilciclohexanona en el EJEMPLO 59A.

EJEMPLO 89B

ácido 7-(1-bencil-3-metil-1,2,3,6-tetrahidropiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando el EJEMPLO 43A en lugar de ácido (E)-estirilborónico y el EJEMPLO 89A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,22 (s, 1H), 10,77 (10,55) (s, 1H), 9,99 (9,54) (s, 1H), 8,22 (d, 1H), 7,86 (d, 1H), 7,63 (m, 3H), 7,45 (m, 8H), 7,03 (m, 2H), 6,88 (d, 1H), 5,82 (m, 1H), 4,51 (m, 2H), 4,18 (t, 2H), 3,80 (m, 2H), 2,98 (m, 1H), 2,20 (m, 2H), 0,92 (0,78) (d, 3H).

EJEMPLO 90

ácido 7-(4-amino-2-(trifluorometil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 4-bromo-3-trifluorometilanilina en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,90 (m, 1H), 10,62 (s, 1H), 8,26 (m, 1H), 7,87 (m, 1H), 7,65 (d, 1H), 7,53 (m, 3H), 7,40 (d, 1H), 7,36 (t, 1H), 7,09 (m, 3H), 6,89 (d, 1H), 6,82 (d, 1H), 4,20 (t, 2H), 3,35 (t, 2H), 2,20 (m, 2H).

EJEMPLO 91

ácido 7-(1,4-dioxa-8-azaespiro(4,5)dec-8-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 1,4-dioxa-8-azaespiro(4,5)decano en lugar de 1-(3-clorofenil)piperazina en el EJEMPLO 76B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,88 (s, 1H), 8,24 (m, 1H), 7,86 (m, 1H), 7,35-7,54 (m, 5H), 6,86 (m, 3H), 4,16 (t, 2H), 3,93 (s, 4H), 3,33 (t, 2H), 3,17 (m, 4H), 2,19 (m, 2H), 1,94 (m, 4H).

EJEMPLO 92

ácido 7-(3-carboxipiperidin-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando piperidin-3-carboxilato de metilo en lugar de 1-(3-clorofenil)piperazina en el EJEMPLO 76B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,00 (m, 1H), 11,10 (s, 1H), 8,24 (m, 1H), 7,86 (m, 1H), 7,30-7,55 (m, 5H), 6,86 (m, 2H), 6,74 (d, 1H), 4,16 (t, 2H), 3,70 (m, 1H), 2,72-3,06 (m, 5H), 2,20 (m, 4H), 1,72 (m, 3H).

EJEMPLO 93

ácido 7-(4-carboxipiperidin-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando piperidin-4-carboxilato de metilo en lugar de 1-(3-clorofenil)piperazina en el EJEMPLO 76B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 11,00 (m, 1H), 8,22 (m, 1H), 7,86 (m, 1H), 7,35-7,54 (m, 5H), 6,97 (m, 2H), 6,86 (d, 1H), 4,16 (t, 2H), 3,45 (m, 4H), 3,29 (t, 2H), 2,90 (m, 1H), 2,19 (t, 2H), 2,00 (m, 4H).

EJEMPLO 94

ácido 3-(3-(1-naftiloxi)propil)-7-pirrolidin-1-il-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando pirrolidina en lugar de 1-(3-clorofenil)piperazina en el EJEMPLO 76B,1H RMN (300 MHz, DMSO-d_6) □ 10,40 (m, 1H), 8,22 (m, 1H), 7,86 (m, 1H), 7,35-7,54 (m, 5H), 7,21 (d, 1H), 6,90 (m, 2H), 6,86 (d, 1H), 6,70 (m, 1H), 4,16 (t, 2H), 3,30 (t, 2H), 2,19 (t, 2H), 1,99 (m, 4H).

EJEMPLO 95

ácido 7-morfolin-4-il-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando morfolina en lugar de 1-(3-clorofenil)piperazina en el EJEMPLO 76B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,91 (m, 1H), 8,22 (m, 1H), 7,86 (m, 1H), 7,34-7,53 (m, 5H), 6,92 (m, 2H), 6,80 (d, 1H), 4,16 (t, 2H), 3,86 (m, 4H), 3,30 (t, 2H), 2,98 (m, 4H), 2,19 (t, 2H).

EJEMPLO 96

ácido 3-(3-(1-naftiloxi)propil)-7-piperidin-1-il-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando piperidina en lugar de 1-(3-clorofenil)piperazina en el EJEMPLO 76B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 8,21 (m, 1H), 7,86 (m, 1H), 7,35-7,56 (m, 6H), 7,09 (m, 1H), 6,88 (d, 1H), 4,16 (t, 2H), 3,35 (t, 2H), 2,19 (m, 2H), 1,87 (m, 4H), 1,63 (m, 2H).

EJEMPLO 97

ácido 7-(4-(aminosulfonil)-2-(trifluorometil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 4-bromo-3-(trifluorometil)bencensulfonamida en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,98 (m, 1H), 11,31 (s, 1H), 8,26 (m, 1H), 8,23 (s, 1H), 8,08 (d, 1H), 7,86 (m, 1H), 7,76 (dd, 1H), 7,36-7,63 (m, 7H), 7,05 (m, 2H), 6,90 (d, 1H), 4,21 (t, 2H), 3,40 (t, 2H), 2,23 (m, 2H).

EJEMPLO 98A

4-bromo-3-metilbenzoato de tert-butilo

A una mezcla de 4-bromo-3-metilbenzoato de metilo (4,85 g) y acetato de tert-butilo (3 ml) se agregó tert-butóxido de potasio en THF 1M (0,3 ml). La mezcla se agitó

bajo vacío durante 10 minutos y se trató con otro equivalente de acetato de tert-butilo y 1 mol % de (1,1'-bis(difenilfosfino)ferrocen)dicloropaladio(II) diclorometano. Este procedimiento se repitió tres veces. La mezcla se diluyó con acetato de etilo (40 ml) y se lavó con HCl acuoso 5%, agua y salmuera. Después de secar sobre Na_2SO_4, la mezcla se concentró.

EJEMPLO 98B

3-metil-4-(4,4,5,5-tetrametil-1,3,2-dioxaborolan-2-il)benzoato de tert-butilo

Este ejemplo se preparó utilizando el EJEMPLO 98A en lugar del EJEMPLO 1C en el EJEMPLO 43A.

EJEMPLO 98C

7-(4-(tert-butoxicarbonil)-2-metilfenil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando el EJEMPLO 98B en lugar de ácido 2-metoxifenilborónico y el EJEMPLO 1C en lugar del EJEMPLO 1B en el EJEMPLO 47A.

EJEMPLO 98D

ácido 4-(2-(etoxicarbonil)-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoico

Una mezcla del EJEMPLO 98C en diclorometano (5 ml) y TFA (5 ml) se agitó a temperatura ambiente durante la noche y se concentró. El concentrado se particionó entre agua (50 ml) y acetato de etilo (200 ml), y la fase orgánica se lavó con salmuera y se secó (Na_2SO_4), se filtró y se concentró. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,88 (m, 1H), 11,00 (s, 1H), 8,22 (m, 1H), 7,85 (m, 3H), 7,86 (m, 1H), 7,73 (d, 1H), 7,32-7,55 (m, 5H), 7,08 (m, 2H), 6,92 (d, 1H), 4,25 (m, 4H), 3,36 (t, 2H), 2,24 (t, 2H), 2,10 (s, 3H), 1,26 (t, 3H).

EJEMPLO 99

ácido 7-(2-metil-4-(morfolin-4-ilcarbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

A una mezcla del EJEMPLO 98D (75 mg) y morfolina (32 mg) en diclorometano (2 ml) se agregó clorhidrato de 1-etil-3-(3-(dimetilamino)propil)carbodiimida (58 mg) y DMAP (38 mg). La mezcla se agitó a temperatura ambiente durante la noche y se concentró. El concentrado se diluyó con acetato de etilo (150 ml), se lavó con HCl 5%, agua y salmuera y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se disolvió en THF (4 ml), metanol (2 ml) y agua (2 ml). Se agregó $LiOH \cdot H_2O$ (100 mg) a la mezcla y la mezcla se agitó durante la noche. La mezcla se concentró, el concentrado se acidificó con HCl 5% y se extrajo con acetato de etilo. El extracto se lavó con salmuera y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se purificó por HPLC en fase reversa (C-18, 30 a 100 % acetonitrilo/ agua/0,1% TFA) . ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,95 (m, 1H), 10,79 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,71 (d, 1H), 7,35-7,57 (m, 6H), 7,27 (s, 1H), 7,08 (m, 2H), 6,90 (d, 1H), 4,21 (t, 1H), 3,64 (m, 8H), 3,37 (t, 2H), 2,26 (t, 2H), 2,07 (s, 3H).

EJEMPLO 100

ácido 7-(4-((4-carboxipiperidin-1-il)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-

2-carboxílico

Este ejemplo se preparó utilizando piperidin-4-carboxilato de metilo en lugar de morfolina en el EJEMPLO 99. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,78 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,71 (d, 1H), 7,32-7,54 (m, 5H), 7,25 (s, 1H), 7,08 (m, 2H), 6,91 (d, 1H), 4,21 (t, 2H), 3,39 (t, 2H), 3,00 (m, 4H), 2,26 (t, 2H), 2,08 (s, 3H), 1,90 (m, 1H), 1,65 (m, 4H).

EJEMPLO 101

ácido 7-(4-((3-carboxipiperidin-1-il)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando piperidin-3-carboxilato de metilo en lugar de morfolina en el EJEMPLO 99. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,82 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,71 (d, 1H), 7,32-7,54 (m, 5H), 7,26 (s, 1H), 7,08 (m, 2H), 6,91 (d, 1H), 4,21 (t, 2H), 3,38 (t, 2H), 3,05 (m, 4H), 2,26 (t, 2H), 2,08 (s, 3H), 1,86 (m, 5H).

EJEMPLO 102

ácido 7-(4-(carboximetilcarbamoil)-2-metilfenil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 2-aminoacetato de metilo en lugar de morfolina en el EJEMPLO 99. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,83 (s, 1H),8,83 (t, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,85 (s, 1H), 7,71 (m, 2H), 7,32-7,54 (m, 4H), 7,29 (d, 1H), 7,08 (m, 2H), 6,91 (d, 1H), 4,21 (t, 2H), 3,96 (d, 2H), 3,37 (t, 2H), 2,24 (m, 2H), 2,11 (s, 3H).

EJEMPLO 103A

7-bromo-3-(3-oxopropil)-1H-indol-2-carboxilato de etilo

A una mezcla enfriada (0°C) del EJEMPLO 1B (3,26 g) en diclorometano (5 ml) se agregó DMSO (1 ml) y trietilamina (0,835 ml) seguidos por sulfato de piridina (636 mg). La mezcla se agitó durante 2 horas, se diluyó con acetato de etilo (150 ml), y se lavó con HCl 5%, $NaHCO_3$ saturado, agua y salmuera y se secó (Na_2SO_4), se filtró y se concentró.

EJEMPLO 103B

7-bromo-3-(3-(3,4-dihidroquinolin-1 (2H)-il)propil)-1H-indol-2-carboxilato de etilo

A una mezcla del EJEMPLO 103A (325 mg) y 1,2,3,4-tetrahidroquinolina (160 mg) en dicloroetano (10 ml) se agregó acetato de sodio (310 mg). La mezcla se agitó a temperatura ambiente durante la noche, se diluyó con acetato de etilo (200 ml) y se lavó con NaOH 1N, agua, y salmuera. Después de secar sobre sulfato de sodio y concentrar, el concentrado se cargó en un cartucho de gel de sílice y se eluyó con 5% acetato de etilo en hexano.

EJEMPLO 103C

ácido 3-(3-(3,4-dihidroquinolin-1 (2H)-il)propil)-7-(2-(trifluorometil)fenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-trifluorometil-fenilborónico en lugar del EJEMPLO 43A y el EJEMPLO 103B en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, $CDCl_3$) □ 8,43 (t, 1H), 7,85 (dd, 1H), 7,57-7,67 (m,

3H), 7,44 (d, 1H), 7,01-7,26 (m, 4H), 3,43 (m, 4H), 3,26 (t, 2H), 2,85 (t, 2H), 2,10 (m, 4H).

EJEMPLO 104A

7-bromo-3-(3-(3-fenoxifenoxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 3-fenoxifenol en lugar de 1-naftol en el EJEMPLO 1C.

EJEMPLO 104B

ácido 7-(2-metilfenil)-3-(3-(3-fenoxifenoxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 104A en lugar del EJEMPLO 1C y ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 10,45 (s, 1H), 7,64 (d, 1H), 7,30 (m, 7H), 7,05 (m, 5H), 6,70 (m, 1H), 6,53 (m, 2H), 3,97 (t, 2H), 3,21 (t, 2H), 2,06 (s, 5H).

EJEMPLO 105A

7-bromo-3-(3-(2,3-dimetilfenoxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 2,3-dimetilfenol en lugar de 1-naftol en el EJEMPLO 1C.

EJEMPLO 105B

ácido 3-(3-(2,3-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 105A en lugar del EJEMPLO 1C y ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,96 (s ancho, 1H), 10,46 (s, 1H), 7,66 (d, 1H), 7,27 (m, 4H), 7,11 (t, 1H), 7,01 (m, 2H), 6,73 (t, 2H), 3,98 (t, 2H), 3,27 (t, 2H), 2,22 (s, 3H), 2,13 (s, 3H), 2,10 (m, 2H), 2,06 (s, 3H)

EJEMPLO 106

ácido 7-(4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando ácido 4-metil-3-piridilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,98 (s ancho, 1H), 11,18 (s, 1H), 8,56 (d, 1H), 8,47 (s, 1H), 8,25 (m, 1H), 7,86 (m, 1H), 7,77 (m, 1H), 7,52 (m, 3H), 7,42 (m, 2H), 7,10 (m, 2H), 6,91 (m, 1H), 4,21 (t, 2H), 2,24 (m, 2H), 2,12 (s, 3H).

EJEMPLO 107

ácido 7-(2-metilbencil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 2-metilbencilbromuro en lugar del EJEMPLO 1C y el EJEMPLO 43A en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,00 (s ancho, 1H), 11,30 (s, 1H), 8,24 (m, 1H), 7,86 (m, 1H), 7,45 (m, 5H), 7,13 (m, 3H), 6,89 (m, 3H), 6,68 (d, 1H), 4,27 (s, 2H), 4,18 (t, 2H), 2,22 (m, 5H).

EJEMPLO 108

ácido 3,3'-bis(3-(1-naftiloxi)propil)-1H,1'H-7,7'-biindol-2,2'-dicarboxílico

Este ejemplo se preparó como subproducto utilizando el EJEMPLO 43A en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,94 (s

ancho, 2H), 10,26 (s, 2H), 8,27 (m, 2H), 7,87 (m, 2H), 7,76 (d, 2H), 7,43 (m, 10H), 7,14 (t, 2H), 6,92 (d, 2H), 4,23 (t, 4H), 3,40 (t, 4H), 2,27 (m, 4H).

EJEMPLO 109A

7-bromo-3-(4-etoxi-4-oxobutil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 2-oxociclohexancarboxilato de etilo en lugar de 2-oxociclopentancarboxilato de etilo en el EJEMPLO 1A.

EJEMPLO 109B

7-bromo-3-(4-hidroxibutil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando el EJEMPLO 109A en lugar del EJEMPLO 1A en el EJEMPLO 1B.

EJEMPLO 109C

7-bromo-3-(4-oxobutil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando el EJEMPLO 109B en lugar del EJEMPLO 1B en el EJEMPLO 103A.

EJEMPLO 109D

etilo 7-bromo-3-(4-(3,4-dihidroquinolin-1 (2H)-il)butil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando el EJEMPLO 109C en lugar del EJEMPLO 103A en el EJEMPLO 103B.

EJEMPLO 109E

ácido 3-(4-(3,4-dihidroquinolin-1 (2H)-il)butil)-7-(2-(trifluorometil)fenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-trifluorometil-fenilborónico en lugar del EJEMPLO 43A y el EJEMPLO 109D en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,93 (s, 1H), 7,83 (dd, 1H), 7,63 (m, 3H), 7,39 (d, 1H), 7,10 (t, 1H), 7,02 (d, 1H), 6,95 (t, 1H), 6,85 (d, 1H), 6,52 (d, 1H), 6,42 (t, 1H), 3,21 (m, 4H), 2,63 (t, 2H), 1,84 (m, 2H), 1,62 (m, 4H).

EJEMPLO 110

ácido 7-(4-carboxi-2-metilfenil)-3-(4-(3,4-dihidroquinolin-1 (2H)-il)butil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 4-(metoxicarbonil)-2-metilfenilborónico en lugar del EJEMPLO 43A y el EJEMPLO 109D en lugar de 4-bromo-3-metilfenol en el EJEMPLO 43B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,76 (s, 1H), 7,89 (s, 1H), 7,82 (dd, 1H), 7,71 (dd, 1H), 7,32 (d, 1H), 7,15 (t, 1H), 7,06 (d, 1H), 6,91 (t, 1H), 6,83 (d, 1H), 6,50 (d, 1H), 6,43 (t, 1H), 3,22 (m, 4H), 3,64 (t, 2H), 2,09 (s, 3H), 1,81 (m, 2H), 1,61 (m, 4H).

EJEMPLO 111A

7-bromo-3-(3-iodopropil)-1H-indol-2-carboxilato de etilo

A una mezcla del EJEMPLO 1B (1,116 g) en diclorometano (30 ml) a 0°C se agregó iodo (1,01 g), trifenilo fosfina (1,03 g) e imidazol (0,535 g). La mezcla se agitó a 0°C durante 1 hora y se trató con $NaHCO_3$ saturado (50 ml). Se continuó la agitación durante 30 minutos, y la fase orgánica se lavó con $Na_2S_2O_3$ acuoso saturado (50 ml),

agua (20 ml), y salmuera (50 ml) y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se purificó por cromatografía en columna sobre gel de sílice (con 0-20% acetato de etilo en hexanos).

EJEMPLO 111B

ioduro de (3-(7-bromo-2-(etoxicarbonil)-1H-indol-3-il)propil)trifenilfosfonio

A una mezcla del EJEMPLO 111A (0,136 g) en CH_3CN (5 ml) se agregó trifenilfosfina (157 mg). La mezcla se sometió a reflujo durante 48 horas, se enfrió a temperatura ambiente, se lavó con hexanos y se concentró.

EJEMPLO 111C

7-bromo-3-(4-(naftalen-1-il)but-3-enil)-1H-indol-2-carboxilato de etilo

Una mezcla de hidruro de sodio en aceite 60% (40 mg) en DMSO (5 ml) se calentó durante 1 hora a 80 °C, se enfrió a 15 °C y se trató con el EJEMPLO 111B (0. 797 g). La mezcla se agitó durante 10 minutos, se trató con 1-naftalaldehído (0. 156 g) y se calentó durante 3 horas a 80°C. Después de dejarse en reposo durante la noche a temperatura ambiente, la mezcla se volcó sobre $NaHSO_4$ saturado y se extrajo con dietiléter. El extracto se lavó con agua y salmuera y se secó ($MgSO_4$), se filtró, y se concentró. El concentrado se purificó por cromatografía flash en columna sobre gel de sílice con 0-20% acetato de etilo en hexanos.

EJEMPLO 111D

ácido 3-(4-(naftalen-1-il)but-3-enil)-7-o-tolil-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 111C en lugar del EJEMPLO 1C en el EJEMPLO 1D.

EJEMPLO 111E

ácido 7-(2-metilfenil)-3-(4-(1-naftil)butil)-1H-indol-2-carboxílico

Una mezcla del EJEMPLO 111D y Pd/C (catalítico) en acetato de etilo/etanol se agitó a temperatura ambiente bajo hidrógeno durante la noche. La mezcla se filtró, se lavó con acetato de etilo/etanol y se concentró. El concentrado se purificó en HPLC en fase reversa (Zorbax SB-C18, 20100 % acetonitrilo / agua / 0,1% TFA) . ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,82 (s ancho, 1H), 10,36 (s, 1H), 8,03 (m, 1H), 7,90(m, 1H), 7,75 (d, 1H), 7,66 (d, 1H), 7,51 (m, 2H), 7,31 (m, 6H), 7,12 (t, 1H), 7,03 (m, 1H), 3,17 (m, 2H), 3,09 (m, 2H), 2,05 (s, 3H), 1,78 (m, 4H).

EJEMPLO 112A

7-bromo-3-(4-(naftalen-1-iloxi)butil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando el EJEMPLO 109B en lugar del EJEMPLO 1B en el EJEMPLO 1C.

EJEMPLO 112B

ácido 7-(2-metilfenil)-3-(4-(1-naftiloxi)butil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 112A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,87 (s ancho, 1H), 10,42 (s, 1H), 8,12 (d, 1H), 7,85 (d,

1H), 7,70 (d, 1H), 7,37 (m, 8H), 7,12 (t, 1H), 7,05 (m, 1H), 6,94 (d, 1H), 4,19 (m, 2H), 3,22 (m, 2H), 2,06 (s, 3H), 1,93 (m, 4H).

EJEMPLO 113A

7-bromo-3-(3-(2,4-dimetilfenoxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 2,4-dimetilfenol en lugar de 1-naftol en el EJEMPLO 1C.

EJEMPLO 113B

ácido 3-(3-(2,4-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 113A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,88 (s ancho, 1H), 10,45 (s, 1H), 7,65 (d, 1H), 7,27 (m, 4H), 7,10 (t, 1H), 7,04 (dd, 1H), 6,92 (m, 2H), 6,73 (d, 1H), 3,97 (t, 2H), 3,25 (t, 2H), 2,19 (s, 3H), 2,17 (s, 3H), 2,07 (m, 5H).

EJEMPLO 114A

7-bromo-3-(3-(2,5-dimetilfenoxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 2,5-dimetilfenol en lugar de 1-naftol en el EJEMPLO 1C.

EJEMPLO 114B

ácido 3-(3-(2,5-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 114A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,89 (s ancho, 1H), 10,45 (s ancho, 1H), 7,66 (d, 1H), 7,33 (m, 2H), 7,25 (m, 2H), 7,11 (t, 1H), 7,02 (m, 2H), 6,64 (m, 2H), 4,00 (t, 2H), 3,26 (t, 2H), 2,22 (s, 3H), 2,15 (s, 3H), 2,08 (m, 5H).

EJEMPLO 115

ácido 7-(1,1'-bifenil-2-il)-3-(4-(1-naftiloxi)butil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-bifenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 112A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,82 (s ancho, 1H), 10,12 (s, 1H), 8,11 (d, 1H), 7,85 (d, 1H), 7,48 (m, 9H), 7,08 (m, 5H), 6,90 (m, 3H), 4,16 (m, 2H), 3,15 (m, 2H), 1,87 (m, 4H).

EJEMPLO 116

ácido 7-(4-((2-carboxipiperidin-1-il)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando piperidin-2-carboxilato de metilo en lugar de morfolina en el EJEMPLO 99. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,96 (m, 1H), 10,84 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,71 (d, 1H), 7,25-7,56 (m, 8H), 7,08 (m, 2H), 6,91 (d, 1H), 4,21 (t, 2H), 3,37 (t, 2H), 2,26 (t, 2H), 2,08 (s, 3H), 1,72 (m, 3H), 1,40 (m, 2H).

EJEMPLO 117

ácido 7-(4-((S)-1-carboxi-2-metilpropilcarbamoil)-2-metilfenil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando metiléster de ácido 2-amino-3-metil-butírico en lugar de morfolina en el EJEMPLO 99. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,79 (s, 1H), 8,37 (d, 1H), 8,25 (m, 1H), 7,89 (s, 1H), 7,87 (m, 1H), 7,71 (d, 1H), 7,30-7,56 (m, 4H), 7,29 (d, 1H), 7,06 (m, 2H), 6,91 (d, 1H), 4,36 (t, 1H), 4,21 (t, 2H), 3,37 (t, 2H), 2,26 (m, 2H), 2,08 (s, 3H), 0,99 (t, 6H).

EJEMPLO 118

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-4-clorofenilalanina

Este ejemplo se preparó utilizando 2-amino-3-(4-clorofenil)propanoato de metilo en lugar de morfolina en el EJEMPLO 99. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,84 (m, 1H), 10,84 (s, 1H), 8,70 (d, 1H), 8,25 (m, 1H), 7,86 (m, 1H), 7,78 (s, 1H), 7,71 (d, 1H), 7,29-7,54 (m, 8H), 7,26 (d, 1H), 7,06 (m, 2H), 6,90 (d, 1H), 4,70 (m, 1H), 4,20 (t, 2H), 3,36 (t, 2H), 3,21 (dd, 2H), 2,23 (m, 2H), 2,08 (s, 3H).

EJEMPLO 119

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-L-triptofano

Este ejemplo se preparó utilizando metiléster de (L)-triptofano en lugar de morfolina en el EJEMPLO 99. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,81 (d, 1H), 8,60 (d, 1H), 8,25 (m, 1H), 7,86 (m, 1H), 7,79 (s, 1H), 7,70 (t, 1H), 7,64 (d, 1H), 7,22-7,54 (m, 9H), 7,04 (m, 4H), 6,90 (d, 1H), 4,75 (m, 1H), 4,20 (t, 2H), 3,36 (t, 2H), 2,23 (m, 2H), 2,08 (s, 3H).

EJEMPLO 120

ácido (3S)-2-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-1,2,3,4-tetrahidroisoquinolin-3-carboxílico

Este ejemplo se preparó utilizando (3S)- 1,2,3,4-tetrahidroisoquinolinecarboxilato de metilo en lugar de morfolina en el EJEMPLO 99. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,94 (m, 1H), 10,84 (d, 1H), 8,26 (m, 1H), 7,88 (m, 1H), 7,76 (m, 1H), 7,09-7,55 (m, 13H), 6,91 (d, 1H), 5,20 (t, 1H), 5,05 (d, 1H), 4,90 (m, 1H), 4,70 (dd, 1H), 4,50 (d, 1H), 4,22 (t, 2H), 3,38 (t, 2H), 2,27 (m, 2H), 2,08 (s, 3H).

EJEMPLO 121

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-L-tirosina

Este ejemplo se preparó utilizando metiléster de L-tirosina en lugar de morfolina en el EJEMPLO 99. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,84 (s, 1H), 9,17 (s, 1H), 8,60 (d, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,79 (s, 1H), 7,74 (m, 1H), 7,53 (m, 2H), 7,40 (d, 1H), 7,36 (d, 1H), 7,26 (d, 1H), 7,08 (m, 4H), 6,90 (d, 1H), 6,66 (d, 2H), 4,60 (m, 1H), 4,20 (t, 2H), 3,36 (t, 2H), 3,00 (m, 3H), 2,23 (m, 2H), 2,08 (s, 3H).

EJEMPLO 122

ácido 7-(4-((R)-2-carboxipirrolidin-1-carbonil)-2-metilfenil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando metiléster de L-prolina en lugar de morfolina en el EJEMPLO 99. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,80 (s, 1H), 8,25 (m, 1H), 7,86 (m, 1H), 7,71 (d, 1H), 7,36-7,54 (m, 6H), 7,28 (d, 1H), 7,08 (m, 2H), 6,91 (d, 1H), 4,45 (m,

1H), 4,20 (t, 2H), 3,64 (t, 2H), 2,25 (m, 2H), 2,08 (s, 3H), 1,92 (m, 3H).

EJEMPLO 123

ácido 7-(4-((S)-1-carboxietilcarbamoil)-2-metilfenil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando metiléster de L-alanina en lugar de morfolina en el EJEMPLO 99. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,81 (s, 1H), 8,66 (d, 1H), 8,25 (m, 1H), 7,87 (m, 2H), 7,78 (d, 1H), 7,71 (d, 1H), 7,36-7,54 (m, 4H), 7,30 (d, 1H), 7,06 (m, 2H), 6,91 (d, 1H), 4,47 (m, 1H), 4,21 (t, 2H), 3,37 (t, 2H), 2,25 (m, 2H), 2,08 (s, 3H), 1,42 (d, 3H).

EJEMPLO 124

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-4-nitro-L-fenilalanina

Este ejemplo se preparó utilizando 2-amino-3-(4-nitrofenil)propanoato de metilo en lugar de morfolina en el EJEMPLO 99. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,90 (s, 1H), 10,83 (s, 1H), 8,78 (d, 1H), 8,25 (m, 1H), 8,17 (d, 2H), 7,87 (m, 2H), 7,71 (s, 1H), 7,70 (d, 1H), 7,63 (d, 2H), 7,36-7,54 (m, 4H), 7,26 (d, 1H), 7,06 (m, 2H), 6,91 (d, 1H), 4,80 (m, 1H), 4,20 (t, 2H), 3,36 (t, 2H), 2,23 (m, 2H), 2,08 (s, 3H).

EJEMPLO 125

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-L-fenilalanina

Este ejemplo se preparó utilizando metiléster de L-fenilalanina en lugar de morfolina en el EJEMPLO 99. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,80 (m, 1H), 10,84 (s, 1H), 8,68 (d, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,78 (s, 1H), 7,72 (d, 1H), 7,22-7,54 (m, 10H), 7,06 (m, 2H), 6,91 (d, 1H), 4,70 (m, 1H), 4,20 (t, 2H), 3,36 (t, 2H), 3,21 (m, 3H), 2,23 (m, 2H), 2,08 (s, 3H).

EJEMPLO 126

ácido 7-(4-((((S)-carboxi(fenil)metil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando (S)- 2-amino-2-fenilacetato de metilo en lugar de morfolina en el EJEMPLO 99. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,92 (s, 1H), 10,79 (s, 1H), 9,02 (d, 1H), 8,25 (m, 1H), 7,93 (s, 1H), 7,85 (m, 2H), 7,70 (d, 1H), 7,31-7,54 (m, 9H), 7,28 (d, 1H), 7,06 (m, 2H), 6,90 (d, 1H), 5,66 (d, 1H), 4,70 (m, 1H), 4,20 (t, 2H), 3,36 (t, 2H), 2,23 (m, 2H), 2,10 (s, 3H).

EJEMPLO 127A

metiléster de ácido 3-metil-4-(4,4,5,5-tetrametil-(1,3,2)dioxaborolan-2-il)-benzoico

Este ejemplo se preparó utilizando metiléster de ácido 4-bromo-3-metil-benzoico en lugar del EJEMPLO 1C en el EJEMPLO 43A.

EJEMPLO 127B

etiléster de ácido 3-(3-hidroxipropil)-7-(4-metoxicarbonil-2-metil-fenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 1B en lugar del EJEMPLO 1C y el EJEMPLO 127A en lugar de ácido 2-metoxifenilborónico en el EJEMPLO 47A.

EJEMPLO 127C

etiléster de ácido 7-(4-metoxicarbonil-2-metil-fenil)-3-(3-(toluen-4-sulfoniloxi)-propil)-1H-indol-2-carboxílico

A una mezcla del EJEMPLO 127B (2,0 g), cloruro de toluen-2-sulfonilo (1,16 g) en diclorometano (30 ml) se agregó DMAP (0,305 g). La mezcla se agitó a temperatura ambiente durante la noche. La mezcla se diluyó con acetato de etilo (300 ml) y se lavó con solución acuosa saturada de bicarbonato de sodio, HCl acuoso 3%, agua y salmuera. Después de secar sobre Na_2SO_4 y filtrar, la mezcla se concentró.

EJEMPLO 127D

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2,4,5-triclorofenoxi)propil)-1H-indol-2-carboxílico

A una mezcla del EJEMPLO 127C (60 mg) en DMF (1 ml) se agregó 2,4,5-triclorofenol (43 mg) y Cs_2CO_3 (500 mg). La mezcla se agitó a temperatura ambiente durante la noche, se diluyó con acetato de etilo (150 ml), y se lavó con agua y salmuera. Después de secar sobre Na_2SO_4, las fases orgánicas combinadas se concentraron, y el concentrado se saponificó con LiOH como se describe en el EJEMPLO 65B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,92 (m, 1H), 10,88 (s, 1H), 7,89 (s, 1H), 7,82 (m, 2H), 7,38 (s, 1H), 7,32 (d, 1H), 7,10 (m, 2H), 4,13 (t, 2H), 3,25 (t, 2H), 2,13 (m, 2H), 2,10 (s, 3H).

EJEMPLO 128

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2,3,4-triclorofenoxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 2,3,4-triclorofenol en lugar de 2,4,5-triclorofenol en el EJEMPLO 127D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,86 (m, 1H), 10,87 (s, 1H), 7,89 (s, 1H), 7,82 (dd, 2H), 7,69 (dd, 1H), 7,56 (d, 1H), 7,32 (d, 1H), 7,06 (m, 3H), 4,13 (t, 2H), 3,25 (t, 2H), 2,13 (m, 2H), 2,10 (s, 3H).

EJEMPLO 129

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 2,3,5-trimetilfenol en lugar de 2,4,5-triclorofenol en el EJEMPLO 127D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,86 (m, 1H), 10,85 (s, 1H), 7,89 (s, 1H), 7,82 (dd, 1H), 7,69 (dd, 1H), 7,32 (d, 1H), 7,13 (t, 1H), 7,06 (d, 1H), 3,97 (t, 2H), 3,26 (t, 2H), 2,13 (m, 2H), 2,14 (s, 3H), 2,10 (s, 3H), 2,08 (S, 3H).

EJEMPLO 130

ácido 3-(3-(2-tert-butilfenoxi)propil)-7-(4-carboxi-2-metilfenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 2-tert-butilfenol en lugar de 2,4,5-triclorofenol en el EJEMPLO 127D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,88 (m, 1H), 10,88 (s, 1H), 7,90 (s, 1H), 7,82 (dd, 1H), 7,72 (dd, 1H), 7,32 (d, 1H), 7,22 (d, 1H), 7,17 (t, 1H), 7,06 (d, 1H), 6,80 (m, 2H), 4,07 (t, 2H), 2,14 (m, 2H), 2,11 (s, 3H), 1,41 (s, 9H).

EJEMPLO 131

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2-(trifluorometil)fenoxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 2-trifluorometilfenol en lugar de 2,4,5-triclorofenol en el EJEMPLO 127D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,87 (m, 1H), 10,87 (s, 1H), 7,94 (s, 1H), 7,82 (dd, 1H), 7,61 (m, 4H), 7,32 (d, 1H), 7,20 (d, 1H), 7,06 (m, 4H),

4,15 (t, 2H), 3,24 (t, 2H), 2,10 (s, 3H), 2,07 (m, 2H).

EJEMPLO 132

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(quinolin-8-iloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando quinolin-8-ol en lugar de 2,4,5-triclorofenol en el EJEMPLO 127D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,84 (m, 1H), 10,88 (s, 1H), 9,05 (dd, 1H), 8,76 (m, 1H), 7,89 (s, 1H), 7,67-7,83 (m, 5H), 7,32 (m, 2H), 7,03 (m, 2H), 4,27 (t, 2H), 3,35 (t, 2H), 2,28 (m, 2H), 2,09 (s, 3H).

EJEMPLO 133

ácido 7-(4-carboxi-2-metilfenil)-3-(3-((5-oxo-5,6,7,8-tetrahidronaftalen-1-il)oxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 5-hidroxi-3,4-dihidro-2H-naftalen-1-ona en lugar de 2,4,5-triclorofenol en el EJEMPLO 127D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,87 (m, 1H), 10,85 (s, 1H), 7,89 (s, 1H), 7,82 (d, 1H), 7,70 (d, 1H), 7,46 (d, 1H), 7,30 (m, 2H), 7,03 (m, 3H), 4,07 (t, 2H), 3,26 (t, 2H), 2,90 (t, 2H), 2,58 (t, 3H), 2,13 (m, 2H), 2,09 (s, 3H).

EJEMPLO 134

ácido 3-(3-(3-benzoilfenoxi)propil)-7-(4-carboxi-2-metilfenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando (3-hidroxi-fenil)-fenil-metanona en lugar de 2,4,5-triclorofenol en el EJEMPLO 127D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,86 (m, 1H), 10,84 (s, 1H), 7,89 (s, 1H), 7,82 (d, 1H), 7,68 (m, 3H), 7,50 (t, 2H), 7,44 (t, 1H), 7,32 (d, 2H), 7,25 (t, 2H), 7,06 (m, 2H), 4,06 (t, 2H), 3,24 (t, 2H), 2,13 (m, 2H), 2,09 (s, 3H).

EJEMPLO 135A

7-bromo-1-(2-morfolino-2-oxoetil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando el EJEMPLO 78A en lugar del EJEMPLO 1C en el EJEMPLO 77A.

EJEMPLO 135B

7-bromo-1-(2-morfolinoetil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando el EJEMPLO 135A en lugar del EJEMPLO 77A en el EJEMPLO 77B.

EJEMPLO 135C

ácido 7-(2-metilfenil)-1-(2-morfolin-4-iletil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 135B en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,43 (s ancho, 1H), 7,77 (d, 1H), 7,41 (m, 4H), 7,20 (t, 1H), 7,01 (m, 2H), 6,65 (m, 2H), 4,66 (m, 1H), 4,02 (m, 4H), 3,26 (t, 2H), 2,66 (m, 8H), 2,05 (m, 6H), 1,72 (m, 4H).

EJEMPLO 136

ácido 7-(4-(ciclohexiloxi)fenil)-3-(4-(1-naftiloxi)butil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 4-ciclohexiloxifenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 112A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,98 (s ancho, 1H), 10,21 (s, 1H), 8,12 (d, 1H), 7,85 (d, 1H), 7,66 (d, 1H), 7,46 (m, 6H), 7,22 (d, 1H), 7,13 (t, 1H), 7,06 (d, 2H), 6,94 (d, 1H), 4,40 (m, 1H), 4,19 (m, 2H), 3,21 (m, 2H), 1,95 (m, 6H), 1,75 (m, 2H), 1,41 (m, 6H).

EJEMPLO 137

ácido 7-(1,1'-bifenil-2-il)-1-(2-morfolin-4-iletil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó como sal de TFA utilizando ácido 2-bifenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 135B en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 13,17 (s ancho, 1H), 7,57 (m, 5H), 7,05 (m, 8H), 6,62 (m, 2H), 4,69 (m, 1H), 4,03 (m, 1H), 3,87 (t, 2H), 3,15 (t, 2H), 2,76 (m, 10H), 1,96 (m, 2H), 1,71 (m, 4H).

EJEMPLO 138A

7-bromo-3-(3-(3,4-dimetilfenoxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 3,4-dimetilfenol en lugar de 1-naftol en el EJEMPLO 1C.

EJEMPLO 138B

ácido 3-(3-(3,4-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 138A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,90 (s ancho, 1H), 10,47 (s, 1H), 7,66 (d, 1H), 7,27 (m, 4H), 7,05 (m, 3H), 6,66 (m, 2H), 3,95 (t, 2H), 3,22 (t, 2H), 2,17 (s, 3H), 2,13 (s, 3H), 2,05 (m, 5H).

EJEMPLO 139A

7-bromo-3-(3-(3,5-dimetilfenoxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 3,5-dimetilfenol en lugar de 1-naftol en el EJEMPLO 1C.

EJEMPLO 139B

ácido 3-(3-(3,5-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 139A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,88 (s ancho, 1H), 10,48 (s, 1H), 7,67 (d, 1H), 7,28 (m, 4H), 7,08 (m, 2H), 6,52 (m, 3H), 3,96 (t, 2H), 3,22 (t, 2H), 2,21 (s, 6H), 2,06 (m, 5H).

EJEMPLO 140A

7-bromo-3-(3-(2,3-dimetoxifenoxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 2,3-dimetoxifenol en lugar de 1-naftol en el EJEMPLO 1C.

EJEMPLO 140B

ácido 3-(3-(2,3-dimetoxifenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 140A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 9,92 (s ancho, 1H), 7,65 (m, 1H), 7,28 (m, 4H), 7,09 (m, 1H), 7,01 (d, 1H), 6,94 (m, 1H), 6,61 (m, 2H), 4,02 (t, 2H), 3,77 (s, 3H), 3,73 (s, 3H), 3,25 (t, 2H), 2,08 (m, 5H).

EJEMPLO 141A

7-bromo-3-(3-(naftalen-1-ilamino)-3-oxopropil)-1H-indol-2-carboxilato de etilo

Una mezcla de ácido 3-(7-bromo-2-(etoxicarbonil)-1H-indol-3-il)propanoico (0,68 g), naftalen-1-amina (0,294 g), DMAP (0,363 g) y clorhidrato de 1-etil-3-(3-(dimetilamino)propil)carbodiimida (0,576 g) se agitó durante 3 días a temperatura ambiente. El producto precipitó y se filtró, se lavó con diclorometano, y se secó bajo vacío.

EJEMPLO 141B

7-bromo-3-(3-(naftalen-1-ilamino)propil)-1H-indol-2-carboxilato de etilo

Al EJEMPLO 141A (0,465 g) se agregó una mezcla de BH_3·THF 1M (4 ml), y la mezcla se agitó durante 16 horas, se neutralizó con metanol y se concentró. El concentrado se trató con HCl y etanol, y la mezcla se concentró. El concentrado se particionó entre bicarbonato de sodio saturado y diclorometano. La fase orgánica se secó (Na_2SO_4), se filtró y se concentró. El concentrado se purificó por cromatografía flash en columna sobre gel de sílice con 0-30 % acetato de etilo/hexanos.

EJEMPLO 141C

ácido 7-(2-metilfenil)-3-(3-(1-naftilamino)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 141B en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 12,99 (s ancho, 1H), 10,46 (s, 1H), 8,14 (d, 1H), 7,73 (m, 2H), 7,25 (m, 10H), 6,47 (d, 1H), 3,26 (m, 4H), 2,09 (m, 5H).

EJEMPLO 142A

7-bromo-1-(2-metoxi-2-oxoetil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 2-cloroacetato de metilo en lugar de 2-cloro-1-morfolinoetanona en el EJEMPLO 77A.

EJEMPLO 142B

ácido 1-(carboximetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 142A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (300 MHz, DMSO-d_6) □ 13,15 (s ancho, 1H), 12,37 (s ancho, 1H), 8,26 (m, 1H), 7,88 (m, 1H), 7,78 (m, 1H), 7,39 (m, 7H), 7,12 (m, 2H), 6,94 (m, 2H), 4,77 (s ancho, 1H), 4,49 (s ancho, 1H), 4,23 (t, 2H), 2,23 (m, 2H), 1,96 (s, 3H).

EJEMPLO 143A

7-bromo-3-(3-(3-dimetilaminofenoxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 3-dimetilaminofenol en lugar de 1-naftol en el EJEMPLO 1C.

EJEMPLO 143B

ácido 3-(3-(3-(dimetilamino)fenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 143A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,90 (s ancho, 1H), 10,48 (s, 1H), 7,68 (m, 1H), 7,26 (m, 4H), 7,07 (m, 3H), 6,37 (m, 3H), 3,99 (t, 2H), 3,22 (t, 2H), 2,90 (s, 6H), 2,06 (m, 5H).

EJEMPLO 144A

morfolino(4-nitro-3-(trifluorometil)fenil)metanona

A una mezcla de ácido 4-nitro-3-trifluorometilbenzoico (10 g), morfolina (3,7 g) en diclorometano (300 ml) se agregó DMAP (5,2 g) y clorhidrato de 1-etil-3-(3-(dimetilamino)propil)-carbodiimida (12,3 g). La mezcla se agitó a temperatura ambiente durante la noche, se lavó con HCl acuoso 5%, agua y salmuera y se concentró.

EJEMPLO 144B

(4-amino-3-(trifluorometil)fenil)(morfolino)metanona

Una mezcla del EJEMPLO 144A (13 g) y Pd/C (1,3 g, 10%) en etanol (300 ml) se agitó bajo hidrógeno a temperatura ambiente durante dos días. El catalizador se filtró y el solvente se evaporó para dar el compuesto final.

EJEMPLO 144C

(4-bromo-3-(trifluorometil)fenil)(morfolino)metanona

A una mezcla del EJEMPLO 144B (8,3 g) se agregó agua (75 ml) y H_2SO_4 (25 ml). La mezcla se agitó a 0°C mientras se agregaba $NaNO_2$ (3,13 g) en agua (30 ml). Después de agitar durante 1 hora, la mezcla se agregó a CuBr (5,45 g) en HBr 48% (200 ml). Esta mezcla se agitó a 60°C durante 3 horas, se enfrió a temperatura ambiente, y se particionó entre agua y acetato de etilo. La fase orgánica se lavó con Na_2CO_3 acuoso y se secó (Na_2SO_4), se filtró y se concentró.

EJEMPLO 144D

etiléster de ácido 3-(4-oxo-butil)-7-(4,4,5,5-tetrametil-(1,3,2)dioxaborolan-2-il)-1H-indol-2-carboxílico

Una mezcla del EJEMPLO 109C (2,3 g), bis(pinacolato)diboro (2,1 g), acetato de potasio (3,34 g) y (1,1'-bis(difenilfosfino)ferrocen)dicloropaladio(II) (278 mg) en DMF (40 ml) se agitó a 60°C durante la noche y se concentró. El concentrado se particionó entre diclorometano y agua. La fase acuosa se extrajo adicionalmente con diclorometano. El extracto se lavó con agua y salmuera y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se purificó por cromatografía flash sobre gel de sílice con 5% acetato de etilo en hexanos.

EJEMPLO 144E

7-(4-(morfolin-4-carbonil)-2-(trifluorometil)fenil)-3-(4-oxobutil)-1H-indol-2-carboxilato de etilo

A una mezcla del EJEMPLO 144D (1,67 g) y el EJEMPLO 144C (1,53 g) en dimetoxietano (80 ml) se agregó tris(dibencilidenacetona)dipaladio(0) (201 mg), tetrafluoroborato de tri-tert-butilfosfina (128 mg) y CsF (1,97 g). La mezcla se agitó a temperatura ambiente durante la noche, se diluyó con acetato de etilo (200 ml), se lavó con agua y salmuera y se secó (Na_2SO_4), se filtró y se concentró. El concentrado se purificó sobre gel de sílice con 20% acetato de etilo en hexanos.

EJEMPLO 144F

ácido 3-(4-(3,4-dihidroquinolin-1 (2H)-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico

A una mezcla del EJEMPLO 144E (52 mg) y 1,2,3,4-tetrahidroquinolina (27 mg) en dicloroetano (2 ml) se agregó triacetoxiborohidruro de sodio (50 mg). La mezcla se agitó a temperatura ambiente durante la noche, se diluyó con acetato de etilo (200 ml), se lavó con agua y salmuera, y se secó sobre sulfato de sodio. La evaporación del solvente y purificación flash en columna sobre gel de sílice con 20% acetato de etilo en hexanos dio el etiléster que se saponificó con LiOH como se describe en el EJEMPLO 65B. ^{1}H RMN (300 MHz, DMSO-d_6) □ 11,09 (s, 1H), 8,29 (s, 1H), 8,21 (dd, 1H), 7,74 (d, 1H), 7,54 (d, 1H), 7,13 (d, 1H), 7,05 (d, 1H), 6,90 (t, 1H), 6,86 (d, 1H), 6,52 (d, 1H), 6,43 (t, 1H), 3,20 (m, 12H), 2,64 (t, 2H), 1,81 (m, 2H), 1,61 (m, 6H).

EJEMPLO 145

ácido 3-(4-(2-metil-3,4-dihidroquinolin-1 (2H)-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 2-metil-1,2,3,4-tetrahidroquinolina en lugar de 1,2,3,4-tetrahidroquinolina en el EJEMPLO 144F. ^{1}H RMN (300 MHz, DMSO-d_6) □ 11,09 (s, 1H), 8,29 (s, 1H), 8,22 (dd, 1H), 7,74 (d, 1H), 7,54 (d, 1H), 7,13 (t, 1H), 7,05 (d, 1H), 6,93 (t, 1H), 6,86 (d, 1H), 6,45 (m, 2H), 3,35 (m, 4H), 3,17 (m, 12H), 2,72 (m, 2H), 1,69 (m, 6H), 1,04 (d, 3H).

EJEMPLO 146

ácido 3-(4-(6-metil-3,4-dihidroquinolin-1 (2H)-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 6-metil-1,2,3,4-tetrahidroquinolina en lugar de 1,2,3,4-tetrahidroquinolina en el EJEMPLO 144F. ^{1}H RMN (300 MHz, DMSO-d_6) □ 11,09 (s, 1H), 8,29 (s, 1H), 8,21 (dd, 1H), 7,72 (d, 1H), 7,53 (d, 1H), 7,12 (t, 1H), 7,05 (d, 1H), 6,75 (d, 1H), 6,69 (s, 1H), 6,48 (m, 1H), 3,17 (m, 12H), 2,62 (t, 2H), 2,11 (s, 3H), 1,83 (t, 2H), 1,63 (m, 4H).

EJEMPLO 147

ácido 3-(4-(6-metoxi-3,4-dihidroquinolin-1 (2H)-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 6-metoxi-1,2,3,4-tetrahidroquinolina en lugar de 1,2,3,4-tetrahidroquinolina en el EJEMPLO 144F. ^{1}H RMN (300 MHz, DMSO-d_6) □ 11,11 (s, 1H), 8,29 (s, 1H), 8,21 (dd, 1H), 7,75 (d, 1H), 7,53 (d, 1H), 7,13 (t, 1H), 7,06 (d, 1H),

6,61 (m, 3H), 3,65 (s, 3H), 3,17 (m, 12H), 2,69 (m, 2H), 1,86 (m, 2H), 1,6 (m, 4H).

EJEMPLO 148

ácido 3-(4-(etil(1-naftil)amino)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando etil-naftalen-1-il-amina en lugar de 1,2,3,4-tetrahidroquinolina en el EJEMPLO 144F. ^{1}H RMN (300 MHz, DMSO-d_6) □ 11,06 (s, 1H), 8,29 (s, 1H), 8,21 (dd, 1H), 7,20-8,00 (m, 8H), 7,04 (m, 3H), 3,17 (m, 12H), 1,63 (m, 5H), 0,95 (t, 3H).

EJEMPLO 149

ácido 3-(4-(2,3-dihidro-1H-indol-1-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 2,3-dihidro-1H-indol en lugar de 1,2,3,4-tetrahidroquinolina en el EJEMPLO 144F. ^{1}H RMN (300 MHz, DMSO-d_6) □ 11,09 (s, 1H), 8,29 (s, 1H), 8,21 (dd, 1H), 7,74 (d, 1H), 7,54 (d, 1H), 6,93-7,14 (m, 4H), 6,55 (t, 1H), 6,47 (d, 1H), 3,14 (m, 12H), 2,85 (m, 3H), 1,67 (m, 5H).

EJEMPLO 150

ácido 3-(4-(2-metil-2,3-dihidro-1H-indol-1-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 2,3-dihidro-2-metil-1H-indol en lugar de 1,2,3,4-tetrahidroquinolina en el EJEMPLO 144F. ^{1}H RMN (300 MHz, DMSO-d_6) □ 11,09 (s, 1H), 8,29 (s, 1H), 8,21 (dd, 1H), 7,74 (d, 1H), 7,54 (d, 1H), 7,12 (t, 1H), 7,07 (d, 1H), 6,49 (t, 1H), 6,33 (d, 1H), 3,62 (m, 2H), 3,14 (m, 12H), 1,70 (m, 5H), 1,18 (d, 3H).

EJEMPLO 151

ácido 7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-3-(4-(5-nitro-2,3-dihidro-1H-indol-1-il)butil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 2,3-dihidro-5-nitro-1H-indol en lugar de 1,2,3,4-tetrahidroquinolina en el EJEMPLO 144F. ^{1}H RMN (300 MHz, DMSO-d_6) □ 11,09 (s, 1H), 8,29 (s, 1H), 8,21 (dd, 1H), 7,96 (dd, 1H), 7,79 (s, 1H), 7,74 (d, 1H), 7,53 (d, 1H), 7,06 (m, 3H), 6,42 (d, 1H), 3,61 (t, 3H), 3,14 (m, 10H), 3,04 (t, 2H), 1,67 (m, 5H).

EJEMPLO 152

ácido 3-(4-(5-bromo-2,3-dihidro-1H-indol-1-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 5-bromo-2,3-dihidro-1H-indol en lugar de 1,2,3,4-tetrahidroquinolina en el EJEMPLO 144F. ^{1}H RMN (300 MHz, DMSO-d_6) □ 11,10 (s, 1H), 8,29 (s, 1H), 8,22 (dd, 1H), 7,74 (d, 1H), 7,54 (d, 1H), 7,06 (m, 4H), 6,38 (d, 1H), 3,17 (m, 10H), 3,04 (t, 2H), 2,86 (t, 2H), 1,67 (m, 5H).

EJEMPLO 153

ácido 3-(4-(2,3-dihidro-4H-1,4-benzoxazin-4-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando 3,4-dihidro-2H-benzo(1,4)oxazina en lugar de

1,2,3,4-tetrahidroquinolina en el EJEMPLO 144F. ^{1}H RMN (300 MHz, DMSO-d_6) □ 11,09 (s, 1H), 8,29 (s, 1H), 8,21 (dd, 1H), 7,74 (d, 1H), 7,53 (d, 1H), 7,12 (t, 1H), 7,05 (d, 1H), 6,71 (t, 1H), 6,65 (d, 2H), 6,46 (t, 1H), 4,12 (t, 2H), 3,14 (m, 10H), 1,65 (m, 6H).

EJEMPLO 154A

7-bromo-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 2,3,5-trimetilfenol en lugar de 1-naftol en el EJEMPLO 1C.

EJEMPLO 154B

ácido 7-(2-metilfenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 154A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,89 (s ancho, 1H), 10,47 (s, 1H), 7,66 (d, 1H), 7,27 (m, 4H), 7,11 (t, 1H), 7,04 (d, 1H), 6,54 (d, 2H), 3,97 (t, 2H), 3,26 (t, 2H), 2,18 (s, 3H), 2,17 (s, 3H), 2,07 (m, 8H).

EJEMPLO 155A

7-bromo-3-(3-(2,3,6-trimetilfenoxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 2,3,6-trimetilfenol en lugar de 1-naftol en el EJEMPLO 1C.

EJEMPLO 155B

ácido 7-(2-metilfenil)-3-(3-(2,3,6-trimetilfenoxi)propil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 155A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,89 (s ancho, 1H), 10,47 (s, 1H), 7,71 (d, 1H), 7,28 (m, 4H), 7,15 (t, 1H), 7,05 (d, 1H), 6,89 (d, 1H), 6,80 (d, 1H), 3,76 (t, 2H), 3,27 (t, 2H), 2,16 (s, 3H), 2,16 (s, 3H), 2,11 (m, 5H), 2,06 (s, 3H).

EJEMPLO 156A

7-bromo-3-(3-(2,3-diclorofenoxi)propil)-1H-indol-2-carboxilato de etilo

Este ejemplo se preparó utilizando 2,3-diclorofenol en lugar de 1-naftol en el EJEMPLO 1C.

EJEMPLO 156B

ácido 3-(3-(2,3-diclorofenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico y el EJEMPLO 156A en lugar del EJEMPLO 1C en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 10,48 (s ancho, 1 H), 7,66 (d, 1H), 7,30 (m, 4H), 7,21 (m, 2H), 7,06 (m, 3H), 4,12 (t, 2H), 3,27 (t, 2H), 2,12 (m, 2H), 2,05 (s, 3H).

EJEMPLO 157A

ácido 7-bromo-3-(4-etoxicarbonil-butil)-1H-indol-2-carboxílico etiléster de

Este ejemplo se preparó utilizando etiléster de ácido 2-oxo-cicloheptancarboxílico en lugar de etiléster de ácido 2-oxo-ciclopentancarboxílico en el EJEMPLO 1A.

EJEMPLO 157B

etiléster de ácido 7-bromo-3-(5-hidroxi-pentil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 157A en lugar del EJEMPLO 1A en el EJEMPLO 1B.

EJEMPLO 157C

etiléster de ácido 7-bromo-3-(5-(5,6,7,8-tetrahidro-naftalen-1-iloxi)-pentil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 157A en lugar del EJEMPLO 1B y 5,6,7,8-tetrahidronaftol en lugar de 1-naftol en el EJEMPLO 1C.

EJEMPLO 157D

ácido 7-(2-metilfenil)-3-(5-(5,6,7,8-tetrahidronaftalen-1-iloxi)pentil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 157C en lugar del EJEMPLO 1C y ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,82 (s ancho, 1H), 10,35 (s, 1H), 7,66 (d, 1H), 7,28 (m, 4H), 7,13 (t, 1H), 7,01 (m, 2H), 6,67 (d, 1H), 6,61 (d, 1H), 3,91 (t, 2H), 3,11 (t, 2H), 2,66 (m, 2H), 2,06 (s, 3H), 1,72 (m, 8H), 1,53 (m, 2H).

EJEMPLO 158A

etiléster de ácido 7-bromo-3-(5-(naftalen-1-iloxi)-pentil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 157B en lugar del EJEMPLO 1B en el EJEMPLO 1C.

EJEMPLO 158B

ácido 7-(2-metilfenil)-3-(5-(1-naftiloxi)pentil)-1H-indol-2-carboxílico

Este ejemplo se preparó utilizando el EJEMPLO 158A en lugar del EJEMPLO 1C y ácido 2-metilfenilborónico en lugar de ácido (E)-estirilborónico en el EJEMPLO 1D. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,81 (s ancho, 1H), 10,37 (s, 1H), 8,12 (d, 1H), 7,85 (d, 1H), 7,68 (d, 1H), 7,46 (m, 4H), 7,28 (m, 4H), 7,12 (m, 1H), 7,04 (m, 1H), 6,95 (d, 1H), 4,15 (t, 2H), 3,15 (t, 2H), 2,06 (s, 3H), 1,92 (m, 2H), 1,77 (m, 2H), 1,63 (m, 2H).

EJEMPLO 159

ácido 7-(2,3-dimetilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,92 (s, 1H), 10,35 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,69 (dd, 1H), 7,52 (m, 2H), 7,42 (m, 2H), 7,19 (m, 2H), 7,04 (m, 3H), 6,91 (dd, 1H), 4,21 (t, 2H), 3,37 (m, 2H), 2,32 (s, 3H), 2,24 (m, 2H), 1,94 (s, 3H).

EJEMPLO 160

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 8,37-8,45 (m, 2H), 8,19-8,26 (m, 1H), 7,84-7,91 (m, 2H), 7,36-7,57 (m, 4H), 7,13-7,28 (m, 3H), 6,83-7,00 (m, 4H), 6,59-6,67 (m, 2H), 5,52-5,63 (m, 1H), 5,17-5,30 (m, 1H), 4,26 (t, 2H), 2,24-2,35 (m, 2H), 1,76 (s, 3H).

EJEMPLO 162

ácido 7-(2-(4-fluorofenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,95 (s, 1H), 10,78 (s, 1H), 8,23-8,24 (m, 1H), 7,85-7,87 (m, 1H), 7,35-7,54 (m, 5H), 7,02-7,05 (m, 2H), 6,84 (d, J = 7,63 Hz, 1H), 6,76-

6,79 (m, 4H), 4,42 (t, J = 6,87 Hz, 2H), 4,10-4,13 (m, 2H), 3,25 (ancho, 2H), 2,39-2,42 (m, 4H), 2,21-2,26 (m, 2H), 1,86 (ancho, 4H).

EJEMPLO 163

ácido 7-(3,5-dimetil-1-(2-(2-oxopirrolidin-1-il)etil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,96 (s, 1H), 10,42 (s, 1H), 8,25-8,27 (m, 1H), 7,86-7,88 (m, 1H), 7,65 (d, J = 7,63 Hz, 1H), 7,38-7,55 (m, 4H), 7,25-7,28 (m, 1H), 7,01-7,07 (m, 2H), 6,91 (d, J = 7,63 Hz, 1H), 4,16-4,22 (m, 4H), 4,03 (ancho, 4H), 3,34-3,37 (m, 2H), 2,21-2,26 (m, 2H), 2,11-2,14 (m, 2H), 2,05 (s, 3H), 1,98 (s, 3H), 1,87-1,93 (m, 2H).

EJEMPLO 164

ácido 1-(tert-butoxicarbonil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)bencil)-1H-indol-2-carboxílico

EJEMPLO 164A

7-bromo-1H-indol

Se agregó 1-bromo-2-nitrobenceno (6,000 g, 29,7 mmol) a tetrahidrofurano (65 ml) y se enfrió a – 40 °C. Se agregó bromuro de vinilmagnesio (1M en tetrahidrofurano, 89 ml) rápidamente. La solución se agitó durante 20 minutos y luego se volcó sobre una solución acuosa saturada de cloruro de amonio. La solución se extrajo con dietiléter y se secó con salmuera y sulfato de sodio anhidro. La solución se concentró y se purificó por cromatografía flash en columna sobre gel de sílice con 5% acetato de etilo en hexanos para dar el compuesto del título.

EJEMPLO 164B

7-o-tolil-1H-indol

Se agregaron el EJEMPLO 164A (2,500 g), ácido *o*-tolilborónico (1,907 g), y carbonato de sodio (solución acuosa 2M, 19,13 ml) a dioxano (43 ml). La solución se desgasificó y se llenó con nitrógeno tres veces. Se agregó aducto dicloro(1,1'-bis(difenilfosfino)ferrocen)paladio (II) diclorometano (833 mg) y la solución se calentó a 80 °C durante la noche. La solución se enfrió, se agregó a HCl acuoso 1M, se extrajo con 20% acetato de etilo / hexanos, y se secó con salmuera y sulfato de sodio anhidro. La solución se concentró y se purificó por cromatografía flash en columna sobre gel de sílice con 5% acetato de etilo en hexanos para dar el compuesto del título.

EJEMPLO 164C

3-(naftalen-1-iloxi)benzaldehído

Se agregaron 1-iodonaftaleno (2,000 g) y 3-hidroxibenzaldehído (1,442 g) a dioxano (25 ml). La solución se desgasificó y se llenó con nitrógeno tres veces. Se agregaron carbonato de cesio (5,13 g), clorhidrato de N,N-dimetilglicina (82 mg), y ioduro de cobre (I) (30 mg), y la solución se calentó a 90°C durante la noche. La solución se enfrió, se agregó a HCl acuoso 1M, se extrajo con dietiléter, se secó con salmuera y sulfato de sodio anhidro. La solución se concentró y se purificó por cromatografía flash en columna sobre gel de sílice con 10% acetato de etilo en hexanos para dar el

compuesto del título.

EJEMPLO 164D

3-(3-(naftalen-1-iloxi)bencil)-7-o-tolil-1H-indol

Se disolvieron el EJEMPLO 164B (133 mg) y el EJEMPLO 164C (175 mg) en diclorometano (3 ml) y se agregó por goteo a una solución de ácido trifluoroacético (0,074 ml, 110 mg) y trietilsilano (0,307 ml, 224 mg) en diclorometano (3 ml), que se había enfriado a 0°C. La solución se mezcló durante una hora a 0°C, se neutralizó con una solución acuosa saturada de cloruro de amonio, se extrajo con acetato de etilo, y se secó con salmuera y sulfato de sodio anhidro. La solución se concentró y se purificó por cromatografía flash en columna sobre gel de sílice con 5% - 10% acetato de etilo en hexanos para dar el compuesto del título.

EJEMPLO 164E

3-(3-(naftalen-1-iloxi)bencil)-7-o-tolil-1H-indol-1-carboxilato de tert-butilo

Se agregaron el EJEMPLO 164D (158 mg) y 4-dimetilaminopiridina (4,4 mg) a acetonitrilo (3 ml). Se agregó dicarbonato de di-tert-butilo (0,088 ml, 82 mg), y la solución se mezcló a temperatura ambiente durante 30 minutos. La solución se concentró y se purificó por cromatografía flash en columna sobre gel de sílice con 5% acetato de etilo en hexanos para dar el compuesto del título.

EJEMPLO 164F

3-(3-(naftalen-1-iloxi)bencil)-7-o-tolil-1H-indol-1,2-dicarboxilato de1-tert-butilo 2-metilo

Se agregó el EJEMPLO 164E (161 mg) a tetrahidrofurano (3 ml). La solución se enfrió a –78°C, y se agregó tert-butillitio(1,7M en pentano, 0,193 ml) lentamente. La solución se mezcló a –78°C durante 45 minutos, y se agregó cloroformato de metilo (0,025 ml, 30,5 mg). La solución se mezcló a –78°C durante 30 minutos y se dejó calentar hasta temperatura ambiente. La solución se concentró y se purificó por cromatografía flash en columna sobre gel de sílice con 5% acetato de etilo en hexanos para dar el compuesto del título.

EJEMPLO 164G

ácido 1-(tert-butoxicarbonil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)bencil)-1H-indol-2-carboxílico

Se disolvió el EJEMPLO 164F (35 mg, 0,059mmol) en una mezcla de tetrahidrofurano (0,6 ml), agua (0,2 ml), y metanol (0,2 ml). Se agregó hidróxido de litio monohidrato (9,8 mg, 0,234 mmol) y la solución se mezcló durante la noche a temperatura ambiente. La solución se acidificó levemente utilizando HCl 1M, se extrajo con acetato de etilo, y se secó con sulfato de sodio anhidro. El solvente se eliminó bajo vacío para dar el compuesto del título. ^{1}H RMN (300MHz, DMSO-d_6) □ 13,72 (br s, 1H), 8,05 (dd, 1H), 7,98 (dd, 1H), 7,73 (d, 1H), 7,66 (dd, 1H), 7,61-7,49 (m, 2H), 7,44 (t, 1H), 7,31-7,18 (m, 5H), 7,12 (dd, 2H), 7,06 (td, 2H), 6,95 (dd, 1H), 6,78 (dd, 1H), 4,35 (s, 2H), 1,99 (d, 3H), 1,17 (s, 9H).

EJEMPLO 165

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)bencil)-1H-indol-2-carboxílico

Se disolvió el EJEMPLO 164G (35 mg) en diclorometano (2 ml). Se agregaron trietilsilano (0,011 ml, 7,7mg) y ácido trifluoroacético (0,018 ml, 27 mg), y la solución se mezcló durante la noche a temperatura ambiente. La solución se concentró y se purificó por cromatografía flash en columna sobre gel de sílice con 50% acetato de etilo en hexanos para dar el compuesto del título. ^{1}H RMN (300MHz, DMSO-d_6) □ 12,98 (s ancho, 1H), 10,61 (s, 1H), 8,05 (dd, 1H), 7,98 (dd, 1H), 7,71 (d, 1H), 7,63-7,49 (m, 3H), 7,43 (t, 1H), 7,35-7,19 (m, 6H), 7,14-7,07 (m, 2H), 7,04 (dd, 1H), 6,93 (dd, 1H), 6,75 (ddd, 1H), 4,48 (s, 2H), 1,99 (s, 3H).

EJEMPLO 166

ácido 7-(2-metilfenil)-4-((E)-2-fenilvinil)-1H-indol-2-carboxílico

EJEMPLO 166A

(Z)- 2-azido-3-(5-bromo-2-clorofenil)acrilato de etilo

A una solución de etóxido de sodio en etanol (15 ml) enfriada –10 °C se agregó por goteo una solución de 5-bromo-2- clorobenzaldehído (1,0 g) y 2-azidoacetato de etilo (11 ml, 18 mmol) en etanol-tetrahidrofurano (15 ml-3 ml). La mezcla de reacción se agitó a –10 °C durante 3 horas, se dejó calentar hasta 10 °C a lo largo de 3 horas y se volcó sobre hielo picado. El sólido se recogió por filtración y se secó en un horno de vacío para dar el compuesto del título.

EJEMPLO 166B

7-bromo-4-cloro-1H-indol-2-carboxilato de etilo

A una solución en reflujo de 1,2-diclorobenceno (17 ml) se agregó por goteo el EJEMPLO 166A (1,2 g, 3,7 mmol) a lo largo de 3 horas. La solución se calentó bajo reflujo durante otras 2 horas. El solvente se eliminó bajo presión reducida y el residuo se purificó por cromatografía flash (0-20% acetato de etilo en hexanos) para dar el compuesto del título.

EJEMPLO 166C

4-cloro-7-o-tolil-1H-indol-2-carboxilato de etilo

A una solución del EJEMPLO 166B (610 mg), ácido o-tolilborónico (330 mg), fluoruro de cesio (930 mg) en dioxano (5 ml) se agregó tetrakis(trifenilfosfin)paladio (240 mg). La mezcla resultante se calentó bajo reflujo durante la noche y se concentró. El residuo se diluyó con acetato de etilo y acetato de amonio saturado, y las fases se separaron. La fase acuosa se extrajo con acetato de etilo (x2) y las fases orgánicas combinadas se lavaron con salmuera, se secó sobre $MgSO_4$, se filtró y se concentró. El residuo se purificó por cromatografía flash (0-20% acetato de etilo en hexanos) para dar el compuesto del título.

EJEMPLO 166D

A una solución del EJEMPLO 166C (80 mg), ácido (E)-estirilborónico (76 mg), fluoruro de cesio (120 mg) en dioxano-metanol (0,4 ml-0,1 ml) se agregó acetato de paladio (5,7 mg) y (2-bifenil)diciclohexilfosfina (18 mg). La mezcla resultante se calentó bajo reflujo durante la noche, se trató con hidróxido de litio acuoso (0,5 ml, 2N), se

calentó bajo reflujo durante 5 horas y se concentró. El residuo se diluyó con acetato de etilo y acetato de amonio saturado, y las fases se separaron. La fase acuosa se extrajo con acetato de etilo (x2) y las fases orgánicas combinadas se lavaron con salmuera, se secó sobre $MgSO_4$, se filtró y se concentró. El residuo se purificó por cromatografía flash (0-20% acetato de etilo en hexanos) para dar el compuesto del título. ^{1}H RMN (500 MHz, DMSO-d_6) □ 12,88 (ancho, 1H), 11,18 (s, 1H), 7,76 (m, 3H), 7,69 (d, 1H), 7,53 (d, 1H), 7,41 (m, 3H), 7,34 (d, 2H), 7,27 (m, 3H), 7,08 (d, 1H), 2,08 (s, 3H).

EJEMPLO 167

ácido 7-(2-metilfenil)-4-(1-naftil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) □ 11,32 (s, 1H), 8,04 (t, 2H), 7,71 (d, 1H), 7,66 (m, 1H), 7,61 (m, 1H), 7,56 (m, 1H), 7,46 (m, 1H), 7,34 (m, 4H), 7,22 (m, 2H), 6,60 (d, 1H), 2,18 (s, 3H).

EJEMPLO 168

ácido 7-(2-metilfenil)-4-(2-naftil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) □ 12,93 (ancho, 1H), 11,35 (s, 1H), 8,25 (s, 1H), 8,08 (m, 2H), 8,00 (m, 1H), 7,90 (dd, 1H), 7,57 (m, 2H), 7,36 (m, 3H), 7,31 (m, 3H), 7,19 (d, 1H), 2,13 (s, 3H).

EJEMPLO 169

ácido 7-(2-metilfenil)-4-(3-(2-naftiloxi)propil)-1H-indol-2-carboxílico

EJEMPLO 169A

A una solución de 2-(aliloxi)naftaleno (71 mg) en tetrahidrofurano a temperatura ambiente se agregó 9-borabiciclo(3,3,1)nonano (0,5 M, 1,5 ml). La solución se agitó a 50 °C durante 2 horas y se enfrió a temperatura ambiente. Se agregaron el EJEMPLO 166C (100 mg), acetato de paladio (7,2 mg), (2-bifenil)diciclohexilfosfina (22 mg) y fluoruro de potasio (56 mg), y la mezcla resultante se calentó bajo reflujo durante la noche. La mezcla de reacción se diluyó con acetato de etilo y cloruro de amonio saturado y las fases se separaron. La fase acuosa se extrajo con acetato de etilo (x2) y las fases orgánicas combinadas se lavaron con salmuera, se secó sobre $MgSO_4$, se filtró y se concentró. El residuo se purificó por cromatografía flash (20% acetato de etilo en hexanos) para dar el compuesto del título.

EJEMPLO 169B

A una solución del EJEMPLO 169A (45 mg) en dioxano (1,0 ml) se agregó hidróxido de litio acuoso (2 N, 0,15 ml). La mezcla resultante se calentó a 60 °C durante la noche y se diluyó con acetato de etilo y cloruro de amonio saturado. Las fases se separaron y la fase acuosa se extrajo con acetato de etilo (x2). Las fases orgánicas combinadas se secaron sobre $MgSO_4$, se filtró y se concentró. El residuo se purificó por cromatografía flash (0-5% metanol en diclorometano) para dar el compuesto del título. ^{1}H RMN (400 MHz, DMSO-d_6) □ 12,82 (ancho, 1H), 11,10 (s, 1H), 7,83 (d, 2H), 7,78 (d, 1H), 7,45 (m, 1H), 7,35 (m, 1H), 7,31 (m, 4H), 7,27 (m, 1H), 7,22 (m, 2H), 7,02 (m, 1H), 6,97 (m, 1H), 4,20 (t, 2H), 3,12 (t, 2H), 2,24 (m, 2H), 2,05 (s, 3H).

EJEMPLO 170

ácido 7-(2-metilfenil)-4-(4-(1-naftiloxi)butil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) □ 12,81 (ancho, 1H), 11,02 (s, 1H), 8,14 (d, 1H), 7,85 (d, 1H), 7,49 (m, 3H), 7,40 (m, 1H), 7,31 (m, 3H), 7,26 (m, 1H), 7,21 (m, 1H), 7,01 (m, 1H), 6,96 (m, 2H), 4,21 (t, 2H), 3,04 (t, 2H), 2,05 (s, 3H), 2,00 (m, 4H).

EJEMPLO 171

ácido 7-(2-metilfenil)-4-(4-(2-naftiloxi)butil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) □ 12,81 (ancho, 1H), 11,01 (s, 1H), 7,80 (m, 3H), 7,44 (m, 1H), 7,31 (m, 5H), 7,25 (m, 1H), 7,20 (m, 1H), 7,17 (dd, 1H), 7,00 (m, 1H), 6,96 (m, 1H), 4,16 (t, 2H), 3,00 (t, 2H), 2,05 (s, 3H), 1,91 (m, 4H).

EJEMPLO 172

ácido 7-(2-metilfenil)-4-(2-(2-naftil)etil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) □ 12,83 (ancho, 1H), 11,05 (s, 1H), 7,86 (m, 3H), 7,80 (s, 1H), 7,53 (dd, 1H), 7,46 (m, 2H), 7,37 (d, 1H), 7,31 (d, 2H), 7,26 (m, 1H), 7,21 (m, 1H), 7,01 (m, 1H), 6,95 (d, 1H), 3,29 (m, 2H), 3,19 (m, 2H), 2,06 (s, 3H).

EJEMPLO 173

ácido 3-(3-(1-naftiloxi)propil)-7-tien-3-il-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,07 (ancho, 1H), 10,23 (s, 1H), 8,22-8,24 (m, 1H), 7,93 (dd, J = 2,9, 1,37 Hz, 1H), 7,85-7,87 (m, 1H), 7,72 (dd, *J* = 4,88, 2,75 Hz, 1H), 7,67 (d, *J* = 7,93 Hz, 1H), 7,79-7,55 (m, 3H), 7,44-7,46 (m, 1H), 7,36-7,40 (m, 2H), 7,05-7,08 (m, 1H), 6,89 (d, J = 7,02 Hz, 1H), 4,18 (t, J = 6,1 Hz, 2H), 3,75-3,78 (m, 2H), 2,21-2,26 (m, 2H).

EJEMPLO 174

ácido 7-((3-(aminocarbonil)fenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,07 (ancho, 1H), 11,22 (s, 1H), 10,23 (s, 1H), 8,20-8,24 (m, 2H), 7,92 (s, 1H), 7,85-7,87 (m, 1H), 7,68 (s, 1H), 7,49-7,54 (m, 2H), 7,44-7,46 (m, 1H), 7,30-7,40 (m, 5H), 7,23 (d, J = 8,24 Hz, 1H), 7,13 (d, J = 7,63 Hz, 1H), 6,88-6,93 (m, 2H), 4,18 (t, J = 5,95 Hz, 2H), 3,31 (m, 2H), 2,19-2,25 (m, 2H).

EJEMPLO 175

ácido 7-((3-cianofenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

EJEMPLO 175A

7-(3-cianofenilamino)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo

Una mezcla de 7-bromo-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo (EJEMPLO 1C) (45,2 mg), 3-aminobenzonitrilo (14,2 mg), 2'-(diciclohexilfosfino)-N,N-dimetilbifenil-2-amina (Cy-map) (5,9 mg), tris(dibencilidenacetona)dipaladio(0) (4,6 mg), y Cs_2CO_3 (46 mg) en dioxano (1 ml) se desgasificó por ciclo vacío-nitrógeno tres veces. La mezcla de reacción se calentó a 100 °C durante 16 horas. La mezcla de reacción se particionó entre agua y acetato de etilo. La fase orgánica se separó, y la fase acuosa se extrajo con más acetato de etilo. Las fases orgánicas combinadas se lavaron con salmuera, se secó sobre $MgSO_4$, se filtró, y se concentró al vacío. El residuo se purificó

por cromatografía flash (1:9 EtOAc/Hex) para dar el compuesto del título.

EJEMPLO 175B

ácido 7-((3-cianofenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

El EJEMPLO 175A (28 mg) se trató con dioxano (3 ml) y LiOH 1,0 N (1 ml). La mezcla de reacción se calentó a 100 °C durante 3 horas. Los solventes se eliminaron al vacío, y el residuo se purificó por RP HPLC para dar el EJEMPLO 175B y el EJEMPLO 174 puros. ^{1}H RMN (500 MHz, DMSO-d_6): □ 13,12 (s, 1H), 11,21 (s, 1H), 8,33 (s, 1H), 8,20-8,22 (m, 1H), 7,85-7,87 (m, 1H), 7,49-7,54 (m, 2H), 7,37-7,46 (m, 5H), 7,32 (d, J = 7,93 Hz, 1H), 7,23-7,25 (m, 1H), 7,17 (d, J = 7,32 Hz, 1H), 6,95 (t, J = 7,78 Hz, 1H), 6,88 (d, J = 7,63 Hz, 1H), 4,18 (t, J = 6,1 Hz, 2H), 3,31 (m, 2H), 2,20-2,24 (m, 2H).

EJEMPLO 176

ácido 7-((2-bencilfenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,01 (s, 1H), 11,31 (s, 1H), 8,21- 8,23 (m, 1H), 7,84 -7,86 (m, 1H), 7,36 -7,54 (m, 5H), 7,07-7,29 (m, 9H), 6,96-7,00 (m, 1H), 6,89 (d, J = 7,36 Hz, 1H), 6,79 (t, J = 7,83 Hz, 1H), 6,57 (d, J = 7,67 Hz, 1H), 4,19 (t, J = 6,14 Hz, 2H), 4,05 (s, 2H), 3,31 (m, 2H), 2,20-2,25 (m, 2H).

EJEMPLO 177

ácido 7-(1,1'-bifenil-2-ilamino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,93 (s, 1H), 11,28 (s, 1H), 8,21- 8,24 (m, 1H), 7,28 -7,55 (m, 13H), 7,12 -7,16 (m, 1H), 6,89 (d, J = 7,36 Hz, 1H), 7,01 (d, J = 7,61 Hz, 1H), 6,89 (d, J = 6,75 Hz, 1H), 6,81 (t, J = 7,67 Hz, 1H), 6,74-6,76 (m, 1H), 4,18 (t, J = 6,14 Hz, 2H), 3,31 (m, 2H), 2,17-2,24 (m, 2H).

EJEMPLO 178

ácido 7-((2-etilfenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,04 (s, 1H), 11,36 (s, 1H), 8,22- 8,24 (m, 1H), 7,85 -7,88 (m, 1H), 7,15 -7,54 (m, 8H), 7,02-7,09 (m, 2H), 6,89 (d, J = 7,63 Hz, 1H), 6,78 (t, J = 7,78 Hz, 1H), 6,50 (d, J = 7,32 Hz, 1H), 4,19 (t, J = 5,95 Hz, 2H), 3,31 (m, 2H), 2,68 (q, J = 7,53 Hz, 2H), 2,19-2,25 (m, 2H), 1,15 (t, J = 7,48 Hz, 3H).

EJEMPLO 179

ácido 3-(3-(1-naftiloxi)propil)-7-((2-propilfenil)amino)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,03 (s, 1H), 11,36 (s, 1H), 8,22- 8,24 (m, 1H), 7,85 -7,87 (m, 1H), 7,50 -7,54 (m, 2H), 7,44-7,46 (m, 1H), 7,39 (t, J = 7,93 Hz, 1H), 7,33 (s, 1H), 7,23-7,27 (m, 1H), 7,16 (t, J = 6,87 Hz, 1H), 7,08 (d, J = 7,93 Hz, 1H), 7,02 (t, J = 7,02 Hz, 1H), 6,89 (d, J = 7,63 Hz, 1H), 6,77 (t, J = 7,78 Hz, 1H), 6,50 (d, J = 7,32 Hz, 1H), 4,19 (t, J = 6,1 Hz, 2H), 3,31 (m, 2H), 2,63-2,66 (m, 2H), 2,19-2,25 (m, 2H), 1,55-1,59 (m, 2H), 0,88 (t, J = 7,32 Hz, 3H).

EJEMPLO 180

ácido 7-(5-carboxi-3-metiltien-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,01 (s, 1H), 11,02 (s, 1H), 8,22- 8,24 (m, 1H), 7,86 -7,88 (m, 1H), 7,77 (d, J = 7,93 Hz, 1H), 7,65 (s, 1H), 7,45-7,53 (m, H), 7,39 (t, J =

7,78 Hz, 1H), 7,21 (d, J = 6,81 Hz, 1H), 7,08 (t, J = 7,63 Hz, 1H), 6,90 (d, J = 7,63 Hz, 1H), 4,20 (t, J = 6,1 Hz, 2H), 3,34-3,38 (m, 2H), 2,21-2,26 (m, 2H).

EJEMPLO 181

ácido 7-((2-carboxifenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,89 (s, 1H), 11,57 (s, 1H), 9,22 (s, 1H), 8,22-8,24 (m, 1H), 7,90 -7,91 (m, 1H), 7,85-7,87 (m, 1H), 7,50 -7,54 (m, 2H), 7,44-7,46 (m, 2H), 7,38 (t, J = 7,93 Hz, 1H), 7,29-7,32 (m, 1H), 7,14 (d, J = 7,32 Hz, 1H), 6,93-6,97 (m, 2H), 6,89 (d, J = 7,63 Hz, 1H), 6,76 (t, J = 7,32 Hz, 1H), 4,18 (t, J = 5,95 Hz, 2H), 3,34-3,38 (m, 2H), 2,21-2,25 (m, 2H).

EJEMPLO 182

ácido 7-((3-carboxifenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,99 (s, 1H), 11,22 (s, 1H), 8,26 (s, 1H), 8,22-8,23 (m, 1H), 7,85 -7,87 (m, 1H), 7,76 (s, 1H), 7,49-7,54 (m, 2H), 7,37-7,46 (m, 5H), 7,26 (d, J = 8,06 Hz, 1H), 7,14 (d, J = 7,33 Hz, 1H), 6,94 (t, J = 7,69 Hz, 1H), 4,18 (t, J = 5,95 Hz, 2H), 3,34-3,38 (m, 2H), 2,21-2,25 (m, 2H).

EJEMPLO 183

ácido 7-(2-morfolin-4-il-5-nitropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,03 (s, 1H), 11,27 (s, 1H), 9,09 (d, J = 2,76 Hz, 1H), 8,22- 8,24 (m, 1H), 8,16 (d, J = 2,76 Hz, 1H), 7,85-7,87 (m, 1H), 7,77 (d, J = 7,98 Hz, 1H), 7,44-7,55 (m, 3H), 7,37 (t, J = 7,98 Hz, 1H), 7,30 (d, J = 7,06 Hz, 1H), 7,09 (t, J = 7,67 Hz, 1H), 6,86 (d, J = 7,36 Hz, 1H), 4,17 (t, J = 6,14 Hz, 2H), 3,05-3,35 (m, 10H), 2,23-2,26 (m, 2H).

EJEMPLO 184

ácido 7-(5-amino-2-morfolin-4-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,96 (s, 1H), 8,23- 8,25 (m, 1H), 7,86-7,88 (m, 1H), 7,79 (d, J = 7,93 Hz, 1H), 7,75 (s, 1H), 7,49-7,55 (m, 2H), 7,43-7,46 (m, 2H), 7,37 (t, J = 7,93 Hz, 1H), 7,30 (d, J = 7,32 Hz, 1H), 7,10-7,13 (m, 1H), 6,86 (d, J = 7,32 Hz, 1H), 4,17 (t, J = 6,14 Hz, 2H), 3,05-3,35 (m, 10H), 2,23-2,26 (m, 2H).

EJEMPLO 185

ácido 7-((3-cloropiridin-4-il)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,20 (s, 1H), 11,72 (s, 1H), 9,77 (s, 1H), 8,73 (s, 1H), 8,24- 8,27 (m, 1H), 8,10 (d, J = 6,71 Hz, 1H), 7,86-7,88 (m, 1H), 7,76 (d, J = 7,93 Hz, 1H), 7,51-7,56 (m, 2H), 7,45-7,47 (m, 1H), 7,39 (t, J = 7,93 Hz, 1H), 7,22 (d, J = 7,32 Hz, 1H), 7,10 (t, J = 7,78 Hz, 1H), 6,89 (d, J = 7,32 Hz, 1H), 6,45 (d, J = 6,71 Hz, 1H), 4,19 (t, J = 6,1 Hz, 2H), 3,36-3,39 (m, 2H), 2,23-2,25 (m, 2H).

EJEMPLO 186

ácido 7-((2-isopropilfenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,99 (s, 1H), 11,32 (s, 1H), 8,21- 8,23 (m, 1H), 7,85-7,87 (m, 1H), 7,37-7,52 (m, 6H), 7,03-7,22 (m, 4H), 6,89 (d, J = 7,36 Hz, 1H), 6,75 (t, J = 7,83 Hz, 1H), 6,35 (d, J = 7,67 Hz, 1H), 4,19 (t, J = 6,1 Hz, 2H), 3,29-3,35 (m, 2H),

2,23-2,25 (m, 3H), 1,17 (d, J = 6,44 Hz, 6H).

EJEMPLO 187

ácido 7-(2-morfolin-4-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,16 (s, 1H), 11,02 (s, 1H), 8,31(dd, J = 5,19, 1,83 Hz, 1H), 8,23-8,25 (m, 1H), 7,86-7,89 (m, 2H), 7,78 (d, J = 7,93 Hz, 1H), 7,49-7,55 (m, 2H), 7,44-7,46 (m, 1H), 7,38 (d, J = 7,93 Hz, 1H), 7,35 (t, J = 7,32 Hz, 1H), 7,18-7,20 (m, 1H), 7,11-7,14 (m, 1H), 6,86 (d, J = 7,63 Hz, 1H), 4,17 (t, J = 6,1 Hz, 2H), 3,39 (t, J = 7,32 Hz, 2H), 3,2 (ancho, 4H), 2,97 (ancho, 4H), 2,21-2,27 (m, 2H).

EJEMPLO 188

ácido 7-(5-(aminocarbonil)-1,2-dimetil-6-oxo-1,6-dihidropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,03 (s, 1H), 11,18 (s, 1H), 9,21(d, J = 4,58 Hz, 1H), 8,22-8,24 (m, 1H), 8,06 (s, 1H), 7,86-7,88 (m, 1H), 7,72-7,74 (m, 1H), 7,49-7,55 (m, 4H), 7,44-7,46 (m, 1H), 7,69 (t, J = 7,93 Hz, 1H), 7,06-7,10 (m, 2H), 6,90 (d, J = 7,32 Hz, 1H), 4,20 (t, J = 6,1 Hz, 2H), 3,63 (s, 3H), 3,32-3,37 (m, 2H), 2,21-2,26 (m, 2H), 2,17 (s, 3H).

EJEMPLO 189

ácido 7-(5-ciano-1,2-dimetil-6-oxo-1,6-dihidropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,07 (s, 1H), 11,23 (s, 1H), 8,22-8,24 (m, 1H), 7,93 (s, 1H), 7,86-7,88 (m, 1H), 7,74 (dd, J = 7,02, 2,14 Hz, 1H), 7,49-7,55 (m, 2H), 7,44-7,46 (m, 1H), 7,39 (t, J = 7,39 Hz, 1H), 7,06-7,10 (m, 2H), 6,89 (d, J = 7,32 Hz, 1H), 4,19 (t, J = 6,1 Hz, 2H), 3,56 (s, 3H), 3,32-3,37 (m, 2H), 2,21-2,26 (m, 2H), 2,13 (s, 3H).

EJEMPLO 190

ácido 7-(5-amino-4-cloro-2-morfolin-4-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,07 (s, 1H), 10,65 (s, 1H), 8,24 d, J = 7,63 Hz, 1H), 7,86 (d, J = 7,32 Hz, 1H), 7,74 (d, J = 7,93 Hz, 1H), 7,49-7,54 (m, 2H), 7,45 (d, J = 8,24 Hz, 1H), 7,37 (t, J = 7,93 Hz, 1H), 7,28 (d, J = 7,02 Hz, 1H), 7,25 (s, 1H), 7,09 (t, J = 7,48 Hz, 1H), 6,86 (d, J = 7,63 Hz, 1H), 4,17 (t, J = 6,1 Hz, 2H), 3,39 (t, J = 7,32 Hz, 2H), 3,24 (ancho, 4H), 2,75 (ancho, 4H), 2,23-2,25 (m, 2H).

EJEMPLO 191

ácido 2-metil-3'-(3-(1-naftiloxi)propil)-2,3-dihidro-1'H-1,7'-biindol-2'-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,01 (s, 1H), 10,89 (s, 1H), 8,25- 8,27 (m, 1H), 7,86-7,88 (m, 1H), 7,58 (d, J = 7,93 Hz, 1H), 7,50-7,55 (m, 2H), 7,45-7,47 (m, 1H), 7,39 (t, J = 7,93 Hz, 1H), 7,17 (d, J = 7,02 Hz, 1H), 7,12 (d, J = 7,02 Hz, 1H), 7,05 (t, J = 7,78 Hz, 1H), 6,91 (d, J = 7,63 Hz, 1H), 6,86 (t, J = 7,63 Hz, 1H), 6,60 (t, J = 7,32 Hz, 1H), 5,97 (d, J = 7,93 Hz, 1H), 4,51-4,54 (m, 1H), 4,21 (t, J = 6,1 Hz, 2H), 3,38 (t, J = 7,32 Hz, 2H), 2,79 (dd, J = 15,1, 8,09 Hz, 1H), 2,21-2,27 (m, 2H).

EJEMPLO 192

ácido 7-(2-fluoro-5-metilpiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

EJEMPLO 192A

7-(2-fluoro-5-metilpiridin-4-il)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de metilo

Una mezcla del EJEMPLO 43A (0,40 g), 2-fluoro-4-iodo-5-metilpiridina (0,209 g), tetrakis(trifenilfosfin)paladio (46 mg) y fluoruro de cesio (0,365 g) en dimetoxietano (3 ml) y metanol (1,5 ml) se calentó a 120 °C durante 20 minutos bajo condiciones de microondas (CEM Discovery). Después de enfriar a temperatura ambiente, la mezcla de reacción se cargó en un cartucho de gel de sílice. El cartucho se secó en horno de vacío durante 1 hora y se eluyó con 1:4 acetato de etilo/hexanos para dar el producto deseado. ^{1}H RMN (500 MHz, DMSO-d_6): 11,33 (s, 1H), 8,23- 8,25 (m, 1H), 8,17 (s, 1H), 7,86-7,88 (m, 1H), 7,79-7,81 (m, 1H), 7,45-7,56 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,12-7,14 (m, 2H), 7,04 (d, J = 2,14 Hz, 1H), 6,91 (d, J = 7,32 Hz, 1H), 4,20 (t, J = 5,95 Hz, 2H), 3,78 (s, 3H), 3,37 (t, J = 7,48 Hz, 2H), 2,20-2,26 (m, 2H), 2,00 (s, 3H).

EJEMPLO 192B

ácido 7-(2-fluoro-5-metilpiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

El compuesto del título se sintetizó de acuerdo con el procedimiento del EJEMPLO 175B reemplazando el EJEMPLO 175A por el EJEMPLO 192A. ^{1}H RMN (500 MHz, DMSO-d6): 13,00 (s, 1H), 11,21 (s, 1H), 8,23- 8,25 (m, 1H), 8,16 (s, 1H), 7,86-7,88 (m, 1H), 7,76-7,79 (m, 1H), 7,50-7,55 (m, 2H), 7,45-7,47 (m, 1H), 7,39 (t, J = 7,93 Hz, 1H), 7,09-7,11 (m, 2H), 7,03 (d, J = 1,83 Hz, 1H), 6,90 (d, J = 7,63 Hz, 1H), 4,20 (t, J = 6,1 Hz, 2H), 3,37 (t, J = 7,32 Hz, 2H), 2,21-2,27 (m, 2H).

EJEMPLO 193

ácido 7-((2-metoxipiridin-3-il)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,04 (ancho, 1H), 11,58 (s, 1H), 8,22- 8,24 (m, 1H), 7,85-7,87 (m, 1H), 7,70 (dd, J = 4,88, 1,53 Hz, 1H), 7,50-7,55 (m, 3H), 7,44-7,46 (m, 1H), 7,38 (t, J = 7,93 Hz, 1H), 7,23 (d, J = 7,93 Hz, 1H), 6,94 (d, J = 7,02 Hz, 1H), 6,68-6,91 (m, 3H), 4,18 (t, J = 6,1 Hz, 2H), 3,98 (s, 3H), 3,33 (t, J = 7,32 Hz, 2H), 2,19-2,24 (m, 2H).

EJEMPLO 194

ácido 7-(5-metil-2-oxo-1,2-dihidropiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Se calentó el EJEMPLO 192 (50 mg) en ácido acético (10 ml) y agua (1 ml) a 100 °C durante 16 horas. Los solventes se eliminaron, y el residuo se purificó por HPLC en fase reversa (RP) para dar el compuesto del título. ^{1}H RMN (500 MHz, DMSO-d_6): □ 13,04 (ancho, 1H), 11,73 (ancho, 1H), 11,16 (s, 1H), 8,23- 8,25 (m, 1H), 7,86-7,88 (m, 1H), 7,72 (d, J = 6,1 Hz, 1H), 7,50-7,55 (m, 2H), 7,45-7,46 (m, 1H), 7,39 (t, J = 7,93 Hz, 1H), 7,32 (s, 1H), 7,04-7,08 (m, 2H), 6,90 (d, J = 7,32 Hz, 1H), 6,24 (s, 1H), 4,20 (t, J = 5,95 Hz, 2H), 3,36 (t, J = 7,32 Hz, 2H), 2,20-2,25 (m, 2H), 1,71 (s, 3H).

EJEMPLO 195

ácido 7-(5-metil-2-(2-pirrolidin-1-iletoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-

carboxílico

Se trató 2-(pirrolidin-1-il)etanol (36,9 mg) en dioxano (2 ml) en un vial de 4 ml con NaH 60% (12,8 mg) a temperatura ambiente. Después de haber cesado el burbujeo, se agregó el EJEMPLO 192 (50 mg) a la solución. El vial se tapó y se calentó a 105 °C durante 3 horas. El solvente se eliminó , y el residuo se purificó por RP HPLC para dar el compuesto del título. ^{1}H RMN (500 MHz, DMSO-d_6): □ 11,00 (s, 1H), 11,16 (s, 1H), 9,78 (s, 1H), 8,23- 8,25 (m, 1H), 8,12 (s, 1H), 7,86-7,88 (m, 1H), 7,76 (d, J = 7,32 Hz, 1H), 7,50-7,55 (m, 2H), 7,45-7,47 (m, 1H), 7,39 (t, J = 7,93 Hz, 1H), 7,06-7,12 (m, 2H), 6,90 (d, J = 7,63 Hz, 1H), 6,76 (s, 1H), 4,58 (s, 2H), 4,20 (t, J = 5,95 Hz, 2H), 3,60-3,61 (m, 4H), 3,36 (t, J = 7,32 Hz, 2H), 3,13 (ancho, 2H), 2,20-2,25 (m, 2H), 1,97-2,01 (m, 5H), 1,87-1,91 (m, 2H).

EJEMPLO 196

ácido 7-(2-(dimetilamino)-5-nitropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,07 (s, 1H), 11,00 (s, 1H), 11,32 (s, 1H), 9,04 (d, J = 2,44 Hz, 1H), 8,21- 8,23 (m, 1H), 8,00 (d, J = 2,75 Hz, 1H), 7,86-7,87 (m, 1H), 7,74 (d, J = 7,63 Hz, 1H), 7,49-7,55 (m, 2H), 7,44-7,46 (m, 1H), 7,38 (t, J = 7,78 Hz, 1H), 7,11-7,13 (m, 1H), 7,04-7,08 (m, 1H), 6,88 (d, J = 7,63 Hz, 1H), 4,19 (t, J = 5,95 Hz, 2H), 3,36 (t, J = 7,32 Hz, 2H), 2,75 (s, 6H), 2,21-2,27 (m, 2H).

EJEMPLO 197

ácido 7-(2-(2-(dimetilamino)etoxi)-5-metilpiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,93 (ancho, 1H), 11,01 (s, 1H), 9,69 (s, 1H), 8,23- 8,25 (m, 1H), 8,12 (s, 1H), 7,86-7,88 (m, 1H), 7,76 (d, J = 7,32 Hz, 1H), 7,45-7,55 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,06-7,12 (m, 2H), 6,90 (d, J = 7,63 Hz, 1H), 6,74 (s, 1H), 4,60 (ancho, 2H), 4,20 (t, J = 6,1 Hz, 2H), 3,60 (ancho, 2H), 3,36 (t, J = 7,32 Hz, 2H), 2,88 (s, 6H), 2,21-2,26 (m, 2H), 1,97 (s, 3H).

EJEMPLO 198

ácido 7-(5-metil-2-(2-morfolin-4-iletoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,00 (s, 1H), 10,24 (s, 1H), 8,24- 8,26 (m, 1H), 8,13 (s, 1H), 7,86-7,88 (m, 1H), 7,76 (d, J = 6,71 Hz, 1H), 7,45-7,55 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,06-7,12 (m, 2H), 6,90 (d, J = 7,32 Hz, 1H), 6,77 (s, 1H), 4,64 (ancho, 2H), 4,20 (t, J = 6,1 Hz, 2H), 3,97 (ancho, 2H), 3,72 (ancho, 2H), 3,60 (t, J = 4,88 Hz, 2H), 3,60 (ancho, 2H), 3,37 (t, J = 7,32 Hz, 2H), 3,22 (ancho, 2H), 2,21-2,26 (m, 2H), 1,98 (s, 3H).

EJEMPLO 199

ácido 7-(2-(1,4-dioxa-8-azaespiro(4,5)dec-8-il)-5-nitropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,02 (s, 1H), 11,25 (s, 1H), 9,07 (d, J = 2,75 Hz, 1H), 8,22- 8,24 (m, 1H), 8,13 (d, J = 2,75 Hz, 1H), 7,85-7,87 (m, 1H), 7,76 (d, J = 7,93 Hz, 1H), 7,44-7,54 (m, 3H), 7,37 (t, J = 7,78 Hz, 1H), 7,29 (d, J = 7,32 Hz, 1H), 7,09-7,12 (m

1H), 6,85 (d, J = 7,32 Hz, 1H), 4,17 (t, J = 6,1 Hz, 2H), 3,72 (s, 4H), 3,37 (m, 2H), 3,14 (ancho, 2H), 2,21-2,26 (m, 2H), 1,35 (ancho, 2H), 1,10 (ancho, 2H).

EJEMPLO 200

ácido 3-(3-(1-naftiloxi)propil)-7-(5-nitro-2-(4-oxopiperidin-1-il)piridin-3-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,39 (s, 1H), 9,12 (d, J = 2,75 Hz, 1H), 8,22-8,24 (m, 1H), 8,17 (d, J = 2,75 Hz, 1H), 7,85-7,87 (m, 1H), 7,78 (d, J = 7,93 Hz, 1H), 7,44-7,54 (m, 3H), 7,37 (t, J = 7,93 Hz, 1H), 7,31 (d, J = 6,41 Hz, 1H), 7,09-7,12 (m 1H), 6,86 (d, J = 7,32 Hz, 1H), 4,17 (t, J = 6,1 Hz, 2H), 3,61 (ancho, 2H), 3,37 (m, 2H), 2,17-2,26 (m, 4H), 1,93 (ancho, 2H).

EJEMPLO 201

ácido 7-(5-amino-2-(dimetilamino)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,15 (ancho, 1H), 8,24- 8,26 (m, 1H), 7,86-7,88 (m, 1H), 7,78 (d, J = 7,93 Hz, 1H), 7,44-7,54 (m, 3H), 7,38 (t, J = 7,93 Hz, 1H), 7,22 (d, J = 7,02 Hz, 1H), 7,08-7,12 (m 1H), 6,88 (d, J = 7,02 Hz, 1H), 4,18 (t, J = 6,1 Hz, 2H), 3,37 (m, 2H), 2,57 (ancho, 6H), 2,21-2,27 (m, 2H).

EJEMPLO 202

ácido 7-(2-(4-hidroxipiperidin-1-il)-5-nitropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,00 (s, 1H), 11,19 (ancho, 1H), 9,05 (d, J = 2,44 Hz, 1H), 8,23- 8,25 (m, 1H), 8,09 (d, J = 2,45 Hz, 1H), 7,86-7,88 (m, 1H), 7,75 (d, J = 7,93 Hz, 1H), 7,44-7,54 (m, 3H), 7,37 (t, J = 7,78 Hz, 1H), 7,25 (d, J = 6,41 Hz, 1H), 7,06-7,10 (m 1H), 6,86 (d, J = 7,32 Hz, 1H), 4,17 (t, J = 6,1 Hz, 2H), 3,75 (ancho, 6H), 3,49-3,52 (m, 1H), 3,40 (ancho, 2H) 2,90 (ancho, 2H), 2,21-2,27 (m, 2H).

EJEMPLO 203

ácido 7-(6-metoxi-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,05 (s, 1H), 8,24- 8,26 (m, 1H), 7,94 (d, J = 2,45 Hz, 1H), 7,86-7,88 (m, 1H), 7,71 (d, J = 7,63 Hz, 1H), 7,45-7,55 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,03-7,09 (m, 2H), 6,91 (d, J = 7,63 Hz, 1H), 6,80 (s, 1H), 4,20 (t, J = 6,1 Hz, 2H), 3,90 (s, 3H), 3,35(m, 2H), 2,21-2,27 (m, 2H), 2,00 (s, 3H).

EJEMPLO 204

ácido 7-(2-fluoro-5-metilpiridin-4-il)-1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 8,22- 8,24 (m, 1H), 7,87-7,91 (m, 2H), 7,46-7,56 (m, 3H), 7,39-7,42 (m, 2H), 7,19-7,22 (m, 1H), 7,08 (d, J = 6,41 Hz, 1H), 6,91 (d, J = 7,32 Hz, 1H), 4,77 (ancho, 1H), 4,23 (t, J = 5,95 Hz, 2H), 3,91 (ancho, 1H), 3,36-3,39 (m, 2H), 2,80 (ancho, 4H), 2,20-2,26 (m, 2H), 1,94 (s, 3H).

EJEMPLO 205

ácido 3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,56 (s, 1H), 8,24- 8,26 (m, 1H), 7,86-7,88 (m,

1H), 7,66 (d, J = 7,32 Hz, 1H), 7,46-7,55 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,02-7,07 (m, 2H), 6,91 (d, J = 7,32 Hz, 1H), 4,21 (t, J = 6,1 Hz, 2H), 3,75 (s, 3H), 3,34-3,37 (m, 2H), 2,21-2,26 (m, 2H), 2,05 (s, 3H), 2,01 (s, 3H).

EJEMPLO 206

ácido 7-((2-morfolin-4-ilpiridin-3-il)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,05 (ancho, 1H), 11,14 (s, 1H), 8,22- 8,24 (m, 1H), 7,92 (d, J = 3,66 Hz, 1H), 7,86-7,87 (m, 1H), 7,44-7,56 (m, 5H), 7,38 (t, J = 7,93 Hz, 1H), 7,24 (d, J = 7,93 Hz, 1H), 7,00 (dd, J = 7,78, 5,03 Hz, 1H), 6,85-6,88 (m, 2H), 6,74 (d, J = 7,32 Hz, 1H), 4,18 (t, J = 5,95 Hz, 2H), 3,63-3,64 (m, 4H), 3,33 (t, J = 7,32 Hz, 2H), 3,23 (m, 4H), 2,20-2,24 (m, 2H).

EJEMPLO 207

ácido 7-(5-metil-2-(2-feniletoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,98 (s, 1H), 8,17 (d, J = 7,63 Hz, 1H), 8,02 (s, 1H), 7,90 (d, J = 7,02 Hz, 1H), 7,67 (d, J = 7,02 Hz, 1H), 7,22-7,47 (m, 8H), 7,15 (t, J = 6,41 Hz, 1H), 6,98-7,03 (m, 2H), 6,83 (d, J = 7,32 Hz, 1H), 6,59 (s, 1H), 4,42 (t, J = 6,41 Hz, 2H), 4,13 (t, J = 5,64 Hz, 2H), 3,28-3,31 (m, 2H), 2,99 (t, J = 6,71 Hz, 2H), 2,20-2,24 (m, 2H), 1,86 (s, 3H).

EJEMPLO 208

ácido 7-(5-metil-2-(2-piridin-3-iletoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,98 (s, 1H), 8,17 (d, J = 7,63 Hz, 1H), 8,02 (s, 1H), 7,90 (d, J = 7,02 Hz, 1H), 7,68 (d, J = 7,02 Hz, 1H), 7,22-7,47 (m, 7H), 7,14 (t, J = 6,41 Hz, 1H), 6,98-7,03 (m, 2H), 6,82 (d, J = 7,32 Hz, 1H), 6,59 (s, 1H), 4,42 (t, J = 6,41 Hz, 2H), 4,13 (t, J = 5,64 Hz, 2H), 3,28-3,31 (m, 2H), 2,99 (t, J = 6,71 Hz, 2H), 2,20-2,24 (m, 2H), 1,86 (s, 3H).

EJEMPLO 209

ácido 7-((2-morfolin-4-ilfenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,50 (s, 1H), 8,17 (s, 1H), 7,79 (s, 1H), 6,75-7,45(m, 12H), 4,41 (ancho, 2H), 2,81 (ancho, 4H), 2,44 (m, 5H), 2,15 (ancho, 2H).

EJEMPLO 210

ácido 7-((4-carboxipiridin-3-il)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,53 (ancho, 1H), 13,04 (ancho, 1H), 11,68 (s, 1H), 8,87 (s, 1H), 8,23 (s, 1H), 8,20-8,22 (m, 1H), 8,00 (d, J = 4,88 Hz, 1H), 7,85-7,87 (m, 1H), 7,69 (d, J = 5,19 Hz, 1H), 7,44-7,54 (m, 4H), 7,38 (t, J = 7,93 Hz, 1H), 7,17 (d, J = 7,32 Hz, 1H), 6,98 (t, J = 7,78 Hz, 1H), 6,89 (d, J = 7,32 Hz, 1H), 4,19 (t, J = 6,41 Hz, 2H), 3,34-3,37 (m, 2H), 2,20-2,25 (m, 2H).

EJEMPLO 211

ácido 3-(3-(1-naftiloxi)propil)-7-((4-(trifluorometil)piridin-3-il)amino)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,11 (ancho, 1H), 11,59 (s, 1H), 8,55 (s, 1H), 8,37 (d, J = 5,19 Hz, 1H), 8,21-8,23 (m, 1H), 7,85-7,87 (m, 1H), 7,68 (d, J = 5,19 Hz, 1H),

7,66 (s,1 H), 7,44-7,54 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,33 (d, J = 7,93 Hz, 1H), 6,86-6,90 (m, 2H), 6,73 (d, J = 7,32 Hz, 1H), 4,19 (t, J = 6,1 Hz, 2H), 3,34-3,37 (m, 2H), 2,20-2,25 (m, 2H).

EJEMPLO 212

ácido 7-(2-(3-aminopropoxi)-5-metilpiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,01 (s, 1H), 8,23-8,25 (m, 1H), 8,08 (s, 1H), 7,86-7,88 (m, 1H), 7,74-7,76 (m, 4H), 7,45-7,55 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,05-7,11 (m, 2H), 6,90 (d, J = 7,32 Hz, 1H), 6,68 (s, 1H), 4,35 (t, J = 6,1 Hz, 2H), 4,20 (t, J = 6,1 Hz, 2H), 3,37 (t, J = 7,48 Hz, 2H), 2,94-3,01 (m, 2H), 2,52 (m, 2H), 2,20-2,26 (m, 2H), 2,00-2,06 (m, 2H), 1,95 (s, 3H).

EJEMPLO 213

ácido 7-(5-metil-2-(tetrahidrofuran-3-ilmetoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,07 (s, 1H), 8,24 (d, J = 7,32 Hz, 1H), 8,07 (s, 1H), 7,86-7,88 (m, 1H), 7,74 (d, J = 7,32 Hz, 1H), 7,45-7,54 (m, 3H), 7,39 (t, J = 7,78 Hz, 1H), 7,05-7,10 (m, 2H), 6,90 (d, J = 7,32 Hz, 1H), 6,67 (s, 1H), 4,16-4,27 (m, 2H), 3,75-3,80 (m, 2H), 3,67 (q, J = 7,83 Hz, 1H), 3,55 (dd, J = 8,54, 5,49 Hz, 1H), 3,36 (t, J = 7,32 Hz, 2H), 2,67-2,71 (m, 1H), 2,21-2,26 (m, 2H), 1,99-2,04 (m, 1H), 1,93 (s, 3H), 1,64-1,70 (m, 1H).

EJEMPLO 214

ácido 7-(5-metil-2-(4-fenilbutoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,96 (s, 1H), 11,05 (s, 1H), 8,23-8,25 (m, 1H), 8,05 (s, 1H), 7,86-7,87 (m, 1H), 7,73 (d, J = 7,02 Hz, 1H), 7,45-7,54 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,15-7,29 (m, 5H), 7,04-7,09 (m, 2H), 6,90 (d, J = 7,63 Hz, 1H), 6,63 (s, 1H), 4,29 (t, J = 5,95 Hz, 2H), 4,20 (t, J = 5,95 Hz, 2H), 3,36 (t, J = 7,32 Hz, 2H), 2,65 (d, J = 6,87 Hz, 1H), 2,21-2,26 (m, 2H), 1,92 (s, 3H), 1,70-1,78 (m, 4H).

EJEMPLO 215

ácido 7-(2-(3-metoxifenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,92 (s, 1H), 10,74 (s, 1H), 8,23-8,25 (m, 1H), 7,85-7,87 (m, 1H), 7,48-7,54 (m, 2H), 7,36-7,45 (m, 3H), 6,78-6,89 (m, 4H), 6,61 (d, J = 7,63 Hz, 1H), 6,58 (d, J = 7,63 Hz, 1H), 6,44 (dd, J = 8,24, 1,83 Hz, 1H), 4,11 (t, J = 6,1 Hz, 2H), 3,34 (s, 3H), 3,25 (t, J = 7,32 Hz, 2H), 2,23-2,45 (m, 4H), 2,11-2,17 (m, 2H), 1,86 (m, 4H).

EJEMPLO 216

ácido 7-(1-(carboximetil)-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,98 (s, 1H), 10,32 (s, 1H), 8,24-8,26 (m, 1H), 7,86-7,88 (m, 1H), 7,66 (dd, J = 7,32, 1,83 Hz, 1H), 7,45-7,55 (m, 3H), 7,39 (d, J = 7,93 Hz, 1H), 7,05-7,09 (m, 2H), 6,91 (d, J = 7,32 Hz, 1H), 4,88 (s, 2H), 4,21 (t, J = 6,1 Hz,

2H), 3,34-3,37 (m, 2H), 2,21-2,26 (m, 2H), 2,03 (s, 3H), 2,01 (s, 3H).

EJEMPLO 217

ácido 7-(1-bencil-1H-imidazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,23 (s, 1H), 11,54 (s, 1H), 9,35 (s, 1H), 8,24-8,26 (m, 1H), 7,83-7,88 (m, 3H), 7,60-7,64 (m, 1H), 7,45-7,57 (m, 4H), 7,38 (d, J = 7,93 Hz, 1H), 7,14-7,20 (m, 3H), 7,04-7,05 (m, 1H), 6,97-7,01 (m, 1H), 6,85-6,89 (m, 3H), 5,14 (s, 2H), 4,17 (t, J = 6,1 Hz, 2H), 3,37 (t, J = 7,32 Hz, 2H), 2,20-2,26 (m, 2H).

EJEMPLO 218

ácido 7-(2-(2-metilfenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,94 (s, 1H), 10,91&10,68 (s, 1H), 8,20-8,24 (m, 1H), 7,85-7,86 (m, 1H), 7,33-7,45 (m, 5H), 6,70-7,06 (m, 7H), 4,10-4,13 (m, 2H), 3,21-3,25 (m, 2H), 2,24-2,44 (m, 4H), 2,21-2,26 (m, 5H), 1,87 (ancho, 4H).

EJEMPLO 219

ácido 7-(3,5-dimetil-1-(2-morfolin-4-iletil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,98 (s, 1H), 10,46 (s, 1H), 8,24-8,26 (m, 1H), 7,86-7,88 (m, 1H), 7,67 (d, J = 7,63 Hz, 1H), 7,45-7,55 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,08 (t, J = 7,48 Hz, 1H), 7,03-7,04 (m, 1H), 6,91 (d, J = 7,63 Hz, 1H), 4,42 (t, J = 6,87 Hz, 2H), 4,21 (t, J = 6,1 Hz, 2H), 3,87 (ancho, 4H), 3,61 (t, J = 6,87 Hz, 2H), 3,34-3,37 (m, 2H), 2,21-2,26 (m, 2H), 2,09 (s, 3H), 2,04 (s, 3H).

EJEMPLO 221

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-nitrofenil)ciclohex-1-en-1-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,04(s, 1H), 8,21-8,22 (m, 1H), 7,81-7,85 (m, 3H), 7,40-7,52 (m, 4H), 7,32-7,35 (m, 1H), 7,25 (d, J = 8,85 Hz, 2H), 6,81 (d, J = 7,63 Hz, 2H), 6,73-6,75 (m, 2H), 4,08 (t, J = 5,95 Hz, 2H), 3,23 (ancho, 2H), 2,45 (ancho, 2H), 210-2,15 (m, 2H), 1,87 (ancho, 4H).

EJEMPLO 222

ácido 7-(4,4-dimetil-2-fenilciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,97 (s, 1H), 10,58 (s, 1H), 8,22-8,24 (m, 1H), 7,85-7,87 (m, 1H), 7,35-7,54 (m, 5H), 6,89-7,00 (m, 5H), 6,84 (d, J = 7,63 Hz, 2H), 6,77 (d, J = 4,27 Hz, 2H), 4,11 (t, J = 6,1 Hz, 2H), 3,25 (t, J = 7,32 Hz, 2H), 2,37 (ancho, 2H), 2,25 (ancho, 2H), 2,12-2,17 (m, 2H), 1,64 (ancho, 2H), 1,09 (s, 6H).

EJEMPLO 223

ácido 1-etil-7-(etil(fenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

EJEMPLO 223A

1-etil-7-(etil(fenil)amino)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo

Se trató el EJEMPLO 224 (139 mg) en N,N-dimetilformamida (2 ml) con NaH 60% (36 mg, 0,9 mmol) a temperatura ambiente. Después de haber cesado el burbujeo, se agregó iodometano (140 mg, 0,9 mmol). La reacción se agitó durante 3 horas. La mezcla de reacción se particionó entre agua y acetato de etilo. La fase orgánica se separó, y la

fase acuosa se extrajo con más acetato de etilo. Las fases orgánicas combinadas se lavaron con salmuera, se secó sobre $MgSO_4$, se filtró, y se concentró al vacío. El residuo se purificó por cromatografía flash sobre gel de sílice (acetato de etilo en hexanos) para dar el EJEMPLO 223A.

EJEMPLO 223B

ácido 1-etil-7-(etil(fenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

El compuesto del título se sintetizó como se describe en el EJEMPLO 175B, utilizando el EJEMPLO 223A en lugar del EJEMPLO 175A. ^{1}H RMN (500 MHz, DMSO-d_6): □ 13,20 (s, 1H), 8,22-8,24 (m, 1H), 7,86-7,88 (m, 1H), 7,72 (dd, J = 7,17, 1,98 Hz, 1H), 7,45-7,55 (m, 3H), 7,40 (t, J = 7,78 Hz, 1H), 7,08-7,14 (m, 4H), 6,91 (d, J = 7,32 Hz, 1H), 6,64 (t, J = 7,32 Hz, 1H), 6,53 (d, J = 8,24 Hz, 2H), 4,48-4,62 (m, 2H), 4,22 (t, J = 6,1 Hz, 2H), 3,88-3,95 (m, 1H), 3,44-3,51 (m, 1H), 2,19-2,24 (m, 2H), 1,18 (t, J = 7,02 Hz, 3H), 0,94 (t, J = 6,87 Hz, 3H).

EJEMPLO 224

ácido 7-anilino-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,07 (s, 1H), 11,22 (s, 1H), 8,22-8,24 (m, 1H), 8,06 (s, 1H), 7,85-7,87 (m, 1H), 7,44-7,54 (m, 3H), 7,38 (t, J = 7,93 Hz, 1H), 7,27-7,30 (m, 2H), 7,18-7,20 (m, 3H), 7,09 (d, J = 7,32 Hz, 1H), 6,86-6,90 (m, 3H), 4,18 (t, J = 5,95 Hz, 2H), 3,32 (m, 2H), 2,19-2,24 (m, 2H).

EJEMPLO 225

ácido 7-(5-metil-2-(tetrahidro-2H-piran-3-ilmetoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,95 (s, 1H), 11,07 (s, 1H), 8,23-8,25 (m, 1H), 8,06 (s, 1H), 7,86-7,88 (m, 1H), 7,74 (d, J = 6,71 Hz, 1H), 7,45-7,54 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,05-7,11 (m, 2H), 7,18-7,20 (m, 3H), 7,09 (d, J = 7,32 Hz, 1H), 6,90 (d, J = 7,32 Hz, 1H), 6,65 (s, 1H), 4,09-4,21 (m, 4H), 3,87-3,90 (m, 2H), 3,73-3,75 (m, 2H), 3,24-3,37 (m, 4H), 2,21-2,26 (m, 2H), 2,01-2,05 (m, 1H), 1,93 (s, 3H), 1,93-1,95 (m, 1H), 1,59-1,60 (m, 1H), 1,51-1,53 (m, 1H), 1,36-1,39 (m 1H).

EJEMPLO 226

ácido 7-(5-metil-2-(2-(2-oxopirrolidin-1-il)etoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,03 (ancho, 1H), 11,06 (s, 1H), 8,23-8,25 (m, 1H), 8,09 (s, 1H), 7,86-7,88 (m, 1H), 7,74 (dd, J = 7,17, 1,68 Hz, 1H), 7,45-7,54 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,06-7,10 (m, 2H), 6,90 (d, J = 7,32 Hz, 1H), 6,68 (s, 1H), 4,38 (t, J = 5,49 Hz, 2H), 4,20 (t, J = 6,1 Hz, 2H), 3,56 (t, J = 5,64 Hz, 2H), 3,46 (t, J = 7,02 Hz, 2H), 3,37 (t, J = 7,48 Hz, 2H), 2,19-2,25 (m, 4H), 1,89-1,95 (m, 5H).

EJEMPLO 227

ácido 7-(5-metil-2-(2-(4-metilpiperazin-1-il)etoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,01 (s, 1H), 8,24-8,25 (m, 1H), 8,09 (s, 1H),

7,86-7,88 (m, 1H), 7,75 (d, J = 7,63 Hz, 1H), 7,45-7,54 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,05-7,11 (m, 2H), 6,90 (d, J = 7,32 Hz, 1H), 6,69 (s, 1H), 4,47 (s, 2H), 4,20 (t, J = 6,1 Hz, 2H), 3,77 (ancho, 8H), 3,35-3,38 (m, 2H), 3,09 (m, 2H), 2,78 (s, 3H), 2,21-2,26 (m, 2H), 1,96 (s, 3H).

EJEMPLO 228

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(2-oxociclohexil)piridin-3-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,13 (s, 1H), 8,72-8,73 (m, 1H), 8,24-8,26 (m, 1H), 7,86-7,88 (m, 2H), 7,76 (d, J = 8,24 Hz, 1H), 7,45-7,54 (m, 4H), 7,37-7,41 (m, 1H), 7,05 (t, J = 7,48 Hz, 1H), 6,87-6,91(m, 2H), 4,20 (t, J = 5,8 Hz, 2H), 3,30-3,55 (ancho, 6H), 1,40-2,24 (m, 7H),

EJEMPLO 229

ácido 7-(2-fluoro-5-metilpiridin-4-il)-1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 9,37 (s, 1H), 8,19-8,21 (m, 2H), 7,87 (t, J = 7,02 Hz, 1H), 7,45-7,56 (m, 4H), 7,40 (t, J = 7,93 Hz, 1H), 7,32 (d, J = 1,83 Hz, 1H), 7,15-7,18 (m 1H), 7,04 (d, J = 6,1 Hz, 1H), 6,90 (d, J = 7,32 Hz, 1H), 4,46-4,50 (m, 1H), 4,21 (t, J = 6,1 Hz, 2H), 3,59-3,61 (m, 1H), 2,75 (ancho, 2H), 2,71 (s, 3H), 2,09-2,25 (m, 6H), 1,95 (s, 3H),

EJEMPLO 230

ácido 7-(5,5-dimetil-2-fenilciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,95 (s, 1H), 10,24 (s, 1H), 8,21-8,23 (m, 2H), 7,85-7,86 (m, 1H), 7,35-7,54 (m, 5H), 7,01-7,03 (m, 2H), 6,95 (t, J = 7,48 Hz, 1H), 6,88-6,91 (m 1H), 6,83 (d, J = 7,02 Hz, 1H), 6,80-6,81 (m, 2H), 4,10 (t, J = 6,1 Hz, 2H), 3,22-3,25 (m, 2H), 2,11-2,25 (m, 6H), 1,6 (ancho, 2H), 1,06 (s, 6H).

EJEMPLO 231

ácido 3-(3-(1-naftiloxi)propil)-7-(piridin-3-ilamino)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,18 (s, 1H), 11,27 (s, 1H), 8,67 (s, 1H), 8,36 (d, J = 2,44 Hz, 1H), 8,21-8,23 (m, 1H), 8,17 (d, J = 4,58 Hz, 1H), 7,86-7,87 (m, 1H), 7,77 (dd, J = 8,54, 1,83 Hz, 1H), 7,61 (dd, J = 8,54, 5,19 Hz, 1H), 7,43-7,54 (m, 4H), 7,39 (t, J = 7,78 Hz, 1H), 7,20 (d, J = 7,32 Hz, 1H), 7,00 (t, J = 7,78 Hz, 1H), 6,89 (d, J = 7,32 Hz, 1H), 4,18 (t, J = 6,1 Hz, 2H), 3,24 (t, J = 7,32 Hz, 2H), 2,20-2,25 (m, 2H).

EJEMPLO 232

ácido 3-(3-(1-naftiloxi)propil)-7-(fenil(propil)amino)-1-propil-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,20 (s, 1H), 8,22 (d, J = 7,63 Hz, 1H), 7,87 (d, J = 7,02 Hz, 1H), 7,70-7,72 (m, 1H), 7,45-7,54 (m, 3H), 7,08-7,13 (m, 4H), 6,90 (d, J = 7,63 Hz, 1H), 6,64 (t, J = 7,17 Hz, 1H), 6,53 (d, J = 7,93 Hz, 2H), 4,44-4,50 (m, 1H), 4,32-4,37 (m, 1H), 4,21 (t, J = 5,95 Hz, 2H), 3,76-3,82 (m, 1H), 2,19-2,23 (m, 2H), 1,74 (m, 1H), 1,58-1,60 (m, 1H), 1,38-1,40 (m, 1H), 1,18-1,23 (m, 1H), 0,88 (t, J = 7,32 Hz, 3H), 0,45 (t, J = 7,17 Hz, 3H).

EJEMPLO 233

ácido 7-(3-ciclohex-1-en-1-ilpiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,21 (s, 1H), 11,12 (s, 1H), 8,76 (d, J = 5,19 Hz, 1H), 8,27-8,29 (m, 1H), 8,15 (s, 1H), 7,85-7,88 (m, 2H), 7,78 (s, 1H), 7,45-7,55 (m, 4H), 7,38 (t, J = 7,93 Hz, 1H), 7,11 (t, J = 7,63 Hz, 1H), 6,86 (d, J = 7,63 Hz, 1H), 5,72 (s, 1H), 4,44-4,50 (m, 1H), 4,16 (t, J = 6,1 Hz, 2H), 3,40 (t, J = 7,32 Hz, 2H), 2,22-2,27 (m, 2H), 1,92 (ancho, 2H), 1,82 (ancho, 2H), 1,34-1,35 (m, 4H).

EJEMPLO 234

ácido 3-(3-(1-naftiloxi)propil)-7-(2-piridin-3-ilciclohex-1-en-1-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,07 (s, 1H), 8,33-8,35 (m, 2H), 8,22-8,23 (m, 1H), 7,93 (d, J = 7,93 Hz, 1H), 7,85-7,87 (m, 1H), 7,44-7,54 (m, 5H), 7,38 (t, J = 7,78 Hz, 1H), 6,89-6,90 (m, 1H), 6,82-6,86 (m, 2H), 4,11 (t, J = 6,1 Hz, 2H), 3,27 (ancho, 2H), 2,10-2,16 (m, 2H), 1,91 (ancho, 4H).

EJEMPLO 235

ácido 3-(3-((8-cloroquinazolin-4-il)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,95 (s, 1H), 10,48 (s, 1H), 8,85 (s, 1H), 8,13 (dd, J = 7,63, 1,22 Hz, 1H), 8,10 (dd, J = 8,24, 1,22 Hz, 1H), 7,70 (d, J = 7,93 Hz, 1H), 7,64 (t, J = 7,93 Hz, 1H), 7,25-7,34 (m, 3H), 7,19 (d, J = 7,32 Hz, 1H), 7,07-7,10 (m, 1H), 7,02-7,02 (m, 1H), 4,60 (t, J = 6,1 Hz, 2H), 3,34 (t, J = 7,02 Hz, 2H), 2,23-2,29 (m, 2H), 2,04 (s, 3H).

EJEMPLO 236

ácido 1-butil-7-(butil(fenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 8,21 (d, J = 7,67 Hz, 1H), 7,86 (d, J = 7,67 Hz, 1H), 7,69-7,71 (m, 1H), 7,36-7,55 (m, 4H), 7,09-7,13 (m, 4H), 6,89 (d, J = 7,67 Hz, 1H), 6,63 (t, J = 7,06 Hz, 1H), 6,52 (d, J = 7,98 Hz, 2H), 4,49-4,53 (m, 1H), 4,37 (m, 1H), 4,21 (t, J = 5,52 Hz, 2H), 3,61 (m, 1H), 2,17-2,25 (m, 2H), 0,78-1,72 (m, 9H), 0,54 (t, J = 7,36 Hz, 3H).

EJEMPLO 237

ácido 3-(3-(7-cloro-1H-pirrolo(2,3-c)piridin-1-il)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,46 (s, 1H), 7,87 (d, J = 5,22 Hz, 1H), 7,78 (d, J = 3,07 Hz, 1H), 7,54-7,57 (m, 2H), 7,20-7,33 (m, 4H), 7,10-7,13 (m, 1H), 7,03-7,05 (m, 1H), 6,62 (d, J = 3,07 Hz, 1H), 4,57-4,61 (m, 2H), 3,16 (t, J = 7,36 Hz, 2H), 2,12-2,20 (m, 2H), 2,06 (s, 3H).

EJEMPLO 238

ácido 7-(3-ciclohexilpiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,27 (s, 1H), 8,70 (d, J = 4,91 Hz, 1H), 8,41 (s, 1H), 8,28-8,30 (m, 1H), 7,86-7,91 (m, 3H), 7,45-7,57 (m, 3H), 7,39 (t, J = 7,98 Hz, 1H), 7,29 (d, J = 7,06 Hz, 1H), 7,16-7,18 (m, 1H), 6,89 (d, J = 7,36 Hz, 1H), 4,20 (t, J = 6,14 Hz, 2H), 3,39-3,42 (m, 2H), 2,46 (m, 2H), 2,21-2,28 (m, 2H), 0,91-1,78 (m, 10H).

EJEMPLO 239

ácido 3-(3-(1-naftiloxi)propil)-7-(1-(1,3-tiazol-5-ilmetil)-1H-pirrolo(2,3-c)piridin-3-il)-1H-

indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,14 (s, 1H), 10,95 (s, 1H), 9,61 (s, 1H), 9,10 (s, 1H), 8,78 (s, 1H), 8,38 (d, J = 6,41 Hz, 1H), 8,22-8,24 (m, 1H), 8,15 (s, 1H), 7,93 (t, J = 6,41 Hz, 1H), 7,86-7,88 (m, 1H), 7,78 (d, J= 7,93 Hz, 1H), 7,35-7,54 (m, 5H), 7,12-7,16 (m, 1H), 6,90 (d, J = 7,63 Hz, 1H), 6,12 (s, 2H), 4,21 (t, J = 5,95 Hz, 2H), 3,40 (t, J = 7,32 Hz, 2H), 2,23-2,28 (m, 2H).

EJEMPLO 240

ácido 7-(1-(3,3-dimetil-2-oxobutil)-1H-pirrolo(2,3-c)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,14 (s, 1H), 10,74 (s, 1H), 9,18 (s, 1H), 8,39 (s, 1H), 8,34 (d, J = 6,1 Hz, 1H), 8,22-8,24 (m, 1H), 7,93 (d, J = 6,1 Hz, 1H), 7,86-7,88 (m, 1H), 7,76 (d, J= 8,24 Hz, 1H), 7,35-7,53 (m, 5H), 7,14-7,18 (m, 1H), 6,90 (d, J = 7,32 Hz, 1H), 5,81 (s, 2H), 4,21 (t, J = 5,95 Hz, 2H), 3,39-3,41 (m, 2H), 2,23-2,28 (m, 2H), 1,30 (s, 9H).

EJEMPLO 241

ácido 7-(4-ciclohex-1-en-1-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,07 (s, 1H), 11,09 (s, 1H), 8,76-8,78 (m, 2H), 8,26-8,28 (m, 1H), 7,86-7,88 (m, 1H), 7,78 (d, J= 7,93 Hz, 1H), 7,74 (d, J = 5,8 Hz, 1H), 7,36-7,56 (m, 5H), 7,14 (d, J = 6,1 Hz, 1H), 7,06-7,09 (m, 1H), 6,84-6,85 (m, 1H), 5,76 (s, 1H), 4,15 (t, J = 6,1 Hz, 2H), 3,38 (t, J = 7,32 Hz, 2H), 2,21-2,27 (m, 2H), 1,76-1,85 (m, 4H), 1,25-1,26 (m, 4H).

EJEMPLO 242

ácido 7-(1-(3,5-difluorobencil)-1H-pirrolo(2,3-c)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,95 (s, 1H), 9,46 (s, 1H), 8,75 (s, 1H), 8,36 (d, J = 6,41 Hz, 1H), 8,23-8,25 (m, 1H), 7,91 (d, J = 6,41 Hz, 1H), 7,86-7,88 (m, 1H), 7,78 (d, J= 8,24 Hz, 1H), 7,37-7,54 (m, 5H), 7,13-7,25 (m, 4H), 6,90 (d, J = 7,63 Hz, 1H), 5,83 (s, 2H), 4,21 (t, J = 6,1 Hz, 2H), 3,39-3,41(m, 2H), 2,24-2,29 (m, 2H).

EJEMPLO 243

ácido 3-(3-(1-naftiloxi)propil)-7-(1-fenilvinil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,03 (s, 1H), 9,82 (s, 1H), 8,22-8,24 (m, 1H), 7,91 (d, J = 6,41 Hz, 1H), 7,86-7,88 (m, 1H), 7,45-7,55 (m, 3H), 7,30-7,40 (m, 6H), 7,09-7,11 (m, 1H), 7,04-7,07 (m, 1H), 6,90 (d, J = 7,32 Hz, 1H), 5,85 (s, 1H), 5,51 (s, 1H), 4,19 (t, J = 6,1 Hz, 2H), 3,34-3,36 (m, 2H), 2,20-2,25 (m, 2H).

EJEMPLO 244

ácido 3-(3-(1-naftiloxi)propil)-7-(1H-pirrolo(2,3-c)piridin-7-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,58 (s, 1H), 11,65 (s, 1H), 8,31-8,32 (m, 2H), 8,13-8,16 (m, 2H), 8,04 (d, J = 7,93 Hz, 1H), 7,88-7,90 (m, 1H), 7,63 (d, J= 7,62 Hz, 1H), 7,45-7,57 (m, 3H), 7,39-7,43 (m 1H), 7,26-7,29 (m, 1H), 7,03 (s, 1H), 6,92 (d, J = 7,32 Hz, 1H), 4,22 (t, J = 6,1 Hz, 2H), 3,43-3,45 (m, 2H), 2,24-2,30 (m, 2H).

EJEMPLO 245

ácido 7-(4-ciclohexilpiridin-3-il)-3-(3-fenoxipropil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,09 (s, 1H), 11,33 (s, 1H), 8,81 (d, J = 6,1 Hz, 1H), 8,72 (s, 1H), 8,26-8,28 (m, 1H), 7,90 (d, J = 5,8 Hz, 1H), 7,83-7,98 (m, 2H), 7,45-7,54 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,12-7,16 (m, 1H), 6,89 (d, J = 7,63 Hz, 1H), 4,19 (t, J = 6,26 Hz, 2H), 3,42-3,46 (m, 2H), 3,32-3,37 (m, 2H), 2,37-2,45 (m, 1H), 2,22-2,27 (m, 2H), 1,45-1,76 (m, 7H), 1,15-1,20 (m 1H), 0,81-0,99 (m, 2H).

EJEMPLO 246

ácido 7-(2,4-dimetil-1,3-tiazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,95 (s, 1H), 8,21-8,23 (m, 1H), 7,85-7,97 (m, 2H), 7,75 (d, J = 7,98 Hz, 1H), 7,36-7,55 (m, 4H), 7,19 (t, J = 6,44 Hz, 1H), 7,06-7,09 (m, 1H), 6,89 (d, J = 7,37 Hz, 1H), 4,19 (t, J = 6,14 Hz, 2H), 3,37 (t, J = 7,52 Hz, 2H), 2,70 (s, 3H), 2,20-2,27 (m, 2H), 2,17 (s, 3H).

EJEMPLO 247

ácido 7-(1-(carboximetil)-1H-pirrolo(2,3-c)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,22 (s, 1H), 8,90 (s, 1H), 8,20-8,23 (m, 2H), 8,06 (s, 1H), 7,85-7,87 (m, 1H), 7,66-7,68 (m, 1H), 7,58-7,60 (m, 1H), 7,36-7,55 (m, 5H), 7,12-7,15 (m, 1H), 6,90 (d, J = 7,67 Hz, 1H), 5,22 (s, 2H), 4,21 (t, J = 6,1 Hz, 2H), 3,28 (t, J = 7,52 Hz, 2H), 2,20-2,27 (m, 2H).

EJEMPLO 248

ácido 3-(3-(1-naftiloxi)propil)-7-(1-feniletil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,09 (s, 1H), 8,23 (d, J = 7,67 Hz, 1H), 7,85-7,87 (m, 1H), 7,66-7,68 (m, 1H), 7,35-7,53 (m, 7H), 7,26 (t, J = 7,52 Hz, 2H), 7,10-7,17 (m, 2H), 6,96 (t, J = 7,67 Hz, 1H), 6,78 (d, J = 7,37 Hz, 1H), 5,00 (d, J = 7,06 Hz, 1H), 4,16 (t, J = 5,98 Hz, 2H), 3,28 (t, J = 7,52 Hz, 2H), 2,15-2,22 (m, 2H), 1,85 (m, 1H), 1,60 (d, J = 7,06 Hz, 3H).

EJEMPLO 249

ácido 7-(1-bencil-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,57 (s, 1H), 8,24-8,26 (m, 1H), 7,85-7,87 (m, 1H), 7,65 (dd, J = 7,06, 1,53 Hz, 1H), 7,26-7,52 (m, 8H), 7,03-7,08 (m, 2H), 6,90 (d, J = 7,67 Hz, 1H), 5,31 (d, J = 7,06 Hz, 1H), 4,21 (t, J = 5,98 Hz, 2H), 3,34-3,37 (m, 2H), 2,18-2,27 (m, 2H), 2,04 (s, 6H).

EJEMPLO 250

ácido 7-(2-(2-clorofenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,93 (s, 1H), 8,21-8,23 (m, 1H), 7,84-7,86 (m, 1H), 7,34-7,54 (m, 8H), 7,20-7,22 (m, 1H), 7,09 (dd, J = 7,36, 1,84 Hz, 1H), 6,82-6,98 (m, 4H), 6,71-6,75 (m, 1H), 5,31 (d, J = 7,06 Hz, 1H), 4,12 (t, J = 6,14 Hz, 2H), 3,20-3,26 (m, 4H), 2,21-2,28 (m, 4H), 1,82-1,96 (m, 4H).

EJEMPLO 251

ácido 3-(3-(1-naftiloxi)propil)-1H,1'H-7,7'-biindol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,02 (s, 1H), 10,70 (s, 1H), 9,88 (s, 1H), 8,27-8,29 (m, 1H), 7,87-7,89 (m, 1H), 7,76 (d, J = 7,93 Hz, 1H), 7,62 (d, J = 7,63 Hz, 1H), 7,37-7,56 (m, 5H), 7,27 (t, J = 2,9 Hz, 1H), 7,21 (d, J = 7,02 Hz, 1H), 7,13-7,18 (m, 2H), 6,92 (d, J = 7,63 Hz, 1H), 6,55 (dd, J = 3,05, 1,83 Hz, 1H), 4,23 (t, J = 6,26 Hz, 2H), 3,39-3,42 (m, 2H), 2,25-2,30 (m, 2H).

EJEMPLO 252

ácido 3-(3-(1-naftiloxi)propil)-7-(1-(2-(2-oxopirrolidin-1-il)etil)-1H-pirrolo(2,3-c)piridin-7-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 15,03 (s, 1H), 11,85 (s, 1H), 8,35 (d, J = 6,1 Hz, 1H), 8,31-8,32 (m, 1H), 8,22 (d, J = 6,41 Hz, 1H), 8,20 (d, J = 3,05 Hz, 1H), 8,08 (d, J = 7,93 Hz, 1H), 7,88-7,90 (m, 1H), 7,61 (d, J = 7,02 Hz, 1H), 7,39-7,55 (m, 5H), 7,25-7,28 (m, 1H), 7,07 (d, J = 3,05 Hz, 1H), 6,92 (d, J = 7,32 Hz, 1H), 4,20 (t, J = 6,1 Hz, 2H), 3,83-3,88 (m, 2H), 3,56-3,60 (m, 2H), 3,42-3,45 (m, 2H), 2,23-2,28 (m, 2H), 1,94-1,98 (m, 2H), 1,64-1,71 (m, 2H).

EJEMPLO 254

ácido 7-(5-metil-3-fenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,53 (s, 1H), 8,26-8,28 (m, 1H), 7,86-7,88 (m, 1H), 7,68 (dd, J = 6,87, 2,29 Hz, 1H), 7,45-7,54 (m, 3H), 7,39 (t, J = 7,78 Hz, 1H), 7,29-7,31 (m, 2H), 7,15-7,17 (m, 3H), 7,01-7,05 (m, 2H), 6,90 (d, J = 7,32 Hz, 1H), 4,20 (t, J = 6,1 Hz, 2H), 3,33-3,36 (m, 2H), 2,21-2,26 (m, 2H), 2,03 (s, 3H).

EJEMPLO 255

ácido 7-(2-metilfenil)-4-(2-(1-naftiloxi)etil)-1H-indol-2-carboxílico

EJEMPLO 255A

4-(1-etoxi-1,3-dioxobutan-2-il)-7-o-tolil-1H-indol-2-carboxilato de etilo

Una mezcla de 4-cloro-7-o-tolil-1H-indol-2-carboxilato de etilo (EJEMPLO 166C) (0,93 g), 3-oxobutanoato de etilo (0,849 g), *di*-tert-butil(2'-metilbifenil-2-il)fosfina (0,093 mg), K_3PO_4 (3,46 g), y acetato de paladio(II) (0,033 g) en tolueno (8 ml) se desgasificó por ciclo vacío-nitrógeno tres veces. La mezcla de reacción se calentó a 93 °C durante 14 horas. La mezcla de reacción se particionó entre agua y acetato de etilo. La fase orgánica se separó, y la fase acuosa se extrajo con más acetato de etilo. Las fases orgánicas combinadas se lavaron con salmuera, se secó sobre $MgSO_4$, se filtró, y se concentró. El residuo se purificó por cromatografía flash sobre gel de sílice (acetato de etilo en hexanos) para dar el compuesto del título.

EJEMPLO 255B

4-(2-metoxi-2-oxoetil)-7-o-tolil-1H-indol-2-carboxilato de metilo

Se trató el EJEMPLO 255A (crudo) en etanol (35 ml) con KOH 20% (15 ml). La mezcla se calentó a 100 C durante 1 hora. El solvente se eliminó y el residuo se disolvió en acetato de etilo. Después de la adición de HCl concentrado, la fase orgánica se separó y la fase acuosa se extrajo con más acetato de etilo. Las fases orgánicas combinadas se

secaron, y se concentró. El residuo se trató con diazometano en CH_2Cl_2 y algunas gotas de metanol. Después de haber cesado el burbujeo, los solventes se evaporaron y el compuesto se purificó por cromatografía flash (15:85 EtOAc/Hex) para dar el EJEMPLO 255B puro. ^{1}H RMN (500 MHz, DMSO-d_6): □ 11,14 (s, 1H), 7,26-7,34 (m, 4H), 7,21 (d, J = 7,32 Hz, 1H), 7,00-7,05 (m, 2H), 3,99 (s, 2H), 3,83 (s, 3H), 3,64 (s, 3H), 2,05 (s, 3H).

EJEMPLO 255C

ácido 7-(2-metilfenil)-4-(2-(1-naftiloxi)etil)-1H-indol-2-carboxílico

El compuesto del título se preparó de acuerdo con el procedimiento del EJEMPLO 164G, utilizando el EJEMPLO 255B en lugar del EJEMPLO 164F. ^{1}H RMN (500 MHz, DMSO-d_6): □ 11,05 (s, 1H), 8,13 (d, J = 7,98 Hz, 1H), 7,84 (d, J = 7,98 Hz, 1H), 7,31-7,51 (m, 7H), 7,18-7,27 (m, 3H), 7,01 (d, J = 6,75 Hz, 1H), 4,50 (t, J = 6,44 Hz, 2H), 3,52 (t, J = 6,44 Hz, 2H), 2,05 (s, 3H).

EJEMPLO 256

ácido 7-(2-metilfenil)-4-(2-(2-naftiloxi)etil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,06 (s, 1H), 7,78-7,83 (m, 3H), 7,13-7,46 (m, 10H), 7,01 (d, J = 7,06 Hz, 1H), 4,46 (t, J = 6,9 Hz, 2H), 3,45 (t, J = 6,75 Hz, 2H), 2,06 (s, 3H).

EJEMPLO 257

ácido 4-(2-(2,3-diclorofenoxi)etil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,02 (s, 1H), 7,36 (d, J = 1,84 Hz, 1H), 7,17-7,32 (m, 7H), 7,12 (d, J = 7,06 Hz, 1H), 7,00 (d, J = 7,36 Hz, 1H), 4,40 (t, J = 6,6 Hz, 2H), 3,28-3,34 (m, 2H), 2,21-2,29 (m, 2H), 2,06 (s, 3H).

EJEMPLO 258

ácido 3-(3-(1H-indol-4-iloxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,02 (s, 1H), 10,41 (s, 1H), 7,71 (d, J = 7,98 Hz, 1H), 7,20-7,33 (m, 5H), 6,93-7,11 (m, 4H), 6,47-6,49 (m, 1H), 6,42 (d, J = 6,44 Hz, 1H), 4,12 (t, J = 6,44 Hz, 2H), 3,40-3,42 (m, 2H), 2,06 (s, 3H).

EJEMPLO 259

ácido 4-(2-(2-cloro-3-(trifluorometil)fenoxi)etil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,03 (s, 1H), 7,45-7,53 (m, 2H), 7,19-7,39 (m, 6H), 7,13 (d, J = 7,36 Hz, 1H), 6,99 (d, J = 7,06 Hz, 1H), 4,49 (t, J = 6,75 Hz, 2H), 3,41-3,44 (m, 2H), 2,05 (s, 3H).

EJEMPLO 260

ácido 1-metil-3-(3-((1-metil-1H-indol-4-il)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,07 (s, 1H), 7,74 (d, J = 7,98 Hz, 1H), 7,27-7,37 (m, 4H), 7,20 (d, J = 3,07 Hz, 1H), 7,09 (t, J = 7,52 Hz, 1H), 6,98-7,05 (m, 3H), 6,49 (d, J = 1,43 Hz, 1H), 6,47 (d, J = 2,76 Hz, 1H), 4,13 (t, J = 6,14 Hz, 2H), 3,76 (s, 3H), 3,24-3,27 (m, 2H), 2,10-2,17 (m, 2H), 2,00 (s, 3H).

EJEMPLO 261

ácido 7-(2-(4-etilfenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,56 (s, 1H), 8,22-8,24 (m, 1H), 7,84-7,86 (m, 1H), 7,34-7,54 (m, 5H), 6,92 (d, J = 8,29 Hz, 1H), 6,84 (d, J = 7,67 Hz, 2H), 6,67-6,80 (m, 4H), 4,11 (t, J = 6,14 Hz, 2H), 3,23-3,27 (m, 2H), 2,31-2,43 (m, 6H), 2,11-2,18 (m, 2H), 1,85 (ancho, 4H), 0,98 (t, J = 7,52 Hz, 3H).

EJEMPLO 262

ácido 7-(2-(4-isopropilfenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,43 (s, 1H), 8,22-8,24 (m, 1H), 7,84-7,86 (m, 1H), 7,34-7,54 (m, 5H), 6,93 (d, J = 7,98 Hz, 1H), 6,79-6,84 (m, 5H), 4,10 (t, J = 6,14 Hz, 2H), 3,22-3,26 (m, 2H), 2,57-2,64 (m, 1H), 2,11-2,44 (m, 6H), 1,85 (ancho, 4H), 0,99 (d, J = 6,75 Hz, 6H).

EJEMPLO 263

ácido 7-(1,3-dimetil-5-fenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,85 (s, 1H), 10,42 (s, 1H), 8,25 (d, J = 7,63 Hz, 1H), 7,85-7,87 (m, 1H), 7,44-7,58 (m, 4H), 7,38 (t, J = 7,93 Hz, 1H), 7,25-7,30 (m, 5H), 6,93-6,97 (m, 2H), 6,88 (d, J = 7,63 Hz, 1H), 4,17 (t, J = 6,1 Hz, 2H), 3,73 (s, 3H), 3,27-3,30 (m, 2H), 2,16-2,20 (m, 2H), 2,00 (s, 3H).

EJEMPLO 264

ácido 7-(1,5-dimetil-3-fenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,87 (s, 1H), 10,60 (s, 1H), 8,26-8,28 (m, 1H), 7,86-7,88 (m, 1H), 7,69 (d, J = 7,63 Hz, 1H), 7,45-7,55 (m, 3H), 7,39 (t, J = 7,78 Hz, 1H), 7,28 (dd, J = 7,32, 2,44 Hz, 2H), 7,11-7,13 (m, 3H), 6,97-7,04 (m, 2H), 6,90 (d, J = 7,63 Hz, 1H), 4,20 (t, J = 6,1 Hz, 2H), 3,85 (s, 3H), 3,36 (ancho, 2H), 2,21-2,27 (m, 2H), 2,01 (s, 3H).

EJEMPLO 265

ácido 7-(3,5-dimetil-1-((3-metiloxetan-3-il)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,24 (s, 1H), 11,06 (s, 1H), 8,23 (d, J = 7,63 Hz, 1H), 7,81-7,88 (m, 2H), 7,39-7,55 (m, 4H), 7,13-7,17 (m, 2H), 6,91 (d, J = 7,32 Hz, 1H), 5,50 (m, 1H), 4,41-4,49 (m, 2H), 4,22-4,29 (m, 4H), 3,56 (s, 3H), 2,20-2,26 (m, 8H), 1,93 (s, 3H).

EJEMPLO 266

ácido 7-(3,5-dimetil-1-tetrahidrofuran-3-il-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,98 (s, 1H), 10,59 (s, 1H), 8,25-8,26 (m, 1H), 7,86-7,88 (m, 1H), 7,65 (d, J = 7,93 Hz, 1H), 7,45-7,55 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,07-7,07 (m, 2H), 6,91 (d, J = 7,63 Hz, 1H), 4,96-5,01 (m, 1H), 4,21 (t, J = 6,1 Hz, 2H), 4,03-4,07 (m, 2H), 3,83-3,88 (m, 2H), 3,34-3,37 (m, 2H), 2,31-2,41 (m, 4H), 2,21-2,26 (m 2H), 2,07 (s, 3H), 2,02 (s, 3H).

EJEMPLO 267

ácido 7-(3,5-dimetil-1-piridin-2-il-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-

carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,98 (s, 1H), 8,48 (d, J = 4,58 Hz, 1H), 8,25-8,28 (m, 1H), 7,86-8,00 (m, 3H), 7,70 (dd, J = 7,17, 1,68 Hz, 1H), 7,45-7,55 (m, 3H), 7,38-7,41 (m, 1H), 7,31-7,33 (m, 1H), 7,07-7,12 (m, 2H), 6,91 (d, J = 7,32 Hz, 1H), 4,22 (t, J = 5,95 Hz, 2H), 3,37 (t, J = 7,63 Hz, 2H), 2,43 (s, 3H), 2,21-2,27 (m, 2H), 2,09 (s, 3H).

EJEMPLO 268

ácido 7-(2-cloro-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,99 (s, 1H), 11,40 (s, 1H), 8,26-8,31 (m, 2H), 8,25-8,28 (m, 2H), 7,86-7,88 (m, 1H), 7,76 (d, J = 7,93 Hz, 1H), 7,38-7,55 (m, 5H), 7,09-7,12 (m, 1H), 7,03 (d, J = 7,02 Hz, 1H), 6,91 (d, J = 7,63 Hz, 1H), 4,22 (t, J = 6,1 Hz, 2H), 3,37 (t, J = 7,63 Hz, 2H), 2,22-2,27 (m, 2H), 1,96 (s, 3H).

EJEMPLO 269

ácido 7-(4-metil-2-(2-(2-oxopirrolidin-1-il)etoxi)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,10 (s, 1H), 8,27-8,30 (m, 1H), 8,05 (d, J = 5,22 Hz, 1H), 7,86-7,88 (m, 1H), 7,68 (d, J = 7,98 Hz, 1H), 7,37-7,55 (m, 4H), 7,03-7,07 (m, 1H), 6,96-6,98 (m, 1H), 6,90 (d, J = 7,36 Hz, 1H), 4,15-4,30 (m, 4H), 3,34 (m, 2H), 3,24 (t, J = 4,91 Hz, 1H), 2,55-2,65 (m, 2H), 2,22-2,27 (m, 2H), 1,96 (s, 3H), 1,90 (t, J = 8,13 Hz, 2H), 1,43-1,49 (m, 2H).

EJEMPLO 270

ácido 7-(3,5-dimetil-1-(tetrahidrofuran-3-ilmetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,51 (s, 1H), 8,24-8,26 (m, 1H), 7,86-7,88 (m, 1H), 7,85-7,88 (m, 1H), 7,64-7,66 (m, 1H), 7,44-7,55 (m, 3H), 7,39 (t, J = 7,83 Hz, 1H), 7,02-7,08 (m, 2H), 6,91 (d, J = 7,36 Hz, 1H), 4,21 (t, J = 5,98 Hz, 2H), 3,95-4,05 (m, 2H), 3,80-3,86 (m, 2H), 3,64-3,74 (m, 4H), 3,35 (t, J = 7,52 Hz, 1H), 2,74-2,81 (m, 1H), 2,20-2,27 (m, 2H), 1,96-2,03 (m, 6H), 1,69-1,75 (m, 1H).

EJEMPLO 271

ácido 7-(1-ciclopentil-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,47 (s, 1H), 8,24-8,26 (m, 1H), 7,85-7,88 (m, 1H), 7,85-7,88 (m, 1H), 7,65 (d, J = 6,75 Hz, 1H), 7,45-7,55 (m, 3H), 7,39 (t, J = 7,83 Hz, 1H), 7,01-7,07 (m, 2H), 6,91 (d, J = 7,36 Hz, 1H), 4,64-4,70 (m, 1H), 4,21 (t, J = 6,14 Hz, 2H), 3,33-3,37 (m, 2H), 2,21-2,26 (m, 2H), 2,02-2,08 (m, 10H), 1,85-1,88 (m, 2H), 1,64-1,66 (m, 2H).

EJEMPLO 272

ácido 7-(1-((2,2-dimetil-1,3-dioxolan-4-il)metil)-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,34 (s, 1H), 8,23-8,26 (m, 1H), 7,85-7,88 (m, 1H), 7,65 (d, J = 7,67 Hz, 1H), 7,37-7,55 (m, 4H), 7,02-7,08 (m, 2H), 6,91 (d, J = 7,36 Hz,

1H), 4,44-4,47 (m, 1H), 4,09-4,23 (m, 5H), 3,87-3,91 (m, 1H), 3,34-3,37 (m, 2H), 2,21-2,27 (m, 2H), 2,09 (s, 3H), 2,01 (s, 3H), 1,33 (s, 3H), 1,29 (s, 3H).

EJEMPLO 273

ácido 7-(4-metil-2-(2-morfolin-4-iletoxi)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,11 (s, 1H), 8,91 (s, 1H), 8,26-8,28 (m, 1H), 8,10 (d, J = 5,22 Hz, 1H), 7,85-7,88 (m, 1H), 7,71 (d, J = 7,98 Hz, 1H), 7,45-7,55 (m, 4H), 7,39 (t, J = 7,83 Hz, 1H), 7,05-7,09 (m, 1H), 6,91 (d, J = 7,36 Hz, 1H), 4,55-4,59 (m, 1H), 4,40-4,46 (m, 1H), 4,21 (t, J = 5,98 Hz, 2H), 3,33-3,37 (m, 2H), 2,93 (ancho, 2H), 2,73 (ancho, 2H), 2,20-2,25 (m, 2H), 1,98 (s, 3H).

EJEMPLO 274

ácido 7-(4-metil-2-morfolin-4-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,28 (s, 1H), 8,27-8,29 (m, 1H), 8,20 (d, J = 5,83 Hz, 1H), 7,86-7,88 (m, 1H), 7,79 (d, J = 7,98 Hz, 1H), 7,45-7,55 (m, 4H), 7,37 (t, J = 7,98 Hz, 1H), 7,20-7,24 (m, 2H), 7,09-7,13 (m, 1H), 6,86 (d, J = 7,37 Hz, 1H), 4,18 (t, J = 6,14 Hz, 2H), 3,39 (t, J = 6,14 Hz, 2H), 2,87-3,17 (m, 8H), 2,21-2,28 (m, 2H), 2,12 (s, 3H).

EJEMPLO 275

ácido 7-(2-cloro-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 8,51 (d, J = 4,3 Hz, 1H), 8,25-8,29 (m, 2H), 7,93 (d, J = 7,98 Hz, 1H), 7,87-7,89 (m, 1H), 7,74 (s, 1H), 7,39-7,56 (m, 5H), 7,19-7,24 (m, 2H), 7,10 (d, J = 7,98 Hz, 1H), 6,99 (d, J = 7,36 Hz, 1H), 6,94 (d, J = 6,75 Hz, 1H), 5,29-5,46 (m, 2H), 4,28 (t, J = 5,98 Hz, 2H), 3,42-3,45 (m, 2H), 2,27-2,33 (m, 2H), 1,66 (s, 3H).

EJEMPLO 276

ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,37 (s, 1H), 8,75 (s, 1H), 8,60 (d, J = 5,22 Hz, 1H), 8,25-8,28 (m, 1H), 7,86-7,88 (m, 1H), 7,74 (d, J = 7,98 Hz, 1H), 7,70 (d, J = 5,22 Hz, 1H), 7,45-7,54 (m, 3H), 7,39 (t, J = 7,98 Hz, 1H), 7,30 (d, J = 7,36 Hz, 2H), 7,02-7,09 (m, 2H), 6,88 (d, J = 7,36 Hz, 1H), 4,17 (t, J = 6,14 Hz, 2H), 3,27-3,39 (m, 2H), 2,18-2,25 (m, 2H), 2,06 (s, 3H).

EJEMPLO 277

ácido 7-(1-(2,3-dihidroxipropil)-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,47 (s, 1H), 8,24-8,26 (m, 1H), 7,86-7,88 (m, 1H), 7,67 (d, J = 7,36 Hz, 1H), 7,37-7,53 (m, 4H), 7,03-7,09 (m, 2H), 6,91 (d, J = 7,67 Hz, 1H), 4,15-4,23 (m, 4H), 3,34-3,46 (m, 2H), 2,21-2,26 (m, 2H), 2,07 (s, 3H), 2,03 (s, 3H).

EJEMPLO 278

ácido 3-(3-(1-naftiloxi)propil)-7-(3-fenil-5-(2-feniletil)-1H-pirazol-4-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,40 (s, 1H), 8,26-8,29 (m, 1H), 7,85-7,88 (m,

1H), 7,68 (d, J = 8,29 Hz, 1H), 7,44-7,55 (m, 3H), 7,31-7,39 (m, 3H), 7,00-7,17 (m, 7H), 6,89-6,95 (m, 4H), 4,19 (t, J = 6,14 Hz, 2H), 3,34-3,46 (m, 2H), 2,65-2,74 (m 4H), 2,21-2,26 (m, 2H).

EJEMPLO 279

ácido 7-(4-metil-2-fenilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,29 (s, 1H), 8,81 (d, J = 5,52 Hz, 1H), 8,24-8,26 (m, 1H), 7,85-7,90 (m, 2H), 7,64-7,66 (m, 1H), 7,31-7,39 (m, 3H), 7,35-7,45 (m, 4H), 7,15-7,28 (m, 5H), 6,92-6,97 (m, 2H), 6,84 (d, J = 7,67 Hz, 1H), 4,12 (t, J = 6,14 Hz, 2H), 3,28-3,34 (m, 2H), 2,17-2,21 (m, 2H), 2,15 (s, 3H).

EJEMPLO 280

ácido 7-(4-metil-2-vinilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,22 (s, 1H), 8,65 (d, J = 5,83 Hz, 1H), 8,25-8,27 (m, 1H), 7,86-7,88 (m, 1H), 7,81 (d, J = 7,98 Hz, 1H), 7,62-7,64 (m, 1H), 7,45-7,54 (m, 3H), 7,39 (t, J = 7,98 Hz, 1H), 7,04 (d, J = 6,44 Hz, 1H), 6,91 (d, J = 7,67 Hz, 1H), 6,16-6,29 (m, 2H), 5,47-5,49 (m, 1H), 4,22 (t, J = 6,14 Hz, 2H), 3,28-3,34 (m, 2H), 2,21-2,28 (m, 2H), 2,04 (s, 3H).

EJEMPLO 281

ácido 7-(4-metil-2-((1E)-prop-1-enil)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,24 (s, 1H), 8,65 (d, J = 5,83 Hz, 1H), 8,25-8,28 (m, 1H), 7,82-7,88 (m, 2H), 7,70 (d, J = 5,83 Hz, 1H), 7,45-7,55 (m, 3H), 7,39 (t, J = 7,98 Hz, 1H), 7,14-7,18 (m, 1H), 7,05 (d, J = 7,14 Hz, 1H), 6,90 (d, J = 7,36 Hz, 1H), 6,16-6,29 (m, 2H), 6,82 (dd, J = 15,65, 6,75 Hz, 1H), 5,92 (dd, J = 15,65, 1,53 Hz, 1H), 4,22 (t, J = 6,14 Hz, 2H), 3,36-3,40 (m, 2H), 2,22-2,28 (m, 2H), 2,04 (s, 3H), 1,69-1,71 (m, 3H).

EJEMPLO 282

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,30 (s, 1H), 8,76 (d, J = 5,83 Hz, 1H), 8,25-8,27 (m, 1H), 7,84-7,88 (m, 2H), 7,45-7,56 (m, 3H), 7,39 (t, J = 7,83 Hz, 1H), 7,12-7,20 (m, 2H), 6,90 (d, J = 7,67 Hz, 1H), 4,22 (t, J = 6,14 Hz, 2H), 3,36-3,40 (m, 2H), 2,59-2,65 (m, 1H), 2,42-2,48 (m, 1H), 2,21-2,27 (m, 2H), 2,10 (s, 3H).

EJEMPLO 283

ácido 7-(3,5-dimetil-1-(piridin-3-ilmetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,95 (s, 1H), 8,60-8,65 (m, 2H), 8,24-8,26 (m, 1H), 7,94 (d, J = 7,98 Hz, 1H), 7,85-7,87 (m, 1H), 7,62-7,67 (m, 2H), 7,44-7,53 (m, 3H), 7,39 (t, J = 7,98 Hz, 1H), 7,03-7,08 (m, 2H), 6,91 (d, J = 7,36 Hz, 1H), 5,41 (s, 2H), 4,21 (t, J = 5,98 Hz, 2H), 3,34-3,38 (m, 2H), 2,21-2,26 (m, 2H), 2,08 (s, 3H), 2,02 (s, 3H).

EJEMPLO 284

ácido 7-(2-isopropenil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,26 (s, 1H), 8,71 (d, J = 5,52 Hz, 1H), 8,26-

8,28 (m, 1H), 7,80-7,88 (m, 2H), 7,77 (d, J = 7,67 Hz, 1H), 7,45-7,55 (m, 3H), 7,38 (t, J = 7,83 Hz, 1H), 7,04-7,11 (m, 2H), 6,88 (d, J = 7,37 Hz, 1H), 5,15 (s, 1H), 5,13 (s, 1H), 4,20 (t, J = 6,14 Hz, 2H), 3,33-3,37 (m, 2H), 2,21-2,26 (m, 2H), 2,10 (s, 3H), 1,67 (s, 3H).

EJEMPLO 285

ácido 7-(4-metil-2-pentilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,23 (s, 1H), 8,74 (d, J = 5,83 Hz, 1H), 8,25-8,28 (m, 1H), 7,83-7,88 (m, 3H), 7,45-7,55 (m, 3H), 7,38 (t, J = 7,83 Hz, 1H), 7,11-7,18 (m, 2H), 6,87 (d, J = 7,67 Hz, 1H), 4,20 (t, J = 6,19 Hz, 2H), 3,33-3,37 (m, 2H), 2,54-2,62 (m, 1H), 2,29-2,46 (m, 1H), 2,22-2,28 (m, 2H), 2,12 (s, 3H), 1,35-1,40 (m, 2H), 0,88-0,99 (m, 4H), 0,58 (t, J = 7,06 Hz, 3H).

EJEMPLO 286

ácido 7-(4-metil-2-propilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,30 (s, 1H), 8,73 (d, J = 5,83 Hz, 1H), 8,26-8,28 (m, 1H), 7,82-7,88 (m, 2H), 7,79 (d, J = 5,83 Hz, 1H), 7,45-7,55 (m, 3H), 7,38 (t, J = 7,83 Hz, 1H), 7,10-7,18 (m, 2H), 6,89 (d, J = 7,36 Hz, 1H), 4,21 (t, J = 5,98 Hz, 2H), 3,37-3,40 (m, 2H), 2,54-2,64 (m, 1H), 2,34-2,42 (m, 1H), 2,22-2,28 (m, 2H), 2,09 (s, 3H), 1,39-1,49 (m, 2H), 0,65 (t, J = 7,36 Hz, 3H).

EJEMPLO 287

ácido 7-(2-isopropil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,26 (s, 1H), 8,65 (d, J = 5,83 Hz, 1H), 8,22-8,24 (m, 1H), 7,84-7,86 (m, 1H), 7,80 (d, J = 7,98 Hz, 1H), 7,72 (d, J = 6,14 Hz, 1H), 7,35-7,45 (m, 3H), 7,37 (t, J = 7,98 Hz, 1H), 7,15 (t, J = 7,52 Hz, 1H), 7,07-7,08 (m, 1H), 6,88 (d, J = 7,36 Hz, 1H), 4,20 (t, J = 5,98 Hz, 2H), 3,36 (m, 2H), 2,67-2,70 (m, 2H), 2,22-2,28 (m, 2H), 2,02 (s, 3H), 1,12 (dd, J = 6,75, 5,22 Hz, 6H).

EJEMPLO 288

ácido 7-(3,5-diisopropil-1-metil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,43 (s, 1H), 8,27-8,29 (m, 1H), 7,86-7,88 (m, 1H), 7,66 (d, J = 7,06 Hz, 1H), 7,45-7,55 (m, 3H), 7,36-7,40 (m, 1H), 6,99-7,06 (m, 2H), 6,89 (d, J = 7,06 Hz, 1H), 4,20 (t, J = 6,14 Hz, 2H), 3,82 (s, 3H), 3,32-3,36 (m, 2H), 2,89-2,94 (m, 1H), 2,43-2,50 (m, 1H), 2,19-2,26 (m, 2H), 1,03-1,06 (m, 6H), 0,96 (d, J = 6,75, Hz, 3H), 0,91 (d, J = 7,06 Hz, 3H).

EJEMPLO 289

ácido 7-(5-carboxi-1,3-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,61 (s, 1H), 8,28-8,30 (m, 1H), 7,86-7,88 (m, 1H), 7,64 (d, J = 7,06, 2,15 Hz, 1H), 7,45-7,55 (m, 3H), 7,40 (t, J = 7,83 Hz, 1H), 7,00-7,05 (m, 2H), 6,92 (d, J = 7,36 Hz, 1H), 4,22 (t, J = 6,14 Hz, 2H), 4,09 (s, 3H), 3,33-3,36 (m, 2H), 2,21-2,26 (m, 2H), 1,92 (s, 3H).

EJEMPLO 290

ácido 7-(4-metil-2-(2-metilprop-1-enil)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-

carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,20 (s, 1H), 8,70 (d, J = 5,83 Hz, 1H), 8,25-8,27 (m, 1H), 7,86-7,88 (m, 1H), 7,80 (d, J = 7,67 Hz, 1H), 7,45-7,55 (m, 3H), 7,38 (t, J = 7,83 Hz, 1H), 7,11-7,14 (m, 1H), 7,04-7,06 (m 1H), 6,88 (d, J = 7,67 Hz, 1H), 5,78 (s, 1H), 4,20 (t, J = 5,98 Hz, 2H), 3,33-3,36 (m, 2H), 2,20-2,28 (m, 2H), 2,11 (s, 3H), 1,78 (s, 3H), 1,60 (s, 3H).

EJEMPLO 291

ácido 7-(4-carboxi-1-fenil-1H-pirazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,40 (s, 1H), 8,27-8,29 (m, 1H), 8,16 (s, 1H), 7,85-7,88 (m, 1H), 7,69 (d, J = 7,98 Hz, 1H), 7,44-7,55 (m, 3H), 7,38 (t, J = 7,98 Hz, 1H), 7,19-7,23 (m, 5H), 7,02 (d, J = 6,75 Hz, 1H), 6,93 (t, J = 7,67 Hz, 1H), 6,87 (d, J = 7,36 Hz, 1H), 5,78 (s, 1H), 4,16 (t, J = 6,14 Hz, 2H), 3,28-3,34 (m, 2H), 2,16-2,24 (m, 2H).

EJEMPLO 292

ácido 7-(2-isobutil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,31 (s, 1H), 8,75 (d, J = 6,14 Hz, 1H), 8,26-8,28 (m, 1H), 7,83-7,88 (m, 1H), 7,44-7,56 (m, 3H), 7,37 (t, J = 7,98 Hz, 1H), 7,12-7,17 (m, 2H), 6,87 (d, J = 7,36 Hz, 1H), 4,19 (t, J = 6,14 Hz, 2H), 3,28-3,34 (m, 2H), 2,54-2,61 (m, 1H), 2,22-2,32 (m, 3H), 2,12 (m, 3H), 1,72-1,78 (m, 1H), 0,66 (d, J = 6,44 Hz, 3H), 0,62 (d, J = 6,75 Hz, 3H).

EJEMPLO 293

ácido 7-(4-metil-2,3'-bipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,32 (s, 1H), 8,71 (d, J = 5,22 Hz, 1H), 8,43 (s, 1H), 8,36 (d, J = 6,1 Hz, 1H), 8,25-8,27 (m, 1H), 7,85-7,88 (m, 1H), 7,71 (d, J= 7,98 Hz, 1H), 7,61-7,65 (m, 2H), 7,44-7,55 (m, 3H), 7,38 (t, J = 7,98 Hz, 1H), 7,26 (dd, J = 7,98, 5,22 Hz, 1H), 6,93-6,96 (m, 2H), 6,86 (d, J = 7,36 Hz, 1H), 4,14 (t, J = 6,14 Hz, 2H), 3,30-3,34 (m, 2H), 2,16-2,20 (m, 2H), 2,06 (s, 3H).

EJEMPLO 294

ácido 7-(2-(4-metoxifenil)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,28 (s, 1H), 8,75 (d, J = 5,83 Hz, 1H), 8,25-8,27 (m, 1H), 7,83-7,88 (m, 2H), 7,68 (dd, J= 7,06, 2,15 Hz, 1H), 7,44-7,55 (m, 3H), 7,37 (t, J = 7,83 Hz, 1H), 7,20 (d, J = 8,59 Hz, 1H), 6,94-6,99 (m, 2H), 6,85 (d, J = 7,67 Hz, 1H), 6,74 (d, J = 8,59 Hz, 1H), 4,14 (t, J = 6,29 Hz, 2H), 3,63 (s, 3H), 3,31-3,35 (m, 2H), 2,18-2,24 (m, 2H), 2,11 (s, 3H).

EJEMPLO 295

ácido 7-(4-metil-2-(1-metil-1H-pirazol-4-il)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,28 (s, 1H), 8,66 (d, J = 5,19 Hz, 1H), 8,27-8,29 (m, 1H), 7,84-7,88 (m, 2H), 7,86 (s, 1H), 7,45-7,55 (m, 3H), 7,37 (t, J = 7,83 Hz, 1H), 7,37-7,40 (m, 1H), 7,07-7,15 (m, 2H), 6,88 (d, J = 7,63 Hz, 1H), 6,78 (s, 1H), 4,18 (t, J = 6,26 Hz, 2H), 3,63 (s, 3H), 3,29-3,33 (m, 2H), 2,21-2,27 (m, 2H), 2,08 (s, 3H).

EJEMPLO 296

ácido 7-(3-(hidroximetil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

EJEMPLO 296A

4-bromo-5-metil-1H-pirazol-3-carboxilato de etilo

Se trató 5-metil-1H-pirazol-3-carboxilato de etilo (3,24 g) en CH_3CN (25 ml) con N-bromosuccinimida (3,92 g) a 0 °C. La solución se agitó a temperatura ambiente durante 2 horas. El solvente se eliminó , y el residuo se purificó por cromatografía flash sobre gel de sílice (acetato de etilo en hexanos) para dar el compuesto del título. ^{1}H RMN (500 MHz, DMSO-d6): 13,61 (s, 1H), 4,27 (q, J = 6,75 Hz, 2H), 2,21(s, 3H), 1,28 (t, J = 7,06 Hz, 3H).

EJEMPLO 296B

4-bromo-1,5-dimetil-1H-pirazol-3-carboxilato de etilo

Se trató el EJEMPLO 296A (2,33 g) en N,N-dimetilformamida con NaH 60% (0,8 g) a 0°C. Después de 10 minutos, a esta solución se agregó iodometano (1,703 g). La solución se agitó a temperatura ambiente durante 3 horas. El tratamiento posterior acuoso seguido por secado, filtrado, y cromatografía flash (acetato de etilo en hexanos) dio el compuesto del título. ^{1}H RMN (500 MHz, DMSO-d_6): 4,26 (q, J = 7,06 Hz, 2H), 3,86 (s, 3H), 2,27(s, 3H), 1,28 (t, J = 7,06 Hz, 3H).

EJEMPLO 296C

(4-Bromo-1,5-dimetil-1H-pirazol-3-il)metanol

Se trató el EJEMPLO 296B (1,43 g) en tetrahidrofurano (10 ml) con $LiAlH_4$ 1N en tetrahidrofurano (5,79 ml) a 0°C. La solución se agitó durante 10 minutos. El tratamiento posterior acuoso seguido por cromatografía flash (acetato de etilo en hexanos) dio el compuesto del título. ^{1}H RMN (500 MHz, DMSO-d6): 4,91 (t, J = 5,68 Hz, 1H), 4,30 (d, J = 5,52 Hz, 2H), 3,73 (s, 3H), 2,21(s, 3H).

EJEMPLO 296D

7-(3-(hidroximetil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de metilo

El compuesto del título se sintetizó de acuerdo con el procedimiento del EJEMPLO 192A reemplazando 2-fluoro-4-iodo-5-metilpiridina por el EJEMPLO 296C. ^{1}H RMN (500 MHz, DMSO-d_6): □ 11,06 (s, 1H), 8,25-8,26 (m, 1H), 7,86-7,88 (m, 1H), 7,65 (dd, J = 7,02, 1,83 Hz, 1H), 7,45-7,55 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,05-7,09 (m, 2H), 6,91 (d, J = 7,63 Hz, 1H), 6,78 (s, 1H), 4,24 (s, 2H), 4,21 (t, J = 6,1 Hz, 2H), 3,83 (s, 3H), 3,34-3,37 (m, 2H), 2,21-2,26 (m, 2H), 2,15 (s, 3H).

EJEMPLO 296E

ácido 7-(3-(hidroximetil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

El compuesto del título se sintetizó de acuerdo con el procedimiento del EJEMPLO 175B reemplazando el EJEMPLO 175A por el EJEMPLO 296D. ^{1}H RMN (500 MHz, DMSO-d6): 11,06 (s, 1H), 8,25-8,26 (m, 1H), 7,86-7,88 (m, 1H), 7,65 (dd, J = 7,02, 1,83

Hz, 1H), 7,45-7,55 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,05-7,09 (m, 2H), 6,91 (d, J = 7,63 Hz, 1H), 6,78 (s, 1H), 4,24 (s, 2H), 4,21 (t, J = 6,1 Hz, 2H), 3,83 (s, 3H), 3,34-3,37 (m, 2H), 2,21-2,26 (m, 2H), 2,15 (s, 3H).

EJEMPLO 297

ácido 3-Bromo-7-(1,3-dimetil-5-fenil-1H-pirazol-4-il)-1H-indol-2-carboxílico

EJEMPLO 297A

4-Bromo-1,3-dimetil-5-fenil-1H-pirazol

El compuesto del título se sintetizó de acuerdo con el procedimiento del EJEMPLO 296B reemplazando 5-metil-1H-pirazol-3-carboxilato de etilo por 5-metil-3-fenil-1H-pirazol. ^{1}H RMN (500 MHz, DMSO-d6): 7,46-7,56 (m, 5H), 3,70 (s, 3H), 2,18 (s, 3H).

EJEMPLO 297B

etiléster de ácido 7-(4,4,5,5-Tetrametil-(1,3,2)dioxaborolan-2-il)-1H-indol-2-carboxílico

Una mezcla de 1H-indol-2-carboxilato de etilo (1,89 g), 5,5'-di-tert-butil-2,2'-bipiridina (0,081 g), y $(Ir(OMe)(COD))_2$ (0,152 g) en hexanos (30 ml) se trató con 4,4,5,5-tetrametil-1,3,2-dioxaborolano (1,66 g) a través de una jeringa. La mezcla de reacción se desgasificó por ciclo vacío-nitrógeno tres veces. La mezcla de reacción se calentó a 62ºC durante 12 horas. Después de esto, el solvente se eliminó y el residuo se purificó por cromatografía flash sobre gel de sílice eluyendo con 1:9 acetato de etilo/hexano para dar el compuesto del título. ^{1}H RMN (500 MHz, DMSO-d_6): 9,75 (s, 1H), 7,87 (d, J = 7,93 Hz, 1H), 7,64-7,65 (m, 1H), 7,24 (s, 1H), 7,16-7,17 (m, 1H), 4,36 (q, J = 7,02 Hz, 2H), 1,38 (s, 12H), 1,35 (q, J = 7,02 Hz, 3H).

EJEMPLO 297C

metiléster de ácido 7-(1,3-dimetil-5-fenil-1H-pirazol-4-il)-1H-indol-2-carboxílico

El compuesto del título se sintetizó de acuerdo con el procedimiento del EJEMPLO 192 reemplazando el EJEMPLO 43A y 2-fluoro-4-iodo-5-metilpiridina por el EJEMPLO 297B y el EJEMPLO 297A, respectivamente.

EJEMPLO 297D

ácido 3-Bromo-7-(1,3-dimetil-5-fenil-1H-pirazol-4-il)-1H-indol-2-carboxílico

Una mezcla del EJEMPLO 279C (60 mg) y N-bromosuccinimida (32 mg) en acetonitrilo (2 ml) se agitó durante 3 horas a temperatura ambiente. El producto deseado se purificó por cromatografía flash sobre gel de sílice. Luego se hidrolizó con LiOH 1,0 N, y se purificó por HPLC preparativa para dar el compuesto del título. ^{1}H RMN (500 MHz, DMSO-d_6): 13,22 (s, 1H), 11,44 (s, 1H), 7,41 (d, J = 7,93 Hz, 1H), 7,24-7,30 (m, 5H), 7,11-7,14 (m, 2H), 7,04 (d, J = 7,02 Hz, 1H), 3,73 (s, 3H), 1,98 (s, 3H).

EJEMPLO 298

ácido 7-(1,3-dimetil-5-(fenoximetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,96 (s, 1H), 10,45 (s, 1H), 8,23-8,25 (m, 2H), 7,85-7,87 (m, 2H), 7,65 (d, J = 7,93 Hz, 1H), 7,44-7,54 (m, 3H), 7,38 (t, J = 7,93 Hz, 1H), 7,17-7,20 (m, 3H), 7,10 (d, J = 7,02 Hz, 1H), 7,01-7,04 (m, 1H), 6,85-6,90 (m, 4H), 4,78

(s, 2H), 4,19 (t, J = 6,1 Hz, 2H), 3,82 (s, 3H), 3,32-3,35 (m, 2H), 2,19-2,24 (m 2H), 2,09 (s, 3H).

EJEMPLO 299

ácido 7-(1-metil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,21 (s, 1H), 8,29 (s, 1H), 8,22-8,24 (m, 1H), 7,84-7,87 (m, 2H), 7,59 (d, J = 7,98 Hz, 1H), 7,44-7,54 (m, 3H), 7,39 (t, J = 7,67 Hz, 1H), 7,33-7,35 (m, 1H), 7,01-7,04 (m, 1H), 6,88 (d, J = 7,67 Hz, 1H), 4,18 (t, J = 5,98 Hz, 2H), 3,93 (s, 3H), 3,35 (t, J = 7,36 Hz, 2H), 2,19-2,26 (m 2H).

EJEMPLO 300

ácido 3-bromo-7-(2-((E)-2-ciclohexilvinil)-4-metilpiridin-3-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,90 (s, 1H), 8,61 (d, J = 5,52 Hz, 1H), 7,67 (d, J = 7,98 Hz, 1H), 7,62 (s, 1H), 7,33-7,36 (m, 1H), 7,17 (d, J = 7,06 Hz, 1H), 6,70 (dd, J = 15,8, 7,21 Hz, 1H), 5,81 (d, J = 15,65 Hz, 1H), 2,04 (s, 3H), 1,95 (m, 2H), 1,43-1,54 (m 5H), 0,99-1,16 (m, 5H).

EJEMPLO 301

ácido 7-(3-isopropil-1-metil-5-(fenoximetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,33 (s, 1H), 8,23-8,25 (m, 1H), 7,85-7,87 (m, 1H), 7,69 (dd, J = 7,32, 1,53 Hz, 1H), 7,44-7,54 (m, 3H), 7,37 (t, J = 7,98 Hz, 1H), 7,18 (t, J = 7,93 Hz, 1H), 7,05-7,09 (m, 2H), 6,89 (t, J = 8,09 Hz, 1H), 6,83 (t, J = 7,93 Hz, 1H), 4,85-4,87 (m, 1H), 4,75-4,77 (m 1H), 4,19 (t, J = 6,26 Hz, 2H), 3,87 (s, 3H), 3,32-3,35 (m, 2H), 2,73-2,79 (m, 1H), 2,19-2,26 (m 2H), 1,09 (d J = 6,71 Hz, 3H), 1,06 (d, J = 7,02 Hz, 3H).

EJEMPLO 302

ácido 7-(1,5-dimetil-3-(fenoximetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Una mezcla del EJEMPLO 296 (0,060 g), fenol (13 mg), y trifenilfosfina (48,8 mg) en tetrahidrofurano (2 ml) se enfrió a 0 °C. A esta solución se agregó (E)- diazen-1,2-dicarboxilato de di-*tert*-butilo (34,3 mg). La solución se agitó a temperatura ambiente durante 15 horas. El solvente se eliminó y el residuo se hidrolizó en LiOH 1,0 N /dioxano. El ácido crudo se purificó por RP HPLC para dar el compuesto del título,1H RMN (500 MHz, DMSO-d_6): □ 10,40 (s, 1H), 8,22-8,24 (m, 1H), 7,85-7,87 (m, 1H), 7,65 (d, J = 7,67 Hz, 1H), 7,44-7,54 (m, 3H), 7,37 (t, J = 7,98 Hz, 1H), 7,16-7,20 (m, 2H), 7,09-7,11 (m, 1H), 7,01-7,05 (m ,1H), 6,84-6,90 (m, 4H), 4,48 (s, 2H), 4,19 (t, J = 6,41 Hz, 2H), 3,82 (s, 3H), 3,31-3,35 (m, 2H), 2,73-2,79 (m, 1H), 2,18-2,25 (m 2H), 2,09 (s, 3H).

EJEMPLO 303

ácido 7-(4-(anilinocarbonil)-1-fenil-1H-pirazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,01 (s, 1H), 11,37 (s, 1H), 9,45 (s, 1H), 8,49 (s, 1H), 8,27-8,29 (m, 1H), 7,86-7,88 (m, 1H), 7,73 (d, J = 7,93 Hz, 1H), 7,44-7,54 (m, 5H),

7,21-7,24 (m, 7H), 7,07 (d, J = 7,32 Hz, 1H), 6,94-7,00 (m, 2H), 6,87 (d, J = 7,63 Hz, 1H), 4,16 (t, J = 6,1 Hz, 2H), 3,31-3,35 (m, 2H), 2,18-2,23 (m 2H).

EJEMPLO 304

ácido 7-(3-((3-clorofenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,41 (s, 1H), 8,22-8,24 (m, 1H), 7,85-7,87 (m, 1H), 7,65 (d, J = 7,67 Hz, 1H), 7,44-7,54 (m, 3H), 7,37 (t, J = 7,98 Hz, 1H), 7,19 (t, J = 8,13 Hz, 1H), 7,07-7,09 (m, 1H), 7,01-7,05 (m, 1H), 6,84-6,95 (m, 4H), 4,82 (s, 2H), 4,19 (t, J = 6,14 Hz, 2H), 3,82 (s, 3H), 3,32-3,36 (m, 2H), 2,19-2,25 (m 2H), 2,09 (s, 3H).

EJEMPLO 305

ácido 7-(1,5-dimetil-3-((3-fenoxifenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,43 (s, 1H), 8,23-8,25 (m, 1H), 7,85-7,87 (m, 1H), 7,64 (d, J = 7,98 Hz, 1H), 7,34-7,54 (m, 6H), 6,95-7,18 (m, 6H), 6,89 (d, J = 7,36 Hz, 1H), 6,67 (dd, J = 8,29, 2,46 Hz, 1H), 6,57 (t, J = 2,3 Hz, 1H), 6,46 (dd, J = 8,13, 2,3 Hz, 1H), 4,78 (s, 2H), 4,19 (t, J = 6,14 Hz, 2H), 3,80 (s, 3H), 3,31-3,35 (m, 2H), 2,17-2,25 (m 2H), 2,08 (s, 3H).

EJEMPLO 306

ácido 3-bromo-4-(2-((4-bromo-1-naftil)oxi)etil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,29 (s, 1H), 11,32 (s, 1H), 8,22 (d, J = 8,29 Hz, 1H), 8,05 (d, J = 8,59 Hz, 1H), 7,73 (d, J = 8,29 Hz, 1H), 7,67-7,70 (m, 1H), 7,56-7,60 (m, 1H), 7,26-7,33 (m, 3H), 7,23 (d, J = 7,06 Hz, 1H), 7,19 (d, J = 7,36 Hz, 1H), 7,06 (d, J = 7,36 Hz, 1H), 7,00 (d, J = 8,29 Hz, 1H), 4,53 (t, J = 6,9 Hz, 2H), 3,89 (ancho, 2H), 3,12 (s, 3H).

EJEMPLO 307

ácido 7-(1,5-dimetil-3-((4-morfolin-4-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,39 (s, 1H), 8,22-8,24 (m, 1H), 7,85-7,87 (m, 1H), 7,66 (d, J = 7,67 Hz, 1H), 7,44-7,54 (m, 3H), 7,37 (t, J = 7,98 Hz, 1H), 7,02-7,11 (m, 2H), 6,79-6,89 (m, 5H), 4,73 (s, 2H), 4,19 (t, J = 6,14 Hz, 2H), 3,81 (s, 3H), 3,71-3,73 (m, 4H), 3,34 (t, J = 7,52 Hz, 2H), 3,01-3,02 (m, 4H), 2,18-2,26 (m 2H), 2,09 (s, 3H).

EJEMPLO 308

ácido 7-(3-(((5-cloropiridin-3-il)oxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,38 (s, 1H), 8,16-8,18 (m, 1H), 8,10 (d, J = 2,4 Hz, 1H), 8,06 (d, J = 2,15 Hz, 1H), 7,78-7,80 (m, 1H), 7,58 (d, J = 7,36 Hz, 1H), 7,37-7,47 (m, 4H), 7,29-7,33 (m, 1H), 6,94-7,02 (m, 2H), 6,82 (d, J = 7,06 Hz, 1H), 4,86 (s, 2H), 4,12 (t, J = 6,14 Hz, 2H), 3,75 (s, 3H), 3,25-3,28 (m, 2H), 2,11-2,17 (m 2H), 2,02 (s, 3H).

EJEMPLO 309

ácido 7-(3,5-dimetil-1-(2-nitrofenil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-

carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,00 (s, 1H), 10,77 (s, 1H), 8,25-8,27 (m, 1H), 8,11 (d, J = 7,63 Hz, 1H), 7,86-7,95 (m, 3H), 7,71-7,76 (m, 2H), 7,45-7,55 (m, 3H), 7,40 (t, J = 7,78 Hz, 1H), 7,10-7,16 (m, 2H), 6,92 (d, J = 7,63 Hz, 1H), 4,23 (t, J = 6,1 Hz, 2H), 3,36-3,39 (m, 2H), 2,23-2,28 (m 2H), 2,06 (s, 3H), 2,05 (s, 3H).

EJEMPLO 310

ácido 3-(3-(1-naftiloxi)propil)-7-((2-(feniltio)etil)amino)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,15 (s, 1H), 8,21-8,23 (m, 1H), 7,85-7,87 (m, 1H), 7,43-7,53 (m, 3H), 7,32-7,40 (m, 5H), 7,21 (t, J = 7,32 Hz, 1H), 6,91 (d, J = 7,93 Hz, 1H), 6,86 (d, J = 7,32 Hz, 1H), 6,77 (t, J = 7,63 Hz, 1H), 6,24 (d, J = 7,32 Hz, 1H), 4,14 (t, J = 6,1 Hz, 2H), 3,42 ((t, J = 6,87 Hz, 2H), 3,23-3,29 (m, 4H), 2,15-2,21 (m 2H), 2,06 (s, 3H), 2,05 (s, 3H).

EJEMPLO 311

ácido 7-(3-((2-cianofenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,94 (s, 1H), 10,62 (s, 1H), 8,23-8,24 (m, 1H), 7,86 (d, J = 8,63 Hz, 1H), 7,64-7,66 (m, 2H), 7,44-7,54 (m, 4H), 7,39 (t, J = 7,93 Hz, 1H), 7,22 (d, J = 8,54 Hz, 1H), 7,18 (d, J = 7,02 Hz, 1H), 6,99-7,03 (m, 2H), 6,89 (d, J = 7,32 Hz, 1H), 5,07 (ancho, 1H), 4,83 (ancho, 1H), 4,19 (t, J = 6,1 Hz, 2H), 3,83 (s, 3H), 3,35 (t, J = 7,48 Hz, 2H), 2,19-2,14 (m 2H), 2,08 (s, 3H).

EJEMPLO 312

ácido 7-(3-((4-(4-acetilpiperazin-1-il)fenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,39 (s, 1H), 8,22-8,24 (m, 1H), 7,85-7,87 (m, 2H), 7,65 (d, J = 7,98 Hz, 1H), 7,44-7,54 (m, 3H), 7,38 (t, J = 7,83 Hz, 1H), 7,09-7,10 (m, 1H), 7,03 (t, J = 7,52 Hz, 1H), 6,80-7,91 (m, 5H), 4,73 (s, 2H), 4,19 (t, J = 6,14 Hz, 2H), 3,81 (s, 3H), 3,56-3,57 (m 2H), 3,34 (t, J = 7,52 Hz, 2H), 2,99-3,05 (m, 4H), 2,18-2,15 (m 2H), 2,09 (s, 3H), 2,02 (s, 3H).

EJEMPLO 313

ácido 3-bromo-7-(2-metilfenil)-4-(2-(1-naftiloxi)etil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,36 (s, 1H), 8,15 (d, J = 8,24 Hz, 1H), 7,85 (d, J = 7,93 Hz, 1H), 7,45-7,53 (m, 3H), 7,39 (t, J = 7,83 Hz, 1H), 7,28-7,35 (m, 2H), 7,24-7,28 (m 2H), 7,20 (d, J = 7,32 Hz, 1H), 7,07 (d, J = 7,32 Hz, 1H), 7,01 (d, J = 7,63 Hz, 1H), 4,52 (t, J = 6,87 Hz, 2H), 3,92 (ancho, 1H), 3,85 (ancho, 1H), 3,34 (t, J = 7,52 Hz, 2H), 2,03 (s, 3H).

EJEMPLO 314

ácido 7-(1-(2-aminofenil)-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,01 (s, 1H), 8,25-8,27 (m, 1H), 7,86-7,88 (m, 3H), 7,68 (d, J = 7,63 Hz, 1H), 7,45-7,55 (m, 3H), 7,39 (t, J = 7,93 Hz, 1H), 7,07-7,20 (m,

4H), 6,91 (d, J = 7,32 Hz, 1H), 6,96 (d, J = 7,93 Hz, 1H), 6,67 (t, J = 7,48 Hz, 1H), 4,22 (t, J = 6,1 Hz, 2H), 3,37 (t, J = 7,48 Hz, 2H), 2,22-2,29 (m, 2H), 2,09 (s, 3H), 1,88 (s, 3H).

EJEMPLO 315

ácido 7-(3-(1H-imidazol-1-ilmetil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,01 (s, 1H), 10,88 (s, 1H), 8,45 (s, 1H), 8,25-8,27 (m, 1H), 7,86-7,88 (m, 1H), 7,68 (d, J = 7,93 Hz, 1H), 7,37-7,55 (m, 6H), 7,96-7,05 (m, 2H), 5,18-5,27 (m, 2H), 4,20 (t, J = 6,1 Hz, 2H), 3,81 (s, 3H), 3,34-3,37 (m, 2H), 2,19-2,26 (m, 2H), 2,05 (s, 3H).

EJEMPLO 316

ácido 7-(2-metilfenil)-4-(2-(1-naftiloxi)etil)-3-vinil-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 12,92 (s, 1H), 10,66 (s, 1H), 8,04 (d, J = 8,24 Hz, 1H), 7,84 (d, J = 7,93 Hz, 1H), 7,43-7,51 (m, 3H), 7,38 (t, J = 7,78 Hz, 1H), 7,26-7,33 (m, 4H), 7,22 (t, J = 7,48 Hz, 1H), 7,18 (d, J = 7,32 Hz, 1H), 7,03 (d, J = 7,32 Hz, 1H), 6,99 (d, J = 7,32 Hz, 1H), 5,47-5,53 (m, 2H), 4,41 (t, J = 6,87 Hz, 2H), 3,86 (ancho, 2H), 2,05 (s, 3H).

EJEMPLO 317

ácido 7-(4-((bencilamino)carbonil)-1-fenil-1H-pirazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,22 (s, 1H), 8,22 (s, 1H), 8,20 (d, J = 4,3 Hz, 1H), 7,88 (t, J = 6,14 Hz, 1H), 7,78-7,81 (m, 1H), 7,61 (d, J = 7,98 Hz, 1H), 7,37-7,48 (m, 3H), 7,30 (t, J = 7,83 Hz, 1H), 7,09-7,17 (m, 8H), 7,00 (d, J = 7,06 Hz, 1H), 6,96 (d, J = 7,36 Hz, 1H), 6,92-6,96 (m, 1H), 6,78 (d, J = 7,67 Hz, 1H), 4,21-4,23 (m, 2H), 4,07 (t, J = 6,14 Hz, 2H), 3,24 (m, 2H), 2,18-2,25 (m, 2H).

EJEMPLO 318

ácido 3-(3-(1-naftiloxi)propil)-7-(1-fenil-4-(((3-pirrolidin-1-ilpropil)amino)carbonil)-1H-pirazol-5-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,26 (s, 1H), 9,24 (s, 1H), 8,27-8,29 (m, 1H), 8,10 (t, J = 5,98 Hz, 1H), 7,86-7,88 (m, 5H), 7,70 (d, J = 7,36 Hz, 1H), 7,45-7,56 (m, 3H), 7,39 (t, J = 7,98 Hz, 1H), 7,16-7,25 (m, 8H), 6,87-6,99 (m, 3H), 4,18 (t, J = 5,98 Hz, 2H), 3,17-3,19 (m, 2H), 3,00 (t, J = 6,9 Hz, 1H), 2,82 (ancho, 1H), 2,17-2,23 (m, 2H), 1,72-2,08 (m, 6H).

EJEMPLO 319

ácido 7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,37 (s, 1H), 8,95 (s, 1H), 8,26-8,28 (m, 1H), 7,86-7,88 (m, 1H), 7,77 (d, J = 7,67 Hz, 1H), 7,45-7,56 (m, 3H), 7,39 (t, J = 7,98 Hz, 1H), 7,06-7,14 (m, 2H), 6,90 (d, J = 7,67 Hz, 1H), 4,22 (t, J = 6,14 Hz, 2H), 3,35-3,39 (m, 2H), 2,22-2,28 (m, 2H), 2,08 (s, 6H).

EJEMPLO 320

ácido 7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-

carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 8,86 (s, 1H), 8,48 (d, J = 4,6 Hz, 1H), 8,26-8,28 (m, 1H), 7,94 (d, J = 7,98 Hz, 1H), 7,87-7,89 (m, 1H), 7,67 (s, 1H), 7,46-7,56 (m, 3H), 7,42 (t, J = 7,67 Hz, 1H), 7,35-7,39 (m, 1H), 7,19-7,23 (m, 1H), 7,02 (d, J = 7,36 Hz, 1H), 6,97 (d, J = 7,67 Hz, 1H), 6,94 (d, J = 7,36 Hz, 1H), 5,31 (s, 2H), 4,29 (t, J = 5,98 Hz, 2H), 3,42-3,46 (m, 2H), 2,28-2,35 (m, 2H), 1,78 (s, 6H).

EJEMPLO 321

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 8,61 (d, J = 4,6 Hz, 1H), 8,43 (s, 1H), 8,25-8,27 (m, 1H), 7,96 (d, J = 7,98 Hz, 1H), 7,87-7,89 (m, 1H), 7,61 (s, 1H), 7,46-7,56 (m, 4H), 7,41 (t, J = 7,83 Hz, 1H), 7,20-7,26 (m, 1H), 7,02 (d, J = 6,44 Hz, 1H), 6,93 (d, J = 7,36 Hz, 1H), 6,86 (d, J = 8,29 Hz, 1H), 5,13-5,37 (m, 2H), 4,28 (t, J = 6,14 Hz, 2H), 3,42-3,46 (m, 2H), 2,19-2,25 (m, 2H), 1,92-2,08 (m, 2H), 1,81 (s, 3H), 0,87 (t, J = 7,52 Hz, 3H).

EJEMPLO 322

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(1,3-tiazol-4-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 8,82 (d, J = 1,84 Hz, 1H), 8,61 (d, J = 5,52 Hz, 1H), 8,22-8,25 (m, 1H), 7,93 (d, J = 7,67 Hz, 1H), 7,86-7,88 (m, 1H), 7,46-7,56 (m, 4H), 7,40 (t, J = 7,83 Hz, 1H), 7,21 (t, J = 7,52 Hz, 1H), 7,02 (d, J = 6,75 Hz, 1H), 6,91 (d, J = 7,36 Hz, 1H), 6,47 (s, 1H), 5,21-5,36 (m, 2H), 4,27 (t, J = 5,98 Hz, 2H), 3,39-3,43 (m, 2H), 2,25-2,33 (m, 2H), 2,15-2,21 (m, 2H), 1,87 (s, 3H), 0,94 (t, J = 7,52 Hz, 3H).

EJEMPLO 323

ácido 7-(2-cloro-4-((4-morfolin-4-ilfenoxi)metil)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,50 (s, 1H), 8,47 (d, J = 4,91 Hz, 1H), 8,26-8,29 (m, 1H), 7,85-7,88 (m, 1H), 7,77 (dd, J = 7,06, 1,84, Hz, 1H), 7,57 (d, J = 7,22, Hz, 1H), 7,44-7,55 (m, 3H), 7,37 (t, J = 7,83 Hz, 1H), 7,07-7,12 (m, 2H), 6,87 (d, J = 7,36 Hz, 1H), 6,77 (d, J = 8,9 Hz, 2H), 6,63 (d, J = 8,9 Hz, 2H), 4,72 (d, J = 14,12 Hz, 1H), 4,50 (d, J = 13,81 Hz, 1H), 4,20 (t, J = 6,29 Hz, 2H), 3,65-3,68 (m, 4H), 3,35-3,39 (m, 2H), 2,90-2,92 (m, 4H), 2,21-2,27 (m, 2H).

EJEMPLO 324

ácido 7-(5-isopropil-1-metil-3-((4-morfolin-4-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □10,20 (s, 1H), 8,25-8,27 (m, 1H), 7,85-7,87 (m, 1H), 7,65 (dd, J = 7,06, 2,15, Hz, 1H), 7,44-7,55 (m, 3H), 7,36 (t, J = 7,98 Hz, 1H), 7,00-7,05 (m, 2H), 6,85 (d, J = 7,67 Hz, 1H), 6,81 (d, J = 8,59 Hz, 2H), 6,65 (d, J = 8,9 Hz, 2H), 4,54-4,60 (m, 2H), 4,17 (t, J = 6,29 Hz, 1H), 3,89 (s, 3H), 3,66-3,69 (m, 4H), 3,28-3,37 (m, 2H), 2,96-3,04 (m, 5H), 2,18-2,25 (m, 2H), 1,12 (d, J = 7,06 Hz, 3H), 0,96 (d, J = 7,06 Hz, 3H).

EJEMPLO 325

ácido 7-(3-isopropil-1-metil-5-((4-morfolin-4-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □10,20 (s, 1H), 8,23-8,25 (m, 1H), 7,85-7,87 (m, 1H), 7,69 (d, J = 6,44, Hz, 1H), 7,44-7,55 (m, 3H), 7,37 (t, J = 7,83 Hz, 1H), 7,03-7,10 (m, 2H), 6,88 (d, J = 7,36 Hz, 1H), 6,81-6,83 (m, 2H), 6,72-6,75 (m, 2H), 4,69-4,82 (m, 2H), 4,19 (t, J = 6,29 Hz, 1H), 3,87 (s, 3H), 3,69-3,72 (m, 4H), 3,32-3,36 (m, 2H), 2,97-2,99 (m, 4H), 2,72-2,79 (m, 1H), 2,18-2,25 (m, 2H), 1,08 (d, J = 6,75 Hz, 3H), 1,06 (d, J = 7,06 Hz, 3H).

EJEMPLO 326

ácido 7-(2-isopropenil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 8,56 (d, J = 5,22 Hz, 1H), 8,25-8,28 (m, 2H), 7,86-7,88 (m, 2H), 7,44-7,55 (m, 3H), 7,39 (t, J = 7,98 Hz, 1H), 7,33 (d, J = 4,6 Hz, 2H), 7,12-7,16 (m, 2H), 7,00 (d, J = 7,06 Hz, 1H), 6,89 (d, J = 7,36 Hz, 1H), 6,27 (d, J = 7,98 Hz, 1H), 5,75 (d, J = 17,8 Hz, 1H), 4,83-5,05 (m, 3H), 4,23 (t, J = 6,29 Hz, 2H), 3,40 (t, J = 7,52 Hz, 2H), 2,25-2,34 (m, 2H), 1,64 (s, 3H), 1,58 (s, 3H).

EJEMPLO 327

ácido 7-(1,5-dimetil-3-((4-morfolin-4-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 8,50 (d, J = 4,6 Hz, 1H), 8,24-8,27 (m, 1H), 7,86-7,88 (m, 1H), 7,79-7,84 (m, 2H), 7,44-7,54 (m, 4H), 7,38-7,40 (m, 1H), 7,06-7,10 (m, 2H), 6,93-6,94 (m, 1H), 6,88 (d, J = 7,36 Hz, 1H), 6,77 (d, J = 9,21 Hz, 2H), 6,60 (d, J = 9,21 Hz, 2H), 5,50-5,69 (m, 2H), 4,51 (s 2H), 4,22 (t, J = 6,44 Hz, 2H), 3,64-3,66 (m, 7H), 3,35-3,43 (m, 2H), 2,90-2,92 (m, 4H), 2,23-2,29 (m, 2H), 1,47 (s, 3H).

EJEMPLO 328

ácido 7-(2-etil-4-((4-morfolin-4-ilfenoxi)metil)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,40 (s, 1H), 8,84 (d, J = 5,83 Hz, 1H), 8,25-8,27 (m, 1H), 7,84-7,89 (m, 4H), 7,44-7,55 (m, 3H), 7,37 (t, J = 7,98 Hz, 1H), 7,14-7,21 (m, 2H), 6,87 (d, J = 7,67 Hz, 1H), 6,77 (d, J = 8,9 Hz, 2H), 6,64 (d, J = 9,21 Hz, 2H), 4,87 (d, J = 15,65 Hz, 1H), 4,52 (d, J = 15,34 Hz, 1H), 4,20 (t, J = 6,14 Hz, 2H), 3,66-3,68 (m, 7H), 3,36-3,39 (m, 2H), 2,89-2,92 (m, 4H), 2,59-2,62 (m 1H), 2,24-2,48 (m, 1H), 2,21-2,28 (m, 2H), 1,03 (t, J = 7,52 Hz, 3H).

EJEMPLO 329

ácido 7-(4-metil-2-pirimidin-5-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 11,36 (s, 1H), 8,99 (s, 1H), 8,72 (d, J = 5,19 Hz, 1H), 8,54 (s, 2H), 8,26-8,28 (m, 1H), 7,86-7,88 (m, 1H), 7,68 (dd, J = 7,32, 1,53 Hz, 1H), 7,60 (d, J = 5,19 Hz, 1H), 7,45-7,55 (m, 3H), 7,38 (t, J = 7,93 Hz, 1H), 6,96-7,01 (m, 2H), 6,86 (d, J = 7,32 Hz, 1H), 4,14 (t, J = 6,26 Hz, 2H), 3,26-3,37 (m, 2H), 2,16-2,22 (m, 2H),

2,06 (s, 3H).

EJEMPLO 330

ácido 7-(4-metil-6'-morfolin-4-il-2,3'-bipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,11 (s, 1H), 11,33 (s, 1H), 8,78 (d, J = 5,8 Hz, 1H), 8,25-8,27 (m, 1H), 8,01 (d, J = 2,14 Hz, 1H), 7,82-7,86 (m, 2H), 7,72-7,75 (m, 1H), 7,45-7,55 (m, 3H), 7,34-7,39 (m, 2H), 7,03 (d, J = 4,88 Hz, 2H), 6,86 (d, J = 7,32 Hz, 1H), 6,61 (d, J = 9,15 Hz, 1H), 4,16 (t, J = 6,41 Hz, 2H), 3,32-3,39 (m, 10H), 2,18-2,24 (m, 2H), 2,10 (s, 3H).

EJEMPLO 331

ácido 7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 8,84 (s, 1H), 8,26-8,30 (m, 2H), 7,87-7,92 (m, 2H), 7,46-7,62 (m, 4H), 7,40 (t, J = 7,93 Hz, 1H), 7,17-7,24 (m, 2H), 6,99 (d, J = 6,1 Hz, 1H), 6,93 (d, J = 7,63 Hz, 1H), 6,34 (d, J = 7,93 Hz, 1H), 5,36 (s, 2H), 4,27 (t, J = 6,1 Hz, 2H), 3,42-3,45 (m, 10H), 2,29-2,33 (m, 2H), 1,79 (s, 6H).

EJEMPLO 332

ácido 7-(4,6-dimetilpirimidin-5-il)-1-(2-(4-metilpiperazin-1-il)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 13,27 (s, 1H), 9,94 (s, 1H), 9,02 (s, 1H), 8,26-8,28 (m, 1H), 7,86-7,89 (m, 2H), 7,46-7,56 (m, 3H), 7,40 (t, J = 7,78 Hz, 1H), 7,16-7,19 (m, 1H), 7,03 (d, J = 6,41 Hz, 1H), 6,92 (d, J = 7,63 Hz, 1H), 6,34 (d, J = 7,93 Hz, 1H), 4,24 (t, J = 6,26 Hz, 2H), 3,42-3,45 (m, 2H), 2,64-2,81 (m, 7H), 2,07-2,11 (m, 6H).

EJEMPLO 333

ácido 1-(2-(dimetilamino)-2-oxoetil)-7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 8,98 (s, 1H), 8,27-8,29 (m, 1H), 7,84-7,89 (m, 2H), 7,46-7,55 (m, 3H), 7,40 (t, J = 7,93 Hz, 1H), 7,14-7,17 (m, 1H), 7,01 (d, J = 7,02 Hz, 1H), 6,92 (d, J = 7,32 Hz, 1H), 4,92 (s, 2H), 4,24 (t, J = 6,1 Hz, 2H), 3,36-3,39 (m, 2H), 2,63 (s, 3H), 2,41 (s, 3H), 2,21-2,27 (m, 2H), 2,08 (s, 6H).

EJEMPLO 334

ácido 7-(3-((4-(1,1-dioxidotiomorfolin-4-il)fenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,43 (s, 1H), 8,98 (s, 1H), 8,24 (d, J = 7,93 Hz, 1H), 7,85-7,87 (m, 2H), 7,65 (d, J = 7,93 Hz, 1H), 7,44-7,54 (m, 3H), 7,38 (t, J = 7,93 Hz, 1H), 7,02-7,11 (m, 2H), 6,85-6,90 (m, 3H), 6,87-6,90 (m, 2H), 4,72 (s, 2H), 4,19 (t, J = 6,1 Hz, 2H), 3,81 (s, 3H), 3,54-3,56 (m, 2H), 3,32-3,35 (m, 2H), 3,38-3,10 (m, 4H), 2,18-2,25 (m, 2H), 2,09 (s, 3H).

EJEMPLO 335

ácido 7-(4,6-dimetilpirimidin-5-il)-1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-

carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 9,04 (s, 1H), 8,23-8,25 (m, 1H), 7,86-7,91 (m, 2H), 7,45-7,56 (m, 3H), 7,40 (t, J = 7,83 Hz, 1H), 7,22 (t, J = 7,67 Hz, 1H), 7,11 (d, J = 7,37 Hz, 1H), 6,92 (d, J = 7,36 Hz, 1H), 4,23-4,33 (m, 4H), 3,36-3,40 (m, 2H), 2,84 (ancho, 4H), 2,18-2,25 (m, 2H), 2,20-2,26 (m, 8H).

EJEMPLO 336

ácido 7-(1,5-dimetil-3-((4-piperazin-1-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,40 (s, 1H), 8,69 (s, 2H), 8,22-8,24 (m, 1H), 7,85-7,87 (m, 1H), 7,65 (d, J = 7,98 Hz, 1H), 7,44-7,55 (m, 3H), 7,38 (t, J = 7,83 Hz, 1H), 7,01-7,11 (m, 2H), 6,89 (d, J = 7,06 Hz, 1H), 6,79-6,85 (m, 4H), 4,72 (s, 2H), 4,20 (t, J = 6,14 Hz, 2H), 3,81 (s, 3H), 3,34 (t, J = 7,52 Hz, 2H), 3,15-3,19 (m, 8H), 2,19-2,25 (m, 2H), 2,09 (s, 3H).

EJEMPLO 337

ácido 7-(3-((4-(4-acetilpiperazin-1-il)fenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 8,51 (d, J = 4,91 Hz, 1H), 8,24-8,27 (m, 1H), 7,79-7,89 (m, 3H), 7,45-7,55 (m, 4H), 7,38 (t, J = 7,83 Hz, 1H), 7,06-7,12 (m, 2H), 6,93 (d, J = 6,75 Hz, 1H), 6,88 (d, J = 7,36 Hz, 1H), 6,80 (d, J = 9,21 Hz, 2H), 6,61 (d, J = 9,21 Hz, 2H), 5,50-5,65 (m, 2H), 4,52 (s, 2H), 4,22 (t, J = 6,44 Hz, 2H), 3,66 (s, 3H), 3,37-3,53 (m, 6H), 2,86-2,95 (m, 4H), 2,23-2,30 (m, 2H), 1,99 (s, 3H), 1,47 (s, 3H).

EJEMPLO 338

ácido 7-(4,6-dimetilpirimidin-5-il)-1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,06 (s, 1H), 9,00 (s, 1H), 8,23-8,25 (m, 1H), 7,84-7,88 (m, 2H), 7,45-7,56 (m, 3H), 7,40 (t, J = 7,83 Hz, 1H), 7,17-7,21 (m, 1H), 7,08 (d, J = 7,06 Hz, 1H), 6,91 (d, J = 7,67 Hz, 1H), 4,23 (t, J = 5,98 Hz, 2H), 4,00-4,04 (m, 2H), 3,25-3,36 (m, 4H), 2,85 (ancho, 2H), 2,70 (s, 3H), 2,18-2,25 (m, 10H).

EJEMPLO 339

ácido 7-(3-((4-(4-(tert-butoxicarbonil)piperazin-1-il)fenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 10,38 (s, 1H), 9,00 (s, 1H), 8,22-8,24 (m, 1H), 7,85-7,87 (m, 1H), 7,65 (d, J = 7,98 Hz, 1H), 7,45-7,56 (m, 3H), 7,37 (t, J = 7,98 Hz, 1H), 7,01-7,10 (m, 2H), 6,78-6,89 (m, 5H), 4,72 (s, 2H), 4,19 (t, J = 6,14 Hz, 2H), 3,81 (s, 3H), 3,42-3,45 (m, 4H), 3,34 (t, J = 7,36 Hz, 2H), 2,94-2,97 (m, 2H), 2,18-2,26 (m, 2H), 2,09 (s, 3H), 1,41 (s, 9H).

EJEMPLO 340

ácido 1-(2-(dimetilamino)etil)-7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6): □ 8,96 (s, 1H), 8,16-8,18 (m, 1H), 7,79-7,84 (m,

2H), 7,38-7,49 (m, 3H), 7,33 (t, J = 7,83 Hz, 1H), 7,16 (t, J = 7,52 Hz, 1H), 7,04 (d, J = 7,06 Hz, 1H), 6,85 (d, J = 7,67 Hz, 1H), 4,16-4,23 (m, 4H), 3,51 (ancho, 6H), 3,30-3,34 (m, 2H), 2,77-2,81 (m, 2H), 2,43 (m, 2H), 2,13-2,26 (m, 8H).

EJEMPLO 341

ácido 3-(3-(1-naftiloxi)propil)-7-(4-(1H-pirazol-1-il)fenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,03 (s, 1H), 10,59 (s, 1H), 8,58 (d, 1H), 8,23 (m, 1H), 7,98 (ddd, 2H), 7,86 (m, 1H), 7,75 (m, 4H), 7,51 (m, 3H), 7,39 (m, 1H), 7,28 (m, 1H), 7,11 (m, 1H), 6,89 (m, 1H), 6,58 (m, 1H), 4,20 (t, 2H), 3,38 (t, 2H), 2,24 (m, 2H).

EJEMPLO 342

ácido 3-(3-(1-naftiloxi)propil)-7-(2,3,4-trifluorofenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,05 (s, 1H), 11,23 (s, 1H), 8,25 (m, 1H), 7,86 (m, 1H), 7,77 (d, 1H), 7,51 (m, 2H), 7,38 (m, 3H), 7,28 (m, 1H), 7,18 (m, 1H), 7,08 (m, 1H), 6,89 (m, 1H), 4,19 (t, 2H), 3,37 (t, 2H), 2,24 (m, 2H).

EJEMPLO 343

ácido 7-(4-hidroxi-3-metoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,01 (s, 1H), 10,23 (s, 1H), 9,10 (s, 1H), 8,23 (td, 7,87 (m, 1H), 7,63 (d, 1H), 7,51 (m, 3H), 7,38 (m, 1H), 7,21 (dd, 1H), 7,12 (d, 1H), 7,05 (m, 2H), 6,90 (m, 2H), 4,18 (t, 2H), 3,83 (s, 3H), 3,36 (m, 2H), 2,23 (m, 2H).

EJEMPLO 344

ácido 3-(3-(1-naftiloxi)propil)-7-(3,4,5-trimetoxifenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,00 (s, 1H), 10,58 (s, 1H), 8,24 (m, 1H), 7,87 (m, 1H), 7,67 (d, 1H), 7,52 (m, 2H), 7,41 (m, 2H), 7,26 (dd, 1H), 7,07 (dd, 1H), 6,89 (dd, 1H), 6,85 (s, 2H), 4,19 (t, 2H), 3,84 (s, 6H), 3,73 (s, 3H), 3,37 (m, 2H), 2,24 (m, 2H).

EJEMPLO 345

ácido 3-(3-(1-naftiloxi)propil)-7-(4-(trifluorometoxi)fenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,05 (s, 1H), 10,78 (s, 1H), 8,23 (m, 1H), 7,87 (m, 1H), 7,72 (m, 3H), 7,51 (m, 5H), 7,38 (m, 1H), 7,24 (dd, 1H), 7,09 (m, 1H), 6,89 (m, 1H), 4,19 (t, 2H), 3,37 (m, 2H), 2,24 (m, 2H).

EJEMPLO 346

ácido 7-(2-metoxi-5-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,97 (s, 1H), 9,97 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,67 (d, 1H), 7,51 (m, 3H), 7,40 (d, 1H), 7,21 (m, 1H), 7,12 (m, 2H), 7,04 (m, 2H), 6,90 (dd, 1H), 4,20 (t, 2H), 3,70 (s, 3H), 3,35 (m, 2H), 2,30 (s, 3H), 2,24 (m, 2H).

EJEMPLO 347

ácido 7-(3-fluoro-4-metoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,05 (s, 1H), 10,61 (s, 1H), 8,23 (m, 1H), 7,87 (m, 1H), 7,67 (d, 1H), 7,51 (m, 2H), 7,40 (m, 4H), 7,29 (t, 1H), 7,21 (dd, 1H), 7,06 (m, 1H), 6,89 (dd, 1H), 4,18 (t, 2H), 3,91 (s, 3H), 3,36 (m, 2H), 2,24 (m, 2H).

EJEMPLO 348

ácido 3-(3-(1-naftiloxi)propil)-7-(4-(5-oxo-2,5-dihidro-1H-pirazol-3-il)fenil)-1H-indol-2-

carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) □ 12,94 (s, 1H), 12,22 (s, 1H), 10,55 (s, 1H), 9,74 (s, 1H), 8,23 (m, 1H), 7,87 (m, 1H), 7,81 (d, 2H), 7,70 (d, 1H), 7,66 (d, 2H), 7,52 (m, 2H), 7,45 (m, 1H), 7,39 (t, 1H), 7,28 (dd, 1H), 7,10 (m, 1H), 6,90 (d, 1H), 5,96 (s, 1H), 4,19 (t, 2H), 3,39 (m, 2H), 2,24 (m, 2H).

EJEMPLO 349

ácido 7-(3-(morfolin-4-ilmetil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 10,58 (s, 1H), 8,24 (m, 1H), 7,87 (m, 1H), 7,73 (m, 3H), 7,62 (t, 1H), 7,51 (m, 4H), 7,39 (m, 1H), 7,27 (dd, 1H), 7,12 (m, 1H), 6,89 (dd, 1H), 4,45 (s, 2H), 4,19 (t, 2H), 3,97 (m, 2H), 3,63 (t, 2H), 3,41 (m, 2H), 3,38 (m, 3H), 3,17 (m, 3H), 2,24 (m, 2H).

EJEMPLO 350

ácido 7-(4-(morfolin-4-ilmetil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,12 (s, 1H), 10,39 (s, 1H), 8,22 (m, 1H), 7,87 (m, 1H), 7,74 (d, 3H), 7,62 (d, 2H), 7,51 (m, 2H), 7,46 (m, 1H), 7,38 (m, 1H), 7,27 (dd, 1H), 7,12 (m, 1H), 6,89 (dd, 1H), 4,44 (s, 2H), 4,20 (t, 2H), 4,00 (m, 2H), 3,66 (t, 2H), 3,38 (m, 3H), 3,21 (m, 3H), 2,24 (m, 2H).

EJEMPLO 351

ácido 7-(4-isopropoxi-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,92 (s, 1H), 10,37 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,66 (dd, 1H), 7,52 (m, 2H), 7,42 (m, 2H), 7,04 (m, 3H), 6,88 (m, 2H), 6,81 (dd, 1H), 4,65 (septeto, 1H), 4,20 (t, 2H), 3,36 (m, 2H), 2,23 (m, 2H), 2,02 (s, 3H), 1,31 (d, 6H).

EJEMPLO 352

ácido 3-(3-(1-naftiloxi)propil)-7-(4-(1H-pirazol-5-il)fenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,01 (s, 1H), 10,46 (s, 1H), 8,24 (m, 1H), 7,94 (d, 2H), 7,87 (m, 1H), 7,71 (m, 4H), 7,50 (m, 3H), 7,39 (m, 1H), 7,28 (m, 1H), 7,10 (m, 1H), 6,89 (m, 1H), 6,78 (d, 1H), 4,20 (t, 2H), 3,38 (t, 2H), 2,25 (m, 2H).

EJEMPLO 354

ácido 7-(2,5-dimetilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,93 (s, 1H), 10,36 (s, 1H), 8,24 (m, 1H), 7,87 (m, 1H), 7,68 (dd, 1H), 7,50 (m, 3H), 7,40 (d, 1H), 7,16 (m, 2H), 7,04 (m, 3H), 6,90 (d, 1H), 4,20 (t, 2H), 3,36 (m, 2H), 2,31 (s, 3H), 2,23 (m, 2H), 2,01 (s, 3H).

EJEMPLO 355

ácido 3-(3-(1-naftiloxi)propil)-7-(2,4,5-trimetilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,91 (s, 1H), 10,25 (s, 1H), 8,24 (m, 1H), 7,87 (m, 1H), 7,66 (dd, 1H), 7,52 (m, 2H), 7,41 (m, 2H), 7,04 (m, 4H), 6,90 (m, 1H), 4,20 (t, 2H), 3,36 (m, 2H), 2,26 (s, 3H), 2,24 (m, 2H), 2,22 (s, 3H), 1,99 (s, 3H).

EJEMPLO 356

ácido 3-(3-(1-naftiloxi)propil)-7-(3-(trifluorometoxi)fenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,05 (s, 1H), 10,80 (s, 1H), 8,21 (m, 1H), 7,86

(m, 1H), 7,73 (d, 1H), 7,62 (m, 2H), 7,47 (m, 6H), 7,26 (d, 1H), 7,10 (t, 1H), 6,89 (d, 1H), 4,19 (t, 2H), 3,37 (m, 2H), 2,22 (m, 2H).

EJEMPLO 357

ácido 7-(2-metil-4-propoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,92 (s, 1H), 10,38 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,66 (dd, 1H), 7,52 (m, 2H), 7,41 (m, 2H), 7,04 (m, 3H), 6,91 (m, 2H), 6,82 (dd, 1H), 4,20 (t, 2H), 3,98 (t, 2H), 3,36 (m, 2H), 2,23 (m, 2H), 2,03 (s, 3H), 1,76 (m, 2H), 1,01 (t, 3H).

EJEMPLO 358

ácido 7-(3-cianofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 11,07 (s, 1H), 8,22 (m, 1H), 8,02 (t, 1H), 7,87 (m, 3H), 7,71 (ddd, 2H), 7,51 (m, 3H), 7,40 (d, 1H), 7,26 (dd, 1H), 7,10 (m, 1H), 6,89 (dd, 1H), 4,19 (t, 2H), 3,37 (m, 2H), 2,24 (m, 2H).

EJEMPLO 359

ácido 3-(3-(1-naftiloxi)propil)-7-(2,3,5,6-tetrametilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 10,22 (s, 1H), 8,28 (m, 1H), 7,87 (m, 1H), 7,68 (d, 1H), 7,53 (m, 2H), 7,42 (m, 2H), 7,08 (dd, 1H), 7,03 (s, 1H), 6,89 (ddd, 2H), 4,22 (t, 2H), 3,39 (m, 2H), 2,25 (m, 2H), 2,22 (s, 6H), 1,73 (s, 6H).

EJEMPLO 360

ácido 7-(3-ciano-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 11,04 (s, 1H), 8,24 (m, 1H), 7,85 (m, 2H), 7,74 (m, 1H), 7,47 (m, 6H), 7,06 (m, 2H), 6,90 (d, 1H), 4,20 (t, 2H), 3,38 (m, 2H), 2,23 (m, 2H), 2,19 (s, 3H).

EJEMPLO 361

ácido 7-(3-etinil-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,93 (s, 1H), 10,87 (s, 1H), 8,26 (m, 1H), 7,87 (m, 1H), 7,70 (dd, 1H), 7,51 (m, 4H), 7,40 (d, 1H), 7,24 (m, 2H), 7,04 (m, 2H), 6,90 (dd, 1H), 4,38 (s, 1H), 4,20 (t, 2H), 3,37 (m, 2H), 2,23 (m, 2H), 2,12 (s, 3H).

EJEMPLO 362

ácido 7-(5-(((3-(dimetilamino)propil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 10,79 (s, 1H), 9,21 (s, 1H), 8,53 (t, 1H), 8,27 (m, 1H), 7,86 (m, 2H), 7,73 (m, 2H), 7,49 (m, 4H), 7,07 (m, 2H), 6,90 (m, 1H), 4,21 (t, 2H), 3,30 (m, 4H), 3,06 (m, 2H), 2,76 (d, 6H), 2,24 (m, 2H), 2,11 (s, 3H), 1,85 (m, 2H).

EJEMPLO 363

ácido 7-(2-isopropilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,93 (s, 1H), 10,35 (s, 1H), 8,26 (m, 1H), 7,87 (m, 1H), 7,69 (d, 1H), 7,53 (m, 2H), 7,41 (m, 4H), 7,25 (td, 1H), 7,15 (m, 1H), 7,04 (m, 2H), 6,91 (dd, 1H), 4,22 (t, 2H), 3,39 (m, 2H), 2,69 (m, 1H), 2,26 (m, 2H), 1,06 (dd, 6H).

EJEMPLO 364

ácido 7-(5-(((2-(dimetilamino)etil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,97 (s, 1H), 10,77 (s, 1H), 9,24 (s, 1H), 8,59 (m, 1H), 8,27 (m, 1H), 7,87 (m, 2H), 7,74 (m, 2H), 7,50 (m, 4H), 7,07 (m, 2H), 6,90 (m, 1H), 4,20 (t, 2H), 3,58 (m, 2H), 3,38 (m, 2H), 3,23 (m, 2H), 2,82 (d, 6H), 2,25 (m, 2H), 2,12 (s, 3H).

EJEMPLO 365

ácido 7-(2-metil-5-(((2-morfolin-4-iletil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,98 (s, 1H), 10,77 (s, 1H), 9,54 (s, 1H), 8,61 (m, 1H), 8,27 (m, 1H), 7,87 (m, 2H), 7,74 (m, 2H), 7,53 (m, 2H), 7,43 (m, 2H), 7,08 (m, 2H), 6,91 (dd, 1H), 4,21 (t, 2H), 3,98 (m, 2H), 3,55 (m, 5H), 3,39 (m, 7H), 2,26 (m, 2H), 2,12 (s, 3H).

EJEMPLO 366

ácido 7-(2-metil-5-(((3-morfolin-4-ilpropil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,97 (s, 1H), 10,79 (s, 1H), 9,50 (s, 1H), 8,55 (t, 1H), 8,27 (m, 1H), 7,86 (m, 2H), 7,73 (m, 2H), 7,53 (m, 2H), 7,42 (m, 2H), 7,07 (m, 2H), 6,91 (dd, 1H), 4,20 (t, 2H), 3,95 (m, 2H), 3,61 (td, 2H), 3,38 (m, 2H), 3,32 (m, 4H), 3,09 (m, 4H), 2,23 (m, 2H), 2,11 (s, 3H), 1,88 (m, 2H).

EJEMPLO 367

ácido 7-(2-metil-5-(((2-feniletil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,94 (s, 1H), 10,83 (s, 1H), 8,49 (t, 1H), 8,28 (m, 1H), 7,87 (m, 1H), 7,81 (dd, 1H), 7,71 (m, 2H), 7,53 (m, 2H), 7,46 (m, 1H), 7,39 (ddd, 2H), 7,22 (m, 5H), 7,08 (m, 2H), 6,91 (dd, 1H), 4,20 (t, 2H), 3,46 (m, 2H), 3,37 (m, 2H), 2,82 (t, 2H), 2,24 (m, 2H), 2,09 (s, 3H).

EJEMPLO 368

ácido 7-(1H-indazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,11 (s, 1H), 13,02 (s, 1H), 10,44 (s, 1H), 8,24 (m, 1H), 8,15 (d, 1H), 8,00 (dd, 1H), 7,87 (m, 1H), 7,67 (m, 2H), 7,58 (dd, 1H), 7,52 (m, 2H), 7,39 (m, 1H), 7,27 (dd, 1H), 7,10 (dd, 1H), 6,90 (dd, 1H), 4,20 (t, 2H), 3,38 (m, 2H), 2,25 (m, 2H).

EJEMPLO 369

ácido 7-(5-((((1S,4R)-biciclo(2,2,1)hept-2-ilmetil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,92 (s, 1H), 10,82 (s, 1H), 8,34 (m, 2H), 7,85 (m, 2H), 7,72 (m, 2H), 7,53 (m, 2H), 7,41 (m, 3H), 7,06 (m, 2H), 6,91 (d, 1H), 4,21 (t, 2H), 3,39 (m, 2H), 3,23 (m, 2H), 3,02 (m, 1H), 2,26 (m, 2H), 2,14 (m, 2H), 2,09 (m, 3H), 2,04 (m, 1H), 1,65 (m, 3H), 1,27 (m, 2H), 1,07 (m, 2H).

Ejemplo 370

ácido 7-(2-metil-5-(((3-fenilpropil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,93 (s, 1H), 10,83 (s, 1H), 8,41 (t, 1H), 8,27 (m, 1H), 7,85 (m, 2H), 7,73 (td, 2H), 7,53 (m, 2H), 7,41 (m, 3H), 7,21 (m, 5H), 7,07 (m, 2H), 6,90 (dd, 1H), 4,21 (m, 2H), 3,43 (m, 2H), 3,27 (m, 2H), 2,60 (m, 2H), 2,24 (m, 2H), 2,09 (s, 3H), 1,81 (m, 2H).

EJEMPLO 371

ácido 7-(2-((2-isopropil-5-metilfenoxi)metil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,97 (s, 1H), 10,56 (s, 1H), 8,24 (m, 1H), 7,86 (m, 1H), 7,71 (d, 1H), 7,65 (dd, 1H), 7,49 (m, 5H), 7,37 (m, 2H), 7,14 (m, 1H), 7,06 (m, 1H), 6,97 (d, 1H), 6,88 (dd, 1H), 6,61 (d, 1H), 6,38 (d, 1H), 4,82 (m, 2H), 4,19 (t, 2H), 3,37 (m, 2H), 3,07 (septeto, 1H), 2,23 (m, 2H), 2,07 (s, 3H), 1,04 (d, 6H).

EJEMPLO 372

ácido 7-(2-cloro-6-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,92 (s, 1H), 11,00 (s, 1H), 8,29 (m, 1H), 7,87 (m, 1H), 7,71 (d, 1H), 7,53 (m, 2H), 7,37 (m, 5H), 7,09 (dd, 1H), 6,96 (dd, 1H), 6,91 (dd, 1H), 4,22 (t, 2H), 3,37 (m, 2H), 2,25 (m, 2H), 1,94 (s, 3H).

EJEMPLO 373

ácido 7-(2-bencilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,94 (s, 1H), 10,41 (s, 1H), 8,26 (m, 1H), 7,87 (m, 1H), 7,69 (dd, 1H), 7,52 (m, 2H), 7,38 (m, 4H), 7,24 (m, 2H), 7,05 (m, 5H), 6,90 (dd, 1H), 6,83 (m, 2H), 4,20 (t, 2H), 3,81 (m, 1H), 3,66 (m, 1H), 3,37 (m, 2H), 2,25 (m, 2H).

EJEMPLO 374

ácido 3-(3-(1-naftiloxi)propil)-7-(2,4,6-triisopropilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,92 (s, 1H), 10,23 (s, 1H),8,28 (m, 1H), 7,87 (m, 1H), 7,67 (d, 1H), 7,51 (m, 3H), 7,39 (m, 1H), 7,08 (m, 3H), 6,93 (m, 2H), 4,23 (t, 2H), 3,37 (m, 2H), 2,95 (m, 1H), 2,33 (m, 2H), 2,25 (m, 2H), 1,29 (d, 6H), 0,99 (dd, 12H).

EJEMPLO 375

ácido 3-(3-(1-naftiloxi)propil)-7-(1-oxo-2,3-dihidro-1H-inden-4-il)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,98 (s, 1H), 10,99 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,75 (dd, 1H), 7,71 (dd, 1H), 7,63 (m, 1H), 7,50 (m, 5H), 7,14 (m, 2H), 6,91 (dd, 1H), 4,21 (t, 2H), 3,38 (m, 2H), 2,82 (m, 2H), 2,58 (m, 2H), 2,24 (m, 2H).

EJEMPLO 376

ácido 7-(2-ciclopentilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,95 (s, 1H), 10,24 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,69 (d, 1H), 7,52 (m, 2H), 7,40 (m, 4H), 7,24 (td, 1H), 7,16 (m, 1H), 7,05 (m, 2H), 6,90 (d, 1H), 4,21 (m, 2H), 3,38 (m, 2H), 2,74 (m, 1H), 2,25 (m, 2H), 1,72 (m, 4H), 1,37 (m, 4H).

EJEMPLO 377

ácido 7-(2',6'-dimetoxi-1,1'-bifenil-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,07 (s, 1H), 8,93 (s, 1H), 8,22 (m, 1H), 7,86 (m, 1H), 7,45 (m, 8H), 7,25 (m, 1H), 6,94 (m, 3H), 6,82 (m, 1H), 6,41 (d, 2H), 4,07 (t, 2H), 3,42 (s, 6H), 3,24 (m, 2H), 2,14 (m, 2H).

EJEMPLO 378

ácido 3-(3-(1-naftiloxi)propil)-7-(5,6,7,8-tetrahidronaftalen-1-il)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,91 (s, 1H), 10,43 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,67 (m, 1H), 7,52 (m, 2H), 7,42 (m, 2H), 7,14 (m, 2H), 7,02 (m, 3H), 6,91 (dd, 1H), 4,21 (t, 2H), 3,38 (td, 2H), 2,82 (t, 2H), 2,29 (m, 4H), 1,73 (m, 2H), 1,60 (m, 2H).

EJEMPLO 379

ácido 7-(4'-tert-butil-1,1'-bifenil-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,85 (s, 1H), 9,87 (s, 1H), 8,23 (m, 1H), 7,86 (m, 1H), 7,50 (m, 9H), 7,06 (ddd, 4H), 6,91 (m, 2H), 6,85 (m, 1H), 4,13 (t, 2H), 3,25 (m, 2H), 2,18 (m, 2H), 1,12 (s, 9H).

EJEMPLO 380

ácido 7-(5-fluoro-2-metil-3-((metilsulfonil)metil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,95 (s, 1H), 10,76 (s, 1H), 8,24 (m, 1H), 7,87 (m, 1H), 7,71 (dd, 1H), 7,52 (m, 2H), 7,41 (m, 2H), 7,28 (dd, 1H), 7,05 (m, 3H), 6,90 (dd, 1H), 4,64 (s, 2H), 4,21 (t, 2H), 3,40 (m, 2H), 3,06 (s, 3H), 2,24 (m, 2H), 2,04 (s, 3H).

EJEMPLO 381

ácido 7-(5-(((2-hidroxi-1,1-dimetiletil)amino)carbonil)-2,3,4-trimetilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 8,24 (m, 1H), 7,86 (m, 1H), 7,63 (d, 1H), 7,51 (m, 4H), 7,38 (m, 1H), 7,03 (m, 1H), 6,95 (m, 2H), 6,89 (d, 1H), 4,87 (s, 1H), 4,20 (t, 2H), 3,46 (s, 2H), 3,39 (m, 2H), 2,29 (s, 3H), 2,26 (m, 2H), 2,24 (s, 3H), 1,99 (s, 3H), 1,26 (s, 6H).

EJEMPLO 382

ácido 7-(2-(4-(etoxicarbonil)piperazin-1-il)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,08 (s, 1H), 10,05 (s, 1H), 8,25 (m, 1H), 7,86 (m, 1H), 7,74 (d, 1H), 7,43 (m, 7H), 7,15 (m, 3H), 6,84 (m, 1H), 4,16 (t, 2H), 3,93 (q, 2H), 3,39 (m, 2H), 2,97 (m, 4H), 2,76 (m, 4H), 2,24 (m, 2H), 1,08 (t, 3H).

EJEMPLO 383

ácido 7-(2-metil-6-nitrofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,01 (s, 1H), 11,04 (s, 1H), 8,28 (m, 1H), 7,86 (m, 2H), 7,65 (m, 2H), 7,54 (m, 3H), 7,41 (m, 2H), 7,02 (m, 1H), 6,89 (ddd, 2H), 4,22 (t, 2H), 3,38 (m, 2H), 2,24 (m, 2H), 1,94 (s, 3H).

EJEMPLO 384

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-propionilpiperazin-1-il)fenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,10 (s, 1H), 10,09 (s, 1H), 8,24 (m, 1H), 7,86 (m, 1H), 7,75 (d, 1H), 7,51 (m, 2H), 7,39 (m, 5H), 7,15 (td, 3H), 6,85 (dd, 1H), 4,16 (t, 2H), 3,39 (m, 2H), 3,17 (m, 2H), 2,94 (m, 2H), 2,75 (m, 4H), 2,24 (m, 2H), 2,12 (q, 2H), 0,85 (t, 3H).

EJEMPLO 385

ácido 7-(2-metil-6-tien-2-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,89 (s, 1H), 10,76 (s, 1H), 8,29 (m, 1H), 7,86 (m, 1H), 7,66 (d, 1H), 7,51 (m, 4H), 7,35 (m, 3H), 7,16 (dd, 1H), 6,96 (dd, 1H), 6,86 (ddd, 2H), 6,72 (m, 1H), 6,67 (m, 1H), 4,17 (t, 2H), 3,38 (m, 2H), 2,23 (m, 2H), 1,93 (s, 3H).

EJEMPLO 386

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-(1,3-tiazol-4-ilmetil)piperazin-1-il)fenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,00 (s, 1H), 10,21 (s, 1H), 9,12 (d, 1H), 8,27 (m, 1H), 7,87 (m, 1H), 7,79 (s, 1H), 7,72 (d, 1H), 7,53 (m, 2H), 7,40 (m, 4H), 7,28 (dd, 1H), 7,17 (t, 2H), 7,10 (dd, 1H), 6,90 (dd, 1H), 4,29 (s, 2H), 4,21 (t, 2H), 3,39 (m, 6H), 3,16 (m, 2H), 2,90 (m, 2H), 2,25 (m, 2H).

EJEMPLO 387

ácido 7-(2-(4-(2-hidroxietil)piperazin-1-il)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,02 (s, 1H), 9,91 (s, 1H), 8,24 (td, 1H), 7,86 (m, 1H), 7,73 (d, 1H), 7,51 (m, 2H), 7,38 (m, 5H), 7,14 (m, 3H), 6,85 (dd, 1H), 4,30 (s, 1H), 4,17 (t, 2H), 3,40 (m, 6H), 2,76 (m, 4H), 2,21 (m, 6H).

EJEMPLO 388

ácido 7-(2-(4-(metilsulfonil)piperazin-1-il)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,21 (s, 1H), 10,13 (s, 1H), 8,24 (m, 1H), 7,86 (m, 1H), 7,73 (d, 1H), 7,52 (m, 2H), 7,41 (m, 4H), 7,33 (m, 1H), 7,14 (m, 3H), 6,87 (dd, 1H), 4,18 (t, 2H), 3,39 (m, 3H), 2,85 (m, 4H), 2,72 (m, 3H), 2,64 (s, 3H), 2,23 (m, 2H).

EJEMPLO 389

ácido 7-(2-((4-(tert-butoxicarbonil)piperazin-1-il)sulfonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 10,33 (s, 1H), 8,28 (m, 1H), 8,07 (dd, 1H), 7,87 (m, 1H), 7,73 (td, 1H), 7,65 (td, 2H), 7,53 (m, 2H), 7,42 (m, 3H), 7,09 (dd, 1H), 6,97 (m, 1H), 6,89 (d, 1H), 4,17 (m, 2H), 3,42 (m, 2H), 3,18 (m, 2H), 2,82 (m, 2H), 2,58 (m, 2H), 2,42 (m, 2H), 2,20 (m, 2H), 1,28 (s, 9H).

EJEMPLO 390

ácido 7-(2-((4-etilpiperazin-1-il)sulfonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,04 (s, 1H), 11,19 (s, 1H), 8,27 (m, 1H), 8,08 (m, 1H), 7,89 (m, 1H), 7,75 (m, 3H), 7,54 (m, 2H), 7,45 (m, 3H), 7,11 (m, 2H), 6,93 (d, 1H), 4,23 (t, 2H), 3,47 (m, 2H), 3,18 (m, 3H), 2,72 (m, 4H), 2,36 (m, 2H), 2,23 (m, 2H),

1,49 (m, 1H), 1,00 (t, 3H).

EJEMPLO 391

ácido 3-(3-(1-naftiloxi)propil)-7-(2-((4-(2-oxopirrolidin-1-il)piperidin-1-il)sulfonil)fenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,95 (s, 1H), 11,08 (s, 1H), 8,27 (m, 1H), 8,07 (dd, 1H), 7,87 (m, 1H), 7,67 (m, 3H), 7,53 (m, 2H), 7,41 (m, 3H), 7,17 (dd, 1H), 7,03 (dd, 1H), 6,89 (dd, 1H), 4,19 (m, 2H), 3,45 (m, 3H), 2,95 (m, 4H), 2,25 (m, 4H), 2,09 (m, 2H), 1,77 (dq, 2H), 1,10 (m, 3H), 0,31 (m, 1H).

EJEMPLO 392

ácido 7-(3-((1S,4R)-2-hidroxibiciclo(2,2,1)hept-2-il)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) □ 12,97 (m, 1H), 10,55 (s, 0,5H), 9,78 (s, 0,5H), 8,24 (m, 1H), 7,87 (d, 1H), 7,69 (m, 1H), 7,48 (m, 4H), 7,39 (t, 1H), 7,19 (m, 1H), 7,07 (m, 2,5H), 6,92 (m, 1,5H), 4,75 (d, 1H), 4,21 (t, 2H), 3,38 (m, 2H), 2,83 (m, 1H), 2,24 (m, 4H), 2,15 (d, 3H), 1,98 (m, 1H), 1,50 (m, 6H).

EJEMPLO 393

ácido 7-((1E)-1-etilbut-1-enil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,01 (s, 1H), 10,41 (s, 1H), 8,23 (m, 1H), 7,86 (m, 1H), 7,51 (m, 4H), 7,39 (d, 1H), 6,98 (m, 2H), 6,89 (dd, 1H), 5,50 (t, 1H), 4,18 (t, 2H), 3,39 (m, 2H), 2,53 (m, 2H), 2,22 (m, 4H), 1,05 (t, 3H), 0,83 (t, 3H).

EJEMPLO 394

ácido 7-((Z)-2-carboxi-1-pentilvinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,97 (s, 1H), 12,13 (s, 1H), 11,07 (s, 1H), 8,23 (m, 1H), 7,86 (m, 1H), 7,66 (d, 1H), 7,51 (m, 2H), 7,41 (m, 2H), 7,12 (m, 1H), 6,99 (m, 1H), 6,89 (m, 1H), 5,90 (s, 1H), 4,18 (t, 2H), 3,40 (m, 2H), 3,07 (m, 2H), 2,21 (m, 2H), 1,23 (m, 6H), 0,76 (m, 3H).

EJEMPLO 395

ácido 7-(5,7-dimetilpirazolo(1,5-a)pirimidin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,56 (s, 1H), 13,08 (s, 1H), 8,92 (s, 1H), 8,25 (m, 1H), 7,86 (m, 2H), 7,59 (d, 1H), 7,52 (m, 2H), 7,41 (m, 2H), 7,03 (m, 2H), 6,89 (dd, 1H), 4,19 (t, 2H), 3,39 (m, 2H), 2,75 (s, 3H), 2,72 (s, 3H), 2,25 (m, 2H).

EJEMPLO 396

ácido 7-(4-(4-fluorofenil)-5-(4-(metilsulfonil)fenil)tien-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,17 (s, 1H), 10,87 (s, 1H), 8,22 (m, 1H), 7,89 (m, 3H), 7,76 (d, 1H), 7,71 (s, 1H), 7,48 (m, 8H), 7,26 (ddd, 2H), 7,11 (m, 1H), 6,90 (dd, 1H), 4,20 (t, 2H), 3,40 (m, 2H), 3,24 (s, 3H), 2,24 (m, 2H).

EJEMPLO 397

ácido 3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-7-(2-(trifluorometil)fenil)-1H-indol-2-

carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,29 (s, 1H), 8,40 (d, 2H), 8,23 (m, 1H), 7,90 (m, 2H), 7,77 (d, 1H), 7,53 (m, 5H), 7,31 (t, 1H), 7,16 (dd, 1H), 7,03 (t, 2H), 6,93 (dd, 1H), 6,63 (d, 2H), 5,61 (d, 1H), 5,01 (d, 1H), 4,26 (t, 2H), 3,42 (m, 2H), 2,29 (m, 2H).

EJEMPLO 398

ácido 7-(5-(((2-(dimetilamino)etil)(piridin-2-il)amino)metil)tien-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) □ 9,77 (s, 1H), 8,16 (m, 2H), 7,82 (d, 1H), 7,68 (m, 1H), 7,59 (m, 1H), 7,44 (m, 4H), 7,35 (dd, 2H), 7,14 (t, 1H), 7,07 (td, 1H), 6,91 (d, 1H), 6,87 (m, 1H), 6,72 (m, 1H), 4,94 (s, 1H), 4,77 (s, 1H), 4,21 (m, 2H), 3,94 (t, 1H), 3,36 (m, 4H), 2,89 (s, 6H), 2,24 (m, 3H).

EJEMPLO 399

ácido 7-(2-morfolin-4-il-6-(trifluorometil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,81 (s, 1H), 10,77 (s, 1H), 8,31 (m, 1H), 7,87 (m, 1H), 7,69 (dd, 1H), 7,55 (m, 4H), 7,40 (m, 3H), 7,00 (m, 2H), 6,83 (d, 1H), 4,16 (m, 2H), 3,40 (d, 2H), 2,92 (m, 2H), 2,75 (m, 2H), 2,62 (m, 4H), 2,24 (m, 2H).

EJEMPLO 400

ácido 7-(4-metoxi-2-fenil-1-benzofuran-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,81 (s, 1H), 10,99 (s, 1H), 8,31 (m, 1H), 7,87 (m, 1H), 7,75 (d, 1H), 7,53 (m, 2H), 7,46 (m, 1H), 7,34 (m, 5H), 7,21 (m, 4H), 7,06 (m, 1H), 6,88 (d, 1H), 6,73 (m, 1H), 4,19 (t, 2H), 3,42 (s, 3H), 3,38 (d, 2H), 2,26 (m, 2H).

EJEMPLO 401

ácido 4-fluoro-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,29 (s, 1H), 10,36 (s, 1H), 8,17 (dd, 1H), 7,85 (m, 1H), 7,43 (m, 6H), 7,30 (dd, 1H), 7,14 (m, 2H), 6,96 (dd, 1H), 6,89 (dd, 1H), 4,22 (t, 2H), 3,48 (m, 2H), 3,23 (m, 4H), 2,75 (m, 4H), 2,25 (m, 2H).

EJEMPLO 402

ácido 4-fluoro-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

EJEMPLO 402A

7-bromo-3-(3-etoxi-3-oxopropil)-4-fluoro-1H-indol-2-carboxilato de etilo

Una mezcla de 2-bromo-5-fluoroanilina (5 g) en etanol (17,5 ml) y HCl 1,6M (50 ml) a -5 °C se trató con $NaNO_2$ 2,5M (10,5 ml). Luego se agregó acetato de potasio 4,5M (29,2 ml), seguido por 2-oxociclopentancarboxilato de etilo (3,8 ml). La mezcla de reacción se agitó a 0 °C durante 15 minutos, se calentó a 20 °C a lo largo de 1,5 horas, se extrajo con diclorometano, se concentró y se secó al vacío. El residuo se disolvió en 67 ml de (H_2SO_4/etanol, 17:50), se sometió a reflujo durante 2 días, se enfrió a temperatura ambiente, se neutralizó con agua y se extrajo con diclorometano. Los extractos combinados se lavaron con salmuera, se secó ($MgSO_4$), se filtró y se concentró. El concentrado se purificó por cromatografía en columna sobre gel de sílice con 5-20% acetato de etilo en hexanos. El producto se purificó adicionalmente por trituración con

etanol.

EJEMPLO 402B

ácido 3-(7-bromo-2-(etoxicarbonil)-4-fluoro-1H-indol-3-il)propanoico

A una mezcla del EJEMPLO 402A (2,3 g) en ácido acético (40 ml) se agregó ácido clorhídrico concentrado (3 ml). La mezcla se calentó a 80 °C durante 4 horas. Después de enfriar a temperatura ambiente, ocurrió la precipitación del producto. Se agregó agua (50mL) para favorecer la precipitación. El sólido se filtró, se enjuagó con agua y se secó al vacío.

EJEMPLO 402C

7-bromo-4-fluoro-3-(3-hidroxipropil)-1H-indol-2-carboxilato

A una suspensión del EJEMPLO 402B (1,9 g) en tetrahidrofurano (10 ml) se agregó borano•tetrahidrofurano 1M (5,8 ml). La mezcla de reacción se agitó a temperatura ambiente durante la noche. Se agregó más 1M borano•tetrahidrofurano (2,0 ml) y se continuó la agitación durante 3 horas. La reacción se neutralizó con metanol y se concentró. El concentrado se disolvió en etanol caliente (30 ml) y 1 ml de HCl concentrado, y se agitó durante 1 hora. Ocurrió la precipitación del producto. Se agregó agua (20 ml) para favorecer la precipitación. El sólido se filtró, se enjuagó con agua y se secó.

EJEMPLO 402D

7-bromo-4-fluoro-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo

A una mezcla del EJEMPLO 402C (1,03 g), naftalen-1-ol (519 mg), y trifenilfosfina (905 mg) en tetrahidrofurano (15 ml) a -10 °C se agregó azodicarboxilato de di-tert-butilo (794 mg) lentamente. Después de una hora, la reacción se dejó calentar hasta temperatura ambiente. Se continuó la agitación durante dos horas a temperatura ambiente. La mezcla de reacción se concentró. El concentrado se purificó por cromatografía en columna sobre gel de sílice con 0-4% acetato de etilo en hexanos.

EJEMPLO 402E

ácido 4-fluoro-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

Una mezcla del EJEMPLO 402D (47 mg), ácido o-tolilborónico (19 mg), tris(dibencilidenacetona)dipaladio(0) (4,6 mg), tetrafluoroborato de tri-t-butil-fosfonio (3,5 mg), fluoruro de cesio (45,6 mg) y tetrahidrofurano (1,5 ml) se agitó a temperatura ambiente bajo una atmósfera de nitrógeno durante la noche. Se agregaron más o-tolilborónico ácido (9,5 mg), tris(dibencilidenacetona)dipaladio(0) (2,3 mg), tetrafluoroborato de tri-t-butil-fosfonio (1,8 mg) y fluoruro de cesio (23 mg) y se continuó la agitación a temperatura ambiente durante la noche. Se agregaron $LiOH-H_2O$ (42 mg) y agua (0,5 ml) y la mezcla se calentó durante la noche a 60 °C. La mezcla de reacción se acidificó con HCl 1 M (aq), se extrajo (3 x 5 ml) con acetato de etilo, se secó ($MgSO_4$), se filtró y se concentró. El concentrado se suspendió en metanol y se filtró a través de un filtro de jeringa. El filtrado se concentró. El concentrado se purificó por HPLC en fase reversa (50-95% acetonitrilo/ agua/0,1% ácido trifluoroacético). ^1H RMN (300 MHz,

DMSO-d_6) □ 13,10 (s, 1H), 10,86 (s, 1H), 8,20 (m, 1H), 7,86 (m, 1H), 7,48 (m, 4H), 7,28 (m, 4H), 6,99 (m, 1H), 6,90 (m, 2H), 4,23 (t, 2H), 3,45 (t, 2H), 2,25 (m, 2H), 2,05 (s, 3H).

EJEMPLO 403

ácido 7-(2-((2-adamantilamino)carbonil)-6-metilimidazo(1,2-a)piridin-8-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,03 (s, 1H), 10,76 (s, 1H), 8,48 (d, 2H), 8,22 (m, 1H), 7,85 (m, 2H), 7,59 (m, 1H), 7,49 (m, 5H), 7,37 (m, 1H), 7,16 (dd, 1H), 6,87 (dd, 1H), 4,19 (t, 2H), 3,95 (m, 1H), 3,41 (m, 2H), 2,39 (d, 3H), 2,26 (m, 2H), 1,86 (m, 2H), 1,78 (m, 6H), 1,62 (m, 4H), 1,43 (m, 2H).

EJEMPLO 404

ácido 7-(1-(1-adamantil)-3-carboxi-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,86 (s, 1H), 12,22 (s, 1H), 10,59 (s, 1H), 8,26 (m, 1H), 7,99 (s, 1H), 7,87 (m, 1H), 7,62 (d, 1H), 7,51 (m, 3H), 7,40 (d, 1H), 7,10 (d, 1H), 6,98 (t, 1H), 6,90 (d, 1H), 4,19 (t, 2H), 3,37 (m, 2H), 2,24 (m, 2H), 2,20 (s, 9H), 1,75 (s, 6H).

EJEMPLO 405

ácido 7-(2-(1-hidroxi-4-metoxiciclohexil)-1-benzotien-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,93 (s, 1H), 10,63 (s, 1H), 8,29 (m, 1H), 7,91 (m, 2H), 7,76 (m, 1H), 7,51 (m, 2H), 7,42 (m, 2H), 7,28 (ddd, 1H), 7,11 (m, 2H), 6,88 (m, 1H), 6,64 (d, 1H), 6,07 (s, 1H), 5,57 (s, 1H), 4,21 (m, 2H), 3,40 (s, 2H), 3,06 (s, 3H), 2,64 (m, 1H), 2,26 (m, 2H), 1,62 (m, 6H).

EJEMPLO 406

ácido 7-(5-cloro-3-metil-1-tetrahidro-2H-piran-2-il-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 10,71 (s, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,69 (dt, 1H), 7,52 (m, 2H), 7,41 (dt, 2H), 7,05 (m, 2H), 6,91 (d, 1H), 5,44 (dd, 1H), 4,20 (t, 2H), 3,94 (d, 1H), 3,69 (m, 1H), 3,46 (m, 2H), 2,25 (m, 3H), 2,13 (s, 3H), 1,99 (m, 2H), 1,73 (m, 1H), 1,55 (m, 2H).

EJEMPLO 407

ácido 3-(3-(1-naftiloxi)propil)-7-(2,2,4-trimetil-1-(fenilsulfonil)-1,2-dihidroquinolin-3-il)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,01 (s, 1H), 11,27 (s, 1H), 8,23 (m, 1H), 7,86 (m, 1H), 7,67 (m, 1H), 7,52 (m, 7H), 7,34 (m, 6H), 6,85 (m, 2H), 6,43 (m, 1H), 4,95 (s, 1H), 4,17 (t, 2H), 3,76 (s, 2H), 3,37 (m, 2H), 2,20 (m, 2H), 1,33 (s, 6H).

EJEMPLO 408

ácido 7-(7,8-dimetil-2-(1-metil-1-feniletil)imidazo(1,2-a)piridin-6-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,50 (s, 1H), 11,16 (s, 1H), 8,67 (s, 1H), 8,26

(m, 1H), 8,16 (s, 1H), 7,85 (m, 2H), 7,53 (m, 2H), 7,38 (m, 7H), 7,16 (m, 2H), 6,91 (dd, 1H), 4,21 (t, 2H), 3,42 (m, 2H), 2,56 (s, 3H), 2,25 (m, 2H), 2,07 (s, 3H), 1,81 (s, 6H).

EJEMPLO 409

ácido 7-(1-(4-((2-fluorobenzoil)amino)fenil)-3-(trifluorometil)-1H-pirazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) □ 11,33 (s, 1H), 10,48 (s, 1H), 8,23 (d, 1H), 7,85 (d, 1H), 7,74 (d, 1H), 7,62 (m, 3H), 7,53 (m, 3H), 7,44 (m, 1H), 7,33 (m, 5H), 7,09 (m, 2H), 6,98 (t, 1H), 6,87 (d, 1H), 4,16 (t, 2H), 3,38 (m, 2H), 2,20 (m, 2H).

EJEMPLO 410

ácido 7-(5-amino-3-(piperidin-1-ilcarbonil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) □ 13,03 (s, 1H), 10,30 (s, 1H), 8,27 (m, 1H), 7,86 (m, 1H), 7,61 (d, 1H), 7,53 (m, 2H), 7,45 (d, 1H), 7,38 (t, 1H), 7,10 (m, 1H), 7,00 (m, 1H), 6,86 (d, 1H), 5,17 (s, 2H), 4,16 (t, 2H), 3,59 (m, 4H), 3,01 (m, 2H), 2,22 (ddd, 2H), 1,28 (m, 4H), 0,76 (m, 2H).

EJEMPLO 411

ácido 7-(3-metil-1-(2-nitrofenil)-5-fenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,99 (s, 1H), 10,72 (s, 1H), 8,26 (m, 1H), 8,04 (dd, 1H), 7,87 (m, 1H), 7,65 (s, 3H), 7,50 (m, 3H), 7,37 (m, 2H), 7,13 (m, 3H), 7,04 (m, 2H), 6,98 (m, 2H), 6,90 (dd, 1H), 4,20 (t, 2H), 3,41 (m, 2H), 2,22 (m, 2H), 2,03 (s, 3H).

EJEMPLO 412

ácido 7-(5-metil-1-(2-oxo-2-((2-feniletil)amino)etil)-3-(trifluorometil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) □ 10,80 (s, 1H), 8,26 (m, 1H), 8,22 (t, 1H), 7,87 (td, 1H), 7,73 (m, 1H), 7,52 (m, 2H), 7,46 (m, 1H), 7,39 (t, 1H), 7,24 (m, 4H), 7,16 (m, 1H), 7,08 (m, 2H), 6,91 (d, 1H), 4,89 (s, 2H), 4,22 (t, 2H), 3,49 (m, 4H), 2,79 (m, 2H), 2,23 (m, 2H), 1,84 (s, 3H).

EJEMPLO 413

ácido 7-(2-(1-adamantil)imidazo(1,2-a)piridin-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) □ 11,30 (s, 1H), 8,17 (dd, 1H), 8,01 (d, 1H), 7,94 (m, 2H), 7,87 (m, 1H), 7,49 (m, 5H), 7,39 (m, 1H), 7,25 (dd, 1H), 7,02 (s, 1H), 6,90 (d, 1H), 4,22 (t, 2H), 3,80 (m, 2H), 2,27 (qd, 2H), 2,01 (m, 3H), 1,88 (m, 6H), 1,70 (m, 6H).

EJEMPLO 414

ácido 7-(1,1-dioxido-1-benzotien-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) □ 11,54 (s, 1H), 8,24 (m, 1H), 7,92 (d, 1H), 7,87 (m, 2H), 7,61 (m, 2H), 7,52 (m, 2H), 7,46 (m, 2H), 7,39 (m, 1H), 7,32 (d, 1H), 7,11 (m, 2H), 6,90 (d, 1H), 4,20 (t, 2H), 3,40 (m, 2H), 2,25 (m, 2H).

EJEMPLO 415

ácido 7-(2-ciclohexil-6-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,87 (s, 1H), 10,39 (s, 1H), 8,29 (m, 1H), 7,87 (m, 1H), 7,69 (d, 1H), 7,53 (m, 2H), 7,45 (m, 1H), 7,37 (m, 1H), 7,25 (m, 2H), 7,09 (m, 2H), 6,88 (m, 2H), 4,19 (t, 2H), 3,38 (m, 2H), 2,25 (m, 2H), 2,02 (m, 1H), 1,83 (s, 3H), 1,54 (m, 5H), 1,33 (m, 2H), 1,09 (m, 1H), 0,82 (m, 1H), 0,71 (m, 1H).

EJEMPLO 416

ácido 7-(4-(((2-(2-(2-aminoetoxi)etoxi)etil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,94 (s, 1H), 10,71 (s, 1H), 8,51 (t, 1H), 8,24 (m, 1H), 7,87 (ddd, 1H), 7,74 (m, 5H), 7,52 (m, 3H), 7,40 (d, 1H), 7,30 (d, 1H), 7,06 (m, 2H), 6,90 (m, 1H), 4,21 (t, 2H), 3,59 (m, 8H), 3,47 (m, 2H), 3,39 (m, 2H), 2,98 (m, 2H), 2,24 (m, 2H), 2,10 (s, 3H).

EJEMPLO 417

ácido 7-(1-metil-3,5-difenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,85 (s, 1H), 10,75 (s, 1H), 8,26 (m, 1H), 7,86 (m, 1H), 7,60 (d, 1H), 7,50 (m, 3H), 7,31 (m, 8H), 7,11 (m, 3H), 7,05 (dd, 1H), 6,93 (dd, 1H), 6,84 (m, 1H), 4,13 (t, 2H), 3,82 (s, 3H), 3,25 (m, 2H), 2,18 (m, 2H).

EJEMPLO 418

ácido 7-((Z)-2-(1H-imidazol-1-il)-1-fenilvinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,20 (m, 1H), 11,04 (m, 1H), 8,25 (m, 1H), 7,87 (m, 1H), 7,76 (m, 1H), 7,52 (m, 4H), 7,35 (m, 6H), 7,22 (m, 2H), 7,11 (m, 1H), 7,00 (m, 2H), 6,89 (d, 1H), 4,19 (t, 2H), 3,54 (m, 2H), 2,23 (m, 2H).

EJEMPLO 419

ácido 7-(1-bencil-2-metil-4-nitro-1H-imidazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 13,05 (s, 1H), 11,61 (s, 1H), 8,26 (m, 1H), 7,87 (m, 1H), 7,80 (d, 1H), 7,51 (m, 2H), 7,41 (m, 2H), 7,20 (m, 4H), 7,03 (m, 1H), 6,92 (m, 3H), 5,07 (d, 1H), 4,75 (d, 1H), 4,19 (t, 2H), 3,39 (m, 2H), 2,30 (s, 3H), 2,20 (m, 2H).

EJEMPLO 420

ácido 3-(3-(1-naftiloxi)propil)-7-(2-prop-1-inilfenil)-1H-indol-2-carboxílico

EJEMPLO 420A

1-bromo-2-(prop-1-inil)benceno

Se agregó solución de hexametildisilazida de litio 1M (6 ml) a 1-bromo-2-etinilbenceno (1 g) en 20 ml de tetrahidrofurano a temperatura ambiente, y la reacción se agitó durante 30 minutos. Se agregó $(CH_3)_2SO_4$ (0,58 ml) y la reacción se agitó durante 30 minutos. La reacción se volcó sobre 20 ml de agua, se extrajo con 2x 50 ml de éter, y las fases orgánicas combinadas se secaron sobre Na_2SO_4, se filtró, y el filtrado se concentró.

EJEMPLO 420B

ácido 2-(prop-1-inil)fenilborónico

Se agregó n-butillitio 2,5M (1,92 ml) al EJEMPLO 420A (850 mg) en 15 ml de tetrahidrofurano a -78 °C. La reacción se agitó durante 1 minuto, se agregó trimetilborato (0,974 ml), y la reacción se dejó calentar hasta temperatura ambiente. La reacción se volcó sobre 20 ml de HCl 1M, se extrajo con 3x 50 ml de éter, y las fases orgánicas se concentraron. El material crudo se recogió en 50 ml de NaOH 1M, y se enjuagó con 2x 50 ml de éter. La fase acuosa se acidificó con HCl concentrado, se extrajo con 3x 50 ml de éter, y los extractos combinados se lavaron con salmuera, se secó sobre Na_2SO_4, y se concentró. El producto crudo se trituró en éter/hexano.

EJEMPLO 420C

ácido 3-(3-(1-naftiloxi)propil)-7-(2-prop-1-inilfenil)-1H-indol-2-carboxílico

Una suspensión del EJEMPLO 1C (0,034 g, 0,075 mmol), el EJEMPLO 420B (0,1 g, 0,68 mmol), tetrakis(trifenilfosfin)paladio (0,004 g, 0,006 mmol), y solución de Na_2CO_3 (2M, 0,5 ml, 1 mmol) en dimetoxietano/EtOH/H_2O (7/2/3) 3 ml se calentó bajo condiciones de microondas a 150 C durante 30 min. La mezcla de reacción se neutralizó con HCl aq. (1M, 0,4 ml) y el producto se extrajo con acetato de etilo (3 x 7 ml). La fase orgánicas se filtraron a través de un cartucho de secado ($MgSO_4$, Alltech Asoc., 2g) y se concentró bajo presión reducida. El producto crudo se purificó por cromatografía sobre SiO2 utilizando 1% AcOH en EtOAc como eluyente. ^{1}H RMN (300 MHz, DMSO-d_6) □12,39 (br s, 1H), 10,28 (s, 1H), 8,25 (dd, 1H), 7,87 (d, 1H), 7,71 (d, 1H), 7,38-7,56 (m, 8H), 7,21 (d, 1H), 7,09 (dd, 1H), 6,89 (d, 1H), 4,20 (m, 2H), 3,38 (m, 2H), 2,24 (m, 2H), 1,91 (s, 3H).

EJEMPLO 421

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(feniletinil)fenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □12,85 (br s, 1H), 10,66 (s, 1H), 8,28 (dd, 1H), 7,87 (d, 1H), 7,78 (d, 1H), 7,68 (d, 1H), 7,40-7,58 (m, 8H), 7,18-7,26 (m, 3H), 7,08 (dd, 1H), 6,89 (m, 3H), 4,21 (t, 2H), 3,40 (t, 2H), 2,26 (m, 2H).

EJEMPLO 422

ácido 3,7-bis(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □12,80 (br s, 1H), 11,35 (s, 1H), 8,21 (dd, 2H), 7,86 (d, 2H), 7,35-7,55 (m, 8H), 7,08 (d, 1H), 6,86-6,96 (m, 4H), 4,18 (m, 4H), 3,37 (m, 4H), 2,21 (m, 4H).

EJEMPLO 423

ácido 1-(2-(dimetilamino)-2-oxoetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,02 (s, 1H), 8,24-8,31 (m, 1H), 7,84-7,91 (m, 1H), 7,75 (dd, J=8,1, 1,4 Hz, 1H), 7,50-7,56 (m, 2H), 7,46 (d, J=8,1, 1H), 7,41 (d, J=7,1 Hz, 1H), 7,31-7,39 (m, 2H), 7,20-7,28 (m, 1H), 7,02-7,12 (m, 2H), 6,91 (dd, J=6,8, 4,4 Hz, 2H), 5,05 (d, J=17,3 Hz, 1H), 4,70 (d, J=17,6 Hz, 1H), 4,23 (t, J=6,1 Hz, 2H), 3,32-3,40 (m, 2H), 2,63 (s, 3H), 2,28 (s, 3H), 2,18-2,27 (m, 2H), 1,95 (s, 3H).

EJEMPLO 424

ácido 1-(2-metilbencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,13 (s, 1H), 8,22-8,30 (m, 1H), 7,81-7,91 (m, 2H), 7,49-7,56 (m, 1H), 7,44-7,49 (m, 1H), 7,36-7,44 (m, 1H), 7,23-7,31 (m, 1H), 7,07-7,19 (m, 2H), 6,99-7,04 (m, 1H), 6,92-6,99 (m, 3H), 6,84-6,92 (m, 2H), 6,74-6,82 (m, 2H), 5,50 (d, *J*=7,8 Hz, 1H), 5,34 (d, *J*=17,6 Hz, 1H), 5,17 (d, *J*=17,6 Hz, 1H), 4,26 (t, *J*=6,1 Hz, 2H), 3,37-3,49 (m, 2H), 2,22-2,36 (m, 2H), 1,61 (s, 3H), 1,57 (s, 3H).

EJEMPLO 425

ácido 1-(3-metilbencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,18 (s, 1H), 8,20-8,29 (m, 1H), 7,83-7,91 (m, 1H), 7,80 (d, *J*=8,3 Hz, 1H), 7,48-7,58 (m, 2H), 7,43-7,48 (m, 1H), 7,34-7,42 (m, 1H), 7,30 (t, *J*=7,3 Hz, 1H), 7,21 (d, *J*=7,1 Hz, 1H), 7,06-7,17 (m, 2H), 7,00 (d, *J*=7,5 Hz, 1H), 6,82-6,96 (m, 4H), 6,04 (s, 1H), 5,98 (d, *J*=6,7 Hz, 1H), 5,29 (d, *J*=16,6 Hz, 1H), 5,19 (d, *J*=16,6 Hz, 1H), 4,22 (t, *J*=6,1 Hz, 2H), 3,34-3,43 (m, 2H), 2,19-2,33 (m, 2H), 2,06 (s, 3H), 1,70 (s, 3H).

EJEMPLO 426

ácido 1-(4-metilbencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,13 (s, 1H), 8,21-8,29 (m, 1H), 7,84-7,92 (m, 2H), 7,80 (d, *J*=6,7 Hz, 1H), 7,50-7,58 (m, 2H), 7,47 (d, *J*=8,7 Hz, 2H), 7,35-7,42 (m, 1H), 7,26-7,33 (m, 1H), 7,23 (d, *J*=7,1 Hz, 1H), 7,08-7,16 (m, 2H), 7,03 (d, *J*=6,7 Hz, 1H), 6,95 (d, *J*=5,9 Hz, 1H), 6,89 (d, *J*=6,7 Hz, 1H), 6,83 (d, *J*=7,9 Hz, 2H), 6,14 (d, *J*=8,3 Hz, 2H), 5,29 (d, *J*=16,7 Hz, 1H), 5,11 (d, *J*=16,7 Hz, 1H), 4,21 (t, *J*=6,1 Hz, 2H), 3,34-3,42 (m, 2H), 2,18-2,32 (m, 2H), 2,14 (s, 3H), 1,76 (s, 3H).

EJEMPLO 427

ácido 7-(2-metilfenil)-1-(3-morfolin-4-ilpropil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,31 (s, 1H), 9,43 (s, 1H), 8,19-8,27 (m, 1H), 7,83-7,91 (m, 1H), 7,79 (dd, *J*=8,1, 1,4 Hz, 1H), 7,49-7,58 (m, 2H), 7,47 (d, *J*=8,4 Hz, 1H), 7,34-7,44 (m, 5H), 7,10-7,18 (m, 1H), 7,00 (d, *J*=5,8 Hz, 1H), 6,92 (d, *J*=6,4 Hz, 1H), 4,26-4,40 (m, 1H), 4,23 (t, *J*=5,9 Hz, 2H), 3,88 (bs, 2H), 3,48-3,65 (m, 4H), 3,29-3,39 (m, 4H), 2,85 (bs, 2H), 1,99 (s, 3H), 1,60 (bs, 2H).

EJEMPLO 428

ácido 7-(2-metilfenil)-1-(2-(4-metilpiperazin-1-il)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,07 (s, 1H), 9,69 (s, 1H), 8,22-8,32 (m, 1H), 7,84-7,92 (m, 1H), 7,77 (dd, *J*=8,1, 1,4 Hz, 1H), 7,50-7,58 (m, 2H), 7,47 (d, *J*=8,1 Hz, 1H), 7,33-7,43 (m, 4H), 7,23-7,32 (m, 1H), 7,05-7,13 (m, 1H), 6,92 (d, *J*=7,5 Hz, 2H), 5,39 (bs, 1H), 4,93 (bs, 1H), 4,23 (t, *J*=6,1 Hz, 2H), 3,36-3,44 (m, 4H), 2,72-2,86 (m, 4H), 2,17-2,30 (m, 2H), 1,93 (s, 3H).

EJEMPLO 429

ácido 7-(2-metilfenil)-1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,17 (s, 1H), 9,20 (s, 1H), 8,17-8,25 (m, 1H), 7,84-

7,90 (m, 1H), 7,76 (dd, *J*=8,1, 1,4 Hz, 1H), 7,49-7,58 (m, 1H), 7,46 (d, *J*=8,4 Hz, 1H), 7,37-7,43 (m, 1H), 7,25-7,36 (m, 4H), 7,07-7,16 (m, 1H), 6,96 (dd, *J*=7,1, 1,4 Hz, 1H), 4,27-4,40 (m, 1H), 4,22 (t, *J*=5,9 Hz, 2H), 3,70-3,85 (m, 1H), 3,27-3,40 (m, 2H), 3,21 (d, *J*=12,5 Hz, 2H), 2,70-2,88 (m, 2H), 2,69 (s, 3H), 2,39 (d, *J*=14,6 Hz, 2H), 2,14-2,30 (m, 2H), 2,06 (m, 4H), 2,00 (s, 3H).

EJEMPLO 430

ácido 1-(1,1'-bifenil-2-ilmetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,97 (s, 1H), 8,18-8,26 (m, 1H), 7,82-7,91 (m, 2H), 7,43-7,58 (m, 3H), 7,35-7,43 (m, 1H), 7,29-7,36 (m, 4H), 7,26 (d, *J*=7,1 Hz, 1H), 7,03-7,19 (m, 3H), 6,87-7,02 (m, 5H), 6,65-6,75 (m, 2H), 5,52 (d, *J*=7,5 Hz, 1H), 5,29 (d, *J*=17,8 Hz, 1H), 5,10 (d, *J*=17,8 Hz, 1H), 4,23 (t, *J*=6,1 Hz, 2H), 3,36-3,45 (m, 2H), 2,27 (qt, *J*=7,3 Hz, 2H), 1,76 (s, 3H).

EJEMPLO 431

ácido 1-(1,1'-bifenil-3-ilmetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,23 (s, 1H), 8,20-8,30 (m, 1H), 7,84-7,91 (m, 1H), 7,81 (d, *J*=7,8 Hz, 1H), 7,48-7,59 (m, 2H), 7,46 (d, *J*=8,1 Hz, 1H), 7,32-7,41 (m, 6H), 7,22-7,32 (m, 2H), 7,06-7,20 (m, 4H), 7,01 (d, *J*=6,8 Hz, 1H), 6,94 (d, *J*=7,1 Hz, 1H), 6,87 (d, *J*=7,5 Hz, 1H), 6,44 (s, 1H), 6,22 (d, *J*=8,1 Hz, 1H), 5,39 (d, *J*=16,6 Hz, 1H), 5,27 (d, *J*=16,6 Hz, 1H), 4,23 (t, *J*=6,3 Hz, 2H), 3,39 (t, *J*=7,5 Hz, 2H), 2,21-2,36 (m, 2H), 1,70 (s, 3H).

EJEMPLO 432

ácido 1-(1,1'-bifenil-4-ilmetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,20 (s, 1H), 8,17-8,27 (m, 1H), 7,80-7,90 (m, 2H), 7,48-7,57 (m, 4H), 7,46 (d, *J*=8,1 Hz, 1H), 7,34-7,43 (m, 3H), 7,26-7,34 (m, 4H), 7,23 (d, *J*=7,1 Hz, 1H), 7,08-7,18 (m, 2H), 7,03 (d, *J*=6,8 Hz, 1H), 6,96 (d, *J*=6,1 Hz, 1H), 6,90 (d, *J*=6,8 Hz, 1H), 6,31 (d, *J*=8,1 Hz, 2H), 5,38 (d, *J*=17,3 Hz, 1H), 5,25 (d, *J*=17,3 Hz, 1H), 4,23 (t, *J*=6,1 Hz, 2H), 3,35-3,45 (m, 2H), 2,21-2,35 (m, 2H), 1,75 (s, 3H).

EJEMPLO 433

ácido 1-(2,4-dimetilbencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,07 (s, 1H), 8,21-8,30 (m, 1H), 7,85-7,91 (m, 1H), 7,83 (d, *J*=7,9 Hz, 1H), 7,49-7,57 (m, 2H), 7,48 (d, *J*=8,1 Hz, 1H), 7,36-7,44 (m, 1H), 7,27 (t, *J*=7,3 Hz, 1H), 7,17 (d, *J*=7,1 Hz, 1H), 7,07-7,14 (m, 1H), 7,02 (t, *J*=7,3 Hz, 1H), 6,91 (d, *J*=7,5 Hz, 1H), 6,88 (d, *J*=7,1 Hz, 1H), 6,81 (d, *J*=7,5 Hz, 1H), 6,76 (s, 1H), 6,56 (d, *J*=7,9 Hz, 1H), 5,38 (d, *J*=7,9 Hz, 1H), 5,28 (d, *J*=17,4 Hz, 1H), 5,09 (d, *J*=17,4 Hz, 1H), 4,25 (t, *J*=6,1 Hz, 2H), 3,41 (t, *J*=7,3 Hz, 2H), 2,22-2,36 (m, 2H), 2,11 (s, 3H), 1,64 (s, 3H), 1,54 (s, 3H).

EJEMPLO 434

ácido 1-(4-carboxibencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,09 (s, 1H), 12,79 (s, 1H), 8,19-8,30 (m, 1H), 7,85-7,91 (m, 1H), 7,83 (d, *J*=7,9 Hz, 1H), 7,62 (d, *J*=8,3 Hz, 2H), 7,49-7,58 (m, 2H), 7,46

(d, *J*=8,3 Hz, 1H), 7,35-7,43 (m, 1H), 7,28 (t, *J*=7,5 Hz, 1H), 7,19 (d, *J*=7,5 Hz, 1H), 7,09-7,16 (m, 1H), 7,06 (t, *J*=7,5 Hz, 1H), 6,89 – 7,01 (m, 3H), 6,33 (d, *J*=8,3 Hz, 2H), 5,43 (d, *J*=17,1 Hz, 1H), 5,25 (d, *J*=17,1 Hz, 1H), 4,23 (t, *J*=6,1 Hz, 2H), 3,36-3,46 (m, 2H), 2,19-2,35 (m, 2H), 1,71 (s, 3H).

EJEMPLO 435

ácido 1-(1,1'-bifenil-2-ilmetil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,90 (s, 1H), 8,23-8,31 (m, 1H), 7,85-7,89 (m, 1H), 7,82 (dd, *J*=7,5, 2,0 Hz, 1H), 7,48-7,58 (m, 2H), 7,42-7,48 (m, 2H), 7,32-7,42 (m, 5H), 7,04-7,15 (m, 4H), 6,96-7,04 (m, 2H), 6,88-6,96 (m, 1H), 6,86 (d, *J*=7,5 Hz, 1H), 6,62-6,72 (m, 2H), 5,55 (d, *J*=18,0 Hz, 1H), 5,47 (d, *J*=7,8 Hz, 1H), 5,16 (d, *J*=18,0 Hz, 1H), 4,19 (t, *J*=6,1 Hz, 2H), 3,31-3,51 (m, 4H), 3,00-3,10 (m, 2H), 2,73-2,84 (m, 2H), 2,20-2,31 (m, 4H).

EJEMPLO 436

ácido 1-(1,1'-bifenil-3-ilmetil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,23 (s, 1H), 8,21-8,33 (m, 1H), 7,83-7,91 (m, 1H), 7,77 (dd, *J*=7,1, 2,4 Hz, 1H), 7,49-7,57 (m, 2H), 7,45 (d, *J*=8,3 Hz, 1H), 7,26-7,41 (m, 8H), 7,18 (dd, *J*=7,5, 1,6 Hz, 1H), 7,05-7,14 (m, 4H), 7,00 (t, *J*=7,3 Hz, 1H), 6,81 (d, *J*=7,5 Hz, 1H), 6,60 (s, 1H), 6,30 (d, *J*=7,9 Hz, 1H), 5,82 (d, *J*=16,7 Hz, 1H), 5,02 (d, *J*=16,7 Hz, 1H), 4,16 (t, *J*=5,9 Hz, 2H), 3,33-3,45 (m, 2H), 3,15-3,26 (m, 4H), 2,89 (s, 2H), 2,53-2,70 (m, 2H), 2,13-2,31 (m, 2H).

EJEMPLO 437

ácido 1-(1,1'-bifenil-4-ilmetil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,20 (s, 1H), 8,22-8,31 (m, 1H), 7,83-7,91 (m, 1H), 7,75-7,82 (m, 1H), 7,50-7,57 (m, 2H), 7,33-7,50 (m, 6H), 7,24-7,33 (m, 3H), 7,21 (dd, *J*=7,5, 1,7 Hz, 1H), 6,97-7,15 (m, 4H), 6,83 (d, *J*=6,8 Hz, 1H), 6,40 (d, *J*=8,1 Hz, 2H), 5,79 (d, *J*=16,3 Hz, 1H), 4,99 (d, *J*=16,3 Hz, 1H), 4,17 (t, *J*=6,1 Hz, 2H), 3,29-3,52 (m, 2H), 3,15-3,28 (m, 2H), 2,90 (s, 2H), 2,53-2,71 (m, 4H), 2,18-2,30 (m, 2H).

EJEMPLO 438

ácido 1-(2,4-dimetilbencil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,05 (s, 1H), 8,23-8,34 (m, 1H), 7,84-7,92 (m, 1H), 7,80 (dd, *J*=7,5, 1,7 Hz, 1H), 7,49-7,59 (m, 2H), 7,46 (d, *J*=8,5 Hz, 1H), 7,30-7,41 (m, 2H), 7,00-7,13 (m, 3H), 6,88-6,98 (m, 2H), 6,86 (d, *J*=6,4 Hz, 1H), 6,52 (d, *J*=8,1 Hz, 1H), 5,65 (d, *J*=17,0 Hz, 1H), 5,41 (d, *J*=8,1 Hz, 1H), 4,99 (d, *J*=17,0 Hz, 1H), 4,20 (t, *J*=6,3 Hz, 2H), 3,38-3,53 (m, 2H), 3,12-3,25 (m, 2H), 2,79-3,01 (m, 2H), 2,51-2,60 (m, 4H), 2,17-2,35 (m, 2H), 2,02-2,10 (m, 3H), 1,59 (s, 3H).

EJEMPLO 439

ácido 1-(2,6-diclorobencil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,90 (s, 1H), 8,23-8,31 (m, 1H), 7,83-7,90 (m, 1H), 7,74 (dd, *J*=7,5, 1,7 Hz, 1H), 7,48-7,57 (m, 2H), 7,45 (d, *J*=8,5 Hz, 1H), 7,30-7,42 (m, 2H), 7,27 (dd, *J*=7,6, 1,5 Hz, 1H), 7,15-7,23 (m, 3H), 6,98-7,14 (m, 4H), 6,80 (d, *J*=6,8 Hz, 1H), 5,80 (d, *J*=16,3 Hz, 1H), 4,97 (d, *J*=15,9 Hz, 1H), 4,06-4,18 (m, 2H), 3,19-3,34 (m, 4H), 2,95 (bs, 2H), 2,60-2,70 (m, 4H), 2,10-2,24 (m, 2H).

EJEMPLO 440

ácido 1-(4-carboxibencil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,14 (s, 1H), 12,79 (s, 1H), 8,23-8,32 (m, 1H), 7,83-7,91 (m, 1H), 7,79 (dd, *J*=5,8, 3,4 Hz, 1H), 7,55-7,61 (m, 2H), 7,49-7,55 (m, 2H), 7,45 (d, *J*=8,5 Hz, 2H), 7,32-7,41 (m, 2H), 7,01-7,14 (m, 4H), 6,95 (t, *J*=8,0 Hz, 1H), 6,84 (d, *J*=6,8 Hz, 1H), 6,37 (d, *J*=8,5 Hz, 2H), 5,86 (d, *J*=17,3 Hz, 1H), 5,02 (d, *J*=17,0 Hz, 1H), 4,16 (t, *J*=6,1 Hz, 2H), 3,38-3,50 (m, 2H), 3,13-3,27 (m, 2H), 2,81-2,97 (m, 2H), 2,52-2,70 (m, 4H), 2,16-2,31 (m, 2H).

EJEMPLO 441

ácido 7-(6,6-dimetilciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,98 (s, 1H), 10,41 (s, 1H), 8,15-8,33 (m, 1H), 7,78-7,95 (m, 1H), 7,34-7,58 (m, 5H), 6,86-6,99 (m, 3H), 5,46 (t, *J*=3,6 Hz, 1H), 4,19 (t, *J*=6,1 Hz, 2H), 3,33-3,38 (m, 2H), 2,10-2,28 (m, 4H), 1,62-1,82 (m, 4H), 0,97 (s, 6H).

EJEMPLO 442

ácido 7-(5,5-dimetilciclopent-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,04 (s, 1H), 10,19 (s, 1H), 8,16-8,30 (m, 1H), 7,79-7,92 (m, 1H), 7,42-7,63 (m, 4H), 7,34-7,42 (m, 1H), 6,93-7,08 (m, 2H), 6,90 (d, *J*=6,4 Hz, 1H), 5,78 (t, *J*=2,4 Hz, 1H), 4,19 (t, *J*=6,1 Hz, 2H), 3,33-3,42 (m, 2H), 2,42-2,49 (m, 2H), 2,13-2,29 (m, 2H), 1,90 (t, *J*=7,0 Hz, 2H), 1,11 (s, 6H).

EJEMPLO 443

ácido 3-(3-(1-naftiloxi)propil)-7-(7-fenilciclohept-1-en-1-il)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,02 (s, 1H), 10,25 (s, 1H), 8,13-8,24 (m, 1H), 7,80-7,90 (m, 1H), 7,32-7,58 (m, 7H), 7,24 (t, *J*=7,6 Hz, 2H), 7,10 (t, *J*=7,1 Hz, 1H), 6,97 (d, *J*=6,1 Hz, 1H), 6,80-6,90 (m, 2H), 6,29 (t, *J*=6,3 Hz, 1H), 4,21 (t, *J*=4,7 Hz, 1H), 4,14 (t, *J*=5,9 Hz, 2H), 3,21-3,32 (m, 2H), 2,31-2,45 (m, 2H), 2,10-2,24 (m, 4H), 1,50-1,85 (m, 3H), 1,30-1,49 (m, 1H).

EJEMPLO 444

ácido 3-(3-(1-naftiloxi)propil)-7-triciclo(4,3,1,1^{3,8})undec-4-en-4-il-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,15 (s, 1H), 9,53 (s, 1H), 8,12-8,32 (m, 1H), 7,72-7,93 (m, 1H), 7,27-7,62 (m, 5H), 7,01-7,07 (m, 1H), 6,93-7,01 (m, 1H), 6,87 (d, *J*=6,4 Hz, 1H), 6,30-6,42 (m, 1H), 4,17 (t, *J*=6,1 Hz, 2H), 3,33-3,41 (m, 2H), 2,63-2,71 (m, 1H), 2,11-2,26 (m, 4H), 1,70-2,06 (m, 11H).

EJEMPLO 445

ácido 3-(3-(1-naftiloxi)propil)-7-(2-fenilciclohept-1-en-1-il)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,94 (s, 1H), 10,53 (s, 1H), 8,17-8,26 (m, 1H), 7,81-7,89 (m, 1H), 7,47-7,56 (m, 2H), 7,32-7,47 (m, 3H), 6,87-6,98 (m, 5H), 6,85 (d, *J*=6,4 Hz, 1H), 6,65-6,77 (m, 2H), 4,13 (t, *J*=6,1 Hz, 2H), 3,18-3,30 (m, 2H), 2,73-3,07 (m, 2H), 2,24-2,44 (m, 2H), 2,16 (t, *J*=6,6 Hz, 2H), 1,38-2,05 (m, 6H).

EJEMPLO 446

ácido 3-(3-(1-naftiloxi)propil)-7-(2,6,6-trimetilciclohex-1-en-1-il)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,96 (s, 1H), 10,46 (s, 1H), 8,19-8,36 (m, 1H), 7,77-7,97 (m, 1H), 7,48-7,60 (m, 3H), 7,46 (d, *J*=8,1 Hz, 1H), 7,34-7,42 (m, 1H), 6,94-7,01 (m, 1H), 6,89 (d, *J*=6,8 Hz, 1H), 6,83 (d, *J*=6,1 Hz, 1H), 4,20 (t, *J*=6,1 Hz, 2H), 3,22-3,33 (m, 2H), 2,12-2,31 (m, 3H), 1,91-2,05 (m, 1H), 1,69-1,84 (m, 3H), 1,45-1,59 (m, 1H), 1,17 (s, 3H), 1,05 (s, 3H), 0,74 (s, 3H).

EJEMPLO 447

ácido 3-(3-(1-naftiloxi)propil)-7-((1R,4R)-1,7,7-trimetilbiciclo(2,2,1)hept-2-en-2-il)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,18 (s, 1H), 9,34 (s, 1H), 8,16-8,27 (m, 1H), 7,81-7,90 (m, 1H), 7,47-7,59 (m, 3H), 7,45 (d, *J*=8,1 Hz, 1H), 7,33-7,41 (m, 1H), 7,07 (d, *J*=7,3 Hz, 1H), 7,00 (t, *J*=7,5 Hz, 1H), 6,89 (d, *J*=7,5 Hz, 1H), 6,38 (d, *J*=3,6 Hz, 1H), 4,18 (t, *J*=5,9 Hz, 2H), 3,32-3,39 (m, 2H), 2,54 (t, *J*=3,4 Hz, 1H), 2,15-2,28 (m, 2H), 1,89-2,04 (m, 1H), 1,64-1,78 (m, 1H), 1,30-1,45 (m, 1H), 1,07-1,19 (m, 1H), 1,04 (s, 3H), 0,98 (s, 3H), 0,86 (s, 3H).

EJEMPLO 448

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-4-(trifluorometil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,23 (s, 1H), 11,20 (s, 1H), 8,21-8,37 (m, 1H), 7,83-7,90 (m, 1H), 7,62 (d, *J*=7,8 Hz, 1H), 7,22-7,58 (m, 8H), 7,20 (d, *J*=7,5 Hz, 1H), 6,99 (d, *J*=7,1 Hz, 1H), 4,25 (t, *J*=5,8 Hz, 2H), 3,35-3,48 (m, 2H), 2,09-2,23 (m, 2H), 2,05 (s, 3H).

EJEMPLO 449

ácido 7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-4-(trifluorometil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,51 (s, 1H), 10,79 (s, 1H), 8,23-8,38 (m, 1H), 7,82-7,91 (m, 1H), 7,67 (d, *J*=7,8 Hz, 1H), 7,35-7,57 (m, 7H), 7,15-7,27 (m, 2H), 6,94-7,04 (m, 1H), 4,25 (t, *J*=5,9 Hz, 2H), 3,37-3,51 (m, 2H), 3,07-3,36 (m, 4H), 2,71-2,87 (m, 4H), 2,17 (s, 2H).

EJEMPLO 450

ácido 1-(2-(dimetilamino)etil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 8,14-8,30 (m, 1H), 7,84-7,92 (m, 1H), 7,80 (d, *J*=7,9 Hz, 1H), 7,32-7,59 (m, 8H), 7,15 (t, *J*=7,7 Hz, 1H), 6,99 (d, *J*=5,9 Hz, 1H), 6,92 (d, *J*=6,3 Hz, 1H), 4,45-4,78 (m, 1H), 4,23 (t, *J*=5,6 Hz, 2H), 3,42 (s, 3H), 3,35-3,41 (m, 2H), 3,19-3,23 (m, 3H), 2,70-2,75 (m, 2H), 2,17-2,35 (m, 4H), 2,00 (s, 3H).

EJEMPLO 451

ácido 7-(1,1'-bifenil-2-ilmetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,99 (s, 1H), 11,25 (s, 1H), 8,15-8,33 (m, 1H), 7,76-7,95 (m, 1H), 7,47-7,57 (m, 2H), 7,23-7,47 (m, 11H), 7,05-7,11 (m, 1H), 6,80-6,91 (m, 2H), 6,58 (d, *J*=6,7 Hz, 1H), 4,26 (s, 2H), 4,17 (t, *J*=5,9 Hz, 2H), 3,28-3,36 (m, 2H), 2,15-2,26 (m, 2H).

EJEMPLO 452

ácido 7-(1,1'-bifenil-3-ilmetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,05 (s, 1H), 11,39 (s, 1H), 8,06-8,34 (m, 1H), 7,81-7,89 (m, 1H), 7,68 (s, 1H), 7,61 (d, *J*=7,1 Hz, 2H), 7,30-7,56 (m, 12H), 7,23-7,30 (m, 1H), 7,07 (d, *J*=6,3 Hz, 1H), 6,89-6,97 (m, 1H), 6,87 (d, *J*=7,5 Hz, 1H), 4,38 (s, 2H), 4,16 (t, *J*=5,9 Hz, 2H), 3,27-3,31 (m, 2H), 2,14 – 2,23 (m, 2H).

EJEMPLO 453

ácido 7-(1-(2-(1-naftiloxi)etil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,03 (s, 1H), 10,51 (s, 1H), 8,14-8,30 (m, 1H), 7,92 (d, *J*=7,5 Hz, 1H), 7,83-7,89 (m, 1H), 7,81 (d, *J*=7,5 Hz, 1H), 7,62 (d, *J*=8,1 Hz, 1H), 7,28-7,54 (m, 8H), 7,18 (d, *J*=6,1 Hz, 1H), 6,94-7,03 (m, 1H), 6,87 (d, *J*=7,5 Hz, 2H), 5,51 (s, 1H), 5,37 (d, *J*=1,7 Hz, 1H), 4,11-4,26 (m, 4H), 3,32-3,37 (m, 2H), 3,16 (t, *J*=6,1 Hz, 2H), 2,15-2,26 (m, 2H).

EJEMPLO 454

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(fenoximetil)bencil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,01 (s, 1H), 11,24 (s, 1H), 8,09-8,34 (m, 1H), 7,72-7,94 (m, 1H), 7,41-7,58 (m, 5H), 7,32-7,41 (m, 1H), 7,17-7,30 (m, 4H), 7,00 (dd, *J*=6,6, 2,5 Hz, 1H), 6,87-6,96 (m, 5H), 6,79-6,87 (m, 1H), 5,13 (s, 2H), 4,39 (s, 2H), 4,17 (t, *J*=6,1 Hz, 2H), 3,32-3,40 (m, 2H), 2,15-2,25 (m, 2H).

EJEMPLO 455

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(2-fenoxietil)fenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,95 (s, 1H), 10,60 (s, 1H), 10,60 (s, 1H), 8,17-8,32 (m, 1H), 7,82-7,91 (m, 1H), 7,70-7,78 (m, 1H), 7,29-7,58 (m, 7H), 7,20-7,27 (m, 1H), 7,04-7,15 (m, 4H), 6,89 (d, *J*=6,4 Hz, 1H), 6,79 (t, *J*=7,5 Hz, 1H), 6,52 (d, *J*=7,8 Hz, 2H), 4,21 (t, *J*=6,1 Hz, 2H), 3,93 (t, *J*=7,6 Hz, 2H), 3,36-3,45 (m, 2H), 2,70-2,95 (m, 2H), 2,16-2,31 (m, 2H).

EJEMPLO 456

ácido 3-(3-(1-naftiloxi)propil)-7-(3-(2-fenoxietil)fenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,06 (s, 1H), 10,34 (s, 1H), 8,10-8,33 (m, 1H), 7,80-7,98 (m, 1H), 7,70 (d, *J*=7,8 Hz, 1H), 7,59 (s, 1H), 7,34-7,56 (m, 8H), 7,22-7,31 (m, 3H), 7,05-7,13 (m, 1H), 6,95 (d, *J*=8,8 Hz, 2H), 6,85-6,93 (m, 2H), 4,26 (t, *J*=6,8 Hz, 2H), 4,19 (t, *J*=5,9 Hz, 2H), 3,35-3,43 (m, 2H), 3,14 (t, *J*=6,8 Hz, 2H), 2,16-2,32 (m, 2H).

EJEMPLO 457

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(3-fenoxipropil)fenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,92 (s, 1H), 10,50 (s, 1H), 8,09-8,41 (m, 1H), 7,82-8,01 (m, 1H), 7,70 (dd, *J*=6,4, 2,7 Hz, 1H), 7,47-7,57 (m, 2H), 7,45 (d, *J*=8,5 Hz, 1H), 7,33-7,42 (m, 2H), 7,25-7,32 (m, 1H), 7,18-7,24 (m, 2H), 7,12-7,18 (m, 2H), 7,01-7,09 (m, 2H), 6,88 (d, *J*=7,5 Hz, 1H), 6,83 (t, *J*=7,3 Hz, 1H), 6,66 (d, *J*=7,8 Hz, 2H), 4,20 (t, *J*=6,1 Hz, 2H), 3,56-3,75 (m, 2H), 3,29-3,41 (m, 2H), 2,63 (d, *J*=6,1 Hz, 2H), 2,18-2,31 (m, 2H), 1,68-1,84 (m, 2H).

EJEMPLO 458

ácido 3-(3-(1-naftiloxi)propil)-7-(3-(3-fenoxipropil)fenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,03 (s, 1H), 10,32 (s, 1H), 8,05-8,32 (m, 1H), 7,80-7,98 (m, 1H), 7,69 (d, *J*=7,8 Hz, 1H), 7,34-7,56 (m, 7H), 7,22-7,32 (m, 3H), 7,20 (d, *J*=6,1 Hz, 1H), 7,03-7,11 (m, 1H), 6,86-6,97 (m, 4H), 4,19 (t, *J*=6,1 Hz, 2H), 4,01 (t, *J*=6,4 Hz, 2H), 3,37 (t, *J*=7,5 Hz, 2H), 2,80-2,90 (m, 2H), 2,16-2,32 (m, 2H), 2,01-2,16 (m, 2H).

EJEMPLO 459

ácido 3-(3-(3-hidroxi-2-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,88 (s ancho, 1H), 10,44 (s ancho, 1H), 9,17 (s, 1H), 7,66 (d, 1H), 7,20-7,36 (m, 4H), 7,11 (t, 1H), 7,02-7,06 (m, 1H), 6,88 (t, 1H), 6,42 (d, 1H), 6,35 (d, 1H), 3,96 (t, 2H), 3,25 (t, 2H), 2,04-2,12 (m, 5H), 2,02 (s, 3H).

EJEMPLO 460

ácido 3-(3-(3-(2-metoxietoxi)-2-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,91 (s ancho, 1H), 10,46 (s, 1H), 7,65 (d, 1H), 7,19-7,37 (m, 4H), 7,01-7,14 (m, 3H), 6,51-6,61 (m, 2H), 4,05-4,09 (m, 2H), 4,00 (t, 2H), 3,65-3,69 (m, 2H), 3,33 (s, 3H), 3,23-3,29 (m, 2H), 2,02-2,15 (m, 8H).

EJEMPLO 461

ácido 7-(1,2-dimetilprop-1-enil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,95 (s ancho, 1H), 10,63 (s, 1H), 8,22-8,29 (m, 1H), 7,83-7,90 (m, 1H), 7,33-7,59 (m, 5H), 6,84-7,00 (m, 3H), 4,18 (t, 2H), 3,27-3,37 (m, 2H), 2,16-2,26 (m, 2H), 1,94 (s, 3H), 1,84 (s, 3H), 1,40 (s, 3H).

EJEMPLO 462

ácido 3-(3-(2-metil-3-(2-morfolin-4-iletoxi)fenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,88 (s ancho, 1H), 10,50 (s, 1H), 7,65 (d, 1H), 7,16-7,36 (m, 4H), 7,02-7,16 (m, 3H), 6,58-6,68 (m, 2H), 4,33 (t, 2H), 3,99-4,04 (m, 4H), 3,49-3,75 (m, 6H), 3,23-3,28 (m, 4H), 2,07-2,14 (m, 5H), 2,05 (s, 3H).

EJEMPLO 463

ácido 3-(3-(2,3-diclorofenoxi)propil)-7-(2-morfolin-4-ilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,04 (s ancho, 1H), 10,04 (s, 1H), 7,71 (d, 1H), 7,31-7,45 (m, 3H), 7,27 (t, 1H), 7,09-7,22 (m, 4H), 7,00-7,07 (m, 1H), 4,09 (t, 2H), 3,18-3,34 (m, 6H), 2,73-2,81 (m, 4H), 2,09-2,19 (m, 2H).

EJEMPLO 464

ácido 1-(2-morfolin-4-iletil)-7-(2-morfolin-4-ilfenil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-

iloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,31 (s ancho, 1H), 7,71-7,80 (m, 1H), 7,50-7,56 (m, 1H), 7,40-7,46 (m, 1H), 7,14-7,23 (m, 3H), 7,07 (d, 1H), 6,99 (t, 1H), 6,59-6,65 (m, 2H), 3,96 (t, 2H), 3,19-3,35 (m, 10H), 3,08-3,18 (m, 4H), 2,55-2,89 (m, 10H), 2,00-2,14 (m, 3H), 1,56-1,85 (m, 5H).

EJEMPLO 465

ácido 7-(2-metilfenil)-3-(3-(1-naftiltio)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,89 (s ancho, 1H), 10,48 (s, 1H), 8,23-8,28 (m, 1H), 7,92-7,97 (m, 1H), 7,78 (d, 1H), 7,54-7,64 (m, 3H), 7,46-7,50 (m, 1H), 7,42 (t, 1H), 7,30-7,35 (m, 2H), 7,24-7,29 (m, 1H), 7,19-7,23 (m, 1H), 7,08 (t, 1H), 7,01-7,05 (m, 1H), 3,24 (t, 2H), 3,11 (t, 2H), 2,04 (s, 3H), 1,94-2,02 (m, 2H).

EJEMPLO 466

ácido 3-(3-(3-(2-metoxietoxi)-5-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,86 (s ancho, 1H), 10,41 (s, 1H), 7,67 (d, 1H), 7,31-7,34 (m, 2H), 7,20-7,30 (m, 2H), 7,11 (t, 1H), 7,02-7,06 (m, 1H), 6,30-6,35 (m, 2H), 6,25-6,28 (m, 1H), 4,00-4,05 (m, 2H), 3,96 (t, 2H), 3,59-3,65 (m, 2H), 3,21 (t, 2H), 2,21 (s, 3H), 2,00-2,11 (m, 5H).

EJEMPLO 467

ácido 7-(2-morfolin-4-ilfenil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,04 (s ancho, 1H), 10,02 (s, 1H), 7,70 (d, 1H), 7,33-7,45 (m, 3H), 7,12-7,22 (m, 3H), 6,97 (t, 1H), 6,61 (t, 2H), 3,96 (t, 2H), 3,20-3,30 (m, 6H), 2,73-2,82 (m, 4H), 2,69 (t, 2H), 2,62 (t, 2H), 2,04-2,16 (m, 2H), 1,63-1,80 (m, 4H).

EJEMPLO 468

ácido 3-(3-(3-metil-5-(3-morfolin-4-ilpropoxi)fenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, $CDCl_3$) □ 8,41 (s, 1H), 7,71 (s, 1H), 7,27-7,40 (m, 4H), 7,16-7,24 (m, 2H), 6,34 (s, 1H), 6,21-6,29 (m, 2H), 3,99-4,09 (m, 6H), 3,93 (t, 2H), 3,65-3,74 (m, 2H), 3,23-3,39 (m, 4H), 2,85-2,98 (m, 2H), 2,11-2,30 (m, 10H).

EJEMPLO 469

ácido 3-(3-(3-(3-ciclohexilpropoxi)-5-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

EJEMPLO 469A

7-bromo-3-(3-(3-hidroxi-5-metilfenoxi)propil)-1H-indol-2-carboxilato de etilo

Una suspensión de 7-bromo-3-(3-hidroxipropil)-1H-indol-2-carboxilato de etilo (EJEMPLO 1C) (0,9 g), 5-metilbencen-1,3-diol (1,028 g), trifenilfosfina (0,868 g), dibencilazodicarboxilato (0,762 g) y tetrahidrofurano (40 ml) se agitó a temperatura ambiente durante 19 horas. Después de eliminar el solvente, el producto crudo se purificó por cromatografía flash en gel de sílice, (Analogix, SF65-200g) eluyendo con 0-10% acetato de etilo en hexano.

EJEMPLO 469B

7-bromo-3-(3-(3-hidroxi-5-metilfenoxi)propil)-1H-indol-2-carboxilato de etilo

Una suspensión del EJEMPLO 469A (0,067 g), 3-ciclohexilpropan-1-ol (0,22 g), trifenilfosfina (0,081 g), dibencilazodicarboxilato (0,071 g) en tetrahidrofurano (3 ml) se agitó a temperatura ambiente durante 2 horas. La muestra se purificó directamente por cromatografía flash en gel de sílice, (Analogix, SF25-40g) eluyendo con 0 a 20% acetato de etilo en hexano.

EJEMPLO 469C

ácido 3-(3-(3-(3-ciclohexilpropoxi)-5-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

El compuesto del título se preparó de acuerdo con el procedimiento del EJEMPLO 164G, reemplazando el EJEMPLO 164F por el EJEMPLO 469B. ^{1}H RMN (500 MHz, $CDCl_3$) □ 8,41 (s, 1H), 7,68-7,76 (m, 1H), 7,28-7,39 (m, 4H), 7,16-7,23 (m, 2H), 6,24-6,35 (m, 3H), 4,00 (t, 2H), 3,88 (t, 2H), 3,33 (t, 2H), 2,15-2,28 (m, 8H), 1,61-1,79 (m, 7H), 1,09-1,35 (m, 6H), 0,83-0,96 (m, 2H).

EJEMPLO 470

ácido 3-(3-(3-(3-(2-carboxi-1H-indol-3-il)propoxi)-5-metilfenoxi)propil)-7-(2-morfolin-4-ilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 11,42 (s, 1H), 10,04 (s, 1H), 7,71 (d, 1H), 7,63 (d, 1H), 7,31-7,44 (m, 4H), 7,12-7,23 (m, 4H), 6,96-7,01 (m, 1H), 6,15-6,32 (m, 3H), 3,86-3,94 (m, 4H), 3,22-3,28 (m, 5H), 3,14-3,20 (m, 4H), 2,71-2,81 (m, 4H), 2,18 (s, 3H), 1,97-2,10 (m, 4H).

EJEMPLO 471

ácido 7-bromo-3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 8,66-8,77 (m, 2H), 8,12 (d, 1H), 7,88 (t, 2H), 7,36-7,56 (m, 7H), 7,01 (t, 1H), 6,89 (d, 1H), 6,34 (s, 2H), 4,21 (t, 2H), 3,38 (t, 2H), 2,20-2,29 (m, 2H).

EJEMPLO 473

ácido 7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 13,47 (s ancho, 1H), 8,46 (d, 2H), 8,25-8,31 (m, 1H), 7,83-7,91 (m, 2H), 7,50-7,58 (m, 2H), 7,47 (d, 1H), 7,39 (t, 1H), 7,29-7,34 (m, 1H), 7,15 (t, 1H), 7,02-7,10 (m, 2H), 6,88 (d, 1H), 6,69-6,81 (m, 4H), 6,20 (d, 1H), 5,25 (d, 1H), 4,22 (t, 2H), 3,38-3,53 (m, 2H), 3,19-3,26 (m, 2H), 2,88-3,05 (m, 2H), 2,60-2,76 (m, 4H), 2,22-2,33 (m, 2H).

EJEMPLO 474

ácido 7-(1,1'-bi(ciclohexan)-2-en-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 13,04 (s ancho, 1H), 10,39 (s, 1H), 8,22-8,28 (m, 1H), 7,84-7,89 (m, 1H), 7,48-7,57 (m, 3H), 7,44 (d, 1H), 7,37 (t, 1H), 6,92-7,02 (m, 2H), 6,87 (d, 1H), 5,90-5,97 (m, 1H), 4,16 (t, 2H), 2,77-2,86 (m, 1H), 2,02-2,26 (m, 4H), 1,58-

1,82 (m, 4H), 1,38-1,57 (m, 4H), 1,12-1,37 (m, 3H), 0,80-1,11 (m, 5H), 0,58-0,71 (m, 1H).

EJEMPLO 475

ácido 3-(3-(2,3-diclorofenoxi)propil)-7-(1,2-dimetilprop-1-enil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 12,88 (s ancho, 1H), 10,63 (s, 1H), 7,50 (s, 1H), 7,28 (t, 1H), 7,17-7,21 (m, 1H), 7,04-7,08 (m, 1H), 6,97 (t, 1H), 6,88-6,92 (m, 1H), 4,09 (t, 2H), 3,22 (t, 2H), 2,05-2,14 (m, 2H), 1,94 (s, 3H), 1,83 (s, 3H), 1,40 (s, 3H).

EJEMPLO 476

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 13,26 (s ancho, 1H), 8,30-8,35 (m, 1H), 8,22-8,27 (m, 1H), 7,81-7,91 (m, 2H), 7,64-7,70 (m, 1H), 7,37-7,58 (m, 4H), 7,08-7,34 (m, 4H), 6,80-6,99 (m, 4H), 6,24-6,33 (m, 1H), 5,52 (d, 1H), 5,22 (d, 1H), 4,25 (t, 2H), 3,35-3,49 (m, 2H), 2,24-2,33 (m, 2H), 1,78 (s, 3H).

EJEMPLO 477

ácido 7-(2-metil-4-(trifluorometil)fenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,74 (s ancho, 1H), 10,96 (s, 1H), 7,65-7,73 (m, 2H), 7,57-7,62 (m, 1H), 7,42 (d, 1H), 7,13 (t, 1H), 7,06 (d, 1H), 6,54 (d, 2H), 3,97 (t, 2H), 3,23-3,30 (m, 2H), 2,15-2,20 (m, 6H), 2,05-2,14 (m, 8H).

EJEMPLO 478

ácido 7-(4-fluoro-2-metilfenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 12,89 (s ancho, 1H), 10,69 (s, 1H), 7,66 (d, 1H), 7,13 (d, 5H), 6,54 (d, 2H), 3,97 (t, 2H), 3,25 (t, 2H), 2,14-2,20 (m, 6H), 2,00-2,13 (m, 8H).

EJEMPLO 479

ácido 7-(4-metoxi-2-metilfenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 10,30 (s, 1H), 7,60-7,66 (m, 1H), 7,05-7,17 (m, 2H), 6,99-7,03 (m, 1H), 6,89-6,92 (m, 1H), 6,82-6,87 (m, 1H), 6,51-6,57 (m, 2H), 3,97 (t, 2H), 3,81 (s, 3H), 2,15-2,20 (m, 6H), 2,02-2,10 (m, 8H).

EJEMPLO 480

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 8,39-8,44 (m, 1H), 8,21-8,28 (m, 1H), 7,80-7,92 (m, 2H), 7,36-7,65 (m, 5H), 7,23-7,34 (m, 2H), 7,11-7,20 (m, 2H), 7,05 (t, 1H), 6,86-6,99 (m, 4H), 5,45 (d, 1H), 5,22 (d, 1H), 4,25 (t, 2H), 2,23-2,32 (m, 2H), 1,73 (s, 3H).

EJEMPLO 481

ácido 6-metil-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,82 (s ancho, 1H), 9,78 (s, 1H), 8,22-8,28 (m, 1H), 7,84-7,90 (m, 1H), 7,49-7,62 (m, 3H), 7,45 (d, 1H), 7,25-7,42 (m, 4H), 7,09 (d, 1H), 6,99 (d, 1H), 6,90 (d, 1H), 4,20 (t, 2H), 2,18-2,28 (m, 2H), 2,02 (s, 3H), 1,92 (s, 3H).

EJEMPLO 482

ácido 3-(3-(2,3-diclorofenoxi)propil)-7-(2-metilfenil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,96 (s ancho, 1H), 8,22-8,27 (m, 1H), 7,76-7,84 (m, 1H), 7,50-7,57 (m, 1H), 7,30 (t, 1H), 7,05-7,26 (m, 6H), 6,99 (t, 1H), 6,91-6,95 (m, 1H), 6,83-6,88 (m, 1H), 6,06-6,12 (m, 1H), 5,46 (d, 1H), 5,19 (d, 1H), 4,16 (t, 2H), 2,09-2,21 (m, 2H), 1,76 (s, 3H).

EJEMPLO 483

ácido 7-(2-metilfenil)-1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 8,23-8,30 (m, 1H), 7,84-7,90 (m, 1H), 7,76 (d, 1H), 7,49-7,59 (m, 2H), 7,31-7,49 (m, 4H), 7,22-7,30 (m, 1H), 7,02-7,15 (m, 2H), 6,88-6,95 (m, 2H), 5,00-5,13 (m, 1H), 4,66-4,81 (m, 1H), 4,23 (t, 2H), 3,07-3,30 (m, 2H), 2,65-2,86 (m, 2H), 2,16-2,29 (m, 2H), 1,95 (s, 3H).

EJEMPLO 484

ácido 3-(3-(3,5-diclorofenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 10,33 (s, 1H), 7,64 (d, 1H), 7,17-7,33 (m, 4H), 6,99-7,13 (m, 3H), 6,93-6,96 (m, 2H), 4,02 (t, 2H), 3,20 (t, 2H), 2,00-2,10 (m, 5H).

EJEMPLO 485

ácido 1-metil-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 8,22-8,25 (m, 1H), 7,85-7,89 (m, 1H), 7,74 (d, 1H), 7,49-7,58 (m, 2H), 7,46 (d, 1H), 7,22-7,43 (m, 5H), 7,05-7,10 (m, 1H), 6,98 (d, 1H), 6,91 (d, 1H), 4,21 (t, 2H), 3,32 (s, 3H), 2,19-2,26 (m, 2H), 1,99 (s, 3H).

EJEMPLO 486

ácido 1-metil-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 8,22-8,29 (m, 1H), 7,84-7,89 (m, 1H), 7,71 (d, 1H), 7,50-7,57 (m, 2H), 7,45 (d, 1H), 7,34-7,42 (m, 3H), 7,08-7,16 (m, 2H), 7,03 (t, 2H), 6,86 (d, 1H), 4,17 (t, 2H), 3,34-3,40 (m, 5H), 3,09-3,16 (m, 2H), 2,78-2,88 (m, 2H), 2,52-2,63 (m, 4H), 2,18-2,27 (m, 2H).

EJEMPLO 487

ácido 1-(3-(aminometil)bencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,15 (s ancho, 1H), 8,21-8,29 (m, 1H), 8,01 (s, 2H), 7,76-7,92 (m, 2H), 7,34-7,59 (m, 3H), 7,23-7,32 (m, 1H), 7,02-7,23 (m, 4H), 6,86-7,01 (m, 2H), 6,45 (s, 1H), 6,10 (d, 1H), 5,42 (d, 1H), 5,19 (d, 1H), 4,24 (t, 2H), 3,83 (dd, 2H), 3,40 (t, 2H), 2,20-2,33 (m, 2H).

EJEMPLO 488

ácido 1-(3-(aminometil)bencil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 8,26-8,31 (m, 1H), 7,91-8,09 (m, 2H), 7,85-7,90 (m, 1H), 7,76-7,83 (m, 1H), 7,49-7,59 (m, 2H), 7,46 (d, 1H), 7,38 (t, 2H), 6,93-7,19 (m, 7H), 6,84 (d, 1H), 6,50 (s, 1H), 6,13 (d, 1H), 5,81 (d, 1H), 4,97 (d, 1H), 4,17 (t, 2H), 3,76-3,82 (m, 2H), 3,30-3,38 (m, 2H), 3,18-3,25 (m, 2H), 2,80-2,99 (m, 2H), 2,53-2,66 (m, 4H), 2,16-

2,29 (m, 2H).

EJEMPLO 489

ácido 7-((E)-2-(2-((E)-2-ciclohexilvinil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 11,66 (s, 1H), 8,18-8,23 (m, 1H), 7,92-8,03 (m, 2H), 7,81-7,88 (m, 1H), 7,68 (d, 1H), 7,32-7,63 (m, 7H), 7,17-7,32 (m, 2H), 7,01 (t, 1H), 6,80-6,90 (m, 2H), 6,02-6,12 (m, 1H), 4,16 (t, 2H), 2,15-2,29 (m, 2H), 1,57-1,85 (m, 5H), 1,11-1,37 (m, 6H).

EJEMPLO 490

ácido 7-(2-(3-carboxifenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 11,42 (s, 1H), 8,20-8,25 (m, 1H), 7,95 (s, 1H), 7,82-7,88 (m, 1H), 7,77 (d, 1H), 7,58 (d, 1H), 7,47-7,55 (m, 3H), 7,32-7,46 (m, 3H), 7,06 (d, 1H), 6,84-6,92 (m, 1H), 4,16 (t, 2H), 2,93-3,01 (m, 2H), 2,14-2,25 (m, 2H).

EJEMPLO 491

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(2-piridin-3-ilfenil)vinil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 11,74 (s, 1H), 8,72-8,76 (m, 2H), 8,04-8,25 (m, 4H), 7,82-7,88 (m, 1H), 7,71-7,78 (m, 1H), 7,26-7,62 (m, 9H), 7,06 (d, 1H), 6,93 (t, 1H), 6,86 (d, 1H), 4,16 (t, 2H), 3,34 (t, 2H), 2,16-2,25 (m, 2H).

EJEMPLO 492

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(3-(((fenilsulfonil)amino)carbonil)fenil)etil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,52 (s ancho, 1H), 11,43 (s, 1H), 8,21-8,26 (m, 1H), 7,99-8,06 (m, 2H), 7,90 (s, 1H), 7,84-7,88 (m, 1H), 7,62-7,77 (m, 4H), 7,48-7,60 (m, 4H), 7,34-7,47 (m, 3H), 7,06 (d, 1H), 6,85-6,93 (m, 2H), 4,16 (t, 2H), 3,19-3,25 (m, 2H), 2,92-2,98 (m, 2H), 2,16-2,24 (m, 2H).

EJEMPLO 493

ácido 7-(2-(3-((4-metilpiperidin-1-il)carbonil)fenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,95 (s ancho, 1H), 11,37 (s, 1H), 7,83-7,89 (m, 1H), 7,42-7,57 (m, 4H), 7,30-7,42 (m, 3H), 7,27 (s, 1H), 7,14 (d, 1H), 7,03 (d, 1H), 6,85-6,91 (m, 2H), 4,17 (t, 2H), 3,32 (t, 2H), 3,22-3,28 (m, 2H), 2,94-3,00 (m, 2H), 2,63-2,92 (m, 2H), 2,14-2,25 (m, 2H), 1,39-1,75 (m, 3H), 0,93-1,13 (m, 2H), 0,90 (d, 3H).

EJEMPLO 494

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(3-(((2-pirrolidin-1-iletil)amino)carbonil)fenil)etil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,96 (s ancho, 1H), 11,42 (s, 1H), 9,36 (s, 1H), 8,60-8,66 (m, 1H), 8,20-8,26 (m, 1H), 7,81-7,91 (m, 2H), 7,67-7,72 (m, 1H), 7,48-7,59 (m, 4H), 7,33-7,48 (m, 3H), 7,06 (d, 1H), 6,85-6,93 (m, 2H), 4,17 (t, 2H), 3,56-3,69 (m, 4H), 2,95-3,12 (m, 4H), 2,15-2,25 (m, 2H), 1,97-2,07 (m, 2H), 1,80-1,92 (m, 2H).

EJEMPLO 495

ácido 7-(2-(3-(((2-morfolin-4-iletil)amino)carbonil)fenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,98 (s ancho, 1H), 11,42 (s, 1H), 9,55 (s, 1H), 8,62-8,69 (m, 1H), 8,20-8,25 (m, 1H), 7,81-7,90 (m, 2H), 7,69 (d, 1H), 7,47-7,59 (m, 4H), 7,33-7,47 (m, 3H), 7,06 (d, 1H), 6,85-6,94 (m, 2H), 4,17 (t, 2H), 3,97-4,05 (m, 2H), 3,50-3,71 (m, 6H), 3,06-3,21 (m, 4H), 2,95-3,04 (m, 2H), 2,16-2,25 (m, 2H).

EJEMPLO 496

ácido 7-(2-(3-(((2-(dimetilamino)etil)amino)carbonil)fenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,94 (s ancho, 1H), 11,41 (s, 1H), 9,26 (s, 1H), 8,58-8,64 (m, 1H), 8,19-8,27 (m, 1H), 7,81-7,88 (m, 2H), 7,68 (d, 1H), 7,47-7,58 (m, 4H), 7,33-7,47 (m, 3H), 7,06 (d, 1H), 6,84-6,94 (m, 2H), 4,17 (t, 2H), 3,33 (t, 2H), 3,21-3,30 (m, 4H), 2,95-3,04 (m, 2H), 2,85 (s, 6H), 2,16-2,26 (m, 2H).

EJEMPLO 497

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-(((fenilsulfonil)amino)carbonil)fenil)vinil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,10 (s ancho, 1H), 12,59 (s ancho, 1H), 11,71 (s, 1H), 8,13-8,27 (m, 3H), 7,95-8,07 (m, 3H), 7,82-7,89 (m, 1H), 7,60-7,77 (m, 6H), 7,47-7,57 (m, 3H), 7,44 (d, 1H), 7,29-7,41 (m, 2H), 7,02 (t, 1H), 6,88 (d, 1H), 4,17 (t, 2H), 3,35 (t, 2H), 2,17-2,27 (m, 2H).

EJEMPLO 498

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(2-piridin-4-ilfenil)vinil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,13 (s ancho, 1H), 11,75 (s, 1H), 8,81-8,88 (m, 2H), 8,15-8,27 (m, 3H), 7,83-7,89 (m, 1H), 7,76-7,80 (m, 2H), 7,56-7,64 (m, 2H), 7,42-7,55 (m, 5H), 7,32-7,40 (m, 2H), 7,10 (d, 1H), 6,94 (t, 1H), 6,86 (d, 1H), 4,16 (t, 2H), 3,34 (t, 2H), 2,16-2,26 (m, 2H).

EJEMPLO 499

ácido 7-((E)-2-(3-clorofenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,11 (s ancho, 1H), 11,68 (s, 1H), 8,12-8,27 (m, 2H), 7,83-7,89 (m, 2H), 7,60-7,72 (m, 3H), 7,48-7,57 (m, 2H), 7,26-7,47 (m, 5H), 6,99-7,08 (m, 1H), 6,88 (d, 1H), 4,18 (t, 2H), 3,35 (t, 2H), 2,17-2,28 (m, 2H).

EJEMPLO 500

ácido 7-((E)-2-(3-((ciclohexilamino)carbonil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,08 (s ancho, 1H), 11,73 (s, 1H), 8,13-8,26 (m, 3H), 8,05-8,09 (m, 1H), 7,92-7,97 (m, 1H), 7,83-7,89 (m, 1H), 7,69 (d, 2H), 7,62 (d, 1H), 7,48 (d, 4H), 7,36 (d, 2H), 7,03 (t, 1H), 6,88 (d, 1H), 4,18 (t, 2H), 3,73-3,85 (m, 1H), 2,16-2,28 (m, 2H), 1,81-1,91 (m, 2H), 1,71-1,79 (m, 2H), 1,26-1,38 (m, 6H).

EJEMPLO 501

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-(((2-fenoxietil)amino)carbonil)fenil)vinil)-1H-indol-

2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,08 (s ancho, 1H), 8,69-8,74 (m, 1H), 8,10-8,27 (m, 3H), 7,95 (d, 1H), 7,82-7,89 (m, 1H), 7,67-7,76 (m, 2H), 7,62 (d, 1H), 7,43-7,56 (m, 4H), 7,22-7,41 (m, 4H), 6,85-7,07 (m, 5H), 4,11-4,21 (m, 4H), 3,63-3,71 (m, 2H), 2,17-2,27 (m, 2H).

EJEMPLO 502

ácido 7-((E)-2-(3-(((2-(2-(2-aminoetoxi)etoxi)etil)amino)carbonil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,12 (s ancho, 1H), 11,70 (s, 1H), 8,52 (t, 1H), 8,13-8,27 (m, 2H), 8,10 (s, 1H), 7,98 (d, 1H), 7,83-7,90 (m, 1H), 7,58-7,83 (m, 5H), 7,42-7,57 (m, 4H), 7,28-7,41 (m, 2H), 7,03 (t, 1H), 6,88 (d, 1H), 4,17 (t, 2H), 3,44-3,50 (m, 2H), 3,35 (t, 2H), 2,90-3,02 (m, 2H), 2,15-2,28 (m, 2H).

EJEMPLO 503

ácido 7-((E)-2-(3-((4-bencilpiperidin-1-il)carbonil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,10 (s ancho, 1H), 11,70 (s, 1H), 8,12-8,28 (m, 2H), 7,82-7,90 (m, 1H), 7,59-7,81 (m, 4H), 7,41-7,57 (m, 4H), 7,13-7,40 (m, 8H), 7,03 (t, 1H), 6,88 (d, 1H), 4,41-4,59 (m, 1H), 4,18 (t, 2H), 3,51-3,69 (m, 1H), 3,35 (t, 2H), 2,92-3,10 (m, 1H), 2,67-2,82 (m, 1H), 2,55 (d, 2H), 2,17-2,28 (m, 2H), 1,63-1,90 (m, 3H), 1,08-1,29 (m, 2H).

EJEMPLO 504

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-((4-fenilpiperazin-1-il)carbonil)fenil)vinil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 11,72 (s, 1H), 8,17-8,25 (m, 2H), 7,80-7,90 (m, 3H), 7,71 (d, 1H), 7,62 (d, 1H), 7,42-7,56 (m, 4H), 7,30-7,41 (m, 3H), 7,24 (t, 2H), 7,03 (t, 1H), 6,98 (s, 2H), 6,88 (d, 1H), 6,82 (t, 1H), 4,17 (t, 2H), 3,75-3,86 (m, 2H), 3,50-3,58 (m, 2H), 3,12-3,26 (m, 4H), 2,18-2,26 (m, 2H).

EJEMPLO 505

ácido 7-((E)-2-(3-((3-metilpiperidin-1-il)carbonil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 11,72 (s, 1H), 8,21-8,24 (m, 1H), 8,18 (d, 1H), 7,85-7,88 (m, 1H), 7,74-7,81 (m, 2H), 7,71 (d, 1H), 7,62 (d, 1H), 7,43-7,56 (m, 4H), 7,32-7,40 (m, 2H), 7,24 (d, 1H), 7,03 (t, 1H), 6,88 (d, 1H), 4,17 (t, 2H), 2,19-2,26 (m, 2H), 1,11-1,85 (m, 5H), 0,84 (d, 3H).

EJEMPLO 506

ácido 7-(2-(3-(((2-(2-(2-aminoetoxi)etoxi)etil)amino)carbonil)fenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 12,97 (s ancho, 1H), 11,45 (s, 1H), 8,47 (t, 1H), 8,21-8,27 (m, 1H), 7,83-7,90 (m, 2H), 7,77 (s ancho, 2H), 7,66 (d, 1H), 7,29-7,58 (m, 7H), 7,07 (d, 1H), 6,86-6,94 (m, 2H), 4,17 (t, 2H), 3,59 (t, 6H), 3,55 (t, 2H), 3,41-3,47 (m, 2H),

3,34 (t, 2H), 3,23-3,29 (m, 2H), 2,92-3,03 (m, 4H), 2,16-2,26 (m, 2H).

EJEMPLO 507

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-((E)-2-fenilvinil)fenil)vinil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 13,13 (s ancho, 1H), 11,69 (s, 1H), 8,21-8,25 (m, 1H), 8,18 (d, 1H), 7,85-7,92 (m, 2H), 7,69-7,75 (m, 2H), 7,61-7,66 (m, 3H), 7,49-7,56 (m, 3H), 7,35-7,47 (m, 6H), 7,27-7,34 (m, 3H), 7,04 (t, 1H), 6,89 (d, 1H), 4,18 (t, 2H), 3,36 (t, 2H), 2,18-2,27 (m, 2H).

EJEMPLO 508

ácido 7-((E)-2-(1,1'-bifenil-3-il)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 11,68 (s, 1H), 8,18-8,27 (m, 2H), 8,04 (s, 1H), 7,85-7,91 (m, 1H), 7,71-7,82 (m, 4H), 7,65 (d, 1H), 7,49-7,61 (m, 6H), 7,34-7,49 (m, 4H), 7,06 (t, 1H), 6,90 (d, 1H), 4,20 (t, 2H), 2,20-2,30 (m, 2H).

EJEMPLO 509

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-((1E)-3-fenilprop-1-enil)fenil)vinil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 13,09 (s ancho, 1H), 11,64 (s, 1H), 8,00-8,27 (m, 2H), 7,81-7,89 (m, 1H), 7,47-7,76 (m, 6H), 7,09-7,46 (m, 10H), 7,02 (t, 1H), 6,88 (d, 1H), 6,52 (s, 1H), 4,17 (t, 2H), 2,62-2,70 (m, 2H), 2,17-2,27 (m, 2H).

EJEMPLO 510

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(4-((E)-2-fenilvinil)fenil)vinil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,09 (s, 1H), 11,71 (s, 1H), 8,20-8,25 (m, 1H), 8,17 (d, 1H), 7,83-7,89 (m, 1H), 7,78 (d, 2H), 7,70 (d, 1H), 7,58-7,67 (m, 5H), 7,22-7,56 (m, 10H), 7,03 (t, 1H), 6,88 (d, 1H), 4,18 (t, 2H), 3,35 (t, 2H), 2,17-2,28 (m, 2H).

EJEMPLO 511

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(4-((1E)-3-fenilprop-1-enil)fenil)vinil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,04 (s ancho, 1H), 11,68 (s, 1H), 8,19-8,27 (m, 1H), 8,06-8,16 (m, 1H), 7,83-7,89 (m, 1H), 7,64-7,75 (m, 3H), 7,56-7,62 (m, 1H), 7,18-7,55 (m, 12H), 7,01 (t, 1H), 6,87 (d, 1H), 6,41-6,56 (m, 2H), 4,17 (t, 2H), 3,53-3,58 (m, 2H), 2,15-2,28 (m, 2H).

EJEMPLO 512

ácido 7-((E)-2-(1,1'-bifenil-4-il)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) □ 13,07 (s ancho, 1H), 11,73 (s, 1H), 8,15-8,26 (m, 2H), 7,82-7,90 (m, 3H), 7,68-7,76 (m, 5H), 7,62 (d, 1H), 7,32-7,56 (m, 8H), 7,03 (t, 1H), 6,88 (d, 1H), 4,18 (t, 2H), 3,36 (t, 2H), 2,18-2,28 (m, 2H).

EJEMPLO 513

ácido 7-(2-(1,1'-bifenil-3-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,95 (s ancho, 1H), 11,36 (s, 1H), 8,21-8,26 (m, 1H), 7,83-7,89 (m, 1H), 7,56-7,66 (m, 3H), 7,30-7,56 (m, 11H), 7,10 (d, 1H), 6,84-6,95 (m, 2H), 4,17 (t, 2H), 2,97-3,05 (m, 2H), 2,15-2,26 (m, 2H).

EJEMPLO 514

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(3-(3-fenilpropil)fenil)etil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,91 (s ancho, 1H), 11,33 (s, 1H), 8,21-8,26 (m, 1H), 7,83-7,89 (m, 1H), 7,41-7,56 (m, 4H), 7,37 (t, 1H), 6,83-7,32 (m, 12H), 4,16 (t, 2H), 3,19-3,26 (m, 2H), 2,87-2,94 (m, 2H), 2,52-2,63 (m, 4H), 2,14-2,26 (m, 2H), 1,79-1,91 (m, 2H).

EJEMPLO 515

ácido 7-((E)-2-(2-clorofenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,07 (s ancho, 1H), 11,75 (s, 1H), 8,13-8,24 (m, 3H), 7,82-7,88 (m, 1H), 7,67 (t, 2H), 7,28-7,57 (m, 8H), 7,04 (t, 1H), 6,88 (d, 1H), 4,17 (t, 2H), 3,35 (t, 2H), 2,17-2,28 (m, 2H).

EJEMPLO 516

ácido 7-((E)-2-(1,1'-bifenil-2-il)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,08 (s ancho, 1H), 11,73 (s, 1H), 8,06-8,24 (m, 3H), 7,82-7,89 (m, 1H), 7,28-7,62 (m, 13H), 7,21 (d, 1H), 7,10 (d, 1H), 6,92 (t, 1H), 6,86 (d, 1H), 4,16 (t, 2H), 2,14-2,27 (m, 2H).

EJEMPLO 517

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(2-((E)-2-fenilvinil)fenil)vinil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,08 (s ancho, 1H), 11,76 (s, 1H), 8,21-8,25 (m, 1H), 8,02-8,10 (m, 2H), 7,81-7,89 (m, 2H), 7,68-7,80 (m, 5H), 7,63 (d, 1H), 7,48-7,56 (m, 2H), 7,45 (d, 1H), 7,26-7,42 (m, 6H), 7,14 (d, 1H), 7,04 (t, 1H), 6,88 (d, 1H), 4,17 (t, 2H), 2,18-2,26 (m, 2H).

EJEMPLO 518

ácido 3-(3-(1-naftiloxi)propil)-7-(2-feniletil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,93 (s ancho, 1H), 11,37 (s, 1H), 8,21-8,26 (m, 1H), 7,83-7,89 (m, 1H), 7,48-7,56 (m, 3H), 7,44 (d, 1H), 7,24-7,41 (m, 4H), 7,14-7,21 (m, 1H), 7,06 (d, 1H), 6,85-6,93 (m, 2H), 4,17 (t, 2H), 3,34 (t, 2H), 3,21-3,27 (m, 2H), 2,89-2,97 (m, 2H), 2,16-2,26 (m, 2H).

EJEMPLO 519

ácido 7-(2-(2-clorofenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,95 (s ancho, 1H), 11,34 (s, 1H), 8,20-8,25 (m, 1H), 7,84-7,88 (m, 1H), 7,34-7,56 (m, 7H), 7,20-7,32 (m, 2H), 7,02 (d, 1H), 6,85-6,93 (m, 2H), 4,17 (t, 2H), 3,19-3,25 (m, 2H), 2,99-3,07 (m, 2H), 2,16-2,26 (m, 2H).

EJEMPLO 520

ácido 7-(2-(1,1'-bifenil-4-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,93 (s ancho, 1H), 11,38 (s, 1H), 8,21-8,26 (m, 1H), 7,84-7,88 (m, 1H), 7,62-7,67 (m, 2H), 7,56-7,61 (m, 2H), 7,31-7,55 (m, 10H), 7,10 (d, 1H), 6,85-6,95 (m, 2H), 4,17 (t, 2H), 2,94-3,01 (m, 2H), 2,16-2,26 (m, 2H).

EJEMPLO 521

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-(2-feniletil)fenil)etil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,93 (s ancho, 1H), 11,33 (s, 1H), 8,20-8,26 (m, 1H), 7,84-7,88 (m, 1H), 7,42-7,57 (m, 4H), 7,37 (t, 1H), 7,09-7,30 (m, 9H), 7,04 (d, 1H), 6,85-6,93 (m, 2H), 4,17 (t, 2H), 2,82-2,93 (m, 6H), 2,15-2,25 (m, 2H).

EJEMPLO 522

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-(3-fenilpropil)fenil)etil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,92 (s ancho, 1H), 11,33 (s, 1H), 8,20-8,25 (m, 1H), 7,84-7,88 (m, 1H), 7,47-7,56 (m, 3H), 7,44 (d, 1H), 7,37 (t, 1H), 7,08-7,31 (m, 9H), 7,05 (d, 1H), 6,84-6,93 (m, 2H), 4,16 (t, 2H), 3,16-3,25 (m, 2H), 2,85-2,93 (m, 2H), 2,53-2,63 (m, 4H), 2,15-2,25 (m, 2H), 1,81-1,92 (m, 2H).

EJEMPLO 523

ácido 7-(4-carboxi-2-metilfenil)-3-(3-((2-cianoquinolin-8-il)oxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 10,85 (s, 1H), 8,51 (d, 1H), 8,18 (d, 1H), 8,04 (s, 1H), 7,89 (s, 1H), 7,80 (m, 3H), 7,58 (m, 2H), 7,32 (d, 1H), 7,24 (m, 1H), 7,04 (m, 2H), 4,26 (t, 2H), 2,26 (m, 2H), 2,10 (s, 3H).

EJEMPLO 524

ácido 3-(3-((2-acetil-1-benzofuran-7-il)oxi)propil)-7-(4-carboxi-2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,87 (s, 2H), 10,87 (s, 1H), 7,89 (s, 2H), 7,82 (dd, 1H), 7,73 (dd, 1H), 7,34 (m, 2H), 7,24 (t, 1H), 7,07 (m, 3H), 4,24 (t, 2H), 2,58 (s, 2H), 2,19 (m, 2H), 2,09 (s, 3H).

EJEMPLO 525

ácido 7-(4-carboxi-2-metilfenil)-3-(3-((2,2-dimetil-2,3-dihidro-1-benzofuran-7-il)oxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,86 (s, 2H), 10,85 (s, 1H), 7,89 (m, 1H), 7,82 (m, 1H), 7,71 (m, 1H), 7,32 (d, 1H), 7,06 (m, 2H), 6,71 (m, 3H), 3,98 (t, 2H), 3,20 (t, 2H), 3,00 (s, 2H), 2,07 (m, 5H), 1,43 (s, 6H).

EJEMPLO 526

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2,3-difluorofenoxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,86 (m, 2H), 10,85 (s, 1H), 7,89 (m, 1H), 7,82 (m, 1H), 7,69 (m, 1H), 7,32 (d, 1H), 7,09 (m, 3H), 6,96 (m, 2H), 4,12 (t, 2H), 3,24 (m, 5H).

EJEMPLO 527

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(3-metil-2-nitrofenoxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,88 (m, 2H), 10,88 (s, 1H), 7,89 (m, 1H), 7,82 (m, 1H), 7,63 (m, 1H), 7,40 (t, 1H), 7,32 (d, 1H), 7,08 (m, 3H), 6,99 (m, 1H), 4,13 (t, 2H), 3,16 (t, 2H), 2,26 (m, 3H), 2,10 (m, 3H), 2,03 (m, 2H).

EJEMPLO 528

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2-metil-3-nitrofenoxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,86 (m, 2H), 10,86 (m, 1H), 7,89 (m, 1H), 7,82 (m, 1H), 7,69 (m, 1H), 7,45 (m, 3H), 7,31 (d, 1H), 7,07 (m, 2H), 4,17 (t, 2H), 3,27 (t, 2H), 2,15 (m, 2H), 2,09 (s, 3H).

EJEMPLO 529

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2-cloro-3-(trifluorometil)fenoxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,86 (m, 2H), 10,86 (m, 1H), 7,90 (m, 1H), 7,82 (m, 1H), 7,69 (m, 1H), 7,34 (m, 4H), 7,10 (m, 2H), 4,12 (t, 2H), 2,29 (m, 3H), 2,14 (m, 2H), 2,10 (m, 3H).

EJEMPLO 530

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2-fluoro-3-(trifluorometil)fenoxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,87 (m, 1H), 7,89 (m, 1H), 7,89 (m, 1H), 7,82 (m, 1H), 7,82 (m, 1H), 7,68 (m, 1H), 7,46 (m, 1H), 7,29 (m, 3H), 7,08 (m, 2H), 4,15 (t, 2H), 3,25 (t, 2H), 2,14 (m, 2H), 2,09 (m, 3H)

EJEMPLO 531

ácido 7-(2-clorofenil)-3-(3-(etil(1-naftil)amino)propil)-1H-indol-2-carboxílico

EJEMPLO 531A

7-bromo-3-(3-oxopropil)-1H-indol-2-carboxilato de etilo

A una solución de 7-bromo-3-(4-hidroxipropil)-1H-indol-2-carboxilato de etilo (EJEMPLO 1C) (3,4 g) y trietilamina (8,5 ml) en diclorometano (100 ml) y dimetilsulfóxido (10 ml), enfriada a 0 °C, se agregó piridin-2-sulfonato (9,54 g). La mezcla se agitó durante 3 horas y se diluyó con acetato de etilo (300 ml) y se lavó con HCl 5%, agua, y salmuera. Después de secar las fases orgánicas combinadas sobre Na_2SO_4, el filtrado se concentró y el producto crudo se purificó por cromatografía flash sobre gel de sílice, eluyendo con 10% acetato de etilo en hexano.

EJEMPLO 531B

7-bromo-3-(3-(etil(naftalen-1-il)amino)propil)-1H-indol-2-carboxilato de etilo

A una solución del EJEMPLO 531A (130 mg) y N-etilnaftalen-1-amina (82 mg) en diclorometano (3 ml) se agregó triacetoxiborohidruro de sodio (2,35 g). La mezcla se agitó a temperatura ambiente durante la noche. Después de esto la mezcla se diluyó con acetato de etilo (1500 ml) y se lavó con NaOH 1N, agua, salmuera, y se secó sobre Na_2SO_4. Después de filtrar y concentrar el filtrado, el residuo se purificó por cromatografía flash utilizando gel de sílice y eluyendo con 5% acetato de etilo en hexano.

EJEMPLO 531C

ácido 7-(2-clorofenil)-3-(3-(etil(1-naftil)amino)propil)-1H-indol-2-carboxílico

A una mezcla del EJEMPLO 531B (192 mg) y ácido 2-clorofenilborónico (76 mg) en tetrahidrofurano (6 ml) se agregó tris(dibencilidenacetona)dipaladio(0) (19 mg), tetrafluoroborato de tri-t-butil-fosfonio (12 mg) y fluoruro de cesio (200 mg). La mezcla se purgó con argón y se agitó a temperatura ambiente durante 24 horas. La mezcla se diluyó con acetato de etilo (200 ml) y se lavó con agua, y salmuera y se secó sobre Na_2SO_4. La concentración de la mezcla y purificación en columna del material crudo (5% acetato de etilo en hexano) dio el compuesto del título. Una porción de este material (50

mg) se disolvió en 1:1 tetrahidrofurano/metanol con algunas gotas de agua y se hidrolizó con LiOH. La purificación consecutiva por RP HPLC dio el compuesto del título. ^{1}H RMN (300 MHz, DMSO-d_6) □ 10,80 (m, 1H), 8,27 (m, 1H), 7,90 (m, 1H), 7,55 (m, 1H), 7,53 (m, 1H), 7,42 (m, 3H), 7,34 (m, 3H), 7,21 (m, 2H), 7,03 (m, 1H), 6,98 (m, 2H), 3,21 (m, 4H), 3,08 (t, 2H), 1,79 (m, 2H), 0,96 (t, 3H).

EJEMPLO 532

ácido 7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-3-(4-(5-oxo-2,3,4,5-tetrahidro-1H-1-benzazepin-1-il)butil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 11,11 (m, 1H), 8,29 (m, 1H), 8,21 (m, 1H), 7,75 (m, 1H), 7,53 (m, 2H), 7,27 (m, 1H), 7,09 (m, 2H), 6,96 (m, 1H), 6,70 (m, 1H), 3,74 (m, 6 H), 3,49 (t, 2H), 3,16 (t, 4H), 2,55 (t, 2H), 2,07 (m, 3H).

EJEMPLO 533

ácido 7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-3-(4-(2,3,4,5-tetrahidro-1H-1-benzazepin-1-il)butil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 11,09 (m, 1H), 8,29 (m, 1H), 8,20 (dd, 2H), 7,68 (dd, 1H), 7,52 (dd, 1H), 7,08 (m, 4H), 6,83 (m, 2H), 4,36 (m, 6 H), 3,13 (m, 4H), 2,76 (m, 3H), 1,59 (m, 8H).

EJEMPLO 534

ácido 3-(4-(2,3-dihidro-4H-1,4-benzotiazin-4-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 11,10 (m, 1H), 8,29 (m, 1H), 8,21 (m, 1H), 7,74 (m, 1H), 7,54 (m, 1H), 7,10 (m, 2H), 6,89 (m, 2H), 6,64 (m, 1H), 6,49 (m, 1H), 3,52 (m, 2H), 3,30 (m, 8H), 3,14 (m, 2H), 1,68 (m, 4H).

EJEMPLO 535

ácido 3-(4-(3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 10,41 (m, 1H), 7,68 (m, 1H), 7,28 (m, 4H), 7,08 (m, 2H), 6,88 (m, 2H), 6,46 (m, 2H), 3,18 (m, 6H), 2,64 (m, 2H), 2,05 (m, 3H), 1,68 (m, 6H).

EJEMPLO 536

ácido 3-(4-(2-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 10,38 (s, 1H), 7,69 (m, 1H), 7,29 (m, 4H), 7,09 (m, 2H), 6,90 (m, 2H), 6,44 (m, 2H), 3,38 (m, 3H), 3,14 (m, 3H), 2,69 (m, 2H), 2,05 (m, 3H), 1,65 (m, 6H), 1,02 (d, 3H).

EJEMPLO 537

ácido 3-(4-(6-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 10,38 (s, 1H), 7,68 (m, 1H), 7,28 (m, 5 H), 7,10 (m, 2H), 6,72 (m, 2H), 6,45 (m, 1H), 3,15 (m, 7 H), 2,61 (m, 2H), 2,11 (s, 3H), 2,05 (s, 3H), 1,69 (m, 5H).

EJEMPLO 538

ácido 3-(4-(8-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 10,41 (m, 1H), 7,70 (m, 1H), 7,24 (m, 8H), 7,03 (m, 2H), 3,13 (m, 4H), 2,78 (m, 4H), 2,25 (m, 4H), 2,03 (s, 3H), 1,75 (m, 5H).

EJEMPLO 539

ácido 3-(4-(2-metil-2,3-dihidro-1H-indol-1-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 10,37 (m, 1H), 7,68 (m, 1H), 7,32 (m, 2H), 7,24 (m, 2H), 7,15 (m, 1H), 7,05 (m, 1H), 6,93 (m, 2H), 6,49 (m, 1H), 6,32 (m, 1H), 3,08 (m, 6 H), 2,06 (s, 3H), 1,63 (m, 4H), 1,18 (d, 3H).

EJEMPLO 540

ácido 7-(2-metilfenil)-3-(4-(2,3,4,5-tetrahidro-1H-1-benzazepin-1-il)butil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 10,35 (m, 1H), 7,62 (m, 1H), 7,27 (m, 4H), 7,07 (m, 4H), 6,83 (m, 2H), 3,07 (m, 5H), 2,77 (m, 4H), 2,08 (s, 3H), 1,63 (m, 8H).

EJEMPLO 541

ácido 3-(4-(3-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 10,36 (m, 1H), 7,67 (m, 1H), 7,27 (m, 4H), 7,09 (m, 2H), 6,86 (m, 2H), 6,47 (m, 2H), 3,22 (m, 6 H), 2,75 (m, 1H), 2,31 (m, 2H), 2,06 (m, 3H), 1,91 (m, 1H), 1,65 (m, 4H), 0,96 (d, 3H).

EJEMPLO 542

ácido 3-(4-(3-(hidroximetil)-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 10,39 (m, 1H), 7,68 (m, 1H), 7,28 (m, 4H), 7,09 (m, 2H), 6,89 (m, 2H), 6,44 (m, 2H), 3,25 (m, 8 H), 2,93 (m, 1H), 2,67 (m, 1H), 2,36 (m, 1H), 2,06 (s, 3H), 1,92 (m, 1H), 1,66 (m, 4H).

EJEMPLO 543

ácido 3-(4-(2,3-dihidro-4H-1,4-benzotiazin-4-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 10,40 (m, 1H), 7,68 (m, 1H), 7,29 (m, 4H), 7,09 (m, 2H), 6,88 (m, 2H), 6,55 (m, 2H), 3,54 (m, 2H), 3,29 (m, 3H), 3,13 (m, 2H), 2,98 (m, 2H), 2,05 (m, 3H), 1,67 (m, 4H).

EJEMPLO 544

ácido 4-metoxi-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 10,23 (m, 1H), 8,23 (m, 1H), 7,86 (m, 1H), 7,47 (m, 4H), 7,23 (m, 4H), 6,94 (m, 2H), 6,59 (m, 2H), 4,23 (t, 2H), 3,87 (s, 3H), 3,49 (m, 2H), 2,24 (m, 2H), 2,06 (m, 3H).

EJEMPLO 545

ácido 3-(3-(((1R,4S)-8-hidroxi-1,2,3,4-tetrahidro-1,4-metanonaftalen-5-il)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 10,45 (m, 1H), 8,57 (m, 1H), 7,65 (m, 1H), 7,27 (m, 4H), 7,07 (m, 2H), 6,43 (m, 2H), 3,90 (m, 2H), 3,48 (m, 2H), 3,22 (m, 2H), 2,06 (s, 3H), 1,79 (m, 2H), 1,28 (m, 5 H).

EJEMPLO 546

ácido 7-(2-metilfenil)-3-(3-((1R,4S)-1,2,3,4-tetrahidro-1,4-metanonaftalen-5-iloxi)propil)-1H-indol-2-carboxílico

EJEMPLO 546A

A una solución de 3',6'-dihidroxibenzonorbornano (3,52 g) e imidazol (1,36 g) en N,N-dimetilformamida (150 ml) se agregó una solución de t-Butilclorodimetilsilano (3,01 g) en N,N-dimetilformamida (30 ml) por goteo. Después de la adición, la mezcla se agitó durante la noche a temperatura ambiente. Después de la concentración del solvente bajo vacío, el residuo se disolvió en acetato de etilo (300 ml) y se lavó con HCl 5%, agua, y salmuera y se secó sobre Na_2SO_4. Después de la evaporación del solvente, el residuo se cargó en una columna de gel de sílice y se eluyó con 20% acetato de etilo en hexano para dar el producto.

EJEMPLO 546B

A una solución enfriada (0 °C) de 7-bromo-3-(3-hidroxipropil)-1H-indol-2-carboxilato de etilo (326 mg) y el EJEMPLO 546A (290 mg) y trifenilfosfina (315 mg) en tetrahidrofurano (10 ml) se agregó azodicarboxilato de di-tert-butilo (276 mg). La mezcla se agitó a 0 °C durante 1 hora y luego se agitó a temperatura ambiente durante 14 horas. Después de esto, la mezcla se diluyó con acetato de etilo (200 ml) y se lavó con agua, salmuera y se secó sobre Na_2SO_4. La concentración del solvente y purificación en columna (10% acetato de etilo en hexano) dio el producto.

EJEMPLO 546C

A una mezcla del EJEMPLO 1C (310 mg) y ácido 2-toluenborónico (84 mg) en dimetoxietano (20 ml) y etanol (10 ml) se agregó tetrakis(trifenilfosfin)paladio(0) (30 mg), y fluoruro de cesio (236 mg). La mezcla se agitó bajo nitrógeno a reflujo durante 4 horas. Después de esto el solvente se concentró bajo vacío y el residuo se particionó entre acetato de etilo (300 ml) y agua (100 ml). La fase orgánica se lavó con agua, salmuera y se secó sobre Na_2SO_4. La evaporación del solvente y purificación en columna (5% acetato de etilo en hexano) dio el producto.

EJEMPLO 546D

7-(2-metilfenil)-3-(3-((8-(((trifluorometil)sulfonil)oxi)-1,2,3,4-tetrahidro-1,4-metanonaftalen-5-il)oxi)propil)-1*H*-indol-2-carboxilato de etilo

A una mezcla del EJEMPLO 546C (85 mg) en piridina (2 ml) a 0°C se agregó anhídrido tríflico (120 mg). La mezcla se agitó a temperatura ambiente durante la noche. La mezcla se particionó entre etiléter (300 ml) y HCl acuoso 5% (50 ml). La fase orgánica se lavó con agua y salmuera y se secó sobre Na_2SO_4. Después de la filtración y la concentración del filtrado el producto crudo se utilizó en el próximo paso sin purificación adicional.

EJEMPLO 546E

7-(2-metilfenil)-3-(3-(1,2,3,4-tetrahidro-1,4-metanonaftalen-5-iloxi)propil)-1*H*-indol-2-carboxilato de etilo

A una solución del EJEMPLO 546D (80 mg) en tetrahidrofurano y metanol (40 ml,

1:1) se agregó hidróxido de paladio 10% (40 mg). La mezcla se agitó bajo 30 psi de hidrógeno durante 4 horas. El catalizador se filtró, el filtrado se concentró y el residuo se hidrolizó con LiOH/tetrahidrofurano/metanol/H_2O. El producto se purificó por HPLC en fase reversa.

EJEMPLO 546F

ácido 7-(2-metilfenil)-3-(3-((1R,4S)-1,2,3,4-tetrahidro-1,4-metanonaftalen-5-iloxi)propil)-1H-indol-2-carboxílico

El compuesto del título se preparó de acuerdo con el procedimiento del EJEMPLO 164G, utilizando el EJEMPLO 546E en lugar del EJEMPLO 164F. ^{1}H RMN (300 MHz, DMSO-d_6) 10,45 (m, 1H), 7,65 (m, 1H), 7,28 (m, 4H), 7,02 (m, 3H), 6,78 (m, 1H), 6,63 (m, 1H), 4,00 (m, 2H), 2,07 (m, 5H), 1,87 (m, 2H), 1,30 (m, 7H).

EJEMPLO 547

ácido 3-(3-((4-metoxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 10,47 (m, 1H), 8,22 (m, 1H), 8,11 (m, 1H), 7,69 (m, 1H), 7,54 (m, 2H), 7,26 (m, 4H), 7,05 (m, 2H), 6,82 (m, 2H), 4,14 (m, 2H), 3,91 (s, 3H), 3,36 (m, 2H), 2,22 (m, 2H), 2,05 (s, 3H).

EJEMPLO 548

ácido 7-(2-metilfenil)-3-(3-((2-nitro-1-naftil)oxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,92 (m, 1H), 10,51 (m, 1H), 8,30 (m, 1H), 8,08 (m, 1H), 7,90 (m, 2H), 7,74 (m, 3H), 7,19 (m, 4H), 4,27 (m, 2H), 2,23 (m, 2H), 2,07 (s, 3H).

EJEMPLO 549

ácido 3-(3-((3-hidroxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,92 (m, 1H), 10,50 (m, 1H), 9,65 (m, 1H), 8,08 (m, 1H), 7,64 (m, 2H), 7,30 (m, 4H), 7,05 (m, 2H), 6,68 (m, 1H), 6,48 (m, 1H), 4,13 (m, 2H), 2,23 (m, 2H), 2,05 (s, 3H).

EJEMPLO 550

ácido 7-(3,5-dimetilisoxazol-4-il)-3-(3-(2,3,6,7-tetrahidro-1H,5H-pirido(3,2,1-ij)quinolin-8-iloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 11,25 (m, 1H), 7,67 (m, 1H), 7,11 (m, 2H), 6,62 (d, 1H), 6,08 (d, 1H), 3,22 (m, 2H), 3,04 (m, 4H), 2,62 (m, 4H), 2,22 (s, 3H), 2,05 (s, 3H), 2,04 (m, 4H), 1,86 (m, 4H).

EJEMPLO 551

ácido 7-(2-metilfenil)-3-(3-(2,3,6,7-tetrahidro-1H,5H-pirido(3,2,1-ij)quinolin-8-iloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 10,46 (m, 1H), 7,65 (m, 1H), 7,27 (m, 4H), 7,08 (m, 2H), 6,63 (d, 1H), 6,10 (d, 1H), 3,93 (m, 2H), 3,23 (m, 2H), 3,05 (m, 4H), 2,64 (m, 4H), 2,05 (m, 5H), 1,86 (m, 4H).

EJEMPLO 552

ácido 7-(2-metilfenil)-3-(3-((2-nitroso-1-naftil)oxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 10,64 (m, 1H), 8,13 (m, 2H), 7,72 (m, 5H), 7,27 (m, 4H), 7,04 (m, 2H), 3,71 (m, 2H), 2,03 (s, 3H), 1,40 (m, 2H).

EJEMPLO 553

ácido 3-(3-((5-hidroxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,92 (m, 1H), 10,46 (m, 1H), 9,99 (m, 1H), 7,69 (m, 3H), 7,28 (m, 6H), 7,06 (m, 2H), 6,88 (m, 2H), 4,17 (t, 2H), 3,35 (t, 2H), 2,22 (m, 2H), 2,06 (s, 3H).

EJEMPLO 554

ácido 7-(2-metilfenil)-3-(3-(2,3,4-trifluorofenoxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,85 (m, 1H), 10,47 (m, 1H), 7,66 (d, 1H), 7,12 (m, 8H), 4,10 (t, 2H), 3,23 (t, 2H), 2,11 (m, 2H), 2,06 (s, 3H).

Ejemplo 555

ácido 3-(3-(3-cloro-2-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) □ 12,87 (m, 1H), 10,45 (m, 1H), 7,65 (d, 1H), 7,27 (m, 4H), 7,07 (m, 2H), 6,88 (d, 1H), 4,04 (t, 2H), 3,27 (t, 2H), 2,24 (s, 3H), 2,12 (m, 2H), 2,06 (s, 3H).

EJEMPLO 556

ácido 3-(3-((8-hidroxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 10,53 (m, 1H), 9,56 (m, 1H), 7,68 (d, 1H), 7,44 (d, 1H), 7,34 (m, 6H), 7,24 (m, 2H), 7,07 (m, 2H), 6,93 (d, 1H), 6,81 (dd, 1H), 4,33 (t, 2H), 2,24 (m, 2H), 2,06 (s, 3H).

EJEMPLO 557

ácido 3-(3-(3-cloro-2-cianofenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,88 (m, 1H), 10,48 (m, 1H), 7,70 (d, 1H), 7,63 (t, 1H), 7,27 (m, 5H), 7,18 (d, 1H), 7,07 (m, 2H), 4,20 (t, 2H), 3,26 (t, 2H), 2,13 (m, 2H), 2,05 (s, 3H).

EJEMPLO 558

ácido 3-(3-(2-bromo-3-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,88 (m, 1H), 10,46 (m, 1H), 7,70 (d, 1H), 7,32 (m, 2H), 7,25 (m, 2H), 7,18 (d, 1H), 7,06 (m, 2H), 6,93 (d, 1H), 6,86 (d, 1H), 4,06 (t, 2H), 3,27 (t, 2H), 2,38 (s, 3H), 2,11 (m, 2H), 2,05 (s, 3H).

EJEMPLO 559

ácido 7-(2-metilfenil)-3-(3-(3-metil-2-vinilfenoxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,88 (m, 1H), 10,47 (m, 1H), 7,65 (d, 1H), 7,32 (m, 2H), 7,24 (m, 3H), 7,08 (m, 3H), 6,80 (d, 2H), 5,81 (dd, 1H), 5,53 (dd, 1H), 4,02 (t, 2H), 3,25 (m, 2H), 2,32 (m, 3H), 2,11 (m, 2H), 2,06 (s, 3H).

EJEMPLO 560

ácido 3-(3-(3-metil-2-nitrofenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 12,89 (m, 1H), 10,51 (m, 1H), 7,60 (d, 1H), 7,40 (t, 1H), 7,32 (m, 2H), 7,24 (m, 3H), 4,13 (t, 2H), 3,15 (t, 2H), 2,26 (s, 3H), 2,05 (s, 3H), 2,03

(m, 2H).

EJEMPLO 561

ácido 3-(3-(2-amino-3-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 10,49 (m, 1H), 7,69 (d, 1H), 7,33 (m, 2H), 7,25 (m, 3H), 7,08 (m, 3H), 6,73 (m, 3H), 4,04 (t, 2H), 3,26 (t, 2H), 2,18 (s, 3H), 2,12 (m, 2H), 2,06 (s, 3H).

EJEMPLO 562

ácido 7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) 11,10 (m, 1H), 8,25 (m, 2H), 7,86 (m, 2H), 7,73 (m, 3H), 7,53 (m, 3H), 7,43 (m, 4H), 7,07 (m, 3H), 6,90 (d, 1H), 4,21 (t, 2H), 3,61 (m, 6H), 2,24 (m, 2H).

EJEMPLO 563

ácido 3-(3-((6-amino-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

EJEMPLO 563A

3-(3-(6-aminonaftalen-1-iloxi)propil)-7-bromo-1H-indol-2-carboxilato de etilo

A una mezcla de 7-bromo-3-(3-hidroxipropil)-1H-indol-2-carboxilato de etilo (EJEMPLO 1C) (100 mg), 6-aminonaftalen-1-ol (98 mg) y trifenilfosfina con soporte polímero (204 mg 0,613 mmol) en tetrahidrofurano (4 ml) se agregó diazen-1,2-dicarboxilato de di-tert-butilo (141 mg). La mezcla de reacción se agitó a temperatura ambiente durante 3 horas. El material insoluble se filtró y el filtrado se concentró. El residuo se purificó por cromatografía flash (acetato de etilo en hexanos) para dar el compuesto del título.

EJEMPLO 563B

ácido 3-(3-((6-amino-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

Una mezcla del EJEMPLO 563A (45 mg), ácido o-tolilborónico (15,7 mg), K_2CO_3 (1 M, 0,17 ml) y dicloruro de bis(trifenilfosfin)paladio(II) (7,2 mg, 0,01 mmol) en una mezcla de dimetoxietano (2,2 ml), etanol (0,6 ml) y agua (0,9 ml) se calentó a 160 °C en un reactor de microondas (CEM Discover) durante 10 minutos. La mezcla de reacción se acidificó con una solución diluida de ácido trifluoroacético en metanol y se concentró. El residuo se suspendió en una mezcla de DMSO y metanol (1:1) y se filtró. El filtrado se purificó por RP HPLC para dar el producto deseado. ^{1}H RMN (400 MHz, DMSO-D_6) □ 10,43 (s, 1 H), 8,08 (d, *J*=8,90 Hz, 1 H), 7,69 (d, *J*=6,75 Hz, 1 H), 7,31-7,34 (m, 2 H), 7,18-7,29 (m, 5 H), 7,02-7,11 (m, 5 H), 6,64 (d, *J*=7,67 Hz, 1 H), 4,15 (t, *J*=5,98 Hz, 2 H), 2,49-2,53 (m, 2 H), 2,17-2,25 (m, 2 H), 2,06 (s, 3 H).

EJEMPLO 564

ácido 7-(2-metilfenil)-3-(3-(1,2,3,4-tetrahidronaftalen-1-iloxi)prop-1-inil)-1H-indol-2-carboxílico

EJEMPLO 564A

7-o-tolil-1H-indol-2-carboxilato de etilo

A una mezcla de 7-(4,4,5,5-tetrametil-1,3,2-dioxaborolan-2-il)-1H-indol-2-carboxilato de etilo (Paul et al. *J. Am. Chem. Soc.* 2006, *128*, 15552-15553) (1,6 g), tetrafluoroborato de tri-(t-butil)fosfonio (0,074 g), tris(dibencilidenacetona)dipaladio(0) (0,116 g) y fluoruro de cesio (2,313 g) se agregó orto-iodotolueno (0,781 ml), luego dioxano (200 ml) y metanol (20 ml). La mezcla de reacción se purgó inmediatamente con nitrógeno y se agitó a temperatura ambiente durante 2 horas. Se agregaron más (dibencilidenacetona)dipaladio(0) (0,116 g), orto-iodotolueno (0,781 ml), CsF (2,313 g), y tetrafluoroborato de tri-(t-butil)fosfonio (0,074 g) al mismo tiempo. La solución resultante se agitó a temperatura ambiente durante la noche. El material insoluble se filtró y el filtrado se concentró y el residuo se purificó por cromatografía flash, eluyendo con 0-100% diclorometano en hexano para dar el compuesto del título.

EJEMPLO 564B

3-iodo-7-o-tolil-1H-indol-2-carboxilato de etilo

A una solución del EJEMPLO 564A (944mg, 3,38 mmol) en diclorometano (10 ml) se agregó 1-iodopirrolidin-2,5-diona (798 mg, 3,55 9 mmol). La mezcla de reacción se agitó a temperatura ambiente durante 3 horas y se cargó directamente en una columna flash, eluyendo con hexano en primer lugar y luego con 0-50% hexano en diclorometano. El compuesto del título se obtuvo como un sólido blanco.

EJEMPLO 564C

ácido 7-(2-metilfenil)-3-(3-(1,2,3,4-tetrahidronaftalen-1-iloxi)prop-1-inil)-1H-indol-2-carboxílico

A una solución del EJEMPLO 564B (180 mg) y 1-(prop-2-iniloxi)-1,2,3,4-tetrahidronaftaleno (165 mg) en trietilamina (5 ml) se agregó dicloruro de bis(trifenilfosfin)paladio(II) (18,71 mg) y ioduro de cobre(I) (4,23 mg). La mezcla de reacción se agitó a 70°C durante 3 horas, se enfrió y se concentró. El residuo se disolvió en diclorometano y se purificó por cromatografía flash, eluyendo con diclorometano, para dar 3-(3-(1,2,3,4-tetrahidronaftalen-1-iloxi)prop-1-inil)-7-o-tolil-1H-indol-2-carboxilato de etilo. Este éster se hidrolizó con NaOH acuoso en tetrahidrofurano y metanol para dar el compuesto del título. ^{1}H RMN (400 MHz, metanol-d_4) 7,76 (dd, *J*=7,98, 1,23 Hz, 1 H), 7,52 (dd, *J*=6,75, 2,46 Hz, 1 H), 7,34-7,40 (m, 2 H), 7,27-7,31 (m, 2 H), 7,26 (d, *J*=7,98 Hz, 1 H), 7,13-7,19 (m, 3 H), 7,07-7,12 (m, 1 H), 4,97 (t, *J*=3,99 Hz, 1 H), 4,52-4,71 (m, 2 H), 2,79-2,90 (m, 1 H), 2,68-2,78 (m, 1 H), 2,14-2,21 (m, 1 H), 2,12 (s, 3 H), 1,91-2,06 (m, 2 H), 1,73-1,84 (m, 1 H).

EJEMPLO 565

ácido 3-(3-((6-(acriloilamino)-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

EJEMPLO 565A

A una mezcla de 7-bromo-3-(3-hidroxipropil)-1H-indol-2-carboxilato de etilo (1 g mmol), 6-aminonaftalen-1-ol (0,732 g), trifenilfosfina con soporte polímero (1,230 g) en tetrahidrofurano (4 ml) se agregó azodicarboxilato de di-t-butilo (1,059 g, 4,60 mmol). La reacción se agitó a temperatura ambiente durante 3 h. El material insoluble se eliminó

por filtración y se lavó extensivamente con acetato de etilo. El filtrado combinado se concentró. El residuo se purificó por cromatografía flash, eluyendo con CH_2Cl_2/acetato de etilo (20:1) para dar el compuesto del título.

EJEMPLO 565B

El compuesto del título se preparó de acuerdo con el procedimiento del EJEMPLO 564A reemplazando 7-(4,4,5,5-tetrametil-1,3,2-dioxaborolan-2-il)-1H-indol-2-carboxilato de etilo por o-tolilborónico ácido, y orto-iodotolueno por el EJEMPLO 565A, respectivamente.

EJEMPLO 565C

ácido 3-(3-((6-(acriloilamino)-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

A una mezcla del EJEMPLO 565B (62,8 mg), ácido acrílico (9,91 µl) y hexafluorofosfato de 2-(1H-7-azabenzotriazol-1-il)--1,1,3,3-tetrametiluronio metanaminio (HATU, 54,9 mg) en tetrahidrofurano (3 ml) se agregó trietilamina (36,6 µl). La reacción se agitó a temperatura ambiente durante la noche, se diluyó con acetato de etilo y se lavó con agua. La fase orgánica se secó sobre sulfato de sodio, se filtró y se concentró. El residuo se purificó por cromatografía flash, eluyendo con diclorometano, para dar 3-(3-(6-acrilamidonaftalen-1-iloxi)propil)-7-o-tolil-1H-indol-2-carboxilato de etilo. Este éster se hidrolizó con NaOH acuoso en tetrahidrofurano y metanol para dar el compuesto del título. ^{1}H RMN (500 MHz, metanol -d_4) □ 8,22-8,25 (m, 2 H), 7,68 (dd, *J*=5,95, 3,20 Hz, 1 H), 7,59 (dd, *J*=9,15, 2,14 Hz, 1 H), 7,25-7,37 (m, 6 H), 7,05-7,08 (m, 2 H), 6,74 (dd, *J*=6,10, 2,44 Hz, 1 H), 6,46-6,55 (m, 1 H), 6,38-6,44 (m, 1 H), 5,80 (dd, *J*=10,07, 1,83 Hz, 1 H), 4,20 (t, *J*=5,95 Hz, 2 H), 3,40-3,56 (m, 2 H), 2,34 (t, *J*=6,71 Hz, 2 H), 2,11 (s, 3 H).

EJEMPLO 566

ácido 7-(2-metilfenil)-3-(3-((6-(propionilamino)-1-naftil)oxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, metanol -d_4) 8,21 (d, *J*=9,15 Hz, 1 H), 8,14 (d, *J*=1,83 Hz, 1 H), 7,67 (dd, *J*=6,26, 2,90 Hz, 1 H), 7,53 (dd, *J*=9,15, 2,14 Hz, 1 H), 7,24-7,37 (m, 6 H), 7,04-7,07 (m, 2 H), 6,71 (dd, *J*=5,03, 3,51 Hz, 1 H), 4,19 (t, *J*=5,95 Hz, 2 H), 3,42-3,49 (m, 2 H), 2,45 (q, *J*=7,63 Hz, 2 H), 2,29-2,37 (m, 2 H), 2,11 (s, 3 H), 1,25 (t, *J*=7,63 Hz, 3 H).

EJEMPLO 567

ácido 7-(2-metilfenil)-3-(3-(1,2,3,4-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico

Una mezcla del EJEMPLO 564 (50 mg) y Raney-Ni (húmedo, 240 mg) en tetrahidrofurano (5 ml) y metanol (3 ml) se agitó bajo hidrógeno a 30 °C durante 1 hora. El material insoluble se filtró. Al filtrado se agregó NaOH 10% (1 ml) y la mezcla resultante se agitó durante la noche y se acidificó con HCl. La mezcla se concentró y el residuo se purificó por HPLC en fase reversa (fase móvil: 10%-100% acetonitrilo en solución acuosa de TFA 0,1% durante 60 min) para dar el compuesto del título. ^{1}H RMN (400 MHz, metanol -d_4) □ 7,69 (dd, *J*=7,98, 1,23 Hz, 1 H), 7,31-7,38 (m, 3 H), 7,27-7,30 (m, 2 H), 7,13-7,17 (m, 3 H), 7,07-7,12 (m, 2 H), 4,43 (t, *J*=4,60 Hz, 1 H), 3,71-3,76 (m, 1 H), 3,59-3,65 (m, 1 H), 3,23-3,27 (m, 2 H), 2,79-2,86 (m, 1 H), 2,67-2,75 (m, 1 H), 2,12 (s, 3 H), 1,94-2,06 (m, 4 H), 1,85-1,93 (m, 1 H), 1,69-1,77 (m, 1 H).

EJEMPLO 568

ácido 3-(3-((6-metoxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, diclorometano-d_2) 8,49 (s, 1 H), 8,22 (d, *J*=9,76 Hz, 1 H), 7,75 (d, *J*=7,32 Hz, 1 H), 7,27-7,38 (m, 7 H), 7,16-7,21 (m, 2 H), 7,12 (s, 2 H), 6,64 (dd, *J*=5,80, 2,75 Hz, 1 H), 4,19 (t, *J*=6,10 Hz, 2 H), 3,89 (s, 3 H), 3,46 (t, *J*=7,48 Hz, 2 H), 2,32-2,38 (m, 2 H), 2,15 (s, 3 H).

EJEMPLO 569

ácido 1-(4-metoxibencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)prop-1-inil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,50 (s, 1 H), 8,21-8,24 (m, 1 H), 7,89-7,92 (m, 1 H), 7,63 (dd, *J*=7,98, 1,23 Hz, 1 H), 7,49-7,57 (m, 4 H), 7,28-7,33 (m, 2 H), 7,24 (t, *J*=7,67 Hz, 2 H), 7,14 (t, *J*=7,52 Hz, 1 H), 7,01-7,04 (m, 2 H), 6,61-6,65 (m, 2 H), 6,18 (s, 1 H), 6,16 (s, 1 H), 5,39 (s, 2 H), 5,29 (d, *J*=15,96 Hz, 1 H), 5,11 (d, *J*=16,26 Hz, 1 H), 3,62 (s, 3 H), 1,72 (s, 3 H).

EJEMPLO 570

ácido 3-(3-((2,3,4,5,6,7,8-heptafluoro-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 12,84 (s, 1 H), 10,51 (s, 1 H), 7,70 (d, *J*=7,93 Hz, 1 H), 7,33 (d, *J*=3,97 Hz, 2 H), 7,25-7,30 (m, 1 H), 7,21-7,23 (m, 1 H), 7,13-7,16 (m, 1 H), 7,05 (d, *J*=6,71 Hz, 1 H), 4,29 (t, *J*=6,41 Hz, 2 H), 3,25-3,29 (m, 2 H), 2,14-2,20 (m, 2 H), 2,05 (s, 3 H).

EJEMPLO 571

ácido 3-(3-(1-benzotien-7-iloxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 12,91 (s, 1 H), 10,50 (s, 1 H), 7,75 (d, *J*=5,49 Hz, 1 H), 7,69 (d, *J*=7,93 Hz, 1 H), 7,45-7,48 (m, 2 H), 7,25-7,33 (m, 4 H), 7,21-7,23 (m, 1 H), 7,08 (t, *J*=7,48 Hz, 1 H), 7,02-7,04 (m, 1 H), 6,87 (d, *J*=7,93 Hz, 1 H), 4,23 (t, *J*=6,10 Hz, 2 H), 3,27-3,32 (m, 2 H), 2,14-2,20 (m, 2 H), 2,06 (s, 3 H).

EJEMPLO 572

ácido 3-(3-((4-fluoro-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 12,97 (s, 1 H), 10,46 (s, 1 H), 8,28 (d, *J*=7,93 Hz, 1 H), 8,00 (d, *J*=7,63 Hz, 1 H), 7,61-7,69 (m, 3 H), 7,33 (d, *J*=3,66 Hz, 2 H), 7,24-7,29 (m, 1 H), 7,19-7,23 (m, 2 H), 7,02-7,08 (m, 2 H), 6,84 (dd, *J*=8,54, 3,97 Hz, 1 H), 4,19 (t, *J*=6,10 Hz, 2 H), 3,32-3,37 (m, 2 H), 2,20-2,26 (m, 2 H), 2,06 (s, 3 H).

EJEMPLO 573

ácido 3-(3-((8-fluoro-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 10,46 (s, 1 H), 7,69-7,72 (m, 2 H), 7,42-7,52 (m, 3 H), 7,33 (d, *J*=3,66 Hz, 2 H), 7,21-7,29 (m, 3 H), 7,02-7,07 (m, 2 H), 6,97 (d, *J*=7,63 Hz, 1 H), 4,15 (t, *J*=6,10 Hz, 2 H), 3,32-3,36 (m, 2 H), 2,16-2,22 (m, 2 H), 2,06 (s, 3 H).

EJEMPLO 574

ácido 3-(3-((5-fluoro-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, DMSO-d_6) 10,43 (s, 1 H), 8,07 (d, *J*=8,54 Hz, 1 H), 7,68 (d, *J*=7,32 Hz, 1 H), 7,57-7,59 (m, 1 H), 7,48-7,52 (m, 2 H), 7,36 (dd, *J*=10,98, 7,63 Hz, 1 H),

7,33 (d, *J*=3,66 Hz, 2 H), 7,25-7,29 (m, 1 H), 7,21-7,23 (m, 1 H), 7,05-7,09 (m, 1 H), 7,01-7,04 (m, 2 H), 4,23 (t, *J*=6,10 Hz, 2 H), 3,22-3,31 (m, 2 H), 2,21-2,27 (m, 2 H), 2,06 (s, 3 H).

EJEMPLO 575

ácido 7-fluoro-3-(2-isopropilfenil)-1-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,87 (s, 1 H), 8,06 (d, *J*=8,29 Hz, 1 H), 7,84 (d, *J*=7,98 Hz, 1 H), 7,50 (t, *J*=6,90 Hz, 1 H), 7,32-7,47 (m, 5 H), 7,12-7,20 (m, 2 H), 6,99-7,05 (m, 2 H), 6,88 (d, *J*=8,59 Hz, 2 H), 5,03 (t, *J*=8,13 Hz, 2 H), 4,18 (t, *J*=5,83 Hz, 2 H), 2,63-2,70 (m, 1 H), 2,38-2,46 (m, 2 H), 1,00 (d, *J*=6,75 Hz, 3 H), 0,93 (d, *J*=6,75 Hz, 3 H).

EJEMPLO 576

ácido 7-fluoro-3-(2-metilfenil)-1-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 8,09 (d, *J*=8,90 Hz, 1 H), 7,85 (d, *J*=8,29 Hz, 1 H), 7,49-7,53 (m, 1 H), 7,36-7,47 (m, 3 H), 7,09-7,31 (m, 5 H), 6,99-7,04 (m, 1 H), 6,88-6,91 (m, 2 H), 5,02 (t, *J*=7,21 Hz, 2 H), 4,20 (t, *J*=5,68 Hz, 2 H), 2,38-2,45 (m, 2 H), 1,99 (s, 3 H).

EJEMPLO 577

ácido 3-(3-((5-fluoro-1-naftil)oxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 10,51 (s, 1 H), 8,07 (d, *J*=8,59 Hz, 1 H), 7,65 (d, *J*=6,75 Hz, 1 H), 7,56-7,60 (m, 1 H), 7,46-7,53 (m, 2 H), 7,36 (dd, *J*=11,05, 6,75 Hz, 1 H), 7,04-7,08 (m, 1 H), 7,01-7,03 (m, 2 H), 4,23 (t, *J*=6,14 Hz, 2 H), 3,75 (s, 3 H), 3,33-3,37 (m, 2 H), 2,19-2,27 (m, 2 H), 2,05 (s, 3 H), 2,00 (s, 3 H).

EJEMPLO 578

ácido 3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 8,62 (d, *J*=6,44 Hz, 2 H), 8,23-8,28 (m, 1 H), 7,83-7,90 (m, 2 H), 7,45-7,57 (m, 3 H), 7,38-7,44 (m, 1 H), 7,12-7,18 (m, 1 H), 6,90-6,96 (m, 4 H), 5,79 (d, *J*=18,41 Hz, 1 H), 5,58 (d, *J*=18,10 Hz, 1 H), 4,28 (t, *J*=5,98 Hz, 2 H), 3,59 (s, 3 H), 3,39-3,46 (m, 2 H), 2,25-2,33 (m, 2 H), 1,65 (s, 3 H), 1,58 (s, 3 H).

EJEMPLO 579

ácido 3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 8,43 (d, *J*=4,30 Hz, 1 H), 8,24-8,27 (m, 1 H), 7,86-7,89 (m, 1 H), 7,81 (d, *J*=7,06 Hz, 1 H), 7,74 (t, *J*=8,29 Hz, 1 H), 7,49-7,56 (m, 2 H), 7,44-7,48 (m, 1 H), 7,38-7,42 (m, 1 H), 7,30-7,35 (m, 1 H), 7,09-7,14 (m, 1 H), 6,92 (d, *J*=7,36 Hz, 1 H), 6,89 (dd, *J*=7,06, 0,92 Hz, 1 H), 6,31 (d, *J*=7,67 Hz, 1 H), 5,73 (d, *J*=18,10 Hz, 1 H), 5,49 (d, *J*=17,49 Hz, 1 H), 4,26 (t, *J*=6,14 Hz, 2 H), 3,59 (s, 3 H), 3,36-3,44 (m, 2 H), 2,24-2,31 (m, 2 H), 1,67 (s, 3 H), 1,56 (s, 3 H).

EJEMPLO 580

ácido 3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-

2-carboxílico

EJEMPLO 580A

3-(3-(naftalen-1-iloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxilato de etilo

A una mezcla de 7-bromo-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo (EJEMPLO 1C) (1,605 g) y 1,3,5-trimetil-4-(4,4,5,5-tetrametil-1,3,2-dioxaborolan-2-il)-1H-pirazol (0,838 g) en tolueno (25 ml) se agregó diacetoxipaladio (0,080 g), diciclohexil(2',6'-dimetoxibifenil-2-il)fosfina (0,291 g), y K_3PO_4 (2,259 g). La mezcla resultante se agitó a 110ºC durante la noche. Se agregó gel de sílice (25 g) y la mezcla se secó cuidadosamente al vacío durante la noche. El polvo de gel se cargó en una columna flash y se eluyó con 0-50% acetato de etilo en diclorometano para dar el compuesto del título.

EJEMPLO 580B

ácido 3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico

Una mezcla del EJEMPLO 580A (90 mg), bromhidrato de 3-(bromometil)piridina (47,3 mg) y carbonato de cesio (183 mg) en N,N-dimetilformamida (3,5 ml) se agitó a temperatura ambiente durante la noche. El material insoluble se filtró y el filtrado se concentró. El residuo se suspendió en tetrahidrofurano-metanol, y se agregó NaOH 10%. La mezcla resultante se agitó a temperatura ambiente durante la noche y se concentró. El residuo se disolvió en una mezcla de DMSO y metanol. La solución se purificó por HPLC en fase reversa (fase móvil: 10%-100% acetonitrilo en solución acuosa de TFA 0,1% durante 60 minutos) para dar el compuesto del título. ^{1}H RMN (400 MHz, DMSO-d_6) □ 8,55 (d, *J*=5,22 Hz, 1 H), 8,23-8,28 (m, 1 H), 7,85-7,90 (m, 1 H), 7,80-7,85 (m, 2 H), 7,49-7,57 (m, 3 H), 7,45-7,49 (m, 1 H), 7,38-7,43 (m, 1 H), 7,19 (d, *J*=7,67 Hz, 1 H), 7,10-7,15 (m, 1 H), 6,92 (t, *J*=7,67 Hz, 2 H), 5,65 (d, *J*=17,49 Hz, 1 H), 5,44 (d, *J*=17,80 Hz, 1 H), 4,26 (t, *J*=5,98 Hz, 2 H), 3,62 (s, 3 H), 3,35-3,49 (m, 2 H), 2,24-2,32 (m, 2 H), 1,67 (s, 3 H), 1,59 (s, 3 H).

Ejemplo 581

7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-2-(1H-tetraazol-5-il)-1H-indol

Ejemplo 581A

7-bromo-1-(4-metoxibencil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo

A una solución de 7-bromo-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxilato de etilo (2,39 g, preparado de manera similar a la descrita en la presente) en N,N-dimetilamida (20 ml) se agregó 1-(clorometil)-4-metoxibenceno (1,0 g) y Cs_2CO_3 (5,16 g). La mezcla se agitó durante la noche a temperatura ambiente. La mezcla se diluyó con éter (300 ml) y agua (200 ml). La fase acuosa se extrajo con éter. Los extractos combinados se lavaron con agua (x3), salmuera y se secó sobre Na_2SO_4. La concentración dio el EJEMPLO 581A.

Ejemplo 581B

7-bromo-1-(4-metoxibencil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxamida

A una solución del EJEMPLO 581A (1 g) en cloruro de oxalilo (10 ml) se agregaron algunas gotas de N,N-dimetilamida. La mezcla se agitó durante 3 horas a temperatura ambiente. La mezcla se concentró bajo vacío y el residuo se disolvió en diclorometano (20 ml) y se agregó a NH_3H_2O concentrado enfriado (0°C) (30 ml). Después de la adición, la mezcla se agitó durante 2 horas antes de extraerse con acetato de etilo (200 ml). El extracto orgánico se lavó con agua , salmuera y se secó sobre Na_2SO_4. Después de la filtración y evaporación del solvente se obtuvo el EJEMPLO 581B.

Ejemplo 581C

7-bromo-1-(4-metoxibencil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carbonitrilo

A una solución enfriada (0 °C) del EJEMPLO 581B (545 mg) en tetrahidrofurano (5 ml) y diclorometano (1 ml) se agregó trietilamina (1 ml) seguida por ácido trifluoroacético (1ml) por goteo. Después de la adición, la mezcla se agitó durante 3 horas a 0°C. La mezcla se diluyó con acetato de etilo (200 ml) y agua (80 ml). La fase acuosa se extrajo con éter. Los extractos orgánicos combinados se lavaron con agua (x3), salmuera y se secó sobre Na_2SO_4. Después de la filtración, la concentración del solvente dio el EJEMPLO 581C.

Ejemplo 581D

1-(4-metoxibencil)-3-(3-(naftalen-1-iloxi)propil)-7-o-tolil-1H-indol-2-carbonitrilo

A una mezcla del EJEMPLO 581C (300 mg) y ácido o-tolilborónico (93 mg) en 1,2-dimetoxietano (10 ml) y metanol (5 ml) se agregó tetrakis(trifenilfosfin)paladio(0) (33 mg) y CsF (260 mg). La mezcla se agitó a reflujo bajo nitrógeno durante 4 horas. La mezcla se concentró bajo vacío y el residuo se particionó entre acetato de etilo (300 ml) y agua (100 ml). La fase acuosa se extrajo adicionalmente con acetato de etilo y los extractos combinados se lavaron con agua, salmuera y se secó sobre Na_2SO_4. . Después de la filtración, la concentración del solvente y purificación en columna (5 a 10% acetato de etilo en hexano) dio el EJEMPLO 581D.

Ejemplo 581E

7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-2-(1H-tetraazol-5-il)-1H-indol

A una mezcla del EJEMPLO 581D (232 mg) en N,N-dimetilamida (10 ml) se agregó NaN_3 (281 mg) y NH_4Cl (231 mg). La mezcla se agitó a reflujo durante la noche. La mezcla se concentró bajo vacío y el residuo se particionó entre acetato de etilo (200 ml) y agua (60 ml). La fase orgánica se lavó con salmuera y se secó sobre Na_2SO_4. La concentración del solvente dio un producto crudo que se disolvió en diclorometano/ácido trifluoroacético (1:1, 4 ml) y se calentó a 125°C en microondas (CEM Discover) durante 20 minutos. La mezcla se concentró y el residuo se disolvió en dimetilsulfóxido/metanol (1/1, 2 ml) y se purificó en HPLC. ^{1}H RMN (300 MHz, DMSO-d_6) δ 10,63 (m, 1H), 8,26 (m, 1H), 7,86 (m, 1H), 7,74 (d, 1H), 7,53 (m, 2H), 7,42 (m, 5 H), 7,33 (m, 2H), 7,11 (m,

3H), 6,90 (d, 1H), 4,23 (t, 2H), 2,29 (m, 2H), 2,13 (s, 3H).

Ejemplo 582

1-(4-metoxibencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-2-(1H-tetraazol-5-il)-1H-indol

^{1}H RMN (300 MHz, DMSO-d_6) δ 8,08 (d, 1H), 7,84 (m, 2H), 7,52 (m, 2H), 7,45 (d, 1H), 7,39 (d, 1H), 7,32 (m, 1H), 7,25 (d, 1H), 7,17 (m, 2H), 7,10 (d, 1H), 6,96 (d, 1H), 6,85 (d, 1H), 6,51 (d, 2H), 6,02 (d, 2H), 4,89 (dd, 2H), 4,14 (t, 2H), 3,57 (s, 3H), 3,16 (m, 2H), 2,20 (m, 2H), 1,80 (s, 3H).

Ejemplo 585

ácido 7-(1-metil-1H-imidazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) δ 14,39 (s, 1H), 13,21 (s, 1H), 11,52 (s, 1H), 9,23 (s, 1H), 8,12-8,32 (m, 1H), 7,83-7,97 (m, 2H), 7,80 (d, *J*=1,7 Hz, 1H), 7,33-7,69 (m, 5H), 7,30 (d, *J*=6,1 Hz, 1H), 7,07-7,22 (m, 1H), 6,89 (d, *J*=6,4 Hz, 1H), 4,19 (t, *J*=6,1 Hz, 2H), 3,55 (s, 3H), 3,38 (t, *J*=7,3 Hz, 2H), 2,11-2,34 (m, 2H).

Ejemplo 586

ácido 1-(2-(dimetilamino)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,01 (s, 1 H), 8,26-8,30 (m, 1 H), 7,84-7,90 (m, 1 H), 7,73 (d, *J*=7,06 Hz, 1 H), 7,50-7,55 (m, 2 H), 7,44-7,48 (m, 1 H), 7,40 (t, *J*=7,98 Hz, 1 H), 7,03-7,08 (m, 1 H), 6,92 (d, *J*=7,36 Hz, 1 H), 6,88 (d, *J*=6,14 Hz, 1 H), 5,07-5,24 (m, 2 H), 4,23 (t, *J*=6,14 Hz, 2 H), 3,74 (s, 3 H), 3,31-3,38 (m, 2 H), 2,69 (s, 3 H), 2,56 (s, 3 H), 2,19-2,26 (m, 2 H), 1,91 (s, 3 H), 1,84 (s, 3 H).

Ejemplo 587

ácido 1-(2-(4-metilpiperazin-1-il)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, piridin-d_5) 8,64-8,68 (m, 1 H), 8,01 (d, *J*=7,02 Hz, 1 H), 7,87-7,90 (m, 1 H), 7,48-7,53 (m, 3 H), 7,36-7,40 (m, 1 H), 7,30-7,33 (m, 1 H), 7,19-7,21 (m, 1 H), 6,87 (d, *J*=7,32 Hz, 1 H), 6,05 (s, br, 1 H), 5,79 (s, br, 1 H), 4,28 (t, *J*=6,26 Hz, 2 H), 3,74-3,87 (m, 6 H), 3,24-3,52 (m, 3 H), 2,40-2,56 (m, 5 H), 2,35 (s, br, 1 H), 2,31 (s, 3 H), 2,22 (s, 3 H), 2,02 (s, 3 H).

Ejemplo 588

ácido 7-(4,6-dimetilpirimidin-5-il)-1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 9,01 (s, 1H), 8,27-8,29 (m, 1H), 7,84-7,88 (m, 2H), 7,45-7,56 (m, 3H), 7,39 (t, J = 7,98 Hz, 1H), 7,16 (t, J = 7,67 Hz, 1H), 7,01 (d, J = 6,44 Hz, 1H), 6,92 (d, J = 7,67 Hz, 1H), 4,92 (ancho, 2H), 4,24 (t, J = 6,14 Hz, 2H), 3,07 (ancho, 2H), 3,35-3,40 (m, 4H), 3,22 (ancho, 2H), 2,93 (ancho, 2H), 2,15-2,28 (m, 2H), 2,09 (s, 6H).

Ejemplo 589

ácido 1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, piridin-d_5) 8,66 (d, *J*=7,93 Hz, 1 H), 8,01 (dd, *J*=8,09, 1,07 Hz, 1 H), 7,89-7,91 (m, 1 H), 7,48-7,55 (m, 3 H), 7,32-7,42 (m, 2 H), 7,18-7,21 (m, 1 H), 6,91 (d, *J*=7,63 Hz, 1 H), 4,96-5,03 (m, 1 H), 4,71-4,78 (m, 1 H), 4,33 (t, *J*=6,10 Hz, 2 H), 3,84 (s, 3 H), 3,77 (t, *J*=7,48 Hz, 2 H), 2,98 (s, 3 H), 2,58 (s, 3 H), 2,42-2,58 (m, 6 H), 2,23 (s, 3 H), 2,21-2,27 (m, 1 H), 2,14 (s, 3 H), 2,10 (d, *J*=7,93 Hz, 1 H).

Ejemplo 590

ácido 1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, piridin-d_5) 8,66-8,69 (m, 1 H), 8,00-8,03 (m, 1 H), 7,89 (d, *J*=7,32 Hz, 1 H), 7,47-7,55 (m, 3 H), 7,31-7,43 (m, 2 H), 7,21 (m, 1 H), 6,92 (d, *J*=7,63 Hz, 1 H), 4,95-5,03 (m, 1 H), 4,83-4,89 (m, 1 H), 4,34 (t, *J*=6,26 Hz, 2 H), 3,76-3,81 (m, 2 H), 3,76 (s, 3 H), 3,61 (t, *J*=4,73 Hz, 4 H), 2,55-2,61 (m, 2 H), 2,39-2,44 (m, 1 H), 2,27 (s, 3 H), 2,20-2,30 (m, 5 H), 2,09 (s, 3 H).

Ejemplo 591

ácido 1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, metanol-d_4) 8,31-8,37 (m, 1 H), 7,74-7,81 (m, 2 H), 7,46-7,50 (m, 2 H), 7,36-7,41 (m, 1 H), 7,33 (t, *J*=7,93 Hz, 1 H), 7,01-7,07 (m, 1 H), 6,91-6,97 (m, 1 H), 6,80-6,83 (m, 1 H), 5,27 (s, 2 H), 4,20-4,24 (m, 2 H), 3,85-3,88 (m, 1 H), 3,85-3,90 (m, 1 H), 3,82-3,85 (m, 3 H), 3,82-3,84 (m, 3 H), 3,55-3,62 (m, 4 H), 3,44-3,50 (m, 3 H), 3,34-3,40 (m, 2 H), 3,16-3,24 (m, 3 H), 2,31-2,37 (m, 2 H), 1,93 – 2,03 (m, 6 H).

Ejemplo 592

ácido 1-(2-(dimetilamino)etil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico

^{1}H RMN (500 MHz, piridin-d_5) 8,65-8,69 (m, 1 H), 8,01 (d, *J*=7,02 Hz, 1 H), 7,89-7,91 (m, 1 H), 7,49-7,55 (m, 3 H), 7,40 (t, *J*=7,93 Hz, 1 H), 7,30-7,36 (m, 1 H), 7,19 (m, 1 H), 6,91 (d, *J*=7,63 Hz, 1 H), 5,01 (t, *J*=7,93 Hz, 2 H), 4,33 (t, *J*=6,10 Hz, 2 H), 3,81 (s, 3 H), 3,75-3,79 (m, 2 H), 2,86-2,99 (m, 2 H), 2,50-2,58 (m, 2 H), 2,47 (s, 6 H), 2,21 (s, 3 H), 2,12 (s, 3 H).

Ejemplo 593

ácido 7-(2-metilimidazo(1,2-a)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,16 (s, 1H), 11,35 (s, 1H), 8,14-8,36 (m, 1H), 7,91-8,08 (m, 4H), 7,84-7,90 (m, 1H), 7,37-7,57 (m, 5H), 7,34 (t, *J*=6,3 Hz, 1H), 7,22-7,29 (m, 1H), 6,92 (d, *J*=7,1 Hz, 1H), 4,23 (t, *J*=6,1 Hz, 2H), 3,37-3,46 (m, 2H), 2,37 (s, 3H), 2,21-2,31 (m, 2H),

Ejemplo 594

ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 13,31 (s, 1H), 8,72 (s, 1H), 8,55 (d, *J*=4,7 Hz, 1H), 8,22-8,33 (m, 1H), 8,19 (d, *J*=4,1 Hz, 1H), 7,83-7,96 (m, 2H), 7,44-7,59 (m, 5H), 7,35-7,43

(m, 1H), 7,32 (s, 1H), 7,19 (s, 1H), 7,06-7,16 (m, 3H), 6,89 (d, *J*=6,8 Hz, 1H), 6,40 (d, *J*=7,8 Hz, 1H), 5,44 (d, *J*=17,3 Hz, 1H), 5,22 (d, *J*=17,3 Hz, 1H), 4,20 (t, *J*=6,1 Hz, 2H), 3,26-3,43 (m, 2H), 2,17-2,30 (m, 2H), 1,83 (s, 3H).

Ejemplo 595

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 8,63-8,67 (m, 1H) 8,22-8,28 (m, 2H) 7,96 (d, 1H) 7,85-7,90 (m, 1H) 7,34-7,72 (m, 6H) 7,15-7,27 (m, 2H) 7,03 (d, 1H) 6,92 (d, 1H) 6,37 (d, 1H) 5,40 (d, 1H) 5,18 (d, 1H) 4,27 (t, 2H) 2,26-2,35 (m, 2H) 1,97-2,15 (m, 2H) 1,86 (s, 3H) 0,90 (t, 3H).

Ejemplo 596

7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-((1-(piridin-4-ilmetil)piridinio-4-il)metil)-1H-indol-2-carboxilato

^{1}H RMN (400 MHz, DMSO-d_6) 8,88-8,92 (m, 2H) 8,69-8,72 (m, 2H) 8,39-8,43 (m, 1H) 8,23-8,28 (m, 1H) 7,95-7,99 (m, 1H) 7,85-7,90 (m, 1H) 7,37-7,58 (m, 6H) 7,22-7,35 (m, 3H) 7,10-7,21 (m, 1H) 6,91-7,06 (m, 2H) 5,85 (s, 2H) 5,24-5,61 (m, 2H) 4,30 (t, 2H) 3,45 (t, 2H) 2,26-2,38 (m, 2H) 1,87-2,13 (m, 2H) 1,70-1,82 (m, 3H) 0,82 (t, 3H).

Ejemplo 597

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 8,60 (d, 1H) 8,43 (d, 2H) 8,22-8,28 (m, 1H) 7,99 (d, 1H) 7,85-7,91 (m, 1H) 7,37-7,59 (m, 5H) 7,25 (t, 1H) 7,02-7,07 (m, 1H) 6,94 (d, 1H) 6,69 (d, 2H) 5,38-5,51 (m, 1H) 5,14-5,28 (m, 1H) 4,29 (t, 2H) 3,46 (t, 2H) 2,27-2,37 (m, 2H) 1,92-2,13 (m, 2H) 1,85 (s, 3H) 0,88 (t, 3H).

Ejemplo 598

ácido 7-(2-etil-4-metilpiridin-3-il)-1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 12,96 (s ancho, 1H) 8,60-8,67 (m, 1H) 8,24-8,29 (m, 1H) 7,84-7,90 (m, 2H) 7,49-7,59 (m, 3H) 7,46 (d, 1H) 7,39 (t, 1H) 7,19 (t, 1H) 7,03 (d, 1H) 6,91 (d, 1H) 4,24 (t, 2H) 2,18-2,40 (m, 4H) 2,01 (s, 3H) 1,02 (t, 3H).

Ejemplo 599

ácido 1-(2-(dimetilamino)-2-oxoetil)-7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 8,51-8,56 (m, 1H) 8,25-8,31 (m, 1H) 7,79-7,90 (m, 2H) 7,26-7,58 (m, 5H) 7,10-7,22 (m, 1H) 6,89-7,02 (m, 2H) 4,24 (t, 2H) 2,63 (s, 2H) 2,20-2,39 (m, 7H) 1,85-1,97 (m, 3H) 1,01 (t, 3H).

Ejemplo 600

ácido 7-(2-etil-4-metilpiridin-3-il)-1-(2-(4-metilpiperazin-1-il)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 10,19 (s, 1H) 8,62-8,77 (m, 1H) 8,21-8,32 (m, 1H)

7,82-7,95 (m, 2H) 7,33-7,74 (m, 5H) 7,18 (t, 1H) 7,02 (d, 1H) 6,90 (d, 1H) 4,23 (t, 2H) 3,34-3,40 (m, 6H) 2,61-2,97 (m, 6H) 2,15-2,41 (m, 3H) 2,01 (s, 3H) 1,02 (t, 3H).

Ejemplo 601

ácido 7-(2-etil-4-metilpiridin-3-il)-1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 8,53-8,57 (m, 1H) 8,21-8,26 (m, 1H) 7,83-7,89 (m, 2H) 7,35-7,58 (m, 5H) 7,20 (t, 1H) 7,02 (d, 1H) 6,91 (d, 1H) 4,25 (t, 2H) 2,18-2,40 (m, 8H) 2,03 (s, 3H) 1,07 (t, 3H).

Ejemplo 602

ácido 1-(2-(dimetilamino)etil)-7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 9,78 (s, 1H) 8,63 (d, 1H) 8,17-8,25 (m, 1H) 7,81-7,91 (m, 2H) 7,31-7,60 (m, 5H) 7,20 (t, 1H) 7,04 (d, 1H) 6,89 (d, 1H) 4,22 (t, 2H) 3,36 (t, 2H) 2,74-2,89 (m, 2H) 2,49 (s, 6H) 2,30-2,43 (m, 2H) 2,16-2,27 (m, 2H) 2,06 (s, 3H) 1,05 (t, 3H).

Ejemplo 603

ácido 7-(2-etil-4-metilpiridin-3-il)-1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (400 MHz, DMSO-d_6) 8,69 (d, 1H) 8,20-8,26 (m, 1H) 7,84-7,91 (m, 2H) 7,66 (d, 1H) 7,44-7,57 (m, 3H) 7,39 (t, 1H) 7,20 (t, 1H) 7,06 (d, 1H) 6,91 (d, 1H) 4,23 (t, 2H) 3,91-3,98 (m, 2H) 3,34 (t, 2H) 3,23-3,30 (m, 2H) 2,75-2,87 (m, 2H) 2,72 (s, 3H) 2,53-2,62 (m, 2H) 2,00-2,31 (m, 10H) 1,08 (t, 3H).

Ejemplo 604

ácido 7-(2-((4-(4-carboxifenil)piperazin-1-il)metil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) δ 12,96 (s, 1H), 12,37 (s, 1H), 11,05 (s, 1H), 9,46 (s, 1H), 8,14-8,30 (m, 1H), 7,82-7,90 (m, 1H), 7,69-7,78 (m, 4H), 7,55-7,63 (m, 2H), 7,47-7,55 (m, 2H), 7,45 (d, *J*=8,1 Hz, 1H), 7,32-7,42 (m, 3H), 7,08-7,12 (m, 2H), 6,83-6,91 (m, 4H), 4,39 (d, *J*=16,7 Hz, 1H), 4,19 (t, *J*=5,9 Hz, 2H), 4,08 (d, *J*=16,7 Hz, 1H), 3,62-3,76 (m, 2H), 3,29-3,42 (m, 2H), 3,13-3,26 (m, 1H), 2,93-3,10 (m, 1H), 2,75-2,87 (m, 2H), 2,16-2,26 (m, 2H).

Ejemplo 605

ácido 3-(3-(1-naftiloxi)propil)-7-(2-piperazin-1-ilpiridin-3-il)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) δ 13,12 (s, 1H), 10,87 (s, 1H), 8,44 (s, 2H), 8,32 (dd, *J*=4,7, 1,7 Hz, 1H), 8,22-8,29 (m, 1H), 7,84-7,90 (m, 1H), 7,70-7,80 (m, 2H), 7,48-7,58 (m, 2H), 7,46 (d, *J*=8,1 Hz, 1H), 7,35-7,43 (m, 1H), 7,31 (d, *J*=6,1 Hz, 1H), 7,07-7,16 (m, 2H), 6,89 (d, *J*=6,4 Hz, 1H), 4,19 (t, *J*=6,1 Hz, 2H), 3,12 (s, 4H), 2,59-2,71 (m, 2H), 2,16-2,31 (m, 2H).

Ejemplo 606

ácido 1-(2-(dimetilamino)-2-oxoetil)-7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-

naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) δ 13,23 (s, 1H), 8,61 (d, *J*=4,7 Hz, 1H), 8,24-8,39 (m, 1H), 8,16-8,25 (m, 1H), 7,76-7,95 (m, 2H), 7,64 (d, *J*=5,1 Hz, 1H), 7,49-7,57 (m, 2H), 7,46 (d, *J*=8,1 Hz, 1H), 7,36-7,43 (m, 1H), 7,26 (s, 1H), 6,99-7,12 (m, 3H), 6,90 (d, *J*=7,5 Hz, 1H), 4,94 (s, 1H), 4,20 (t, *J*=6,3 Hz, 2H), 3,39-3,52 (m, 2H), 2,57 (s, 3H), 2,16-2,25 (m, 2H), 2,07 (s, 3H).

Ejemplo 607

ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) δ 13,44 (s, 1H), 8,55 (d, *J*=4,7 Hz, 1H), 8,14-8,37 (m, 3H), 7,90-7,98 (m, 1H), 7,84-7,90 (m, 1H), 7,36-7,58 (m, 6H), 7,08-7,21 (m, 4H), 6,98 (s, 1H), 6,91 (d, *J*=7,5 Hz, 1H), 6,69 (d, *J*=8,5 Hz, 1H), 5,52 (d, *J*=17,3 Hz, 1H), 4,97 (d, *J*=17,3 Hz, 1H), 4,21 (t, *J*=6,3 Hz, 2H), 3,38 (t, 2H), 3,11-3,21 (m, 2H), 2,16-2,30 (m, 2H), 1,68 (s, 3H).

Ejemplo 608

ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) δ 13,26 (s, 1H), 8,66 (d, *J*=5,1 Hz, 1H), 8,41 (s, 1H), 8,23-8,31 (m, 1H), 7,80-7,91 (m, 2H), 7,71 (d, *J*=5,1 Hz, 1H), 7,49-7,57 (m, 2H), 7,46 (d, *J*=8,1 Hz, 1H), 7,36-7,43 (m, 1H), 7,31 (s, 1H), 7,15-7,23 (m, 1H), 7,00-7,10 (m, 2H), 6,90 (d, *J*=7,5 Hz, 1H), 4,88 (d, 2H), 4,20 (t, *J*=6,1 Hz, 2H), 3,34 (s, 4H), 3,17 (s, 2H), 3,04 (s, 2H), 2,14-2,25 (m, 2H), 2,09 (s, 3H).

Ejemplo 609


ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(2-oxo-2-piperazin-1-iletil)-1H-indol-2-carboxílico

^{1}H RMN (300 MHz, DMSO-d_6) δ 13,22 (s, 1H), 8,69 (s, 2H), 8,57 (d, *J*=4,7 Hz, 1H), 8,24-8,31 (m, 1H), 7,82-7,91 (m, 2H), 7,49-7,61 (m, 3H), 7,47 (d, *J*=8,1 Hz, 1H), 7,35-7,44 (m, 1H), 7,10 (t, *J*=7,6 Hz, 3H), 6,89 (d, *J*=6,8 Hz, 2H), 6,47 (s, 1H), 5,01 (s, 1H), 4,21 (t, *J*=5,8 Hz, 2H), 3,12-3,29 (m, 4H), 2,81-3,06 (m, 4H), 2,16-2,25 (m, 2H), 2,03 (s, 3H).

Los ejemplos expuestos se dan con el fin de ilustrar la invención pero no constituyen una limitación de la misma. Se comprenderá que diversos cambios y variantes evidentes para un especialista en la materia están comprendidos en el alcance de la invención tal como se define en las reivindicaciones adjuntas.

REIVINDICACIONES:

1. Un compuesto de la Fórmula I,



(I),

o una sal aceptable para terapia del mismo, donde

A^1 es A^2, OA^2, SA^2, $S(O)A^2$, SO_2A^2, NH_2, NHA^2, $N(A^2)_2$, $C(O)A^2$, $C(O)NH_2$, $C(O)NHA^2$, $C(O)N(A^2)_2$, $NHC(O)A^2$, $NA^2C(O)A^2$, $NHSO_2A^2$, $NA^2SO_2A^2$, $NHC(O)OA^2$, $NA^2C(O)OA^2$, SO_2NH_2, SO_2NHA^2, $SO_2N(A^2)_2$, $NHC(O)NH_2$, $NHC(O)A^2$ $NHC(O)N(A^2)_2$, $NA^2C(O)N(A^2)_2$ F, Cl, Br, o I;

A^2 es R^1, R^2, R^3, o R^4;

R^1 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{1A}; R^{1A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^2 es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{2A}; R^{2A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^3 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{3A}; R^{3A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^4 es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^5, OR^5, SR^5, $S(O)R^5$, SO_2R^5, NH_2, NHR^5, $N(R^5)_2$, $C(O)R^5$, $C(O)NH_2$, $C(O)NHR^5$, $C(O)N(R^5)_2$, $NHC(O)R^5$, $NR^5C(O)R^5$, $NHSO_2R^5$, $NR^5SO_2R^5$, $NHC(O)OR^5$, $NR^5C(O)OR^5$, SO_2NH_2, SO_2NHR^5, $SO_2N(R^5)_2$, $NHC(O)NH_2$, $NHC(O)R^5$, $NHC(O)N(R^5)_2$, $NR^5C(O)N(R^5)_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^5 es R^6, R^7 o R^8;

R^6 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{6A}; R^{6A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^7 es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{7A}; R^{7A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^8 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{8A}; R^{8A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

L^1 es un enlace o es alquileno, alquenileno, alquinileno o L^2; y B^1 es C(O)OH o un bioisóstero del mismo o es $C(O)OR^1$, $C(O)OR^2$, $C(O)OR^3$ o $C(O)OR^4$;

L^2 es C_2-C_6-alquileno, C_4-C_6-alquenileno o C_4-C_6-alquinileno, en cada uno de los cuales una porción CH_2 se reemplaza por O, S, S(O), SO_2, NH o $N(W^1)$;

W^1 es alquilo, alquenilo o alquinilo;

C^1 y D^1 son en forma independiente H, R^9, R^{10}, R^{11}, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, o uno de C^1 y D^1 es H, y el otro es R^9, R^{10}, R^{11} R^{12}, $C(O)OR^{12}$, F, Cl, Br, o I;

R^9 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{9A}; R^{9A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{10} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{10A}; R^{10A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{11} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{11A}; R^{11A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{12} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, NH_2, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHSO_2R^{13}$, $NR^{13}SO_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $NHC(O)NH_2$, $NHC(O)R^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)N(R^{13})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{13} es R^{14}, R^{15} R^{16}, o R^{16A};

R^{14} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{14A}; R^{14A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; donde cada uno de los cuales no está fusionado o está fusionado con R^{14B}; R^{14B} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{15} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{15A}; R^{15A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{16} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{16A}; R^{16A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{16A} es alquilo, alquenilo, o alquinilo; y

uno o dos o cada uno de E^1 y F^1 y G^1 son en forma independiente H, CF_3, F, Cl, Br o I, y los demás son en forma independiente R^{17}, R^{18}, R^{19}, R^{20} o OR^{20};

R^{17} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{17A}; R^{17A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{18} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{18A}; R^{18A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{19} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{19A}; R^{19A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{20} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{20}, OR^{20}, SR^{20}, $S(O)R^{20}$, SO_2R^{20}, NH_2, NHR^{20}, $N(R^{20})_2$, $C(O)R^{20}$, $C(O)NH_2$, $C(O)NHR^{20}$, $C(O)N(R^{20})_2$, $NHC(O)R^{20}$, $NHC(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NHSO_2R^{20}$, $NR^{20}SO_2R^{20}$, $NHC(O)OR^{20}$, $NR^{20}C(O)OR^{20}$, SO_2NH_2, SO_2NHR^{20}, $SO_2N(R^{20})_2$, $NHC(O)NH_2$, $NHC(O)R^{20}$, $NHC(O)N(R^{20})_2$, $NR^{20}C(O)N(R^{20})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{20} es R^{21}, R^{22} o R^{23};

R^{21} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{21A}; R^{21A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{22} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{22A}; R^{22A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{23} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{23A}; R^{23A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

donde cada porción cíclica que se ha mencionado en forma independiente no está sustituida o está sustituida con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre espiroheteroalquilo, R^{30}, OR^{30}, OCH_2R^{30}, SR^{30}, $S(O)R^{30}$, SO_2R^{30}, $C(O)R^{30}$, $CO(O)R^{30}$, $OC(O)R^{30}$, $OC(O)OR^{30}$, NO, NO_2, NH_2, NHR^{30}, $N(R^{30})_2$, CH_2R^{30}, $C(O)NH_2$, $C(O)NHR^{30}$, $C(O)N(R^{30})_2$, $NHC(O)R^{30}$, $NR^{30}C(O)R^{30}$, C(O)NHOH, $C(O)NHOR^{30}$, $C(O)NHSO_2R^{30}$, $C(O)NR^{30}SO_2R^{30}$, SO_2NH_2, SO_2NHR^{30}, $SO_2N(R^{30})_2$, CF_3, CF_2CF_3, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{30}$, $C(N)N(R^{30})_2$, =NO-(alquilen)-$C(O)CF_3$, CNOH, $CNOCH_3$, OH, (O), CN, N_3, CF_3, CF_2CF_3, OCF_3, OCF_2CF_3, F, Cl, Br, o I;

R^{30} es R^{31}, R^{32}, R^{33} o R^{34};

R^{31} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{31A}; R^{31A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{32} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{32A}; R^{32A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{33} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{33A}; R^{33A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{34} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, NHR^{35}, $N(R^{35})_2$, $C(O)R^{35}$, $C(O)NH_2$, $C(O)NHR^{35}$, $C(O)N(R^{35})_2$, $NHC(O)R^{35}$, $NR^{35}C(O)R^{35}$, $NHSO_2R^{35}$, $NR^{35}SO_2R^{35}$, $NHC(O)OR^{35}$, $NR^{35}C(O)OR^{35}$, SO_2NH_2, SO_2NHR^{35}, $SO_2N(R^{35})_2$, $NHC(O)NH_2$, $NHC(O)R^{35}$ $NHC(O)N(R^{35})_2$, $NR^{35}C(O)N(R^{35})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{35} es R^{36}, R^{37}, R^{38} o R^{39};

R^{36} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{36A}; R^{36A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{37} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{37A}; R^{37A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{38} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{38A}; R^{38A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{39} es alquilo, alquenilo o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con NH_2, $N(R^{40})_2$, OR^{40}, o R^{40};

R^{40} es alquilo, alquenilo, alquinilo, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo;

donde las porciones representadas por R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} y R^{40} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O) o OH;

R^{50} es R^{51}, R^{52}, R^{53} o R^{54};

R^{51} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{51A}; R^{51A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{52} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{52A}; R^{52A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{53} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{53A}; R^{53A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{54} es alquilo, alquenilo, o alquinilo; donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O), OH, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo y

donde las porciones representadas por R^{51}, R^{52}, y R^{53} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre R^{55}, OR^{55}, OCH_2R^{55}, SR^{55}, $S(O)R^{55}$, SO_2R^{55}, $C(O)R^{55}$, $CO(O)R^{55}$, $OC(O)R^{55}$, $OC(O)OR^{55}$, NO_2, NH_2, NHR^{55}, $N(R^{55})_2$, CH_2R^{55}, $C(O)NH_2$, $C(O)NHR^{55}$, $C(O)N(R^{55})_2$, $NHC(O)R^{55}$, $NR^{55}C(O)R^{55}$, C(O)NHOH, $C(O)NHOR^{55}$, $C(O)NHSO_2R^{55}$, $C(O)NR^{55}SO_2R^{55}$, SO_2NH_2, SO_2NHR^{55}, $SO_2N(R^{55})_2$, CF_3, CF_2CF_3, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{55}$, $C(N)N(R^{55})_2$, =NO-(alquilen)-$C(O)CF_3$, CNOH, $CNOCH_3$, OH, (O), CN, N_3, CF_3, CF_2CF_3, OCF_3, OCF_2CF_3, F, Cl, Br o I; y

R^{55} es alquilo, alquenilo, alquinilo, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo.

2. Un compuesto de la reivindicación 1 o una sal aceptable para terapia del mismo, donde

A^1 es A^2, OA^2, SA^2, $S(O)A^2$, SO_2A^2, NH_2, NHA^2, $N(A^2)_2$, $C(O)A^2$, $C(O)NH_2$, $C(O)NHA^2$, $C(O)N(A^2)_2$, $NHC(O)A^2$, $NA^2C(O)A^2$, $NHSO_2A^2$, $NA^2SO_2A^2$, $NHC(O)OA^2$, $NA^2C(O)OA^2$, SO_2NH_2, SO_2NHA^2, $SO_2N(A^2)_2$, $NHC(O)NH_2$, $NHC(O)A^2$ $NHC(O)N(A^2)_2$, $NA^2C(O)N(A^2)_2$ F, Cl, Br, o I;

A^2 es R^1, R^2, R^3, o R^4;

R^1 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{1A}; R^{1A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^2 es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{2A}; R^{2A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^3 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{3A}; R^{3A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^4 es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^5, OR^5, SR^5, $S(O)R^5$, SO_2R^5, NH_2, NHR^5, $N(R^5)_2$, $C(O)R^5$, $C(O)NH_2$, $C(O)NHR^5$, $C(O)N(R^5)_2$, $NHC(O)R^5$, $NR^5C(O)R^5$, $NHSO_2R^5$, $NR^5SO_2R^5$, $NHC(O)OR^5$, $NR^5C(O)OR^5$, SO_2NH_2, SO_2NHR^5, $SO_2N(R^5)_2$, $NHC(O)NH_2$, $NHC(O)R^5$, $NHC(O)N(R^5)_2$, $NR^5C(O)N(R^5)_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^5 es R^6, R^7 o R^8;

R^6 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{6A}; R^{6A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^7 es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{7A}; R^{7A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^8 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{8A}; R^{8A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

L^1 es un enlace o es alquileno, alquenileno, alquinileno o L^2; y B^1 es C(O)OH o un bioisóstero del mismo o es $C(O)OR^1$, $C(O)OR^2$, $C(O)OR^3$ o $C(O)OR^4$;

L^2 es C_2-C_6-alquileno, C_4-C_6-alquenileno o C_4-C_6-alquinileno, en cada uno de los cuales una porción CH_2 se reemplaza por O, S, S(O), SO_2, NH o $N(W^1)$;

W^1 es alquilo, alquenilo o alquinilo;

C^1 y D^1 son en forma independiente H, R^9, R^{10}, R^{11}, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, o uno de C^1 y D^1 es H, y el otro es R^9, R^{10}, R^{11} R^{12}, $C(O)OR^{12}$, F, Cl, Br, o I;

R^9 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{9A}; R^{9A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{10} es heteroarilo que no está fusionado o está fusionado con benceno,

heteroareno o R^{10A}; R^{10A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{11} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{11A}; R^{11A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{12} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, NH_2, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHSO_2R^{13}$, $NR^{13}SO_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $NHC(O)NH_2$, $NHC(O)R^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)N(R^{13})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{13} es R^{14}, R^{15} R^{16}, o R^{16A};

R^{14} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{14A}; R^{14A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; donde cada uno de los cuales no está fusionado o está fusionado con R^{14B}; R^{14B} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{15} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{15A}; R^{15A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{16} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{16A}; R^{16A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{16A} es alquilo, alquenilo, o alquinilo; y

uno o dos o cada uno de E^1 y F^1 y G^1 son en forma independiente H, CF_3, F, Cl, Br o I, y los demás son en forma independiente R^{17}, R^{18}, R^{19}, R^{20} o OR^{20};

R^{17} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{17A}; R^{17A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{18} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{18A}; R^{18A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{19} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{19A}; R^{19A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{20} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{20}, OR^{20}, SR^{20}, $S(O)R^{20}$, SO_2R^{20}, NH_2, NHR^{20}, $N(R^{20})_2$, $C(O)R^{20}$, $C(O)NH_2$, $C(O)NHR^{20}$, $C(O)N(R^{20})_2$, $NHC(O)R^{20}$, $NHC(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NHSO_2R^{20}$, $NR^{20}SO_2R^{20}$, $NHC(O)OR^{20}$, $NR^{20}C(O)OR^{20}$, SO_2NH_2, SO_2NHR^{20}, $SO_2N(R^{20})_2$, $NHC(O)NH_2$, $NHC(O)R^{20}$, $NHC(O)N(R^{20})_2$, $NR^{20}C(O)N(R^{20})_2$, OH, (O),

C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{20} es R^{21}, R^{22} o R^{23};

R^{21} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{21A}; R^{21A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{22} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{22A}; R^{22A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{23} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{23A}; R^{23A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

donde cada porción cíclica que se ha mencionado en forma independiente no está sustituida o está sustituida con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre espiroheteroalquilo, R^{30}, OR^{30}, SO_2R^{30}, $C(O)R^{30}$, NO, NO_2, NH_2, $N(R^{30})_2$, $C(O)NH_2$, $C(O)NHR^{30}$, $NHC(O)R^{30}$, $C(O)NHSO_2R^{30}$, SO_2NH_2, C(O)OH, OH, (O), CN, CF_3, OCF_3, F, Cl, Br, o I;

R^{30} es R^{31}, R^{32}, R^{33} o R^{34};

R^{31} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{31A}; R^{31A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{32} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{32A}; R^{32A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{33} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{33A}; R^{33A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{34} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, NHR^{35}, $N(R^{35})_2$, $C(O)R^{35}$, $C(O)NH_2$, $C(O)NHR^{35}$, $C(O)N(R^{35})_2$, $NHC(O)R^{35}$, $NR^{35}C(O)R^{35}$, $NHSO_2R^{35}$, $NR^{35}SO_2R^{35}$, $NHC(O)OR^{35}$, $NR^{35}C(O)OR^{35}$, SO_2NH_2, SO_2NHR^{35}, $SO_2N(R^{35})_2$, $NHC(O)NH_2$, $NHC(O)R^{35}$ $NHC(O)N(R^{35})_2$, $NR^{35}C(O)N(R^{35})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{35} es R^{36}, R^{37}, R^{38} o R^{39};

R^{36} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{36A}; R^{36A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{37} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{37A}; R^{37A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{38} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{38A}; R^{38A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{39} es alquilo, alquenilo o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con NH_2, $N(R^{40})_2$, OR^{40}, o R^{40};

R^{40} es alquilo, alquenilo, alquinilo, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo;

donde las porciones representadas por R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} y R^{40} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O) o OH;

R^{50} es R^{51}, R^{52}, R^{53} o R^{54};

R^{51} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{51A}; R^{51A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{52} es heteroarilo que no está fusionado o está fusionado con benceno, heteroareno o R^{52A}; R^{52A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{53} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno, heteroareno o R^{53A}; R^{53A} es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno;

R^{54} es alquilo, alquenilo, o alquinilo; donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O), OH, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo y

donde las porciones representadas por R^{51}, R^{52}, y R^{53} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre $CO(O)R^{55}$, C(O)OH, (O), F, Cl, Br o I; y

R^{55} es alquilo, alquenilo, alquinilo, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo.

3. Un compuesto de la reivindicación 2 o una sal aceptable para terapia del mismo, donde

A^1 es A^2, OA^2, SA^2, $S(O)A^2$, SO_2A^2, NH_2, NHA^2, $N(A^2)_2$, $C(O)A^2$, $C(O)NH_2$, $C(O)NHA^2$, $C(O)N(A^2)_2$, $NHC(O)A^2$, $NA^2C(O)A^2$, $NHSO_2A^2$, $NA^2SO_2A^2$, $NHC(O)OA^2$, $NA^2C(O)OA^2$, SO_2NH_2, SO_2NHA^2, $SO_2N(A^2)_2$, $NHC(O)NH_2$, $NHC(O)A^2$ $NHC(O)N(A^2)_2$, $NA^2C(O)N(A^2)_2$ F, Cl, Br, o I;

A^2 es R^1, R^2, R^3, o R^4;

R^1 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{1A}; R^{1A} es cicloalcano, heterocicloalcano o heterocicloalqueno;

R^2 es heteroarilo que no está fusionado o está fusionado con benceno o heteroareno;

R^3 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^4 es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está

sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^5, OR^5, SR^5, $S(O)R^5$, SO_2R^5, NH_2, NHR^5, $N(R^5)_2$, $C(O)R^5$, $C(O)NH_2$, $C(O)NHR^5$, $C(O)N(R^5)_2$, $NHC(O)R^5$, $NR^5C(O)R^5$, $NHSO_2R^5$, $NR^5SO_2R^5$, $NHC(O)OR^5$, $NR^5C(O)OR^5$, SO_2NH_2, SO_2NHR^5, $SO_2N(R^5)_2$, $NHC(O)NH_2$, $NHC(O)R^5$, $NHC(O)N(R^5)_2$, $NR^5C(O)N(R^5)_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^5 es R^6, R^7 o R^8;

R^6 es fenilo que no está fusionado o está fusionado con benceno;

R^7 es heteroarilo;

R^8 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo;

L^1 es un enlace o es alquileno, alquenileno, alquinileno o L^2; y B^1 es C(O)OH o un bioisóstero del mismo o es $C(O)OR^1$, $C(O)OR^2$, $C(O)OR^3$ o $C(O)OR^4$;

L^2 es C_2-C_6-alquileno, C_4-C_6-alquenileno o C_4-C_6-alquinileno, en cada uno de los cuales una porción CH_2 se reemplaza por O, S, S(O), SO_2, NH o $N(W^1)$;

W^1 es alquilo, alquenilo o alquinilo;

C^1 y D^1 son en forma independiente H, R^9, R^{10}, R^{11}, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, o uno de C^1 y D^1 es H, y el otro es R^9, R^{10}, R^{11} R^{12}, $C(O)OR^{12}$, F, Cl, Br, o I;

R^9 es fenilo;

R^{10} es heteroarilo;

R^{11} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo;

R^{12} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, NH_2, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHSO_2R^{13}$, $NR^{13}SO_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $NHC(O)NH_2$, $NHC(O)R^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)N(R^{13})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{13} es R^{14}, R^{15} R^{16}, o R^{16A};

R^{14} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{14A}; R^{14A} es cicloalcano, o heterocicloalcano; donde cada uno de los cuales no está fusionado o está fusionado con R^{14B}; R^{14B} es cicloalcano;

R^{15} es heteroarilo que no está fusionado o está fusionado con benceno o heteroareno;

R^{16} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^{16A} es alquilo, alquenilo, o alquinilo; y

uno o dos o cada uno de E^1 y F^1 y G^1 son en forma independiente H, CF_3, F, Cl, Br o I, y los demás son en forma independiente R^{17}, R^{18}, R^{19}, R^{20} o OR^{20};

R^{17} es fenilo que no está fusionado o está fusionado con benceno;

R^{18} es heteroarilo;

R^{19} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo;

R^{20} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{20}, OR^{20}, SR^{20}, $S(O)R^{20}$, SO_2R^{20}, NH_2, NHR^{20}, $N(R^{20})_2$, $C(O)R^{20}$, $C(O)NH_2$, $C(O)NHR^{20}$, $C(O)N(R^{20})_2$, $NHC(O)R^{20}$, $NHC(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NR^{20}C(O)R^{20}$, $NHSO_2R^{20}$, $NR^{20}SO_2R^{20}$, $NHC(O)OR^{20}$, $NR^{20}C(O)OR^{20}$, SO_2NH_2, SO_2NHR^{20}, $SO_2N(R^{20})_2$, $NHC(O)NH_2$, $NHC(O)R^{20}$, $NHC(O)N(R^{20})_2$, $NR^{20}C(O)N(R^{20})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{20} es R^{21}, R^{22} o R^{23};

R^{21} es fenilo que no está fusionado o está fusionado con benceno;

R^{22} es heteroarilo;

R^{23} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo;

donde cada porción cíclica que se ha mencionado en forma independiente no está sustituida o está sustituida con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre espiroheteroalquilo, R^{30}, OR^{30}, SO_2R^{30}, $C(O)R^{30}$, NO, NO_2, NH_2, $N(R^{30})_2$, $C(O)NH_2$, $C(O)NHR^{30}$, $NHC(O)R^{30}$, $C(O)NHSO_2R^{30}$, SO_2NH_2, C(O)OH, OH, (O), CN, CF_3, OCF_3, F, Cl, Br, o I;

R^{30} es R^{31}, R^{32}, R^{33} o R^{34};

R^{31} es fenilo que no está fusionado o está fusionado con benceno;

R^{32} es heteroarilo;

R^{33} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^{34} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, NHR^{35}, $N(R^{35})_2$, $C(O)R^{35}$, $C(O)NH_2$, $C(O)NHR^{35}$, $C(O)N(R^{35})_2$, $NHC(O)R^{35}$, $NR^{35}C(O)R^{35}$, $NHSO_2R^{35}$, $NR^{35}SO_2R^{35}$, $NHC(O)OR^{35}$, $NR^{35}C(O)OR^{35}$, SO_2NH_2, SO_2NHR^{35}, $SO_2N(R^{35})_2$, $NHC(O)NH_2$, $NHC(O)R^{35}$ $NHC(O)N(R^{35})_2$, $NR^{35}C(O)N(R^{35})_2$, OH, (O), C(O)OH, CN, CF_3, OCF_3, CF_2CF_3, F, Cl, Br o I;

R^{35} es R^{36}, R^{37}, R^{38} o R^{39};

R^{36} es fenilo que no está fusionado o está fusionado con benceno o R^{36A}; R^{36A} es cicloalqueno;

R^{37} es heteroarilo que no está fusionado o está fusionado con benceno;

R^{38} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^{39} es alquilo, alquenilo o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con NH_2, $N(R^{40})_2$, OR^{40}, o R^{40};

R^{40} es alquilo, alquenilo, alquinilo, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo;

donde las porciones representadas por R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} y R^{40} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes

seleccionados en forma independiente entre R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O) o OH;

R^{50} es R^{51}, R^{52}, R^{53} o R^{54};

R^{51} es fenilo;

R^{52} es heteroarilo;

R^{53} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo;

R^{54} es alquilo, alquenilo, o alquinilo; donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, CF_3, (O), OH, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo y

donde las porciones representadas por R^{51}, R^{52}, y R^{53} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre $CO(O)R^{55}$, C(O)OH, (O), F, Cl, Br o I; y

R^{55} es alquilo, alquenilo, alquinilo, fenilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo.

4. Un compuesto de la reivindicación 3 o una sal aceptable para terapia del mismo, donde

A^1 es A^2, NHA^2, $N(A^2)_2$, F, Cl, Br, o I;

A^2 es R^1, R^2, R^3, o R^4;

R^1 es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{1A}; R^{1A} es cicloalcano, heterocicloalcano o heterocicloalqueno;

R^2 es heteroarilo que no está fusionado o está fusionado con benceno o heteroareno;

R^3 es cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^4 es alquilo o alquenilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^5, OR^5, SR^5, C(O)OH, F, Cl, Br o I;

R^5 es R^6, R^7 o R^8;

R^6 es fenilo que no está fusionado o está fusionado con benceno;

R^7 es heteroarilo;

R^8 es cicloalquilo;

L^1 es un enlace y B^1 es C(O)OH o un bioisóstero del mismo o es $C(O)OR^4$;

C^1 y D^1 son en forma independiente H, R^9, R^{12}, $C(O)OR^{12}$, F, Cl, Br, I, o

uno de C^1 y D^1 es H, y el otro es R^{12}, F, Cl, Br, o I;

R^9 es fenilo;

R^{12} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{13}, OR^{13}, SR^{13}, NHR^{13}, $N(R^{13})_2$, $C(O)R^{13}$, $C(O)N(R^{13})_2$, C(O)OH, F, Cl, Br o I;

R^{13} es R^{14}, R^{15} R^{16}, o R^{16A};

R^{14} es fenilo que no está fusionado o está fusionado con benceno, heteroareno o R^{14A}; R^{14A} es cicloalcano, o heterocicloalcano; donde cada uno de los cuales no está fusionado o está fusionado con R^{14B}; R^{14B} es cicloalcano;

R^{15} es heteroarilo que no está fusionado o está fusionado con benceno o heteroareno;

R^{16} es cicloalquilo o heterocicloalquilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^{16A} es alquilo; y

uno o dos o cada uno de E^1 y F^1 y G^1 son en forma independiente H, CF_3, F, Cl, Br o I, y los demás son en forma independiente R^{17}, R^{20} o OR^{20};

R^{17} es fenilo que no está fusionado o está fusionado con benceno;

R^{18} es heteroarilo;

R^{19} es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo;

R^{20} es alquilo o alquenilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{20}, OR^{20}, F, Cl, Br o I;

R^{20} es R^{21};

R^{21} es fenilo que no está fusionado o está fusionado con benceno;

donde cada porción cíclica que se ha mencionado en forma independiente no está sustituida o está sustituida con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre espiroheteroalquilo, R^{30}, OR^{30}, SO_2R^{30}, $C(O)R^{30}$, NO, NO_2, NH_2, $N(R^{30})_2$, $C(O)NH_2$, $C(O)NHR^{30}$, $NHC(O)R^{30}$, $C(O)NHSO_2R^{30}$, SO_2NH_2, C(O)OH, OH, (O), CN, CF_3, OCF_3, F, Cl, Br, o I;

R^{30} es R^{31}, R^{32}, R^{33} o R^{34};

R^{31} es fenilo que no está fusionado o está fusionado con benceno;

R^{32} es heteroarilo;

R^{33} es cicloalquilo, cicloalquenilo, o heterocicloalquilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^{34} es alquilo, alquenilo, o alquinilo, donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre R^{35}, OR^{35}, SR^{35}, $S(O)R^{35}$, SO_2R^{35}, NH_2, $N(R^{35})_2$, $C(O)NHR^{35}$, OH, C(O)OH, F, Cl, Br o I;

R^{35} es R^{36}, R^{37}, R^{38} o R^{39};

R^{36} es fenilo que no está fusionado o está fusionado con benceno o R^{36A}; R^{36A} es cicloalqueno;

R^{37} es heteroarilo que no está fusionado o está fusionado con benceno;

R^{38} es cicloalquilo, o heterocicloalquilo, donde cada uno de los cuales no está fusionado o está fusionado con benceno;

R^{39} es alquilo, donde cada uno de los cuales no está sustituido o está sustituido

con NH_2, $N(R^{40})_2$, o OR^{40};

R^{40} es alquilo o fenilo;

donde las porciones representadas por R^{31}, R^{32}, R^{33} R^{36}, R^{37}, R^{38} y R^{40} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre R^{50}, OR^{50}, $C(O)R^{50}$, $C(O)OR^{50}$, SO_2R^{50}, $NHC(O)R^{50}$, F, Cl, Br, I, C(O)OH, CN, NO_2, NH_2, (O) o OH;

R^{50} es R^{51}, R^{52}, R^{53} o R^{54};

R^{51} es fenilo;

R^{52} es heteroarilo;

R^{53} es heterocicloalquilo;

R^{54} es alquilo; donde cada uno de los cuales no está sustituido o está sustituido con uno, dos, tres, cuatro o cinco sustituyentes seleccionados en forma independiente entre OH, fenilo, o heteroarilo;

donde las porciones representadas por R^{51} y R^{53} en forma independiente no están sustituidas o están sustituidas con uno o dos o tres sustituyentes seleccionados en forma independiente entre $CO(O)R^{55}$, C(O)OH, (O), F, Cl, Br o I; y

R^{55} es alquilo.

5. El compuesto

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-fenilvinil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-fenil-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((1E)-3-fenilprop-1-enil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-ciclohexilvinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-(benciloxi)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-fluorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-naftil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-naftil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,1'-bifenil-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-fluoro-1,1'-bifenil-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(benciloxi)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-piridin-3-il-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-piridin-4-il-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((1E)-5-fenilpent-1-enil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-carboxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(benciloxi)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-etoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-etilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-isopropoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-fenoxifenil)-1H-indol-2-carboxílico;

ácido 7-(2-carboxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-((5,6,7,8-tetrahidronaftalen-1-iloxi)metil)fenil)-1H-indol-2-carboxílico;

ácido 7-(4-ciclohexilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-clorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-cloropiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,5-diclorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-diclorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,3-dimetoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,4-dimetoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,5-dimetoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,6-dimetoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metoxipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metoxipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-quinolin-4-il-1H-indol-2-carboxílico;

ácido 7-(4-hidroxi-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-metilpiperazin-1-il)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,4-diclorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metoxifenil)-3-(3-((2-metil-1-naftil)oxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-fluoro-2-isopropoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-etoxi-1-naftil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-amino-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(((2-(dimetilamino)etil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-cloro-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,3-diclorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 7-(3-cloro-2-fluorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,3-difluorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-ciclopent-1-en-1-il-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-ciclohex-1-en-1-il-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-fenilciclohex-1-en-1-il)-1H-indol-2-carboxílico;

ácido 7-(2-ciclohexilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(6-carboxipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-metil-5-nitropiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,3-dihidro-1,4-benzodioxin-6-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,3-benzodioxol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((4-cloro-1-naftil)oxi)propil)-7-(2-metoxifenil)-1H-indol-2-carboxílico;

ácido 3-(3-(2-bromofenoxi)propil)-7-(2-metoxifenil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-4-(((2-morfolin-4-iletil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-metilquinolin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(hidroximetil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-(hidroximetil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 5-cloro-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-metilpiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2,6-dimetilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(6-amino-2-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-piperazin-1-ilfenil)-1H-indol-2-carboxílico;

ácido 7-(4-(3-clorofenil)piperazin-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 5-cloro-3-(3-(1-naftiloxi)propil)-7-fenil-1H-indol-2-carboxílico;

ácido 5-cloro-7-(4-cloro-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 5-cloro-7-ciclopent-1-en-1-il-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dicloropiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-(aminocarbonil)piridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-cloro-5-(trifluorometil)piridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-amino-2-(trifluorometoxi)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-carboxi-2-metoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-nitrofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-carboxi-2-clorofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-bencil-3-metil-1,2,3,6-tetrahidropiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-amino-2-(trifluorometil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,4-dioxa-8-azaespiro(4,5)dec-8-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-carboxipiperidin-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxipiperidin-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-pirrolidin-1-il-1H-indol-2-carboxílico;

ácido 7-morfolin-4-il-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-piperidin-1-il-1H-indol-2-carboxílico;

ácido 7-(4-(aminosulfonil)-2-(trifluorometil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 4-(2-(etoxicarbonil)-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoico;

ácido 7-(2-metil-4-(morfolin-4-ilcarbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-((4-carboxipiperidin-1-il)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-((3-carboxipiperidin-1-il)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(carboximetilcarbamoil)-2-metilfenil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3,4-dihidroquinolin-1(2H)-il)propil)-7-(2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(3-fenoxifenoxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,3-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilbencil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3,3'-bis(3-(1-naftiloxi)propil)-1H,1'H-7,7'-biindol-2,2'-dicarboxílico;

ácido 3-(4-(3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(4-(3,4-dihidroquinolin-1(2H)-il)butil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(4-(1-naftil)butil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(4-(1-naftiloxi)butil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,4-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,5-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(1,1'-bifenil-2-il)-3-(4-(1-naftiloxi)butil)-1H-indol-2-carboxílico;

ácido 7-(4-((2-carboxipiperidin-1-il)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-((S)-1-carboxi-2-metilpropilcarbamoil)-2-metilfenil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-4-clorofenilalanina;

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-L-triptofano;

ácido (3S)-2-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-1,2,3,4-tetrahidroisoquinolin-3-carboxílico;

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-L-tirosina;

ácido 7-(4-((R)-2-carboxipirrolidin-1-carbonil)-2-metilfenil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-((S)-1-carboxietilcarbamoil)-2-metilfenil)-3-(3-(naftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-4-nitro-L-fenilalanina;

N-(4-(2-carboxi-3-(3-(1-naftiloxi)propil)-1H-indol-7-il)-3-metilbenzoil)-L-fenilalanina;

ácido 7-(4-((((S)-carboxi(fenil)metil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2,4,5-triclorofenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2,3,4-triclorofenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(2-tert-butilfenoxi)propil)-7-(4-carboxi-2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2-(trifluorometil)fenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(quinolin-8-iloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-((5-oxo-5,6,7,8-tetrahidronaftalen-1-il)oxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-benzoilfenoxi)propil)-7-(4-carboxi-2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-1-(2-morfolin-4-iletil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(ciclohexiloxi)fenil)-3-(4-(1-naftiloxi)butil)-1H-indol-2-carboxílico;

ácido 7-(1,1'-bifenil-2-il)-1-(2-morfolin-4-iletil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3,4-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(3,5-dimetilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,3-dimetoxifenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftilamino)propil)-1H-indol-2-carboxílico;

ácido 1-(carboximetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-(dimetilamino)fenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(4-(3,4-dihidroquinolin-1(2H)-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(2-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(6-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(6-metoxi-3,4-dihidroquinolin-1(2H)-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(etil(1-naftil)amino)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(2,3-dihidro-1H-indol-1-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(2-metil-2,3-dihidro-1H-indol-1-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-3-(4-(5-nitro-2,3-dihidro-1H-indol-1-il)butil)-1H-indol-2-carboxílico;

ácido 3-(4-(5-bromo-2,3-dihidro-1H-indol-1-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(2,3-dihidro-4H-1,4-benzoxazin-4-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(2,3,6-trimetilfenoxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,3-diclorofenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(5-(5,6,7,8-tetrahidronaftalen-1-iloxi)pentil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(5-(1-naftiloxi)pentil)-1H-indol-2-carboxílico;

ácido 7-(2,3-dimetilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-fluorofenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-(2-(2-oxopirrolidin-1-il)etil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(tert-butoxicarbonil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)bencil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)bencil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-((E)-2-fenilvinil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(1-naftil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(2-naftil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(3-(2-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(4-(1-naftiloxi)butil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(4-(2-naftiloxi)butil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(2-(2-naftil)etil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-tien-3-il-1H-indol-2-carboxílico;

ácido 7-((3-(aminocarbonil)fenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((3-cianofenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((2-bencilfenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,1'-bifenil-2-ilamino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((2-etilfenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((2-propilfenil)amino)-1H-indol-2-carboxílico;

ácido 7-(5-carboxi-3-metiltien-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((2-carboxifenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((3-carboxifenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-morfolin-4-il-5-nitropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-amino-2-morfolin-4-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((3-cloropiridin-4-il)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((2-isopropilfenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-morfolin-4-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-(aminocarbonil)-1,2-dimetil-6-oxo-1,6-dihidropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-ciano-1,2-dimetil-6-oxo-1,6-dihidropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-amino-4-cloro-2-morfolin-4-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 2-metil-3'-(3-(1-naftiloxi)propil)-2,3-dihidro-1'H-1,7'-biindol-2'-carboxílico;

ácido 7-(2-fluoro-5-metilpiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((2-metoxipiridin-3-il)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-oxo-1,2-dihidropiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(2-pirrolidin-1-iletoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(dimetilamino)-5-nitropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(2-(dimetilamino)etoxi)-5-metilpiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(2-morfolin-4-iletoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(1,4-dioxa-8-azaespiro(4,5)dec-8-il)-5-nitropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(5-nitro-2-(4-oxopiperidin-1-il)piridin-3-il)-1H-indol-2-carboxílico;

ácido 7-(5-amino-2-(dimetilamino)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-hidroxipiperidin-1-il)-5-nitropiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(6-metoxi-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-fluoro-5-metilpiridin-4-il)-1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 7-((2-morfolin-4-ilpiridin-3-il)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(2-feniletoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(2-piridin-3-iletoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((2-morfolin-4-ilfenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((4-carboxipiridin-3-il)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((4-(trifluorometil)piridin-3-il)amino)-1H-indol-2-carboxílico;

ácido 7-(2-(3-aminopropoxi)-5-metilpiridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(tetrahidrofuran-3-ilmetoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(4-fenilbutoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(3-metoxifenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-(carboximetil)-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-bencil-1H-imidazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(2-metilfenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-(2-morfolin-4-iletil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-nitrofenil)ciclohex-1-en-1-il)-1H-indol-2-carboxílico;

ácido 7-(4,4-dimetil-2-fenilciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-etil-7-(etil(fenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-anilino-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(tetrahidro-2H-piran-3-ilmetoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(2-(2-oxopirrolidin-1-il)etoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-2-(2-(4-metilpiperazin-1-il)etoxi)piridin-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(2-oxociclohexil)piridin-3-il)-1H-indol-2-carboxílico;

ácido 7-(2-fluoro-5-metilpiridin-4-il)-1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5,5-dimetil-2-fenilciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(piridin-3-ilamino)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(fenil(propil)amino)-1-propil-1H-indol-2-carboxílico;

ácido 7-(3-ciclohex-1-en-1-ilpiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-piridin-3-ilciclohex-1-en-1-il)-1H-indol-2-carboxílico;

ácido 3-(3-((8-cloroquinazolin-4-il)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 1-butil-7-(butil(fenil)amino)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(7-cloro-1H-pirrolo(2,3-c)piridin-1-il)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(3-ciclohexilpiridin-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1-(1,3-tiazol-5-ilmetil)-1H-pirrolo(2,3-c)piridin-3-il)-1H-indol-2-carboxílico;

ácido 7-(1-(3,3-dimetil-2-oxobutil)-1H-pirrolo(2,3-c)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-ciclohex-1-en-1-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-(3,5-difluorobencil)-1H-pirrolo(2,3-c)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1-fenilvinil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1H-pirrolo(2,3-c)piridin-7-il)-1H-indol-2-carboxílico;

ácido 7-(4-ciclohexilpiridin-3-il)-3-(3-fenoxipropil)-1H-indol-2-carboxílico;

ácido 7-(2,4-dimetil-1,3-tiazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-(carboximetil)-1H-pirrolo(2,3-c)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1-feniletil)-1H-indol-2-carboxílico;

ácido 7-(1-bencil-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-

carboxílico;

ácido 7-(2-(2-clorofenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-1H,1'H-7,7'-biindol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1-(2-(2-oxopirrolidin-1-il)etil)-1H-pirrolo(2,3-c)piridin-7-il)-1H-indol-2-carboxílico;

ácido 7-(5-metil-3-fenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(2-(1-naftiloxi)etil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(2-(2-naftiloxi)etil)-1H-indol-2-carboxílico;

ácido 4-(2-(2,3-diclorofenoxi)etil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1H-indol-4-iloxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 4-(2-(2-cloro-3-(trifluorometil)fenoxi)etil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 1-metil-3-(3-((1-metil-1H-indol-4-il)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-etilfenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-isopropilfenil)ciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,3-dimetil-5-fenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,5-dimetil-3-fenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-((3-metiloxetan-3-il)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-tetrahidrofuran-3-il-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-piridin-2-il-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-cloro-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-(2-(2-oxopirrolidin-1-il)etoxi)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-(tetrahidrofuran-3-ilmetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-ciclopentil-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-((2,2-dimetil-1,3-dioxolan-4-il)metil)-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-(2-morfolin-4-iletoxi)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-

2-carboxílico;

ácido 7-(4-metil-2-morfolin-4-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-cloro-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-(2,3-dihidroxipropil)-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(3-fenil-5-(2-feniletil)-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-fenilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-vinilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-((1E)-prop-1-enil)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-(piridin-3-ilmetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-isopropenil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-pentilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-propilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-isopropil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-diisopropil-1-metil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-carboxi-1,3-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-(2-metilprop-1-enil)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-1-fenil-1H-pirazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-isobutil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2,3'-bipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-metoxifenil)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-(1-metil-1H-pirazol-4-il)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-(hidroximetil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-bromo-7-(1,3-dimetil-5-fenil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 7-(1,3-dimetil-5-(fenoximetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-metil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-bromo-7-(2-((E)-2-ciclohexilvinil)-4-metilpiridin-3-il)-1H-indol-2-carboxílico;

ácido 7-(3-isopropil-1-metil-5-(fenoximetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,5-dimetil-3-(fenoximetil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(anilinocarbonil)-1-fenil-1H-pirazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-((3-clorofenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,5-dimetil-3-((3-fenoxifenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-bromo-4-(2-((4-bromo-1-naftil)oxi)etil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(1,5-dimetil-3-((4-morfolin-4-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-(((5-cloropiridin-3-il)oxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetil-1-(2-nitrofenil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((2-(feniltio)etil)amino)-1H-indol-2-carboxílico;

ácido 7-(3-((2-cianofenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-((4-(4-acetilpiperazin-1-il)fenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-bromo-7-(2-metilfenil)-4-(2-(1-naftiloxi)etil)-1H-indol-2-carboxílico;

ácido 7-(1-(2-aminofenil)-3,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-(1H-imidazol-1-ilmetil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-4-(2-(1-naftiloxi)etil)-3-vinil-1H-indol-2-carboxílico;

ácido 7-(4-((bencilamino)carbonil)-1-fenil-1H-pirazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1-fenil-4-(((3-pirrolidin-1-ilpropil)amino)carbonil)-1H-pirazol-5-il)-1H-indol-2-carboxílico;

ácido 7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-

indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(1,3-tiazol-4-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-cloro-4-((4-morfolin-4-ilfenoxi)metil)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-isopropil-1-metil-3-((4-morfolin-4-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-isopropil-1-metil-5-((4-morfolin-4-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-isopropenil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(1,5-dimetil-3-((4-morfolin-4-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-((4-morfolin-4-ilfenoxi)metil)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-2-pirimidin-5-ilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metil-6'-morfolin-4-il-2,3'-bipiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(4,6-dimetilpirimidin-5-il)-1-(2-(4-metilpiperazin-1-il)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)-2-oxoetil)-7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-((4-(1,1-dioxidotiomorfolin-4-il)fenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4,6-dimetilpirimidin-5-il)-1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,5-dimetil-3-((4-piperazin-1-ilfenoxi)metil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-((4-(4-acetilpiperazin-1-il)fenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(4,6-dimetilpirimidin-5-il)-1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-((4-(4-(tert-butoxicarbonil)piperazin-1-il)fenoxi)metil)-1,5-dimetil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)etil)-7-(4,6-dimetilpirimidin-5-il)-3-(3-(1-naftiloxi)propil)-1H-

indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(4-(1H-pirazol-1-il)fenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2,3,4-trifluorofenil)-1H-indol-2-carboxílico;

ácido 7-(4-hidroxi-3-metoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(3,4,5-trimetoxifenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(4-(trifluorometoxi)fenil)-1H-indol-2-carboxílico;

ácido 7-(2-metoxi-5-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-fluoro-4-metoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(4-(5-oxo-2,5-dihidro-1H-pirazol-3-il)fenil)-1H-indol-2-carboxílico;

ácido 7-(3-(morfolin-4-ilmetil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(morfolin-4-ilmetil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-isopropoxi-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(4-(1H-pirazol-5-il)fenil)-1H-indol-2-carboxílico;

ácido 7-(2,5-dimetilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2,4,5-trimetilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(3-(trifluorometoxi)fenil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-4-propoxifenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-cianofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2,3,5,6-tetrametilfenil)-1H-indol-2-carboxílico;

ácido 7-(3-ciano-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-etinil-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-(((3-(dimetilamino)propil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-isopropilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-(((2-(dimetilamino)etil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-5-(((2-morfolin-4-iletil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-5-(((3-morfolin-4-ilpropil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-5-(((2-feniletil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1H-indazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-((((1S,4R)-biciclo(2,2,1)hept-2-ilmetil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-5-(((3-fenilpropil)amino)carbonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-((2-isopropil-5-metilfenoxi)metil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-cloro-6-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-bencilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2,4,6-triisopropilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(1-oxo-2,3-dihidro-1H-inden-4-il)-1H-indol-2-carboxílico;

ácido 7-(2-ciclopentilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2',6'-dimetoxi-1,1'-bifenil-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(5,6,7,8-tetrahidronaftalen-1-il)-1H-indol-2-carboxílico;

ácido 7-(4'-tert-butil-1,1'-bifenil-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-fluoro-2-metil-3-((metilsulfonil)metil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-(((2-hidroxi-1,1-dimetiletil)amino)carbonil)-2,3,4-trimetilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-(etoxicarbonil)piperazin-1-il)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-6-nitrofenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-propionilpiperazin-1-il)fenil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-6-tien-2-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-(1,3-tiazol-4-ilmetil)piperazin-1-il)fenil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-(2-hidroxietil)piperazin-1-il)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(4-(metilsulfonil)piperazin-1-il)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-((4-(tert-butoxicarbonil)piperazin-1-il)sulfonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-((4-etilpiperazin-1-il)sulfonil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-((4-(2-oxopirrolidin-1-il)piperidin-1-il)sulfonil)fenil)-1H-indol-2-carboxílico;

ácido 7-(3-((1S,4R)-2-hidroxibiciclo(2,2,1)hept-2-il)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((1E)-1-etilbut-1-enil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((Z)-2-carboxi-1-pentilvinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5,7-dimetilpirazolo(1,5-a)pirimidin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(4-fluorofenil)-5-(4-(metilsulfonil)fenil)tien-2-il)-3-(3-(1-naftiloxi)propil)-

1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-7-(2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 7-(5-(((2-(dimetilamino)etil)(piridin-2-il)amino)metil)tien-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-morfolin-4-il-6-(trifluorometil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metoxi-2-fenil-1-benzofuran-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 4-fluoro-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 4-fluoro-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-((2-adamantilamino)carbonil)-6-metilimidazo(1,2-a)piridin-8-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-(1-adamantil)-3-carboxi-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(1-hidroxi-4-metoxiciclohexil)-1-benzotien-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-cloro-3-metil-1-tetrahidro-2H-piran-2-il-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2,2,4-trimetil-1-(fenilsulfonil)-1,2-dihidroquinolin-3-il)-1H-indol-2-carboxílico;

ácido 7-(7,8-dimetil-2-(1-metil-1-feniletil)imidazo(1,2-a)piridin-6-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-(4-((2-fluorobenzoil)amino)fenil)-3-(trifluorometil)-1H-pirazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-amino-3-(piperidin-1-ilcarbonil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(3-metil-1-(2-nitrofenil)-5-fenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5-metil-1-(2-oxo-2-((2-feniletil)amino)etil)-3-(trifluorometil)-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(1-adamantil)imidazo(1,2-a)piridin-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,1-dioxido-1-benzotien-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-ciclohexil-6-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(((2-(2-(2-aminoetoxi)etoxi)etil)amino)carbonil)-2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-metil-3,5-difenil-1H-pirazol-4-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((Z)-2-(1H-imidazol-1-il)-1-fenilvinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-

carboxílico;

ácido 7-(1-bencil-2-metil-4-nitro-1H-imidazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-prop-1-inilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(feniletinil)fenil)-1H-indol-2-carboxílico;

ácido 3,7-bis(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)-2-oxoetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-metilbencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(3-metilbencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(4-metilbencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-1-(3-morfolin-4-ilpropil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-1-(2-(4-metilpiperazin-1-il)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(1,1'-bifenil-2-ilmetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(1,1'-bifenil-3-ilmetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(1,1'-bifenil-4-ilmetil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2,4-dimetilbencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(4-carboxibencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(1,1'-bifenil-2-ilmetil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(1,1'-bifenil-3-ilmetil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(1,1'-bifenil-4-ilmetil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2,4-dimetilbencil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2,6-diclorobencil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(4-carboxibencil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(6,6-dimetilciclohex-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(5,5-dimetilciclopent-1-en-1-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(7-fenilciclohept-1-en-1-il)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-triciclo(4,3,1,$1^{3,8}$)undec-4-en-4-il-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-fenilciclohept-1-en-1-il)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2,6,6-trimetilciclohex-1-en-1-il)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((1R,4R)-1,7,7-trimetilbiciclo(2,2,1)hept-2-en-2-il)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-4-(trifluorometil)-1H-indol-2-carboxílico;

ácido 7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-4-(trifluorometil)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)etil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,1'-bifenil-2-ilmetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1,1'-bifenil-3-ilmetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(1-(2-(1-naftiloxi)etil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(fenoximetil)bencil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(2-fenoxietil)fenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(3-(2-fenoxietil)fenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(3-fenoxipropil)fenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(3-(3-fenoxipropil)fenil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-hidroxi-2-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-(2-metoxietoxi)-2-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(1,2-dimetilprop-1-enil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(2-metil-3-(2-morfolin-4-iletoxi)fenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,3-diclorofenoxi)propil)-7-(2-morfolin-4-ilfenil)-1H-indol-2-carboxílico;

ácido 1-(2-morfolin-4-iletil)-7-(2-morfolin-4-ilfenil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftiltio)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-(2-metoxietoxi)-5-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-morfolin-4-ilfenil)-3-(3-(5,6,7,8-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-metil-5-(3-morfolin-4-ilpropoxi)fenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-(3-ciclohexilpropoxi)-5-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-(3-(2-carboxi-1H-indol-3-il)propoxi)-5-metilfenoxi)propil)-7-(2-morfolin-4-ilfenil)-1H-indol-2-carboxílico;

ácido 7-bromo-3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(1,1'-bi(ciclohexan)-2-en-2-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,3-diclorofenoxi)propil)-7-(1,2-dimetilprop-1-enil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-metil-4-(trifluorometil)fenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-fluoro-2-metilfenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-metoxi-2-metilfenil)-3-(3-(2,3,5-trimetilfenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico;

ácido 6-metil-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(2,3-diclorofenoxi)propil)-7-(2-metilfenil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3,5-diclorofenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 1-metil-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-metil-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(3-(aminometil)bencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(3-(aminometil)bencil)-7-(2-morfolin-4-ilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(2-((E)-2-ciclohexilvinil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(3-carboxifenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(2-piridin-3-ilfenil)vinil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(3-(((fenilsulfonil)amino)carbonil)fenil)etil)-1H-indol-2-carboxílico;

ácido 7-(2-(3-((4-metilpiperidin-1-il)carbonil)fenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(3-(((2-pirrolidin-1-iletil)amino)carbonil)fenil)etil)-1H-indol-2-carboxílico;

ácido 7-(2-(3-(((2-morfolin-4-iletil)amino)carbonil)fenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(3-(((2-(dimetilamino)etil)amino)carbonil)fenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-(((fenilsulfonil)amino)carbonil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(2-piridin-4-ilfenil)vinil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(3-clorofenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(3-((ciclohexilamino)carbonil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-(((2-fenoxietil)amino)carbonil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(3-(((2-(2-(2-aminoetoxi)etoxi)etil)amino)carbonil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(3-((4-bencilpiperidin-1-il)carbonil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-((4-fenilpiperazin-1-il)carbonil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(3-((3-metilpiperidin-1-il)carbonil)fenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(3-(((2-(2-(2-aminoetoxi)etoxi)etil)amino)carbonil)fenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-((E)-2-fenilvinil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(1,1'-bifenil-3-il)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(3-((1E)-3-fenilprop-1-enil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(4-((E)-2-fenilvinil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(4-((1E)-3-fenilprop-1-enil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(1,1'-bifenil-4-il)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(1,1'-bifenil-3-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(3-(3-fenilpropil)fenil)etil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(2-clorofenil)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-((E)-2-(1,1'-bifenil-2-il)vinil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-((E)-2-(2-((E)-2-fenilvinil)fenil)vinil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-feniletil)-1H-indol-2-carboxílico;

ácido 7-(2-(2-clorofenil)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(1,1'-bifenil-4-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-(2-feniletil)fenil)etil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-(4-(3-fenilpropil)fenil)etil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-((2-cianoquinolin-8-il)oxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((2-acetil-1-benzofuran-7-il)oxi)propil)-7-(4-carboxi-2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-((2,2-dimetil-2,3-dihidro-1-benzofuran-7-il)oxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2,3-difluorofenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(3-metil-2-nitrofenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2-metil-3-nitrofenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2-cloro-3-(trifluorometil)fenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(4-carboxi-2-metilfenil)-3-(3-(2-fluoro-3-(trifluorometil)fenoxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-clorofenil)-3-(3-(etil(1-naftil)amino)propil)-1H-indol-2-carboxílico;

ácido 7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-3-(4-(5-oxo-2,3,4,5-tetrahidro-1H-1-benzazepin-1-il)butil)-1H-indol-2-carboxílico;

ácido 7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-3-(4-(2,3,4,5-tetrahidro-1H-1-benzazepin-1-il)butil)-1H-indol-2-carboxílico;

ácido 3-(4-(2,3-dihidro-4H-1,4-benzotiazin-4-il)butil)-7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-1H-indol-2-carboxílico;

ácido 3-(4-(3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(4-(2-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(4-(6-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(4-(8-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(4-(2-metil-2,3-dihidro-1H-indol-1-il)butil)-7-(2-metilfenil)-1H-indol-2-

carboxílico;

ácido 7-(2-metilfenil)-3-(4-(2,3,4,5-tetrahidro-1H-1-benzazepin-1-il)butil)-1H-indol-2-carboxílico;

ácido 3-(4-(3-metil-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(4-(3-(hidroximetil)-3,4-dihidroquinolin-1(2H)-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(4-(2,3-dihidro-4H-1,4-benzotiazin-4-il)butil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 4-metoxi-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(((1R,4S)-8-hidroxi-1,2,3,4-tetrahidro-1,4-metanonaftalen-5-il)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-((1R,4S)-1,2,3,4-tetrahidro-1,4-metanonaftalen-5-iloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((4-metoxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-((2-nitro-1-naftil)oxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((3-hidroxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(3,5-dimetilisoxazol-4-il)-3-(3-(2,3,6,7-tetrahidro-1H,5H-pirido(3,2,1-ij)quinolin-8-iloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(2,3,6,7-tetrahidro-1H,5H-pirido(3,2,1-ij)quinolin-8-iloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-((2-nitroso-1-naftil)oxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((5-hidroxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(2,3,4-trifluorofenoxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-cloro-2-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-((8-hidroxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-cloro-2-cianofenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(2-bromo-3-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(3-metil-2-vinilfenoxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(3-metil-2-nitrofenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(2-amino-3-metilfenoxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(4-(morfolin-4-ilcarbonil)-2-(trifluorometil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((6-amino-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1,2,3,4-tetrahidronaftalen-1-iloxi)prop-1-inil)-1H-indol-2-carboxílico;

ácido 3-(3-((6-(acriloilamino)-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-((6-(propionilamino)-1-naftil)oxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-metilfenil)-3-(3-(1,2,3,4-tetrahidronaftalen-1-iloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((6-metoxi-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 1-(4-metoxibencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)prop-1-inil)-1H-indol-2-carboxílico;

ácido 3-(3-((2,3,4,5,6,7,8-heptafluoro-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-benzotien-7-iloxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-((4-fluoro-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-((8-fluoro-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 3-(3-((5-fluoro-1-naftil)oxi)propil)-7-(2-metilfenil)-1H-indol-2-carboxílico;

ácido 7-fluoro-3-(2-isopropilfenil)-1-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-fluoro-3-(2-metilfenil)-1-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-((5-fluoro-1-naftil)oxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-2-(1H-tetraazol-5-il)-1H-indol;

1-(4-metoxibencil)-7-(2-metilfenil)-3-(3-(1-naftiloxi)propil)-2-(1H-tetraazol-5-il)-1H-indol;

ácido 7-(1-metil-1H-imidazol-5-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 1-(2-(4-metilpiperazin-1-il)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 7-(4,6-dimetilpirimidin-5-il)-1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)etil)-3-(3-(1-naftiloxi)propil)-7-(1,3,5-trimetil-1H-pirazol-4-il)-1H-indol-2-carboxílico;

ácido 7-(2-metilimidazo(1,2-a)piridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-

carboxílico;

ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-2-ilmetil)-1H-indol-2-carboxílico;

7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-((1-(piridin-4-ilmetil)piridinio-4-il)metil)-1H-indol-2-carboxilato;

ácido 7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-4-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)-2-oxoetil)-7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-1-(2-(4-metilpiperazin-1-il)-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-1-(2-morfolin-4-iletil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)etil)-7-(2-etil-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-etil-4-metilpiridin-3-il)-1-(2-(4-metilpiperazin-1-il)etil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-((4-(4-carboxifenil)piperazin-1-il)metil)fenil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 3-(3-(1-naftiloxi)propil)-7-(2-piperazin-1-ilpiridin-3-il)-1H-indol-2-carboxílico;

ácido 1-(2-(dimetilamino)-2-oxoetil)-7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico;

ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(piridin-3-ilmetil)-1H-indol-2-carboxílico;

ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-1-(2-morfolin-4-il-2-oxoetil)-3-(3-(1-naftiloxi)propil)-1H-indol-2-carboxílico; o

ácido 7-(2-(1H-imidazol-1-il)-4-metilpiridin-3-il)-3-(3-(1-naftiloxi)propil)-1-(2-oxo-2-piperazin-1-iletil)-1H-indol-2-carboxílico;

o una sal aceptable para terapia de los mismos.

6. Una composición que comprende un excipiente y una cantidad eficaz para terapia de un compuesto de la Fórmula I.

INDOLES SUSTITUIDOS EN LA POSICIÓN 7 INHIBIDORES DE Mcl-1

RESUMEN

Compuestos que inhiben la actividad de la proteína antiapoptótica Mcl-1, composiciones que contienen los compuestos, y métodos para tratar enfermedades relacionadas con la sobreexpresión o falta de regulación de la proteína Mcl-1.

595

Industria y Comercio
SUPERINTENDENCIA

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISION DE NUEVAS CREACIONES
TARJETA ARCHIVO PROPIETARIOS

PATENTE DE INVENCION ____ PCT __X__ MODELO DE UTILIDAD ____ DISEÑO INDUSTRIAL ____

(21) Nº de solicitud: (22) Fecha de solicitud:
(51) Clasificación Internacional :

(71)Solicitante(s) **ABBOTT LABORATORIES**

(72) Inventor(es) **STEVEN ELMORE, ANDREW J. SOUERS, MILAN BRUNCKO, XIAOHONG SONG, XILU WANG, LISA A. HASVOLD, LE WANG, AARON, R. KUNZER, CHEOL-MIN PARK, MICHAEL, D. WENDT, ZHI-FU TAO**

(74) Apoderado: **DRA. MARGARITA CASTELLANOS ABONDANO**

(30) Prioridad	(31) No. Prioridad	32) Fecha	(33) País
	60/912.038	16/04/2007	US
	60/949.650	13/07/2007	US

(85) Fecha inicio fase nacional:
(86) Datos relativos a la presentación de la solicitud PCT
Fecha de presentación de la solicitud: **16/04/2008**
No. de solicitud **PCT/US2008/060472**

(87) Publicación internacional
Fecha: **30/10/2008**
Nº publicación: **WO 2008/131000 A3**

(54) Titulo: **INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1**

PATENT COOPERATION TREATY PCT/US2008/060472

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92*bis*.1 and Administrative Instructions, Section 422)

To:

DONNER, B., Gregory
ABBOTT LABORATORIES
Dept. 0377, Bldg. AP6A-1A
100 Abbott Park Road
Abbott Park, Illinois 60064-6008
ETATS-UNIS D'AMERIQUE

Date of mailing *(day/month/year)*
29 September 2009 (29.09.2009)

Applicant's or agent's file reference
8796WOO1

IMPORTANT NOTIFICATION

International application No.
PCT/US2008/060472

International filing date *(day/month/year)*
16 April 2008 (16.04.2008)

1. The following indications appeared on record concerning:

☒ the applicant ☒ the inventor ☐ the agent ☐ the common representative

Name and Address	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	E-mail address	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address	State of Nationality	State of Residence
MADAR, David 4776 East Guadalupe Road Apt. 2075 Gilbert, Arizona 85234 United States of America	US	US
	Telephone No.	
	Facsimile No.	
	E-mail address ☐ Notifications by e-mail authorized	

3. Further observations, if necessary:
The person identified in Box 2 should be added to the record as applicant for the United States of America only and inventor for all designated States.

4. A copy of this notification has been sent to:

☒ the receiving Office
☐ the International Searching Authority
☐ the Authority(ies) specified for supplementary search
☐ the International Preliminary Examining Authority
☒ the designated Offices concerned
☐ the elected Offices concerned
☐ other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. +41 22 338 71 30

Authorized officer
Suarez Javier
e-mail pt09.pct@wipo.int
Telephone No. +41 22 338 74 09

Industria y Comercio
SUPERINTENDENCIA

Delegatura de Propiedad Industrial
División de Nuevas Creaciones

REQUISITOS NECESARIOS PARA PRESENTACION Y AGILIZACION DEL TRÁMITE

	USUARIO	RADICADOR
PATENTE DE INVENCION (X) MODELO DE UTILIDAD ( )	(X)	( )
- Indicación de que se solicita la concesión de una patente	(X)	( )
- Datos de identificación del solicitante o de la persona que presenta la solicitud	(X)	( )
- Descripción de la invención	(X)	( )
- Dibujos de ser estos pertinentes	( )	( )
- Comprobante de pago de las tasas establecidas	(X)	( )

COMPLETA (X) INCOMPLETA ( )

DISEÑO INDUSTRIAL ( )

- Indicación de que se solicita el registro de Diseño Industrial	( )	( )
- Datos de identificación del solicitante o de la persona que presenta la solicitud	( )	( )
- Representación gráfica y fotográfica del Diseño Industrial o muestra del material que incorpora el diseño	( )	( )
- Comprobante de pago de las tasas establecidas	( )	( )

COMPLETA ( ) INCOMPLETA ( )

ESQUEMA DE TRAZADO ( )

- Indicación de que se solicita el registro de Diseño Industrial	( )	( )
- Datos de identificación del solicitante o de la persona que presenta la solicitud	( )	( )
- Representación gráfica del Esquema de Trazado	( )	( )
- Comprobante de pago de las tasas establecidas	( )	( )

COMPLETA ( ) INCOMPLETA ( )

Firma responsable: _____

Fecha: _____

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

No. 09-111589- -00000-0000

Fecha: 2009-10-08 14:40:14 Dep. 2020 NUECREACIONI
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 597

BICENTENARIO

Industria y Comercio
SUPERINTENDENCIA

Bogotá,
2020

Doctor(a)
MARGARITA CASTELLANOS ABONDANO
Apoderado(a) y/o Representante de
ABBOTT LABORATORIES

REFERENCIA	Radicación No.	9 111589
	Solicitud internacional	PCT/US2008/060472
	Fecha inicio fase nacional	16/11/2009
	Trámite	11
	Evento	378
	Actuación	430
	Oficio No.	238

Como resultado del examen de forma, realizado con fundamento en el artículo 38 de la Decisión 486 de la Comisión de la Comunidad Andina, artículo 27 del Tratado de Cooperación en Materia de Patentes (PCT), regla 51 bis del Reglamento y Circular Única de la Superintendencia de Industria y Comercio, se le comunica que:

1. La solicitud no contiene la copia del documento en que consta la cesión del derecho a la patente del inventor al solicitante o a su causante, conforme a lo establecido por el artículo 26 literal k) de la Decisión 486 de la Comisión de la Comunidad Andina. Cuando se trate de documentos otorgados en el extranjero, estos deberán legalizarse de conformidad con lo dispuesto por los artículos 259 y 260 del Código de Procedimiento Civil. Cuando se trate de las declaraciones a que hace referencia la Regla 4.17 ii) del Tratado de Cooperación en Materia de Patentes PCT., el alcance de las tales declaraciones se determinará según indiquen claramente una cesión de derechos del inventor al solicitante o su causante, de conformidad con lo dispuesto en el numeral 5.2.15 del Capítulo Quinto, Título X de la Circular Única de Superintendencia de Industria y Comercio.

En cumplimiento de lo dispuesto por el artículo 39 de la Decisión 486, se le requiere para que dentro del término de dos meses siguientes a la fecha de notificación del presente oficio, complete los requisitos anteriormente enunciados. En caso de no dar cumplimiento al presente requerimiento, la solicitud se considerará abandonada y perderá su prelación.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo quinto del título primero de la Circular Unica No.10 de 2001.

JESUS FERNEL GARCIA GARCIA
Director de Nuevas Creaciones (E)

El anterior requerimiento fue notificado por fijación en lista de fecha 08 ENE. 2010
adpa11